# ECCO'23 Conflict of Interest Indication

| Presentation Number | Conflict of Interest |
|---|---|
| DOP01 | Williams, Kyle: No conflict of interest\|\|Shows, Donna: No conflict of interest\|\|Kongala, Ramya: No conflict of interest\|\|Clarke, Astrid: No conflict of interest\|\|Dr. Lord, James: No conflict of interest |
| DOP02 | Dr. Grant, Sarah: No conflict of interest\|\|Johnson, Kristy: No conflict of interest\|\|Thomas, Tom: No conflict of interest\|\|Honig, Gerard: No conflict of interest\|\|Bielecki, Piotr: No conflict of interest\|\|Dendrou, Calliope: No conflict of interest\|\|Guo, Sean: No conflict of interest\|\|Kulicke, Ruth: No conflict of interest\|\|Li, Ping: No conflict of interest\|\|L'Italien, Larry: No conflict of interest\|\|Spies, Noah: No conflict of interest\|\|Stransky, Nicolas: No conflict of interest\|\|Uhlig, Holm: No conflict of interest\|\|Varma, Mukund: No conflict of interest\|\|Travis, Simon:\|:\|as per ECCO ICMJE\|\|Buckley, Christopher:\|:\|Grants from Celsius, Janssen, Roche, GSK, Sitryx. Consulting fees from Novartis, GSK and shareholder in Mestag. \|\|Magram, Jeanne: No conflict of interest |
| DOP03 | Voisin, Athalia: No conflict of interest\|\|Mahmood, Ramsha: No conflict of interest\|\|Jeanson, Terri-Lyn: No conflict of interest\|\|Bernstein, Charles: No conflict of interest\|\|Prof. Armstrong, Heather: No conflict of interest |
| DOP04 | Dr. Hornsby, Eve:\|:\|Has received honorarium from Gilead for seminar presentation\|\|Gadhok, Radha: No conflict of interest\|\|Yadon, Adam N.: No conflict of interest\|\|Lindsay, James O.:\|:\|Has received honoraria for consulting with Gilead and Galapagos as part of an advisory board.\|Has received honorarium from Gilead for seminar presentation\|\|Stagg, Andy J.:\|:\|Has received honorarium from Gilead for seminar presentation\|The work is funded by an investigator initiated research grant from Gilead. |
| DOP05 | Melon, Elisa:\|:\|Elisa Melón-Ardanaz has a FPI grant (grant RH042155) from the Ministerio de Ciencia e Innovación\|\|Veny, Marisol: No conflict of interest\|\|Corraliza, Ana-María: No conflict of interest\|\|Garrido-Trigo, Alba: No conflict of interest\|\|Esteller, Miriam: No conflict of interest\|\|Rodrigo, Maite: No conflict of interest\|\|Verstockt, Bram: No conflict of interest\|\|Vermeire, Severine: No conflict of interest\|\|Masamunt, Maria Carme: No conflict of interest\|\|Giner, Ángel: No conflict of interest\|\|Ordás, Ingrid: No conflict of interest\|\|Fernández-Clotet, Agnès: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Panés, Julian:\|:\|Julian Panés has received consulting fees from AbbVie, Arena, Boehringer Ingelheim, Celgene, GoodGut, GSK, Janssen, MSD, Nestlé, Oppilan, Pfizer, Takeda, Theravance, and TiGenix, and unrestricted research grants from AbbVie and MSD.\|\|Salas, Azucena:\|:\|Azucena Salas has a Pfizer Independent Medical Grant (grant 54549477). |

| | |
|---|---|
| DOP06 | Dr. Cairns, Junmei: No conflict of interest\|\|Monkley, Sue: No conflict of interest\|\|Tian, Sun: No conflict of interest\|\|Angermann, Bastian: No conflict of interest\|\|Liu, Zhi: No conflict of interest\|\|Öberg, Lisa: No conflict of interest\|\|Muthas, Daniel: No conflict of interest\|\|Cabrera, Claudia: No conflict of interest\|\|Rapsomaniki, Eleni: No conflict of interest\|\|Fernández Llaneza, Daniel: No conflict of interest\|\|Olsson, Marita: No conflict of interest\|\|Paraskos, Jonathan: No conflict of interest\|\|Ellison, Gillian: No conflict of interest\|\|Khan, Emon: No conflict of interest\|\|Duncan, Elizabeth A: No conflict of interest\|\|Neisen, Jessica: No conflict of interest\|\|Gehrmann, Ulf: No conflict of interest\|\|Chamberlain, Chris: No conflict of interest |
| DOP07 | Ms. Buck, Annalisa: No conflict of interest\|\|Weber, Marie-Christin: No conflict of interest\|\|Friess, Helmut: No conflict of interest\|\|Neumann, Philipp-Alexander: No conflict of interest |
| DOP08 | Bosáková, Veronika: No conflict of interest\|\|Frič, Jan: No conflict of interest |
| DOP09 | Ms. Jacobs, Inge: No conflict of interest\|\|Deleu, Sara: No conflict of interest\|\|Cremer, Jonathan: No conflict of interest\|\|De Hertogh, Gert:\|:\|Gert De Hertogh receives fees for his activities as central pathology reader from Centocor and receives speakers' fees from Janssen.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Breynaert, Christine: No conflict of interest\|\|Vanuytsel, Tim:\|:\|Tim Vanuytsel reports financial support for research from Danone and MyHealth; has served on the Speaker bureau for Abbott, Fresenius Kabi, Kyowa Kirin, Menarini, Remedus, Takeda and Will Pharma; consultancy fees from Baxter, Dr. Falk Pharma, Takeda, Tramedico, Truvion, VectivBio and Zealand Pharma.\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. |

| | |
|---|---|
| DOP10 | Mr. Grellier, Nathan: No conflict of interest\|\|Kirchgesner, Julien:\|:\|JK received research support from the French National Society of Gastroenterology (SNFGE) and has received consulting fees from Roche and Pfizer, and research support from Abbvie for unrelated studies.\|\|Uzzan, Mathieu:\|:\|MU has received consulting fees from Celltrion, Abbvie, Galapagos, Takeda, Janssen\|\|Mclellan, Paul: No conflict of interest\|\|Stefanescu, Carmen: No conflict of interest\|\|Lefèvre, Jérémie H:\|:\|JHL reports lecture fees from Ethicon, Takeda, Intuitive, B-Braun, invitation to a medical congress by Biomup, Intuitive and MD start. He is a consultant for Safeheal, Coloplast and FSK. He is a personal investor in 1 digital companies, medical device companies or biotech companies. \|\|Panis, Yves: No conflict of interest\|\|Sokol, Harry:\|:\|HS report lecture fee, board membership, or consultancy from Carenity, AbbVie, Astellas, Danone, Ferring, Mayoly Spindler, MSD, Novartis, Roche, Tillots, Enterome, BiomX, Biose, Novartis, Takeda, Biocodex and is cofounder of Exeliom Biosciences\|\|Beaugerie, Laurent:\|:\|LB has received consulting fees from Janssen, Pfizer and Allergan, lecture fees from Abbvie, Janssen, MSD, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda and Tillots, and research support from Abbott, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Takeda and Tillots for unrelated studies.\|\|Treton, Xavier:\|:\|Abbvie, Takeda, Celgene, Sandoz, Pfizer, Janssen, MSD, Amgen, Thabor Therapeutics\|\|Seksik, Philippe:\|:\|Declares financial support for scientific works from Biocodex, MSD, Takeda, Janssen, Sandoz, consultant fees from Abbvie, Merk, MSD, Gilead, Pfizer, Sandoz, Janssen, Fresenius Kabi but no conflict of interest linked to this work. |
| DOP11 | Ms. Bache-Wiig Mathisen, Charlotte:\|:\|Dr. Bache/Wiig Mathisen has as served as advisory board member for Tillots Pharma\|\|Nyström, Niklas:\|:\|Dr Nyström has served as speaker and/or advisory board member for Abigo, Baxter, Ferring, Fresenius-Kabi, Mylan/Meda, Nutricia, Shire, Takeda, Thermo Fisher Scientific, Tillotts\|\|Bazov, Igor: No conflict of interest\|\|Andersen, Svend: No conflict of interest\|\|Olbjørn, Christine: No conflict of interest\|\|Perminow, Gøri: No conflict of interest\|\|Kristensen, Vendel A:\|:\|Has served as speaker, consultant, and advisory member for or has received investigator inititated research funding from Takeda, Janssen, Ferring and Tillotts Pharma\|\|Opheim, Randi: No conflict of interest\|\|Ricanek, Petr: No conflict of interest\|\|D`Amato, Mauro: No conflict of interest\|\|Carlson, Marie: No conflict of interest\|\|Hedin, Charlotte RH:\|:\|Charlotte R H Hedin has received speaker fees from Takeda, Ferring, AbbVie, and Janssen, and consultancy fees from Pfizer, has acted as local principal investigator for clinical trials for Janssen and GlaxoSmithKline and has received project grants from Takeda and Tillotts Pharma. \|\|Keita, Åsa V: No conflict of interest\|\|Kruse, Robert: No conflict of interest\|\|Lindqvist, Carl Mårten: No conflict of interest\|\|Magnusson, Maria K: No conflict of interest\|\|Salihovic, Samira: No conflict of interest\|\|Söderholm, Johan D: No conflict of interest\|\|Öhman, Lena:\|:\|Lena Öhman has received financial support for research from Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as Consultant/Advisory Board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and MEDA\|\|Repsilber, Dirk: No conflict of interest\|\|Høivik, Marte Lie:\|:\|Dr Høivik Has served as speaker, consultant, and advisory member for or has received investigator inititated research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma\|\|Halfvarson, Jonas:\|:\|Dr Halfvarson has served has received personal fees as speaker and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD and Takeda. |

| | |
|---|---|
| DOP12 | Dr. Sleiman, Joseph:\|:\|N.S.G has received funding from Pfizer\|\|Chirra, Prathyush: No conflict of interest\|\|Gandhi, Namita:\|:\|N.S.G has received funding from Pfizer\|\|Gordon, Ilyssa O.:\|:\|I.O.G. does not receive and direct funding, but the Cleveland Clinic receives funding on her behalf from Celgene, UCB, GB004, Pliant, Morphic Therapeutics, and Helmsley Charitable Trust\|\|Viswanath, Satish:\|:\|S.E.V has received funding from Pfizer\|\|Rieder, Florian:\|:\|F.R. is consultant to Agomab. Allergan, AbbVie, Boehringer Ingelheim, Celgene, Cowen, Falk Pharma, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Origo, Pfizer, Pliant, Prometheus, Receptos, RedX, Roche, Samsung, Takeda, Techlab, Theravance, Thetis, UCB and received funding from the National Institute of Health, Helmsley Charitable Trust, Crohn's and Colitis Foundation, Rainin Foundation, UCB, Boehringer-Ingelheim, Pliant, Morphic, BMS, 89Bio. |
| DOP13 | Farkas, Klaudia: No conflict of interest\|\|Endre, Gábor: No conflict of interest\|\|Dr. Bacsur, Péter: No conflict of interest\|\|Resál, Tamás: No conflict of interest\|\|Kocsmárszky-Koósz, Violetta: No conflict of interest\|\|Tömösi, Ferenc: No conflict of interest\|\|Tóth, Eszter: No conflict of interest\|\|Rutka, Mariann: No conflict of interest\|\|Bálint, Anita: No conflict of interest\|\|Fábián, Anna: No conflict of interest\|\|Bor, Renáta: No conflict of interest\|\|Szepes, Zoltán: No conflict of interest\|\|Goretity, Árpád: No conflict of interest\|\|Thibodeau, Ildikó: No conflict of interest\|\|Molnár, Tamás: No conflict of interest |
| DOP14 | Ms. Salihovic, Samira: No conflict of interest\|\|Nyström, Niklas:\|:\|Speaker and/or advisory board member for Abigo, Baxter, Ferring, Fresenius-Kabi, Mylan/Meda, Nutricia, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, and Viatris.\|\|Bache-Wiig Mathisen, Charlotte:\|:\|Has received advisory board fees from Tillots Pharma.\|\|\|Andersen, Svend: No conflict of interest\|\|Olbjørn, Christine: No conflict of interest\|\|Perminow, Gøri: No conflict of interest\|\|Opheim, Randi: No conflict of interest\|\|Detlie, Trond Espen:\|:\|Personal fees from Ferring, Tillotts, pPharmacosmos, and Vifor Pharma\|\|Huppertz-Hauss, Gert: No conflict of interest\|\|Bazov, Igor: No conflict of interest\|\|Kruse, Robert: No conflict of interest\|\|Lindqvist, Carl Mårten: No conflict of interest\|\|Hedin, Charlotte R H:\|:\|Has received speaker fees from Takeda, Ferring, AbbVie, and Janssen, and consultancy fees from Pfizer, has acted as local principal investigator for clinical trials for Janssen and GlaxoSmithKline and has received project grants from Takeda and Tillotts Pharma. \|\|Carlson, Marie: No conflict of interest\|\|Öhman, Lena:\|:\|Has received financial support for research from Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as Consultant/Advisory Board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and MEDA.\|\|Magnusson, Maria: No conflict of interest\|\|Keita, Åsa V: No conflict of interest\|\|Söderholm, Johan D: No conflict of interest\|\|D'Amato, Mauro: No conflict of interest\|\|Orešič, Matej: No conflict of interest\|\|Repsilber, Dirk: No conflict of interest\|\|Hyötyläinen, Tuulia: No conflict of interest\|\|Hoivik, Marte Lie:\|:\|Has served as speaker, consultant, and advisory member for or has received investigator inititated research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma.\|\|Halfvarson, Jonas:\|:\|Has received personal fees as speaker and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD and Takeda. |

| | |
|---|---|
| DOP15 | Dr. Morão, Bárbara: No conflict of interest\|\|Revés, Joana: No conflict of interest\|\|Nascimento, Catarina: No conflict of interest\|\|Frias Gomes, Catarina: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Freitas, Marta: No conflict of interest\|\|Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest\|\|Pereira, Flávio: No conflict of interest\|\|Caldeira, Ana: No conflict of interest\|\|Sousa, Rui: No conflict of interest\|\|Coelho, Rosa: No conflict of interest\|\|Macedo, Guilherme: No conflict of interest\|\|Macedo, Cláudia: No conflict of interest\|\|Ferreira, Margarida: No conflict of interest\|\|Glória, Luísa: No conflict of interest\|\|Torres, Joana: No conflict of interest\|\|Palmela, Carolina: No conflict of interest |
| DOP16 | Dr. Livanos, Alexandra: No conflict of interest\|\|Dunn, Alexandra: No conflict of interest\|\|Fischer, Jeremy: No conflict of interest\|\|Ungaro, Ryan C:\|:\|RCU has served as an advisory board member or consultant for AbbVie, Bristol Myer Squibb, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, Eli Lily, and Pfizer.\|\|Turpin, Williams: No conflict of interest\|\|Lee, Sun-Ho: No conflict of interest\|\|Rui, Shumin: No conflict of interest\|\|Del Valle, Diane Marie: No conflict of interest\|\|Jougon, Julia J: No conflict of interest\|\|Martinez-Delgado, Gustavo: No conflict of interest\|\|Riddle, Mark S: No conflict of interest\|\|Murray, Joseph A:\|:\|JAM reports receiving grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Allakos, Oberkotter, Cour; and consultancy fees from Bionix, Lilly Research Laboratory, Johnson & Johnson, Dr. Schar USA, UCB Biopharma, Celimmune, Intrexon Corporation, Dren Bio, Reistone pharma, Chugai Pharma, Kanyos, Boehringer Ingelheim, Equillium and Torax Medical.\|\|Laird, Renee M: No conflict of interest\|\|Torres, Joana:\|:\|JT received grants from Abbvie and Janssen, payment for lectures from Janssen, Abbvie, and Pfizer, and consulting fees from Janssen, Abbvie, Pfizer, and BMS.\|\|Agrawal, Manasi: No conflict of interest\|\|Magee, Jared S: No conflict of interest\|\|Dervieux, Thierry:\|:\|TD is employee of Prometheus Laboratories and hold stock options.\|\|Gnjatic, Sacha:\|:\|SG reports other research funding from Genentech, Boehringer-Ingelheim, EMD Serono, Takeda, and Regeneron.\|\|Sheppard, Dean:\|:\|DS is a founder of Pliant Therapeutics, receives research funding from AbbVie and is on the Scientific Review Board for Genentech and Amgen.\|\|Sands, Bruce E: No conflict of interest\|\|Porter, Chad K: No conflict of interest\|\|Croitoru, Kenneth: No conflict of interest\|\|Petralia, Francesca: No conflict of interest\|\|Colombel, Jean-Frederic:\|:\|JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development.\|\|Mehandru, Saurabh:\|:\|SM reports receiving research grants from Genentech and Takeda; receiving payment for lectures from Takeda, Genentech, Morphic; and receiving consulting fees from Takeda, Morphic, Ferring and Arena Pharmaceuticals. |

| | |
|---|---|
| DOP17 | Dr. Calafat Sard, Margalida: No conflict of interest\|\|Súria, Carles: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|de Francisco, Ruth: No conflict of interest\|\|Yagüe Caballero, Carmen: No conflict of interest\|\|de la Peña, Luisa: No conflict of interest\|\|Hernández-Camba, Alejandro: No conflict of interest\|\|Marcè, Ainhoa: No conflict of interest\|\|Gallego, Beatriz: No conflict of interest\|\|Martín-Vicente, Noelia: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Iborra, Marisa: No conflict of interest\|\|Guerra, Iván: No conflict of interest\|\|Carrillo-Palau, Marta: No conflict of interest\|\|Madero, Lucía: No conflict of interest\|\|Burgueño, Beatriz: No conflict of interest\|\|Montfort, David: No conflict of interest\|\|Torres, Gisela: No conflict of interest\|\|Teller, Marta: No conflict of interest\|\|Ferrer Rosique, Juan Ángel: No conflict of interest\|\|Vega Villaamil, Pablo: No conflict of interest\|\|Roig, Cristina: No conflict of interest\|\|Ponferrada, Ángel: No conflict of interest\|\|Betoré Glaría, Elena: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|P. Gisbert, Javier: No conflict of interest\|\|Alcaide, Noelia: No conflict of interest\|\|Camps, Blau: No conflict of interest\|\|Legido, Jesús: No conflict of interest\|\|González Vivo, Maria: No conflict of interest\|\|Bosca-Watts, Marta Maia: No conflict of interest\|\|Pérez-Martínez, Isabel: No conflict of interest\|\|Casas Deza, Diego: No conflict of interest\|\|Guardiola, Jordi: No conflict of interest\|\|Arranz Hernández, Laura: No conflict of interest\|\|Navarro, Mercè: No conflict of interest\|\|Gomollon, Fernando: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Mañosa, Míriam: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest |
| DOP18 | Dr. Thomann, Anne: No conflict of interest\|\|Schmitgen, Mike: No conflict of interest\|\|Szabo, Kristina: No conflict of interest\|\|Ebert, Matthias: No conflict of interest\|\|Reindl, Wolfgang: No conflict of interest\|\|Wolf, Christian: No conflict of interest |
| DOP19 | Dr. Attauabi, Mohamed: No conflict of interest\|\|Madsen, Gorm Roager: No conflict of interest\|\|Wewer, Anne Vibeke: No conflict of interest\|\|Bendtsen, Flemming:\|:\|Tillotts, Ferring\|\|Jakobsen, Christian: No conflict of interest\|\|Dorn-Rasmussen, Maria: No conflict of interest\|\|Malham, Mikkel: No conflict of interest\|\|Theede, Klaus:\|:\|Ferring, Janssen, Takeda, Pfizer and Tillotts\|\|Bjerrum, Jacob Tveiten: No conflict of interest\|\|Boysen, Trine: No conflict of interest\|\|Seidelin, Jakob Benedict:\|:\|has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim.\|\|Burisch, Johan:\|:\|reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work. |

| | |
|---|---|
| DOP20 | Jawad, Ali: No conflict of interest\|\|Jansson, Sabine: No conflict of interest\|\|Dr. Malham, Mikkel: No conflict of interest\|\|Wewer, Vibeke: No conflict of interest |
| DOP21 | Mr. Wewer, Mads Damsgaard: No conflict of interest\|\|Jansson, Sabine: No conflict of interest\|\|Malham, Mikkel: No conflict of interest\|\|Burisch, Johan:\|:\|Personal fees from AbbVie, Janssen-Cilag, Celgene, and Pfizer. Grants and personal fees from MSD. Grants and personal fees from Takeda for participating in advisory boards. Grants and personal fees from Tillotts Pharma. Personal fees from Samsung Bioepis. Grants from Bristol Myers Squibb and Novo Nordisk. All unrelated to the work submitted.\|\|Wewer, Vibeke: No conflict of interest |
| DOP22 | Dr. Faye, Adam: No conflict of interest\|\|Allin, Kristine: No conflict of interest\|\|Iversen, Aske: No conflict of interest\|\|Agrawal, Manasi: No conflict of interest\|\|Faith, Jeremiah: No conflict of interest\|\|Colombel, Jean-Frederic: No conflict of interest\|\|Jess, Tine: No conflict of interest |
| DOP23 | Mr. Roukas, Chris: No conflict of interest\|\|Miller , Laura: No conflict of interest\|\|Hamborg, Thomas: No conflict of interest\|\|Gordeev, Vladimir: No conflict of interest\|\|Lindsay, James: No conflict of interest\|\|Norton, Christine:\|:\|Lecture fees from Janssen and Tillotts. \|\|Mihaylova, Borislava: No conflict of interest |
| DOP24 | Mr. Fantodji, Canisius: No conflict of interest\|\|Rousseau, Marie-Claude: No conflict of interest\|\|Nicolau, Belinda: No conflict of interest\|\|Madathil, Sreenath: No conflict of interest\|\|Benedetti, Andrea: No conflict of interest\|\|Jantchou, Prévost: No conflict of interest |
| DOP25 | Dr. Brenner, Erica: No conflict of interest\|\|Zhang, Xian: No conflict of interest\|\|Long, Millie: No conflict of interest\|\|Dubinsky, Marla: No conflict of interest\|\|Kappelman, Michael: No conflict of interest |

| | |
|---|---|
| DOP26 | Gonczi, Lorant: No conflict of interest\|\|Lakatos, Laszlo: No conflict of interest\|\|Golovics, Petra A.: No conflict of interest\|\|Pandur, Tunde: No conflict of interest\|\|David, Gyula: No conflict of interest\|\|Erdelyi, Zsuzsanna: No conflict of interest\|\|Szita, Istvan: No conflict of interest\|\|Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest |
| DOP27 | Dr. Distante, Manuela: No conflict of interest\|\|Rotulo, Silvia: No conflict of interest\|\|Ranalli, Marco: No conflict of interest\|\|Pedace, Eugenio: No conflict of interest\|\|Lionetti, Paolo: No conflict of interest\|\|Arrigo, Serena: No conflict of interest\|\|Alvisi, Patrizia: No conflict of interest\|\|Miele, Erasmo: No conflict of interest\|\|Martinelli, Massimo: No conflict of interest\|\|Zuin, Giovanna: No conflict of interest\|\|Bramuzzo, Matteo: No conflict of interest\|\|Cananzi, Mara: No conflict of interest\|\|Aloi, Marina: No conflict of interest |
| DOP28 | Dr. Jones, Gareth-Rhys: No conflict of interest\|\|Hegarty, Lizi: No conflict of interest\|\|T'Jonck, Wouter: No conflict of interest\|\|Adams, Claire: No conflict of interest\|\|Drury, Broc: No conflict of interest\|\|Byrne, Adam: No conflict of interest\|\|Ho, Gwo-Tzer: No conflict of interest\|\|Bain, Calum: No conflict of interest |
| DOP29 | Ms. Becker, Marte: No conflict of interest\|\|Koelink, Pim: No conflict of interest\|\|Bemelman, Willem: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|Wildenberg, Manon: No conflict of interest |
| DOP30 | Haberman Ziv, Yael: No conflict of interest\|\|Braun, Tzipi: No conflict of interest\|\|Amir, Amnon: No conflict of interest\|\|Levhar, Nina: No conflict of interest\|\|Toren, Itamar: No conflict of interest\|\|Malik, Alona: No conflict of interest\|\|Neuman, Sandra: No conflict of interest\|\|Hadar, Rotem: No conflict of interest\|\|Efroni, Gilat: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest |
| DOP31 | Prof. Gerasimidis, Konstantinos:\|:\|Received funding from Nestle Heath Science\|\|Nichols, Ben: No conflict of interest\|\|Briola, Anny: No conflict of interest\|\|Havlik, Jaroslav: No conflict of interest\|\|Mascellani, Anna: No conflict of interest\|\|Milling, Simon: No conflict of interest\|\|Ijaz, Umer: No conflict of interest\|\|Quince, Christopher: No conflict of interest\|\|Svolos, Vaios: No conflict of interest\|\|Russell, Richard K: No conflict of interest\|\|Hansen, Richard: No conflict of interest |

| | |
|---|---|
| DOP32 | Lin, Sinan: No conflict of interest\|\|Wang, Jie: No conflict of interest\|\|Mukherjee, Pranab: No conflict of interest\|\|Mao, Ren: No conflict of interest\|\|West, Gail: No conflict of interest\|\|Czarnecki, Doug: No conflict of interest\|\|Zhao, Shuai: No conflict of interest\|\|Elias, Michael: No conflict of interest\|\|Nguyen, Quang Tam: No conflict of interest\|\|Chandra, Jyotsna: No conflict of interest\|\|Le, Thi Hong Nga: No conflict of interest\|\|Chen, Mih-hu: No conflict of interest\|\|Dejanovic, Dina: No conflict of interest\|\|Holubar, Stefan: No conflict of interest\|\|Olman, Mitchell: No conflict of interest\|\|Southern, Brian: No conflict of interest\|\|Hu, Shaomin: No conflict of interest\|\|Gordon, Ilyssa O.: No conflict of interest\|\|Atabai, Kamran: No conflict of interest\|\|Fiocchi, Claudio: No conflict of interest\|\|Prof. Rieder, Florian: No conflict of interest |
| DOP33 | Ke, Bo-Jun: No conflict of interest\|\|Abdurahiman, Saeed: No conflict of interest\|\|Biscu, Francesca: No conflict of interest\|\|Verstockt, Sare: No conflict of interest\|\|Verstockt, Bram: No conflict of interest\|\|de Hertogh, Gert: No conflict of interest\|\|Vermeire, Severine: No conflict of interest\|\|Prof. Dr. Matteoli, Gianluca: No conflict of interest |
| DOP34 | Ms. Li, Yue:\|:\|Y.L. has received Care-for-Rare scholarship.\|\|Yu, Ziqi:\|:\|Z.Y. is supported by the China Scholarship Council\|\|Schenk, Madlin: No conflict of interest\|\|Lagovsky, Irena: No conflict of interest\|\|Illig, David: No conflict of interest\|\|Walz, Christoph: No conflict of interest\|\|Rohlfs, Meino: No conflict of interest\|\|Conca, Raffaele: No conflict of interest\|\|Muise, Aleixo:\|:\|A.M. receives grant funding from NIH 5RC2DK122532 and the Helmsley Charitable Trust.\|\|Snapper, Scott:\|:\|S.S. receives grant funding from NIH 5RC2DK122532 and the Helmsley Charitable Trust, and declares the following interests: Scientific advisory board participation for Pfizer, Pandion, Celgene, Lilly, Takeda, Cosmo Pharmaceuticals, Merck, and EcoR1. Grant support from Pfizer, Novartis, Amgen, and Takeda. Consulting for Amgen, Kyverna, Bristol Myers Squibb, Dualyx, Third Rock, Sonoma Biotherapeutics, 89bio, GentiBio and Apple Tree Life Sciences.\|\|Uhlig, Holm:\|:\|H.U. receives grant funding from the Helmsley Charitable Trust and is supported by the Oxford Biomedical research centre.\|\|Garty, Ben: No conflict of interest\|\|Klein, Christoph:\|:\|C.K. receives grant funding from NIH 5RC2DK122532 and the Helmsley Charitable Trust.\|\|Kotlarz, Daniel:\|:\|D.K. has been supported by the Leona M. and Harry B. Helmsley Charitable Trust, DFG (Gottfried-Wilhelm-Leibniz Program, Heinz Maier-Leibnitz-Preis, Collaborative Research Consortium SFB1054 project A05, Research Grant 447562338), PID-NET (BMBF), and the Care-for-Rare Foundation. D.K. has been a scholar funded by the Daimler und Benz Stiftung, Reinhard-Frank Stiftung, and Else-Kroener-Fresenius Stiftung. |

| | |
|---|---|
| DOP35 | Dr. Li, Mengfan: No conflict of interest\|\|Dong, Yue: No conflict of interest\|\|Zhang, Kexin: No conflict of interest\|\|Ma, Jiahui: No conflict of interest\|\|He, Linlin: No conflict of interest\|\|Wei, Jingge: No conflict of interest\|\|Jiang, Jiaying: No conflict of interest\|\|Zhao, Qianjing: No conflict of interest\|\|Zhao, Qing: No conflict of interest\|\|Cao, Hailong: No conflict of interest |
| DOP36 | Dr. Pisani, Laura Francesca: No conflict of interest\|\|Crespi, Giorgia: No conflict of interest\|\|Mellai, Marta: No conflict of interest\|\|Flavio, Caprioli: No conflict of interest\|\|Annunziata, Maria Laura: No conflict of interest\|\|Manfredi, Marcello: No conflict of interest\|\|Luca, Pastorelli: No conflict of interest\|\|Porta, Chiara: No conflict of interest |
| DOP37 | Danese, Silvio:\|:\|received honoraria as a speaker, consultant and/or advisory board member from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB and Vifor Pharma.\|\|Abreu, Maria T.:\|:\|consulted and/or served on an advisory board for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Celsius Therapeutics, Eli Lilly, Gilead, Janssen, Microba, Pfizer, Prometheus Biosciences, UCB Biopharma and WebMD Global; served as a teacher, lecturer or speaker for Alimentiv, Intellisphere (HCP Live Institutional Perspectives in GI), Janssen, Prime CME and Takeda; received grants/research support from Alimentiv, Bristol Myers Squibb and Takeda.\|\|Wolf, Douglas C.:\|:\|received research funding from AbbVie, Bristol Myers Squibb, Genentech, Janssen, Pfizer (Arena) and Takeda; consulted for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer and Takeda; received speaker fees from AbbVie, Bristol Myers Squibb, Janssen and Takeda.\|\|Canavan, James B.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Jain, Anjali:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Petersen, AnnKatrin:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Charles, Lorna:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Panaccione, Remo:\|:\|received consulting fees from AbbVie, Abbott, Alimentiv, Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Mylan, Oppilan Pharma, Pandion Therapeutics, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB and Takeda; received speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire and Takeda; received research/educational support from AbbVie, Ferring, Janssen, Pfizer and Takeda; served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Takeda and Theravance.\|\|Afzali, Anita:\|:\|served as consultant for AbbVie, Bristol Myers Squibb, DiaSorin, Eli Lilly, Gilead, Janssen, Pfizer, Takeda and TLL Pharmaceuticals; received speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer and Takeda. |

| | |
|---|---|
| DOP38 | Colombel, Jean-Frédéric:\|:\|Jean-Frederic Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi, Takeda, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development \|\|Hisamatsu, Tadakazu:\|:\|Tadakazu Hisamatsu has received research grants from AbbVie, Alfresa Pharma, Daiichi Sankyo, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, and Zeria Pharmaceutical; consulting fees from AbbVie, Celgene, EA Pharma, Janssen, Nichi-Iko, and Pfizer; and lecture fees from AbbVie, EA Pharma, Janssen, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, and Takeda.\|\|Bresso , Francessca:\|:\|Francesca Bresso has served as an investigator for clinical trials sponsored by AbbVie, Ferring and Janssen. Dr. Bresso is also a scientific committee member for Janssen. \|\|Thin, Lena:\|:\|Lena Thin is an advisory board member for AbbVie; receives advisory board/steering committees fees for education from AbbVie, Takeda, Janssen, Ferring, BMS, Pfizer, Celltrion, Chiesi; receives research grants from Celltrion, Takeda, Pfizer; and is an executive member of the Australian New Zealand IBD consortium.\|\|Parra, Rogerio:\|:\|Rogerio Parra received lecture fees from AbbVie, Janssen, Takeda, Pfizer, and Abbvie; is advisory committee member for Janssen and AbbVie.\|\|Ford, Sharanya:\|:\|Sharanya Ford is an employee of AbbVie and may own stock options.\|\|Remple, Valencia:\|:\|Valencia Remple is an employee of AbbVie and may own stock options.\|\|Lacerda, Ana Paula:\|:\|Ana Paula Lacerda is an employees of AbbVie and may own stock options.\|\|\|Hecht, Patrick:\|:\|Patrick Hecht is an employee of AbbVie and may own stock options.\|\|Mallick, Madhuja:\|:\|Madhuja Mallickis an employee of AbbVie and may own stock options.\|\|Garrison, Andrew:\|:\|Andrew Garrison is an employee of AbbVie and may own stock options.\|\|Regueiro, Miguel:\|:\|Miguel Regueiro has served as a consultant, speaker, and advisory board member for AbbVie. |

| | |
|---|---|
| DOP39 | Vermeire, Séverine:\|:\|Received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand.\|\|Dignass, Axel:\|:\|Received fees for participation in clinical trials and review activities (ie, data monitoring boards, statistical analysis, and endpoint committees) from AbbVie, Abivax, Celgene/Bristol Myers Squibb, Falk Foundation, Gilead, Janssen, and Pfizer; received consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Eli Lilly, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor; received payment for lectures, including service on speaker bureaus, from AbbVie, Eli Lilly, Falk Foundation, Ferring, Gilead/Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, and Vifor; received payment for development of educational presentations from Ferring and Tillotts.\|\|Colombel, Jean-Frederic:\|:\|Received research grants from AbbVie, Janssen, and Takeda; received payment for lectures from AbbVie, Allergan, Amgen, Bristol Myers Squibb, Ferring Pharmaceuticals, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Immunic, lmtbio, Inotrem, Ipsen, Iterative Scopes, Janssen, Landos, LimmaTech Biologics, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, TiGenix, and Viela Bio; holds stock options in Intestinal Biotech Development.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Lawlor, Garrett:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Osterman, Mark T.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Rubin, David T.:\|:\|Served as a consultant for AbbVie, Celgene, Janssen, Pfizer, and Takeda; received grant support from Takeda.\|\|Regueiro, Miguel:\|:\|Served on advisory boards or as a consultant for AbbVie, Alfasigma, Allergan, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target RWE, and UCB. |

| | |
|---|---|
| DOP40 | Dubinsky, Marla C:\|:\|MCD has been a consultant for AbbVie, Arena, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Merck, Pfizer, Prometheus, Takeda, and UCB; and has received research grants from AbbVie, Janssen, and Prometheus.\|\|D'Haens, Geert:\|:\|GD'H has received honoraria for consulting and/or speaking activities from AbbVie, Alimentiv, Boehringer Ingelheim, Celltrion, Eli Lilly, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Janssen, MSD, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Takeda, and Tillotts.\|\|Dewit, Olivier:\|:\|OD has received consultancy and/or speaking honoraria from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Ferring, Galapagos, Janssen, Merck, Mylan, Pfizer, Sandoz, and Takeda.\|\|Juillerat, Pascal:\|:\|PJ has received a research grant from Vifor and consultancy and/or speaking honoraria from AbbVie, Amgen, Arena, Bristol Myers Squibb, Eli Lilly, Ferring, Gilead, Janssen, MSD, Pfizer, Pierre Fabre, Roche, Sandoz, Takeda, Tillotts, and UCB.\|\|Panaccione, Remo:\|:\|RP has received consultancy and/or speaking honoraria from AbbVie, AI4GI, Amgen, Arena, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai, Elan, Eli Lilly, EnGene, Ferring, Genentech, Gilead, Given Imaging, GlaxoSmithKline, Janssen, Lycera, Meda, Merck, Merck Research, Merck Serono, Novo Nordisk, PDL Biopharma, Pfizer, Prometheus, Protagonist, Receptos, Robarts Clinical Trials, Salix, Soz, Sanofi Genzyme, Shire, Sigmoid, Sublimity, Takeda, and Theravance.\|\|Fujii, Toshimitsu:\|:\|TF has received research grants from AbbVie, Boehringer Ingelheim, Celgene, EA Pharma, Eisai, Eli Lilly, and Gilead; and speaking honoraria from AbbVie, Ajinomoto Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Janssen, Kirin, Kyorin, Kyowa Hakko, Nichiiko, Nippon Kayaku, Kissei Pharma, and Zeria Pharma.\|\|Lacerda, Ana P:\|:\|APL is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Dubcenco, Elena:\|:\|ED is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Anyanwu, Samuel:\|:\|SA is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Doshi, Chirag:\|:\|CD is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Mallick, Madhuja:\|:\|MM is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Garrison, Andrew:\|:\|AG is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Liu, John:\|:\|JL is an employee or contractor of AbbVie, and may own AbbVie stock and/or stock options.\|\|Loftus Jr, Edward V:\|:\|EL has received consultancy honoraria from AbbVie, Amgen, Arena, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Sun Pharma, Surrozen, Takeda, and UCB; and has received research support from AbbVie, Bristol Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. |
| | |

| | |
|---|---|
| DOP41 | Sands, Bruce E.:\|:\|B.E. Sands reports consulting fees from Abivax, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Entera, Evommune, Galapagos, Genentech, Gilead Sciences, GSK, Gossamer Bio, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, Miro Bio, Morphic Therapeutics, MRM Health, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Surrozen, Takeda, Teva, TLL Pharmaceutical, USWM Enterprises, and Viela Bio; speaking fees from Abivax, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and grant/research support from Janssen.\|\|Rubin, David T.:\|:\|D.T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc.\|\|Panés, Julian:\|:\|J. Panés received consulting fees from AbbVie, Arena Pharmaceuticals, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GSK, Janssen, Mirum, Morphic, Nestle, Origo, Pandion, Progenity, Pfizer, Revolo, Robarts, Roche, Takeda, Theravance, and Wassermann; speaker fees from AbbVie, Biogen, Ferring, Janssen, Pfizer, and Takeda; and research funding from AbbVie and Pfizer.\|\|Gecse, Krisztina B.:\|:\|K.B. Gecse has received grants from Pfizer Inc, Celltrion, and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda; and speaker's honoraria from AbbVie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts.\|\|Leung, Yvette:\|:\|Y. Leung has served as a consultant for AbbVie, Bristol Myers Squibb, Janssen Pharmaceuticals, Eli Lilly, Pfizer, and Takeda; and received speaker fees from AbbVie, Pfizer, and Takeda.\|\|Goetsch, Martina:\|:\|M. Goetsch is an employee of Pfizer.\|\|Wang, Wenjin:\|:\|W. Wang is an employee of Pfizer Inc.\|\|Shan, Kevin:\|:\|K. Shan is an employee of Pfizer Inc.\|\|Woolcott, John:\|:\|J. Woolcott is an employee of Pfizer Inc.\|\|Smith, Christina C.:\|:\|C.C. Smith is an employee of Pfizer Inc.\|\|Ms. Wosik, Karolina: No conflict of interest\|\|Schreiber, Stefan Wolfgang:\|:\|S. Schreiber has been a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb; Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresenius, Galapagos, Genentech, GSK, Gilead, I-MAB Biopharma, Janssen, Lilly, Merck, Novartis/Sandoz, Pfizer, Protagonist, Takeda, and Theravance. |

| | |
|---|---|
| DOP42 | Chaparro, Maria:\|:\|Served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Galapagos.\|\|Armuzzi, Alessandro:\|:\|Served on consultant/advisory boards for AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Gilead, Janssen, Lilly, Merck, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz, and Takeda; received speaker fees from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Ferring, Gilead, Janssen, Merck, Mitsubishi Tanabe Pharma, Nikkiso, Novartis, Pfizer, Roche, Samsung Bioepis, and Takeda; received research funding from Merck, Pfizer, and Takeda.\|\|Irving, Peter M.:\|:\|Reports grants and/or personal fees from Takeda, MSD, Pfizer, Galapagos, Gilead, Abbvie, Janssen, Boehringer Ingelheim, Topivert, VH2, Celgene, Arena, Samsung Bioepis, Sandoz, Procise, Prometheus.\|\|Allez, Matthieu:\|:\|Received Honoria from Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Galapagos, Genentech, Gilead, IQVIA, Janssen, Lilly Novartis, Pfizer, Roche, and Takeda, Tillots.\|\|Dubinsky, Marla C.:\|:\|Consulting fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; and is founder and a shareholder of Trellus Health.\|\|Sands, Bruce E.:\|:\|Received consulting fees from Abivax, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Entera, Evommune, Galapagos, Genentech, Gilead Sciences, GSK, Gossamer Bio, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, Miro Bio, Morphic Therapeutics, MRM Health, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Surrozen, Takeda, Teva, TLL Pharmaceutical, USWM Enterprises, and Viela Bio; speaking fees from Abivax, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and grant/research support from Janssen.\|\|Goetsch, Martina:\|:\|Employee of Pfizer, Inc.\|\|Wang, Wenjin:\|:\|Employee of Pfizer Inc.\|\|Shan, Kevin:\|:\|K. Shan is an employee of Pfizer Inc.\|\|Woolcott, John:\|:\|J. Woolcott is an employee of Pfizer Inc.\|\|Bartolome, Lauren:\|:\|L. Bartolome is an employee of Pfizer Inc. \|\|Ms. Wosik, Karolina:\|:\|Employee of Pfizer, Inc. \|\|Panaccione, Remo:\|:\|Reports consulting fees from AbbVie, Abbott, Alimentiv, Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; speaker fees from AbbVie, Arena, Celgene, Ferring, Gilead Sciences, Janssen, Lilly, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; research or educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and has served on advisory boards for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance, and Takeda. |
| | |

| | |
|---|---|
| DOP43 | Dignass, Axel:\|:\|Received fees for participation in clinical trials and review activities (ie, data monitoring boards, statistical analysis, and end point committees) from AbbVie, Celgene/Bristol Myers Squibb, Falk Foundation, Gilead, Janssen, and Pfizer received consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Eli Lilly, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor and received payment for lectures, including service on speaker bureaus, from AbbVie, Eli Lilly, Falk Foundation, Ferring, Gilead/Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, and Vifor received payment for development of educational presentations from Ferring and Tillotts. \|\|Regueiro, Miguel:\|:\|Served on advisory boards and consulted for AbbVie, Alfasigma, Allergan, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Miraca Labs, Pfizer, Prometheus, Seres, Salix, Takeda, Target RWE, and UCB.\|\|Colombel, Jean-Frederic:\|:\|Received research grants from AbbVie, Janssen, and Takeda received payment for lectures from AbbVie, Amgen, Allergan, Bristol Myers Squibb, Ferring, Shire, and Takeda received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Janssen, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, TiGenix, and Viela Bio holds stock options in Intestinal Biotech Development.\|\|Jain, Anjali:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Lawlor, Garrett:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Osterman, Mark T.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Vermeire, Severine:\|:\|Received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand.\|\|Rubin, David T.:\|:\|Received grant support from Takeda consulted for AbbVie, AltruBio, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Genentech/Roche, Gilead, Iterative Scopes, Janssen, Pfizer, Prometheus Biosciences, Takeda, and Techlab. |
| DOP44 | Dr. Singh, Arshdeep: No conflict of interest\|\|Midha, Vandana: No conflict of interest\|\|Mahajan, Ramit: No conflict of interest\|\|Kaur, Kirandeep: No conflict of interest\|\|Singh, Dharmatma: No conflict of interest\|\|Sood, Ajit: No conflict of interest |

| | |
|---|---|
| DOP45 | Dr. Matsuoka, Katsuyoshi:\|:\|Katsuyoshi Matsuoka reports personal fees from AbbVie, Bristol Myers Squibb, Celltrion, EA Pharma, Eli Lilly, Gilead Sciences, Inc., Janssen, JIMRO Co., Ltd., Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd., Pfizer, Takeda Pharmaceutical and Zeria Pharmaceutical and research grants from AbbVie, EA Pharma, JIMRO Co., Ltd., Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku and Takeda Pharmaceutical.\|\|Löwenberg, Mark:\|:\|Mark Löwenberg has served as speaker and/or principal investigator for AbbVie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk Pharma, Ferring Pharmaceuticals, Galapagos NV, Gilead Sciences, Inc., GSK plc, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist Therapeutics, Receptos, Inc., Takeda Pharmaceutical, Tillotts and Tramedico and received research grants from AbbVie, Merck Sharp & Dohme, Dr. Falk Pharma, Achmea Healthcare, Galapagos NV and ZonMw.\|\|Fumery, Mathurin:\|:\|Mathurin Fumery has served as speaker or consultant for AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, CTMA, Eli Lilly, Ferring Pharmaceuticals, Fresenius, Galapagos, Gilead Sciences, Inc., Hospira, Janssen, Merck Sharp & Dohme, Pfizer, Tillotts, Takeda Pharmaceutical and Viatris.\|\|Takatori, Yoshie:\|:\|Yoshie Takatori is an employee of Gilead Sciences K.K. and a shareholder of Gilead Sciences, Inc.\|\|Fujitani, Yasushi:\|:\|Yasushi Fujitani is an employee of Gilead Sciences K.K. and a shareholder of Gilead Sciences, Inc.\|\|Oortwijn, Alessandra:\|:\|Alessandra Oortwijn is an employee and shareholder of Galapagos NV.\|\|Faes, Margaux:\|:\|Margaux Faes is an employee and shareholder of Galapagos NV.\|\|Jamoul, Corinne:\|:\|Corinne Jamoul is a contractor for Galapagos NV.\|\|Hibi, Toshifumi:\|:\|Toshifumi Hibi has received lecture fees from Aspen Japan K.K., Janssen, JIMRO Co., Ltd.,, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd., Pfizer and Takeda Pharmaceutical research grants from AbbVie GK, Activaid, Alfresa Pharma Corporation, Bristol Myers Squibb, Eli Lilly Japan K.K., Ferring Pharmaceuticals, Gilead Sciences, Inc., Janssen Pharmaceutical K.K., JMDC Inc., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc. and Takeda Pharmaceutical scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd. and Zeria Pharmaceutical Co., Ltd. and study group sponsorship from AbbVie GK, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Otsuka Holdings Co., Ltd and Zeria Pharmaceutical Co., Ltd. |
| DOP46 | Bourgonje, Arno: No conflict of interest\|\|Hu, Shixian: No conflict of interest\|\|Gacesa, Ranko: No conflict of interest\|\|Jansen, Bernadien H.: No conflict of interest\|\|Björk, Johannes R.: No conflict of interest\|\|Bangma, Amber: No conflict of interest\|\|Hidding, Iwan J.: No conflict of interest\|\|van Dullemen, Hendrik M.: No conflict of interest\|\|Visschedijk, Marijn C.: No conflict of interest\|\|Faber, Klaas Nico: No conflict of interest\|\|Dijkstra, Gerard: No conflict of interest\|\|Harmsen, Hermie J. M.: No conflict of interest\|\|Festen, Eleonora A. M.: No conflict of interest\|\|Vich Vila, Arnau: No conflict of interest\|\|Spekhorst, Lieke M.: No conflict of interest\|\|Weersma, Rinse K.: No conflict of interest |

| | |
|---|---|
| DOP47 | Ms. Liu, Xinyu: No conflict of interest\|\|Tang, Hao: No conflict of interest\|\|Zhou, Qingyang: No conflict of interest\|\|Zeng, Yanlin: No conflict of interest\|\|Lu, Bo: No conflict of interest\|\|Chen, Minjiang: No conflict of interest\|\|Xu, Yan: No conflict of interest\|\|Wang, Mengzhao: No conflict of interest\|\|Li, Yue: No conflict of interest\|\|Tan, Bei: No conflict of interest\|\|Qian, Jiaming: No conflict of interest |
| DOP48 | Teh, Jing Jie: No conflict of interest\|\|Kang, Seungha: No conflict of interest\|\|Leonard, Alarna: No conflict of interest\|\|Zhang, Jingwan: No conflict of interest\|\|Hu, Jielun: No conflict of interest\|\|Hamilton, Amy L.: No conflict of interest\|\|Wilson-O'Brien, Amy: No conflict of interest\|\|Trakman, Gina L.: No conflict of interest\|\|Lin, Winnie: No conflict of interest\|\|Ching , Jessica: No conflict of interest\|\|Sung, Joseph J.Y.: No conflict of interest\|\|Yu, Jun: No conflict of interest\|\|Ng, Siew C.: No conflict of interest\|\|Kamm, Michael Albert: No conflict of interest\|\|Prof. Morrison, Mark: No conflict of interest |
| DOP49 | Kang, Seungha: No conflict of interest\|\|Teh, Jing Jie: No conflict of interest\|\|Zhang, Jingwan: No conflict of interest\|\|Hu, Jielun: No conflict of interest\|\|Hamilton, Amy L.: No conflict of interest\|\|Wilson-O'Brien, Amy: No conflict of interest\|\|Trakman, Gina L.: No conflict of interest\|\|Lin, Winnie: No conflict of interest\|\|Ching, Jessica: No conflict of interest\|\|Sung, Joseph J.Y.: No conflict of interest\|\|Yu, Jun: No conflict of interest\|\|Ng, Siew C.: No conflict of interest\|\|Kamm, Michael Albert: No conflict of interest\|\|Prof. Morrison, Mark: No conflict of interest |
| DOP50 | Mr. Grellier, Nathan: No conflict of interest\|\|Suzuki, Marcelino: No conflict of interest\|\|Brot, Loïc: No conflict of interest\|\|Rodrigues, Alice: No conflict of interest\|\|Humbert, Lydie: No conflict of interest\|\|Escoubeyrou, Karine: No conflict of interest\|\|Rainteau, Dominique: No conflict of interest\|\|Grill, Jean-Pierre: No conflict of interest\|\|Lami, Raphaël: No conflict of interest\|\|Seksik, Philippe:\|:\|P Seksik declares speaker and consulting fees from Takeda, Merck MSD, Biocodex, Ferring, Janssen, Amgen, Pfizer, Pileje, Fresenius Kabi and Abbvie but has no confict of interest linked to this work. |

| | |
|---|---|
| DOP51 | Ms. Hageman, Ishtu: No conflict of interest\|\|Joustra, Vincent: No conflict of interest\|\|Zafeiropoulou , Konstantina: No conflict of interest\|\|Davids, Mark: No conflict of interest\|\|Hakvoort, Theo: No conflict of interest\|\|Probert, Fay: No conflict of interest\|\|Satsangi, Jack: No conflict of interest\|\|D'Haens, Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|MF\|\|\|De Jonge, Wouter: No conflict of interest |
| DOP52 | Prof. Gerasimidis, Konstantinos: No conflict of interest\|\|Nichols, Ben: No conflict of interest\|\|Papadopoulou, Rodanthi: No conflict of interest\|\|Ijaz, Umer: No conflict of interest\|\|Rajendran, Ranjith: No conflict of interest\|\|Quince, Christopher: No conflict of interest\|\|Russell, Richard K: No conflict of interest\|\|Hansen, Richard: No conflict of interest\|\|Ramage, Gordon: No conflict of interest |
| DOP53 | Mr. Jansen, Daan: No conflict of interest\|\|Falony, Gwen: No conflict of interest\|\|Vieira-Silva, Sara: No conflict of interest\|\|Simsek, Ceren: No conflict of interest\|\|Marcelis, Tine: No conflict of interest\|\|Machiels, Kathleen: No conflict of interest\|\|Caenepeel, Clara: No conflict of interest\|\|Raes, Jeroen: No conflict of interest\|\|Severine, Vermeire: No conflict of interest\|\|Matthijnssens, Jelle: No conflict of interest |
| DOP54 | Dr. Attauabi, Mohamed: No conflict of interest\|\|Steenholdt, Casper: No conflict of interest\|\|Burisch, Johan:\|:\|reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work.\|\|Gubatan, John: No conflict of interest\|\|Nielsen, Ole Haagen: No conflict of interest\|\|Seidelin, Jakob Benedict:\|:\|has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here. |

| | |
|---|---|
| DOP55 | Dr. Burisch, Johan: No conflict of interest |
| DOP56 | Gonczi, Lorant: No conflict of interest\|\|Lakatos, Laszlo: No conflict of interest\|\|Golovics, Petra A.: No conflict of interest\|\|Pandur, Tunde: No conflict of interest\|\|David, Gyula: No conflict of interest\|\|Erdélyi, Zsuzsanna: No conflict of interest\|\|Szita, Istvan: No conflict of interest\|\|Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest |
| DOP57 | Ms. Christensen, Heidi Soegaard: No conflict of interest\|\|Andersen, Diana: No conflict of interest\|\|Jess, Tine: No conflict of interest\|\|Allin, Kristine Højgaard: No conflict of interest |
| DOP58 | Lujan, Rona: No conflict of interest\|\|Atia, Ohad: No conflict of interest\|\|Gili, Focht: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Loewenberg Weisband, Yiska: No conflict of interest\|\|Lederman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris:\|:\|ID - received in the last 3 years consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Genentech/Roche, Neopharm, Ferring, Rafa Laboratories, Falk Pharma, Nestle, Given Imaging/Medtronic, Gilead, Galapagos, Celgene/BMS, Arena, Sublimity, Sangamo, Celltrion, Wilbio, Cambridge Healthcare, Abbott, Food Industries Organization, Altman, Athos \|\|Turner, Dan:\|:\|DT – Last 3 years received consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS |

| | |
|---|---|
| DOP59 | Hart, Ailsa: No conflict of interest\|\|Miller, Laura: No conflict of interest\|\|Hamborg, Thomas: No conflict of interest\|\|Stagg, Imogen: No conflict of interest\|\|McGuinness, Serena: No conflict of interest\|\|Wileman, Vari: No conflict of interest\|\|Tzorovili, Evangelia: No conflict of interest\|\|Mihaylova, Boby: No conflict of interest\|\|Roukas, Chris: No conflict of interest\|\|Aziz, Qasim: No conflict of interest\|\|Czuber-Dochan, Wladzia: No conflict of interest\|\|Dibley, Lesley:\|:\|Speaker fees from Abbvie, Dr Falk, Ferring, Janssen and WedMD; funding to support research from Takeda and Janssen\|\|Moss-Morris, Rona: No conflict of interest\|\|Pollok, Richard: No conflict of interest\|\|Saxena, Sonia: No conflict of interest\|\|Winsor, Gemma: No conflict of interest\|\|Prof. Norton, Christine:\|:\|Speakers fees from Takeda and Janssen. |
| DOP60 | Dr. Banerjee, Rupa: No conflict of interest\|\|Pal, Partha: No conflict of interest\|\|Prakash, Nissi: No conflict of interest\|\|Mudigonda, Shirisha: No conflict of interest\|\|Joseph, Sumitha: No conflict of interest\|\|Patel, Rajendra: No conflict of interest\|\|Khalil, Musab: No conflict of interest\|\|Komawar, Akshay: No conflict of interest\|\|Korikana, Shobha: No conflict of interest\|\|Mekala, Dhanush: No conflict of interest\|\|Akki, Yamunasrivalli: No conflict of interest\|\|Gaddam, Aravind: No conflict of interest\|\|Valluri, Sadhana: No conflict of interest |
| DOP61 | Dr. Boaz, Elad: No conflict of interest\|\|Ledder, Oren: No conflict of interest\|\|Dagan, Amir: No conflict of interest\|\|Lujan, Rona: No conflict of interest\|\|Koslowsky, Benjamin: No conflict of interest\|\|Friss, Chagit: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Loewenberg Weisband , Yisca: No conflict of interest\|\|Lederman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Yellinek, Shlomo: No conflict of interest\|\|Turner, Dan: No conflict of interest |
| DOP62 | Dr. Bonfils, Linéa: No conflict of interest\|\|Karachalia Sandri, Anastasia: No conflict of interest\|\|Juul Poulsen, Gry: No conflict of interest\|\|Agrawal, Manasi: No conflict of interest\|\|Ward, Daniel Joseph: No conflict of interest\|\|Jess, Tine: No conflict of interest\|\|Colombel, Jean-Frederic: No conflict of interest\|\|H. Allin, Kristine: No conflict of interest |

| | |
|---|---|
| DOP63 | Wetwittayakhlang, Panu: No conflict of interest\|\|Gonczi , Lorant: No conflict of interest\|\|Lakatos , Laszlo: No conflict of interest\|\|Golovics , Petra: No conflict of interest\|\|Pandur , Tunde: No conflict of interest\|\|David , Gyula: No conflict of interest\|\|Erdelyi , Zsuzsanna: No conflict of interest\|\|Szita , Istvan: No conflict of interest\|\|Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest |
| DOP64 | Dr. Ashton, James: No conflict of interest\|\|Cheng, Guo: No conflict of interest\|\|Stafford, Imogen: No conflict of interest\|\|Beattie, R Mark: No conflict of interest\|\|Ennis, Sarah: No conflict of interest |
| DOP65 | Dr. Gudiño, Victoria: No conflict of interest\|\|Cho, Jae-Won: No conflict of interest\|\|Corraliza, Ana M: No conflict of interest\|\|Caballol, Berta: No conflict of interest\|\|Garrido-Trigo, Alba: No conflict of interest\|\|Masamunt, M Carme: No conflict of interest\|\|Ordás, Ingrid: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Hemberg, Martin: No conflict of interest\|\|Panés, Julià: No conflict of interest\|\|Salas, Azucena: No conflict of interest |
| DOP66 | Mrs. Bauset, Cristina: No conflict of interest\|\|Carda-Diéguez, Miguel: No conflict of interest\|\|Buetas, Elena: No conflict of interest\|\|Lis-López, Lluis: No conflict of interest\|\|Seco-Cervera, Marta: No conflict of interest\|\|Coll, Sandra: No conflict of interest\|\|Ortiz-Masiá, Dolores: No conflict of interest\|\|Calatayud, Sara: No conflict of interest\|\|Barrachina, Maria Dolores: No conflict of interest\|\|Mira, Álex: No conflict of interest\|\|Cosín-Roger, Jesús: No conflict of interest |
| DOP67 | Dr. Cozzetto, Domenico: No conflict of interest\|\|Lo, Jonathan: No conflict of interest\|\|Powell, Nick: No conflict of interest |

| | |
|---|---|
| DOP68 | Mr. Saha, Kushal: No conflict of interest\|\|Ganapathy, Ashwinkumar Subramenium: No conflict of interest\|\|Wang, Alexandra: No conflict of interest\|\|Morris, Nathan: No conflict of interest\|\|Yochum, Gregory: No conflict of interest\|\|Koltun, Walter: No conflict of interest\|\|Ding, Wei: No conflict of interest\|\|Nighot, Meghali: No conflict of interest\|\|Ma, Thomas: No conflict of interest\|\|Nighot, Prashant: No conflict of interest |
| DOP69 | Rodrigues, Cláudia: No conflict of interest\|\|Gaifem, Joana: No conflict of interest\|\|Pereira, Márcia: No conflict of interest\|\|Lavelle, Aonghus: No conflict of interest\|\|Colombel, Jean-Frederic: No conflict of interest\|\|Sokol, Harry: No conflict of interest\|\|Prof. Dr. Pinho, Salomé: No conflict of interest |
| DOP70 | Dr. Kayal, Maia:\|:\|MK has served as a consultant for GoodRx and Abbvie and receives grant support from NIH-DK127241-01A1, Crohn's and Colitis Foundation and Rainin Foundation.\|\|Tankelevich, Michael: No conflict of interest\|\|Guo, Yin: No conflict of interest\|\|Fischer, Jeremy: No conflict of interest\|\|Jimenez, Darwin: No conflict of interest\|\|Canales-Herrerias, Pablo: No conflict of interest\|\|Livanos, Alexandra: No conflict of interest\|\|Colombel, Jean-Frederic:\|:\|JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development. \|\|Dubinsky, Marla:\|:\|MCD has served as a consultant for Abbvie, Arena Pharmaceuticals, Boehringer Ingelheim International, Bristol-Myers Squibb, Celgene, Eli Lilly, F. Hoffman-La Roche, Genentech, Gilead, Janssen, Pfizer, Prometheus, Takeda, UCB and has research grants from Pfizer, Abbvie, Janssen, and Prometheus.\|\|Faith, Jeremiah: No conflict of interest\|\|Ko, Huaibin: No conflict of interest\|\|Mehandru, Saurabh:\|:\|SM reports receiving research grants from Genentech and Takeda; receiving payment for lectures from Takeda, Genentech, Morphic; and receiving consulting fees from Takeda, Morphic, Ferring and Arena Pharmaceuticals. |

| | |
|---|---|
| DOP71 | Dr. Saifuddin, Aamir: No conflict of interest\|\|Madgwick, Matthew: No conflict of interest\|\|Cozzetto, Domenico: No conflict of interest\|\|Pavlidis, Polychronis: No conflict of interest\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Hart, Ailsa:\|:\|Dr. Hart reports personal fees from Abbvie, personal fees from Allergan, personal fees from BMS, personal fees from Celltrion, personal fees from Falk, personal fees from GSK, personal fees from Takeda, personal fees from Pfizer, personal fees from Janssen, personal fees from Galapogos, personal fees from AstraZeneca, outside the submitted work.\|\|Korcsmaros, Tamas: No conflict of interest\|\|Powell, Nick:\|:\|Dr. Powell reports personal fees from Takeda, personal fees from Janssen, personal fees from Pfizer, personal fees from Bristol-Myers Squibb, personal fees from Abbvie, personal fees from Roche, personal fees from Lilly, personal fees from Allergan, personal fees from Celgene, outside the submitted work; and Dr. Powell has served as a speaker/advisory board member for Abbvie, Allergan, Bristol-Myers Squibb, Celgene, Falk, Ferring, Janssen, Pfizer, Tillotts, Takeda and Vifor Pharma. |
| DOP72 | Ms. Bergstein, Suzannah:\|:\|Suzannah Bergstein is partially funded by the Digestive Disease Research Foundation (DDRF) Fellowship Program.\|\|Spencer, Elizabeth A.:\|:\|Dr. Elizabeth A. Spencer is supported by a grant from the NIH (K23DK125760-01). Elizabeth A. Spencer serves on an advisory board for Prometheus Laboratories. |

| | |
|---|---|
| DOP73 | Wong, Emily C.L.: No conflict of interest\|\|Dulai, Parambir S.:\|:\|Parambir S. Dulai has received consulting and/or research support from Takeda, Pfizer, Janssen, BMS, Gilead, Novartis, Lily; Stock options DigbiHealth; Royalties: PreciDiag.\|\|Marshall, John K.:\|:\|John K. Marshall has received honoraria from Janssen, AbbVie, Allergan, Bristol-Meyer-Squibb, Ferring, Janssen, Lilly, Lupin, Merck, Pfizer, Pharmascience, Roche, Shire, Takeda and Teva.\|\|\|Jairath, Vipul:\|:\|VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx, Vividion; speaker's fees from, Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi\|\|Reinisch, Walter:\|:\|Walter Reinisch has received support for the following:\|Speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, \|Consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, \|Advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC\|\|Dr. Narula, Neeraj:\|:\|Neeraj Narula has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Merck, Sandoz, Novartis, and Ferring. |
| | |

| | |
|---|---|
| DOP74 | Dr. Takabayashi, Kaoru: No conflict of interest\|\|Kobayashi, Taku: No conflict of interest\|\|Matsuoka, Katsutoshi: No conflict of interest\|\|G Levesque, Barrett: No conflict of interest\|\|Kawamura, Takuji: No conflict of interest\|\|Tanaka, Kiyohito: No conflict of interest\|\|Kadota, Takeaki: No conflict of interest\|\|Bise, Ryoma: No conflict of interest\|\|Uchida, Seiichi: No conflict of interest\|\|Kanai, Takanori: No conflict of interest\|\|Ogata, Haruhiko: No conflict of interest |
| DOP75 | Dr. Thurm, Tamar: No conflict of interest\|\|Zmora, Niv: No conflict of interest\|\|Hirsh, Ayal: No conflict of interest\|\|Deutsch, Liat: No conflict of interest\|\|Maharshak, Nitsan: No conflict of interest |
| DOP76 | Dr. Serclova, Zuzana:\|:\|Consulting: Takeda\|\|Tremerova, Aneta: No conflict of interest\|\|Lengalova, Marketa: No conflict of interest\|\|Petra, Zuskova: No conflict of interest |
| DOP77 | Dr. Abdalla, Solafah: No conflict of interest\|\|Benoist, Stephane: No conflict of interest\|\|Maggiori, Leon: No conflict of interest\|\|Lefevre, Jeremie: No conflict of interest\|\|Denost, Quentin: No conflict of interest\|\|Cotte, Eddy: No conflict of interest\|\|Germain, Adeline: No conflict of interest\|\|Beyer-Berjot, Laura: No conflict of interest\|\|Desfourneaux, Veronique: No conflict of interest\|\|Rahili, Amine: No conflict of interest\|\|Duffas, Jean-Pierre: No conflict of interest\|\|Pautrat, Karine: No conflict of interest\|\|Denet, Christine: No conflict of interest\|\|Bridoux, Valérie: No conflict of interest\|\|Meurette, Guillaume: No conflict of interest\|\|Faucheron, Jean-Luc: No conflict of interest\|\|Loriau, Jerome: No conflict of interest\|\|Souche, François-Regis: No conflict of interest\|\|Corte, Helene: No conflict of interest\|\|Zerbib, Philippe: No conflict of interest\|\|Panis, Yves: No conflict of interest\|\|Brouquet, Antoine: No conflict of interest |

| | |
|---|---|
| DOP78 | Alibert, Line: No conflict of interest\|\|Betton, Louis: No conflict of interest\|\|Falcoz, Antoine: No conflict of interest\|\|Manceau, Gilles: No conflict of interest\|\|Benoist, Stéphane: No conflict of interest\|\|Zerbib, Philippe: No conflict of interest\|\|Podevin, Juliette: No conflict of interest\|\|Maggiori, Léon: No conflict of interest\|\|Brouquet, Antoine: No conflict of interest\|\|Tyrode, Gaëlle: No conflict of interest\|\|Vuitton, Lucine: No conflict of interest\|\|Vernerey, Dewi: No conflict of interest\|\|Lefevre, Jérémie: No conflict of interest\|\|Prof. Lakkis, Zaher: No conflict of interest |
| DOP79 | Ms. Mateos, Beatriz: No conflict of interest\|\|Gaite, Adrián: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|M. Marigorta, Urko: No conflict of interest |
| DOP80 | Mrs. Lawal, Ololade: No conflict of interest\|\|Rodriguez-Sosa, Alejandra: No conflict of interest\|\|McDonnell, Ciaran: No conflict of interest\|\|Grant, Luke: No conflict of interest\|\|O'Brien, John: No conflict of interest\|\|Kel, Alexander: No conflict of interest\|\|Dominik, Anna: No conflict of interest\|\|Stack, Roisin: No conflict of interest\|\|Yochum, Gregory: No conflict of interest\|\|Koltun, Walter: No conflict of interest\|\|Doherty, Glen: No conflict of interest\|\|Hussey, Seamus: No conflict of interest |
| DOP81 | Dr. Lee, Ho-Su: No conflict of interest\|\|Lee, Yoonho: No conflict of interest\|\|Baek, Jiwon: No conflict of interest\|\|Kim, Yongjae: No conflict of interest\|\|Park, Sojung: No conflict of interest\|\|Jung, Seulgi: No conflict of interest\|\|Kim, Kyuwon Kim: No conflict of interest\|\|Hwang, Sung Wook: No conflict of interest\|\|Lee, Jong Lyul: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Yang, Suk-Kyun: No conflict of interest\|\|Han, Buhm: No conflict of interest\|\|Song, Kyuyoung: No conflict of interest\|\|Yoon, Yong Sik: No conflict of interest\|\|Ye, Byong Duk: No conflict of interest |

| | |
|---|---|
| DOP82 | Dr. Noor, Nurulamin: No conflict of interest\|\|Sousa, Paula: No conflict of interest\|\|Bettenworth, Dominik:\|:\|Personal fees: MSD, AbbVie, Falk Foundation, janssen-Cilag, Vifor, Ferring, Roche, Tillotts, Pharmacosmos, Pfizer\|\|Gomollon, Fernando: No conflict of interest\|\|Lobaton, Triana:\|:\|Grant: Abbvie, Mylan, MSD, Mundipharma, Biogen, Janssen, Pfizer and Takeda\|Personal Fees: Speaker fees from Ferring, MSD, Abbvie, Janssen, Amgen, Fresenius Kabi and Takeda\|Consultancy Fees: Janssen, Galapagos, Amgen, Bristol Myers Squibb and Fresenius Kab\|\|Bossuyt, Peter:\|:\|Grant: Pfizer, Amgen, Celltrion, Takeda and Mylan\|Personal Fees: Lecture fees from AbbVie, Takeda, Lilly, Celltrion and Janssen\|Advisory board fees: Abbvie, Arena pharmaceuticals, BMS, Celltrion, Takeda, Galapagos, Janssen, Dr Falk, Lilly, Roche and PSI\|\|Casanova, Maria Jose:\|:\|Education fees: Pfizer, Takeda, Janssen, MSD, Ferring and Abbvie\|\|Ding, Nik:\|:\|Personal Fees: Abbvie, Pfizer, BMS, Janssen\|\|Dragoni, Gabriele: No conflict of interest\|\|Furfaro, Federica:\|:\|Grant: IG-IBD\|Personal Fees: Pfizer, Biogen, J&J, Abbvie, Amgen\|\|van Rheenen, Patrick:\|:\|Grant: Innovation Fund Dutch Insurance Companies, Buhlmann Laboratories AG\|Personal Fees: Janssen\|Non-financial Support: Buhlmann Laboratories AG\|\|Chaparro, Maria:\|:\|Grant: MSD, Hospira, Pfizer, Takeda, Janssen\|Personal Fees: Gilead, Pfizer, Faes\|Non-financial Support: Abbvie, Ferring, Dr. Falk Pharma\|\|Gisbert, Javier:\|:\|Grant: MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead/Galapagos, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norg\|\|Louis, Edouard:\|:\|Grant: Abbvie, Takeda, Janssen, Pfizer\|Personal Fees: Abbvie, Takeda, Ferring, Pfizer, Janssen, Lilly, Galapagos, Celltrion, Arena, BMS\|Non-financial Support: Abbvie, Takeda, Ferring\|\|Papamichael, Konstantinos:\|:\|Personal Fees: Lecture fees from Mitsubishi Tanabe Pharma and Physicians Education Resource LLC, consultancy fees from Prometheus Laboratories Inc, and scientific advisory board fees from ProciseDx Inc and Scipher Medicine Corporation |
| DOP83 | Prof. Kang, Ben: No conflict of interest\|\|Moon, Jin Soo: No conflict of interest\|\|Lee, Yeoun Joo: No conflict of interest\|\|Kim, Mi Jin: No conflict of interest\|\|Choe, Byung-Ho: No conflict of interest\|\|Ko, Jae Sung: No conflict of interest\|\|Park, Jae Hong: No conflict of interest\|\|Choe, Yon Ho: No conflict of interest |

| | |
|---|---|
| DOP84 | Sebastian, Shaji:\|:\|Research grants from Takeda, Pfizer, Tillotts Pharma, Abbvie, Biogen, personal fees for Speaker role and advisory board meetings from Janssen, Amgen, Tillotts Pharma, Abbvie, Takeda, Celgene, Roche, Phramacosmos , Falk pharma. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Siegel, Corey:\|:\|Consultant/Advisory Board: Abbvie, BMS, Fresnius, Lilly, Janssen, Pfizer, Takeda; Speaker for CME activities: Abbvie, Janssen, Pfizer, Takeda; Grant support: Abbvie, Janssen, Pfizer, Takeda; Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Siegmund, Britta:\|:\|Consulting fees from: Abbvie, BMS, Boehringer, Falk, Galapagos, Jassen, Lilly, Pfizer, PredictImmeune, Landos, Takeda; Speaker Fees: Abbvie, Falk, Ferring, Janssen, Pfizer, BMS, Takeda, CED Service GmbH, Lilly; Grant: Pfizer. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Zhou, Jie:\|:\|An employee of Takeda and holds Takeda stock or stock options. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Jones, Stephen:\|:\|Consultant to Takeda. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Adsul, Shashi:\|:\|An employee of Takeda and holds Takeda stock or stock options. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Louis, Edouard:\|:\|Research grants/support, educational grants, consultancy fees and/or honoraria (Takeda). This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda. |
| DOP85 | Schulberg, Julien: No conflict of interest\|\|Hamilton, Amy: No conflict of interest\|\|Dr. Wright, Emily Kate: No conflict of interest\|\|Holt, Bronte: No conflict of interest\|\|Lovett, Grace: No conflict of interest\|\|Sutherland, Tom: No conflict of interest\|\|Ross, Alyson: No conflict of interest\|\|Vogrin, Sara: No conflict of interest\|\|Kamm, Michael: No conflict of interest |

| | |
|---|---|
| DOP86 | Colombel, Jean-Frédéric:\|:\|Receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda;\|Receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda;\|Receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; \|Hold stock options in Intestinal Biotech Development\|\|Hanauer, Stephen B.:\|:\|Consultancy from AbbVie, Allergan, Amgen, Arena, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos, Catalys Pacific, Covance, Genentech, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, Takeda, VHsquared, TLL Pharma, UCB Pharma\|Clinical Research for AbbVie, Allergan, Amgen, Celgene, Celltrion, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma\|Speaker for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda\|Independent Data Monitoring Conference for Arena, Boehringer Ingelheim, Bristol Myers Squibb, Gossamer, Prometheus, Protagonist\|\|Sandborn, William:\|:\|Consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv, Beigene, Biora (Progenity), Celltrion, Forbion, Genentech, Gossamer Biosciences, Index Pharmaceuticals, Prometheus Biosciences, Protagonist Therapeutics, Shoreline Biosciences, Vedanta Biosciences, Ventyx Biosciences, Zealand Pharma\|Stock or stock options from BeiGene, Gossamer Bio, Biora (Progenity), Prometheus Biosciences, Prometheus Laboratories, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; \|Employee at Shoreline Biosciences and Ventyx Biosciences\|\|Sands, Bruce E.:\|:\|Consultant/ Speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio\|Stock options from Ventyx Biosciences\|\|Schreiber, Stefan:\|:\|Consultancy and |

| | |
|---|---|
| | personal fees from AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, and Theravance\|\|Danese, Silvio:\|:\|Consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor\|Reports lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda\|\|Kierkus, Jaroslaw: No conflict of interest\|\|Kulynych, Roman: No conflict of interest\|\|Klopocka, Maria: No conflict of interest\|\|Lahat, Adi: No conflict of interest\|\|Gonciarz, Maciej: No conflict of interest\|\|Osipenko, Marina: No conflict of interest\|\|Borzan, Vladimir:\|:\|Consulting: MSD, Abbvie, Viatris, Takeda, Janssen \|\|Kowalski, Maciej: No conflict of interest\|\|Saenko, Daria: No conflict of interest\|\|Sardinov, Ruslan: No conflict of interest\|\|Kim, Sunghyun:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Bae, Yunju:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Lee, Sunhee:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Yang, Siyoung:\|:\|Employee of Celltrion\|\|Lee, Juhyun:\|:\|Employee of Celltrion\|\|Lee, Sang Joon:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Lee, Seul Gi:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Park, GaHee:\|:\|Employee of Celltrion,\|Celltrion share holder |

| | |
|---|---|
| DOP87 | Feagan , B.G.:\|:\| Is a consultant for AbbVie, AbolerIS, AgomAB Therapeutics, Allianthera, Amgen, AnaptysBio, Applied Molecular Transport Inc, Arena Pharma, Avoro Capital Advisors, Atomwise,, BioJamp, Biora Therapeutics, Boehringer-Ingelheim, Boxer, Celsius Therapeutics,Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Duality, EcoR1, Eli Lilly, Equillium, Ermium,, First Wave, First Word Group, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, Hinge Bio, Hot Spot Therapeutics, Index Pharma, Imhotex, Immunic Therapeutics, JAKAcademy, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Landos Biopharma, Leadiant, L.E.K. Consulting, Lenczner Slaght, LifeSci Capital, Lument AB, Millennium, MiroBio, Morgan Lewis, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Orphagen, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Therapeutics and Diagnostics, Play to Know AG, Progenity, Protagonist, PTM Therapeutics, Q32 Bio, Rebiotix, REDX, Roche, Sandoz, Sanofi, Seres Therapeutics, Silverback Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Tigenix, Tillotts, Ventyx Biosciences, VHSquared Ltd., Viatris, Ysios, Ysopia, Zealand Pharma; on the Speakers' Bureau for AbbVie, Janssen, Takeda; and on advisory boards for AbbVie, Amgen, AMT, AnaptysBio, Boehringer-Ingelheim, Celgene/BMS Eli Lilly, Genentech/Roche, Janssen, MiroBio, Origo BioPharma, Pfizer, Prometheus, REDX Pharma, Sanofi, Takeda,Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, GSK, Axio Research\|\|Sands , B.:\|:\| has served as a consultant or received speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio, and stock options from Ventyx Biosciences. \|\| Siegel , C.A.:\|:\|consultant/advisory board, AbbVie, BMS, Fresnius, Lilly, Janssen, Napo, Pfizer, Prometheus, Takeda; speaker for CME activities, AbbVie, Janssen, Pfizer, and Takeda; grant support, AbbVie, Janssen, Pfizer, and Takeda\|\|Dubinsky , M.:\|:\|Has consulted for Janssen, Arena, Abbvie, Astra Zeneca, Merck, Takeda, Pfizer, Genentech, Gilead, Prometheus Lab's, Prometheus Biosciences, Celgene, UCB , Thabor, and has received grant support from Janssen, Abbvie, and |

| | |
|---|---|
| | Prometheus Labs. Share Holder Trellus Health. \|\|Longman , R.:\|:\|consultant for Pfizer and enzymetrics\|\|Sabinho , J.:\|:\|Receives Speaker's fees from; Pfizer, Abbvie, Ferring, Falk, Takeda, Janssen, Fresenius, and Galapagos. Consultancy fees from; Janssen, Ferring, Fresenius, Abbvie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia. Research support from; Galapagos and Viatris. JS is supported by a Senior Clinical researcher grant from the Research foundation – Flanders.\|\|Laurent , O.:\|:\|is an employee of Prometheus Biosciences\|\|Luo , A.:\|:\|is an employee of Prometheus Biosciences\|\|Lu, JD.:\|:\|is an employee of Prometheus Biosciences\|\|Nguyen, D.:\|:\|is an employee of Prometheus Biosciences\|\|Towfic , F.:\|:\|is an employee of Prometheus Biosciences\|\|DuVall, A.:\|:\|No disclousres\|\|Woyranowski , M.:\|:\|No Disclosures\|\|Al Kharrat , H.:\|:\|No disclosures\|\|McGovern, D.P.B.:\|:\|Consultant and Shareholder for Prometheus Biosciences; Consultant for Gilead Sciences, Boehringer-Ingelheim, Pfizer, Prometheus Laboratories, Takeda, Palatin Technologies |
| DOP88 | Dr. Lin, Simeng:\|:\|Meeting support fees from Pfizer and Ferring outside the submitted work.\|\|Hannon, Eilis: No conflict of interest\|\|Waring, Jeffrey F:\|:\|Jeffrey Waring is an employee of AbbVie and may own stock/options.\|\|Reppell, Mark:\|:\|Mark Reppell is an employee of AbbVie and owns stock in the company. \|\|Smaoui, Nizar:\|:\|Nizar Smaoui is an employee of AbbVie and may own stock/options. \|\|Pivorunas, Valerie L:\|:\|Valerie Pivorunas is an employee of AbbVie and may own stock/options. \|\|Guay, Heath:\|:\|Heath Guay is an employee of AbbVie and may own stock/options. \|\|Chanchlani, Neil: No conflict of interest\|\|Bewshea, Claire: No conflict of interest\|\|Bai, Benjamin Y H: No conflict of interest\|\|Kennedy, Nicholas A:\|:\|Nicholas Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, personal fees and non-financial support from Dr Falk, outside the submitted work. \|\|Goodhand, James R:\|:\|James Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik.\|\|Mill, Jonathan: No conflict of interest\|\|Ahmad, Tariq:\|:\|Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, non-financial support from Tillotts, outside the submitted work. |

| | |
|---|---|
| DOP89 | Prof. Fumery, Mathurin: No conflict of interest\|\|Nancey, Stephane: No conflict of interest\|\|Nachury, Maria: No conflict of interest\|\|Allez, Matthieu: No conflict of interest\|\|Rouillon, Cléa: No conflict of interest\|\|Boureille, Arnaud: No conflict of interest\|\|Altwegg, Romain: No conflict of interest\|\|Serrero, Melanie: No conflict of interest\|\|Vuitton, Lucine: No conflict of interest\|\|Bouguen, Guillaume: No conflict of interest\|\|Abitbol, Vered: No conflict of interest\|\|Boualit, Medina: No conflict of interest\|\|Biron, Amelie: No conflict of interest\|\|Panis, Yves: No conflict of interest\|\|Laharie, David: No conflict of interest\|\|Amiot, Aurelien: No conflict of interest\|\|Simon, Marion: No conflict of interest\|\|Caillo, Ludovic: No conflict of interest\|\|Hébuterne, Xavier: No conflict of interest\|\|Vidon, Mathias: No conflict of interest\|\|Benezech, Alban: No conflict of interest\|\|Elgharabawy , Yasmine: No conflict of interest\|\|Peyrin-biroulet, Laurent: No conflict of interest |
| DOP90 | Panaccione, Remo:\|:\|Remo Panaccione reports fees from: AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, Takeda Pharmaceuticals\|\|Speaker Fees: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals; Advisory Board: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma, Takeda Pharmaceuticals\|\|Research/Educational Support: AbbVie, Ferring, Janssen, Pfizer, Takeda. \|\|Sapin, Christophe:\|:\|Christophe Sapin is a Lilly employee and stockholder.\|\|Chan-Diehl, Faye W.:\|:\|Faye W. Chan-Diehl is a Lilly employee and stockholder\|\|Moses, Richard E.:\|:\|Richard E. Moses is a Lilly employee and stockholder.\|\|Siegmund, Britta:\|:\|Britta Siegmund reports consulting fees, payment for lectures and presentations, fees for participation in monitoring boards and fees related to 10Leadership or fiduciary role in other board, society, committee or advocacy group from: Pfizer, Abbvie, BMS, Boehringer, Falk, Ferring, Galapagos, Janssen, Lilly, PredictImmune, Landos, Takeda, CED Service GmbH, President-Elect ECCO\|\|\|Walsh, Alissa:\|:\|Alissa Walsh reports consulting fees and support for attending meetings from Galapagos, Abbvie, Ferring, Janssen\|\|Kobayashi, Taku:\|:\|Taku Kobayashi reports grants or contracts, Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events, payment for expert testimony, participation on a Data Safety Monitoring Board or Advisory Board from: Abbie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc,Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc.,Takeda Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Holdings, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Google Asia Pacific Pte.Ltd., Thermo Fisher Diagnostics K.K, JIMRO Co., Ltd., Janssen Pharmaceutical K.K., Galapagos, KISSEI Pharmaceutical Co., Ltd, Bristol Myers Squibb, Eli Lilly\|\|Parambir, Dulai S.:\|:\|Parambir S. Dulai reports grants or contracts, royalties or licences, consulting fees, stock or stock options from: Takeda, Janssen, Pfizer, PreciDiag, Abbvie, BMS, Lilly, Digbihealth\|\|\|Travis, Simon:\|:\|Simon Travis reports: grants from Ferring, AbbVie, Schering-Plough, MSD, Procter & Gamble, Warner Chilcott, International Organisation of IBD, ECCO, |

| | |
|---|---|
| | UCB, Vifor, Norman Collison Foundation, Takeda Pharmaceutical Co. Ltd, Janssen, Pfizer Inc, Lilly; Other: Abacus; AbbVie; Actial; ai4gi; Alcimed; Allergan; Amgen; Aptel; Arena Pharmaceuticals; Asahi Kasei Pharma; Aspen; Astellas; Atlantic; AstraZeneca; Barco; Biocare; Biogen; BL Pharma; Boehringer Ingelheim; BMS; Buhlmann; Calcico; Celgene Corporation; Cellerix; Cerimon; ChemoCentryx; Chiesi; CisBio; ComCast; Coronado; Cosmo; Ducentis; Dynavax; Elan; Enterome; Equillium; Dr Falk Pharma; Ferring; FPRT Bio; Galapagos; Genentech/Roche; Genzyme; Gilead; Glenmark; Grunenthal; GSK; GW Pharmaceuticals; Immunocore; Immunometabolism; Indigo; Janssen; Lexicon; Lilly; Medarex; Medtrix; Merck; Merrimack; Mestag; Millenium; Neovacs; Novartis; Novo Nordisk; NPS-Nycomed; Ocera; Optima; Origin; Otsuka; Palau; Pentax; Pfizer Inc; PharmaVentures; Phesi; Phillips; P&G; Pronota; Proximagen; Resolute; Robarts; Sandoz; Santarus; Satisfai; Sensyne Health; Shire; Sigmoid Pharma; Sorriso; Souffinez; Syndermix; Synthon; Takeda Pharmaceutical Co. Ltd; Theravance; TiGenix; Tillotts; Topivert; Trino Therapeutics with Welcome Trust; TxCell; UCB Pharma; Vertex; VHsquared; Vifor; Warner Chilcott and Zeria. |
| P001 | Dr. Santo, Julien:\|:\|Julien Santo is an Abivax employee\|\|Gineste, Paul:\|:\|Paul Gineste is an Abivax employee\|\|Scherrer, Didier:\|:\|Didier Scherrer is an Abivax employee\|\|Nitcheu, Josianne:\|:\|Josianne Nitcheu is an Abivax employee\|\|Ehrlich, Hartmut:\|:\|Hartmut Ehrlich is an Abivax employee\|\|Sands, Bruce E:\|:\|Bruce E Sands has served as a consultant or received speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio, and stock options from Ventyx Biosciences.\|\|Vermeire, Séverine:\|:\|Abivax, AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, GenentechRoche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. |

| | |
|---|---|
| P002 | Mr. Bajaj, Aditya: No conflict of interest\|\|Markandey, Manasvini: No conflict of interest\|\|Vuyyuru, Sudheer: No conflict of interest\|\|Mohta, Srikant: No conflict of interest\|\|Singh, Mukesh: No conflict of interest\|\|Verma, Mahak: No conflict of interest\|\|Kumar, Sambuddha: No conflict of interest\|\|Kante, Bhaskar: No conflict of interest\|\|Kumar, Peeyush: No conflict of interest\|\|Makharia, Govind: No conflict of interest\|\|Kedia, Saurabh: No conflict of interest\|\|Travis, Simon: No conflict of interest\|\|Ahuja, Vineet: No conflict of interest |
| P003 | Mrs. Pallikkunnath James, Jaslin: No conflict of interest\|\|Riis, Lene Buhl: No conflict of interest\|\|Malham, Mikkel: No conflict of interest\|\|Høgdall, Estrid: No conflict of interest\|\|Langholz, Ebbe: No conflict of interest\|\|Nielsen, Boye S: No conflict of interest |
| P004 | Ms. Levhar, Nina: No conflict of interest\|\|Hadar, Rotem: No conflict of interest\|\|Braun, Tzipi: No conflict of interest\|\|Efroni, Gilat: No conflict of interest\|\|Abramovich, Ifat: No conflict of interest\|\|Gottlieb, Eyal: No conflict of interest\|\|Granot, Maya: No conflict of interest\|\|Sandra, Neuman: No conflict of interest\|\|Selinger, Limor: No conflict of interest\|\|Picard, Orit: No conflict of interest\|\|Yavzori, Miri: No conflict of interest\|\|Lahat, Adi: No conflict of interest\|\|Eliakim, Rami: No conflict of interest\|\|Weiss, Batia: No conflict of interest\|\|Kopylov, Uri: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Amir, Amnon: No conflict of interest\|\|Haberman Ziv, Yael: No conflict of interest |

| | |
|---|---|
| P005 | Mrs. Seyed Tabib, Nasim Sadat: No conflict of interest\|\|Verstockt, Sare: No conflict of interest\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|\|Sabino, Joao:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring. João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|\|Vermeire, Severine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. Séverine Vermeire holds a BOF-FKO from the KU Leuven. |
| P006 | Ms. Feng, Zelin: No conflict of interest\|\|Wang, Xiaoli: No conflict of interest\|\|Kang, Guangbo: No conflict of interest\|\|Zhao, Jingwen: No conflict of interest\|\|Ye, Yulin: No conflict of interest\|\|Liu, Limin: No conflict of interest\|\|Huang, He: No conflict of interest\|\|Cao, Xiaocang: No conflict of interest |
| P007 | Ms. Fitzpatrick, Jessica: No conflict of interest\|\|Gibson, Peter R: No conflict of interest\|\|Taylor, Kirstin M: No conflict of interest\|\|Halmos, Emma P: No conflict of interest |

| | |
|---|---|
| P008 | Ms. Jacobs, Inge: No conflict of interest\|\|Ke, Bo-Jun: No conflict of interest\|\|Cremer, Jonathan: No conflict of interest\|\|D'Hoore, André: No conflict of interest\|\|Bislenghi, Gabriele:\|:\|Gabriele Bislenghi receives speakers' fees from Galapago, Janssen and Takeda.\|\|Matteoli, Gianluca: No conflict of interest\|\|De Hertogh, Gert:\|:\|Gert De Hertogh receives fees for his activities as central pathology reader from Centocor and receives speakers' fees from Janssen\|\|Sabino, Joao:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring.\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Breynaert, Christine: No conflict of interest\|\|Vanuytsel, Tim:\|:\|Reports financial support for research from Danone and MyHealth; has served on the Speaker bureau for Abbott, Fresenius Kabi, Kyowa Kirin, Menarini, Remedus, Takeda and Will Pharma; consultancy fees from Baxter, Dr. Falk Pharma, Takeda, Tramedico, Truvion, VectivBio and Zealand Pharma.\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. |

| | |
|---|---|
| P009 | Ms. Ullrich, Karen: No conflict of interest\|\|Derdau, Julia: No conflict of interest\|\|Baltes, Carsten: No conflict of interest\|\|Rosso, Gonzalo: No conflict of interest\|\|Uderhardt, Stefan: No conflict of interest\|\|Schulze, Lisa Lou: No conflict of interest\|\|Liu, Li-Juan: No conflict of interest\|\|Dedden, Mark: No conflict of interest\|\|Spocinska, Marta: No conflict of interest\|\|Kainka, Lucina: No conflict of interest\|\|Kubánková, Markéta:\|:\|MK is co-founder of Rivercyte GmbH, a company that develops biomedical applications for RT-DC.\|\|Müller, Tanja M.: No conflict of interest\|\|Schmidt, Nina-Maria: No conflict of interest\|\|Becker, Emily: No conflict of interest\|\|Atreya, Imke: No conflict of interest\|\|Neurath-Finotto, Susetta: No conflict of interest\|\|Prots, Iryna: No conflict of interest\|\|Weigmann, Benno: No conflict of interest\|\|López-Posadas, Rocío: No conflict of interest\|\|Atreya, Raja: No conflict of interest\|\|Ekici, Arif B.: No conflict of interest\|\|Lautenschläger, Franziska: No conflict of interest\|\|Guck, Jochen:\|:\|JG is co-founder of Rivercyte GmbH, a company that develops biomedical applications for RT-DC.\|\|Neurath, Markus F.:\|:\|MFN has served as an advisor for Pentax, Giuliani, MSD, Abbvie, Janssen, Takeda and Boehringer. MFN received research support from Takeda, Shire (a part of Takeda) and Roche.\|\|Zundler, Sebastian:\|:\|SZ received honoraria from Takeda, Roche, Galapagos, Ferring, Lilly and Janssen. SZ received research support from Takeda, Shire (a part of Takeda) and Roche. |
| P011 | Frias, Javier: No conflict of interest\|\|Derksen, Merel: No conflict of interest\|\|Verissimo, Carla S: No conflict of interest\|\|van Dooremalen, Wies T M: No conflict of interest\|\|Oldenburg, Bas: No conflict of interest\|\|Vries, Robert G J: No conflict of interest\|\|Boj, Sylvia F: No conflict of interest\|\|Pourfarzad, Farzin: No conflict of interest\|\|Dr. Pott, Johanna: No conflict of interest |
| P012 | Dr. Seco-Cervera, Marta: No conflict of interest\|\|Argilés-Arberola, Diego: No conflict of interest\|\|Bauset, Cristina: No conflict of interest\|\|Lis-López, Lluis: No conflict of interest\|\|Coll, Sandra: No conflict of interest\|\|Cosín-Roger, Jesús: No conflict of interest\|\|Ortiz-Masià, Dolores: No conflict of interest\|\|Calatayud, Sara: No conflict of interest\|\|Barrachina, Maria Dolores: No conflict of interest |

| | |
|---|---|
| P013 | Ms. Hecker, Julia: No conflict of interest\|\|Saurenbach, Judith: No conflict of interest\|\|Letizia, Marilena: No conflict of interest\|\|Löscher , Britt-Sabina: No conflict of interest\|\|Franke, Andre: No conflict of interest\|\|Kühl, Anja A.: No conflict of interest\|\|Atreya, Raja: No conflict of interest\|\|Koop, Kristina: No conflict of interest\|\|Neufert, Clemens: No conflict of interest\|\|Trajanoski , Zlatko: No conflict of interest\|\|Schütz, Anja: No conflict of interest\|\|Siegmund, Britta:\|:\|B.S. has served as consultant for Abbvie, Arena, BMS, Boehringer, Celgene, Falk, Janssen, Lilly, Pfizer, Prometheus, and Takeda and received speaker's fees from Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Pfizer, and Takeda (served as a representative of the Charité).\|\|Weidinger, Carl: No conflict of interest |
| P014 | Dr. Truyens, Marie: No conflict of interest\|\|Lernout, Hannah: No conflict of interest\|\|Vandendriessche, Charysse: No conflict of interest\|\|Bruggeman, Arnout: No conflict of interest\|\|Xie, Junhua: No conflict of interest\|\|De Vos, Martine: No conflict of interest\|\|Vermeirssen, Vanessa: No conflict of interest\|\|Vandenbroucke, Roosmarijn: No conflict of interest\|\|Laukens, Debby: No conflict of interest |
| P015 | Wils, Pauline: No conflict of interest\|\|Mehta, Heena: No conflict of interest\|\|rubio, Manuel: No conflict of interest\|\|Sarfati, Marika: No conflict of interest\|\|Dr. Chapuy, Laurence: No conflict of interest |
| P016 | Mr. Nascimento, Roberto De Paula Do: No conflict of interest\|\|Rizzato, Julia Soto: No conflict of interest\|\|Polezi, Gabriele: No conflict of interest\|\|Moya, Amanda Maria Tomazini Munhoz: No conflict of interest\|\|Silva, Milena Ferreira: No conflict of interest\|\|Franchi Junior, Gilberto Carlos: No conflict of interest\|\|Borguini, Renata Galhardo: No conflict of interest\|\|Santiago, Manuela Cristina Pessanha de Araújo: No conflict of interest\|\|Paiotti, Ana Paula Ribeiro: No conflict of interest\|\|Pereira, José Aires: No conflict of interest\|\|Martinez, Carlos Augusto Real: No conflict of interest\|\|Marostica Junior, Mario Roberto: No conflict of interest |

| | |
|---|---|
| P017 | Dan, Stav: No conflict of interest\|\|Dr. Ungar, Bella: No conflict of interest\|\|Ben-Moshe, Shani: No conflict of interest\|\|Bahar Halpern, Keren: No conflict of interest\|\|Yavzori, Miri: No conflict of interest\|\|Fudim, Ella: No conflict of interest\|\|Picard, Orit: No conflict of interest\|\|Abitbol, Chaya Mushka: No conflict of interest\|\|Harnik, Sivan: No conflict of interest\|\|Kopylov, Uri: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Itzkovitz, Shalev: No conflict of interest |
| P018 | Mr. Koga Ito, Henrique Toshiaki: No conflict of interest\|\|Lice , Izabella: No conflict of interest\|\|R. S. Sasso, Gisela: No conflict of interest\|\|Artigiani, Ricardo: No conflict of interest\|\|D. Gil, Cristiane: No conflict of interest |
| P019 | Dr. Holani, Ravi: No conflict of interest\|\|Bar-Yoseph, Haggai: No conflict of interest\|\|Krekhno, Zakhar: No conflict of interest\|\|Moon, Kyung-Mee: No conflict of interest\|\|Stacey, R Greg: No conflict of interest\|\|Serapio-Palacios, Antonio: No conflict of interest\|\|Bressler, Brian: No conflict of interest\|\|Donald, Katherine: No conflict of interest\|\|Foster, Leonard J: No conflict of interest\|\|Finlay, B Brett: No conflict of interest |
| P020 | Dr. Kramer, Catharina: No conflict of interest\|\|Ziegler, Jörn: No conflict of interest\|\|Alzain, Nadra: No conflict of interest\|\|Schroeter, Sabine: No conflict of interest\|\|Almalla, Ahed: No conflict of interest\|\|Elomaa, Laura: No conflict of interest\|\|Addante, Annalisa: No conflict of interest\|\|Kuppe, Aditi: No conflict of interest\|\|Fentker, Kerstin: No conflict of interest\|\|Nazat Martinez Medina, Jennifer: No conflict of interest\|\|Jarquin-Diaz, Victor Hugo: No conflict of interest\|\|Rulff, Hanna: No conflict of interest\|\|Gradzielski, Michael: No conflict of interest\|\|Forslund, Sofia: No conflict of interest\|\|Mertins, Philipp: No conflict of interest\|\|Mall, Marcus: No conflict of interest\|\|Weinhart, Marie: No conflict of interest\|\|Glauben, Rainer: No conflict of interest\|\|Siegmund, Britta: No conflict of interest |

| | |
|---|---|
| P021 | Dr. Spathakis, Michail: No conflict of interest\|\|Dovrolis, Nikolas: No conflict of interest\|\|Tarapatzi, Gesthimani: No conflict of interest\|\|Filidou , Eirini: No conflict of interest\|\|Kandilogiannakis, Leonidas: No conflict of interest\|\|Valatas, Vassilis: No conflict of interest\|\|Drygiannakis, Ioannis: No conflict of interest\|\|Manolopoulos, Vangelis G.: No conflict of interest\|\|Kolios, George: No conflict of interest\|\|Arvanitidis, Konstantinos: No conflict of interest\|\|Vradelis, Stergios: No conflict of interest |
| P022 | Dr. Łukawska, Agata: No conflict of interest\|\|Mulak, Agata: No conflict of interest |
| P023 | Mr. Suau, Roger: No conflict of interest\|\|Pardina, Eva: No conflict of interest\|\|López-Tejero, María Dolores: No conflict of interest\|\|Lorén, Violeta: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|Llaves, Mariona: No conflict of interest\|\|Cordobilla, Begoña: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Guasch, Montserrat: No conflict of interest\|\|Ricart-Jané, David: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|Domingo, Joan Carles: No conflict of interest\|\|Manyé, Josep: No conflict of interest |
| P024 | Ms. Soleto, Irene: No conflict of interest\|\|Ramirez, Cristina: No conflict of interest\|\|Gómez, Cristina: No conflict of interest\|\|Montse, Baldan: No conflict of interest\|\|García, Sara: No conflict of interest\|\|Orejudo, Macarena: No conflict of interest\|\|Mecado, Jorge: No conflict of interest\|\|Chaparro, Maria: No conflict of interest\|\|P. Gisbert, Javier: No conflict of interest |
| P025 | Dr. Csomor, Eszter: No conflict of interest\|\|Gehrmann, Ulf: No conflict of interest\|\|Monkley, Sue: No conflict of interest\|\|Tian, Sun: No conflict of interest\|\|Cairns, Junmei: No conflict of interest\|\|Angermann, Bastian: No conflict of interest\|\|Khan, Emon: No conflict of interest\|\|Nys, Josquin: No conflict of interest\|\|Marks, Daniel: No conflict of interest |

| | |
|---|---|
| P026 | Elgart, Jorge:\|:\|Jorge Elgart has received consulting and speaker honorariums from pharmaceutical industry including Abbvie\|\|Balderramo, Sergio:\|:\|Domingo Balderramo has received consulting and speaker fees from Abbvie, Takeda and Janssen.\|\|Calvi, Guido:\|:\|Guido Calvi is an employee of AbbVie Inc. and may own AbbVie stock or stock options.\|\|Kanevsky, Diego:\|:\|Diego Kanevsky is an employee of AbbVie Argentina and may own AbbVie stock or stock options.\|\|Dr. Sánchez Gonzalez, Yuri:\|:\|Yuri Sanchez Gonzalez is an employee of AbbVie Inc. and may own AbbVie stock or stock options. |
| P027 | Dr. Costache, Roxana: No conflict of interest\|\|Dimitriu, Anca: No conflict of interest\|\|Les, Anda: No conflict of interest\|\|Gheorghe, Cristian: No conflict of interest |
| P028 | Mr. Hilley, Patrick: No conflict of interest\|\|Wong, Darren: No conflict of interest\|\|Ma, Ronald: No conflict of interest\|\|Peterson, Adam: No conflict of interest\|\|De Cruz, Peter:\|:\|PDC is supported by a NHMRC Emerging Leader Fellowship and has received research funding from Janssen, AbbVie, Takeda, Celltrion, Shire, Ferring and Baxter. |
| P029 | Mr. Nielsen, Malte Hasle: No conflict of interest\|\|Zachariassen, Line Fisker: No conflict of interest\|\|Sárvári, Anitta Kinga: No conflict of interest\|\|Marstrand-Jørgensen, Adam Bøgh: No conflict of interest\|\|Hansen, Henrik H.: No conflict of interest\|\|Feigh, Michael: No conflict of interest |

| | |
|---|---|
| P030 | Ms. Norman, Evangeline: No conflict of interest\|\|Hoque, Sami: No conflict of interest |
| P031 | Lee, Jae-Young: No conflict of interest\|\|Ma, Hyun Woo: No conflict of interest\|\|Kim, Ji Hyung: No conflict of interest\|\|Park, I Seul: No conflict of interest\|\|Son, Mijeong: No conflict of interest\|\|Ryu, Keun Ho: No conflict of interest\|\|Shin, Jieun: No conflict of interest\|\|Kim, Won Ho: No conflict of interest\|\|Dr. Kim, Seung Won: No conflict of interest\|\|Cheon, Jae Hee: No conflict of interest |
| P032 | Mrs. Bronze, Mariana: No conflict of interest\|\|Vilstrup Johansen, Jens: No conflict of interest\|\|Attauabi, Mohamed: No conflict of interest\|\|Tveiten Bjerrum, Jacob: No conflict of interest\|\|Ramírez Galera, Marina: No conflict of interest\|\|Woetmann, Anders: No conflict of interest\|\|Benedict Seidelin, Jakob:\|:\|Jakob Benedict Seidelin has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. |
| P033 | Dr. Bertani, Lorenzo: No conflict of interest\|\|Antonioli, Luca: No conflict of interest\|\|Fornili, Marco: No conflict of interest\|\|D'Antongiovanni, Vanessa: No conflict of interest\|\|Coppini, Francesca: No conflict of interest\|\|Ceccarelli, Linda: No conflict of interest\|\|Carmisciano, Luca: No conflict of interest\|\|Benvenuti, Laura: No conflict of interest\|\|Mumolo, Maria Gloria: No conflict of interest\|\|Bottari, Andrea: No conflict of interest\|\|Baglietto, Laura: No conflict of interest\|\|Bellini, Massimo: No conflict of interest\|\|Fornai, Matteo: No conflict of interest\|\|De Bortoli, Nicola: No conflict of interest\|\|Costa, Francesco: No conflict of interest |
| P034 | Dr. Clough, Jennie: No conflict of interest\|\|Roberts, Luke: No conflict of interest\|\|Goldberg, Rimma: No conflict of interest\|\|Lord, Graham: No conflict of interest\|\|Irving, Peter: No conflict of interest |

| | |
|---|---|
| P035 | Tirosh, Osnat:\|:\|Works at Biomica Ltd.\|\|Meshner, Shiri:\|:\|Works at Biomica Ltd.\|\|Eshar, Shiri:\|:\|Works at Biomica Ltd.\|\|Kruger Ben-Shabat, Sheerli:\|:\|Works at Biomica Ltd.\|\|Polonski, Omri:\|:\|Works at Biomica Ltd.\|\|Haber, Elran:\|:\|Works at Biomica Ltd.\|\|Liu, Bo: No conflict of interest\|\|Herzog, Jeremy: No conflict of interest\|\|Sartor, R. Balfour:\|:\|Advisor for Biomica Ltd.\|\|Prof. Ringel, Yehuda:\|:\|Co-founder and works at Biomica Ltd. |
| P036 | Dr. Baldan-Martin, Montserrat: No conflict of interest\|\|Lloro, Ibon: No conflict of interest\|\|Azkargorta, Mikel: No conflict of interest\|\|Ramírez, Cristina: No conflict of interest\|\|Soleto Fernández, Irene: No conflict of interest\|\|Orejudo, Macarena: No conflict of interest\|\|García, Sara: No conflict of interest\|\|Mercado, Jorge: No conflict of interest\|\|Gordillo, Carlos Humberto: No conflict of interest\|\|Riestra, Sabino: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Fernández-Salazar, Luis: No conflict of interest\|\|Ceballos, Daniel: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Bastón-Rey, Iria: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|Lorente, Rufo: No conflict of interest\|\|Ber, Yolanda: No conflict of interest\|\|Royo, Vanesa: No conflict of interest\|\|Esteve, María: No conflict of interest\|\|Elortza, Félix: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest\|\|Chaparro, María: No conflict of interest |
| P037 | Dr. Moniruzzaman, Md: No conflict of interest\|\|Rewatkar, Prarthana: No conflict of interest\|\|Begun, Jakob: No conflict of interest\|\|Popat, Amirali: No conflict of interest |
| P038 | Marti-Chafer, Sara: No conflict of interest\|\|Jimenez-Mallen, Ester: No conflict of interest\|\|Mendoza, Teresa: No conflict of interest\|\|Macias-Ceja, Dulce Carolina: No conflict of interest\|\|Bauset, Cristina: No conflict of interest\|\|Seco-Cervera, Marta: No conflict of interest\|\|Calatayud, Sara: No conflict of interest\|\|Cosin-Roger, Jesus: No conflict of interest\|\|Barrachina, Maria Dolores: No conflict of interest\|\|Prof. Dr. Ortiz-Masiá, Dolores: No conflict of interest |

| | |
|---|---|
| P039 | Dr. Al-Ani, Aysha: No conflict of interest\|\|Samson, Andre: No conflict of interest\|\|Rickard, James: No conflict of interest\|\|Christensen, Britt: No conflict of interest\|\|Murphy, James: No conflict of interest |
| P040 | Singh, Raminder: No conflict of interest\|\|Rossini, Valerio: No conflict of interest\|\|Stockdale , Stephen: No conflict of interest\|\|Draper, Lorraine: No conflict of interest\|\|Hill, Colin: No conflict of interest\|\|Nally, Ken: No conflict of interest\|\|Shanahan, Fergus: No conflict of interest\|\|Andersson-Engels, Stefan: No conflict of interest\|\|Dr. Melgar, Silvia: No conflict of interest |
| P041 | Dr. Drygiannakis, Ioannis: No conflict of interest\|\|Tzenaki, Niki: No conflict of interest\|\|Archontoulaki, Evaggelia: No conflict of interest\|\|Filidou, Eirini: No conflict of interest\|\|Kandilogiannakis, Leonidas: No conflict of interest\|\|Valatas, Vassilios: No conflict of interest\|\|Kolios, George: No conflict of interest\|\|Koutroubakis, Ioannis E.: No conflict of interest |
| P042 | Alsøe, Lene: No conflict of interest\|\|Lefol, Yohan: No conflict of interest\|\|Wennerström, Anna Berit: No conflict of interest\|\|Liu, Yan: No conflict of interest\|\|Andersen, Solveig Norheim: No conflict of interest\|\|Klepp, Pasquale: No conflict of interest\|\|Dr. Brackmann, Stephan: No conflict of interest\|\|Nilsen, Hilde: No conflict of interest |
| P043 | Dr. Dotti, Isabella: No conflict of interest\|\|Álvarez, Iris: No conflict of interest\|\|Esteller, Míriam: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Salas, Azucena: No conflict of interest |

| | |
|---|---|
| P044 | Dr. Baldan-Martin, Montserrat: No conflict of interest\|\|Rubín de Célix, Cristina: No conflict of interest\|\|Orejudo, Macarena: No conflict of interest\|\|Ortega, Lorena: No conflict of interest\|\|Fernández-Tomé, Samuel: No conflict of interest\|\|Soleto, Irene: No conflict of interest\|\|Ramírez, Cristina: No conflict of interest\|\|Arroyo, Ricardo: No conflict of interest\|\|Fernández, Paloma: No conflict of interest\|\|Santander, Cecilio: No conflict of interest\|\|Moreno-Monteagudo, José Andrés: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|Casals, Fernando: No conflict of interest\|\|Casabona, Sergio: No conflict of interest\|\|Becerro, Irene: No conflict of interest\|\|Marigorta, Urko M: No conflict of interest\|\|Aransay, Ana M.: No conflict of interest\|\|Bernardo, David: No conflict of interest\|\|Chaparro, María: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest |
| P045 | Ms. Sebbagh, Anna: No conflict of interest\|\|Mathieu, Noëlle: No conflict of interest\|\|Demarquay, Christelle: No conflict of interest\|\|Geiger, Mallia: No conflict of interest\|\|Sémont, Alexandra: No conflict of interest\|\|Simon, Camille:\|:\|Camille Simon is employed by the spin-off EVerZom.\|\|Branchu, Julien:\|:\|Julien Branchu is employed by the spin-off EVerZom.\|\|Milliat, Fabien: No conflict of interest\|\|Gazeau, Florence:\|:\|Florence Gazeau is a co-founder of the spin-off Evora Biosciences.\|\|Wilhelm, Claire:\|:\|Claire Wilhelm is a co-founder of the spin-offs EVerZom and Evora Biosciences.\|\|Silva Brun, Amanda:\|:\|Amanda Silva Brun is a co-founder of the spin-offs EVerZom and Evora Biosciences.\|\|Rahmi, Gabriel:\|:\|Gabriel Rahmi is a co-founder of the spin-off Evora Biosciences. |
| P046 | Ms. Levhar, Nina: No conflict of interest\|\|Hadar, Rotem: No conflict of interest\|\|Braun, Tzipi: No conflict of interest\|\|Efroni, Gilat: No conflict of interest\|\|Abramovich, Ifat: No conflict of interest\|\|Gottlieb, Eyal: No conflict of interest\|\|Granot, Maya: No conflict of interest\|\|Neuman, Sandra: No conflict of interest\|\|Selinger, Limor: No conflict of interest\|\|Picard, Orit: No conflict of interest\|\|Yavzori, Miri: No conflict of interest\|\|Lahat, Adi: No conflict of interest\|\|Eliakim, Rami: No conflict of interest\|\|Weiss, Batia: No conflict of interest\|\|Kopylov, Uri: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Amir, Amnon: No conflict of interest\|\|Haberman Ziv, Yael: No conflict of interest |

| | |
|---|---|
| P047 | Mr. Manna, Subhakankha: No conflict of interest\|\|Sehn, Maximillian: No conflict of interest\|\|Cardoso da Silva, Danielle: No conflict of interest\|\|Heldt, Claudia: No conflict of interest\|\|Horstkorte, Lillith: No conflict of interest\|\|Elezkurtaj, Sefer: No conflict of interest\|\|Siegmund, Britta: No conflict of interest\|\|Weixler, Benjamin: No conflict of interest\|\|Hummel, Michael: No conflict of interest\|\|Gröne, Jörn: No conflict of interest\|\|Schumann, Michael: No conflict of interest |
| P048 | Dr. Haag, Lea Maxie: No conflict of interest\|\|Walling, Sonja: No conflict of interest\|\|Kunkel, Desirée: No conflict of interest\|\|Hecker, Julia: No conflict of interest\|\|Letizia, Marilena: No conflict of interest\|\|Huck, Adrian: No conflict of interest\|\|Weidinger, Carl: No conflict of interest\|\|Glauben, Rainer: No conflict of interest\|\|Kuehl, Anja: No conflict of interest\|\|Siegmund, Britta: No conflict of interest |
| P049 | Ms. Soleto, Irene: No conflict of interest\|\|Baldan, Montse: No conflict of interest\|\|Ramírez, Cristina: No conflict of interest\|\|Orejudo, Macarena: No conflict of interest\|\|García, Sara: No conflict of interest\|\|Mercado, Jorge: No conflict of interest\|\|Azkargorta, Mikel: No conflict of interest\|\|Lloro, Ibon: No conflict of interest\|\|Ortega Moreno, Lorena: No conflict of interest\|\|Aldars Garcia, Laila: No conflict of interest\|\|Riestra, Sabino: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Fernández, Luis: No conflict of interest\|\|Ceballos, Daniel: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Bastón Rey, Iria: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|Lorente, Rufo: No conflict of interest\|\|Ber, Yolanda: No conflict of interest\|\|Ginard, Daniel: No conflict of interest\|\|Esteve, María: No conflict of interest\|\|Elortza, Felix: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest\|\|Martin-Cofreces, Noa: No conflict of interest\|\|Chaparro, María: No conflict of interest |
| P050 | Prof. Dr. Byeon, Ju Ran: No conflict of interest\|\|Song, Eun Mi: No conflict of interest\|\|Joo, Yang Hee: No conflict of interest\|\|Park, Yehyun: No conflict of interest\|\|Shim , Ki-Nam: No conflict of interest\|\|Choe, A Reum: No conflict of interest\|\|Tae, Chung Hyun: No conflict of interest\|\|Kim, Seong-Eun: No conflict of interest\|\|Moon, Chang Mo: No conflict of interest\|\|Jung, Hye-Kyung: No conflict of interest\|\|Hong, Ji Teak: No conflict of interest\|\|Jung, Sung-Ae: No conflict of interest |

| | |
|---|---|
| P051 | Dr. Meringer, Hadar: No conflict of interest\|\|Canales-Herrerias, Pablo: No conflict of interest\|\|Jha, Divya: No conflict of interest\|\|Livanos, Alexandra: No conflict of interest\|\|Jougon, Julia: No conflict of interest\|\|Cossarini, Francesca: No conflict of interest\|\|Tankelevich, Michael: No conflict of interest\|\|Kayal, Maia: No conflict of interest\|\|Colombel, Jean-Frederic: No conflict of interest\|\|Mehandru, Saurabh: No conflict of interest |
| P052 | Ms. Heredia, Maud: No conflict of interest\|\|Barendregt, Daniëlle M.H.: No conflict of interest\|\|van den Bogaerdt, Sanne: No conflict of interest\|\|Samsom, Janneke N.: No conflict of interest |
| P053 | Dr. Lord, James: No conflict of interest\|\|Konecny, Andrew: No conflict of interest\|\|Shows, Donna: No conflict of interest |
| P054 | Dr. Corcoran, Roisin: No conflict of interest\|\|O'Connell, Fiona: No conflict of interest\|\|O'Sullivan, Jacintha: No conflict of interest\|\|Kevans, David: No conflict of interest |
| P055 | Dr. Qian, Wenwei: No conflict of interest\|\|Li, Yi: No conflict of interest\|\|Zhu, Weiming: No conflict of interest |
| P056 | Dr. Haberman Ziv, Yael: No conflict of interest\|\|Feng, Rui: No conflict of interest\|\|Mao, Ren: No conflict of interest\|\|Braun, Tzipi: No conflict of interest\|\|Zhuo, Shuoyu: No conflict of interest\|\|Toren, Itamar: No conflict of interest\|\|Efroni, Gilat: No conflict of interest\|\|Malik, Alona: No conflict of interest\|\|Picard, Orit: No conflict of interest\|\|Yavzori, Miri: No conflict of interest\|\|Hadar, Rotem: No conflict of interest\|\|Amir, Amnon: No conflict of interest\|\|Chen, Minhu: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest |

| | |
|---|---|
| P057 | Mr. Khater, Georges: No conflict of interest\|\|Noguier, Guillaume: No conflict of interest\|\|Daviere, Simon: No conflict of interest\|\|Guilbert, Virginie: No conflict of interest\|\|Montaillier, Christophe: No conflict of interest |
| P058 | Soleto, Irene: No conflict of interest\|\|C. Marin, Alicia: No conflict of interest\|\|Mora, Irene: No conflict of interest\|\|Villagrasa, Jose Ramon: No conflict of interest\|\|Baldan-Martin, Montse: No conflict of interest\|\|Ramírez, Cristina: No conflict of interest\|\|Bernardo, David: No conflict of interest\|\|Chaparro, María: No conflict of interest\|\|P. Gisbert, Javier: No conflict of interest |
| P059 | Ms. Karaliute, Indre: No conflict of interest\|\|Tilinde, Deimante: No conflict of interest\|\|Ramonaite, Rima: No conflict of interest\|\|Kupcinskas, Juozas: No conflict of interest\|\|Misiunas, Audrius: No conflict of interest\|\|Denkovskiene, Erna: No conflict of interest\|\|Gleba, Yuri: No conflict of interest\|\|Razanskiene, Ausra: No conflict of interest\|\|Skieceviciene, Jurgita: No conflict of interest |
| P060 | Tsounis, Efthymios: No conflict of interest\|\|Geramoutsou, Christina: No conflict of interest\|\|Aggeletopoulou, Ioanna: No conflict of interest\|\|Lourida, Theoni: No conflict of interest\|\|Pastras, Ploutarchos: No conflict of interest\|\|Theocharis, Georgios: No conflict of interest\|\|Diamantopoulou, Georgia: No conflict of interest\|\|Zolota, Vasiliki: No conflict of interest\|\|Assimakopoulos, Stelios F: No conflict of interest\|\|Bravou, Vasiliki: No conflict of interest\|\|Thomopoulos, Konstantinos: No conflict of interest\|\|Prof. Triantos, Christos: No conflict of interest |

| | |
|---|---|
| P061 | Dr. Canales-Herrerias, Pablo: No conflict of interest\|\|Uzzan*, Mathieu: No conflict of interest\|\|Seki*, Akihiro: No conflict of interest\|\|Czepielewski, Rafael S.: No conflict of interest\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Dunn, Alexandra: No conflict of interest\|\|Dai, Daniel: No conflict of interest\|\|Ko, Huaibin M.: No conflict of interest\|\|Furtado, Glaucia C.: No conflict of interest\|\|Tokuyama, Minami: No conflict of interest\|\|Tankelevich, Michael: No conflict of interest\|\|Meringer, Hadar: No conflict of interest\|\|Cossarini, Francesca: No conflict of interest\|\|Jha, Divya: No conflict of interest\|\|Paulsen, John D.: No conflict of interest\|\|Nakadar, M. Zuber: No conflict of interest\|\|Wong, Joshua: No conflict of interest\|\|Sharma, Keshav: No conflict of interest\|\|Rosenstein, Adam: No conflict of interest\|\|Dawson, Travis: No conflict of interest\|\|Singh, Harpriya: No conflict of interest\|\|Lim, Jean: No conflict of interest\|\|Lira, Sergio A.: No conflict of interest\|\|Yajnik, Vijay: No conflict of interest\|\|Reboldi, Andrea: No conflict of interest\|\|Petralia, Francesca: No conflict of interest\|\|Vermeire, Severine: No conflict of interest\|\|Polydorides, Alexandros D.: No conflict of interest\|\|Randolph, Gwendalyn J.: No conflict of interest\|\|Colombel , Jean Frederic: No conflict of interest\|\|Mehandru, Saurabh: No conflict of interest |
| P062 | González Cueto, Elizabeth: No conflict of interest\|\|Matthew, Edmans: No conflict of interest\|\|Dr. Wellens, Judith: No conflict of interest\|\|Martinez Pazos, Vicky: No conflict of interest\|\|Thompson, Craig: No conflict of interest\|\|Klenerman, Paul: No conflict of interest\|\|Cadwell, Ken: No conflict of interest\|\|Colombel, Jean-Frédéric:\|:\|Dr. Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development.\|\|Satsangi, Jack:\|:\|Lecture fees from Roche. Research funding from the Helmsley Trust, European Commission, ECCO, Action Medical Research, Crohn's Colitis UK. Director UK IBD Registry.\|\|Wong, Serre-Yu: No conflict of interest |

| | |
|---|---|
| P063 | Dr. De Salvo, Carlo: No conflict of interest\|\|Wargo, Hannah: No conflict of interest\|\|Vidmar, Kaylynn: No conflict of interest\|\|Di Martino, Luca: No conflict of interest\|\|Mahabaleshwar, Ganapati: No conflict of interest\|\|Cominelli, Fabio: No conflict of interest\|\|Ghannoum, Mahmoud: No conflict of interest\|\|Pizarro, Theresa: No conflict of interest |
| P064 | Nugteren, Sandrine: No conflict of interest\|\|Ms. Calado, Beatriz: No conflict of interest\|\|Simons-Oosterhuis, Ytje: No conflict of interest\|\|H. Hulleman-van Haaften, Danielle: No conflict of interest\|\|Klomberg, Renz: No conflict of interest\|\|Tuk, Bastiaan: No conflict of interest\|\|Charrout, Mohammed: No conflict of interest\|\|J. Lindenbergh-Kortleve, Dicky: No conflict of interest\|\|K. Smits, Willem: No conflict of interest\|\|Doukas, Michail: No conflict of interest\|\|A. Sanders, Mathijs: No conflict of interest\|\|van Beek, Gregory: No conflict of interest\|\|C. Escher, Johanna: No conflict of interest\|\|de Ridder, Lissy: No conflict of interest\|\|N. Samsom, Janneke: No conflict of interest |
| P065 | Kappel-Latif, Sonja: No conflict of interest\|\|Kotagiri, Prasanti: No conflict of interest\|\|Schuld, Gabor: No conflict of interest\|\|Schlager, Lukas: No conflict of interest\|\|Walterskirchen, Natalie: No conflict of interest\|\|Schimek, Vanessa: No conflict of interest\|\|Jobst, Johanna: No conflict of interest\|\|Murthy, Supriya: No conflict of interest\|\|Messner, Barbara: No conflict of interest\|\|Lyons, Paul A.: No conflict of interest\|\|Oehler, Rudolf: No conflict of interest\|\|Bergmann, Michael: No conflict of interest\|\|Stift, Anton: No conflict of interest\|\|Dr. Unger, Lukas: No conflict of interest |
| P066 | Dr. Ferhat, Maroua: No conflict of interest\|\|Mangano, Katia: No conflict of interest\|\|Nicoletti, Ferdinando: No conflict of interest\|\|Landlinger, Christine: No conflict of interest\|\|Michael, Thiele: No conflict of interest |

| | |
|---|---|
| P067 | Dr. Weber, Marie-Christin: No conflict of interest\|\|Schmidt, Konstantin: No conflict of interest\|\|Buck, Annalisa: No conflict of interest\|\|Kasajima, Atsuko: No conflict of interest\|\|Becker, Simon: No conflict of interest\|\|Wilhelm, Dirk: No conflict of interest\|\|Friess, Helmut: No conflict of interest\|\|Neumann, Philipp-Alexander: No conflict of interest |
| P068 | Dr. Meyer, Moritz: No conflict of interest\|\|Grabherr, Felix: No conflict of interest\|\|Schwärzler, Julian: No conflict of interest\|\|Mayr, Lisa: No conflict of interest\|\|Jukic, Almina: No conflict of interest\|\|Rao, Zhigang: No conflict of interest\|\|Rieder, Dietmar: No conflict of interest\|\|Zollner, Andreas: No conflict of interest\|\|Grander, Christoph: No conflict of interest\|\|Trajanoski, Zlatko: No conflict of interest\|\|Koeberle, Andreas: No conflict of interest\|\|Tilg, Herbert: No conflict of interest\|\|Adolph, Timon Erik: No conflict of interest |
| P069 | Ms. Barendregt, Danielle: No conflict of interest\|\|Joosse, Maria E.: No conflict of interest\|\|Alexander, Katie L.: No conflict of interest\|\|Costes, Lea M.M.: No conflict of interest\|\|Tindemans, Irma: No conflict of interest\|\|Simons-Oosterhuis, Ytje: No conflict of interest\|\|Aardoom, Martine A.: No conflict of interest\|\|Klomberg, Renz C.W.: No conflict of interest\|\|Heredia, Maud: No conflict of interest\|\|Hulleman- van Haaften, Daniëlle H.: No conflict of interest\|\|Tuk, Bastiaan: No conflict of interest\|\|Nugteren, Sandrine: No conflict of interest\|\|Doukas, Michail: No conflict of interest\|\|Escher, Johanna C.: No conflict of interest\|\|de Ridder, Lissy: No conflict of interest\|\|Elson, Charles O.: No conflict of interest\|\|Samsom, Janneke N.: No conflict of interest |
| P070 | Dr. Olbei, Marton: No conflict of interest\|\|Modos, Dezso: No conflict of interest\|\|Cozzetto, Domenico: No conflict of interest\|\|Powell, Nicholas:\|:\|Dr. Powell reports personal fees from Takeda, personal fees from Janssen, personal fees from Pfizer, personal fees from Bristol-Myers Squibb, personal fees from Abbvie, personal fees from Roche, personal fees from Lilly, personal fees from Allergan, personal fees from Celgene, outside the submitted work; and Dr. Powell has served as a speaker/advisory board member for Abbvie, Allergan, Bristol-Myers Squibb, Celgene, Falk, Ferring, Janssen, Pfizer, Tillotts, Takeda and Vifor Pharma.\|\|Korcsmaros, Tamas: No conflict of interest |

| | |
|---|---|
| P071 | Mr. Wiese, Jakob Johann: No conflict of interest\|\|Fascì, Alberto: No conflict of interest\|\|Kühl, Anja A.: No conflict of interest\|\|Atreya, Raja: No conflict of interest\|\|Patankar, Jay: No conflict of interest\|\|Siegmund, Britta: No conflict of interest\|\|Prüß, Magdalena S.: No conflict of interest\|\|Schumann, Michael: No conflict of interest |
| P072 | Dr. Swanson, Garth: No conflict of interest\|\|Shaikh, Maliha: No conflict of interest\|\|Keshavarzian, Ali: No conflict of interest\|\|Scheer, Frank: No conflict of interest |
| P073 | Lindenthal, Daniel: No conflict of interest\|\|Kranzeder, Alexandra: No conflict of interest\|\|Hirning, Christian: No conflict of interest\|\|von Wietersheim, Jörn: No conflict of interest\|\|Klaus, Jochen: No conflict of interest |
| P074 | Prof. Hong, Sung Noh: No conflict of interest\|\|Lee, Chansu: No conflict of interest\|\|Kim, Ji Eun: No conflict of interest\|\|Kim, Eun Ran: No conflict of interest\|\|Chang, Dong Kyung: No conflict of interest\|\|Kim, Young-Ho: No conflict of interest |
| P075 | Mr. Schmidt, Konstantin: No conflict of interest\|\|Li, Chunqiao: No conflict of interest\|\|Buck, Annalisa: No conflict of interest\|\|Wilhelm, Dirk: No conflict of interest\|\|Friess, Helmut: No conflict of interest\|\|Weber, Marie-Christin: No conflict of interest\|\|Neumann, Philipp-Alexander: No conflict of interest |

| | |
|---|---|
| P076 | Dr. Van Thiel, Isabelle: No conflict of interest\|\|Maasland, Troy: No conflict of interest\|\|van Wassenaer, Elsa: No conflict of interest\|\|Hoekman, Daniël: No conflict of interest\|\|Spooren, Corinne: No conflict of interest\|\|Hakvoort, Theodorus: No conflict of interest\|\|Admiraal, Iris: No conflict of interest\|\|Theelen, Bart: No conflict of interest\|\|Levin, Evgeni: No conflict of interest\|\|Benninga, Marc: No conflict of interest\|\|Jonkers, Daisy: No conflict of interest\|\|D'Haens, Geert:\|:\|Reports being a consultant or speaker for AbbVie, Alimentiv Boehringer Ingelheim, Celltrion, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Janssen, Lilly, MSD, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Progenity, Takeda, Tillotts.\|\|Rosendahl, Soren: No conflict of interest\|\|Boekhout, Teun: No conflict of interest\|\|Hagen, Ferry: No conflict of interest\|\|de Jonge, Wouter: No conflict of interest\|\|van den Wijngaard, René: No conflict of interest |
| P077 | Dr. Mori, Ryota: No conflict of interest\|\|Ogino, Takayuki: No conflict of interest\|\|Sekido, Yuki: No conflict of interest\|\|Hata, Tsuyoshi: No conflict of interest\|\|Hamabe, Atsushi: No conflict of interest\|\|Takahashi, Hidekazu: No conflict of interest\|\|Miyoshi, Norikatsu: No conflict of interest\|\|Uemura, Mamoru: No conflict of interest\|\|Mizushima, Tsunekazu: No conflict of interest\|\|Doki, Yuichiro: No conflict of interest\|\|Eguchi, Hidetoshi: No conflict of interest |
| P078 | Mr. Walaas, Gunnar A: No conflict of interest\|\|Gopalakrishnan, Shreya: No conflict of interest\|\|Bakke, Ingunn: No conflict of interest\|\|Skovdahl, Helene Kolstad: No conflict of interest\|\|Flatberg, Arnar: No conflict of interest\|\|Østvik, Ann Elisabet: No conflict of interest\|\|Sandvik, Arne Kristian: No conflict of interest\|\|Bruland, Torunn: No conflict of interest |

| | |
|---|---|
| P079 | Ms. Deleu, Sara: No conflict of interest\|\|Trindade de Carvalho , Bruna:\|:\|Inventor on a patent application (EP 22153700.4.) that has been submitted by VIB on the commercial exploitation of the results.\|\|Jacobs, Inge: No conflict of interest\|\|Arnauts, Kaline: No conflict of interest\|\|Deprez, Lowie: No conflict of interest\|\|Vissers , Eva: No conflict of interest\|\|Lenfant, Matthias: No conflict of interest\|\|De Hertogh, Gert:\|:\|Fee for activities as central pathology reader from Centocor. Speaker's fees: Janssen\|\|Huys, Geert: No conflict of interest\|\|Thevelein, Johan:\|:\|Inventor on a patent application (EP 22153700.4.) that has been submitted by VIB on the commercial exploitation of the results and owner/managing director of NovelYeast bv with commercial interest in engineered Sb. \|\|Raes, Jeroen:\|:\|Financial support for research: Danone, Nestle, MRM health, Prodigest, Janssen Pharmaceuticals, Cargill, Beneo. Consulting and/or speaking fees: Yakult, Tsumura, Dr Falk Pharma, GSK, MRM health, Biofortis, Ferring, Merck, Nutricia, Takeda, Janssen Pharmaceuticals.\|\|Vermeire, Séverine:\|:\|Financial support for research: AbbVie, J&J, Pfizer, and Takeda. Consulting and/or speaking fees: AbbVie, Arena Pharmaceuticals, Avaxia, Boehringer Ingelheim, Celgene, Dr Falk pharma, Ferring, Galapagos, Genentech-Roche, Gilead, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Takeda, Theravance, and Tillots Pharma AG. |
| P080 | Labes, Sapir: No conflict of interest\|\|Tabach, Yuval: No conflict of interest\|\|Matar, Manar: No conflict of interest\|\|Shamir, Raanan: No conflict of interest\|\|Shouval, Dror S.: No conflict of interest\|\|Froy, Oren: No conflict of interest\|\|Dr. Weintraub, Yael: No conflict of interest |
| P081 | Prof. Dr. Maccalli, Cristina: No conflict of interest\|\|Gupta, Ishita: No conflict of interest\|\|Toufiq, Mohammed: No conflict of interest\|\|Habib, Tanwir: No conflict of interest\|\|Mathew, Rebecca: No conflict of interest\|\|Shobha Manjunath, Harshitha: No conflict of interest\|\|Missous, Ghalia Noria: No conflict of interest\|\|Mifsud, William: No conflict of interest\|\|Charles, Adrian: No conflict of interest\|\|Ammar, Adham A.: No conflict of interest\|\|Tomei, Sara: No conflict of interest\|\|van Panhuys, Nicholas: No conflict of interest\|\|Al-Kaabi, Saad: No conflict of interest\|\|Akobeng, Anthony: No conflict of interest\|\|Al-Mohannadi, Muneera Jassim: No conflict of interest\|\|Elawad, Mamoun: No conflict of interest |

| | |
|---|---|
| P082 | Dr. Gehrmann, Ulf: No conflict of interest\|\|Csomor, Eszter:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Monkley, Sue:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Georgi, Benjamin:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Tian, Sun:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Cairns, Junmei:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Angermann, Bastian:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Khan, Emon:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Nys, Josquin:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Marks, Daniel:\|:\|Employee of AstraZeneca and holds AZ stock. |
| P083 | Calviño Suárez, Cristina: No conflict of interest\|\|Martinez-Rodriguez, Anton L.: No conflict of interest\|\|Baston-Rey, Iria: No conflict of interest\|\|Moreira-Alvarez, David: No conflict of interest\|\|Ferreiro-Iglesias, Rocio: No conflict of interest\|\|Ardao-Palacios, Ines: No conflict of interest\|\|de la Iglesia-Garcia, Daniel: No conflict of interest\|\|Porto-Silva, Sol: No conflict of interest\|\|Nieto-Garcia, Laura: No conflict of interest\|\|Varela-Liste, Maria J.: No conflict of interest\|\|Brea-Floriani, Jose M.: No conflict of interest\|\|Dominguez-Munoz, J. Enrique: No conflict of interest\|\|Loza-Garcia, Mabel: No conflict of interest\|\|Dr. Barreiro-de Acosta, Manuel: No conflict of interest |
| P084 | Ms. Becker, Marte: No conflict of interest\|\|Heuthorst, Lianne: No conflict of interest\|\|van Roest, Manon: No conflict of interest\|\|van der Bilt, Jarmila: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|Wildenberg, Manon: No conflict of interest |
| P085 | Ms. Inčiūraitė, Rūta: No conflict of interest\|\|Gedgaudas, Rolandas: No conflict of interest\|\|Lukosevicius, Rokas: No conflict of interest\|\|Plingyte, Kornelija: No conflict of interest\|\|Muskieta, Tomas: No conflict of interest\|\|Juzenas, Simonas: No conflict of interest\|\|Kupcinskas, Juozas: No conflict of interest\|\|Skieceviciene, Jurgita: No conflict of interest |
| P086 | Prof. Dr. Kim, Sang Hyun: No conflict of interest\|\|Jeen, Yoon Tae: No conflict of interest\|\|Jeon, Han Jo: No conflict of interest\|\|Kim , Eun Sun: No conflict of interest\|\|Keum, Bora: No conflict of interest\|\|Chun, Hoon Jai: No conflict of interest |

| | |
|---|---|
| P087 | Ms. Pascual, Marta: No conflict of interest\|\|Gárate, Gabriel: No conflict of interest\|\|Serrano, María Soledad: No conflict of interest\|\|García García, María José: No conflict of interest\|\|Castro, Beatriz: No conflict of interest\|\|González Quintanilla, Vicente: No conflict of interest\|\|Crespo, Javier: No conflict of interest\|\|Pascual, Julio: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest |
| P088 | Dr. Jeong, Eui Sun: No conflict of interest\|\|Bae, Seryun: No conflict of interest\|\|Song, Eun Mi: No conflict of interest\|\|Byeon, Ju Ran: No conflict of interest\|\|Lee, Ayoung: No conflict of interest\|\|Choe, A Reum: No conflict of interest\|\|Hong, Ji Teak: No conflict of interest\|\|Park, Ye Hyun: No conflict of interest\|\|Tae, Chung Hyun: No conflict of interest\|\|Moon, Chang Mo: No conflict of interest\|\|Jung, Hye-kyung: No conflict of interest\|\|Shim, Ki-Nam: No conflict of interest\|\|Jung, Sung-Ae: No conflict of interest\|\|Kim, Seong-Eun: No conflict of interest |
| P089 | Dr. McShane, Cathy: No conflict of interest\|\|Corcoran, Roisin: No conflict of interest\|\|O'Connell, Fiona: No conflict of interest\|\|McDonagh, Padraic: No conflict of interest\|\|O'Sullivan, Jacintha: No conflict of interest\|\|Kevans, David: No conflict of interest |
| P090 | Mr. Mendieta Escalante, Erick Arturo: No conflict of interest\|\|Dijkstra, Gerard: No conflict of interest\|\|Faber, Klaas Nico: No conflict of interest\|\|Yamamoto Furusho, Jesus Kazuo: No conflict of interest\|\|Barrera-Vargas, Ana: No conflict of interest\|\|Torres-Ruiz, Jose J: No conflict of interest\|\|Merayo-Chalico, Francisco: No conflict of interest |
| P091 | Kranzeder, Alexandra: No conflict of interest\|\|Lindenthal, Daniel: No conflict of interest\|\|Hirning, Christian: No conflict of interest\|\|von Wietersheim, Jörn: No conflict of interest\|\|Klaus, Jochen: No conflict of interest |

| | |
|---|---|
| P092 | Mrs. Rizzo, Giulia: No conflict of interest\|\|Pineda Chavez, Samuel Elias: No conflict of interest\|\|Vandenkoornhuyse, Elisa: No conflict of interest\|\|Cardenas, Cindy: No conflict of interest\|\|Cento, Valeria: No conflict of interest\|\|Meanti, Lisa: No conflict of interest\|\|Roda, Giulia: No conflict of interest\|\|Loy, Laura: No conflict of interest\|\|Dal Buono, Arianna: No conflict of interest\|\|Gabbiadini, Roberto: No conflict of interest\|\|Lovisa, Sara: No conflict of interest\|\|Rusconi, Roberto: No conflict of interest\|\|Repici, Alessandro: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest\|\|Vetrano, Stefania: No conflict of interest |
| P093 | Le, Thi Hong Nga: No conflict of interest\|\|Mao, Ren: No conflict of interest\|\|Liu, WeiWei: No conflict of interest\|\|Czarnecki, Doug: No conflict of interest\|\|Chandra, Jyotsna: No conflict of interest\|\|Gordon, Ilyssa O.: No conflict of interest\|\|Plesec, Thomas: No conflict of interest\|\|Wang, Jie: No conflict of interest\|\|Lin, Sinan: No conflict of interest\|\|Zhao, Shuai: No conflict of interest\|\|Dejanovic, Dina: No conflict of interest\|\|Mukherjee, Pranab: No conflict of interest\|\|West, Gail: No conflict of interest\|\|Fiocchi, Claudio: No conflict of interest\|\|Brown, Jonathan Mark: No conflict of interest\|\|Prof. Rieder, Florian: No conflict of interest |
| P094 | Ms. Wada, Haruka: No conflict of interest\|\|Miyoshi, Jun: No conflict of interest\|\|Kuronuma, Satoshi: No conflict of interest\|\|Hibi, Noritaka: No conflict of interest\|\|Nishinarita, Yuu: No conflict of interest\|\|Oguri, Noriaki: No conflict of interest\|\|Matsuura, Minoru: No conflict of interest\|\|Takeuchi, Osamu: No conflict of interest\|\|Kobayashi, Taku: No conflict of interest\|\|Akimoto, Yoshihiro: No conflict of interest\|\|Hibi, Toshifumi: No conflict of interest\|\|Hisamatsu, Tadakazu: No conflict of interest |
| P095 | Ms. Papatheodoridi, Margarita: No conflict of interest\|\|Giuffrida , Paolo: No conflict of interest\|\|Canetti, Diana: No conflict of interest\|\|Yutaka, Yasui: No conflict of interest\|\|Hodgetts, Harry: No conflict of interest\|\|Di Sabatino, Antonio: No conflict of interest\|\|Johnston, Harvey: No conflict of interest\|\|Verona, Guglielmo: No conflict of interest\|\|Rendell, Nigel: No conflict of interest\|\|Al-Akkad, Walid: No conflict of interest\|\|Frenguelli, Luca: No conflict of interest\|\|Hall, Andrew: No conflict of interest\|\|Luong , TuVinh: No conflict of interest\|\|Sampietro, Gianluca: No conflict of interest\|\|Pinzani, Massimo: No conflict of interest\|\|Rombouts, Krista: No conflict of interest\|\|Belloti, Vittorio: No conflict of interest\|\|Mazza, Giuseppe: No conflict of interest |

| | |
|---|---|
| P096 | Ms. Frigerio, Sofía: No conflict of interest\|\|Saris, Job: No conflict of interest\|\|Franco Fernandez, Rosalia: No conflict of interest\|\|Koelink, Pim: No conflict of interest\|\|van Roest, Manon: No conflict of interest\|\|Wildenberg, Manon: No conflict of interest\|\|D'Haens, Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|Grootjans, Joep: No conflict of interest |
| P097 | Modos, Dezso: No conflict of interest\|\|Poletti, Martina: No conflict of interest\|\|Brooks-Warburton, Johanne:\|:\|JB-W holds research grants from AbbVie, and has received speaker fees from Dr Falk Pharma. \|\|Bohar, Balazs: No conflict of interest\|\|Madgwick, Matthew:\|:\|MM has a PhD scholarship founded by Benevolent AI.\|\|Verstockt, Bram:\|:\|Financial support for research from Pfizer\|Consultancy fees from Janssen, Guidepont and Sandoz\|Speakers fees from Abbvie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R Biopharm, Takeda and Truvion.\|\|Vermeire, Séverine:\|:\|Financial support for research: AbbVie, J&J, Pfizer, and Takeda\|Consulting and/or speaking fees: AbbVie, Arena Pharmaceuticals, Avaxia, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Takeda, Theravance, and Tillots Pharma AG\|\|Carding, Simon: No conflict of interest\|\|Dr. Korcsmaros, Tamas: No conflict of interest |
| P098 | Dr. Lee, Jaehun: No conflict of interest\|\|Kim, Gukdo: No conflict of interest\|\|Kim, Joon-Chul: No conflict of interest\|\|Park, Jung-Hyuck: No conflict of interest\|\|Han, Choongseong: No conflict of interest\|\|Kim, Minkyung: No conflict of interest |
| P099 | Prof. Dr. Lopetuso, Loris Riccardo: No conflict of interest\|\|Privitera, Giuseppe: No conflict of interest\|\|Di Martino, Luca: No conflict of interest\|\|Scaldaferri, Franco: No conflict of interest\|\|Gasbarrini, Antonio: No conflict of interest\|\|Cominelli, Fabio: No conflict of interest\|\|De Salvo, Carlo: No conflict of interest\|\|Pizarro, Theresa: No conflict of interest |

| | |
|---|---|
| P100 | Mr. Mendieta Escalante, Erick Arturo: No conflict of interest\|\|Faber, Klaas Nico: No conflict of interest\|\|Hermoso Ramello, Marcela: No conflict of interest\|\|Parada-Venegas, Daniela: No conflict of interest\|\|Bourgonje, Arno: No conflict of interest\|\|Roozendaal, Caroline: No conflict of interest\|\|Dijkstra, Gerard: No conflict of interest |
| P101 | Atanassova, Antonia: No conflict of interest\|\|Dr. Georgieva, Avgustina Chavdarova: No conflict of interest |
| P102 | Redhu, Naresh S.:\|:\|Shareholder and Employee of Morphic Therapeutic, Waltham, MA, USA.\|\|Rowe, Michael:\|:\|Shareholder and Employee of Morphic Therapeutic, Waltham, MA, USA.\|\|Lee, Dooyoung:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Jain, Dhawal:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Sang, Allison:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Granata, Danielle:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Harrison, Bryce:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Cui, Dan:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Bursavich, Matthew:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Ray, Adrian S.:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Lippa, Blaise:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Rogers, Bruce N.:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA.\|\|Wong , Jamie:\|:\|Paid employee and shareholder of Morphic Therapeutic, Waltham, MA, USA. |
| P103 | Dr. Casado-Bedmar, Maite: No conflict of interest\|\|Roy, Maryline: No conflict of interest\|\|Hugot, Jean-Pierre: No conflict of interest\|\|Le Gall, Maude: No conflict of interest\|\|Chassaing, Benoit: No conflict of interest\|\|Viennois, Emilie: No conflict of interest |
| P104 | Dr. Khaled, Mariam: No conflict of interest\|\|Hamdy, Khaled:\|:\|Presenting Author's Father \|\|Abou-Aisha, Khaled: No conflict of interest\|\|Mansour, Manar: No conflict of interest |

| | |
|---|---|
| P105 | Dr. Moon, Jung Min: No conflict of interest\|\|Kim, Ki-Uk: No conflict of interest\|\|Shin, Seung Yong: No conflict of interest\|\|Joo, Hyun Jin: No conflict of interest\|\|Min, Hyeyoung: No conflict of interest\|\|Choi, Chang Hwan:\|:\|National Research Foundation of Korea (NRF) grant funded by Ministry of Science and ICT (NRF-2020R1F1A1075489) |
| P106 | Dr. Baldan-Martin, Montserrat: No conflict of interest\|\|Azkargorta, Mikel: No conflict of interest\|\|Lloro, Ibon: No conflict of interest\|\|Soleto Fernández, Irene: No conflict of interest\|\|Orejudo, Macarena: No conflict of interest\|\|Ramírez, Cristina: No conflict of interest\|\|García, Sara: No conflict of interest\|\|Mercado, Jorge: No conflict of interest\|\|Riestra, Sabino: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Fernández-Salazar, Luis: No conflict of interest\|\|Ceballos, Daniel: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Bastón-Rey, Iria: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|Lorente, Rufo: No conflict of interest\|\|Ber, Yolanda: No conflict of interest\|\|Royo, Vanesa: No conflict of interest\|\|Esteve, María: No conflict of interest\|\|Elortza, Felix: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest\|\|Chaparro, María: No conflict of interest |
| P107 | Ms. Becker, Marte: No conflict of interest\|\|Koelink, Pim: No conflict of interest\|\|Bemelman, Willem: No conflict of interest\|\|D'Haens, Geert: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|Wildenberg, Manon: No conflict of interest |
| P108 | Mr. Khater, Georges: No conflict of interest\|\|Noguier, Guillaume: No conflict of interest\|\|Daviere, Simon: No conflict of interest\|\|Montaillier, Christophe: No conflict of interest\|\|Guilbert, Virginie: No conflict of interest |
| P109 | Dr. Granot, Maya: No conflict of interest\|\|Braun, Tzipi: No conflict of interest\|\|Efroni, Gilat: No conflict of interest\|\|Fudim, Ella: No conflict of interest\|\|Yavzori, Miri: No conflict of interest\|\|Haj, Ola: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Kopylov, Uri:\|:\|This is a researcher sponsored project that was funded by Jansen (Uri kopylov), but the company was not involved in the research itself and in analyzing the results.\|\|Haberman Ziv, Yael: No conflict of interest |

| | |
|---|---|
| P110 | Mrs. Lartey, Dalia: No conflict of interest\|\|van Roest, Manon: No conflict of interest\|\|Verhoeff, Jan: No conflict of interest\|\|Grootjans, Joep: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|van der Bilt, Jarmila: No conflict of interest\|\|Wildenberg, Manon: No conflict of interest\|\|D'Haens, Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|Löwenberg, Mark:\|:\|has served as speaker and/or principal investigator for: Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Dr Falk, Achmea healthcare, Galapagos and ZonMW. |
| P111 | Dr. Van De Bunt, Martijn: No conflict of interest\|\|D'Alessio, Silvia: No conflict of interest\|\|Norrild, Jens Chr: No conflict of interest\|\|Kjølbye, Anne Louise: No conflict of interest\|\|Jorgensen, Rasmus: No conflict of interest |

| | |
|---|---|
| P112 | Prof. Dr. Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Verstockt, Sare: No conflict of interest\|\|Cremer, Jonathan: No conflict of interest\|\|Sabino, João:\|:\|João Sabino receives financial support for research from Galapagos and Viatris; receives speakers' fees from Pfizer, Abbvie, Ferring, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Ferring, Fresenius, Abbvie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia.\|João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|Marc Ferrante is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. |
| P113 | Dr. Pehrsson, Martin: No conflict of interest\|\|Sorokina Alexdottir, Marta: No conflict of interest\|\|Asser Karsdal, Morten:\|:\|Employed at and hold stocks in Nordic Bioscience A/S\|\|Høg Mortensen, Joachim:\|:\|Employed at Nordic Bioscience A/S |
| P114 | Ms. Pascual, Marta: No conflict of interest\|\|Gárate, Gabriel: No conflict of interest\|\|Serrano, María Soledad: No conflict of interest\|\|García García, María José: No conflict of interest\|\|Castro, Beatriz: No conflict of interest\|\|González Quintanilla, Vicente: No conflict of interest\|\|Crespo, Javier: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Pascual, Julio: No conflict of interest |

| | |
|---|---|
| P115 | Ms. Li, Yue: No conflict of interest\|\|Law, Helen Ka Wai: No conflict of interest |
| P116 | Dr. Panayotova, Elena: No conflict of interest\|\|Atanassova, Antonia: No conflict of interest |
| P117 | Pineda Chavez, Samuel Elias: No conflict of interest\|\|Rizzo, Giulia: No conflict of interest\|\|Cafarelli, Andrea: No conflict of interest\|\|Sorriento, Angela: No conflict of interest\|\|Loy, Laura: No conflict of interest\|\|dal Buono, Arianna: No conflict of interest\|\|Gabbiadini, Roberto: No conflict of interest\|\|Meanti, Lisa: No conflict of interest\|\|Allocca, Mariangela: No conflict of interest\|\|Danese, Silvio: No conflict of interest\|\|Repici, Alessandro: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest\|\|Ricotti, Leonardo: No conflict of interest\|\|Vetrano, Stefania: No conflict of interest |
| P118 | Dr. Seco-Cervera, Marta: No conflict of interest\|\|Argilés-Alberola, Diego: No conflict of interest\|\|Bauset, Cristina: No conflict of interest\|\|Lis-López, Lluis: No conflict of interest\|\|Coll, Sandra: No conflict of interest\|\|Cosín-Roger, Jesús: No conflict of interest\|\|Ortiz-Masià, Dolores: No conflict of interest\|\|Calatayud, Sara: No conflict of interest\|\|Barrachina, Maria Dolores: No conflict of interest |
| P119 | Dr. Johansen, Martha Pollen: No conflict of interest |

| | |
|---|---|
| P120 | Prof. Dr. Buisson, Anthony:\|:\|Consulting fees for Abbvie, Amgen, Arena, Biogen, Celtrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts. Lecture fees for Abbvie, Amgen, Biogen, Fresenius-Kabi Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts and Vifor Pharma. Research grants from Abbvie, Celltrion, Janssen, Pfizer, Takeda.\|\|Junda, Jérémy: No conflict of interest\|\|Vignette, Jeanne: No conflict of interest\|\|Lecoq, Emma: No conflict of interest\|\|Bouguen, Guillaume:\|:\|received lecture fees from Abbvie, Ferring, MSD, Takeda and Pfizer and consultant fees from Takeda, Janssen.\|\|Pereira, Bruno: No conflict of interest\|\|Hordonneau, Constance: No conflict of interest |
| P121 | Hu, Wen: No conflict of interest\|\|Liang, Xi: No conflict of interest\|\|Luo, Jinjin: No conflict of interest\|\|Li, Peng: No conflict of interest\|\|Shen, Keren: No conflict of interest\|\|Li, Jiaqi: No conflict of interest\|\|Li, Shuyan: No conflict of interest\|\|Xin, Jiaojiao: No conflict of interest\|\|Jiang, Jing: No conflict of interest\|\|Shi, Dongyan: No conflict of interest\|\|Wang, Xiaoying: No conflict of interest\|\|Xu, Dingting: No conflict of interest\|\|Yu, Qiao: No conflict of interest\|\|Zhang, Hanyun: No conflict of interest\|\|Zhang, Xiaoqi: No conflict of interest\|\|Song, Xiaomei: No conflict of interest\|\|Guo, Hong: No conflict of interest\|\|Ge, Qian: No conflict of interest\|\|Chen, Yuanwen: No conflict of interest\|\|Chen, Xin: No conflict of interest\|\|Chen, Yan: No conflict of interest\|\|Prof. Li, Jun: No conflict of interest |
| P122 | Dr. Parigi, Tommaso Lorenzo: No conflict of interest\|\|Cannatelli, Rosanna: No conflict of interest\|\|Nardone, Olga Maria: No conflict of interest\|\|Zammarchi, Irene: No conflict of interest\|\|Shivaji, Uday: No conflict of interest\|\|Furfaro, Federica: No conflict of interest\|\|Zardo, Davide: No conflict of interest\|\|Spaggiari, Paola: No conflict of interest\|\|Del Sordo, Rachele: No conflict of interest\|\|Setti, Orsola: No conflict of interest\|\|Majumder, Snehali: No conflict of interest\|\|Smith, Samuel Charles Loyd: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Danese, Silvio: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest\|\|Villanacci, Vincenzo: No conflict of interest\|\|Iacucci, Marietta:\|:\|MI has received research grants and equipment loans from Pentax USA, Olympus, Fujifilm, and is partially funded by NHIR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health |

| | |
|---|---|
| P123 | Vieira, Marcela:\|:\|Employee of Clario, a company providing central reading services for clinical trials.\|\|Mishkin, Daniel S.:\|:\|Owner of GI Reviewers, LLC, a company providing central reading services in clinical trials. Consultant to BMS, Takeda, Braintree, Sebela, CelMax Life. \|\|Gaither, Kenneth W.:\|:\|Employee of Clario, a company providing central reading services for clinical trials.\|\|Safran, Moshe: No conflict of interest\|\|Dashuta, Artium: No conflict of interest\|\|Tarakanov, Aliza: No conflict of interest\|\|Zfira, Lior: No conflict of interest\|\|Mr. Fuerst, Thomas: No conflict of interest |
| P124 | Mrs. Rasmussen, Nathalie Fogh: No conflict of interest\|\|Gregersen , Laura Helene Keiding: No conflict of interest\|\|Hikmat, Zainab: No conflict of interest\|\|Moos, Caroline Margaret: No conflict of interest\|\|Green, Anders: No conflict of interest\|\|Andersen, Vibeke: No conflict of interest\|\|Madsen, Gunvor Iben: No conflict of interest\|\|Jess, Tine: No conflict of interest\|\|Kjeldsen, Lene Juel: No conflict of interest |
| P125 | Dr. Cassinotti, Andrea: No conflict of interest\|\|Zadro, Valentina: No conflict of interest\|\|Parravicini, Marco: No conflict of interest\|\|Ferraris, Matteo: No conflict of interest\|\|Balzarini, Marco: No conflict of interest\|\|Sessa, Fausto: No conflict of interest\|\|La Rosa, Stefano: No conflict of interest\|\|Segato, Simone: No conflict of interest\|\|Cortelezzi, Claudio Camillo: No conflict of interest\|\|Segato, Sergio: No conflict of interest |
| P126 | Dr. Rimmer, Peter: No conflict of interest\|\|Cheesbrough, Jonathan: No conflict of interest\|\|Quraishi, Mohammed Nabil: No conflict of interest\|\|Sharma, Naveen: No conflict of interest\|\|Cooney, Rachel: No conflict of interest\|\|Love, Melanie: No conflict of interest\|\|Iqbal, Tariq: No conflict of interest |

| | |
|---|---|
| P127 | Dr. Porter, Ross: No conflict of interest\|\|Gillespie, Sarah-Louise: No conflict of interest\|\|Song, Michael: No conflict of interest\|\|Ball, Grace: No conflict of interest\|\|Crawford, Angus: No conflict of interest\|\|Churchhouse, Antonia: No conflict of interest\|\|Gardner, Maximilian: No conflict of interest\|\|Plevris, Nikolas: No conflict of interest\|\|Chuah, Cher Shiong: No conflict of interest\|\|Brindle, William: No conflict of interest\|\|Watson, Eleanor: No conflict of interest\|\|Jenkinson, Philip: No conflict of interest\|\|Fulforth, James: No conflict of interest\|\|Kedziora, Marta: No conflict of interest\|\|Dickson, Bruce: No conflict of interest\|\|Megan, Abbi: No conflict of interest\|\|Jones, Gareth-Rhys: No conflict of interest\|\|Din, Shahida: No conflict of interest |
| P128 | Dr. Avni Biron, Irit: No conflict of interest\|\|Ollech, Jacob E.: No conflict of interest\|\|Toth , Ervin: No conflict of interest\|\|Nemet, Artur: No conflict of interest\|\|Wurm Johansson, Gabriele: No conflict of interest\|\|Schweinstein, Hagai: No conflict of interest\|\|Kopylov , Uri: No conflict of interest\|\|Margalit Yehuda , Reuma: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Yanai, Henit: No conflict of interest |
| P129 | Dr. Allocca, Mariangela: No conflict of interest\|\|Dell'Avalle, Cecilia: No conflict of interest\|\|Furfaro, Federica: No conflict of interest\|\|Zilli, Alessandra: No conflict of interest\|\|Radice, Simona: No conflict of interest\|\|D'Amico, Ferdinando: No conflict of interest\|\|Peyrin-Biroulet, Laurent: No conflict of interest\|\|Fiorino, Gionata: No conflict of interest\|\|Danese, Silvio: No conflict of interest |
| P130 | Dr. Yzet, Clara: No conflict of interest\|\|Meudjo, Erica: No conflict of interest\|\|Moreau, Capucine: No conflict of interest\|\|Brazier, Franck: No conflict of interest\|\|Hautefeuille, Vincent: No conflict of interest\|\|Decrombecque, Catherine: No conflict of interest\|\|Sarba, Ruxandra: No conflict of interest\|\|Pichois, Raphaël: No conflict of interest\|\|Meynier, Jonathan: No conflict of interest\|\|Fumery, Mathurin: No conflict of interest |

| | |
|---|---|
| P131 | Dr. Borghede, Märta: No conflict of interest\|\|Marsal, Jan: No conflict of interest\|\|Faresjö, Tomas: No conflict of interest\|\|Hjortswang, Henrik:\|:\|Abbvie, Takeda, Pfizer, Janssen, Tillotts, Ferring, Norgine, Pharmacosmos, Fresenius Kabi |
| P132 | Dr. Hammoudi, Nassim:\|:\|NH received honoraria for consultancy from Janssen and Takeda. \|\|Lehmann-Che , Jacqueline: No conflict of interest\|\|Lambert, Jérôme: No conflict of interest\|\|Amoyel, Maxime: No conflict of interest\|\|Maggiori, Leon: No conflict of interest\|\|Salfati, Delphine: No conflict of interest\|\|Tran Minh, My-Linh:\|:\|MLTM received honoraria from Abbvie and Janssen.\|\|Baudry, Clotilde: No conflict of interest\|\|Asesio, Nicolas: No conflict of interest\|\|Poirot, Brigitte: No conflict of interest\|\|Lourenco, Nelson:\|:\|NL has been a speaker for Sanofi. \|\|Corte, Hélène: No conflict of interest\|\|Allez, Matthieu:\|:\|MA received grant supports from Innate Pharma, Janssen, Takeda, Genentech/Roche, and honoraria for teaching activities or consultancy from Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Genentech, Gilead, IQVIA, Janssen, Novartis, Pfizer, Roche, Takeda, Tillots. \|\|Aparicio, Thomas:\|:\|TA presented conferences for Shire, Ipsen, Amgen, BMS, Servier, Pfizer, Roche Sanofi and meeting grants for Ipsen, Novartis, Roche and Hospira. He also obtained research grant from Novartis and Innate Pharma. \|\|Gornet, Jean-Marc:\|:\|JMG has been a speaker and/advisory board member for Abbvie, Amgen, Celltrion, Takeda, Janssen and Sanofi Genzyme. |
| P133 | Prof. Dr. Jung, Sung Hoon: No conflict of interest\|\|Kim, Tae-Oh: No conflict of interest\|\|Kang, Sang-Bum: No conflict of interest\|\|Kim, Jinsu: No conflict of interest |
| P134 | Ms. Guvendir Bakkaloglu, Irem: No conflict of interest\|\|Calim Gurbuz, Begum: No conflict of interest\|\|Zemheri, Itir Ebru: No conflict of interest |

| | |
|---|---|
| P135 | Dr. Kim, Kwang Woo: No conflict of interest\|\|Koh, Seong-Joon:\|:\|This work was supported by a National Research Foundation of Korea grant funded by the Korea government (MSIT; No. 2019R1C1C1002243) and the Basic Science Research Program through the National Research Foundation of Korea funded by the \|Ministry of Education (NRF-2016R1D1A1B03931961 and NRF-2020R1A1F10666419). This work was also supported by the Seoul National University Hospital Research Foundation (No.3020160160).\|\|Kang, Hyoun Woo:\|:\|This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (No. 2021R1F1A1062000) \|\|Park, Hyunsun:\|:\|This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2019R1C1C1002243 and 2022R1A2C200911311). Also, it was supported by grant no 03-2022-0410 from the SNUH Research Fund.\|\|Ha, Hyeonjin: No conflict of interest\|\|Park, Jin: No conflict of interest\|\|Kim, Kyunghoon: No conflict of interest\|\|Jun, Yukyung: No conflict of interest\|\|Lee, Hyun Jung: No conflict of interest\|\|Yoon, Hyuk: No conflict of interest\|\|Im, Jong Pil: No conflict of interest\|\|Park, Young Soo: No conflict of interest\|\|Kim, Ji Won: No conflict of interest\|\|Kim, Joo Sung: No conflict of interest |
| P136 | Atanasova, Konstantina: No conflict of interest\|\|knoedler, Laura-Louise: No conflict of interest\|\|Schmitteckert, Stefanie: No conflict of interest\|\|Ebert, Matthias: No conflict of interest\|\|Reindl, Wolfgang: No conflict of interest\|\|Dr. Thomann, Anne: No conflict of interest |
| P137 | Ms. Dal Buono, Arianna: No conflict of interest\|\|Gabbiadini, Roberto: No conflict of interest\|\|Alfarone, Ludovico: No conflict of interest\|\|Brunetti, Alessandro: No conflict of interest\|\|Solitano, Virginia: No conflict of interest\|\|D'Amico, Ferdinando: No conflict of interest\|\|Vena, Walter: No conflict of interest\|\|Pizzocaro, Alessandro: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest |
| P138 | Ms. Nicolaou, Pinelopi: No conflict of interest\|\|Theodoropoulou, Angeliki: No conflict of interest\|\|Psistakis, Andrew: No conflict of interest\|\|Arna, Despoina: No conflict of interest\|\|Velegraki, Magdalini: No conflict of interest\|\|Fragkaki, Maria: No conflict of interest\|\|Karmiris, Konstantinos: No conflict of interest\|\|Vardas, Emmanouil: No conflict of interest\|\|Paspatis, Gregorios: No conflict of interest |
| P139 | Ms. Mtir, Maha: No conflict of interest\|\|Kchir, Hela: No conflict of interest\|\|Mechergui, Najla: No conflict of interest\|\|Cherif, Dhouha: No conflict of interest\|\|Debbabi, Habiba: No conflict of interest\|\|Yacoub, Haythem: No conflict of interest\|\|Hassine, Hajer: No conflict of interest\|\|Maamouri, Nadia: No conflict of interest |

| | |
|---|---|
| P140 | Mrs. Al-Sheikh, Marwah: No conflict of interest\|\|Olsen, Jens:\|:\|Incentive is a paid vendor to Calpro AS\|\|Spangaard, Maria:\|:\|Incentive is a paid vendor to Calpro AS.\|\|Egedesø, Peter:\|:\|of Incentive is a paid vendor to Calpro AS.\|\|Peters-Lehm, Charlotte: No conflict of interest\|\|Fjordside, Eva: No conflict of interest\|\|Bennedsen, Mette: No conflict of interest\|\|Burisch, Johan: No conflict of interest\|\|Munkholm, Pia: No conflict of interest |
| P141 | Muiño, Daniel: No conflict of interest\|\|Dr. Carballo-Folgoso, Lorena: No conflict of interest\|\|Ortega-Carriedo , Jorge: No conflict of interest\|\|Flórez-Díez, Pablo: No conflict of interest\|\|de Francisco, Ruth: No conflict of interest\|\|Pérez-Martínez, Isabel: No conflict of interest\|\|Castaño-García, Andrés: No conflict of interest\|\|Fernández-González, Emilia: No conflict of interest\|\|García-Pérez, Cristina: No conflict of interest\|\|Martínez-González, Susana: No conflict of interest\|\|Rolle, Valeria: No conflict of interest\|\|Riestra, Sabino: No conflict of interest |
| P142 | Bokemeyer, Arne: No conflict of interest\|\|Buskermolen, Joost: No conflict of interest\|\|Ketelhut, Steffi: No conflict of interest\|\|Tepasse, Phil: No conflict of interest\|\|Vollenberg, Richard: No conflict of interest\|\|Vieth, Michael: No conflict of interest\|\|Kemper, Björn: No conflict of interest\|\|Bettenworth, Dominik: No conflict of interest |
| P143 | Park, Suhyun: No conflict of interest\|\|Hong, Seung Wook: No conflict of interest\|\|Hwang, Sung Wook: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Ye, Byong Duk: No conflict of interest\|\|Byeon, Jeong-Sik: No conflict of interest\|\|Myung, Seung-Jae: No conflict of interest\|\|Yang, Suk-Kyun: No conflict of interest\|\|Yang, Dong-Hoon: No conflict of interest |

| | |
|---|---|
| P144 | Meunier, Camille: No conflict of interest\|\|Monte, Celia: No conflict of interest\|\|Hadjisavvas, Helena: No conflict of interest\|\|Rozieres, Aurore: No conflict of interest\|\|Roblin, Xavier: No conflict of interest\|\|Venturin, Chloe: No conflict of interest\|\|Gay, Claire: No conflict of interest\|\|Flourie, Bernard: No conflict of interest\|\|Boschetti, Gilles: No conflict of interest\|\|Danion, Pauline: No conflict of interest\|\|Mathieu, Nicolas: No conflict of interest\|\|Charlois, Anne Laure: No conflict of interest\|\|Faure, Mathias: No conflict of interest\|\|Prof. Nancey, Stéphane: No conflict of interest |
| P145 | Mrs. Ben Safta, Nour: No conflict of interest\|\|Ben Mustpha, Nadia: No conflict of interest\|\|Khemiri, Wafa: No conflict of interest\|\|Serghini, Meriem: No conflict of interest\|\|Laabidi, Sarra: No conflict of interest\|\|Fekih, Monia: No conflict of interest\|\|Labidi, Asma: No conflict of interest\|\|Boubaker, Jalel: No conflict of interest |
| P146 | Dr. Broglio, Giacomo: No conflict of interest\|\|Lenti, Marco Vincenzo: No conflict of interest\|\|Mengoli, Caterina: No conflict of interest\|\|Borrelli De Andreis, Federica: No conflict of interest\|\|Vernero, Marta: No conflict of interest\|\|Pitotti, Lavinia: No conflict of interest\|\|Padovini, Lucia: No conflict of interest\|\|Delliponti, Mariangela: No conflict of interest\|\|Klersy, Catherine: No conflict of interest\|\|Corazza, Gino Roberto: No conflict of interest\|\|Di Sabatino, Antonio: No conflict of interest |
| P147 | Mr. Fernando, Suni: No conflict of interest\|\|Abu-Rgeef, Reeham: No conflict of interest\|\|Menon, Shankar: No conflict of interest\|\|So, Kenji: No conflict of interest\|\|Venugopal, Kannan: No conflict of interest\|\|Picardo, Sherman: No conflict of interest |
| P148 | Ms. Mtir, Maha: No conflict of interest\|\|Mechergui, Najla: No conflict of interest\|\|Kchir, Hela: No conflict of interest\|\|Cherif, Dhouha: No conflict of interest\|\|Dabbabi, Hbiba: No conflict of interest\|\|Yacoub, Haythem: No conflict of interest\|\|Hassine, Hajer: No conflict of interest\|\|Maamouri, Nadia: No conflict of interest |

| | |
|---|---|
| P149 | Ms. Brosi, Larissa: No conflict of interest\|\|Reinhard, Christian:\|:\|Employee of BÜHLMANN Laboratories AG\|\|Anchling , Leslie:\|:\|Employee of BÜHLMANN Laboratories AG\|\|Afonso, Joana:\|:\|Employee of BÜHLMANN Laboratories AG\|\|Schuster, Thomas:\|:\|Employee of BÜHLMANN Laboratories AG\|\|Gerhold, Christian-Benedikt:\|:\|Employee of BÜHLMANN Laboratories AG\|\|Ricken, Benjamin:\|:\|Employee of BÜHLMANN Laboratories AG |
| P150 | Tal-Shifman, Noa: No conflict of interest\|\|Tzivinikos, Christos: No conflict of interest\|\|Gasparetto, Marco: No conflict of interest\|\|Serban, Daniela E.: No conflict of interest\|\|Zifman, Eyal: No conflict of interest\|\|Hojsak, Iva: No conflict of interest\|\|Ledder, Oren: No conflict of interest\|\|Yerushalmy Feler, Anat: No conflict of interest\|\|Rolandsdotter, Helena: No conflict of interest\|\|Aloi, Marina: No conflict of interest\|\|Bramuzzo, Matteo: No conflict of interest\|\|Buderus, Stephan: No conflict of interest\|\|Lionetti, Paolo: No conflict of interest\|\|Norsa, Lorenzo: No conflict of interest\|\|Norden, Christoph: No conflict of interest\|\|Urlep, Darja: No conflict of interest\|\|Romano, Claudio: No conflict of interest\|\|Shaoul, Ron: No conflict of interest\|\|Martinez-Vinson, Christine: No conflict of interest\|\|Karoliny, Anna: No conflict of interest\|\|Veereman, Gigi: No conflict of interest\|\|Kang, Ben: No conflict of interest\|\|Vlčková, Eva: No conflict of interest\|\|Alvisi, Patrizia: No conflict of interest\|\|Kori, Michal: No conflict of interest\|\|Tavares, Marta: No conflict of interest\|\|Weiss, Batia: No conflict of interest\|\|Hussey, Seamus: No conflict of interest\|\|Essen Qamhawi, Maria: No conflict of interest\|\|Palomino Pérez, Laura María: No conflict of interest\|\|Henderson, Paul: No conflict of interest\|\|Parmar, Raj: No conflict of interest\|\|Miele, Erasmo: No conflict of interest\|\|Firas Rinawi, Firas: No conflict of interest\|\|Lonzano-Ruf, Ana: No conflict of interest\|\|Zamvar, Veena: No conflict of interest\|\|Kolho, Kaija-Leena: No conflict of interest\|\|Shouval, Dror: No conflict of interest |

| | |
|---|---|
| P151 | Prof. Dr. Schreiber, Stefan Wolfgang: No conflict of interest\|\|Danese , Silvio:\|:\|S. Danese reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB, Vial, Vifor, and lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda\|\|Dignass, Axel:\|:\|A. Dignass reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Arena Pharmaceuticals, Dr Falk Foundation, Gilead/Galapagos, Janssen and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, Celltrion, Falk Foundation, Ferring, Gilead/Galapagos, High5ImmunoTV, Janssen, MSD, Pfizer, Takeda, Tillotts and Vifor Pharma; payment for manuscript preparation from Falk Foundation, Takeda, Thieme and UniMed Verlag.\|\|Domènech , Eugeni:\|:\|E. Domènech has served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Galapagos, Gilead, IMIDomics, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda and Tillotts Pharma.\|\|Fantini , Massimo:\|:\|M. Fantini has received consultancy fees from AbbVie, Biogen, Bristol Myers Squibb, Galapagos, Janssen-Cilag, MSD, Pfizer, Sandoz and Takeda, and research grants from Janssen-Cilag and Pfizer.\|\|Ferrante, Marc:\|:\|M. Ferrante has received research grants from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; consultancy fees from AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Janssen-Cilag, Lilly, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and Thermo Fisher Scientific; and speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Dr Falk Pharma, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris.\|\|Halfvarson, Jonas:\|:\|J. Halfvarson has served as speaker, consultant and/or advisory board member for AbbVie, Aqilion, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, InDex Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma and UCB, and received grant support from Janssen, MSD and Takeda.\|\|Hart, Ailsa:\|:\|A. Hart has served as consultant, advisory board member or speaker for AbbVie, Arena Pharmaceuticals, Atlantic Pharmaceuticals, Bristol Myers Squibb, Celgene, Celltrion, Dr |

| | |
|---|---|
| | Falk Pharma, Ferring, Galapagos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech.\|\|Magro, Fernando:\|:\|F. Magro has received fees from Abbvie, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Dr Falk Pharma, Ferring, Hospira, Janssen, Laboratórios Vitoria, Lilly, MSD, Pfizer, Sandoz, Takeda, UCB and Vifor. \|\|Lees, Charlie:\|:\|C. Lees has acted as a speaker and/or consultant for Abbvie, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresnius Kabi, Galapagos, Gilead, GSK, Iterative Scopes, Janssen, Novartis, Pfizer, Sandoz, Takeda, Tillotts, Trellus Health and Vifor Pharma.\|\|Leone, Salvo:\|:\|S. Leone has received consulting fees from Pierre-Fabre, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Galapagos and Janssen. \|\|Pierik, Marieke:\|:\|M. J. Pierik reports grants and non-financial support from Abbvie, Dr Falk Pharma, Johnson and Johnson and Takeda, grants from ZonMw (Dutch national research fund), and non-financial support from Ferring, Immunodiagnostics and MSD.\|\|Field, Polly:\|:\|P. Field is an employee of Oxford PharmaGenesis.\|\|Schofield, Helen:\|:\|H. Schofield is an employee of Oxford PharmaGenesis.\|\|Peyrin-Biroulet , Laurent:\|:\|L. Peyrin-Biroulet has received personal fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celgene, Celltrion, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Mopac, Morphic, MSD, Mylan, Norgine, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Prometheus, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance, Thermo Fisher, Tillots, Viatris, Vifor. |
| P152 | Wu, Yi-Hua: No conflict of interest\|\|Dr. Chou, Jen-Wei: No conflict of interest\|\|Po, Ju Huang: No conflict of interest\|\|Wang, Chu Ping: No conflict of interest\|\|Cheng, Ken Sheng: No conflict of interest |
| P153 | Mr. Serra-Ruiz, Xavier: No conflict of interest\|\|Claudia, Herrera-de Guise: No conflict of interest\|\|Mayorga Ayala, Luis: No conflict of interest\|\|Robles Alonso, Virginia: No conflict of interest\|\|Céspedes Martínez, Elena: No conflict of interest\|\|Casellas, Francesc: No conflict of interest\|\|Miarons, Marta: No conflict of interest\|\|Garcia-Garcia, Sonia: No conflict of interest\|\|Pérez Martínez, Zahira: No conflict of interest\|\|Oller, Elena: No conflict of interest\|\|Borruel Sainz, Natalia: No conflict of interest |

| | |
|---|---|
| P154 | Bazov, Igor: No conflict of interest\|\|Kruse, Robert: No conflict of interest\|\|Bergemalm, Daniel:\|:\|Has received personal fees as speaker and/or advisory board member for Ferring, Janssen, Pfizer, and Takeda.\|\|Eriksson, Carl: No conflict of interest\|\|Hedin, Charlotte RH:\|:\|has received speaker fees from Takeda, Ferring, AbbVie, and Janssen, and consultancy fees from Pfizer, has acted as local principal investigator for clinical trials for Janssen and GlaxoSmithKline and has received project grants from Takeda and Tillotts Pharma. \|\|Carlson, Marie: No conflict of interest\|\|van Nieuwenhoven, Michiel: No conflict of interest\|\|Keita, Åsa V: No conflict of interest\|\|Magnusson, Maria K: No conflict of interest\|\|Almer, Svend: No conflict of interest\|\|Strid, Hans: No conflict of interest\|\|Bache-Wiig Mathisen, Charlotte:\|:\|Has received advisory board fees from Tillots Pharma.\|\|Bengtsson, May-Bente: No conflict of interest\|\|Bergene Aabrekk, Tone: No conflict of interest\|\|Medhus, Asle Wilhelm:\|:\|Has received unrestricted research grant from Takeda\|\|Detlie, Trond Espen:\|:\|Reports personal fees from Ferring, personal fees from Tillotts, personal fees from Pharmacosmos, personal fees from Vifor Pharma, outside the submitted work. \|\|Frigstad, Svein Oskar:\|:\|Reports personal fees from Tillotts Pharma, Janssen-Cilag, Pfizer, Takeda, Intercept Pharma, and AbbVie \|\|Huppertz-Hauss, Gert: No conflict of interest\|\|Opheim, Randi: No conflict of interest\|\|Ricanek, Petr: No conflict of interest\|\|Kristensen, Vendel Ailin:\|:\|Has served as speaker, consultant, and advisory member for or has received investigator initiated research funding from Takeda, Janssen, Ferring and Tillotts Pharma\|\|Salihovic, Samira: No conflict of interest\|\|D'Amato, Mauro: No conflict of interest\|\|Öhman, Lena:\|:\|has received financial support for research from Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as Consultant/Advisory Board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and MEDA\|\|Söderholm, Johan D: No conflict of interest\|\|Lindqvist, Carl Mårten: No conflict of interest\|\|Repsilber, Dirk: No conflict of interest\|\|Prof. Dr. Høivik, Marte Lie:\|:\|Has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma\|\|Halfvarson, Jonas:\|:\|JH has received personal fees as speaker and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD and Takeda. |
| P155 | Mortreux, Perinne: No conflict of interest\|\|Leroyer, Ariane: No conflict of interest\|\|Ley, Delphine: No conflict of interest\|\|Dupont-Lucas, Claire: No conflict of interest\|\|Bertrand, Valerie: No conflict of interest\|\|Wils, Pauline: No conflict of interest\|\|Coevoet, Hugues: No conflict of interest\|\|Paupard, Thierry: No conflict of interest\|\|Gower-Rousseau, Corinne: No conflict of interest\|\|Siproudhis, Laurent: No conflict of interest\|\|Guillon, Nathalie: No conflict of interest\|\|Sarter, Helene: No conflict of interest\|\|Savoye, Guillaume: No conflict of interest\|\|Turck, Dominique: No conflict of interest\|\|Prof. Fumery, Mathurin: No conflict of interest |

| | |
|---|---|
| P156 | Kucharzik, Torsten:\|:\|T. Kucharzik has received lecture and consulting fees from AbbVie. \|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship.\|\|\|Helwig, Ulf:\|:\| U. Helwig has received lecture and consulting fees from AbbVie.\|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship.\|\|\|Strobel, Deike:\|:\|D. Strobel has received lecture and consulting fees from AbbVie.\|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship.\|\|\|Fischer, Imma:\|:\|I. Fischer has received consulting fees from AbbVie. \|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship.\|\|\|Mrs. Hammer, Leonie:\|:\|L. Hammer is an AbbVie employee and may own AbbVie stock or options. \|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship.\|\|\|Rath, Stefan:\|:\|S. Rath is an AbbVie employee and may own AbbVie stock or options. \|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship.\|\|\|Maaser, Christian:\|:\|C. Maaser has received lecture and consulting fees from AbbVie. \|AbbVie sponsored the study; contributed to the design; participated in the collection, analysis, and interpretation of data; in writing, reviewing, and approval of the final version. Statistical analysis support was provided by Dr. Imma Fischer, Biostatistik Tübingen, which was funded by AbbVie. No honoraria or payments were made for authorship. |
| | |

| | |
|---|---|
| P157 | Prof. Tsuchiya, Kiichiro:\|:\|Grants from Hitachi.ltd.\|\|Nagahori, Masakazu:\|:\|Grants from Hitachi ltd.\|\|Hanazawa, Ryoichi: No conflict of interest\|\|Sasaki, Masanao: No conflict of interest\|\|Sato, Hiroyuki: No conflict of interest\|\|Hirakawa, Akihiro:\|:\|Grant from Hitachi ltd.\|\|Anzai, Tatsuhiko: No conflict of interest\|\|Takahashi, Kunihiko:\|:\|Grant from Hitachi ltd.\|\|Kobayashi, Yuto:\|:\| employee of Hitachi ltd.\|\|Hibiya, Shuji: No conflict of interest\|\|Takenaka, Kento: No conflict of interest\|\|Watanabe, Mamoru: No conflict of interest |
| P158 | Dr. Madsen, Gorm Roager:\|:\|Grants from Pharmacosmos and Takeda. Speaker's fee from Tillotts Pharma, outside the submitted work. \|\|\|Attauabi, Mohamed: No conflict of interest\|\|Wilkens, Rune: No conflict of interest\|\|Ilvemark, Johan F.K.F.: No conflict of interest\|\|Theede, Klaus: No conflict of interest\|\|Bjerrum, Jacob Tveiten: No conflict of interest\|\|Bendtsen, Flemming: No conflict of interest\|\|Seidelin, Jakob Benedict: No conflict of interest\|\|Boysen, Trine: No conflict of interest\|\|Burisch, Johan: No conflict of interest |
| P159 | Mrs. Fierens, Liselotte: No conflict of interest\|\|Bossuyt , Peter:\|:\|PB reports research grants from Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda; Lecture fees from AbbVie, Celltrion, Janssen, Lilly and Takeda // Lecture fee; and consulting fees Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros\|\|Baert, Filip:\|:\|A financial interest/relationship or affiliation in the form of: Grant/Research Support from AbbVie Inc.; Amgen Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited. Speakers Bureau participant with AbbVie Inc.; Ferring Holding SA; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; and Takeda Pharmaceutical Company Limited. Honoraria from AbbVie Inc.; Amgen Inc.; Arena Pharmaceuticals, Inc.; Celgene Corporation; Ferring Holding SA; Fresenius Kabi AG; Galapagos Inc Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; and Takeda Pharmaceutical Company Limited.\|\|Baert, Didier: No conflict of interest\|\|Lavaerts, Marga: No conflict of interest\|\|Weltens , Caroline: No conflict of interest\|\|Ferrante, Marc:\|:\|MF reports research support from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; speaker's\|fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD,\|Mylan, Pfizer, Sandoz, Takeda and Truvion Healthcare consultancy fees from AbbVie, Boehringer\|Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis,\|Sandoz, Takeda and Thermo Fisher |

| | |
|---|---|
| P160 | Dr. O'Neill, Catarina: No conflict of interest\|\|Haenen, Shana: No conflict of interest\|\|Coudyzer, Walter: No conflict of interest\|\|Bislenghi, Gabriele: No conflict of interest\|\|D'Hoore, André: No conflict of interest\|\|Verstockt, Bram: No conflict of interest\|\|Ferrante, Marc: No conflict of interest\|\|Vermeire, Séverine: No conflict of interest\|\|Sabino, João: No conflict of interest |
| P161 | Dr. Macedo Silva, Vítor: No conflict of interest\|\|Ferreira, Ana Isabel: No conflict of interest\|\|Lima Capela, Tiago: No conflict of interest\|\|Arieira, Cátia: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Boal Carvalho, Pedro: No conflict of interest\|\|Dias de Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest |
| P162 | IBD Latam Consortium, Surgical: No conflict of interest\|\|Mr. Avellaneda, Nicolas Luis: No conflict of interest\|\|Saddy Rodrigues Coy, Claudio: No conflict of interest\|\|Sarubbi Fillmann , Henrique: No conflict of interest\|\|Saad-Hossne , Rogerio: No conflict of interest\|\|Muñoz, Juan Pablo: No conflict of interest\|\|García-Duperly , Rafael: No conflict of interest\|\|Bellolio, Felipe: No conflict of interest\|\|Rotholtz, Nicolas: No conflict of interest\|\|Rossi, Gustavo: No conflict of interest\|\|Marquez V, Juan Ricardo: No conflict of interest\|\|Cillo, Mariano: No conflict of interest\|\|Lacerda-Filho, Antonio: No conflict of interest\|\|Carrie, Augusto: No conflict of interest\|\|Yuki Maruyama , Beatriz: No conflict of interest\|\|Sarubbi Fillmann , Lucio: No conflict of interest\|\|Ferro, Ezequiel: No conflict of interest\|\|Londoño-Schimmer , Eduardo: No conflict of interest\|\|Iglesias, Andres: No conflict of interest\|\|Bras Harriott, Camila: No conflict of interest\|\|Campana, Juan Pablo: No conflict of interest\|\|Londoño Estrada, Daniel: No conflict of interest\|\|Kotze, Paulo Gustavo: No conflict of interest |
| P163 | Dr. Kim, Seong Jung: No conflict of interest\|\|Kim, Eun Jung: No conflict of interest\|\|Lee, Su Min: No conflict of interest\|\|Park, Hye Seon: No conflict of interest\|\|Noh, Yoon Kyoo: No conflict of interest\|\|Lee, Jun: No conflict of interest |

| | |
|---|---|
| P164 | Dr. Snir, Yifat: No conflict of interest\|\|Ollech, Jacob E: No conflict of interest\|\|Peleg, Noam: No conflict of interest\|\|Avni-Biron, Irit: No conflict of interest\|\|Eran-Banai, Hagar: No conflict of interest\|\|Broitman, Yelena: No conflict of interest\|\|Sharar-Fischler, Tali: No conflict of interest\|\|Goren, Idan: No conflict of interest\|\|Zohar, Levi: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Yanai, Henit: No conflict of interest |
| P165 | Ms. Walker, Caroline: No conflict of interest\|\|Stacey, William: No conflict of interest\|\|Ramkalawan, Krista-Marie: No conflict of interest\|\|Kafienah, Yaser: No conflict of interest\|\|Connaughton, Roisin: No conflict of interest\|\|Breslin, Niall: No conflict of interest\|\|McNamara, Deirdre: No conflict of interest\|\|O'Donnell, Sarah: No conflict of interest\|\|Ryan, Barbara: No conflict of interest\|\|O'Connor, Anthony: No conflict of interest |
| P166 | Ms. Becker, Marte: No conflict of interest\|\|Stevens, Toer: No conflict of interest\|\|de Voogd, Floris: No conflict of interest\|\|Wildenberg, Manon: No conflict of interest\|\|Gecse, Krisztina: No conflict of interest\|\|Buskens, Christianne: No conflict of interest |
| P167 | Durak, Muhammed Bahaddin: No conflict of interest\|\|Simsek, Cem: No conflict of interest\|\|Inan, Bayram: No conflict of interest\|\|Prof. Dr. Yuksel, Ilhami: No conflict of interest |
| P168 | Dr. Lee, Chanhyung: No conflict of interest\|\|Koh, Seong-Joon: No conflict of interest\|\|Choi, Kookhwan: No conflict of interest\|\|Lee, Hyun Jung: No conflict of interest\|\|Im, Jong Pil: No conflict of interest\|\|Kim, Joo Sung: No conflict of interest |

| | |
|---|---|
| P169 | Dr. Kanmura, Shuji: No conflict of interest\|\|Tanaka, Akihito: No conflict of interest\|\|Maeda, Nobuhisa: No conflict of interest\|\|Kuwazuru, Kosuke: No conflict of interest\|\|Komaki, Fukiko: No conflict of interest\|\|Sameshima, Yoichi: No conflict of interest\|\|Komaki, Yuga: No conflict of interest\|\|Ido, Akio: No conflict of interest |
| P170 | Dr. Temido, Maria José: No conflict of interest\|\|Gama, João: No conflict of interest\|\|Caetano Oliveira, Rui: No conflict of interest\|\|Silva, Andrea: No conflict of interest\|\|Lopes, Sandra: No conflict of interest\|\|Mendes, Sofia: No conflict of interest\|\|Ferreira, Margarida: No conflict of interest\|\|Ferreira, Manuela: No conflict of interest\|\|Narra Figueiredo, Pedro: No conflict of interest\|\|Portela, Francisco:\|:\|FP received speaker fees from Abbvie, Falk, Ferring, Janssen, Pfizer, Pharmakern, Takeda and Tillotts. |
| P171 | Dr. Gutiérrez Casbas, Ana: No conflict of interest\|\|Bernal, Lorena: No conflict of interest\|\|Zapater, Pedro: No conflict of interest\|\|Herreros, Belen: No conflict of interest\|\|Rodríguez, Andrés: No conflict of interest\|\|Muñoz, Roser: No conflict of interest\|\|Madero, Lucia: No conflict of interest\|\|Orts, Beatriz: No conflict of interest\|\|Belen, Olivia: No conflict of interest\|\|Sempere, Laura: No conflict of interest\|\|Torregrosa, Maria Eugenia: No conflict of interest\|\|Moreno-Pérez, Oscar: No conflict of interest\|\|Francés, Rubén: No conflict of interest |
| P172 | Ms. Walker, Caroline: No conflict of interest\|\|Stapleton, Erica: No conflict of interest\|\|Dempsey, Molly: No conflict of interest\|\|Carroll, Andrew: No conflict of interest\|\|Connaughton, Roisin: No conflict of interest\|\|Breslin, Niall: No conflict of interest\|\|McNamara, Deirdre: No conflict of interest\|\|O'Donnell, Sarah: No conflict of interest\|\|Ryan, Barbara: No conflict of interest\|\|O'Connor, Anthony: No conflict of interest |

| | |
|---|---|
| P173 | Dr. Ukashi, Offir: No conflict of interest\|\|Kopylov , Uri:\|:\|Uri Kopylov received speaker fees from Abbvie, Janssen and Takeda, research support from Takeda and Janssen and consulting fees from Takeda and CTS.\|\|Ungar , Bella:\|:\|Bella Ungar received consultation fees from Neopharm, Takeda, Janssen and Abbvie. \|\|Haj-Natour , Ola: No conflict of interest\|\|Selinger , Limor: No conflict of interest\|\|Neuman , Sandra: No conflict of interest\|\|Yanai , Henit:\|:\|Henit Yanai reports institutional research grants from Pfizer and the ISF; consulting fees from Abbvie, Janssen, Pfizer, and Takeda; honoraria for lectures from Abbvie, Janssen, Pfizer, and Takeda; participation on a Data Safety Monitoring Board or Advisory Board from Abbvie, Pfizer and, Takeda.\|\|Dotan , Iris:\|:\|Iris Dotan reports grants from : Abbott, Abbvie, Athos, Arena, Altman Research, Cambridge Healthcare, Celltrion, Celgene/BMS, Ferring, Falk Pharma, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Integra Holdings, Janssen, Neopharm, Nestle, Pfizer, Rafa laboratories, Roche/Genentech, Sangamo, Sublimity, Sandoz, Takeda, Wildbio. \|\|Yablecovitch , Doron: No conflict of interest\|\|Lahat , Adi: No conflict of interest\|\|Eliakim , Rami:\|:\|Rami Eliakim received consultant and speaker fees from Janssen, Abbvie, Takeda and Medtronic. \|\|Ben-Horin , Shomron:\|:\|Shomron Ben-Horin has received Advisory board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, BMS and Eli Lilly, holds stocks/options in Predicta Med, Evinature & Galmed, and received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, & Galmed. |
| P174 | Ferreiro Iglesias, Rocio: No conflict of interest\|\|Calvino-Suarez, Cristina: No conflict of interest\|\|Baston-Rey, Iria: No conflict of interest\|\|Mauriz-Barreiro, Violeta: No conflict of interest\|\|Dominguez-Munoz, J. Enrique: No conflict of interest\|\|Dr. Barreiro-de Acosta, Manuel: No conflict of interest |

| | |
|---|---|
| P175 | Prof. Dr. Yamamoto-Furusho, Jesús Kazuo: No conflict of interest\|\|Martinez-Vazquez, Manuel:\|:\|M. A. Martínez Vázquez is a speaker bureau member for Abbvie, Janssen, Pfizer, Takeda, Alfasigma, UCB de Mexico, Pfizer; is a clinical research investigator Abbvie, Janssen, Takeda, UCB de Mexico, Pfizer; has been member of advisory boards for Abbvie, Janssen, Takeda, Alfasigma, UCB de Mexico; has received research grants from Abbvie, Takeda, Alfasigma; consulting fees from Abbvie, Janssen, Takeda, Alfasigma; payments for lectures from Abbvie, Janssen, Pfizer, Takeda, Alfasigma, UCB de Mexico, Ferring, Pfizer. \|\|Miranda-Cordero, Rosa:\|:\|R. M. Miranda-Cordero is a speaker bureau member for Janssen, Abbvie, Ferring, Takeda, Pfizer; is a clinical research investigator Takeda, Abbvie; has been member of advisory boards for Janssen, Abbvie, Takeda; has received payments for lectures from Janssen, Abbvie, Ferring, Takeda, Pfizer. \|\|Bosques.Padilla, Francisco:\|:\|F. J. Bosques-Padilla is a speaker bureau member for Falk, Ferring, Alfa Wassermann, AbbVie, Janssen, Takeda, Pfizer; is a clinical research investigator Bristol Myers Squibb, Roche, Celgene, Takeda; has received consulting fees from Alfa Wassermann, AbbVie, Janssen, Takeda. |
| P176 | Prof. Kim, Dong Hyun: No conflict of interest\|\|Kim, Hyun-Soo: No conflict of interest\|\|Kim, Eun Soo: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Kim, Seong-Jung: No conflict of interest\|\|Kim, Kyeong Ok: No conflict of interest\|\|Lee, Yoo Jin: No conflict of interest\|\|Song, Eun Mi: No conflict of interest\|\|Kim, Dae Sung: No conflict of interest |
| P177 | Tomasic, Vedran: No conflict of interest\|\|Biscanin, Alen: No conflict of interest\|\|Dr. Ćaćić, Petra: No conflict of interest\|\|Palac, Leon: No conflict of interest\|\|Dorosulic, Zdravko: No conflict of interest\|\|Kralj, Dominik: No conflict of interest\|\|Babic, Filip: No conflict of interest\|\|Ogresta, Doris: No conflict of interest\|\|Hrabar, Davor: No conflict of interest |
| P178 | Hudson, Alexandra: No conflict of interest\|\|Ma, Henry: No conflict of interest\|\|Lo, Christine: No conflict of interest\|\|Kim, Justin: No conflict of interest\|\|Kuc, Anna: No conflict of interest\|\|Novak, Kerri: No conflict of interest\|\|Carroll, Matthew: No conflict of interest\|\|Wine, Eytan: No conflict of interest\|\|Isaac, Daniela: No conflict of interest\|\|Prof. Dr. Huynh, Hien: No conflict of interest |

| | |
|---|---|
| P179 | Blumenstein, Irina:\|:\|has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Lilly, Ferring, Falk Pharma, Galapagos, Gilead Sciences, Janssen, Pharmacosmos, Pfizer, Takeda Pharmaceuticals; speaker fees from AbbVie, Arena Pharmaceuticals, Bristol-Myers Squibb, Lilly, Ferring, Falk Pharma, Janssen, Pfizer, Pharmacosmos, Takeda Pharmaceuticals, Viatris.\|\|Xuan, Si:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Panaccione, Remo:\|:\|has received consulting fees from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, Takeda Pharmaceuticals; speaker fees from AbbVie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals; advisory board member for AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma, Takeda Pharmaceuticals; and research/educational support from AbbVie, Ferring, Janssen, Pfizer and Takeda.\|\|Baert, Filip:\|:\|has served as a consultant or speaker for AbbVie, Arena, Celltrion, Falk, Ferring, Janssen, Mundipharma, MSD, Pfizer, Sandoz, Takeda, Vifor; and received research grants from AbbVie, Amgen, Chiesi, Ipsen, Janssen, and MSD.\|\|Barreiro-de Acosta, Manuel:\|:\|has served as a speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, GALAPAGOS, Pfizer, Sandoz, Biogen, Fresenius, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, Gebro Pharma, Adacyte and Vifor Pharma.\|\|Ye, Byong Duk:\|:\|has received consulting fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Chong Kun Dang Pharm., CJ Red BIO, Daewoong Pharma., Ferring Korea, IQVIA, Janssen Korea, Kangstem Biotech, Korea Otsuka Pharm., Korea United Pharm. Inc., Medtronic Korea, NanoEntek, ORGANOIDSCIENCES LTD., Pfizer Korea, Takeda, Takeda Korea; speaker fees from AbbVie Korea, Celltrion, Cornerstones Health, Curacle, Ferring Korea, Janssen Korea, Pfizer Korea, Takeda Korea, IQVIA; and research support from Celltrion and Pfizer Korea.\|\|Klaff, Justin:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Vladea, Ramona:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Levy, Gwen:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Holweg, Cecile T.J.:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Sanchez Gonzalez, Yuri:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Dubinsky, Marla C.:\|:\|has received consultancy fees from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Pfizer, Prometheus Labs, Roche, Takeda, UCB, Share Holder Trellus Health. |

| | |
|---|---|
| P180 | Dr. Druvefors, Emma: No conflict of interest\|\|Myrelid, Pär: No conflict of interest\|\|Andersson, Roland E.: No conflict of interest\|\|Landerholm, Kalle: No conflict of interest |
| P181 | Prof. Dr. Laharie, David: No conflict of interest\|\|Rabizadeh, Shervin: No conflict of interest\|\|D'Haens, Geert: No conflict of interest\|\|Dubinsky, Marla: No conflict of interest\|\|Panetta, John C: No conflict of interest\|\|Everts-van der Wind, Annelie: No conflict of interest\|\|Dreesen, Erwin: No conflict of interest\|\|Spencer, Elisabeth: No conflict of interest\|\|Vermeire, Severine: No conflict of interest\|\|Dervieux, Thierry: No conflict of interest |
| P182 | Dr. Capela, Tiago: No conflict of interest\|\|Ferreira, Ana isabel: No conflict of interest\|\|Macedo Silva, Vitor: No conflict of interest\|\|Freitas, Marta: No conflict of interest\|\|Arieira, Cátia: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Dias de Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest |
| P183 | Mr. Yaguchi, Katsuki: No conflict of interest\|\|Kunisaki, Reiko: No conflict of interest\|\|Sato, Sho: No conflict of interest\|\|Izumi, Misato: No conflict of interest\|\|Fukuno, Yoshimi: No conflict of interest\|\|Ebina, Toshiaki: No conflict of interest\|\|Matsune, Yusuke: No conflict of interest\|\|Hama, Takanori: No conflict of interest\|\|Onishi, Misa: No conflict of interest\|\|Kobayashi, Kei: No conflict of interest\|\|Shibui, Shunsuke: No conflict of interest\|\|Toritani, Kenichiro: No conflict of interest\|\|Nishida, Daisuke: No conflict of interest\|\|Matsubayashi, Mao: No conflict of interest\|\|Nakamori, Yoshinori: No conflict of interest\|\|Nishio, Masafumi: No conflict of interest\|\|Umezawa, Shotaro: No conflict of interest\|\|Ogashiwa, Tsuyoshi: No conflict of interest\|\|Sasaki, Tomohiko: No conflict of interest\|\|Fujii, Ayako: No conflict of interest\|\|Kimura, Hideaki: No conflict of interest\|\|Numata, Kazushi: No conflict of interest\|\|Maeda, Shin: No conflict of interest |

| | |
|---|---|
| P184 | Mr. Jójárt, Boldizsár:\|:\|Boldizsár Jójárt is a junior scientist in the EpiPharma Ltd.\|\|Molnár, Tünde: No conflict of interest\|\|Diána, Kata: No conflict of interest\|\|Szabó, Viktória: No conflict of interest\|\|Varga, Árpád: No conflict of interest\|\|Resál, Tamás: No conflict of interest\|\|Bacsúr, Péter: No conflict of interest\|\|Szántó, Kata: No conflict of interest\|\|Földesi, Imre: No conflict of interest\|\|Molnár, Tamás: No conflict of interest\|\|Maléth, József:\|:\|József Maléth is the CSO of the EpiPharma Ltd.\|\|Farkas, Klaudia: No conflict of interest |
| P185 | Mr. Van Oostrom, Joep: No conflict of interest\|\|Anjie, Suzanne: No conflict of interest\|\|Braad, Marlou: No conflict of interest\|\|Horrigan, Jamie: No conflict of interest\|\|Karimi, Neda:\|:\|Neda Karimi has received grant support from Janssen and conference attendance support from Ferring, and Pfizer\|\|Adi, Bhargavi: No conflict of interest\|\|Ganesh, Girish: No conflict of interest\|\|Yang, Suk-Kyun: No conflict of interest\|\|Lasa, Juan:\|:\|Juan Lasa has received consulting fees from AbbVie and honoraria from Janssen\|\|Broër, Christian: No conflict of interest\|\|de Kruif, Anja: No conflict of interest\|\|Olivera Sendra, Pablo:\|:\|Pablo A. Olivera has received consulting fees from AbbVie, Takeda, and Janssen; honoraria from Takeda and Janssen; and financial support for attending meetings, travel, or both from AbbVie, Takeda, Janssen, and Ferring.\|\|Ye, Byong Duk:\|:\|Byong Duk Ye has received consulting fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Chong Kun Dang Pharm, CJ Red BIO, Daewoong Pharma., Ferring Korea, IQVIA, Janssen Korea, Kangstem Biotech, Korea Otsuka Pharm., Korea United Pharm. Inc., Medtronic Korea, NanoEntek, ORGANOIDSCIENCES LTD., Pfizer Korea, Takeda, Takeda Korea; speaker fees from AbbVie Korea, Celltrion, Cornerstones Health, Curacle, Ferring Korea, Janssen Korea, Pfizer Korea, Takeda Korea, IQVIA; and research support from Celltrion and Pfizer Korea.\|\|Banerjee, Rupa: No conflict of interest\|\|Connor, Susan:\|:\|Susan Connor has received honoraria for Advisory Board participation, speaker fees, educational support and/or research support from: Abbvie, BMS, Celltrion, Chiesi, Eli-Lilly, DrFalk, Ferring, Fresenius Kabi, Gilead, GSK, Janssen, MSD, Novartis, Organon, Pfizer, Sandoz, Takeda, Agency for Clinical Innovation, Gastroenterological Society of Australia, Medical Research Future Fund and The Leona M and Harry B Helmsley Charitable Trust.\|\|Siegel, Corey:\|:\|Corey A Siegel has received grant support from Abbvie, Janssen, Pfizer and Takeda; has served as a consultant for Abbvie, BMS, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, ProciseDx, Prometheus Biosciences, Takeda, and Trellus Health; has served as a speaker for CME activities for Abbvie, Janssen, Pfizer and Takeda; has received licensing fees from Takeda for intellectual property created by MiTest Health, LLC; and is a co-founder of MiTest Health, LLC.\|\|Peyrin-Biroulet, Laurent:\|:\|Laurent Peyrin-Biroulet reports personal fees from Galapagos, AbbVie, Janssen Pharmaceuticals, Genentech, Alimentiv, Ferring Pharmaceuticals, Tillots Pharma, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena Pharmaceuticals, Gilead Sciences, Amgen, BMS, Vifor Pharma, Norgine, Mylan, Eli Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, and Thermo Fisher; grants from AbbVie, MSD, Takeda, and Fresenius Kabi; and stock options from Clinical Trials Mobile Application.\|\|Gecse, Krisztina:\|:\|Krisztina B. Gecse has received grants from Pfizer Inc, Celltrion and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, |

| | |
|---|---|
| | Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Abbvie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts.\|\|D'Haens, Geert:\|:\|Geert R. D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences. |
| P186 | Dubinsky, Marla C:\|:\|Personal fees (consulting): AbbVie, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Genentech, Gilead Sciences, Janssen Pharmaceuticals, Pfizer Inc, Prometheus Laboratories, Takeda, Trellus Health, UCB \|\|Gardiner, Sean:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Hur, Peter:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc\|\|Guo, Xiang: No conflict of interest\|\|Paulissen, Jerome:\|:\|Other (employee): Syneos Health; Other (paid contractor): Pfizer Inc\|\|Cappelleri, Joseph C:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Bushmakin, Andrew G:\|:\|Personal fees: Pfizer Inc; Other: Pfizer Inc (employee)\|\|Panés, Julian:\|:\|Grants: AbbVie, Pfizer Inc; Personal fees: AbbVie, Arena, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Immunic, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer Inc, Progenity, Revolo, Takeda, Theravance Biopharma, Wassermann |

| | |
|---|---|
| P187 | Mr. Pruijt, Maarten:\|:\|Maarten Pruijt received speaker fees from Janssen\|\|de Voogd, Floris:\|:\|Floris de Voogd received speaker or honoraria fees from AbbVie and Janssen\|\|Montazeri, Nahid: No conflict of interest\|\|Jamaludin, Faridi: No conflict of interest\|\|D'Haens, Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|Gecse, Krisztina:\|:\|Krisztina Gecse has received grants from Pfizer Inc, Celltrion and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Abbvie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts. |
| P188 | Dr. Ukashi, Offir: No conflict of interest\|\|Yablecovitch, Doron: No conflict of interest\|\|Lahat, Adi: No conflict of interest\|\|Selinger, Limor: No conflict of interest\|\|Neuman, Sandra: No conflict of interest\|\|Eliakim, Rami:\|:\|Rami Eliakim received consultant and speaker fees from Janssen, Abbvie, Takeda and Medtronic. \|\|Ben-Horin, Shomron:\|:\|Shomron Ben-Horin has received Advisory board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, BMS and Eli Lilly, holds stocks/options in Predicta Med, Evinature & Galmed, and received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, & Galmed. \|\|Kopylov, Uri:\|:\|Uri Kopylov received speaker fees from Abbvie, Janssen and Takeda, research support from Takeda and Janssen and consulting fees from Takeda and CTS. |

| | |
|---|---|
| P189 | Dr. Zittan, Eran:\|:\|EZ- has received research support and consulting fees from Janssen, AbbVie, Takeda, Neopharm, Celgene and Pfizer.\|\|Levy, Matthew: No conflict of interest\|\|Saban , Lotem: No conflict of interest\|\|Vered, Shiraz: No conflict of interest\|\|Steinhart, A. Hillary:\|:\|has received research grants - AbbVie, Celgene, Red Hill Biopharma, Janssen, Takeda, Roche, Arena.\|Honorarium for Educational Event Presentations - AbbVie, Ferring, Janssen, Pfizer, Takeda, Shire. \|Advisory Board - AbbVie, Janssen, Merck, Pfizer, Pendopharm, Takeda, Shire.\|\|\|Milgrom, Raquel: No conflict of interest\|\|Gralnek, Ian M: No conflict of interest\|\|Silverberg, Mark S:\|:\|MSS - received research support and consulting fees from Janssen, AbbVie, Takeda, Pfizer and Prometheus.\|\|Zelber-Sagi, Shira: No conflict of interest |
| P190 | Dr. Rao, Abhishek: No conflict of interest\|\|Bazarova, Alina: No conflict of interest\|\|Mitra, Pathrabali: No conflict of interest\|\|Majumder, Snehali: No conflict of interest\|\|Parigi , Tommaso: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Iacucci, Marietta: No conflict of interest\|\|Shivaji, Uday: No conflict of interest |
| P191 | Dr. Karri, Rama: No conflict of interest\|\|Grewal, Callum: No conflict of interest\|\|Yassin, Nuha: No conflict of interest |
| P192 | Prof. Dr. Na, Ji Eun: No conflict of interest\|\|Sung Noh, Hong: No conflict of interest\|\|Young-Ho, Kim: No conflict of interest\|\|Tae-Oh, Kim: No conflict of interest\|\|Sang-Bum, Kang: No conflict of interest\|\|Sung Hoon, Jung: No conflict of interest |

| | |
|---|---|
| P193 | Dr. Miyoshi, Jun:\|:\|Lecture fees from AbbVie GK, Miyarisan Pharma. Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K.\|\|Morikubo, Hiromu: No conflict of interest\|\|Yonezawa, Hiromi: No conflict of interest\|\|Kimura, Yoko: No conflict of interest\|\|Moue, Chihiro: No conflict of interest\|\|Komatsu, Haruka: No conflict of interest\|\|Matsuura, Minoru:\|:\|Research grants from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nippon Kayaku Co., Ltd., and Kissei Pharmaceutical Co., Ltd. Commercial research funding from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and JIMRO Co.\|\|Hisamatsu, Tadakazu:\|:\|Joint research with Alfresa Pharma Co., Ltd. and EA Pharma Co., Ltd. Grant support from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd. Consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Celgene K.K., EA Pharma Co., Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Inc. |
| P194 | Bequet, Emeline: No conflict of interest\|\|Salée, Catherine: No conflict of interest\|\|Bletard, Noella: No conflict of interest\|\|Vieujean, Sophie: No conflict of interest\|\|Massot, Charlotte: No conflict of interest\|\|Fonzé, Florian: No conflict of interest\|\|Sarter, Hélène: No conflict of interest\|\|Ley, Delphine: No conflict of interest\|\|Colinet, Stéphanie: No conflict of interest\|\|Delvenne, Phlippe: No conflict of interest\|\|Seghaye, Marie-Christine: No conflict of interest\|\|Louis, Edouard: No conflict of interest\|\|Meuwis, Marie-Alice: No conflict of interest |
| P195 | Dr. Rafael, Maria Ana: No conflict of interest\|\|Bordalo Ferreira, Filipa: No conflict of interest\|\|Oliveira, Ana Maria: No conflict of interest\|\|Nassauer Mónica, Ana: No conflict of interest\|\|Santos, Liliana: No conflict of interest |

| | |
|---|---|
| P196 | Ms. Van Der Does De Willebois, Eline: No conflict of interest\|\|Bellato, Vittoria: No conflict of interest\|\|van Dieren, Susan: No conflict of interest\|\|Duijvestein, Marjolijn: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|Vignali, Andrea: No conflict of interest\|\|Bemelman, Willem: No conflict of interest |
| P197 | Ms. Sorokina Alexdóttir, Marta: No conflict of interest\|\|Pehrsson, Martin: No conflict of interest\|\|Karsdal, Morten A.:\|:\|Shareholder at Nordic Bioscience\|\|Godskesen, Line E.: No conflict of interest\|\|Krag , Aleksander: No conflict of interest\|\|Kjeldsen , Jens: No conflict of interest\|\|Mortensen, Joachim H.: No conflict of interest |
| P198 | Dr. Silva Mendes, Sofia: No conflict of interest\|\|Lepore, Federica: No conflict of interest\|\|Hussey, Mary: No conflict of interest\|\|Cataletti, Giovanni: No conflict of interest\|\|Maconi, Giovanni: No conflict of interest |
| P199 | Ms. Van Lierop, Lisa: No conflict of interest\|\|te Groen, Maarten: No conflict of interest\|\|Derikx, Lauranne: No conflict of interest\|\|Ylstra, Bauke: No conflict of interest\|\|Hoentjen, Frank: No conflict of interest\|\|Nagtegaal, Iris: No conflict of interest\|\|Simmer, Femke: No conflict of interest |
| P200 | Dr. Hyun, Hye Kyung: No conflict of interest\|\|Lee, Hye Won: No conflict of interest\|\|Jihye, Park: No conflict of interest\|\|Park, Soo Jung: No conflict of interest\|\|Park, Jae Jun: No conflict of interest\|\|Kim, Tae Il: No conflict of interest\|\|Kim, Won Ho: No conflict of interest\|\|Lee, Jae Seung: No conflict of interest\|\|Kim, Beom Kyung: No conflict of interest\|\|Park, Jun Yong: No conflict of interest\|\|Kim, Do Young: No conflict of interest\|\|Ahn, Sang Hoon: No conflict of interest\|\|Kim, Seung Up: No conflict of interest\|\|Cheon, Jae Hee: No conflict of interest |

| | |
|---|---|
| P201 | Dr. Domislović, Viktor: No conflict of interest\|\|Hrabric Sonje, Kristina: No conflict of interest\|\|Brinar, Marko: No conflict of interest\|\|Cukovic-Cavka, Silvija: No conflict of interest\|\|Turk, Niksa: No conflict of interest\|\|Grgic, Dora: No conflict of interest\|\|Barisic, Ana: No conflict of interest\|\|Jelakovic, Mislav: No conflict of interest\|\|Prutki, Maja: No conflict of interest\|\|Krznaric, Zeljko: No conflict of interest |
| P202 | Mr. Serra-Ruiz, Xavier: No conflict of interest\|\|Herrera-de Guise, Claudia: No conflict of interest\|\|Esperalba, Juliana: No conflict of interest\|\|Mayorga Ayala, Luis: No conflict of interest\|\|Céspedes Martínez, Elena: No conflict of interest\|\|Robles Alonso, Virginia: No conflict of interest\|\|Casellas, Francesc: No conflict of interest\|\|Pérez Martínez, Zahira: No conflict of interest\|\|Oller, Elena: No conflict of interest\|\|Borruel Sainz, Natalia: No conflict of interest |
| P203 | Dr. Rendek, Zlatica: No conflict of interest\|\|Falk, Magnus: No conflict of interest\|\|Grodzinsky, Ewa: No conflict of interest\|\|Kechagias, Stergios: No conflict of interest\|\|Hjortswang, Henrik: No conflict of interest |
| P204 | Mrs. Molina Arriero, Gema: No conflict of interest\|\|Mauriz Barreiro, María Violeta: No conflict of interest\|\|Echarri Piudo, Ana: No conflict of interest\|\|Fraga Iriso, Rebeca: No conflict of interest\|\|González Furelos, Tania: No conflict of interest\|\|López de Ullibarri, Ignacio: No conflict of interest\|\|Vázquez Rey, María Teresa: No conflict of interest\|\|Calviño Suárez, Cristina: No conflict of interest\|\|Carmona Campos, Amalia: No conflict of interest\|\|Tejido Sandoval, Coral: No conflict of interest\|\|García Morales, Natalia: No conflict of interest |

| | |
|---|---|
| P205 | Gabbiadini, Roberto: No conflict of interest\|\|Spaggiari, Paola: No conflict of interest\|\|Ms. Dal Buono, Arianna: No conflict of interest\|\|Iuzzolino, Martina: No conflict of interest\|\|Furfaro, Federica: No conflict of interest\|\|D'Amico, Ferdinando: No conflict of interest\|\|Repici, Alessandro: No conflict of interest\|\|Spinelli, Antonino: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest |
| P206 | Dr. Gutierrez Becker, Benjamin: No conflict of interest\|\|Arús-Pous, Josep:\|:\|Employee of Roche\|\|Yao, Heming:\|:\|Employee of Genentech\|\|Luscher, Jerome:\|:\|Genentech Employee\|\|Richmond, David:\|:\|Genentech Employee\|\|Fisher, Emily:\|:\|Roche Employee\|\|Bojic, Daniela:\|:\|Roche employee\|\|Bigorgne, Amelie:\|:\|Roche employee\|\|Prunotto, Marco:\|:\|Roche Employee |
| P207 | Prof. Fumery, Mathurin: No conflict of interest\|\|Savoye, Guillaume: No conflict of interest\|\|Ley, Delphine: No conflict of interest\|\|Dupont-Lucas, Claire: No conflict of interest\|\|Bertrand, Valérie: No conflict of interest\|\|Wils, Pauline: No conflict of interest\|\|Guillon, Nathalie: No conflict of interest\|\|Sarter, Helene: No conflict of interest\|\|Gower-Rousseau, Corinne: No conflict of interest\|\|Turck, Dominique: No conflict of interest\|\|Leroyer, Ariane: No conflict of interest |
| P208 | Dr. Garrido, Isabel: No conflict of interest\|\|Lopes, Susana: No conflict of interest\|\|Dias, Cláudia: No conflict of interest\|\|Macedo, Guilherme: No conflict of interest |
| P209 | Dr. Rao, Abhishek: No conflict of interest\|\|Bazarova, Alina: No conflict of interest\|\|Mitra, Pathrabali: No conflict of interest\|\|Parigi , Tommaso: No conflict of interest\|\|Majumder, Snehali: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Iacucci, Marietta: No conflict of interest\|\|Shivaji, Uday: No conflict of interest |

| | |
|---|---|
| P210 | Catassi, Giulia: No conflict of interest\|\|D'Arcangelo, Giulia: No conflict of interest\|\|Norsa, Lorenzo: No conflict of interest\|\|Bramuzzo, Matteo: No conflict of interest\|\|Hojsak, Iva: No conflict of interest\|\|Kolho, Kaija-Leena: No conflict of interest\|\|Romano, Claudio: No conflict of interest\|\|Gasparetto, Marco: No conflict of interest\|\|Di Giorgio, Angelo: No conflict of interest\|\|Hussey, Seamus: No conflict of interest\|\|Yerushalmy-Feler, Anat: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Matar, Manar: No conflict of interest\|\|Vais, Batya: No conflict of interest\|\|Karoliny, Anna: No conflict of interest\|\|Alvisi, Patrizia: No conflict of interest\|\|Tzivinikos, Christos: No conflict of interest\|\|Aloi, Marina: No conflict of interest |
| P211 | Ms. Demers, Karlijn: No conflict of interest\|\|Rezazadeh Ardabili , Ashkan: No conflict of interest\|\|Bongers, Bart C.: No conflict of interest\|\|Romberg-Camps , Mariëlle J.L.: No conflict of interest\|\|van Bodegraven, Ad A.:\|:\|Ad A. van Bodegraven has served as speaker, adviser and/or principal investigator for AbbVie, Arandal, Arena, Celgene, Ferring, Galapagos, Janssen, MSD, Pfizer, Roche, Takeda, TEVA, and received research grants from Pfizer, TEVA, Eurostars funding, ZonMW, all outside the submitted work.\|\|Jonkers , Daisy M.A.E.:\|:\|Daisy M.A.E. Jonkers reports grants from Top Knowledge Institute (Well on Wheat), grants from Horizon 2020 DISCOvERIE, grants from NWO-CCC Partnership program (Carbokinetics), all outside the submitted work. \|\|Pierik, Marieke J.:\|:\|Marieke J. Pierik reports grants and non-financial support from Falk Pharma, grants from European commission, grants from ZONMW (Dutch national research fund), grants and non-financial support from Takeda, grants and non-financial support from Johnson and Johnson, grants and non-financial support from Abbvie, non-financial support from Ferring, non-financial support from Immunodiagnostics, non-financial support from MSD, all outside the submitted work.\|\|Stassen, Laurents P.S.:\|:\|Laurents P.S. Stassen has served as a speaker and received research support from Takeda, outside the submitted work. |
| P212 | Dr. Johansen, Martha Pollen: No conflict of interest |

| | |
|---|---|
| P213 | Dr. Flores, Cristina: No conflict of interest\|\|Souza, Rosenir Korpalski: No conflict of interest\|\|De Bona, Laura Renata: No conflict of interest\|\|Deconto, Mariana Dall'agnol: No conflict of interest\|\|Arrojo, Raul Salinas: No conflict of interest\|\|Gazzoni, Fernando Ferreira: No conflict of interest\|\|Oliveira, Tiago Franco: No conflict of interest |
| P214 | Dr. Miller, Charles: No conflict of interest\|\|Taylor, Stuart: No conflict of interest\|\|Emmanuel, Anton: No conflict of interest\|\|Zarate-Lopez, Natalia: No conflict of interest\|\|Pakpoor, Jina: No conflict of interest\|\|Fitzke, Heather: No conflict of interest\|\|Menys, Alex: No conflict of interest\|\|Holmes, Judith: No conflict of interest\|\|Atkinson, David: No conflict of interest\|\|Markus, Julia: No conflict of interest\|\|Blad, William: No conflict of interest\|\|Bloom, Stuart: No conflict of interest |
| P215 | Dr. Catalàn-Serra, Ignacio: No conflict of interest\|\|Xu, Weili: No conflict of interest\|\|Bruland, Torunn: No conflict of interest\|\|Larbi, Anis: No conflict of interest\|\|Sandvik, Arne Kristian: No conflict of interest |
| P216 | Dajti, Gerti: No conflict of interest\|\|Cardelli, Stefano: No conflict of interest\|\|Rizzello, Fernando: No conflict of interest\|\|Gionchetti, Paolo: No conflict of interest\|\|Poggioli, Gilberto: No conflict of interest\|\|Rottoli, Matteo: No conflict of interest |
| P217 | Dr. Ribaldone, Davide Giuseppe: No conflict of interest\|\|Arezzo, Alberto: No conflict of interest\|\|Cardenia, Vladimiro: No conflict of interest\|\|Caviglia, Gian Paolo: No conflict of interest\|\|Abate, Maria Lorena: No conflict of interest\|\|Saracco, Giorgio Maria: No conflict of interest\|\|Astegiano, Marco: No conflict of interest\|\|Morino, Mario: No conflict of interest |

| | |
|---|---|
| P218 | Dr. Nardone, Olga Maria: No conflict of interest\|\|Martinelli, Massimo: No conflict of interest\|\|De sire, Roberto: No conflict of interest\|\|Calabrese, Giulio: No conflict of interest\|\|Caiazzo, Anna: No conflict of interest\|\|Fioretti, Maria Teresa: No conflict of interest\|\|Testa, Anna: No conflict of interest\|\|Limansky, Lara: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|Di Luna, Imma: No conflict of interest\|\|Miele, Erasmo: No conflict of interest\|\|Staiano, Annamaria: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest |
| P219 | Dr. Lee, Chanhyung: No conflict of interest\|\|Han, Kyungdo: No conflict of interest\|\|Yu, Hosun: No conflict of interest\|\|Kim, Seulji: No conflict of interest\|\|Choi, Kookhwan: No conflict of interest\|\|Lee, Hyun Jung: No conflict of interest\|\|Koh, Seong-Joon: No conflict of interest\|\|Im, Jong Pil: No conflict of interest\|\|Kim, Joo Sung: No conflict of interest |
| P220 | Dr. Elosua Gonzalez, Alfonso: No conflict of interest\|\|Rubio, Saioa: No conflict of interest\|\|Irisarri, Rebeca: No conflict of interest\|\|Campillo, Ana: No conflict of interest\|\|Nantes, Óscar: No conflict of interest\|\|Vicuña, Miren: No conflict of interest\|\|Angós, Ramón: No conflict of interest\|\|Zozaya, José Manuel: No conflict of interest\|\|Rodríguez, Cristina: No conflict of interest |

| | |
|---|---|
| P221 | Mr. Van Linschoten, Reinier: No conflict of interest\|\|Huberts, Anouk Sjoukje: No conflict of interest\|\|van Leeuwen, Nikki: No conflict of interest\|\|Hazelzet, Jan Antonius: No conflict of interest\|\|van der Woude, C. Janneke:\|:\|C. van der Woude has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. \|\|West, Rachel Louise:\|:\|Dr. West reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, Galapagos and Takeda and personal fees from AbbVie, Janssen and Pfizer outside the submitted work.\|\|van Noord, Desirée:\|:\|Dr. Leemreis reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, Galapagos and Takeda and personal fees from Janssen and Takeda outside the submitted work. |
| P222 | Dr. Mardare, Roxana: No conflict of interest\|\|Eskell, Lucy: No conflict of interest\|\|Machta, Joseph: No conflict of interest\|\|Fell, John Michael Edgar: No conflict of interest\|\|Thangarajah, Dhamyanthi: No conflict of interest |
| P223 | Dr. Szymanska, Edyta: No conflict of interest\|\|Szymanska, Sylwia: No conflict of interest\|\|Karkucinka-Wieckowska, Agnieszka: No conflict of interest\|\|Aldona, Wierzbicka: No conflict of interest\|\|Kierkus, Jaroslaw: No conflict of interest\|\|Dadalski, Maciej: No conflict of interest |
| P224 | Cantoro, Laura: No conflict of interest\|\|Monterubbianesi, Rita: No conflict of interest\|\|Camastra, Caterina: No conflict of interest\|\|Falasco, Giuliano: No conflict of interest\|\|Pantanella, Paolo: No conflict of interest\|\|Cosintino, Rocco: No conflict of interest\|\|Faggiani, Roberto: No conflict of interest\|\|Dr. Fiorino, Gionata: No conflict of interest |

| | |
|---|---|
| P225 | Mr. Katsaros, Marios: No conflict of interest\|\|Palmela, Carolina: No conflict of interest\|\|Kalogirou, Maria: No conflict of interest\|\|Frias Gomes, Catarina: No conflict of interest\|\|Katsoula, Anastasia: No conflict of interest\|\|Torres, Joana: No conflict of interest\|\|Giouleme, Olga: No conflict of interest |
| P226 | Dr. Dyall, Lovesh: No conflict of interest\|\|Kyle, Janet: No conflict of interest\|\|Misra, Ravi: No conflict of interest\|\|Clark, Heather: No conflict of interest\|\|Limdi, Jimmy: No conflict of interest\|\|Cooney, Rachel: No conflict of interest\|\|Brookes, Matthew: No conflict of interest\|\|Fogden, Edward: No conflict of interest\|\|Pattni, Sanjeev: No conflict of interest\|\|Sharma, Naveen: No conflict of interest\|\|Iqbal, Tariq: No conflict of interest\|\|Munkholm, Pia: No conflict of interest\|\|Burisch, Johan: No conflict of interest\|\|Arebi, Naila: No conflict of interest |
| P227 | Dr. Kim, Chong:\|:\|Chong Kim is an employee and shareholder of Gilead. \|\|Brown, Fiona L:\|:\|Fiona L Brown is an employee of Evidera, which received funding from Gilead to conduct the study.\|\|Burk, Caroline:\|:\|Caroline Burk is a contractor of Gilead. \|\|Anatchkova, Milena:\|:\|Milena Anatchkova is an employee of Evidera, which received funding from Gilead to conduct the study.\|\|Sargalo, Nashmel:\|:\|Nashmel Sargalo is an employee of Evidera, which received funding from Gilead to conduct the study.\|\|Kaushik, Ankita:\|:\|Ankita Kaushik is an employee and shareholder of Gilead. |

| | |
|---|---|
| P228 | Dr. Kempinski, Radoslaw: No conflict of interest\|\|Kraszewski, Sebastian: No conflict of interest\|\|Nizioł, Patrycja: No conflict of interest\|\|Neubauer, Katarzyna: No conflict of interest |
| P229 | Prof. Shin, Jongbeom: No conflict of interest\|\|Kim, Sun Young: No conflict of interest\|\|Kwon, Dam: No conflict of interest\|\|Cha, Boram: No conflict of interest\|\|Kong, Sung Min: No conflict of interest\|\|Kim, Jun-Seob: No conflict of interest\|\|Kwon, Kye Sook: No conflict of interest\|\|Kim, Hyungkil: No conflict of interest |
| P230 | Dr. Saravanapavan, Hajeena: No conflict of interest\|\|Rath, Silke: No conflict of interest\|\|Inniss, Saskia: No conflict of interest\|\|Ong, Meryl: No conflict of interest\|\|Sabalić, Maja: No conflict of interest\|\|D'Aiuto, Francesco: No conflict of interest\|\|Rahman, Farooq: No conflict of interest\|\|Smith, Andrew M: No conflict of interest |
| P231 | Dr. Orfanoudaki, Eleni: No conflict of interest\|\|Chlorakis, Georgios: No conflict of interest\|\|Foteinogiannopoulou, Kalliopi: No conflict of interest\|\|Drygiannakis, Ioannis: No conflict of interest\|\|Theodoraki, Eirini: No conflict of interest\|\|Tsafaridou, Maria: No conflict of interest\|\|Koutroubakis, Ioannis:\|:\|Ioannis Koutroubakis has received support by Abbvie, Genesis, Ferring, Janssen, MSD, Pfizer, Shire, Vianex and Takeda |
| P232 | Ali, Kareem: No conflict of interest\|\|Bahgat, Monir: No conflict of interest\|\|Borg, Asmaa: No conflict of interest\|\|Maher, Maha: No conflict of interest\|\|Dr. Abozeid, Fatma: No conflict of interest |
| P233 | Mrs. Kijora-Jaroszewska, Olga: No conflict of interest\|\|Neubauer, Katarzyna: No conflict of interest |

| | |
|---|---|
| P234 | Dr. Uchino, Motoi: No conflict of interest\|\|Ikeuchi, Hiroki: No conflict of interest\|\|Noiguchi, Tatsuki: No conflict of interest\|\|Okabayashi, Koji: No conflict of interest\|\|Futami, Kitaro: No conflict of interest\|\|Tanaka, Shinji: No conflict of interest\|\|Ohge, Hiroki: No conflict of interest\|\|Watanabe, Kazuhiro: No conflict of interest\|\|Itabashi, Michio: No conflict of interest\|\|Okamoto, Kinya: No conflict of interest\|\|Okita, Yoshiki: No conflict of interest\|\|Mzushima, Tsunekazu: No conflict of interest\|\|Mizuuchi, Yusuke: No conflict of interest\|\|Yamada, Kazutaka: No conflict of interest\|\|Shimada, Yoshifumi: No conflict of interest\|\|Sato, Yu: No conflict of interest\|\|Kimura, Hideaki: No conflict of interest\|\|Takahashi, Kenichi: No conflict of interest\|\|Hida, Koya: No conflict of interest\|\|Kinugasa, Yusuke: No conflict of interest\|\|Okuda, Junji: No conflict of interest\|\|Daito, Koji: No conflict of interest\|\|Koyama, Fumikazu: No conflict of interest\|\|Ueno, Hideaki: No conflict of interest\|\|Yamamoto, Takayuki: No conflict of interest\|\|Hanai, Tsunekazu: No conflict of interest\|\|Kobayashi, Hirotoshi: No conflict of interest\|\|Kono, Toru: No conflict of interest\|\|Ajioka, Yoichi: No conflict of interest\|\|Sugihara, Kenichi: No conflict of interest\|\|Ishihara, Soichiro: No conflict of interest |
| P235 | Dr. Qazi, Taha:\|:\|TQ is on the advisory board and a speaker for Abbvie, Pfizer, and BMS. He is also on the advisory board for Itierative Scope and a speaker for BMS and Janssen. \|\|Ottichilo, Ronald: No conflict of interest\|\|Grove, David: No conflict of interest\|\|Rayan, Carla: No conflict of interest\|\|Cohen, Benjamin:\|:\|BLC receives the following financial support: Advisory Boards and Consultant for Abbvie, Celgene-Bristol Myers Squibb, Pfizer, Sublimity Therapeutics, Takeda, TARGET RWE; CME Companies: Cornerstones, Vindico; Speaking: Abbvie; Educational Grant: Pfizer\|\|Bhat, Shubha: No conflict of interest\|\|Regueiro, Miguel:\|:\|Unrestricted Educational Grants from Abbvie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead, BMS, Lilly\|\|Advisory Boards and Consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., BMS, Trellis\|\|CME Companies: CME Outfitters, Imedex, GI Health Foundation (GiHF), Cornerstones, Remedy, MJH life sciences, Medscape, MDEducation, WebMD, HMPGlobal\|\|Royalties and Editorships: Wolters Kluwer Health as Author/Editor of UpToDate, Crohn's and Colitis Foundation as Editor-in-Chief, CC360\|\|Dweik, Raed:\|:\|RD: BreathTech\|\|Rieder, Florian:\|:\|FR is on the advisory board for or consultant to Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Cowen, Ferring, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Organovo, Origo, Pfizer, fPliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, 89Bio. FR is supported by grants from the National Institutes of Health (R01DK123233), Rainin Foundation and the Helmsley Charitable Trust through the Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. |

| | |
|---|---|
| P236 | Ms. Van Der Does De Willebois, Eline: No conflict of interest\|\|Duijvestein, Marjolijn: No conflict of interest\|\|Wasmann, Karin: No conflict of interest\|\|D'Haens, Geert: No conflict of interest\|\|van der Bilt, Jarmila: No conflict of interest\|\|Mundt, Marco: No conflict of interest\|\|Hompes, Roel: No conflict of interest\|\|van der Vlugt, Manon: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|Bemelman, Willem: No conflict of interest |
| P237 | Piazza, Nicole: No conflict of interest\|\|Dr. Noviello, Daniele: No conflict of interest\|\|Filippi, Elisabetta: No conflict of interest\|\|Conforti, Francesco: No conflict of interest\|\|Furfaro, Federica:\|:\|F Furfaro received consulting fees form MSD and Abbvie and lecture fees from Janssen and Pfizer.\|\|Fraquelli, Mirella: No conflict of interest\|\|Fiorino, Gionata:\|:\|G Fiorino received consultancy fees from Ferring, Merck Sharp & Dohme (MSD), AbbVie, Takeda, Janssen, Amgen, Sandoz, Samsung Bioepis, Celltrion.\|\|Danese, Silvio:\|:\|S Danese has served as a speaker, consultant and advisory board member for Schering- Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & John-son, Nikkiso Europe GMBH, Theravance.\|\|Allocca, Mariangela:\|:\|M. Allocca received consulting fees from Nikkiso Europe and lecture fees from Janssen and Pfizer.\|\|Caprioli, Flavio:\|:\|FC has served as consultant to Mundipharma, AbbVie, MSD, Takeda, Janssen, Roche, and Celgene; received lecture fees from AbbVie, Ferring, Takeda, Allergy Therapeutics, and Janssen; and received unrestricted research grants from Giuliani, SOFAR, MS&D, Takeda, and AbbVie. |
| P238 | xia, Qing: No conflict of interest\|\|Mujiri, Shorena: No conflict of interest\|\|Mr. Syme, Graeme: No conflict of interest\|\|Mehta, Shameer: No conflict of interest |

| | |
|---|---|
| P239 | Dr. Khan, Nabeel:\|:\|Nabeel Khan has received an unrestricted research grant from Pfizer, Luitpold, and Takeda Pharmaceuticals as well as Samsung BioEpis. . He has served on Advisory Board of Pharmacosmos. \|\|Mahmud, Nadim: No conflict of interest\|\|Patel, Manthankumar: No conflict of interest\|\|Sundararajan, Ramaswamy: No conflict of interest\|\|Reinisch, Walter:\|:\|Walter Reinisch has served (1) as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, (2) as a consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Tx, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, (3) as an advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC, and (4) has received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnostik, MSD". |

| | |
|---|---|
| P240 | Lund, Charlotte: No conflict of interest\|\|Strande, Vibeke:\|:\|Grants from Takeda\|\|Småstuen, Milada C.: No conflict of interest\|\|Bengtson, May-Bente: No conflict of interest\|\|Cetinkaya, Raziye Boyar: No conflict of interest\|\|Detlie, Trond Espen:\|:\|Served as a speaker, consultant or advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and\|Vifor Pharma. Received unrestricted research grants from AbbVie and Pharmacosmos.\|\|\|Frigstad, Svein Oskar: No conflict of interest\|\|Medhus, Asle Wilhelm:\|:\|Received "unrestricted research grant" from Takeda.\|\|Henriksen, Magne: No conflict of interest\|\|Holten, Kristina I. Aass: No conflict of interest\|\|Hovde, Øistein:\|:\|Lecturer and advisory board etc. for Takeda, Janssen, Bristol-Myers Squibb Norway, Abbvie.\|\|\|Huppertz-Hauss, Gert: No conflict of interest\|\|Johansen, Ingunn: No conflict of interest\|\|Olsen, Bjørn Christian: No conflict of interest\|\|Opheim, Randi: No conflict of interest\|\|Pallenschat, Jens: No conflict of interest\|\|Perminow, Gøri: No conflict of interest\|\|Ricanek, Petr: No conflict of interest\|\|Vatn, Simen: No conflict of interest\|\|Aabrekk, Tone Bergene: No conflict of interest\|\|Kristensen, Vendel A.:\|:\|Consultant fee from Takeda, Tillotts Pharma and Janssen-Cilag.\|\|Høivik, Marte Lie:\|:\|Served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma |
| P241 | Pillet, Julie: No conflict of interest\|\|Perrin, Julia: No conflict of interest\|\|Martel, Myriam: No conflict of interest\|\|Kherad, Omar: No conflict of interest\|\|Dr. Restellini, Sophie: No conflict of interest |
| P242 | Vuyyuru, Sudheer: No conflict of interest\|\|Solitano, Virginia: No conflict of interest\|\|Nguyen, Tran: No conflict of interest\|\|Rieder, Florian:\|:\|Consultant to Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX,Roche, Samsung, Surmodics, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB, Ysios, 89Bio.\|\|Jairath, Vipul:\|:\|Received has received consulting/advisory board fees from AbbVie, Alimentiv Inc., Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker’s fees from, Abbvie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi. |

| | |
|---|---|
| P243 | Mr. Klomberg, Renz: No conflict of interest\|\|Kaper, Damey: No conflict of interest\|\|Barendregt, Daniëlle: No conflict of interest\|\|Vuijk, Stephanie: No conflict of interest\|\|Schreurs, Marco: No conflict of interest\|\|Charrout, Mohammed: No conflict of interest\|\|Ruemmele, Frank: No conflict of interest\|\|Kemos, Polychronis: No conflict of interest\|\|Croft, Nicholas: No conflict of interest\|\|Samsom, Janneke: No conflict of interest\|\|de Ridder, Lissy: No conflict of interest |
| P244 | Gagnaire, Marion: No conflict of interest\|\|Bendavid, Claude: No conflict of interest\|\|Dewitte, Marie: No conflict of interest\|\|Brunet, Tanguy: No conflict of interest\|\|Desfourneaux, Véronique: No conflict of interest\|\|Bordet, Martin: No conflict of interest\|\|Siproudhis, Laurent: No conflict of interest\|\|Prof. Dr. Bouguen, Guillaume: No conflict of interest |
| P245 | Dr. Smith, Emily: No conflict of interest\|\|Chen, Johnson: No conflict of interest\|\|Pan, Yushan: No conflict of interest\|\|Mahtani , Prerna: No conflict of interest\|\|Lukin, Dana:\|:\|Consulting: Abbvie, BI, BMS, Eli Lilly, Janssen, Palatin Technologies, Pfizer Speaking: Abbvie Grants: Abbvie, Janssen, Takeda, Kenneth Rainin Foundation\|\|Ahmed, Waseem: No conflict of interest\|\|Longman, Randy:\|:\|Randy Longman: Consulting: Abbvie, BI, BMS, Eli Lilly, Janssen, Palatin Technologies, Pfizer Speaking: Abbvie Grants: Abbvie, Janssen, Takeda, Kenneth Rainin Foundation\|\|Burakoff, Robert: No conflict of interest\|\|Scherl, Ellen:\|:\|Ellen Scherl: Grant/Research Support: Abbott (AbbVie), AstraZeneca, CCFA, Janssen Research & Development, Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney (NIDDK), National Institute of Health (NIH), New York Crohn's Foundation, Pfizer, UCB, UCSF–CCFA Clinical Research Alliance, Genentech. Seres Therapeutics, Celgene Corporation Consultant/Advisory Board: AbbVie, Crohn's and Colitis Foundation of America (CCFA), Entera Health, Evidera, GI Health Foundation, Janssen, Protagonist Therapeutics, Seres Health, Takeda Pharmaceuticals, Bristol Myers Squibb, Stock Shareholder: Gilead Honoraria: GIHealth Foundation for non-branded speaker's bureau, Janssen for nonbranded speaker's bureau\|\|Battat, Robert:\|:\|Research Support: Weill Cornell Medicine Fund for the Future. Consulting: Prometheus Laboratories, Consulting/Speaking Fees: Bristol Myers Squibb |
| P246 | Demir, Emre: No conflict of interest\|\|Cindoruk, Mehmet: No conflict of interest\|\|Karataş, Ali: No conflict of interest\|\|Dr. Karakan, Tarkan: No conflict of interest\|\|Kılıç, Güner: No conflict of interest\|\|Ergin, Mustafa: No conflict of interest\|\|Cerit, Mahi Nur: No conflict of interest\|\|Ozbas, Cansu: No conflict of interest\|\|Oktar, Suna Ozhan: No conflict of interest\|\|Ucar, Murat: No conflict of interest\|\|Gulbahar, Ozlem: No conflict of interest\|\|Demir, Beril: No conflict of interest |

| | |
|---|---|
| P247 | Dr. Nguyen, Anke: No conflict of interest\|\|Sturm, Gregor: No conflict of interest\|\|Plattner, Christina: No conflict of interest\|\|Trajanoski, Zlatko: No conflict of interest\|\|Atreya, Raja: No conflict of interest\|\|IBDome Consortium, IBDome Consortium: No conflict of interest\|\|Siegmund, Britta:\|:\|Britta Siegmund served as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Falk, Janssen, Lilly, Pfizer, PredictImmune and Takeda; and received speaker's fees from AbbVie, BMS, CED Service GmbH, Falk, Ferring, Janssen, Pfizer and Takeda (served as representative of the Charité)\|\|Hegazy, Ahmed N.: No conflict of interest |
| P248 | Ms. Vos, Hannah: No conflict of interest\|\|van Wassenaer, Elsa: No conflict of interest\|\|van Schuppen, Joost: No conflict of interest\|\|van Rijn, Rick: No conflict of interest\|\|D'Haens, Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|Benninga, Marc: No conflict of interest\|\|Koot, Bart: No conflict of interest |
| P249 | Dr. McShane, Cathy: No conflict of interest\|\|Corcoran, Roisin: No conflict of interest\|\|O'Connell, Fiona: No conflict of interest\|\|MacDonagh, Padraic: No conflict of interest\|\|O'Sullivan, Jacintha: No conflict of interest\|\|Kevans, David: No conflict of interest |
| P250 | Arar, Amr: No conflict of interest\|\|Scott, Frank:\|:\|Janssen (consulting, research funding), Takeda Pharmaceuticals (consulting, research funding)\|\|Click, Benjamin:\|:\|Consultant or advisory board for Janssen, Takeda, AbbVie, Bristol Myers Squibb, Prometheus Biosciences, TARGET-RWE\|\|Fennimore, Blair: No conflict of interest\|\|Ahmed, Waseem: No conflict of interest\|\|Oonk, Alexis: No conflict of interest\|\|Dr. Gerich, Mark: No conflict of interest |

| | |
|---|---|
| P251 | Menesy, Ayman: No conflict of interest\|\|Hammad, Mohamed: No conflict of interest\|\|Aref, Salah: No conflict of interest\|\|Dr. Abozeid, Fatma: No conflict of interest |
| P252 | Dr. Ribaldone, Davide Giuseppe: No conflict of interest\|\|Vieujean, Sophie: No conflict of interest\|\|Julsgaard, Mette:\|:\|Mette Julsgaard has received research grants for other investigator-driven studies from Takeda, has received consultation fee from Ferring and Takeda, and has received speaker's fees from MSD, Ferring, and Takeda.\|\|Zingone, Fabiana: No conflict of interest\|\|Savarino, Edoardo: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Aratari, Annalisa: No conflict of interest\|\|Imperatore, Nicola: No conflict of interest\|\|Ramos, Laura: No conflict of interest\|\|Plaza, Rocio: No conflict of interest\|\|Pugliese, Daniela: No conflict of interest\|\|Barberio, Brigida:\|:\|Brigida Barberio: has served as speaker for Alfasigma, Janssen, Procise, Sofar, Takeda; has served as consultant for Doxapharma.\|\|Drobne, Davide: No conflict of interest\|\|Chaparro, María: No conflict of interest |
| P253 | Dr. Shehab, Mohammad: No conflict of interest\|\|Akram, Sahad Al: No conflict of interest\|\|Hassan, Amro: No conflict of interest\|\|Alrashed, Fatema: No conflict of interest\|\|Bessissow, Talat: No conflict of interest |
| P254 | Dr. Kim, Ji Eun: No conflict of interest\|\|Choi, Yoon Ho: No conflict of interest\|\|Lee, Yeong Chan: No conflict of interest\|\|Seong, Gyeol: No conflict of interest\|\|Song, Joo Hye: No conflict of interest\|\|Kim, Eun Ran: No conflict of interest\|\|Hong, Sung Noh: No conflict of interest\|\|Chang, Dong Kyung: No conflict of interest\|\|Kim, Young-Ho: No conflict of interest\|\|Shin, Soo-Yong: No conflict of interest\|\|Kim, Tae Jun: No conflict of interest |
| P255 | Dr. Todeschini, Alessia: No conflict of interest\|\|Angelini, Chiara: No conflict of interest\|\|Tessari, Roberto: No conflict of interest\|\|Ossato, Andrea: No conflict of interest\|\|Lunardi, Gianluigi: No conflict of interest\|\|Geccherle, Andrea: No conflict of interest\|\|Zuppini, Teresa: No conflict of interest\|\|Variola, Angela: No conflict of interest |

| | |
|---|---|
| P256 | Dr. Mignini, Irene: No conflict of interest\|\|Masucci, Luca: No conflict of interest\|\|De Maio, Flavio: No conflict of interest\|\|Laterza, Lucrezia: No conflict of interest\|\|Scaldaferri, Franco: No conflict of interest\|\|Settanni, Carlo Romano: No conflict of interest\|\|Napolitano, Daniele: No conflict of interest\|\|Baroni, Silvia: No conflict of interest\|\|Garcovich, Matteo: No conflict of interest\|\|Riccardi, Laura: No conflict of interest\|\|Gasbarrini, Antonio: No conflict of interest\|\|Ferraro, Pietro Manuel: No conflict of interest\|\|Papa, Alfredo: No conflict of interest |
| P257 | Saeidinejad, Mohammadmahdi: No conflict of interest\|\|Dawson, Hannah E: No conflict of interest\|\|Newbury, Cristopher M: No conflict of interest\|\|Searle, Harry: No conflict of interest\|\|Gordon, John N: No conflict of interest |
| P258 | Dr. Jeong, Eui Sun: No conflict of interest\|\|Lee, Ye Ji: No conflict of interest\|\|Song, Eun Mi: No conflict of interest\|\|Byeon, Ju Ran: No conflict of interest\|\|Lee, Ayoung: No conflict of interest\|\|Choe , A Reum: No conflict of interest\|\|Hong, Ji Teak: No conflict of interest\|\|Park, Ye Hyun: No conflict of interest\|\|Tae, Chung Hyun: No conflict of interest\|\|Moon, Chang Mo: No conflict of interest\|\|Jeong, Hye-Kyung: No conflict of interest\|\|Shim, Ki-Nam: No conflict of interest\|\|Jung, Sung-Ae: No conflict of interest\|\|Kim, Yuri: No conflict of interest\|\|Kim, Seong-Eun: No conflict of interest |
| P259 | Dr. Gibbons, Eimear: No conflict of interest\|\|Afridi, Ibrahim: No conflict of interest\|\|Sheehan, Thomas: No conflict of interest\|\|Smyth, Claire: No conflict of interest\|\|Farrell, Richard: No conflict of interest\|\|Hall, Barry: No conflict of interest\|\|Kelly, Orlaith B.: No conflict of interest |
| P260 | Ms. Radford, Shellie: No conflict of interest\|\|Tench, Chris: No conflict of interest\|\|Moran, Gordon: No conflict of interest |

| | |
|---|---|
| P261 | Dr. Khan, Nabeel:\|:\|Nabeel Khan has received an unrestricted research grant from Pfizer, Luitpold, and Takeda Pharmaceuticals as well as Samsung BioEpis\|\|Trivedi, Chinmay: No conflict of interest\|\|Shah, Yash: No conflict of interest\|\|Patel, Manthankumar: No conflict of interest\|\|Sundararajan, Ramaswamy: No conflict of interest\|\|Xie, Dawei: No conflict of interest\|\|Yang , Yu-Xiao: No conflict of interest |
| P262 | Dr. Subhaharan, Deloshaan: No conflict of interest\|\|Ramaswamy, Pradeep Kakkadasam: No conflict of interest\|\|Willmann, Laura: No conflict of interest\|\|Moattar, Hadi: No conflict of interest\|\|Bhullar, Maneesha: No conflict of interest\|\|Ishaq, Naveed: No conflict of interest\|\|Dorrington, Alexander: No conflict of interest\|\|Shukla, Dheeraj: No conflict of interest\|\|McIvor, Carolyn: No conflict of interest\|\|Edwards, John: No conflict of interest\|\|Mohsen, Waled: No conflict of interest |
| P263 | Buchan, Emma: No conflict of interest\|\|Dr. Majumder, Snehali: No conflict of interest\|\|Nardone, Olga: No conflict of interest\|\|N Shivaji, Uday: No conflict of interest\|\|Abdawn, Zainab: No conflict of interest\|\|Hejmadi, Rahul: No conflict of interest\|\|Iacucci, Marietta: No conflict of interest\|\|Goldberg Oppenheimer, Pola: No conflict of interest |
| P264 | Dyer, Emma: No conflict of interest\|\|Kliper, Efrat: No conflict of interest\|\|Zamstein, Noa: No conflict of interest\|\|Hodik, Gabriel: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Dr. Cohen, Nathaniel Aviv: No conflict of interest |

| | |
|---|---|
| P265 | Prof. Dr. Vilela, Eduardo: No conflict of interest\|\|Serafim Parra, Rogério: No conflict of interest\|\|Yukie Sassaki, Ligia: No conflict of interest\|\|da Costa Ferreira, Sandro: No conflict of interest\|\|Araújo Lisboa, Raíssa: No conflict of interest\|\|Oliveira Santana, Genoile: No conflict of interest\|\|Luiz Parente, José Miguel: No conflict of interest\|\|Cassol, Ornella: No conflict of interest\|\|Gustavo Kotze, Paulo: No conflict of interest\|\|Pereira Westphalen, André: No conflict of interest\|\|Zaltman, Cyrla: No conflict of interest\|\|Marques dos Santos, Carlos Henrique: No conflict of interest\|\|Hamer Sousa Clara, Ana Paula: No conflict of interest\|\|Lovatti, Rodrigo: No conflict of interest\|\|de Assis Gonçalves Filho , Francisco: No conflict of interest\|\|Vieira, Andrea: No conflict of interest\|\|Filardi Simiqueli Durante , Renata: No conflict of interest\|\|Bafutto, Mauro: No conflict of interest\|\|Botelho Quaresma, Abel: No conflict of interest\|\|de Freitas Lins Neto, Manoel Álvaro: No conflict of interest\|\|Barrio Bortoli , Zuleica: No conflict of interest\|\|Coelho Ludvig, Juliano: No conflict of interest\|\|Machado de Souza , Mardem: No conflict of interest\|\|Freire, Caio: No conflict of interest\|\|Martinelli, Valeria: No conflict of interest\|\|Antunes de Brito, Carlos Alexandre: No conflict of interest\|\|Pandolfo Zabot, Gilmara: No conflict of interest\|\|Medeiros Soares Celani, Lívia: No conflict of interest\|\|Mônica de Oliveira Leite, Sinara: No conflict of interest\|\|Saad Hossne, Rogerio: No conflict of interest |
| P266 | Dr. Park, Soo-Kyung: No conflict of interest\|\|Kim, Hyunwoo: No conflict of interest\|\|Kim, Sangsoo: No conflict of interest\|\|Lee, Chil Woo: No conflict of interest\|\|Jung, Yunho: No conflict of interest\|\|Choi, Chang Hwan: No conflict of interest\|\|Kang, Sang-Bum: No conflict of interest\|\|Kim, Tae Oh: No conflict of interest\|\|Bang, Ki Bae: No conflict of interest\|\|Chun, Jaeyoung: No conflict of interest\|\|Cha , Jae Myung: No conflict of interest\|\|Im, Jong Pil: No conflict of interest\|\|Ahn, Kwang Sung: No conflict of interest\|\|Park, Dong II: No conflict of interest |
| P267 | Dr. Levartovsky, Asaf: No conflict of interest\|\|Levy, Idan: No conflict of interest\|\|Bruckmayer, Liora: No conflict of interest\|\|Klang, Eyal: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Kopylov, Uri: No conflict of interest |

| | |
|---|---|
| P268 | Sedano, Rocio:\|:\|RS is an employee of Alimentiv Inc.\|\|Ma, Christopher:\|:\|CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, and Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Takeda, Pendopharm, and Pfizer; royalties from Springer Publishing; and research support from Ferring and Pfizer.\|\|Hogan, Malcolm:\|:\|MH is an employee of Alimentiv Inc.\|\|Silverberg, Mark S.:\|:\|MSS has received consulting, advisory board, and/or speaker fees from Abbvie, Alimentiv, Amgen, Pfizer, Janssen, Takeda, Gilead, Fresenius Kabi, Celltrion, and BMS.\|\|Zou, Guangyong:\|:\|GZ has received consulting fees from Alimentiv Inc.\|\|D'Haens, Geert R.:\|:\|GRD has served as a consultant and/or received speaker fees from AbbVie, Alimentiv, AstraZeneca, Biora (Progenity), Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, and Ventyx Biosciences.\|\|Rémillard, Julie:\|:\|JR is an employee of Alimentiv Inc.\|\|Mrs. Mcfarlane, Stefanie C.:\|:\|SCM is an employee of Alimentiv Inc.\|\|Bojic, Bozidar:\|:\|BoB has nothing to disclose.\|\|Bressler, Brian:\|:\|BrB has served as an advisor/speaker for Ferring, Janssen, Abbvie, Takeda, Pfizer, Novartis, BMS, Merck, Sandoz, and Organon; as an advisor for Alimentiv, Gilead, Iterative Scopes, AMT, Celgene, Microbiome Insights, Merck, Amgen, Pendopharm, Genentech, BMS, Allergan, Protagonist, Fresenius Kabi, Mylan, Viatris, Bausch Health, Celltrion Healthcare, Jamp Pharma, and Eupraxia; has received research support from Janssen, Abbvie, GSK, BMS, Amgen, Genentech, Merck, BI, and Qu Biologic; and stock options from Qu Biologic.\|\|Rosenfeld, Gregory:\|:\|GR has received consultancy and speaker fees from Abbvie, Alimentiv, BMS, Fresenius Kabi, Ferring, Janssen, Merck, Organon, Pendopharm, Pfizer, Sandoz, Takeda, Viatris; and grant support from Abbvie, Ferring, Janssen, Pfizer, and Crohn's and Colitis Canada.\|\|Feakins, Roger M.:\|:\|RMF receives consulting fees from Alimentiv Inc.; and has received fees from Bristol Myers Squibb, Janssen, Decibio, and Takeda.\|\|Kirsch, Richard:\|:\|RK has received consulting fees from Alimentiv Inc.\|\|Marchal, Aude:\|:\|AM has nothing to disclose.\|\|Samaan, Mark A.:\|:\|MAS has received advisory fees from Bristol-Myers Squibb, Janssen, Takeda, Sandoz, Samsung Bioepis, Galapagos, and AbbVie; and has received lecture fees from Bristol-Myers Squibb, Janssen, Takeda, MSD, Falk, AbbVie, and Galapagos.\|\|Panaccione, Remo:\|:\|RP has received consulting and speaker fees from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, |

| | |
|---|---|
| | Janssen, Merck, Mylan, Oppilan Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals.\|\|Hart, Ailsa:\|:\|AH has served as a consultant, advisory board member, or speaker for AbbVie, Arena, Atlantic, AstraZeneca, Bristol-Myers Squibb, BI, Celgene, Celltrion, Falk, Ferring, Galapogos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda; and serves on the Global Steering Committee for Genentech.\|\|Sands, Bruce E.:\|:\|BES has received consulting and speaking fees from Abivax, Bristol Myers Squibb, Janssen, Lilly Pfizer, and Takeda; consulting fees from AbbVie, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Calibr, Celltrion Healthcare, ClostraBio, Cytoki Pharma, Connect Biopharma, Entera; Evommune, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunic, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Kaleido, Kallyope, MiroBio, Morphic Therapeutics, MRM Health, OSE Immunotherapeutics, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Sun Pharma, Surrozen, Synlogic, Target RWE, Teva, Theravance Biopharma, TLL Pharmaceutical, USWM Enterprises, VielaBio, and VTA Labs; and personal fees and stock options for consulting from Ventyx Biosciences.\|\|Travis, Simon:\|:\|ST has received grants/research support from AbbVie, Buhlmann, Celgene, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor, and Norman Collisson Foundation; consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Apexian, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Barco, Biocare, Biogen, BLPharma, Boehringer Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, Chiesi, CisBio, ComCast, Coronado, Cosmo, Ducentis, Dynavax, Elan, Enterome, EQrX, Equillium, Falk, Ferring, FPRT Bio, Galapagos, Genentech/Roche, Genzyme, Gilead, Glenmark, Grunenthal, GSK, GW Pharmaceuticals, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Medarex, Medtrix, Merck, Merrimack, Mestag, Millenium, Neovacs, Novartis, Novo Nordisk, NPS-Nycomed, Ocera, Optima, Origin, Otsuka, Palau, Pentax, Pfizer, Pharmaventure, Phesi, Phillips, P&G, Pronota, Protagonist, Proximagen, Resolute, Robarts, Sandoz, Sanofi, Santarus, Satisfai, Sensyne Health, Shire, SigmoidPharma, Sorriso, Souffinez, Syndermix, Synthon, Takeda, Theravance, Tigenix, Tillotts, Topivert, Trino Therapeutics with Wellcome Trust, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria; speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda, and UCB. He has no stocks or share options.\|\|Feagan, Brian G.:\|:\|BGF has received grant/research support from AbbVie Inc., Amgen Inc., |

| | |
|---|---|
| | optional||Feagan, Brian G||Dr. has received grant, research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc./Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, and UCB; consulting fees from Abbott/AbbVie, Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestle, Nextbiotix, Novonordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., and Zyngenia; speakers bureau fees from Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; is a scientific advisory board member for Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestle, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, and UCB Pharma; and is the Senior Scientific Officer of Alimentiv Inc.||Jairath, Vipul:|:|VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker's fees from, Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen, Pfizer, Shire, Takeda, and Fresenius Kabi. |
| P269 | Dr. Lev Zion, Raffi: No conflict of interest\|\|Dolev, Amir S: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Ledderman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Kopylov, Uri: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Lerner, Boaz: No conflict of interest |

| | |
|---|---|
| P270 | Prof. Dr. Bettenworth, Dominik: No conflict of interest\|\|Baker, Mark E: No conflict of interest\|\|Bemelmann, Willem: No conflict of interest\|\|Bruining, David: No conflict of interest\|\|D'Haens, Geert: No conflict of interest\|\|D'Hoore, Andre: No conflict of interest\|\|Dignass, Axel: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Feagan, Brian G.: No conflict of interest\|\|Feakins, Roger: No conflict of interest\|\|Fleshner, Phil: No conflict of interest\|\|Fletcher, Joel G: No conflict of interest\|\|Gordon, Ilyssa: No conflict of interest\|\|Ha, Christina: No conflict of interest\|\|Gaylyn , Henderson: No conflict of interest\|\|Jairath, Vipul: No conflict of interest\|\|Lu, Cathy: No conflict of interest\|\|Lyu, Ruishen: No conflict of interest\|\|Ng, Siew C.: No conflict of interest\|\|Panes, Julian: No conflict of interest\|\|Rogler, Gerhard: No conflict of interest\|\|Mao, Ren: No conflict of interest\|\|Rimola, Jordi: No conflict of interest\|\|Sandborn, William J.: No conflict of interest\|\|Siegmund, Britta: No conflict of interest\|\|Silverberg, Mark S.: No conflict of interest\|\|Taylor, Stuart: No conflict of interest\|\|Verstockt , Bram: No conflict of interest\|\|Rieder , Florian: No conflict of interest |
| P271 | Dr. Lenfant, Matthias: No conflict of interest\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Sabino, João:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring.\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|De Hertogh, Gert:\|:\|Gert De Hertogh receives fees for his activities as central pathology reader from Centocor and receives speakers' fees from Janssen. |

| | |
|---|---|
| P272 | Ms. Munster, Liesbeth: No conflict of interest\|\|de Groof, Elisabeth Joline: No conflict of interest\|\|van Dieren, Susan: No conflict of interest\|\|Mundt, Marco W: No conflict of interest\|\|D'Haens, Geert R A M: No conflict of interest\|\|Bemelman, Wilhelmus Adrianus: No conflict of interest\|\|Buskens, Christianne Johanna: No conflict of interest\|\|van der Bilt, Jarmila Dagmara Wendelien: No conflict of interest |
| P273 | Al Sulais, Eman: No conflict of interest\|\|Dr. Mukhtar, Mariam Saud H: No conflict of interest\|\|Parkes, Gareth: No conflict of interest\|\|Hart, Ailsa: No conflict of interest\|\|Raine , Tim: No conflict of interest |
| P274 | Hsieh, Ching-Reigh: No conflict of interest\|\|Prof. Dr. Le, Puo-Hsien: No conflict of interest\|\|Kuo, Chia-Jung: No conflict of interest\|\|Yeh , Pai-Jui: No conflict of interest\|\|Chiu, Cheng-Tang: No conflict of interest |
| P275 | Dr. Nardone, Olga Maria: No conflict of interest\|\|Luglio, Gaetano: No conflict of interest\|\|Calabrese, Giulio: No conflict of interest\|\|Giglio, Mariano: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Iacucci, Marietta: No conflict of interest |
| P276 | Prof. Yao, Jiayin: No conflict of interest\|\|Zhong, Yingkui: No conflict of interest\|\|Zhou, Jie: No conflict of interest\|\|Zhi, Min: No conflict of interest |
| P277 | Mokhtari, Ricardo: No conflict of interest\|\|Hamidinekoo , Azam: No conflict of interest\|\|Lewis, Arthur: No conflict of interest\|\|Sutton, Daniel: No conflict of interest\|\|Angermann, Bastian: No conflict of interest\|\|Gehrmann, Ulf: No conflict of interest\|\|Lundin, Pal: No conflict of interest\|\|Khachapuridze , Nia: No conflict of interest\|\|Adissu , Hibret: No conflict of interest\|\|Marks, Daniel: No conflict of interest\|\|Cairns, Junmei: No conflict of interest\|\|Dr. Burlutskiy, Nikolay: No conflict of interest |

| | |
|---|---|
| P278 | Mr. Lasa, Juan: No conflict of interest\|\|Martínez, Soledad: No conflict of interest\|\|Smolarczuk, Astrid: No conflict of interest\|\|Navar, Sofía: No conflict of interest\|\|Espinosa, Federico: No conflict of interest\|\|Pereyra, Lisandro:\|:\|Consulting fees from Takeda\|\|Rainero, Germán: No conflict of interest\|\|Meligrana, Noelia: No conflict of interest\|\|Marturano, Victoria: No conflict of interest\|\|Steinberg, Leandro:\|:\|Consulting fees from Takeda\|\|Reyes, Kevin: No conflict of interest\|\|Giraudo, Florencia: No conflict of interest\|\|Garbi, Laura: No conflict of interest\|\|Gullino, Lorenzo: No conflict of interest\|\|Yantorno, Martín: No conflict of interest\|\|Correa, Gustavo: No conflict of interest\|\|Ponce, Carla: No conflict of interest\|\|Orellana, Daniel: No conflict of interest\|\|Galvarini, Martín: No conflict of interest\|\|Caruso, Emiliano: No conflict of interest\|\|Olivera, Pablo:\|:\|Pablo A. Olivera has received consulting fees from AbbVie, Takeda, and Janssen; honoraria from Takeda and Janssen; and financial support for attending meetings, travel, or both from AbbVie, Takeda, Janssen, and Ferring |
| P279 | Dr. Azzouzi, Driss: No conflict of interest |
| P280 | Mrs. Ben Safta, Nour: No conflict of interest\|\|Medhioub, Amal: No conflict of interest\|\|Mohamed, Ghanem: No conflict of interest\|\|Boughoula, Khouloud: No conflict of interest\|\|Ben Slimane, Baha: No conflict of interest\|\|Ben Abdallah, Hatem: No conflict of interest\|\|Bouali, Riadh: No conflict of interest\|\|Bizid, Sondes: No conflict of interest\|\|Abdelli, Mohamed Nebil: No conflict of interest |
| P281 | Dr. Hermanson, Maria: No conflict of interest\|\|Bengtson, Jonas: No conflict of interest\|\|Block, Mattias: No conflict of interest |

| | |
|---|---|
| P282 | Mrs. Ben Safta, Nour: No conflict of interest\|\|Ben Mustpha, Nadia: No conflict of interest\|\|Khemiri, Wafa: No conflict of interest\|\|Serghini, Meriem: No conflict of interest\|\|Laabidi, Sarra: No conflict of interest\|\|Fekih, Monia: No conflict of interest\|\|Labidi, Asma: No conflict of interest\|\|Boubaker, Jalel: No conflict of interest |
| P283 | Dr. Liu, Eleanor: No conflict of interest\|\|Erande, Aditi: No conflict of interest\|\|McLaughlin, John: No conflict of interest\|\|Limdi, Jimmy K: No conflict of interest |
| P284 | Ms. Sheldon, Elena: No conflict of interest\|\|Roman, Stefan: No conflict of interest\|\|Bursnall, Matthew: No conflict of interest\|\|Hawkins, Rachel: No conflict of interest\|\|Lobo, Alan: No conflict of interest\|\|Hind, Daniel: No conflict of interest\|\|Randall, Kevin: No conflict of interest\|\|Wakeman, Ruth: No conflict of interest\|\|Ainley, Rachel: No conflict of interest |
| P285 | Dr. Gibbons, Eimear: No conflict of interest\|\|Afridi, Ibrahim: No conflict of interest\|\|Sheehan, Thomas: No conflict of interest\|\|Smyth, Claire: No conflict of interest\|\|Farrell, Richard: No conflict of interest\|\|Hall, Barry: No conflict of interest\|\|Kelly, Orlaith B.: No conflict of interest |
| P286 | Mr. Mattila, Juho: No conflict of interest\|\|Virtanen, Johanna: No conflict of interest\|\|Nuutila, Pirjo: No conflict of interest\|\|Koffert, Jukka: No conflict of interest |
| P287 | Dr. Sambuelli, Alicia: No conflict of interest\|\|Gil , Anibal: No conflict of interest\|\|Rohwain, Maria Jose: No conflict of interest\|\|Candel , Ivanna: No conflict of interest\|\|Huernos , Sergio: No conflict of interest\|\|Tirado , Pablo: No conflict of interest\|\|Negreira, Silvia: No conflict of interest\|\|Balaban, Ezequiel: No conflict of interest |

| | |
|---|---|
| P288 | Dr. Rodrigues, Cláudio: No conflict of interest\|\|Valério, Fernando: No conflict of interest\|\|Casimiro, Carlos: No conflict of interest\|\|Soares, Caroline: No conflict of interest\|\|Ventura, Sofia: No conflict of interest\|\|Domingues, Ângela: No conflict of interest\|\|Silva, Américo: No conflict of interest\|\|Cancela, Eugénia: No conflict of interest\|\|Ministro, Paula: No conflict of interest |
| P289 | Navrátil, Vit: No conflict of interest\|\|Pipek, Barbora: No conflict of interest\|\|Krivinka, Jan: No conflict of interest\|\|Gregar, Jan: No conflict of interest\|\|Dr. Kunovsky, Lumir: No conflict of interest\|\|Falt, Premysl: No conflict of interest |
| P290 | Prof. Dr. Kim, Eun Soo: No conflict of interest\|\|Lee, Jung Won: No conflict of interest\|\|Kim, Sung Kook: No conflict of interest\|\|Lee, Hyun Seok: No conflict of interest\|\|Lee, Yoo Jin: No conflict of interest\|\|Kim, Jeongseok: No conflict of interest\|\|Kim, Kyeong Ok: No conflict of interest\|\|Jang, Byung Ik: No conflict of interest\|\|Kim, Eun Young: No conflict of interest\|\|Jung, Yun Jin: No conflict of interest\|\|Park, Soo-Kyung: No conflict of interest\|\|Park, Dong-Il: No conflict of interest\|\|Woo, Dongwon: No conflict of interest\|\|Jeong, Sungmoon: No conflict of interest |
| P291 | Dr. Pigneur, Benedicte: No conflict of interest\|\|Cochet, Manon: No conflict of interest\|\|Delphine , Ley: No conflict of interest\|\|Coopman, Stéphanie: No conflict of interest\|\|Raphael , Enaud: No conflict of interest\|\|Thierry, Lamireau: No conflict of interest\|\|Claire , Dupont: No conflict of interest\|\|Stéphanie , Willot: No conflict of interest\|\|Rémi , Duclaux-Loras: No conflict of interest\|\|Georges , Dimitrov: No conflict of interest\|\|Valérie, Bertrand: No conflict of interest\|\|Anne, Breton: No conflict of interest\|\|Christine, Martinez: No conflict of interest\|\|Jerome, Viala: No conflict of interest\|\|Frank, Ruemmele: No conflict of interest\|\|Julie, Lemale: No conflict of interest |

| | |
|---|---|
| P292 | Dr. Ben Hur, Dana: No conflict of interest\|\|Lebedenko, Boris: No conflict of interest\|\|Issaschar, Guy: No conflict of interest\|\|Moshe, Ran: No conflict of interest\|\|Lujan, Rona: No conflict of interest\|\|Focht, Gili: No conflict of interest\|\|Loewenberg Weisband, Yisca: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Ledderman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Pinto, Gabrieal: No conflict of interest\|\|Waterman , Matti: No conflict of interest |
| P293 | Dr. Attauabi, Mohamed: No conflict of interest\|\|Madsen, Gorm Roager: No conflict of interest\|\|Bendtsen, Flemming:\|:\|Tillotts, Ferring\|\|Bjerrum, Jacob Tveiten: No conflict of interest\|\|Wilkens, Rune:\|:\|Pfizer, AbbVie, Takeda, Janssen, Alimentiv\|\|Theede, Klaus:\|:\|Ferring, Janssen, Takeda, Pfizer, and Tillotts\|\|Ilvemark, Johan F.K.F.:\|:\|Abbvie, Takeda, Janssen, ParaTech\|\|Boysen, Trine: No conflict of interest\|\|Seidelin, Jakob Benedict:\|:\|has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. \|\|Burisch, Johan:\|:\|reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work. |
| P294 | Kang, Sang-Bum: No conflict of interest\|\|Prof. Dr. Jung, Sung Hoon: No conflict of interest\|\|Kim, Tae Oh: No conflict of interest |

| | |
|---|---|
| P295 | Rispo, Antonio:\|:\|Advisory board for Abbvie, MSD, Takeda, Janssen, Pfizer\|\|Calabrese, Giulio: No conflict of interest\|\|Testa, Anna:\|:\|Advisory board for Abbvie, Takeda, Janssen\|\|Patturelli, Marta: No conflict of interest\|\|Imperatore, Nicola: No conflict of interest\|\|Nardone, Olga Maria:\|:\|Advisory board for Takeda, Janssen\|\|Guarino, Alessia Dalila: No conflict of interest\|\|Cantisani, Nicola Mattia: No conflict of interest\|\|Toro, Benedetta: No conflict of interest\|\|Castiglione, Fabiana:\|:\|Advisory board for Abbvie, Msd, Takeda, Janssen, Pfizer |
| P296 | Beek, Kim: No conflict of interest\|\|Mulders, Lieven: No conflict of interest\|\|Tielbeek, Jeroen: No conflict of interest\|\|Horsthuis, Karin: No conflict of interest\|\|Buskens, Christianne: No conflict of interest\|\|D'Haens, Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|Gecse, Krisztina:\|:\|Krisztina B. Gecse has received grants from Pfizer Inc, Celltrion and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Abbvie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts.\|\|Stoker, Jaap: No conflict of interest |

| | |
|---|---|
| P297 | Dr. Zittan, Eran:\|:\|EZ- has received research support and consulting fees from Janssen, AbbVie, Takeda, Neopharm, Celgene and Pfizer.\|\|Levy, Matthew: No conflict of interest\|\|Saban , Lotem: No conflict of interest\|\|Vered, Shiraz: No conflict of interest\|\|Steinhart, A. Hillary:\|:\|AHS – has received research grants - AbbVie, Celgene, Red Hill Biopharma, Janssen, Takeda, Roche, Arena.\|Honorarium for Educational Event Presentations - AbbVie, Ferring, Janssen, Pfizer, Takeda, Shire. \|Advisory Board - AbbVie, Janssen, Merck, Pfizer, Pendopharm, Takeda, Shire.\|\|\|Milgrom, Raquel: No conflict of interest\|\|Gralnek, Ian M: No conflict of interest\|\|Silverberg, Mark S:\|:\|MSS - received research support and consulting fees from Janssen, AbbVie, Takeda, Pfizer and Prometheus.\|\|Zelber-Sagi, Shira: No conflict of interest |
| P298 | Ms. Walker, Caroline: No conflict of interest\|\|Dempsey, Molly: No conflict of interest\|\|Connaughton, Roisin: No conflict of interest\|\|Carroll, Andrew: No conflict of interest\|\|Breslin, Niall: No conflict of interest\|\|McNamara, Deirdre: No conflict of interest\|\|O'Donnell, Sarah: No conflict of interest\|\|Ryan, Barbara: No conflict of interest\|\|O'Connor, Anthony: No conflict of interest |

| | |
|---|---|
| P299 | Prof. Tinoco da Silva Torres, Joana:\|:\|Joana Torres has received advisory board fees from Arena, Galapagos, Janssen, and Pfzer Inc; research support from AbbVie and Janssen; and lecture fees from Galapagos and Janssen. \|\|Ellul, Pierre:\|:\|COI: Educational grants Jannsen\|\|Vieujean, Sophie:\|:\|Speaker fees from Abbvie, Takeda and Janssen.\|\|Ordas, Ingrid: No conflict of interest\|\|Burisch, Johan:\|:\|Dr. Burisch reports grants and personal fees from AbbVie, grants and personal fees from Janssen-Cilag, personal fees from Celgene, grants and personal fees from MSD, personal fees from Pfizer, grants and personal fees from Takeda, grants and personal fees from Tillots Pharma, personal fees from Samsung Bioepis, grants and personal fees from Bristol Myers Squibb, grants from Novo Nordisk, personal fees from Pharmacosmos, personal fees from Ferring, personal fees from Galapagos, outside the submitted work.\|\|Mocanu, Irina: No conflict of interest\|\|Duricova, Dana:\|:\|Lecture fee from: Takeda, Pfizer, Janssen\|\|Rodríguez-Lago, Iago:\|:\|IR-L has received financial support for travelling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Celltrion, Chiesi, Danone, Dr. Falk Pharma, Ferring, Faes Farma Janssen, Galapagos, MSD, Otsuka Pharmaceutical, Pfizer, Roche, Takeda, and Tillotts Pharma.\|\|Buisson, Anthony: No conflict of interest\|\|Goldis, Adrian: No conflict of interest\|\|Hernandez, Vincent: No conflict of interest\|\|Arebi, Naila: No conflict of interest\|\|Kaimakliotis, Ioannis: No conflict of interest\|\|Nachury, Maria:\|:\|COI: Board membership, consultancy, or lecture fees from Abbvie, Amgen, Arena, CTMA, Celltrion, Ferring, Fresenius-Kabi, Janssen, Mayoli-Spindler, MSD, Pfizer, Takeda, Viatris.\|\|Fumery, Mathurin:\|:\|COI: lecture and consulting fees from Abbvie, Pfizer, Tillots, Takeda, Gilead, Celgene, Boehringer, Biogen, Viatris, Amgen, Fresenius, Celltrion, CTMA, Ferring and Janssen. \|\|Allocca, Mariangela:\|:\|COI: Speaker and consulting fees from Abbvie, Pfizer, Ferring and Janssen. \|\|Pedersen, Natalia: No conflict of interest\|\|Barberio, Brigida:\|:\|Speaker and consulting fees from Janssen, Takeda, Sofar, Alfasigma, Doxapharma.\|\|Shaji, Sebastian: No conflict of interest\|\|Guedes, Ana: No conflict of interest\|\|Ribeiro, Raquel: No conflict of interest\|\|Ungaro, Ryan: No conflict of interest\|\|Lambert, Jérome: No conflict of interest\|\|Colombel, Jean-Frédéric:\|:\|Dr. Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Anaptysbio, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Galxo Smith Kline, Japan Gastroenterological Endoscopy Society, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microba, Morgan, Lewis & Bockius LLP, Novartis, Otsuka Pharmaceutical Development PBM Capital, Pfizer, Protagonist Therapeutics Sanofi,Takeda, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development |

| | |
|---|---|
| P300 | Ms. Khemiri, Wafa: No conflict of interest\|\|Ben Mustapha, Nadia: No conflict of interest\|\|Ben Safta, Nour: No conflict of interest\|\|Serghini, Meriem: No conflict of interest\|\|Laabidi, Sarra: No conflict of interest\|\|Fekih, Monia: No conflict of interest\|\|Labidi, Asma: No conflict of interest\|\|Boubaker, Jalel: No conflict of interest |
| P301 | Dr. Gallagher, Annika: No conflict of interest\|\|Sheridan, Juliette: No conflict of interest\|\|Doherty, Glen: No conflict of interest\|\|Mulcahy, Hugh: No conflict of interest\|\|Cullen, Garret: No conflict of interest |
| P302 | Dr. Schwärzler, Julian Peter: No conflict of interest\|\|Zollner, Andreas: No conflict of interest\|\|Dolejsi, Theresa: No conflict of interest\|\|Enrich, Barbara: No conflict of interest\|\|Mayr, Lisa: No conflict of interest\|\|Sturm, Wolfgang: No conflict of interest\|\|Tancevski, Ivan: No conflict of interest\|\|Zschocke, Johannes: No conflict of interest\|\|Adolph, Timon Erik: No conflict of interest\|\|Tilg, Herbert: No conflict of interest |
| P303 | Dr. Yzet, Clara: No conflict of interest\|\|Brazier, Franck: No conflict of interest\|\|Hautefeuille, Vincent: No conflict of interest\|\|Decrombecque, Catherine: No conflict of interest\|\|Sarba, Ruxandra: No conflict of interest\|\|aygalenq, Philippe: No conflict of interest\|\|Venezia, Franck: No conflict of interest\|\|Buisson, Anthony: No conflict of interest\|\|Pichois, Raphaël: No conflict of interest\|\|Michaud, Audrey: No conflict of interest\|\|Fumery, Mathurin: No conflict of interest |
| P304 | Dr. Hayashi, Tomoyuki: No conflict of interest\|\|Takatori, Hajime: No conflict of interest\|\|Yamashita, Taro: No conflict of interest |

| | |
|---|---|
| P305 | Dr. Schoorl, Marianne: No conflict of interest\|\|Beugelink, Timo: No conflict of interest\|\|Grasman, Matthijs E: No conflict of interest\|\|Jongbloed, Wesley: No conflict of interest |
| P306 | Prof. Karakan, Tarkan: No conflict of interest\|\|Karatas, Ali: No conflict of interest\|\|Cindoruk, Mehmet: No conflict of interest\|\|Gulbahar, Ozlem: No conflict of interest |
| P307 | Dr. Neri, Benedetto: No conflict of interest\|\|Russo, Consuelo: No conflict of interest\|\|Mossa, Michelangela: No conflict of interest\|\|Martire, Francesco Giuseppe: No conflict of interest\|\|Aikaterini, Selntigia: No conflict of interest\|\|Mancone, Roberto: No conflict of interest\|\|Calabrese, Emma: No conflict of interest\|\|Rizzo, Giuseppe: No conflict of interest\|\|Exacoustos, Caterina: No conflict of interest\|\|Biancone, Livia: No conflict of interest |
| P308 | Dr. Saito, Daisuke: No conflict of interest\|\|Hirai, Fumihito: No conflict of interest\|\|Uchiyama, Kazuhiko: No conflict of interest\|\|Takagi, Tomohisa: No conflict of interest\|\|Naito, Yuji: No conflict of interest\|\|Takatsu, Noritaka: No conflict of interest\|\|Tanabe, Hiroshi: No conflict of interest\|\|Kishimoto, Mitsuo: No conflict of interest\|\|Matsuura, Minoru: No conflict of interest\|\|Miyoshi, Jun: No conflict of interest\|\|Watanabe, Kenji: No conflict of interest\|\|Esaki, Motohiro: No conflict of interest\|\|Naganuma, Makoto: No conflict of interest\|\|Hisamatsu, Tadakazu: No conflict of interest |
| P309 | Dr. Bacsur, Péter: No conflict of interest\|\|Wetwittayakhlang, Panu: No conflict of interest\|\|Resál, Tamás: No conflict of interest\|\|Rutka, Marianna: No conflict of interest\|\|Bessissow, Talat: No conflict of interest\|\|Atif, Waqqas: No conflict of interest\|\|Bálint, Anita: No conflict of interest\|\|Fábián, Anna: No conflict of interest\|\|Bor, Renáta: No conflict of interest\|\|Szepes, Zoltán: No conflict of interest\|\|Farkas, Klaudia: No conflict of interest\|\|Lakatos, Peter L: No conflict of interest\|\|Molnár, Tamás: No conflict of interest |

| | |
|---|---|
| P310 | Mr. Sharara, Ala: No conflict of interest\|\|Halablab, Saleem: No conflict of interest\|\|Sadaka, Christian: No conflict of interest\|\|Slika, Hasan: No conflict of interest\|\|Adra, Nour: No conflict of interest\|\|Ghusn, Wissam: No conflict of interest\|\|Shmeis, Manar: No conflict of interest\|\|Al Razim, Ayman: No conflict of interest |
| P311 | Prof. Rieder, Florian: No conflict of interest\|\|Ma, Christopher:\|:\|Consultant to Alimentiv\|\|Hanzel, Jurij: No conflict of interest\|\|Fletcher, Joel G.: No conflict of interest\|\|Baker, Mark: No conflict of interest\|\|Wang, Zhongya:\|:\|Employee of Alimentiv\|\|Guizetti, Leonardo:\|:\|Employee to Alimentiv\|\|Patel, Mihir: No conflict of interest\|\|Niu, Jiafei: No conflict of interest\|\|Shackelton, Lisa:\|:\|Employee at Alimentiv\|\|Ottichilo, Ronald: No conflict of interest\|\|Santillan, Cynthia: No conflict of interest\|\|Capozzi, Nunzia: No conflict of interest\|\|Taylor, Stuart A.: No conflict of interest\|\|Zhou, Guangyong:\|:\|Employee at Alimentiv\|\|Bruining, David: No conflict of interest\|\|Feagan, Brian: No conflict of interest\|\|Jairath, Vipul: No conflict of interest\|\|Rimola, Jordi: No conflict of interest |
| P312 | Mr. Fukushima, Shinya: No conflict of interest\|\|Katsurada, Takehiko: No conflict of interest\|\|Keiya, Aoyama: No conflict of interest\|\|Sakurai, Kensuke: No conflict of interest\|\|Yamanashi, Kana: No conflict of interest\|\|Omotehara, Satomi: No conflict of interest\|\|Onishi, Reizo: No conflict of interest\|\|Nishida, Mutsumi: No conflict of interest\|\|Sakamoto, Naoya: No conflict of interest |
| P313 | Ms. Zelinsky, Sandra: No conflict of interest\|\|Daley, Kim:\|:\|K.Daley has done some consultative work for Takeda Canada\|\|Patel, Ashely: No conflict of interest\|\|Jeffs, Lianne: No conflict of interest\|\|Zeng, Lily: No conflict of interest\|\|Targownik, Laura:\|:\| Laura Targownik has received funds for investigatorinitiated research from Janssen-Ortho Canada, and from Astra-Zeneca\|Canada, and has served on the advisory board for Janssen-Ortho Canada. She\|has also served on the advisory board for the Canadian Agency for Drugs and\|Technology in Healthcare for developing best practices guidelines for use of\|proton pump inhibitors in Canada and has been a consultant for Takeda Canada |

| | |
|---|---|
| P314 | Ms. Reijntjes, Maud: No conflict of interest\|\|Pruijt, Maarten: No conflict of interest\|\|Visser, Eva: No conflict of interest\|\|de Voogd, Floris:\|:\|Honoraria or speakers' fees from AbbVie and Janssen.\|\|d'Haens, Geert R:\|:\|GD has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma, enGene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novo Nordisk, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts and Vifor\|\|Mookhoek, Aart: No conflict of interest\|\|Gecse, Krisztina B:\|:\|KG has received grants from Pfizer Inc, Celltrion and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts. RH none.\|\|Buskens, Christianne J:\|:\|CB received an unrestricted grant from Boehringer Ingelheim and Roche, and honoraria or speaker fees from Abbvie, Tillotts, Takeda and Janssen. \|\|Bemelman, Wilhelmus A:\|:\|WB Speaker fees: Takeda, Johnson & Johnson, Medtronic, Braun Grant: VIFOR, Braun. |
| P315 | Dr. Müller, Katalin: No conflict of interest\|\|Dohos , Dóra: No conflict of interest\|\|Imrei, Marcell: No conflict of interest\|\|Gombos, Eszter: No conflict of interest\|\|Szentannay , Judit: No conflict of interest\|\|Szabó, András: No conflict of interest\|\|Oberfrank, Míra: No conflict of interest\|\|Karoliny, Anna: No conflict of interest |
| P316 | Dr. Istemihan, Zülal: No conflict of interest\|\|Çavuş, Bilger: No conflict of interest\|\|Bardak, Ali Emre: No conflict of interest\|\|Kırkoğlu, Ayşe Merve: No conflict of interest\|\|Kızıltaş, Cansu: No conflict of interest\|\|Silay, Rüveyda: No conflict of interest\|\|Şenkal, İbrahim Volkan: No conflict of interest\|\|İmanov, Ziya: No conflict of interest\|\|Nuriyev, Kenan: No conflict of interest\|\|Rüstemzade, Aynure: No conflict of interest\|\|Genç, Sezen: No conflict of interest\|\|Güllüoğlu, Mine: No conflict of interest\|\|Çifcibaşı Örmeci, Aslı: No conflict of interest\|\|Demir, Kadir: No conflict of interest\|\|Beşışık, Fatih: No conflict of interest\|\|Kaymakoğlu, Sabahattin: No conflict of interest\|\|Akyüz, Filiz: No conflict of interest |

| | |
|---|---|
| P317 | Mukhtar, Mariam Saud H: No conflict of interest\|\|Lim, Wei Jin: No conflict of interest\|\|Tozer, Phil: No conflict of interest\|\|Hart , Ailsa: No conflict of interest |
| P318 | Dr. Mortensen, Joachim:\|:\|Full time employee at Nordic Bioscience A/S\|\|Focht, Gili: No conflict of interest\|\|Pehrsson, Martin:\|:\|Full time employee at Nordic Bioscience A/S\|\|Griffiths, Anne M.: No conflict of interest\|\|Alexdóttir, Marta Sorokina:\|:\|Full time employee at Nordic Bioscience A/S\|\|Quteineh, Ahmad: No conflict of interest\|\|Church, Peter C.: No conflict of interest\|\|Baldassano, Robert N.: No conflict of interest\|\|Silverstein, Jared: No conflict of interest\|\|Karsdal, Morten Asser:\|:\|Full time employee and stock owner at Nordic Bioscience A/S\|\|Turner, Dan: No conflict of interest |

| | |
|---|---|
| P319 | Prof. Dr. Kobayashi, Taku:\|:\|Taku Kobayashi has served as a speaker, consultant or advisory board member for AbbVie, Activaid, Ajinomoto Pharma, Astellas, Alfresa Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO, JMDC, Kissei, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical.\|\|Dignass, Axel:\|:\|Axel Dignass reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Arena Pharmaceuticals, Falk Foundation, Gilead/Galapagos NV, Janssen and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, Celltrion, Falk Foundation, Ferring, Gilead/Galapagos NV, High5ImmunoTV, Janssen, MSD, Pfizer, Takeda, Tillotts and Vifor Pharma; payment for manuscript preparation from Falk Foundation, Takeda, Thieme and UniMed Verlag.\|\|Roblin, Xavier:\|:\|Xavier Roblin has served as a speaker, consultant or advisory board member for AbbVie, Amgen, Biogen, Celltrion, Ferring Pharmaceuticals, Galapagos NV, Janssen, MSD, Pfizer, Sandoz and Takeda.\|\|Fujitani, Yasushi:\|:\|Yasushi Fujitani is an employee of Gilead Sciences K.K.\|\|Oortwijn, Alessandra:\|:\|Alessandra Oortwijn is an employee and shareholder of Galapagos NV.\|\|Jamoul, Corinne:\|:\|Corinne Jamoul is a contractor for Galapagos NV.\|\|Hibi, Toshifumi:\|:\|Toshifumi Hibi has received lecture fees from Aspen Japan K.K., Janssen, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co., Ltd., Pfizer and Takeda; research grants from AbbVie GK, Activaid, Alfresa Pharma Corporation, Bristol Myers Squibb, Eli Lilly Japan K.K., Ferring Pharmaceuticals, Gilead Sciences, Inc., Janssen Pharmaceutical K.K., JMDC Inc., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc. and Takeda; scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd. and Zeria Pharmaceutical Co., Ltd.; and study group sponsorship from AbbVie GK, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Otsuka Holdings and Zeria Pharmaceutical Co., Ltd. |
| | |

| | |
|---|---|
| P320 | Quénéhervé, Lucille: No conflict of interest\|\|Trang-Poisson, Caroline: No conflict of interest\|\|Fantou, Aurelie: No conflict of interest\|\|Flamant, Mathurin: No conflict of interest\|\|Durand, Tony: No conflict of interest\|\|Bouguen, Guillaume: No conflict of interest\|\|Bregeon, Jeremy: No conflict of interest\|\|Oullier, Thibaud: No conflict of interest\|\|Amil, Morgane: No conflict of interest\|\|Dewitte, Marie: No conflict of interest\|\|Bardot, Stephanie: No conflict of interest\|\|Braudeau, cecile: No conflict of interest\|\|Josien, Regis: No conflict of interest\|\|Neunlist, Michel: No conflict of interest\|\|Prof. Bourreille, Arnaud: No conflict of interest |
| P321 | Dr. Xie, Chenxi: No conflict of interest\|\|Su, jingling: No conflict of interest\|\|Liu, Lupeng: No conflict of interest\|\|Lin, Yumei: No conflict of interest\|\|Hu, Yiqun: No conflict of interest\|\|Shi, Huaxiu: No conflict of interest |
| P322 | Murugesan, Selvasankar: No conflict of interest\|\|Kumar, Manoj: No conflict of interest\|\|Saadaoui, Marwa: No conflict of interest\|\|Elhag, Duaa Ahmed: No conflict of interest\|\|Hendaus, Mohamed A: No conflict of interest\|\|Ibrahim, Nazira: No conflict of interest\|\|Al-Mudhaka, Fatma: No conflict of interest\|\|AbuHazima, Khaled: No conflict of interest\|\|Akobeng, Anthony: No conflict of interest\|\|Elawad, Mamoun: No conflict of interest\|\|Dr. Al Khodor, Souhaila: No conflict of interest |
| P323 | Altuwaijiri, Mansour: No conflict of interest\|\|Alharbi, Othman: No conflict of interest\|\|Alruthia, Yazed: No conflict of interest\|\|Aljebreen, Abdulrahman: No conflict of interest\|\|Almadi , Majid: No conflict of interest\|\|Almalki , Yazeed: No conflict of interest\|\|Alrashed, Ahmad Waleed: No conflict of interest\|\|Alzahran, Shahad Awad: No conflict of interest\|\|Almuhaya, Hind: No conflict of interest\|\|Alhowaish, Nasser: No conflict of interest\|\|Alshehri, Khalid Faiz: No conflict of interest\|\|Alrushud , Saad Saud: No conflict of interest\|\|Alanazi, Waleed Suliman: No conflict of interest\|\|Azzam, Nahla: No conflict of interest |

| | |
|---|---|
| P324 | Mrs. Derks, Monica: No conflict of interest\|\|van Lierop, Lisa: No conflict of interest\|\|te Groen, Maarten: No conflict of interest\|\|Kuijpers, Chantal: No conflict of interest\|\|Nagtegaal, Iris D: No conflict of interest\|\|Hoentjen, Frank: No conflict of interest |
| P325 | Dr. Barrau, Mathilde: No conflict of interest\|\|Duru, Gerard: No conflict of interest\|\|Nancey, Stephane: No conflict of interest\|\|Phelip, Jean Marc: No conflict of interest\|\|Cheifetz, Adam: No conflict of interest\|\|Papamichael, Konstantinos: No conflict of interest\|\|Paul, Stephane: No conflict of interest\|\|Xavier, Roblin: No conflict of interest |
| P326 | Ms. Munster, Liesbeth: No conflict of interest\|\|de Groof, Elisabeth Joline: No conflict of interest\|\|van Dieren, Susan: No conflict of interest\|\|Mundt, Marco W: No conflict of interest\|\|D'Haens, Geert R A M: No conflict of interest\|\|Bemelman, Wilhelmus Adrianus: No conflict of interest\|\|Buskens, Christianne Johanna: No conflict of interest\|\|van der Bilt, Jarmila Dagmara Wendelien: No conflict of interest |
| P327 | Dr. López García, Alicia: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Maroto-Martín, Carlos: No conflict of interest\|\|Fernández-Prada, Samuel Juan: No conflict of interest\|\|Marquina, Victoria: No conflict of interest\|\|Rodríguez, Gloria Esther: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Lucendo, Alfredo J: No conflict of interest\|\|Flórez-Díez, Pablo: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|García-Morales, Natalia: No conflict of interest\|\|Miranda, José: No conflict of interest\|\|Vicuña, Miren: No conflict of interest\|\|Font, Guillem: No conflict of interest\|\|Suárez-Ferrer, Cristina: No conflict of interest\|\|Bernal, Lorena: No conflict of interest\|\|Peries, Laia: No conflict of interest\|\|Mínguez, Alejandro: No conflict of interest\|\|Tejedor, Javier: No conflict of interest\|\|Pérez-Galindo, Pablo: No conflict of interest\|\|Elosua, Alfonso: No conflict of interest\|\|Lastiri, Ernesto Alejandro: No conflict of interest\|\|Brunet, Eduard: No conflict of interest\|\|Llaó, Jordina: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Ferreiro-Iglesias, Rocío: No conflict of interest\|\|López, Laura: No conflict of interest\|\|González, Irene: No conflict of interest\|\|Ortega, Silvia Patricia: No conflict of interest\|\|Monsalve, Sara: No conflict of interest\|\|Márquez-Mosquera, Lucía: No conflict of interest\|\|González-Vivó, María: No conflict of interest\|\|Murciano, Francisca: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest |

| | |
|---|---|
| P328 | Hall, Rebecca: No conflict of interest\|\|Chuah, Cher Siong: No conflict of interest\|\|Brownson, Emily: No conflict of interest\|\|Poulose, Beena: No conflict of interest\|\|Athena, Oddy: No conflict of interest\|\|Mowat, Craig: No conflict of interest\|\|Macdonald, Jonathan: No conflict of interest\|\|Seenan, John Paul: No conflict of interest\|\|Dr. Ho, Gwo-Tzer: No conflict of interest |
| P329 | Dr. Kutar, Manek: No conflict of interest\|\|Desai, Devendra: No conflict of interest\|\|Abraham, Philip: No conflict of interest\|\|Gupta, Tarun: No conflict of interest |
| P330 | Dr. Allocca, Mariangela: No conflict of interest\|\|Dell'Avalle , Cecilia: No conflict of interest\|\|Furfaro, Federica: No conflict of interest\|\|Zilli, Alessandra: No conflict of interest\|\|Radice, Simona: No conflict of interest\|\|D'Amico, Ferdinando: No conflict of interest\|\|Peyrin-Biroulet, Laurent: No conflict of interest\|\|Fiorino, Gionata: No conflict of interest\|\|Danese, Silvio: No conflict of interest |
| P331 | Dr. Wang, Can: No conflict of interest\|\|Yang, Fan: No conflict of interest\|\|Qiao, Lichao: No conflict of interest\|\|Chen, Qi: No conflict of interest\|\|Chen, Hongjin: No conflict of interest\|\|Li, Yi: No conflict of interest\|\|Zhang, Xiaoqi: No conflict of interest\|\|Liao, Xiujun: No conflict of interest\|\|Cao, Lei: No conflict of interest\|\|Xu, Haixia: No conflict of interest\|\|Xiang, Yu: No conflict of interest\|\|Wang, Xiaoxiao: No conflict of interest\|\|Yang, Bolin: No conflict of interest |
| P332 | Aronskyy, Illya: No conflict of interest\|\|Spencer, Elizabeth:\|:\|Consulting for Prometheus Biosciences\|\|Kellar, Amelia: No conflict of interest\|\|Pittman, Nanci:\|:\|Consulting fees from Prometheus Biosciences\|\|Dubinsky, Marla:\|:\|Consulting fees from Abbvie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer ¬Ingelheim, Celgene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Janssen, Pfizer, Prometheus Biosciences, Takeda, Target PharmaSolutions. Research funding from Abbvie, Janssen, Pfizer, Prometheus Biosciences Takeda. \|\|Dr. Dolinger, Michael: No conflict of interest |

| | |
|---|---|
| P333 | Dr. Revés, Joana: No conflict of interest\|\|Morão, Bárbara: No conflict of interest\|\|Nascimento, Catarina: No conflict of interest\|\|Frias-Gomes, Catarina: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Freitas, Marta: No conflict of interest\|\|Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest\|\|Pereira, Flávio: No conflict of interest\|\|Caldeira, Ana: No conflict of interest\|\|Sousa, Rui: No conflict of interest\|\|Coelho, Rosa: No conflict of interest\|\|Macedo, Guilherme: No conflict of interest\|\|Glória, Luísa: No conflict of interest\|\|Torres, Joana: No conflict of interest\|\|Palmela, Carolina: No conflict of interest |
| P334 | Ms. Fortes, Flora: No conflict of interest\|\|Gonçalves, Julia: No conflict of interest\|\|Nery, Erick: No conflict of interest\|\|Arenas, Lara: No conflict of interest\|\|Mota, Jaciane: No conflict of interest\|\|Pimentel, Andrea: No conflict of interest\|\|Almeida, Neogelia: No conflict of interest\|\|Santos, Ana Maria: No conflict of interest\|\|Surlo, Valdiana: No conflict of interest\|\|Santana, Genoile: No conflict of interest |
| P335 | Mr. Pérez Galindo, Pablo: No conflict of interest\|\|Benítez, Jose Manuel: No conflict of interest\|\|Rubín de Célix, Cristina: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Castaño García, Andrés: No conflict of interest\|\|García, Maria José: No conflict of interest\|\|Vicuña, Miren: No conflict of interest\|\|Bernal, Lorena: No conflict of interest\|\|Bertoletti, Federico: No conflict of interest\|\|Ramírez Castro, Cynthia: No conflict of interest\|\|Sánchez-Azofra, María: No conflict of interest\|\|Sánchez-Delgado, Laura: No conflict of interest\|\|Ponferrada, Ángel: No conflict of interest\|\|Tejido Sandoval, Coral: No conflict of interest\|\|Capilla, María: No conflict of interest\|\|Laredo de la Torre, Viviana: No conflict of interest\|\|Diz-Lois, María Teresa: No conflict of interest\|\|Dueñas Sadornil, Carmen: No conflict of interest\|\|García-Morales, Natalia: No conflict of interest\|\|González-Vivo, María: No conflict of interest\|\|López-Cauce, Beatriz: No conflict of interest\|\|Melcarne, Luigi: No conflict of interest\|\|Calviño-Suárez, Cristina: No conflict of interest\|\|Lastiri González, Ernesto: No conflict of interest\|\|Ramírez de la Piscina, Patricia: No conflict of interest\|\|Pérez-Gisbert, Javier: No conflict of interest\|\|Pérez Martínez, Isabel: No conflict of interest\|\|Castro, Beatriz: No conflict of interest\|\|Cousillas, Antía: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Carpio, Daniel: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest |

| | |
|---|---|
| P336 | Dr. Ferreira, Ana Isabel: No conflict of interest\|\|Lima Capela, Tiago: No conflict of interest\|\|Xavier, Sofia: No conflict of interest\|\|Arieira, Cátia: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Dias de Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest |
| P337 | Zhang, Heng: No conflict of interest\|\|Li, Lanlan: No conflict of interest\|\|Deng, Ke: No conflict of interest\|\|Li , Wenru: No conflict of interest\|\|Ren, Donglin: No conflict of interest |
| P338 | Dr. Yzet, Clara: No conflict of interest\|\|Brazier, Franck: No conflict of interest\|\|Hautefeuille, Vincent: No conflict of interest\|\|Grados, Lucien: No conflict of interest\|\|Decrombecque, Catherine: No conflict of interest\|\|Diouf, Momar: No conflict of interest\|\|Fumery, Mathurin: No conflict of interest |
| P339 | Prof. Knyazev, Oleg: No conflict of interest\|\|Kulakov, Dmitriy: No conflict of interest\|\|Kagramanova, Anna: No conflict of interest\|\|Tishaeva, Irina: No conflict of interest\|\|Baranova, Tatyana: No conflict of interest\|\|Poletova, Anna: No conflict of interest |

| | |
|---|---|
| P340 | Prof. Akyüz, Filiz: No conflict of interest\|\|An, Yoon Kyo: No conflict of interest\|\|Aniwan, Satimai: No conflict of interest\|\|Bui, Huu Hoang: No conflict of interest\|\|Chan, Webber PW: No conflict of interest\|\|Choi, Chang Hwan: No conflict of interest\|\|Chopdat, Nazeer: No conflict of interest\|\|Connor, Susan: No conflict of interest\|\|Desai, Devendra: No conflict of interest\|\|Flanagan, Emma: No conflict of interest\|\|Kobayashi, Taku: No conflict of interest\|\|Leong, Rupert W: No conflict of interest\|\|Leow, Alex: No conflict of interest\|\|Leung, Wai Keung: No conflict of interest\|\|Limsrivilai, Julajak: No conflict of interest\|\|Peddi, Kiran: No conflict of interest\|\|Pribadi, Rabbinu Rangga: No conflict of interest\|\|Ran, Zhihua: No conflict of interest\|\|Wei, Shu-Chen: No conflict of interest\|\|Wu, Kaichun: No conflict of interest\|\|Ye, Byong Duk: No conflict of interest |
| P341 | Prof. Dr. Ji Min, Lee: No conflict of interest\|\|Lee, Kang-Moon: No conflict of interest\|\|Han, Kyung-Do: No conflict of interest |
| P342 | McKay, Caroline:\|:\|CM is currently an employee and shareholder in Takeda and a shareholder in Merck and Johnson & Johnson\|\|Pacis, Scarlette:\|:\|SB is an employee of Cytel. Cytel's work was financially supported by Takeda Pharmaceuticals USA\|\|Bolzani, Anna:\|:\|AB is an employee of Cytel. Cytel's work was financially supported by Takeda Pharmaceuticals USA\|\|Geransar, Parnia:\|:\|PG is an employee and shareholder of Takeda Pharmaceuticals\|\|Panés, Julian:\|:\|JP received financial support for research from AbbVie and Pfizer; consultancy fees/honorarium from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance and Wasserman; reports payment for lectures including service on speaker bureau from Abbott, Ferring, Janssen, Pfizer and Takeda; and reports payment for development of educational presentations from Abbott, Janssen, Pfizer Roche and Takeda. |

| | |
|---|---|
| P343 | Prof. Dr. Babayeva-Sadigova, Gulustan: No conflict of interest\|\|Asadova, Gunay: No conflict of interest\|\|Quliyev , Farid: No conflict of interest\|\|Makhmudov , Umud: No conflict of interest\|\|Ismayilova , Khalida: No conflict of interest\|\|Samedova , Tunzala: No conflict of interest\|\|Hasanova , Aychin: No conflict of interest\|\|Mirzazada , Orkhan: No conflict of interest\|\|Mahammadaliyeva , Mukhasta: No conflict of interest\|\|Abdulzada , Cavad: No conflict of interest\|\|Musayev, Camal: No conflict of interest\|\|Iskenderov , Namiq: No conflict of interest |
| P344 | Mrs. Ascari, Francesca: No conflict of interest\|\|Barugola, Giuliano: No conflict of interest\|\|Ruffo, Giacomo: No conflict of interest |
| P345 | Ms. Hennlich, Barbara: No conflict of interest\|\|Madl, Christian: No conflict of interest\|\|Pachofszky, Thomas: No conflict of interest |
| P346 | Ramírez, Cynthia: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|Cabriada, José Luis: No conflict of interest\|\|Dr. Rodríguez-Lago, Iago: No conflict of interest |

| | |
|---|---|
| P347 | Mrs. Fierens, Liselotte: No conflict of interest\|\|Casellas, Francesc:\|:\|FC received research support from AbbVie, Ferring, MSD, Shire, Takeda and Zambon; speaker fees from\|AbbVie, Chiesi, Ferring, Gebro, MSD, Shire, Takeda and Zambon.\|\|\|Borruel , Natalia:\|:\|NB received research support from AbbVie,Janssen, Takeda, Adacyte, Actial; speaker's fees from AbbVie,\|Adacyte, Janssen-Cilag, MSD, Pfizer, Takeda; consultancy fees from Janssen-Cilag, Abbvie\|\|\|van der Woude , C. Janneke:\|:\|CJvdW has served on advisory boards for Abbvie, Takeda, Pfizer, Galapagos and Celltrion. She is supported\|by research funding from ZonMW, Tramedico, Falk Benelux and Pfizer.\|\|\|Huberts, Anouk S.: No conflict of interest\|\|Siegmund, Britta:\|:\|BS served as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Falk, Janssen, Lilly, Pfizer, PredictImmune and Takeda; and received speaker's fees from AbbVie, BMS, CED Service GmbH, Falk, Ferring, Janssen, Pfizer and Takeda (served as representative of the Charité)\|\|Sonnenberg , Elena:\|:\|ES has received speaker fees from Biogen, Takeda, BMS, AbbVie and Janssen. Consultancy fees from\|Janssen. None of these activities have any relation to the present study.\|\|\|Novacek , Gottfried:\|:\|GN received lecture fees/consultant fees/advisory board member from AbbVie, Merck Sharp & Dohme,\|Takeda, Janssen-Cilag, Pfizer, Gilead, Galapagos, Ferring, Vifor, AstroPharma, Falk, Bristol Myers Squibb,\|Arena Pharmaceuticals\|\|\|Gerold, Nathalie: No conflict of interest\|\|Stamm , Tanja:\|:\|TS reports grants and personal fees from AbbVie, Roche, Sanofi, Takeda, and Novartis, all outside the\|submitted work.\|\|\|Hedin , Charlotte RH:\|:\|CH received speaker fees from Takeda, Ferring, AbbVie, and Janssen, and consultancy fees from Pfizer. She\|has acted as local principal investigator for clinical trials for Janssen and GlaxoSmithKline. She is PI on\|projects at the Karolinska Institutet partly funded by investigator-initiated grants from Takeda and Tillotts.\|None of these activities have any relation to the present study.\|\|\|Julsgaard, Mette:\|:\|MJ has served as a consultant for Ferring and Takeda Pharma and received speakers fee from MSD, Ferring and Takeda Pharma. She is the PI on projects at Aarhus University Hospital partly funded by investigator-initiated grants from Taheda pharma. Non of these activities have any relation to the present study.\|\|Fiorino, Gionata:\|:\|GF served as a consultant for AbbVie, Takeda, Janssen, Pfizer, Galapagos, Sandoz, Amgen, Ferring\|\|Radice, Simona: No conflict of interest\|\|Zini , Michela Luciana Luisa: No conflict of interest\|\|Gross, Evelyn: \|:\|Grants: AbbVie, Boehringer Ingelheim RCV, Celgene, Coloplast, Dr. Falk, Ferring, Galapagos Biopharma, Gilead, Janssen, Merck, MSD, Pfizer, Takeda Pharma \| Personal Fees: AbbVie, Boehringer Ingelheim RCV, Eli Lilly, Ferring, Galapagos Biopharma, Gilead, Janssen, Peri Consulting, Pfizer, Takeda Pharma\| Non-financial support: AbbVie, Takeda Pharma\|\|Sander, Cornelia: No conflict of interest\|\|Arijs, Ingrid: No conflict of interest\|\|Vakouftsi, Vasiliki-Rafaela: No conflict of interest\|\|Carney , Nicholas:\|:\|NC is an employee and shareholder of F. Hoffmann-La Roche Ltd\|\|Charlafti , Ilias:\|:\|IC is an employee of F. Hoffmann-La Roche Ltd\|\|Ferrante, Marc:\|:\|MF reports research support from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; speaker's\|fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD,\|Mylan, Pfizer, Sandoz, Takeda and Truvion Healthcare consultancy fees from AbbVie, Boehringer\|Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis,\|Sandoz, Takeda and Thermo Fisher |

| | |
|---|---|
| P348 | Schreiber, Stefan Wolfgang:\|:\|Consultancy and personal fees from AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, and Theravance.\|\|Danese, Silvio:\|:\|Lecture fees: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim; Consultancy: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim.\|\|Dirk, Lindner:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Agboton, Christian:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Colombel, Jean-Frederic:\|:\|Research grants: AbbVie, Janssen Pharmaceuticals, Takeda; Lecture fees: AbbVie, Amgen, Allergan, Inc., Ferring Pharmaceuticals, Shire, Takeda; Consulting fees: AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Geneva, Genentech, Janssen Pharmaceuticals, Immunic, Landos, Ipsen, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; Stock options: Intestinal Biotech Development, Genfit. |
| P349 | Dr. Steinsbø, Øyvind: No conflict of interest\|\|Aasprong, Ole Gunnar: No conflict of interest\|\|Karlsen, Lars Normann: No conflict of interest\|\|Aabakken, Lars: No conflict of interest\|\|Grimstad, Tore:\|:\|Unrestricted grants from Abbvie and Tillotts Pharma |
| P350 | Dr. Levartovsky, Asaf: No conflict of interest\|\|Cohen, Tal: No conflict of interest\|\|Klang, Eyal: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Kopylov, Uri: No conflict of interest |
| P351 | Dr. Mc Gettigan, Neasa: No conflict of interest\|\|Saeidi, Reza: No conflict of interest\|\|Hanley, Marion: No conflict of interest\|\|Clarke, Maeve: No conflict of interest\|\|O'Toole, Aoibhlinn: No conflict of interest\|\|Morrin, Martina: No conflict of interest\|\|Boland, Karen: No conflict of interest |

| | |
|---|---|
| P352 | Dr. Khan, Nabeel:\|:\|Nabeel Khan has received an unrestricted research grant from Pfizer, Luitpold, and Takeda Pharmaceuticals as well as Samsung BioEpis. He has served on Advisory Board of Pharmacosmos. \|\|Patel, Manthankumar: No conflict of interest\|\|Sundararajan, Ramaswamy: No conflict of interest |
| P353 | Dr. Strande, Vibeke:\|:\|This work was sponsored by funds from Takeda\|\|Lund, Charlotte: No conflict of interest\|\|Småstuen, Milada C.: No conflict of interest\|\|Bengtson, May-Bente: No conflict of interest\|\|Cetinkaya, Raziye Boyar: No conflict of interest\|\|Detlie, Trond Espen:\|:\|Detlie TE/Trond Espen Detlie has served as a speaker, consultant or advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and Vifor Pharma. He has received unrestricted research grants from AbbVie and Pharmacosmos.\|\|Frigstad, Svein Oskar: No conflict of interest\|\|Medhus, Asle W.:\|:\|Unrestricted research grant from Takeda\|\|Henriksen, Magne: No conflict of interest\|\|Holten, Kristina I. Aass: No conflict of interest\|\|Hovde, Øistein:\|:\|Advisory board. Takeda, Janssen, Bristol-Myers Squibb Norway, abbvie\|\|Huppertz-Hauss, Gert: No conflict of interest\|\|Johansen, Ingunn: No conflict of interest\|\|Olsen, Bjørn Christian: No conflict of interest\|\|Pallenschat, Jens: No conflict of interest\|\|Perminow, Gøri: No conflict of interest\|\|Ricanek, Petr: No conflict of interest\|\|Torp, Roald: No conflict of interest\|\|Tønnessen, Tor: No conflict of interest\|\|Vatn, Simen: No conflict of interest\|\|Aabrekk, Tone Bergene: No conflict of interest\|\|Opheim, Randi: No conflict of interest\|\|Høivik, Marte Lie:\|:\|Dr. Høivik has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma\|\|Kristensen, Vendel A.:\|:\|Takeda, Tillotts Pharma, Janssen-Cilag |
| P354 | Dulai, Parambir:\|:\|Research support, travel support, and honorarium from Takeda, research support from Pfizer, and support from a training grant through the National Institute of Diabetes\|and Digestive and Kidney Diseases (5T32DK007202).\|\|\|Lindner, Dirk:\|:\|Employee of the study sponsor, Takeda and holds Takeda stock or stock options.\|\|Agboton, Christian:\|:\|Employee of the study sponsor, Takeda and holds Takeda stock or stock options.\|\|Alric, Hadrien:\|:\|Research support, travel support, and honorarium from Janssen, Fujifilm and Boston Scientific\|\|Bamias, Giorgios:\|:\|Advisor/lecturer for Janssen, Pfizer, Takeda, AbbVie, Merck Sharp & Dohme, Mylan, Genesis Pharma, Adacyte Therapeutics, Amgen, Ferring and Cooper. Grants/honoraria from Pfizer, Takeda, AbbVie and Aenorasis. Investigator in research/clinical trials for AbbVie and Takeda\|\|Peyrin-Biroulet, Laurent:\|:\|Personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enterome, Enthera, Ferring, Fresenius Kabi, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, MSD, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Therevance, Tillotts and Vifor; grants from AbbVie, MSD and Takeda; and stock options from CTMA. |

| | |
|---|---|
| P355 | Ms. Beek, Kim: No conflict of interest\|\|de Jonge, Catherina Sofieke: No conflict of interest\|\|van Rijn, Kyra: No conflict of interest\|\|de Voogd, Floris Anthonius Elias:\|:\|FV received speaker or honoraria fees from AbbVie and Janssen \|\|Buskens , Christianne Johanna: No conflict of interest\|\|D'Haens , Geert:\|:\|Geert D'Haens has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|Gecse, Krisztina Barbara:\|:\|Krisztina B. Gecse has received grants from Pfizer Inc, Celltrion and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Abbvie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts.\|\|Stoker, Jaap: No conflict of interest |
| P356 | Dr. Varghese, Jijo: No conflict of interest |
| P357 | Dr. Morão, Bárbara: No conflict of interest\|\|Nascimento, Catarina: No conflict of interest\|\|Revés, Joana: No conflict of interest\|\|Abreu, Bárbara: No conflict of interest\|\|Bravo, Ana Catarina: No conflict of interest\|\|Saraiva, Susana: No conflict of interest\|\|Glória, Luísa: No conflict of interest\|\|Torres, Joana: No conflict of interest\|\|Palmela, Carolina: No conflict of interest\|\|Frias Gomes, Catarina: No conflict of interest |
| P358 | Dr. Park, Jihye: No conflict of interest\|\|Park, Soo Jung: No conflict of interest\|\|Park, Jae Jun: No conflict of interest\|\|Kim, Tae Il: No conflict of interest\|\|Kim, Won Ho: No conflict of interest\|\|Cheon, Jae Hee: No conflict of interest |

| | |
|---|---|
| P359 | Solhaug, Helene: No conflict of interest\|\|Haukø, Ingvild: No conflict of interest\|\|Mørk, Einar: No conflict of interest |
| P360 | Mrs. Amor Costa, Carmen: No conflict of interest\|\|Suárez Ferrer , Cristina: No conflict of interest\|\|Poza Cordón, Joaquín: No conflict of interest\|\|Yebra Carmona , Jorge: No conflict of interest\|\|Rueda García , José Luís: No conflict of interest\|\|Sánchez Azofra , María: No conflict of interest\|\|Martín Arranz, Eduardo: No conflict of interest\|\|González Díaz, Irene: No conflict of interest\|\|Amiama Roig, Clara: No conflict of interest\|\|Martín Arranz, María Dolores: No conflict of interest |
| P361 | Dr. Jeay, Marine: No conflict of interest\|\|Carbonnel, Franck:\|:\|Received board or lecture fees from Enterome, MSD, BMS, Janssen, Pfizer, Abbvie, Mayoly Spindler, Takeda, Pileje, Tillotts, Celltrion, Roche, Ferring.\|\|Robert, Caroline: No conflict of interest\|\|Bellanger, Christophe:\|:\|received board or lecture fees from Janssen, Takeda, Tillotts.\|\|Meyer, Antoine: No conflict of interest |
| P362 | Dr. Shamsiddinova, Amira: No conflict of interest\|\|Deputy, Mohammed: No conflict of interest\|\|Worley, Guy: No conflict of interest\|\|Rao, Christopher: No conflict of interest\|\|Dean, Harry: No conflict of interest\|\|Thomas-Gibson, Siwan: No conflict of interest\|\|Faiz, Omar: No conflict of interest |
| P363 | Prof. Dr. Țurcan, Svetlana: No conflict of interest\|\|Platon, Valentina: No conflict of interest\|\|Negru, Iulian: No conflict of interest |

| | |
|---|---|
| P364 | Ms. Karachaliou, Alexandra: No conflict of interest\|\|Lekakis, Vasileios: No conflict of interest\|\|Bletsa, Maria: No conflict of interest\|\|Mantzaris, Gerassimos J.: No conflict of interest\|\|Tzouvala, Maria: No conflict of interest\|\|Bamias, Giorgos: No conflict of interest\|\|Kontogianni, Meropi D.: No conflict of interest |
| P365 | Kilic, Diler Tas: No conflict of interest\|\|Yuksel, Ilhami: No conflict of interest |
| P366 | Ms. Lin, Lingling: No conflict of interest\|\|Qu, ying: No conflict of interest\|\|Zhao, Xinmei: No conflict of interest |
| P367 | Ms. Koppelman, Lola: No conflict of interest\|\|Roozemoind, Sara: No conflict of interest\|\|Cornelissen, Lisa: No conflict of interest\|\|Hommes, Daniel: No conflict of interest\|\|Voorneveld, Philip: No conflict of interest\|\|Maljaars, Jeroen: No conflict of interest\|\|Kubben, Francois: No conflict of interest\|\|Verweij, Evelyne: No conflict of interest\|\|van der Meulen - de Jong, Andrea: No conflict of interest |

| | |
|---|---|
| P368 | Prof. Kim, Dong Hyun: No conflict of interest\|\|Kim, Eun Soo: No conflict of interest\|\|Kim, Hyun Soo: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Kim, Seong-Jung: No conflict of interest\|\|Kim, Kyeong Ok: No conflict of interest\|\|Lee, Yoo Jin: No conflict of interest\|\|Song, Eun Mi: No conflict of interest\|\|Kim, Dae Sung: No conflict of interest\|\|Lee, Jun: No conflict of interest |
| P369 | Dr. Cerqueira, Rute: No conflict of interest\|\|Correia, Manuel: No conflict of interest\|\|Veloso, Ricardo: No conflict of interest\|\|Manso, M Conceição: No conflict of interest |
| P370 | Mr. Katsaros, Marios: No conflict of interest\|\|Kalogirou, Maria: No conflict of interest\|\|Katsoula, Anastasia: No conflict of interest\|\|Paschos, Paschalis: No conflict of interest\|\|Karabatsou, Sofia: No conflict of interest\|\|Tsionis, Theodoros: No conflict of interest\|\|Soufleris, Konstantinos: No conflict of interest\|\|Giouleme, Olga: No conflict of interest |
| P371 | Dr. Benammi, Sarah: No conflict of interest\|\|Naddouri, Jaouad: No conflict of interest\|\|Bakkali, Youness: No conflict of interest\|\|Alaoui, Mouna: No conflict of interest\|\|Sebbah, Farid: No conflict of interest\|\|Raiss, Mohamed: No conflict of interest\|\|Hrora, Abdelmalek: No conflict of interest |
| P372 | Prof. Dr. Belousova, Elena: No conflict of interest |

| | |
|---|---|
| P373 | Dr. Alessa, Sara: No conflict of interest\|\|Aldraiweesh, Saleh: No conflict of interest\|\|Albogami, Fahad: No conflict of interest |
| P374 | Dr. Wang, Zhigang: No conflict of interest\|\|Verstockt , Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Sabino , João:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring.\|João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|Ferrante , Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|\|Vermeire , Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Dreesen, Erwin:\|:\|Erwin Dreesen received consultancy fees from argenx (all fees paid to University). |
| P375 | Schreiber, Stefan:\|:\|Consulting\|\|Reinisch, Walter: No conflict of interest\|\|Nguyen, Deanna:\|:\|Former employee of Theravance Biopharma\|\|Guerin, Tadhg:\|:\|Emplyee of Theravance Biopharma\|\|Kierkus, Jaroslaw: No conflict of interest\|\|Rozpondek, Piotr: No conflict of interest\|\|Bourdet, David:\|:\|Employed by Theravance Biopharma\|\|Dr. Abhyankar, Brihad:\|:\|Former Employee of Theravance Biopharma Ireland Ltd\|\|Peyrin-Biroulet, Laurent:\|:\|consulting |

| | |
|---|---|
| P376 | Sands, Bruce E:\|:\|received fees for consulting and speaking from Abivax, Bristol Myers Squibb, Janssen, Eli Lilly, Pfizer, and Takeda; received fees for consulting from AbbVie, Adiso Therapeutics, Alimentiv, Amgen, Arena, Artizan Biosciences, Artugen, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Calibr, Celltrion, ClostraBio, Cytoki Pharma, Connect Biopharma, Entera, Evommune, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunic, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Kaleido Biosciences, Kallyope, MiroBio, Morphic Therapeutics, MRM Health, OSE Immunotherapeutics, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Sun Pharma, Surrozen, Synlogic, Target RWE, Teva, Theravance Biopharma, TLL Pharmaceutical, USWM Enterprises, Viela Bio, and VTA Labs; received personal fees and stock options for consulting from Ventyx Biosciences and Thelium Therapeutics.\|\|Jain, Anjali:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Ahmad, Harris A.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Osterman, Mark:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Memaj, Arteid:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Axelrad, Jordan E.:\|:\|received consulting fees from AbbVie, BioFire Diagnostics, Janssen, and Pfizer; received research grants from BioFire Diagnostics. |
| P377 | Dr. Wils, Pauline: No conflict of interest\|\|Cartier, Laurine: No conflict of interest\|\|Azahaf, Mustapha: No conflict of interest\|\|Hambli, Sofia: No conflict of interest\|\|Branche, Julien: No conflict of interest\|\|Gérard, Romain: No conflict of interest\|\|Desreumaux, Pierre: No conflict of interest\|\|Louvet, Alexandre: No conflict of interest\|\|Nachury, Maria: No conflict of interest |
| P378 | Dr. Prentice, Ralley:\|:\|Ralley Prentice has received research support from Ferring\|\|Flanagan, Emma: No conflict of interest\|\|Wright, Emily K.:\|:\|Emily K. Wright has received research support from Janssen\|\|Gibson, Peter R.:\|:\|Peter Gibson has served as a consultant or advisory board member for Anatara, Atmo Biosciences, Falk Pharma, Immunic Therapeutics, Janssen, Novozymes, Pfizer, and Takeda. He has received research grants for investigator-driven studies from Atmo Biosciences. He holds shares in Atmo Biosciences.\|\|Rosella, Sam: No conflict of interest\|\|Rosella, Ourania: No conflict of interest\|\|Goldberg, Rimma: No conflict of interest\|\|Prideaux, Lani: No conflict of interest\|\|Kiburg, Katerina: No conflict of interest\|\|Ross, Alyson L: No conflict of interest\|\|Burns, Megan: No conflict of interest\|\|Bell, Sally J.:\|:\|Sally Bell has received consultation fees from AbbVie and Janssen, has received research grants for other investigator-driven studies/clinical trial funding from AbbVie, Janssen and Shire and has received speaker's fees from AbbVie and Janssen. |

| | |
|---|---|
| P379 | Vermeire, Séverine:\|:\|SV has received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Avaxia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CVasThera, Cytoki Pharma, Eli Lilly, Falk, Ferring, Galapagos, Genentech-Roche, Gilead, GlaxoSmithKline, Hospira, Imidomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand Pharma.\|\|Danese, Silvio:\|:\|SD has received lecture fees from AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Mundipharma, Pfizer, Sandoz, Takeda, Tigenix, UCB Pharma, and Vifor; and has served as a consultant for AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Mundipharma, Pfizer, Sandoz, Takeda, Tigenix, UCB Pharma, and Vifor.\|\|Cohen, Benjamin L.:\|:\|BLC has served as an advisory board member for or has received consulting fees from AbbVie, Bristol Myers Squibb, Celgene, Pfizer, Sublimity Therapeutics, and Target RWE; consulting fees from Cornerstones and Vindico; and has received speaker fees from AbbVie.\|\|Magro, Fernando:\|:\|FM has been a speaker and has received honoraria for services from AbbVie, Biogen, Falk, Ferring, Hospira, Laboratorios Vitoria, Merck, and Vifor.\|\|Chen, Yan: No conflict of interest\|\|Ha, Christina:\|:\|CH has served as a consultant, advisory board member, and/or participated in research for AbbVie, Bristol Myers Squibb, Eli Lilly, Genentech, InDex Pharmaceuticals, Janssen, Pfizer, and Takeda. \|\|Dubcenco, Elena:\|:\|ED is a full-time employee of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents.\|\|Lacerda, Ana P.:\|:\|APL is a full-time employee of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents.\|\|Marced, Elena:\|:\|EM is a full-time employee of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents.\|\|Oomen, Jessica:\|:\|JO is a full-time employee of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents.\|\|Garrison, Andrew:\|:\|AG is a full-time employee of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents.\|\|Peyrin-Biroulet, Laurent:\|:\|LP-B has received personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Boehringer Ingelheim, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enterome, Enthera, Ferring, Fresenius Kabi, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, MSD, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Therevance, and Vifor; has received grants from AbbVie, MSD, and Takeda; and owns stock options from CTMA. |
| | |

| | |
|---|---|
| P380 | Mr. Svolos, Vaios: No conflict of interest\|\|Hansen, Richard: No conflict of interest\|\|Russell, Richard K: No conflict of interest\|\|Gaya, Daniel R: No conflict of interest\|\|John Paul, Seenan: No conflict of interest\|\|Macdonald, Jonathan: No conflict of interest\|\|Wilson, David: No conflict of interest\|\|Henderson, Paul: No conflict of interest\|\|Din, Shahida: No conflict of interest\|\|Ho, Gwo-Tzer: No conflict of interest\|\|Quince, Christopher: No conflict of interest\|\|Ijaz, Umer Z: No conflict of interest\|\|Milling, Simon: No conflict of interest\|\|Nichols, Ben: No conflict of interest\|\|Papadopoulou, Rodanthi: No conflict of interest\|\|McKirdy, Shona: No conflict of interest\|\|Gervais, Lisa: No conflict of interest\|\|Shields, Stephanie: No conflict of interest\|\|Gerasimidis, Konstantinos: No conflict of interest |
| P381 | Dr. Kellar, Amelia: No conflict of interest\|\|Aronskyy, Illya: No conflict of interest\|\|Dubinsky, Marla C:\|:\|Consulting fees from Abbvie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer ¬Ingelheim, Celgene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Janssen, Pfizer, Prometheus Biosciences, Takeda, Target PharmaSolutions. Research funding from Abbvie, Janssen, Pfizer, Prometheus Biosciences Takeda.\|\|Dolinger, Michael T:\|:\|Consultant for Neurologica Corp., a subsidiary of Samsung Electronics Co., Ltd. |
| P382 | Ms. Chen, Kaylie: No conflict of interest\|\|Chen, Johnson: No conflict of interest\|\|Smith, Emily: No conflict of interest\|\|Mathani, Prerna: No conflict of interest\|\|Longman, Randy:\|:\|RL: Consulting/Speaking Fees: Pfizer, Enzymetrics, Ancilia Biosciences\|\|Lukin, Dana:\|:\|DL: Consulting/Speaking Fees: AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Palatin Technologies, Pfizer; Grant Support: AbbVie, Janssen, Takeda.\|\|Scherl, Ellen:\|:\|ES: Consulting/Speaking Fees: AbbVie, Crohn's and Colitis Foundation of America (CCFA), Entera Health, Evidera, GI Health Foundation, Janssen, Protagonist Therapeutics, Seres Health, Takeda Pharmaceuticals, Bristol Myers Squibb; Grant Support: Abbott (AbbVie), AstraZeneca, CCFA, Janssen Research & Development, Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney (NIDDK), National Institute of Health (NIH), New York Crohn's Foundation, Pfizer, UCB, UCSF–CCFA Clinical Research Alliance, Genentech, Seres Therapeutics, Celgene \|\|Battat, Robert: No conflict of interest |

| | |
|---|---|
| P383 | Dr. Iborra Colomino, Marisa Isabel: No conflict of interest\|\|Garrido Marín, Alejandro: No conflict of interest\|\|Caballol Oliva, Berta: No conflict of interest\|\|Huguet Malavés, José María: No conflict of interest\|\|Arias García, Lara: No conflict of interest\|\|Mesonero Gismero, Francisco: No conflict of interest\|\|Fernández Prada, Samuel Juan: No conflict of interest\|\|Boscá Watts, Marta Maia: No conflict of interest\|\|Ponferrada Díaz, Ángel: No conflict of interest\|\|Calvet Calvo, Xavier: No conflict of interest\|\|Gutiérrez Casbas, Ana: No conflict of interest\|\|Ordás Jiménez, Ingrid: No conflict of interest\|\|Ruiz Sanchez, Lucia: No conflict of interest\|\|Sicilia Aladren, Beatriz: No conflict of interest\|\|Garcia de la Filia, Irene: No conflict of interest\|\|Domènech Morral, Eugeni: No conflict of interest\|\|Nos Mateu, Pilar: No conflict of interest |
| P384 | Ms. Van De Meeberg, Maartje: No conflict of interest\|\|Fidder, Herma: No conflict of interest\|\|Sundaresan, Janani: No conflict of interest\|\|Struys, Eduard: No conflict of interest\|\|Oldenburg, Bas: No conflict of interest\|\|Mares, Wout: No conflict of interest\|\|Mahmmod, Nofel: No conflict of interest\|\|van Asseldonk, Dirk: No conflict of interest\|\|Lutgens, Maurice: No conflict of interest\|\|Kuyvenhoven, Johan: No conflict of interest\|\|Rietdijk, Svend: No conflict of interest\|\|Nissen, Loes: No conflict of interest\|\|Koehestanie, Parweez: No conflict of interest\|\|de Jonge, Robert: No conflict of interest\|\|Bulatović Ćalasan, Maja: No conflict of interest\|\|Bouma, Gerd: No conflict of interest |
| P385 | Dr. D'Amico, Ferdinando:\|:\|F D'Amico has served as a speaker for Janssen, Galapagos, Sandoz, and Omega Pharma\|\|Caron, Benedicte:\|:\|B Caron reports lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Takeda.\|\|Vieujean, Sophie:\|:\|S Vieujean received speaker's fees from Abbvie and Janssen Pfizer Shire.\|\|Peyrin-Biroulet, Laurent:\|:\|L Peyrin-Biroulet : personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals , Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine ; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance ; Pandion Therapeutics, grants from Abbvie, MSD, Takeda, Fresenius Kabi, stock options : CTMA.\|\|Danese, Silvio:\|:\|S Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. |

| | |
|---|---|
| P386 | Guerra Marina, Ivan: No conflict of interest\|\|Bujanda, Luis: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Pérez-Martínez, Isabel: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|de la Peña, Luisa: No conflict of interest\|\|de Benito, Marina: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Varela, Pilar: No conflict of interest\|\|Bernal, Lorena: No conflict of interest\|\|Franco, Ana Carolina: No conflict of interest\|\|Ber, Yolanda: No conflict of interest\|\|Piqueras, Marta: No conflict of interest\|\|Tardillo, Carlos: No conflict of interest\|\|Ponferrada, Ángel: No conflict of interest\|\|Olivares, Sonsoles: No conflict of interest\|\|Lucendo, Alfredo J.: No conflict of interest\|\|Gilabert, Pau: No conflict of interest\|\|Sierra Ausín, Mónica: No conflict of interest\|\|Bellart, María: No conflict of interest\|\|Herrarte, Amaia: No conflict of interest\|\|Calafat, Margalida: No conflict of interest\|\|de Francisco, Ruth: No conflict of interest\|\|P. Gisbert, Javier: No conflict of interest\|\|Guardiola, Jordi: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest |
| P387 | Dr. De Sire, Roberto: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|Caiazzo, Anna: No conflict of interest\|\|Testa, Anna: No conflict of interest\|\|Nardone, Olga Maria: No conflict of interest\|\|Guarino, Alessia Dalila: No conflict of interest\|\|Olmo, Oriana: No conflict of interest\|\|Calabrese, Giulio: No conflict of interest\|\|Fierro, Giuseppe: No conflict of interest\|\|Toro, Benedetta: No conflict of interest\|\|Cantisani, Nicola Mattia: No conflict of interest\|\|Ferrante, Mario: No conflict of interest\|\|La Mantia, Alessia: No conflict of interest\|\|D'Alessandro, Ermelinda: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest |

| | |
|---|---|
| P388 | Dr. Sagami, Shintaro:\|:\|Shintaro Sagami served as a speaker for AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Gilead Sciences, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical, and Zeria Pharmaceutical and as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, and EA Pharma. \|\|Morikubo, Hiromu:\|:\|Morikubo has received research grants from Japan Foundation for Takeda Pharmaceutical, Applied Enzymology. \|\|Miyatani, Yusuke:\|:\|Yusuke Miyatani has served as a speaker of AbbVie; received research funding from Japan Foundation for Applied Enzymology; and as an endowed chair of AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, and EA Pharma.\|\|Fukuda, Tomohiro: No conflict of interest\|\|Asonuma, Kunio:\|:\|Kunio Asonuma has an endowed chair from AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, EA Pharma.\|\|Maeda, Masa:\|:\|Masa Maeda has served as an endowed chair of AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, and EA Pharma.\|\|Yoko, Yamana:\|:\|Yoko Yamana has served as an endowed chair of AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, and EA Pharma.\|\|Karashima, Ryo: No conflict of interest\|\|Hojo, Aya: No conflict of interest\|\|Nakano, Masaru:\|:\|Masaru Nakano has served as a speaker or a consultant in Covidien, Mochida Pharmaceutical, Takeda Pharmaceutical, Zeria Pharmaceutical, Kyorin Pharmaceutical, and Nippon Kayaku; received research funding from Mitsubishi Tanabe Pharma and Japanese foundation for research and promotion of endoscopy.\|\|Hibi, Toshifumi:\|:\|Toshifumi Hibi has received Lecture fees from Aspen Japan K.K, Abbvie GK, Ferring, Gilead Sciences, Janssen, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Takeda Pharmaceutical, Advisory/consultancy fees from Apo Puls Station, Abbvie GK, Bristol-Myaers Squibb, Celltrion, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Kyorin, Mitsubishi-Tanabe Pharma., Nichi-Iko Pharmaceutical, Pfizer, Takeda Pharmaceutical, Zeria Pharmaceutical and research grants from Abbvie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc., Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Ferring Pharmaceuticals and Bristol-Myers Squibb; received scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd.; Pfizer Japan Inc. belonged to study group sponsorship by Otsuka Holdings, Abbvie GK, EA Pharma Co., Ltd., Zeria Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd.\|\|Kobayashi, Taku:\|:\|Taku Kobayashi has received research grant from Otsuka Holdings, Abbvie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc., Mochida Pharmaceutical, Pfizer, Zeria Pharmaceutical, Nippon Kayaku, JIMRO, Google Asia Pacific, served as a speaker, a consultant or an advisory role for Takeda Pharmaceutical, Activaid, Alfresa Pharma Corporation, Zeria Pharmaceutical, Kyorin Pharmaceutical, Nippon Kayaku, Mitsubishi Tanabe Pharma Corporation, Abbvie GK, Pfizer, Janssen, Thermo Fisher Diagnostics, JIMRO, Bristol-Myers Squibb, Gilead Sciences, Eli Lilly, Galapagos, KISSEI Pharmaceutical. Hiromu Morikubo has received research grants from Japan Foundation for Takeda Pharmaceutical, Applied Enzymology. |

| | |
|---|---|
| P389 | Dr. Rahmany, Sohail: No conflict of interest\|\|Young, David: No conflict of interest\|\|Moyses, Helen: No conflict of interest\|\|Gonclaves, Joao:\|:\|Speaker for Sandoz, Astra Zeneca, Pfizer, Samsung Bioepis, Libbs. Research projects for Astra Zeneca and Pfizer.\|\|Latter, Susan: No conflict of interest\|\|Cummings, Fraser:\|:\|Dr. Cummings has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Sandoz, Biogen, Samsung and Takeda. He has received research funding from Biogen, Amgen, Celltrion, Hospira/Pfizer, Janssen, Takeda, GSK and AZ\|\|This study is an investigator-initiated study funded by Celltrion Healthcare |
| P390 | Richards, Dylan:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson.\|\|Venkat, Swati:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson.\|\|\|Freeman, Tom C.:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson.\|\|Mcrae, Bradford:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson.\|\|Hoops, Timothy:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson.\|\|Marano, Colleen:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson.\|\|Branigan, Patrick:\|:\|Employee of Janssen Research and Development, LLC, and owns stock or stock options in Johnson & Johnson. |

| | |
|---|---|
| P391 | Sands, Bruce E:\|:\|Grants: Arena Pharmaceuticals, Janssen, Bristol Myers Squibb\|Consulting fees: AbbVie, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Genentech, Glaxo SmithKline, Janssen, Lilly, Merck & Co., Pfizer, Sun Pharma Global, Takeda Pharmaceuticals International, Teva Branded Pharmaceutical Products R&DSupport for travel for meetings to support study: Lilly\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen, Pfizer, Takeda, Pharmaceuticals International, Bristol Myers Squibb\|Shareholder: Ventyx Biosciences\|Participation on a Data Safety Monitoring Board or Advisory Board: AbbVie, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Genentech, Glaxo SmithKline, Janssen, Lilly, Merck & Co., Pfizer, Sun Pharma Global\|Takeda Pharmaceuticals International, Teva Branded Pharmaceutical Products R&D\|Provision of writing assistance: Lilly, Takeda, Pfizer, Janssen\|\|\|\|\|Feagan, Brian:\|:\|Consultant: AbbVie, AbolerIS, AgomAB Therapeutics, Allianthera, Amgen, AnaptysBio, Applied Molecular Transport Inc., Arena Pharma, Avir, Azora Therapeutics, BioJamp, Biora Therapeutics, Boehringer-Ingelheim, Boston Pharma, Boxer, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Duality, EcoR1, Everest Clinical Research Corp., Lilly, Equillium, Ermium, Ferring, First Wave, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Glenmark, Gossamer Pharma, GSK, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, Imhotex, ImmunExt, Immunic Therapeutics, Intact Therapeutics, JAKAcademy, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Landos Biopharma, Leadiant, L.E.K. Consulting, LifeSci Capital, Lument AB, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Orphagen, Otsuka, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Play to Know AG, Progenity, Protagonist, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, REDX, Roche, Sandoz, Sanofi, Seres Therapeutics, Silverback Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB Pharma, VHSquared Ltd., Viatris, Ysios, Ysopia, Zealand Pharma; speakers bureau: AbbVie, Janssen, Takeda; scientific advisory board member: AbbVie, Amgen, Boehringer-Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, GSK; stock shareholder: Gossamer Pharma; employment: Western University, Alimentiv Inc.\|\|Gibble, Theresa Hunter:\|:\|Employment: Eli Lilly and Company\|\|Keohane, Anthony: No conflict of interest\|\|Eastman, William:\|:\|Employment: Eli Lilly and Company\|\|Traxler, Kristina:\|:\|Employment: Eli Lilly and Company\|\|Schreiber, Stefan:\|:\|Consulting in advisory boards: AbbVie, Arena, Amgen, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos/Gilead, Hikma, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, |

| | |
|---|---|
| | Provention Bio, Sandoz/Hexal, Takeda, UCB, and Theravance\|Personal fees: Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, Falk, Ferring, UCB, Amgen, Sandoz/Hexal, Lilly, Galapagos\|\|Jairath, Vipul:\|:\|Consulting/advisory board fees: AbbVie, Alimentiv Inc., Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, BMS, Celltrion, Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx, Vividion; speaker's fees: Abbvie, Ferring, BMS, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi.\|\|Armuzzi, Alessandro:\|:\|Consulting/advisory board fees: AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda; speaker's fees: AbbVie, Amgen, Arena, Biogen, BMS, Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix; research grants: MSD, Takeda, Pfizer, Biogen. |
| P392 | Dr. van Renterghem, Alexander: No conflict of interest\|\|van der Holst, Antonius: No conflict of interest\|\|van Kuijk, Sander: No conflict of interest\|\|Pierik, Marie: No conflict of interest\|\|Belgers, Eric: No conflict of interest\|\|Romberg-Camps, Marielle: No conflict of interest\|\|Jeuring, Steven: No conflict of interest\|\|Demandt, Danique: No conflict of interest\|\|Stassen, Laurents: No conflict of interest |
| P393 | Ms. Loveikyte, Roberta:\|:\|RL has received travel expenses and speaker fees from Cablon Medical. \|\|de Haas, Angela:\|:\|AdH is an employee and shareholder of Galapagos NV.\|\|Oortwijn, Alessandra:\|:\|AO is an employee and shareholder of Galapagos NV.\|\|Eskens, Bart:\|:\|BE is an employee and shareholder of Galapagos NV.\|\|Jamoul, Corinne:\|:\|CJ is a contractor at Galapagos NV. \|\|Muller, Karine:\|:\|KM is an employee and shareholder of Galapagos NV.\|\|van der Meulen-de Jong, Andrea:\|:\|AEvdM-dJ has received unrestricted research grants from Galapagos, Nestlé, Norgine and Vedanta, and has received speaker fees from Galapagos, Janssen Pharmaceuticals, Takeda and Tramedico. |

| | |
|---|---|
| P394 | Dr. Berghog, John: No conflict of interest\|\|Hermansson, Maria: No conflict of interest\|\|Risto, Anton: No conflict of interest\|\|Strömbäck, Jesper: No conflict of interest\|\|Unger, David: No conflict of interest\|\|Gustafsson, Hanna: No conflict of interest\|\|Hagavall, Martin: No conflict of interest\|\|Landerholm, Kalle: No conflict of interest\|\|Buchwald, Pamela: No conflict of interest\|\|Nordenvall, Caroline: No conflict of interest\|\|Myrelid, Pär: No conflict of interest\|\|Block, Mattias: No conflict of interest |
| P395 | Mr. Kaku, Koji: No conflict of interest\|\|Sato, Toshiyuki: No conflict of interest\|\|Takeuchi, Jiro: No conflict of interest\|\|Uchino , Motoi: No conflict of interest\|\|Fujihira, Yutaro: No conflict of interest\|\|Shimizu, Kazuma: No conflict of interest\|\|Yokoyama, Keiko: No conflict of interest\|\|Yagi , Soichi: No conflict of interest\|\|Takashima, Yusuke: No conflict of interest\|\|Ikenouchi, Maiko: No conflict of interest\|\|Kojima, Kentaro: No conflict of interest\|\|Kawai, Mikio: No conflict of interest\|\|Nagase , Kazuko: No conflict of interest\|\|Kamikozuru, Koji: No conflict of interest\|\|Yokoyama , Yoko: No conflict of interest\|\|Takagawa, Tetsuya: No conflict of interest\|\|Ikeuchi, Hiroki: No conflict of interest\|\|Watanabe, Kenji:\|:\|Kenji Watanabe has received honoraria and research funding from AbbVie GK, Mitsubishi Tanabe Pharma, EA Pharma, Takeda Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, and Janssen Pharmaceutical; and research funding from Astellas Pharma, JIMRO, Zeria Pharmaceutical, Otsuka Pharmaceutical, and Asahi Kasei Medical. \|\|Shinzaki , Shinichiro:\|:\|Shinichiro Shinzaki has received advisor fees from Abbvie GK, Janssen Pharmaceutical, Takeda Pharmaceutical, and honoraria from Abbvie GK, Alfressa Pharma, Astra Zeneka, EA Pharma, Eisa, Gilead Sciences, Kissei Pharmaceutical, Kyorin Pharmaceutical, Janssen Pharmaceutical, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutidal, Nippon Kayaku, Pfizer, Sekisui Medical, Takeda Pharmaceutial, Zeria Pharmaceutical. |

| | |
|---|---|
| P396 | Dr. Macaluso, Fabio Salvatore:\|:\|Fabio Salvatore Macaluso served as an advisory board member and/or received lecture grants from Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. \|\|Grova, Mauro: No conflict of interest\|\|Mocciaro, Filippo: No conflict of interest\|\|Di Mitri, Roberto: No conflict of interest\|\|Privitera, Antonino Carlo: No conflict of interest\|\|Distefano, Maria Emanuela: No conflict of interest\|\|Vitello, Alessandro: No conflict of interest\|\|Camilleri, Salvatore: No conflict of interest\|\|Ferracane, Concetta: No conflict of interest\|\|Pluchino, Dario: No conflict of interest\|\|Belluardo, Nunzio: No conflict of interest\|\|Giangreco, Emiliano: No conflict of interest\|\|Fries, Walter:\|:\|Walter Fries served as an advisory board member and/or received lecture grants from AbbVie, Biogen, MSD, Pfizer, Mundipharma, Zambon, Janssen, Sandoz, and Takeda Pharmaceuticals \|\|Viola, Anna: No conflict of interest\|\|Cappello, Maria:\|:\|Maria Cappello served as an advisory board member for AbbVie, MSD, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Chiesi, and Takeda Pharmaceuticals.\|\|Amato, Livia: No conflict of interest\|\|Bertolami, Carmelo: No conflict of interest\|\|Ventimiglia, Marco: No conflict of interest\|\|Renna, Sara:\|:\|Sara Renna served as an advisory board member for AbbVie and MSD Pharmaceuticals, and received lecture grants from AbbVie, Janssen, MSD, and Takeda Pharmaceuticals\|\|Casà, Angelo: No conflict of interest\|\|De Vivo, Simona: No conflict of interest\|\|Orlando, Ambrogio:\|:\|Ambrogio Orlando served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals, and received lecture grants from AbbVie, Galapagos, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. |

| | |
|---|---|
| P397 | Mr. Lasa, Juan: No conflict of interest\|\|Nazario, Ezequiel: No conflict of interest\|\|Zubiaurre, Ignacio:\|:\|Consulting fees from Abbvie, Takeda, Janssen and Ferring\|\|Rausch, Astrid:\|:\|Speaker fees for Abbvie, Takeda and Janssen\|\|Hermida, Raquel: No conflict of interest\|\|Cassella, Federico: No conflict of interest\|\|Marzullo, Santiago: No conflict of interest\|\|Suarez Pellegrino, Andrea: No conflict of interest\|\|Deborah, Balfour: No conflict of interest\|\|Toro, Martín:\|:\|Consulting fees from Abbvie, Takeda, Pfizer and Janssen. Fees for advisory Bristol Myers Squibb\|\|Novillo, Abel:\|:\|Fees from Abbvie, Pfizer, Takeda, Janssen and GSK\|\|Omodeo, Javier:\|:\|Fees from Abbvie, Janssen, Takeda, GSK\|\|Tirado, Pablo:\|:\|Fees from Abbvie, Janssen, Roemmers, Biostoscana, Takeda, Amgen\|\|Bellicoso, Maricel:\|:\|Fees from Abbvie, Janssen, Takeda, Pfizer, Biotoscana, GSK, Bristol Myers Squibb\|\|Olivera, Pablo:\|:\|Pablo A. Olivera has received consulting fees from AbbVie, Takeda, and Janssen; honoraria from Takeda and Janssen; and financial support for attending meetings, travel, or both from AbbVie, Takeda, Janssen, and Ferring\|\|Balderramo, Domingo: No conflict of interest\|\|Torello, Rosario: No conflict of interest\|\|Chiaraviglio, Laura: No conflict of interest\|\|Scacchi, Agustina: No conflict of interest\|\|Linares, María:\|:\|Fees from Abbvie, Janssen, Takeda and Abbott\|\|Gonzalez, Raquel: No conflict of interest\|\|Bentolila, Federico: No conflict of interest\|\|Lubrano, Pablo: No conflict of interest\|\|Quintero, Olga: No conflict of interest\|\|De Paula, Juan:\|:\|Fees from Amgen, Abbvie, Danone, Biosidus, Ferring, Janssen, Pfizer, Roche y Takeda\|\|Gonzalez Sueyro, Ramiro:\|:\|Fees from Abbvie, Janssen, Takeda and Ferring\|\|Sanchez, Belen:\|:\|Fees from Abbvie and Janssen\|\|Fuxman, Claudia:\|:\|Fees from Abbvie, Janssen, Takeda\|\|Velazquez , Andrea: No conflict of interest |
| P398 | Dr. Andronic, Andrei-Mihai: No conflict of interest\|\|Toader, Elena: No conflict of interest |
| P399 | Aksan, Aysegül:\|:\|Dr Aksan is an employee of Immundiagnostik and has received consultancy fees and research funding from Vifor.\|\|Mangold, Carla: No conflict of interest\|\|Stötzel, Julia: No conflict of interest\|\|Tessmer, Lea: No conflict of interest\|\|Schröder, Oliver:\|:\|Lecturing fees: Abbvie, Falk, Janssen, Takeda, Norgine and Pfizer. Congress expenses: Abbvie, Falk, Janssen, Pfizer, Takeda.\|\|Prof. Dr. Stein, Jürgen Michael:\|:\|Consulting: Abbvie, Bristol Myers Squibb, Dr Schär, Falk, Ferring, Fresenius Kabi, Immundiagnostik, Janssen, Medice, MSD, Pfizer, Pharmacosmos, Shire, Takeda, Thermofisher, Vifor. Board member: Abbvie, Bristol Myers Squibb, Dr Schär, Ferring, Fresenius Kabi, Immundiagnostik, Janssen, MSD, NPS, Pharmacosmos, Takeda, Vifor and Shield. Lecturing fees: Vifor Pharma |

| | |
|---|---|
| P400 | Dr. McDonnell, Martin:\|:\|Dr McDonnell has received a grant to fund PhD and research studies as part of a collaborative investigator led research program from Nestle Health Sciences. Has received educational support from nutriticia.\|\|Westoby, Catherine:\|:\|Mrs Westoby has received speaker fees for talks at educational meetings organised and funded by Nestle Health Sciences\|Received payment and study support as part of an investigator led collaborative research agreement between Nestle Health Sciences and University Hospital Southampton.\|\|\|Sartain , Stephanie:\|:\|Dr Sartain has received educational support from nutriticia.\|\|Giannasca, Paul: No conflict of interest\|\|Corthésy, John: No conflict of interest\|\|Grzywinski, Yohan: No conflict of interest\|\|Frézal, Adrien: No conflict of interest\|\|Capt, Pauline: No conflict of interest\|\|Cummings, Fraser:\|:\|Dr. Cummings has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Sandoz, Biogen, Samsung and Takeda. He has received research funding from Biogen, Amgen, Celltrion, Hospira/Pfizer, Janssen, Takeda, GSK and AZ\|\|Wootton, Stephen: No conflict of interest |
| P401 | Prof. Dr. Toruner, Murat: No conflict of interest\|\|Guvenir, Tugce: No conflict of interest\|\|Er, Ramazan Erdem: No conflict of interest\|\|Soykan, Irfan: No conflict of interest |
| P402 | Dr. Kumar, Aditi: No conflict of interest\|\|Quraishi, Mohammed Nabil: No conflict of interest\|\|Al-Hassi, Hafid Omar: No conflict of interest\|\|Elasrag, Mohammed: No conflict of interest\|\|Segal, Jonathan P:\|:\|JPS has received speaker fees for Abbvie, Takeda and Janssen outside of the submitted work. \|\|Jain, Manushri: No conflict of interest\|\|Steed, Helen:\|:\|HS has received travel and conference expenses from Tillotts Pharma, Norgine, MSD, Abbvie and Janssen outside of the submitted work.\|\|Butterworth, Jeffrey: No conflict of interest\|\|Farmer, Adam: No conflict of interest\|\|McLaughlin, John: No conflict of interest\|\|Beggs, Andrew: No conflict of interest\|\|Brookes, Matthew:\|:\|MJB has received grants and travel expenses from Vifor International and Tillotts Pharma, outside of the submitted work. The research department of MJB also received funding from Tillotts Pharma to support part of the described work. |

| | |
|---|---|
| P403 | Ms. Hajlaoui, Amal: No conflict of interest\|\|Sabbah, Meriam: No conflict of interest\|\|Bibani, Norsaf: No conflict of interest\|\|Jlassi, Houssaina: No conflict of interest\|\|Bellil , Nawel: No conflict of interest\|\|Lassoued, Khouloud: No conflict of interest\|\|Trad, Dorra: No conflict of interest\|\|Gargouri, Dalila: No conflict of interest |
| P404 | Prof. Dr. Mathieu, Nicolas: No conflict of interest\|\|Riviere, Pauline:\|:\|Personal Fees\|- Consulting: CELLTRION\|\|Heluwaert, Frederic:\|:\|Personal Fees\| Consulting: CELLTRION\|\|Hébuterne, Xavier:\|:\|Personal Fees\| Consulting: CELLTRION\|\|Chupin, Antoine: No conflict of interest\|\|Bouguen, Guillaume:\|:\|Personal Fees\|Consulting: CELLTRION\|\|Vuitton, Lucine:\|:\|Personal Fees\|Consulting: CELLTRION\|\|Allez, Matthieu:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Montuclard, Céline: No conflict of interest\|\|Nachury, Maria:\|:\|Personal Fees\|Consulting: CELLTRION\|\|Nancey, Stéphane:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Amélie, Biron: No conflict of interest\|\|Gilletta, Cyrielle:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Abitbol, Vered:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Altwegg, Romain: No conflict of interest\|\|de Maissin, Astrid: No conflict of interest\|\|Plastaras , Laurianne: No conflict of interest\|\|Ah Soune, Philippe: No conflict of interest\|\|Boureille, Arnaud:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Bouhnik, Yoram:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Seksik, Philippe:\|:\|Personal Fees\|\| Consulting: Celltrion\|\|Chanteloup, Elise: No conflict of interest\|\|marion, simon: No conflict of interest\|\|Uzzan, Matthieu: No conflict of interest\|\|Andrau, Pierre: No conflict of interest\|\|Rouillon, Clea: No conflict of interest\|\|Arondel, Yves: No conflict of interest\|\|Peyrin Biroulet, Laurent:\|:\|Personal Fees\|\| Consulting: CELLTRION\|\|Laharie, David:\|:\|Personal Fees\|\| Consulting: CELLTRION |

| | |
|---|---|
| P405 | Panaccione, Remo:\|:\|Received consulting fees from Abbott, AbbVie, Alimentiv, Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Therapeutics, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; received speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; received research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Takeda, and Theravance.\|\|Danese, Silvio:\|:\|Received honoraria as a speaker, consultant, and/or advisory board member from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, and Vifor.\|\|Wolf, Douglas C.:\|:\|Received research funding from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Elan, Given Imaging, Genentech, Janssen, Millennium, Pfizer, Prometheus, and UCB; lectured for AbbVie, Bristol Myers Squibb, Janssen, Prometheus, Santarus, Salix, Takeda, and UCB; consulted for AbbVie, Bristol Myers Squibb, Genentech, Given Imaging, Janssen, Prometheus Biosciences, Salix, Takeda, and UCB.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Petersen, AnnKatrin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Charles, Lorna:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Afzali, Anita:\|:\|Served as a consultant for AbbVie, Bristol Myers Squibb, DiaSorin, Eli Lilly, Gilead, Janssen, Pfizer, Takeda, and TLL Pharmaceuticals; and received speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda.\|\|Abreu, Maria T.:\|:\|Served as a consultant or advisory board member for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen Ortho, Janssen Global Services, Janssen Biotech NART, Janssen Biotech (nonbranded), Janssen Biotech (Women in GI Advisory Board), Microba, Prometheus Biosciences, UCB Biopharma, and WebMD Global; served as a speaker for Alimentiv, Intellisphere (HCP Live Institutional Perspectives in GI), Janssen, Prime CME, and Takeda; received research support from Pfizer, Prometheus, and Takeda. |
| | |

| | |
|---|---|
| P406 | Dr. Chatzinikolaou, Matina-Lydia:\|:\|Consulting: Takeda, Amgen, Ferring\|Research/Clinical trials: Abbvie, Takeda, Arena Pharmaceuticals, Janssen\|\|\|Kifnidi, Christina:\|:\|TROVE is a Takeda Hellas SA Sponsored phIV study\|\|Kokkotis, Georgios: No conflict of interest\|\|Gatopoulou, Anthia:\|:\|Research/Advisory : Amgen, Abbvie, Boehringer Ingelheim, Ferring, MSD, Pfizer, Roche, Takeda \|\|Michopoulos, Spyridon:\|:\|Honoraria (Takeda, MSD, Pfizer)\|Advisory Boards (Takeda,Ferring)\|Research funding (Takeda, BMS, Abbvie, Janssen)\|Support for attending meetings and/or travel etc (Enorasis, Faran, Amgen)\|\|\|Soufleris, Konstantinos: No conflict of interest\|\|Poulopoulos, Georgios: No conflict of interest\|\|Theodoropoulou, Angeliki: No conflict of interest\|\|Mantzaris, Gerassimos:\|:\|Dr G Mantzaris has declared his disclosures/COI to ECCO directly\|\|Ntelis, Vasileios: No conflict of interest\|\|Papatheodoridis, Georgios:\|:\|Advisor/lecturer for Abbvie, Albireo, Amgen, Dicerna, Elpen, Gilead,\|GlaxoSmithKline, Ipsen, Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche,\|SOBI and Takeda\|Research grants from Abbvie and Gilead.\|Support for attending meetings from Abbvie, Gilead, Ipsen, Janssen, Novo\|Nordisk and Roche.\|\|\|Tzouvala, Maria:\|:\|MSD Sharp & Dohme, AbbVie Pharmaceuticals S.A, Takeda HELLAS SA, Janssen-Cilag Pharmaceutical SACI, Genesis, Galenica, Pfizer, Amgen\|\|\|Koutroubakis, Ioannis E.:\|:\|Ioannis Koutroubakis has received support by Abbvie, Genesis, Ferring, Janssen, MSD, Pfizer, Shire, Vianex and Takeda\|\|Theocharis, Georgios: No conflict of interest\|\|Kourikou, Anastasia: No conflict of interest\|\|Christodoulou, Dimitrios:\|:\|Honoraria for lectures from MSD, Janssen, Takeda, Pfizer, Galenica. \|\|Grammatopoulos, Anastasios: No conflict of interest\|\|Michalopoulos, Georgios:\|:\|Speaker fees: MSD, Pfizer, Janssen, Abbvie, TAKEDA, Amgen\|\|Georgopoulos, Sotirios:\|:\|Research funding by Takeda Hellas\|\|Akriviadis, Evangelos: No conflict of interest\|\|Vradelis, Stergios: No conflict of interest\|\|Gkagkari, Vassiliki: No conflict of interest\|\|Zampeli, Evanthia:\|:\|advisory boards: JANSSEN TAKEDA \|support for attending meetings : AMGEN GALENICA ABBVIE JANSSEN \|\|\|Fasoulas, Konstantinos: No conflict of interest\|\|Charalampidis, MIchail: No conflict of interest\|\|Velegraki, Magdalini: No conflict of interest\|\|Karampekos, Georgios: No conflict of interest\|\|Viazis, Nikos:\|:\|Honoraria from TAKEDA, Pfizer, Janssen, MSD, Ferring, Abbvie and Amgen.\|\|Andrianakou , Georgia: No conflict of interest\|\|Karatzas, Pantelis: No conflict of interest\|\|Tribonias, Georgios: No conflict of interest\|\|Zacharopoulou, Eirini:\|:\|Speaking fees by Takeda, Abbvie; Support for attending meetings by Abbvie, Aenorasis, Ferring, Faran, Genesis, MSD, Takeda, Janssen\|\|Orfanoudaki, Eleni:\|:\|support by Vianex\|\|Tsellou, Erasmia:\|:\|TROVE is a Takeda Hellas SA Sponsored phIV study\|\|Psyrilos, Antonios:\|:\|TROVE is a Takeda Hellas SA Sponsored phIV study\|\|Roussou, Dimitra:\|:\|TROVE is a Takeda Hellas SA Sponsored phIV study\|\|Bamias, Georgios:\|:\|GB: Advisor/lecturer for Janssen, Pfizer, Takeda, Abbvie, MSD, Mylan, Genesis Pharma,\|Adacyte Therapeutics, Amgen, Ferring, Cooper; Funding (Grants/Honoraria): Pfizer, Takeda,\|Abbvie, Aenorasis; Research/Clinical Trials: Abbvie, Takeda. |

| | |
|---|---|
| P407 | Peyrin-Biroulet, Laurent:\|:\|Received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillotts, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, and ONO Pharma; and is a stockholder of CTMA.\|\|Dubinsky, Marla C.:\|:\|Received consulting fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; and is founder and a shareholder of Trellus Health.\|\|Sands, Bruce E.:\|:\|Reports consulting fees from Abivax, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Entera, Evommune, Galapagos, Genentech, Gilead Sciences, GSK, Gossamer Bio, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, Miro Bio, Morphic Therapeutics, MRM Health, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Surrozen, Takeda, Teva, TLL Pharmaceutical, USWM Enterprises, and Viela Bio; speaking fees from Abivax, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and grant/research support from Janssen.\|\|Panés, Julian:\|:\|Received consulting fees from AbbVie, Arena Pharmaceuticals, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GSK, Janssen, Mirum, Morphic, Nestle, Origo, Pandion, Progenity, Pfizer, Revolo, Robarts, Roche, Takeda, Theravance, and Wassermann; speaker fees from AbbVie, Biogen, Ferring, Janssen, Pfizer, and Takeda; and research funding from AbbVie and Pfizer.\|\|Schreiber, Stefan:\|:\|Consultant for AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb; Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresenius, Galapagos, Genentech, GSK, Gilead, I-MAB Biopharma, Janssen, Lilly, Merck, Novartis/Sandoz, Pfizer, Protagonist, Takeda, and Theravance.\|\|Reinisch, Walter:\|:\|Served as a speaker for Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; served as a consultant for Abbott Laboratories, AbbVie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid |

| | |
|---|---|
| | Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; and served as an advisory board member for Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC.\|\|Feagan, Brian G.:\|:\|Consultant for AbbVie, Admirx, AgomAb Therapeutics, Applied Molecular Transport Inc, Arena Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, F. Hoffmann-La Roche, Janssen, Morphic Therapeutics, OM Pharma, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Theravance, TiGenix, Tillotts, and Zealand Pharma; has received speakers bureau fees from AbbVie, Janssen, and Takeda; served on the Scientific Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, and GSK; is a stockholder of Gossamer Pharma; and is an employee of Western University and Alimentiv Inc.\|\|Danese, Silvio:\|:\|Received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor; and reports payment for expert testimony from AbbVie, Amgen, Ferring Pharmaceuticals Inc, Gilead, Janssen, Mylan, Pfizer, and Takeda.\|\|Yarur, Andres:\|:\|Received consulting fees from Takeda, Prometheus Labs, Arena Pharmaceuticals, and Bristol Myers Squibb; and speakers bureau fees from Bristol Myers Squibb.\|\|D'Haens, Geert:\|:\|Consultant for AbbVie, AgomAb, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GSK, Gossamer Bio, Pfizer, Immunic, Johnson & Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus |

| | |
|---|---|
| | Bio, Pfizer, Millennium, Johnson & Johnson, Origo, Pelpharma, Precise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist; and has received speakers bureau fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Pfizer, BMS, and Takeda.\|\|Goetsch, Martina:\|:\|Is an employee of Pfizer.\|\|Wosik, Karolina:\|:\|Is an employee of Pfizer Inc.\|\|Wu, Joseph:\|:\|Is an employee and shareholder at Pfizer Inc. \|\|Modesto, Irene:\|:\|Is an employee of Pfizer Inc. \|\|McDonnell, Aoibhinn:\|:\|Is an employee of Pfizer, Inc.\|\|Bartolome, Lauren:\|:\|Is an employee of Pfizer Inc. \|\|Dr. Rabbat, Christopher J.:\|:\|Is an employee of Pfizer Inc.\|\|Vermeire, Séverine:\|:\|Grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma. |
| P408 | Mr. Kolar, Martin: No conflict of interest\|\|Kastylova, Kristyna: No conflict of interest\|\|Lukas, Martin: No conflict of interest\|\|Duricova, Dana: No conflict of interest\|\|Hruba, Veronika: No conflict of interest\|\|Machkova, Nadezda: No conflict of interest\|\|Cerna, Karin: No conflict of interest\|\|Jirsa, Jakub: No conflict of interest\|\|Kubickova, Kristyna: No conflict of interest\|\|Vojtechova, Gabriela: No conflict of interest\|\|Lukás, Milan: No conflict of interest |
| P409 | Dr. Moulton, Calum: No conflict of interest\|\|Avery, Pearl: No conflict of interest\|\|Hart, Ailsa: No conflict of interest |

| | |
|---|---|
| P410 | Dr. Gargallo-Puyuelo, Carla: No conflict of interest\|\|Ricard, Elena: No conflict of interest\|\|Iborra, Marisa: No conflict of interest\|\|Iglesias-Flores, Eva: No conflict of interest\|\|Vera Mendoza, Isabel: No conflict of interest\|\|De Francisco García, Ruth: No conflict of interest\|\|Calafat Sard, Margalida: No conflict of interest\|\|Minguez, Miguel: No conflict of interest\|\|Lopez- San Roman, Antonio: No conflict of interest\|\|Taxonera, Carlos: No conflict of interest\|\|Guardiola, Jordi: No conflict of interest\|\|Barrio, Jesús: No conflict of interest\|\|Laredo, Viviana: No conflict of interest\|\|De Castro, Luisa: No conflict of interest\|\|Gisbert, Javier: No conflict of interest\|\|García-Lopez, Santiago: No conflict of interest\|\|García Planella, Esther: No conflict of interest\|\|Martín Arranz, Dolores: No conflict of interest\|\|Calvet, Xavier: No conflict of interest\|\|Merino, Olga: No conflict of interest\|\|Sierra, Mónica: No conflict of interest\|\|Marquez, Lucia: No conflict of interest\|\|Madero, Lucia: No conflict of interest\|\|Varela, Pilare: No conflict of interest\|\|Carpio, Daniel: No conflict of interest\|\|Esteve, María: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Ramos , Laura: No conflict of interest\|\|Sicilia, Beatriz: No conflict of interest\|\|Lorente POyatos, Rufo: No conflict of interest\|\|Marin, Ignacio: No conflict of interest\|\|Monfort, David: No conflict of interest\|\|Navarro, Merce: No conflict of interest\|\|VEga, Pablo: No conflict of interest\|\|Hinojosa, Joaquein: No conflict of interest\|\|Tardillo, Carlos: No conflict of interest\|\|García Sepulcre, Mariana FE: No conflict of interest\|\|Barreiro, Manuel: No conflict of interest\|\|Domenech, Eugeni: No conflict of interest\|\|Gomollón, Fernando: No conflict of interest |
| P411 | Prof. Calabrese, Emma: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest\|\|De Cristofaro, Elena: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|Capacchione , Claudia: No conflict of interest\|\|Testa, Anna: No conflict of interest\|\|Guarino, Alessia Dalila: No conflict of interest\|\|Caiazzo, Anna: No conflict of interest\|\|Monteleone, Giovanni: No conflict of interest\|\|Zorzi, Francesca: No conflict of interest |

| | |
|---|---|
| P412 | Dr. Komatsu, Koichi: No conflict of interest\|\|Shinagawa, Takahide: No conflict of interest\|\|Noguchi, Tatsuki: No conflict of interest\|\|Uchino, Motoi: No conflict of interest\|\|Ikeuchi, Hiroki: No conflict of interest\|\|Okabayashi, Koji: No conflict of interest\|\|Tanaka, Shinji: No conflict of interest\|\|Futami, Kitaro: No conflict of interest\|\|Itabashi, Michio: No conflict of interest\|\|Watanabe, Kazuhiro: No conflict of interest\|\|Nagahara, Hisashi: No conflict of interest\|\|Okita, Yoshiki: No conflict of interest\|\|Shimada, Yoshifumi: No conflict of interest\|\|Mizuuchi, Yusuke: No conflict of interest\|\|Okamoto, Kinya: No conflict of interest\|\|Yamada, Kazutaka: No conflict of interest\|\|Sato, Yu: No conflict of interest\|\|Mizushima, Tsunekazu: No conflict of interest\|\|Kimura, Hideaki: No conflict of interest\|\|Takahashi, Kenichi: No conflict of interest\|\|Hida, Koya: No conflict of interest\|\|Kinugasa, Yusuke: No conflict of interest\|\|Ishida, Fumio: No conflict of interest\|\|Okuda, Junji: No conflict of interest\|\|Daito, Koji: No conflict of interest\|\|Yamamoto, Takayuki: No conflict of interest\|\|Yamamoto, Seiichiro: No conflict of interest\|\|Koyama, Fumikazu: No conflict of interest\|\|Hanai, Tsunekazu: No conflict of interest\|\|Komori, Koji: No conflict of interest\|\|Shida, Dai: No conflict of interest\|\|Arakaki, Junya: No conflict of interest\|\|Akagi, Yoshito: No conflict of interest\|\|Yamaguchi, Shigeki: No conflict of interest\|\|Ueno, Hideki: No conflict of interest\|\|Matsuda, Keiji: No conflict of interest\|\|Ajioka, Yoichi: No conflict of interest\|\|Sugihara, Kenichi: No conflict of interest\|\|Ishihara, Soichiro: No conflict of interest |

| | |
|---|---|
| P413 | Dr. Pudipeddi, Aviv:\|:\|Received speaker fees from AbbVie and Takeda\|\|Paramsothy, Sudarshan:\|:\|Consultant for Finch Therapeutics and has received consulting/speaker fees from Abbvie, Ferring, Janssen and Takeda\|\|Kariyawasam, Viraj:\|:\|Received educational, research, speaker and ad board fees from Ferring pharmaceuticals, AbbVie, Jansse, Dr Falk Pharma, Celltrion and Takeda\|\|Paramsothy, Ramesh: No conflict of interest\|\|Ghaly, Simon:\|:\|Speaker fees, educational support, advisory boards or research grants from St Vincent's clinic foundation, GESA, Gilead, Dr. Falk, Janssen, Pfizer, Takeda, Ferring, Sandoz, Celltrion and Abbvie\|\|Haifer, Craig:\|:\|Speaker fees, educational support, advisory boards and research grants from St Vincent's clinic foundation, GESA, Ferring, Royal Australasian College of Physicians, Pfizer, Takeda, Abbvie, Sandoz and Janssen.\|\|An, Yoon-Kyo:\|:\|Received speaking and consulting fees from Abbvie, Bristol Myers Squibb, Celltrion, Chiesi, Dr Falk, Ferring, Janssen, Pfizer, Sandoz, Shire and Takeda; served on advisory boards member for Abbvie, Bristol Myers Squibb, Chiesi, Janssen, NPS Medicine wise, Seres Therapeutics; received research and educational funding from Abbvie, Celltrion, Dr Falk, Janssen, Pfizer, Sandoz and Takeda.\|\|Begun, Jakob: No conflict of interest\|\|Connor, Susan:\|:\|Advisory boards: Abbvie, Amgen, BMS, Celltrion, Chiesi, Eli-Lilly, Ferring, Fresenius Kabi, GSK, Janssen, Novartis, Organon, Pfizer, Takeda\|Speaker fees: Abbvie, DrFalk, Ferring, Janssen, Pfizer, Takeda\|Educational support: BMS, DrFalk, Pfizer\|Pharma Research Support: Abbvie, BMS, Chiesi, DrFalk, Ferring, Janssen, MSD, Pfizer, Sandoz, Takeda.\|Non-pharma research support: Agency for Clinical Innovation, Gastroenterological Society of Australia, Medical Research Future Fund (2021-25), The Leona M and Harry B Helmsley Charitable Trust (2020-23), South Western Sydney Local Health District (2018-2023)\|Other memberships: Board Crohn's Colitis Cure, Executive Board Member ANZIBD Consortium\|\|Corte, Crispin: No conflict of interest\|\|Ward, Mark: No conflict of interest\|\|De Cruz, Peter: No conflict of interest\|\|Fung, Caroline: No conflict of interest\|\|Redmond, Diane: No conflict of interest\|\|Leong, Rupert W:\|:\|Advisory board: AbbVie, Aspen, BMS, Celgene, Chiesi, Ferring, Glutagen, Hospira, Janssen, MSD, Novartis, Pfizer, Takeda \|Research grants: Joanna Tiddy Research Grant University of Sydney; Celltrion, Shire, Janssen, Takeda, Gastroenterological Society of Australia, NHMRC, Gutsy Group, Pfizer |

| | |
|---|---|
| P414 | Bokemeyer, Bernd:\|:\|consulting fees from: AbbVie, MSD, Shire, Ferring, Hospira, Takeda, Galapagos, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, and Celgene, outside the submitted work. Financial support for lectures and teaching from: AbbVie, Ferring, MSD, Merckle, Falk, Galapagos, Shield Therapeutics, Pfizer, Celltrion, Takeda, Janssen, and Galapagos, outside the submitted work. Grant and financial support for research from AbbVie; Takeda, Jansen, Pfizer, Galapagos and Ferring, outside the submitted work\|\|Plachta-Danielzik, Sandra: No conflict of interest\|\|Efken, Philipp:\|:\|Personal fees from: Abbvie, BMS, Galapagos, Janssen, Amgen outside the submitted work\|\|Mohl, Wolfgang:\|:\|consulting fees from: Abbvie, Amgen, Hexal, Janssen, Pfizer, Synformulas, Takeda, outside the submitted work. Fees for lectures and further education from: Abbvie, Alanta health service GmbH, Almirall, Aptalis, Biogen, Falk, Gilead, Janssen, Pfizer, Medtronic, MSD, Shire, Takeda, Vifor, outside the submitted work. Fees for studies from: Abbvie, Janssen, MSD, Pfizer, Takeda, outside the submitted work. Fees for activities in public law bodies as member of the Advisory Commission of the Examination Office for the Saarland, the State Committee of Physicians and Health Insurance Companies and the Extended State Committee, outside the submitted work. Dependent employment in the group of Alanta health group GmbH, Hamburg, outside the submitted work. Shares, other fees from: Abbvie, Gilead, outside the submitted work\|\|Hoffstadt, Martin: No conflict of interest\|\|Krause, Thomas:\|:\|personal fees from: AbbVie, Janssen, Takeda outside the submitted work\|\|Schweitzer, Axel:\|:\|Personal fees from: AbbVie Deutschland GmbH & Co. KG, Janssen-Cilag GmbH, Tillotts Pharma outside the submitted work\|\|Schnoy, Elisabeth:\|:\|Personal fees from: Janssen-Cilag GmbH, Janssen Steering, Pharmacosmos GmbH, Takeda Pharma GmbH, AbbVie Deutschland, Pfizer GmbH, Tillotts Pharma GmbH, AstraZeneca, Galapagos Biopharma, Lilly GmbH, Celltrion, Dr. Falk Pharma GmbH, BMS outside the submitted work\|\|Atreya, Raja:\|:\|Personal fees from: AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr. Falk Pharma, Ferring, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, MSD Sharp & Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepsis, Stelic Institute, Sterna Biologicals, Takeda Pharma, Tillotts Pharma AG, Viatris outside the submitted work\|\|Teich, Niels:\|:\|personal fees from Abbvie, Falk Foundation, Janssen and Takeda outside the submitted work\|\|Trentmann, Leo: No conflict of interest\|\|Ehehalt, Robert:\|:\|Personal fees from: Takeda, Abbvie, MSD, Biogen, Hexal, Amgen, Celltrion, Viatris\|outside the submitted work\|\|Franzenburg, Sina: No conflict of interest\|\|Hartmann, Petra:\|:\|Personal fees from: Abbvie, MSD, Shire, Ferring, UCB, Hospira, Takeda, Movetis, Biogen, Mylan, Janssen, BMS, Amgen, Hexal, Stada, Merckle, Mundipharma, Falk, HLR; outside the submitted work\|\|di Giuseppe, Romina: No conflict of interest\|\|Schreiber, Stefan:\|:\|personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, and Falk, outside the submitted work |

| | |
|---|---|
| P415 | Stallmach, Andreas:\|:\|Andreas Stallmach is involved in the data collection for this study. Takeda Pharma Vertrieb GmbH & Co. KG pays participating study centres fees for contributing to this study.\|\|Schulze, Hermann:\|:\|Hermann Schulze is involved in the data collection for this study. Takeda Pharma Vertrieb GmbH & Co. KG pays participating study centres fees for contributing to this study. Hermann Schulze also receives payments from Takeda Pharma Vertrieb GmbH & Co. KG for his participation as advisory member of the study steering committee.\|\|Teich, Niels:\|:\|Niels Teich is involved in the data collection for this study. Takeda Pharma Vertrieb GmbH & Co. KG pays participating study centres fees for contributing to this study. Niels Teich also receives payments from Takeda Pharma Vertrieb GmbH & Co. KG for his participation as advisory member of the study steering committee.\|\|Cavlar, Taner:\|:\|Taner Cavlar is employee of Takeda Pharma Vertrieb GmbH & Co. KG. Taner Cavlar is owner of Takeda shares.\|\|Jana, Knop:\|:\|Jana Knop is employee of Takeda Pharma Vertrieb GmbH & Co. KG.\|\|Ms. Henneberger, Sonja:\|:\|Sonja Henneberger participated in this study as a staff member of Institut Dr. Schauerte GmbH (IDS). The work of IDS was funded by Takeda Pharma Vertrieb GmbH & Co. KG. |
| P416 | Patel, Kamal Vijaykant: No conflict of interest\|\|Salmon, Phoebe:\|:\|Phoebe Salmon is a full time employee of Adelphi Real World and has received consulting fees and research support from AbbVie.\|\|Marin-Jiménez, Ignacio:\|:\|Ignacio Marin-Jiménez is a full time employee of Adelphi Real World and has received consulting fees and research support from AbbVie.\|\|Thessen, Melanie:\|:\|Melanie Thessen is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Kligys, Kristina:\|:\|Kristina Kligys is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Sharma, Dolly:\|:\|Dolly Sharma is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Sanchez Gonzalez, Yuri:\|:\|Yuri Sanchez Gonzalez is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Kershaw, Jim:\|:\|Jim Kershaw is a full time employee of Adelphi Real World and have received consulting fees and research support from AbbVie. |
| P417 | Wetwittayakhlang, Panu: No conflict of interest\|\|Karkout, Khaled: No conflict of interest\|\|Tselekouni, Paraskevi: No conflict of interest\|\|Aljabri, Reem: No conflict of interest\|\|Bessissow, Talat: No conflict of interest\|\|Afif, Waqqas: No conflict of interest\|\|Wild, Gary: No conflict of interest\|\|Bitton, Alain: No conflict of interest\|\|Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest |

| | |
|---|---|
| P418 | Mr. Aoki, Yasuhiro: No conflict of interest\|\|Fukuda, Tomohiro: No conflict of interest\|\|Kiyohara, Hiroki: No conflict of interest\|\|Yokoyama, Ayumi: No conflict of interest\|\|Nakazawa, Atsushi: No conflict of interest\|\|Yoshimatsu, Yusuke: No conflict of interest\|\|Sugimoto, Shinya: No conflict of interest\|\|Nanki, Kosaku: No conflict of interest\|\|Mikami, Yohei: No conflict of interest\|\|Fukuhara, Kayoko: No conflict of interest\|\|Mizuno, Shinta: No conflict of interest\|\|Sujino, Tomohisa: No conflict of interest\|\|Mutaguchi, Makoto: No conflict of interest\|\|Takabayashi, Kaoru: No conflict of interest\|\|Morohoshi, Yuichi: No conflict of interest\|\|Hosoda, Yasuo: No conflict of interest\|\|Ogata, Haruhiko:\|:\|Joint research support from AbbVie GK, Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co. Ltd., and lecture fees from Takeda Pharmaceutical Co., Ltd. \|\|Iwao, Yasushi: No conflict of interest\|\|Naganuma, Makoto: No conflict of interest\|\|Kanai, Takanori:\|:\|Joint research support from Ezaki Glico Co. Ltd, Miyarisan Pharma Corporation; grant support from AbbVie GK, Mochida Pharmaceutical Co., Ltd, Kyorin Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd, Daiichi-Sankyo Co. Ltd, Mitsubishi Tanabe Pharma Corporation, JIMRO Co. Ltd, ZERIA Pharmaceutical Co. Ltd, Sumitomo Dainippon Pharma Co., Ltd, Bayer Yakuhin, Ltd, EA Pharma Co. Ltd.; and lecture fees from Mitsubishi Tanabe Pharma Corporation, Miyairisan Pharma Corporation, Takeda Pharmaceutical Co. Ltd, Mylan Inc., EA Pharma Co. Ltd., AbbVie GK. |
| P419 | Dr. Eqbal, Ali: No conflict of interest\|\|Hilley, Patrick: No conflict of interest\|\|Gilmore, Robert: No conflict of interest\|\|Li Wai Suen, Christopher: No conflict of interest\|\|Choy, Matthew: No conflict of interest\|\|De Cruz, Peter: No conflict of interest |
| P420 | Holubar, Stefan: No conflict of interest\|\|Cohen, Benjamin: No conflict of interest\|\|Uchino, Tairin: No conflict of interest\|\|Dr. Lincango, Eddy: No conflict of interest\|\|Prien, Christopher: No conflict of interest\|\|Joseph, Abel: No conflict of interest\|\|Achkar, Jean-Paul: No conflict of interest\|\|Gunter, Rebecca: No conflict of interest\|\|Lashner, Bret: No conflict of interest\|\|DeLaney, Conor: No conflict of interest\|\|Ban, Kristen: No conflict of interest\|\|Bolshinsky, Vladimir: No conflict of interest\|\|Lipman, Jeremy: No conflict of interest\|\|Liska, David: No conflict of interest\|\|Philpott, Jessica: No conflict of interest\|\|Naseer, Maliha: No conflict of interest\|\|Kanters, Arielle: No conflict of interest\|\|Braga-Neto, Manuel: No conflict of interest\|\|Rieder, Florian: No conflict of interest\|\|Somovilla, Joshua: No conflict of interest\|\|Qazi, Taha: No conflict of interest\|\|Regueiro, Miguel: No conflict of interest\|\|Hull, Tracy: No conflict of interest\|\|Steele, Scott: No conflict of interest |

| | |
|---|---|
| P421 | Liebert, Ariel:\|:\|Ariel Liebert received payment for lectures from Janssen, Takeda, Egis, Abbvie, and Pharmabest and travel/accommodation/meeting expenses from Janssen, Takeda, Egis, and Abbvie.\|\|Kłopocka, Maria:\|:\|Maria Kłopocka has received payment for lectures from Janssen, Takeda, Ferring, Alfa-Sigma, and Pharmabest and travel/accommodation/meeting expenses from Ferring, Janssen, Takeda, Alfa-Sigma, and Pharmabest.\|\|Cichoż-Lach, Halina:\|:\|Halina Cichoż-Lach received lectures fees from Takeda.\|\|Michalak, Agata:\|:\|Agata Michalak received lectures fees from Takeda\|\|Talar-Wojnarowska, Renata:\|:\|Renata Talar-Wojnarowska received lecture fees and/or travel grants from Abbvie, Astellas, Ferring, Janssen, and Takeda.\|\|Domżał-Magrowska, Danuta: No conflict of interest\|\|Filipiuk, Aleksandra:\|:\|Aleksandra Filipiuk received payment for lectures from Janssen, Pfizer and travel/accommodation/meeting expenses from Takeda, Janssen.\|\|Krogulecki, Michał: No conflict of interest\|\|Kopertowska-Majchrzak, Maria: No conflict of interest\|\|Eder, Piotr:\|:\|Piotr Eder received lecture fees and/or travel grants from Takeda, Ferring, Astellas, Pfizer, and Janssen.\|\|Stawczyk-Eder, Kamila:\|:\|Kamila Stawczyk-Eder received travel grants and lecture fees from Janssen, Pfizer, and Takeda\|\|Waszak, Katarzyna:\|:\|Katarzyna Waszak received payment for travel/accommodation/meeting expenses from Janssen-Cilag, Pfizer, Pro.Med.CS, Samsung Bioepis and Takeda. \|\|Zagórowicz, Edyta:\|:\|Edyta Zagórowicz received lecture fees from Janssen, Sandoz, Ferring, and Pfizer; consultancy fees from Pfizer, Janssen, and Takeda; and other compensations from Takeda and Janssen.\|\|Wojciechowski, Krzysztof:\|:\|Krzysztof Wojciechowski is a former employee of Takeda Pharma sp. z o.o, currently invited external lecturer for Takeda. Krzysztof Wojciechowski is now an employee of: Independent Public Health Care Center in Tarczyn, Warszawska 42, Tarczyn, Poland\|\|Mr. Drygała, Szymon:\|:\|Szymon Drygała is a permanent employee of Takeda Pharma sp. z o.o. |
| P422 | Dr. Todeschini, Alessia: No conflict of interest\|\|Geccherle, Andrea: No conflict of interest\|\|Signoretto, Paola: No conflict of interest\|\|Fasoli, Elisa: No conflict of interest\|\|Variola, Angela: No conflict of interest |

| | |
|---|---|
| P423 | Dr. Romeo, Samanta: No conflict of interest\|\|Carvalhas Gabrielli, Anna Maria: No conflict of interest\|\|Ferretti, Francesca: No conflict of interest\|\|Piazza O Sed, Nicole: No conflict of interest\|\|Mazzola, Anna Maria: No conflict of interest\|\|Alicante, Saverio: No conflict of interest\|\|Berté, Roberto: No conflict of interest\|\|Scribano, Maria Lia: No conflict of interest\|\|Buscarini, Elisabetta: No conflict of interest\|\|Ricci, Chiara: No conflict of interest\|\|Caprioli, Flavio: No conflict of interest\|\|Ardizzone, Sandro: No conflict of interest\|\|Cannatelli, Rosanna: No conflict of interest |
| P424 | Madero Velázquez, Lucía: No conflict of interest\|\|Jovani, Vega: No conflict of interest\|\|Andrés, Mariano: No conflict of interest\|\|Más, Patricio: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Vicens, Elvira: No conflict of interest\|\|Ojeda, Asunción: No conflict of interest\|\|Noguera-Pons, José Raúl: No conflict of interest\|\|Ranieri, Laura: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|Pujol, Manel: No conflict of interest\|\|Barreiro de Acosta, Manuel: No conflict of interest\|\|Pérez-Pampin, Eva: No conflict of interest\|\|Bernal, Lorena: No conflict of interest\|\|Belen, Olivia: No conflict of interest\|\|Moreno, Violeta: No conflict of interest\|\|García, Mariana Fé: No conflict of interest\|\|Sempere, Laura: No conflict of interest\|\|Zapater, Pedro: No conflict of interest\|\|Gutiérrez Casbas, Ana: No conflict of interest |
| P425 | Dr. Yeaman, Fiona: No conflict of interest\|\|Panaccione, Remo: No conflict of interest\|\|Ma, Chris: No conflict of interest\|\|Lu, Cathy: No conflict of interest\|\|Seow, Cynthia: No conflict of interest\|\|Kaplan, Gilaad: No conflict of interest\|\|Maracle, Brooke: No conflict of interest\|\|Novak, Kerri: No conflict of interest |

| | |
|---|---|
| P426 | Anafy, Adi: No conflict of interest\|\|Cohen, Shlomi: No conflict of interest\|\|Matar, Manar: No conflict of interest\|\|Shouval, Dror S.: No conflict of interest\|\|Shamir, Raanan: No conflict of interest\|\|Dr. Weintraub, Yael: No conflict of interest |
| P427 | Dr. Lightner, Amy: No conflict of interest\|\|Otero Pineiro MD , Ana: No conflict of interest\|\|Reese, Jane: No conflict of interest\|\|Ream, Justin: No conflict of interest\|\|Nachand, Douglas: No conflict of interest\|\|Obi, Megan: No conflict of interest\|\|Adams, Ashely: No conflict of interest\|\|VanDenBossche , Alexandra: No conflict of interest\|\|Dadgar, Neda: No conflict of interest\|\|Hull, Tracy: No conflict of interest |
| P428 | Mr. Kwok, Jon: No conflict of interest\|\|Smith, Joe: No conflict of interest\|\|Gashau, Wadi: No conflict of interest\|\|Shuttleworth, Elinor: No conflict of interest |
| P429 | Ms. Inniss, Saskia: No conflict of interest\|\|Simpson, Kate: No conflict of interest\|\|Fragkos, Konstantinos: No conflict of interest\|\|Wood, Christopher: No conflict of interest\|\|Smith, Andrew: No conflict of interest\|\|Rahman, Farooq: No conflict of interest |
| P430 | Dr. Piñero, Gisela Soledad: No conflict of interest\|\|Mañosa , Míriam: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Calafat, Margalida: No conflict of interest\|\|González, Laura: No conflict of interest\|\|Ruffinengo, Orlando: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest |

| | |
|---|---|
| P431 | Dignass, Axel:\|:\|AD reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Arena Pharmaceuticals, Falk Foundation, Gilead/Galapagos, Janssen and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, Celltrion, Falk Foundation, Ferring, Gilead/Galapagos, High5ImmunoTV, Janssen, MSD, Pfizer, Takeda, Tillotts and Vifor Pharma; payment for manuscript preparation from Falk Foundation, Takeda, Thieme and UniMed Verlag. \|\|Gisbert, Javier P.:\|:\|JG has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma.\|\|Bossa, Fabrizio:\|:\|FB has served as a speaker, a consultant and advisory member for or has received research funding from MSD, AbbVie, Pfizer, Biogen, Takeda, Janssen, Sandoz, Celgene, and Mundipharma GmbH.\|\|Kelly, Orlaith:\|:\|OK has served as a speaker, research participant, advisory board member, symposia chair, or provided input on educational activities for Abbvie, Pfizer, Janssen, Takeda, Bristol Myer Squibb and Biogen. MR has no conflicts to declare.\|\|Rahman, Monira: No conflict of interest\|\|Lobatón, Triana:\|:\|TL has served as a speaker, a consultant and advisory member for or has received research funding from AbbVie, Viatris, MSD, Mundipharma, Biogen, Janssen, Pfizer, Takeda, Ferring, Amgen, Fresenius Kabi, Galapagos and Bristol Myers Squibb.\|\|Addison, Janet:\|:\|JA is an employee of Biogen and may hold company stock. |

| | |
|---|---|
| P432 | Dr. Matini, Lawrence: No conflict of interest\|\|Stokes, Elizabeth A: No conflict of interest\|\|Parra Mujica, Fiorella: No conflict of interest\|\|Kormilitzin, Andrey:\|:\|Received grants from GSK, Alzheimer's Research UK and the UK National Institute for Health and Care Research\|\|Kantschuster, Ramona: No conflict of interest\|\|Punj Sharda, Anita: No conflict of interest\|\|Dunbar, Grace: No conflict of interest\|\|Song, Kaiyang: No conflict of interest\|\|White, Lydia: No conflict of interest\|\|Travis, Simon P L:\|:\|Grants/Research Support: AbbVie, Buhlmann, Celgene, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor, and Norman Collisson Foundation. Consulting Fees: Abacus; AbbVie; Actial; ai4gi; Alcimed; Allergan; Amgen; Apexian; Aptel; Arena; Asahi; Aspen; Astellas; Atlantic; AstraZeneca; Barco; Biocare; Biogen; BLPharma; Boehringer Ingelheim; BMS; Buhlmann; Calcico; Celgene; Cellerix; Cerimon; ChemoCentryx; Chiesi; CisBio; ComCast; Coronado; Cosmo; Ducentis; Dynavax; Elan; Enterome; EQrX; Equillium; Falk; Ferring; FPRT Bio; Galapagos; Genentech/Roche; Genzyme; Gilead; Glenmark; Grunenthal; GSK; GW Pharmaceuticals; Immunocore; Immunometabolism; Indigo; Janssen; Lexicon; Lilly; Medarex; Medtrix; Merck; Merrimack; Mestag; Millenium; Neovacs; Novartis; Novo Nordisk; NPS-Nycomed; Ocera; Optima; Origin; Otsuka; Palau; Pentax; Pfizer; Pharmaventure; Phesi; Phillips; P&G; Pronota; Protagonist; Proximagen; Resolute; Robarts; Sandoz; Sanofi; Santarus; Satisfai; Sensyne Health; Shire; SigmoidPharma; Sorriso; Souffinez; Syndermix; Synthon; Takeda; Theravance; Tigenix; Tillotts; Topivert; Trino Therapeutics with Wellcome Trust; TxCell; UCB Pharma; Vertex; VHsquared; Vifor; Warner Chilcott and Zeria. Speaker fees: AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda, UCB. No stocks or share options\|\|Walsh, Alissa:\|:\|Received research/consulting/advisory board fees from AbbVie, BMS, Buhlmann, Falk, Ferring, Galapagos, Helmsley Trust, Janssen, Lilly, Norman Collisson Foundation, Pfizer, Takeda, Tillots, UCB Pharma, Vifor; No stocks or share options. |

| | |
|---|---|
| P433 | Panaccione, Remo:\|:\|RP has received consulting fees from AbbVie, Abbott, Alimentiv (formerly Robarts Clinical Trials), Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, Takeda, and UCB. He has received speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and has served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Takeda, and Theravance.\|\|D'Haens, Geert:\|:\|GD'H reports being a speaker or consultant for AbbVie, Alimentiv, Boehringer Ingelheim, Celltrion, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Janssen, Lilly, MSD, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Takeda, and Tillotts.\|\|Seenan, John Paul:\|:\|JPS has received speaker fees from AbbVie, Fresenius Kabi, Galapagos, Janssen-Cilag, Pharmacosmos, Takeda, and Tillotts Pharma. He has received advisory board fees from AbbVie, Bristol Myers Squibb, Dr Falk Pharma, and Galapagos.\|\|Caprioli, Flavio:\|:\|FC has served as consultant to AbbVie, Biogen, Bristol Meyers Squibb, Celgene, Ferring, Galapagos, Gilead, Janssen, MSD, Mundipharma, Pfizer, Roche, and Takeda. He has received lecture fees from AbbVie, Allergy Therapeutics, Biogen, Ferring, Janssen, Pfizer, and Takeda, and unrestricted research grants from AbbVie, Celltrion, Giuliani, MSD, Pfizer, Sofar, and Takeda.\|\|Siegel, Corey:\|:\|CS has consulted or served on advisory boards for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Pfizer, Prometheus, Sandoz, Sebela, and Takeda. He has been a speaker for AbbVie, Janssen, Pfizer, and Takeda, and has received grant support from AbbVie, Agency for Healthcare Research and Quality (1R01HS021747-01), Crohn's and Colitis Foundation, Janssen, Pfizer, and Takeda. He reports intellectual property from MiTest Health LLC, and ColonaryConcepts LLC, and equity interest from MiTest Health and ColonaryConcepts.\|\|Nakamura, Masanao:\|:\|MN has received honoraria from Janssen.\|\|Wei, Shu Chen:\|:\|SCW has consulted or served on advisory boards for AbbVie, Bristol Myers Squibb, Celltrion, Ferring Pharmaceuticals, Janssen, Pfizer, Takeda, and Tanabe. She has received lecture fees from AbbVie, Bristol Myers Squibb, Celltrion, Ferring Pharmaceuticals, Janssen, Pfizer, Takeda, and Tanabe.\|\|Kligys, Kristina:\|:\|KK is a full-time employee of AbbVie, and may own AbbVie stock or options.\|\|Zhang, Yafei:\|:\|YZ is a full-time employee of AbbVie, and may own AbbVie stock or options.\|\|Zambrano, Javier:\|:\|JZ is a full-time employee of AbbVie, and may own AbbVie stock or options.\|\|Song, Alexandra P.:\|:\|APS is a full-time employee of AbbVie, and may own AbbVie stock or options.\|\|Ferrante, Marc:\|:\|MF reports being a consultant or speaker for AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk, Eli Lilly, Ferring, Janssen-Cilag, Lamepro, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda, Thermo Fisher Scientific, and Truvion Healthcare; and research grants from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda, and Viatris. |

| | |
|---|---|
| P434 | Ghosh, Subrata:\|:\|Ghosh S received lecture fee[s] from AbbVie, Janssen, Takeda, Pfizer, Celltrion, Eli Lilly, Shield, Ferring, Falk Pharma; is steering/advisory committee member for Pfizer, Janssen, AbbVie, Bristol Myers Squibb, Celgene, Boehringer Ingelheim, Celltrion, Gilead, Galapagos, Eli Lilly, Takeda; and received research support from GSK, AbbVie, and Vertex.\|\|Feagan, Brian:\|:\|Feagan B is a consultant for AbbVie, AbolerIS, AgomAB Therapeutics, Allianthera, Amgen, AnaptysBio, Applied Molecular Transport Inc, Arena Pharma, Avoro Capital Advisors, Atomwise, BioJamp, Biora Therapeutics, Boehringer-Ingelheim, Boxer, Celsius Therapeutics, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Duality, EcoR1, Eli Lilly, Equillium, Ermium, First Wave, First Word Group, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, Hinge Bio, Hot Spot Therapeutics, Index Pharma, Imhotex, Immunic Therapeutics, JAKAcademy, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Landos Biopharma, Leadiant, L.E.K. Consulting, Lenczner Slaght, LifeSci Capital, Lument AB, Millennium, MiroBio, Morgan Lewis, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Orphagen, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Therapeutics and Diagnostics, Play to Know AG, Progenity, Protagonist, PTM Therapeutics, Q32 Bio, Rebiotix, REDX, Roche, Sandoz, Sanofi, Seres Therapeutics, Silverback Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Tigenix, Tillotts, Ventyx Biosciences, VHSquared Ltd., Viatris, Ysios, Ysopia, and Zealand Pharma; is a member of the speakers bureau for AbbVie, Janssen, and Takeda; a member of the scientific advisory board for AbbVie, Amgen, AMT, AnaptysBio, Boehringer-Ingelheim, Celgene/BMS, Eli Lilly, Genentech/Roche, Janssen, MiroBio, Origo BioPharma, Pfizer, Prometheus, REDX Pharma, Sanofi, Takeda, Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, GSK, and Axio Research; is a stock shareholder for Gossamer Pharma; is an employee of Western University; and is Senior Scientific Director of Alimentiv Inc.\|\|Parra, Rogerio Serafim:\|:\|Parra RS received lecture fee[s] from AbbVie, Janssen, Takeda, Pfizer, and Abbvie; is an advisory committee member for Janssen and AbbVie.\|\|Lopes, Susana: No conflict of interest\|\|Steinlauf, Adam: No conflict of interest\|\|Kakuta, Yoichi:\|:\|Kakuta Y received lecture fees from AbbVie, Takeda, Pfizer, EA Pharma, JIMRO, Mochida and Janssen, and received financial support for research from AbbVie, Takeda, EA Pharma, JIMRO, Mochida, Mitsubishi Tanabe, Janssen, Daiichi Sankyo, and Kyowa Kirin.\|\|Joshi, Namita:\|:\|Joshi N is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Lee, Wan-Ju:\|:\|Lee WJ is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Remple, Valencia:\|:\|Remple V is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Lacerda, Ana P.:\|:\|Lacerda AP is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Zhou, Qian:\|:\|Zhou Q is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Xuan, Si:\|:\|Xuan S is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Louis, Edouard:\|:\|Louis E received financial support for research from Takeda, Pfizer, and Janssen; received lecture fee[s] from AbbVie, Celgene, Falk, Ferring, MSD, Takeda, Janssen, and Pfizer; received consultancy\|fees from AbbVie; received educational grants from AbbVie, Takeda, and Janssen; and served on advisory boards for AbbVie, Ferring, MSD, Takeda, Celgene, Janssen, Gilead-Galapagos, Arena, Pfizer, and Eli Lilly. |

| | |
|---|---|
| P435 | Prof. Dr. Buisson, Anthony:\|:\|Consulting fees for Abbvie, Amgen, Arena, Biogen, Celtrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts. Lecture fees for Abbvie, Amgen, Biogen, Fresenius-Kabi Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts and Vifor Pharma. Research grants from Abbvie, Celltrion, Janssen, Pfizer, Takeda.\|\|Jammet, Arthur: No conflict of interest\|\|Pereira, Bruno: No conflict of interest\|\|Fumery, Mathurin:\|:\|Consulting/lecture fees for Abbvie, Amgen, Arena, Biogen, Celtrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts. MSD, Gilead, Celgene, Sandoz and Ferring. |
| P436 | Schreiber, Stefan Wolfgang:\|:\|S Schreiber has received personal fees from AbbVie, Amgen, Arena, Biogen, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr. Falk Pharma, Fresenius, Galapagos/Gilead, I-Mab, Hikma, Janssen, MSD, Mylan, Pfizer, Protagonist, ProventionBio, Takeda and Theravance Biopharma\|\|Lee, Scott:\|:\|S Lee served as a consultant for Applied Molecular Transport, Arena, Boehringer Ingelheim, Bridge Biotherapeutics, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Cornerstones Health, Eli Lilly and Company, Janssen, KCRN Research, Samsung Bioepis and UCB; and received research grants from AbbVie, AbGenomics, Arena, Celgene, Janssen, Salix, Takeda and UCB\|\|van der Woude , C Janneke:\|:\|C.J van der Woude received grant support from Falk Ben-elux, Ferring and Pfizer; received speaker fees from AbbVie, Takeda, Ferring, Dr Falk Pharma, Pfizer; and served as a consultant for Janssen\|\|Marín-Jiménez , Ignacio:\|:\|I Marín-Jiménez has served as a consultant, advisory member, speaker or has received research funding from Abbvie, Chiesi, Faes Farma, FalkPharma, Ferring, Gebro Pharma, Hospira, Janssen, MSD, Otsuka Pharmaceutical, Pfizer, Shire, Takeda, Tillots and UCB Pharma\|\|Wolf, Doug:\|:\|D Wolf has received honoraria as a speaker, consultant and/or advisory board member from AbbVie, Arena, Celgene/Bristol Myers Squibb, Janssen, Pfizer and Takeda\|\|Schnoy, Elizabeth:\|:\|E Schnoy AbbVie, Bristol Myers Squibb, Celltrion Healthcare, Dr. Falk Pharma, Galapagos/Gilead, I-Mab, Janssen, Lilly, Pfizer, Pharmacosmos, Takeda, Tillotts Pharma\|\|Salzberg , Bruce:\|:\|B Salzberg served as a consultant for Johnson and Johnson and has received honoraria as a speaker from AbbVie, Bristol-Myers Squibb and Johnson and Johnson\|\|Busse , Christopher:\|:\|C Busse reports employment with Janssen Scientific Affairs, LLC, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson\|\|Nazar, Maciej:\|:\|M. Nazar is an employee of Janssen-Cilag Polska Sp. z o.o, and has restricted stocks\|\|Langholff, Wayne:\|:\|W Langholff reports employment with Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson\|\|Borghorst, Stephan:\|:\|S Borghorst is an employee of Janssen-Cilag GMBH and has restricted stocks\|\|Gasink, Christopher:\|:\|C Gasink reports previous employment with Janssen Scientific Affairs, LLC, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson\|\|Baker, Thomas:\|:\|T Baker reports employment with Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson\|\|Godwin, Bridget:\|:\|B Godwin reports employment with Janssen Scientific Affairs, LLC, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson\|\|Feagan, Brian:\|:\|B Feagan received grant/research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann- |

| | |
|---|---|
| | La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc./Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG and UCB; was a consultant for Abbott/AbbVie, AdMIRx Inc., Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Asta Pharma, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, Galen/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc., Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Rebiotix, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd. and Zyngenia; was a member of the speakers bureau for Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts and UCB Pharma; a member of the scientific advisory board for Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG and UCB Pharma; and was a Senior Scientific Officer for Robarts Clinical Trials Inc |
| P437 | Dr. Carrillo Palau, Marta: No conflict of interest\|\|Alonso-Abreu, Inmaculada: No conflict of interest\|\|Morant, Andrea: No conflict of interest\|\|Vera, Belen: No conflict of interest\|\|Vela , Milagros: No conflict of interest\|\|Ramos, Laura: No conflict of interest\|\|Franco, Andres: No conflict of interest\|\|Reygosa, Cristina: No conflict of interest\|\|Barrios, Yvelise: No conflict of interest\|\|Medina Chico, J. Sergio: No conflict of interest\|\|Globio, Vanesa: No conflict of interest\|\|Hernández-Perez, Anjara: No conflict of interest\|\|Jiménez, Alejandro: No conflict of interest\|\|Hernández-Guerra, Manuel: No conflict of interest |

| | |
|---|---|
| P438 | Hisamatsu, Tadakazu:\|:\|Tadakazu Hisamatsu, MD, PhD reports joint research with Alfresa Pharma Co. Ltd. and EA Pharma Co. Ltd. grant support from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd. consulting fees from EA Pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., and Nichi-Iko Pharmaceutical Co., Ltd. and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., and Pfizer Inc.\|\|Kim, Hyo Jong:\|:\|Hyo Jong Kim, MD, PhD reports consultancy fees from Celltrion and speaking fees from Pfizer Inc. and Takeda Pharmaceutical Co. Ltd.\|\|Motoya, Satoshi:\|:\|Satoshi Motoya, MD, PhD reports personal fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Mochida Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Janssen Pharmaceutical K.K. and grants from Pfizer, Inc., AbbVie GK, EA Pharma Co., Ltd, Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Co. Ltd.\|\|Suzuki, Yasuo:\|:\|Yasuo Suzuki, MD, PhD (at the time the study was conducted) reports speaking fees from Janssen Pharmaceutical K.K, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Co. Ltd.\|\|Ohnishi, Yoshifumi:\|:\|Yoshifumi Ohnishi, PhD reports grant support from AbbVie GK.\|\|Marano, Colleen:\|:\|Colleen Marano, PhD reports employment with Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson.\|\|Imai, Yuya:\|:\|Yuya Imai, PhD reports employment (at the time the study was conducted) with Janssen Pharmaceuticals K.K. Japan, Tokyo, Japan, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson.\|\|Saadoun, Carine:\|:\|Carine Saadoun, MD reports employment with Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson.\|\|Zhuo, Jianmin:\|:\|Jianmin Zhuo, MS reports employment with Janssen China Research & Development, Shanghai, China, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson.\|\|Kawamura, Shiho:\|:\|Shiho Kawamura, PhD reports employment with Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore, a wholly owned subsidiary of Johnson & Johnson, and stock ownership in Johnson & Johnson. |

| | |
|---|---|
| P439 | Panés, Julián:\|:\|Julian Panes: received financial support for research from AbbVie and Pfizer; consultancy fees/honorarium from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance and Wasserman; reports payment for lectures including service on speaker bureau from Abbott, Ferring, Janssen, Pfizer and Takeda; and reports payment for development of educational presentations from Abbott, Janssen, Pfizer Roche and Takeda.\|\|Louis, Edouard:\|:\|Edouard Louis: received research grants from Janssen, Pfizer, and Takeda; educational grant from AbbVie, Janssen, MSD, and Takeda; speaker fees for AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda; served on an advisory board for AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda, Galapagos, Gilead, Arena; served as a consultant for AbbVie.\|\|Bossuyt, Peter:\|:\|Peter Bossuyt: received research grants from AbbVie, Amgen, Celltrion, Mylan, Pfizer and Takeda; received lectura fees from AbbVie, Celltrion, Janssen, Lilly and Takeda; served as a consultant for AbbVie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros.\|\|Joshi, Namita:\|:\|Namita Joshi is an AbbVie employee and may own AbbVie stock and/or options.\|\|Lee, Wan-Ju:\|:\|Wan-Ju Lee is an AbbVie employee and may own AbbVie stock and/or options.\|\|Lacerda, Ana:\|:\|Ana Lacerda is an AbbVie employee and may own AbbVie stock and/or options.\|\|Remple, Valencia:\|:\|Valencia Remple is an AbbVie employee and may own AbbVie stock and/or options.\|\|Xuan, Si:\|:\|Si Xuan is an AbbVie employee and may own AbbVie stock and/or options.\|\|Loftus Jr. , Edward V.:\|:\|Edward V. Loftus: served as a consultant for AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Calibr, Celgene, Celltrion Healthcare, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Morphic Therapeutics, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Surrozen, Sun Pharma, Takeda, and UCB; and received research grants from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. |
| P440 | Dr. Yu, Natalie: No conflict of interest\|\|Sriranganathan, Danujan: No conflict of interest\|\|Walker, Gareth J: No conflict of interest\|\|Sazonovs, Aleksejs: No conflict of interest\|\|Wilding, Helen: No conflict of interest\|\|Kennedy, Nicholas A: No conflict of interest\|\|Ahmad, Tariq: No conflict of interest\|\|Boyapati, Ray K: No conflict of interest\|\|Segal, Jonathan P: No conflict of interest\|\|Ding, Nik John Sheng: No conflict of interest |

| | |
|---|---|
| P441 | Siegmund, Britta:\|:\|Consulting fees from: Abbvie, BMS, Boehringer, Falk, Galapagos, Jassen, Lilly, Pfizer, PredictImmeune, Landos, Takeda; Speaker Fees: Abbvie, Falk, Ferring, Janssen, Pfizer, BMS, Takeda, CED Service GmbH, Lilly; Grant: Pfizer.\|\|Siegel, Corey A.:\|:\|Advisory board for Abbvie, BMS, Fresnius, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, ProciseDx, Prometheus, Takeda, Trellus Health; Speaker for CME activities for Abbvie, Janssen, Pfizer and Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.\|\|Sebastian, Shaji:\|:\|Research grants from Takeda, Pfizer, Tillotts Pharma, Abbvie, Biogen , personal fees for Speaker role and advisory board meetings from Janssen, Amgen, Tillotts Pharma, Abbvie, Takeda, Celgene, Roche, Phramacosmos , Falk pharma outside the submitted work\|\|Zhou, Jie:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Jones, Stephen:\|:\|Consultant to Takeda\|\|Adsul, Shashi:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Louis, Edouard:\|:\|Educational and research grant: Janssen, Pfizer, Abbvie and Takeda, Fresenius-Kabi; speaker fees: Abbvie, Falk, Ferring, Janssen, Pfizer, Celgene, BMS, Galapagos and Takeda; advisory board: Abbvie, Celgene, Ferring, Janssen, BMS, Pfizer,Takeda, Gilead-Galapagos, Arena, Elli Lilly; consultant: Abbvie |
| P442 | Busacca, Anita: No conflict of interest\|\|Dr. De Sire, Roberto: No conflict of interest\|\|Capogreco, Antonio: No conflict of interest\|\|Dal Buono, Arianna: No conflict of interest\|\|Gabbiadini, Roberto: No conflict of interest\|\|Loy, Laura: No conflict of interest\|\|Finati, Elena: No conflict of interest\|\|Spadaccini, Marco: No conflict of interest\|\|Maselli, Roberta: No conflict of interest\|\|Hassan, Cesare: No conflict of interest\|\|Repici, Alessandro: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest |

| | |
|---|---|
| P443 | Dr. Le Cosquer, Guillaume:\|:\|Lecture fees from Abbvie\|\|Gilletta, Cyrielle:\|:\|Consultant/lecture fees from Abbvie, Celltrion, Ferring, Fresenius, Janssen, MSD, Pfizer and Takeda.\|\|Amiot, Aurélien:\|:\|Consulting fees from Abbvie, Hospira, Janssen, Tillotts, Pfizer, Takeda, Gilead and Biocodex \|Lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Pfizer, Biogen, Amgen, Fresenius Kabi, Ferring, Tillotts, Takeda and MSD.\|\|Rivière, Pauline:\|:\|Consultancy fees from Amgen and Janssen.\|\|Nachury, Maria:\|:\|Board membership, consultancy, or lecture fees from Abbvie, Adacyte, Amgen, Arena, Biogen, CTMA, Celltrion, Ferring, Fresenius-Kabi, Janssen, Mayoli-Spindler, MSD, Pfizer, Takeda\|\|Rouillon, Cléa: No conflict of interest\|\|Bouhnik, Yoram:\|:\|Lecture and consulting fees from Abbvie, Biogaran, Boehringer-Ingelheim, CTMA, Ferring, Gilead, Hospira, ICON, Inception IBD, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Robarts Clinical Trials, Roche, Sanofi, Shire, Takeda, UCB and Vifor Pharma\|\|Abitbol, Vered:\|:\|Lecture fees from Biogen Amgen Sandoz Mylan Pfizer Takeda Janssen Gilead Tillots.\|\|Nancey, Stephane:\|:\|Consulting fees from Merck, Abbvie, Takeda, Ferring, Norgine, Vifor Pharma, Novartis, Janssen-Cilag, Hospira, Takeda and HAC-Pharma\|\|Fumery, Mathurin:\|:\|Lecture and consulting fees from Abbvie, MSD, Boehringer, Pfizer, Takeda, Celgene, Gilead, Celltrion, Amgen, Biogen, Pfizer, Lilly, Arena, Janssen and Ferring.\|\|Savoye, Guillaume:\|:\|Lecture fees from Vifor Pharma, Takeda, Pfizer, HAC Pharma, Abbvie, MSD, and Ferring France. \|This author has also received travel accommodations from Ferring, Abbvie, and MSD France as well as a research grant from Ferring. \|\|Biron , Amélie: No conflict of interest\|\|Picon, Laurence: No conflict of interest\|\|Peyrin-Biroulet, Laurent:\|:\|Consulting fees from Merck, Abbvie, Janssen, Genentech, Ferring, Norgine, Tillots, Vifor, Shire, Therakos, Pharmacosmos, Pilège, BMS, UCB-Pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, and HAC-Pharma. \|Lecture fees from Merck, Abbvie, Takeda, Janssen Cilag, Ferring, Norgine, Tillots, Vifor, Therakos, HAC-Pharma, and Mitsubishi.\|\|Vidon, Mathias: No conflict of interest\|\|Reenaers, Catherine:\|:\|Speaker and advisory board member for Abbvie, Janssen, Pfizer, Takeda, Celltrion.\|\|Simon, Marion:\|:\|Travel fees from Abbvie, mylan, Takeda. \|\|Caron, Bénedicte:\|:\|Lecture and/or consulting fees from Abbvie, Amgen, Celltrion, Janssen, Takeda.\|\|Serrero , Mélanie:\|:\| Lecture and consulting fees for Abbvie, Celltrion, Ferring, Janssen, MSD, Takeda and Tillotts. \|\|Altwegg, Romain:\|:\|Counseling, boards, transports or fees from Abbvie, Amgen, Biogen, Ferring, Janssen, MSD, Pfizer, Takeda, Tillotts.\|\|Benezech, Alban: No conflict of interest\|\|Goutorbe, Felix:\|:\|Lecture and consultant fees from Abbvie, Amgen, Biogen, Janssen, Pfizer, Takeda\|\|Rahier, Jean-Francois:\|:\|Speaker fees from Abbvie, MSD, Takeda, Pfizer, Ferring, Falk, Biogen, Amgen, Celltrion. \|Consultancy: Abbvie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK and Janssen;\|Research grant from Takeda and Abbvie.\|\|Beaugerie, Laurent:\|:\|Consulting fees from Janssen, Pfizer and Allergan\|Lecture fees from Abbvie, Janssen, MSD, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda and Tillots\|Research support from Abbott, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Takeda and Tillots for unrelated studies. \|\|Pelletier, Anne-Laure: No conflict of interest\|\|Caillo, Ludovic:\|:\|Lecture and consulting fees for Abbvie, Pfizer, Ferring, Janssen, Amgen, Biogen, Takeda and Tillotts\|\|Laharie, David:\|:\|Counseling, boards or transports fees from Abbvie, Biogaran, Biogen, Ferring, HAC-pharma, Janssen, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillots.\|\|Poullenot, Florian:\|:\|Fees from AbbVie, MSD, Takeda, Ferring, Janssen, Pfizer. |

| | |
|---|---|
| P444 | Irving, Peter Miles:\|:\|Peter Irving has received Lecture fees: \|AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, Warner Chilcott \|\|Financial support for research:\|Celltrion, MSD, Pfizer, Takeda, Galapagos\|\|Advisory fees: \|AbbVie, Arena, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, Warner Chilcott\|\|Hur, Peter:\|:\|Peter Hur is an employee of Pfizer Inc and may hold shares in Pfizer Inc.\|\|Gautam, Raju: No conflict of interest\|\|Guo, Xiang:\|:\|Xiang Guo is an employee of Pfizer Inc. and may hold shares in Pfizer Inc.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire has received grants from AbbVie, J&J, Pfizer, Takeda and Galapagos; \|Séverine Vermeire has received consulting and/or speaking fees from: AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma |

| | |
|---|---|
| P445 | Peyrin-Biroulet, Laurent:\|:\|Laurent Peyrin-Biroulet received personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger-Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance.\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Bossuyt, Peter:\|:\|Peter Bossuyt reports research grants from Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda; Lecture fees from AbbVie, Celltrion, Janssen, Lilly and Takeda // Lecture fee; and consulting fees Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros.\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Bettenworth, Dominik:\|:\|Dominik Bettenworth is on the advisory board or has acted as a consultant for AbbVie, Amgen, Arena, Atheneum, BNG Service GmbH, Bristol Myers Squibb, CED-Service GmbH, Celltrion, DGVS, Diaplan, Else Kröner-Fresenius Foundation, Falk Foundation, Galapagos, Guidepoint, Impulze, Ferring, Janssen Cilag, Lilly, Medical Tribune, MedTriX, MSD, Mylan, Onkowissen, Pharmacosmos, Pfizer, Roche, Sandoz, Takeda, Tetrameros, Thieme, Tillotts Pharma, UCB Biopharma, Viatris and Vifor Pharma.\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Loftus Jr., Edward V:\|:\|Edward Loftus has acted as a consultant for AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, CALIBR, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Sun Pharma, Surrozen, Takeda and UCB; and received research support from AbbVie, Bristol Myers Squibb, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Takeda, Theravance and UCB.\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Anjie, Suzanne:\|:\|Suzanne Anjie declares no conflicts of interest.\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by |

Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).||D'Haens, Geert:|:|Geert D'Haens has received consultancy fees for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity and Protagonist. Speakers bureau for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda. Data montoring board for Galapagos, Astrazeneca and Seres.|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).||Saruta, Masayuki:|:|Masayuki Saruta received honoraria from Abbvie GK, Janssen Pharma K.K., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Co.,Ltd., EA Pharma Co.,Ltd, Gilead Sciences K.K., writing fees from EA Pharma Co., Ltd., grants for commissioned/joint research from EPS Corporation, scholarship grants from Zeria Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd, EA Pharma Co.,Ltd, Kissei Pharmaceutical Co., Ltd.|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).||Arkkila, Perttu:|:|Perttu Arkkila has been an advisory board member of Janssen.|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).||Kim, Dong-Hyeon:|:|Dong-Hyeon Kim, DVM, PhD is an employee of Celltrion Healthcare Co., Ltd.|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).||Ms. Choi, Dasom:|:|Dasom Choi, DVM, MSc is an employee of Celltrion Healthcare Co., Ltd.|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).||Reinisch, Walter:|:|Walter Reinisch has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Celltrion, Falk Pharma, Ferring, Janssen, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer, Pharmacosmos. PLS Education. Roche. Shire. Takeda. Therakos. and Vifor: served as a consultant for

| | |
|---|---|
| | Pharmacosmos, PES Education, Roche, Shire, Takeda, Therakos, and Vifor; served as a consultant for AbbVie, Algernon, Amgen, Arena Pharmaceuticals, Astellas, AstraZeneca, Bioclinica, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celgene, Celltrion, Eli Lilly, Ernst & Young, Falk Pharma, Ferring, Fresenius, Galapagos, Gatehouse Bio, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Landos Biopharma, LivaNova, Mallinckrodt, Medahead, MedImmune, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Novartis, OMass, Otsuka, Parexel, Periconsulting, Pfizer, Pharmacosmos, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Roche, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Vifor, and Zealand; received support for attending meetings and/or travel from AbbVie, Janssen, and Takeda; and served on a Data Safety Monitoring Board or advisory board for OSE Pharma.\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK) and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). |
| P446 | Ms. Perrott, Claire: No conflict of interest\|\|Calini, Giacomo: No conflict of interest\|\|Gori, Alice: No conflict of interest\|\|Rottoli, Matteo: No conflict of interest\|\|Garoufalia, Zoe: No conflict of interest\|\|Wexner, Steven: No conflict of interest\|\|Celentano, Valerio: No conflict of interest |

| | |
|---|---|
| P447 | Frasson, Matteo:\|:\|Frasson M has served as a speaker, a consultant and advisory member for Johnson & Johnson\|\|Pinkney, Thomas: No conflict of interest\|\|Gisbert, Javier P:\|:\|Gisbert JP. has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma.\|\|Rodriguez-Lago, Iago:\|:\|Rodriguez-Lago I has received financial support for travelling and educational activities from or has served as an advisory board member for MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Shire Pharmaceuticals, Roche, Ferring, Dr. Falk Pharma, Otsuka Pharmaceutical, Celltrion, Faes Farma, and Adacyte. Financial support for research: Tillotts Pharma.\|\|Blackwell, Sue: No conflict of interest\|\|Gecse, Krisztina B:\|:\|Gecse KB has received grants from Pfizer Inc, Galapagos and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from AbbVie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts. \|\|Buskens , Christianne J: No conflict of interest\|\|Knowles, Charles: No conflict of interest\|\|Zmora, Oded: No conflict of interest\|\|Brookes, Matthew:\|:\|Brookes M' s research department has received grant support from Tillotts Pharma and Vifor Pharma (Switzerland) and Norgine Pharma. He has received honoraria and travel support for consulting or lecturing from Vifor Pharma, Tillotts Pharma, and Abbvie\|\|Fiorino, Gionata:\|:\|Fiorino G served as a consultant and Advisory Board member for Takeda, Janssen, Galapagos, Pfizer, Sandoz, Celltrion, Amgen, Ferring, AlphaSigma.\|\|Nos, Pilar: No conflict of interest\|\|Gallo, Gaetano: No conflict of interest\|\|Pata, Francesco: No conflict of interest\|\|Verjee, Azmina: No conflict of interest\|\|Leone, Salvatore: No conflict of interest\|\|Prof. Dr. Pellino, Gianluca: No conflict of interest |
| P448 | Ms. Vuijk, Stephanie:\|:\|S.A. Vuijk: TISKids study was supported by ZonMw, Crocokids and an Investigator-Sponsored Research Award from Pfizer. \|\|Jongsma, Maria: No conflict of interest\|\|Cozijnsen, Maarten: No conflict of interest\|\|van Pieterson, Merel: No conflict of interest\|\|de Meij, Tim: No conflict of interest\|\|Norbruis, Obbe: No conflict of interest\|\|Groeneweg, Michael: No conflict of interest\|\|Wolters, Victorien: No conflict of interest\|\|van Wering, Herbert: No conflict of interest\|\|Hojsak, Iva: No conflict of interest\|\|Kolho, Kaija-Leena: No conflict of interest\|\|Hummel, Thalia: No conflict of interest\|\|Stapelbroek, Janneke: No conflict of interest\|\|van der Feen, Cathelijne: No conflict of interest\|\|van Rheenen, Patrick: No conflict of interest\|\|van Wijk, Michiel: No conflict of interest\|\|Teklenburg, Sarah: No conflict of interest\|\|Escher, Johanna: No conflict of interest\|\|de Ridder, Lissy:\|:\|L. de Ridder: Collaboration with Abbvie, Lilly, Takeda, Janssen and Pfizer. Grant from ZonMw, ECCO, Pfizer. |

| | |
|---|---|
| P449 | Dr. Fortuna, Laura: No conflict of interest\|\|Bottari, Andrea: No conflict of interest\|\|Ficari, Ferdinando: No conflict of interest\|\|Cricchio, Marta: No conflict of interest\|\|Cianchi, Fabio: No conflict of interest\|\|Scaringi, Stefano: No conflict of interest |
| P450 | Fumery, Mathurin:\|:\|Consulting or grants from MSD, Abbvie, Janssen, Takeda, Pfizer, Tillots, Ferring, Biogen, Amgen, Celgene, Sandoz, Boehringer, Galapagos, Gilead\|\|\|Bouhnik, Yoram:\|:\|Consultancies from Abbvie, Amgen, Biogaran, Biogen, Boehringer Ingelheim, Celltrion, Ferring, Fresenius Kabi, Galapagos, Gilead, Hospira, Iterative Scopes, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Roche, Sandoz, Sanofi, Takeda, Tillotts\|\|\|Faure, Patrick:\|:\|Consultancies : Pfizer, janssen, takeda, MSd, Celltrion, Abbvie, Galápagos, Amgen, Sandoz, fresenus, Mayoly spindler, provepharm, nordicpharma. \|\|Bouzidi, Amira:\|:\|Pfizer employee\|\|Brault, Yves:\|:\|Pfizer employee\|\|Peyrin-Biroulet, Laurent:\|:\|Personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Biogen, Inotrem, MSD, Amgen, BMS, Vifor, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Pandion Therapeutics, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied Molecular Transport, GSK, Abivax.\|\|Laharie, David:\|:\|Counseling, boards, transports or fees from Abbvie, Biogaran, Biogen, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillotts. |
| P451 | Ms. Bevers, Nanja: No conflict of interest\|\|Aliu, Arta: No conflict of interest\|\|Wong, Dennis: No conflict of interest\|\|Derijks, Luc: No conflict of interest\|\|Winkens, Bjorn: No conflict of interest\|\|Vreugdenhil, Anita: No conflict of interest\|\|Pierik, Marieke:\|:\|\|Marieke J. Pierik reports grants and non-financial support from Falk Pharma, grants from European commission, grants from ZONMW (Dutch national research fund), grants and non-financial support from Takeda, grants and non-financial support from Johnson and Johnson, grants and non-financial support from Abbvie, non-financial support from Ferring, non-financial support from Immunodiagnostics, non-financial support from MSD, all outside the submitted work.\|\|\|van Rheenen, Patrick: No conflict of interest |

| | |
|---|---|
| P452 | Prof. Dr. Le, Puo-Hsien: No conflict of interest\|\|Chiu, Cheng-Hsun: No conflict of interest\|\|Chiu, Cheng-Tang: No conflict of interest\|\|Kuo, Chia-Jung: No conflict of interest\|\|Yeh, Pai-Jui: No conflict of interest\|\|Chen, Chien-Chang: No conflict of interest\|\|Pan, Yu-Bin: No conflict of interest |
| P453 | Zviaglova, Mariya: No conflict of interest\|\|Knyazev, Oleg: No conflict of interest\|\|Kagramanova, Anna: No conflict of interest\|\|Lischinskaya, Albina: No conflict of interest\|\|Podolskaya, Dariya: No conflict of interest\|\|Nanaeva, Bella: No conflict of interest |
| P454 | Dr. De Greef, Ine: No conflict of interest\|\|Bislenghi, Gabriele:\|:\|Gabriele Bislenghi receives speakers' fees from Galapago, Janssen and Takeda.\|\|Terrasson, Isabelle: No conflict of interest\|\|Sabino, João:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring. João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|Marc Ferrante is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|D'Hoore, André: No conflict of interest\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|Séverine Vermeire holds a BOF-FKO from the KU Leuven.\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. |

| | |
|---|---|
| P455 | Dr. Dragoni, Gabriele: No conflict of interest\|\|Castiglione, Fabiana:\|:\|FC reports advisory boards for AbbVie, Fresenius, Janssen, Pfizer and Takeda. \|\|Bezzio, Cristina:\|:\|CB received lecture fees and served as a consultant for Ferring, Galapagos, Janssen, MSD and Takeda. \|\|Pugliese, Daniela:\|:\|DP received speaker fees and/or advisory board fees from AbbVie, Janssen, MSD, Pfizer and Takeda.\|\|Spagnuolo, Rocco: No conflict of interest\|\|Viola, Anna: No conflict of interest\|\|Cocomazzi, Francesco: No conflict of interest\|\|Aratari, Annalisa:\|:\|AA received consultancy fees from Galapagos. \|\|Savarino, Edoardo Vincenzo:\|:\|EVS has served as speaker for AbbVie, AGPharma, Alfasigma, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Unifarco; has served as consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Falk, Fresenius Kabi, Janssen, Merck & Co, Reckitt Benckiser, Regeneron, Sanofi, Shire, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco; he received research support from Reckitt Benckiser, SILA, Sofar, Unifarco. \|\|Balestrieri, Paola:\|:\|PB has participated to advisory boards for Janssen and Takeda.\|\|Onali, Sara:\|:\|SO received speaker fees from AbbVie, Galapagos, Janssen, Norgine, and Takeda.\|\|Viganò, Chiara: No conflict of interest\|\|Ribaldone, Davide Giuseppe:\|:\|DGR reports consultancies with AbbVie, Galapagos, Janssen and Takeda. \|\|Innocenti, Tommaso: No conflict of interest\|\|Testa, Anna:\|:\|AT reports advisory boards for Galapagos, Janssen, Pfizer, Takeda. \|\|Saibeni, Simone:\|:\|SS received lecture fees from Janssen and Takeda; served as a consultant and advisory board member for AbbVie and Janssen. \|\|Privitera, Giuseppe:\|:\|GP reports consultancy fees from Alphasigma and Janssen. \|\|Milla, Monica: No conflict of interest\|\|Armuzzi, Alessandro:\|:\|. AA has received consulting/advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda; speaker's fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix; research support from Biogen, MSD, Pfizer and Takeda. \|\|Fantini, Massimo Claudio:\|:\|MCF received consultancy fees from AbbVie, Biogen, Bristol-Myers Squibb, Galapagos, Janssen-Cilag, Pfizer, Sandoz, Takeda, and research grants from Janssen-Cilag and Pfizer. \|\|Fiorino, Gionata:\|:\|GF served as a Consultant for AbbVie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Pfizer, Sandoz and Takeda. |
| P456 | Ms. Fernandez Clotet, Agnes: No conflict of interest\|\|Ordás, Ingrid: No conflict of interest\|\|Masamunt, Maria Carme: No conflict of interest\|\|Caballol, Berta: No conflict of interest\|\|Rodriguez, Sonia: No conflict of interest\|\|Panés, Julian: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Rimola, Jordi: No conflict of interest |

| | |
|---|---|
| P457 | Kosa, Fruzsina:\|:\|Fruzsina Kosa is an employee of Janssen.\|\|Nair, Sandhya:\|:\|Sandhya Nair is an employee of Janssen.\|\|He, Jianming:\|:\|Jianming He is an employee of Janssen.\|\|Lin, Xiwu:\|:\|Xiwu Lin is an employee of Janssen.\|\|Di Scala, Lilla:\|:\|Lilla Di Scala is an employee of Janssen.\|\|Dr. Lehne, Moritz:\|:\|Moritz Lehne is an employee of Cytel. The work of Cytel on this study was sponsored by Janssen.\|\|Ghiani, Marco: No conflict of interest\|\|Maywald, Ulf:\|:\|Ulf Maywald is an employee of AOK PLUS.\|\|Wilke, Thomas: No conflict of interest |
| P458 | Mrs. Pfeffer-Gik, Tamar: No conflict of interest\|\|Godny, Lihi: No conflict of interest\|\|Ollech, Jacob: No conflict of interest\|\|Wasserberg, Nir: No conflict of interest\|\|White, Ian: No conflict of interest\|\|Cohen, Shaked: No conflict of interest\|\|Broitman, Yelena: No conflict of interest\|\|Avni-Biron, Irit: No conflict of interest\|\|Banai, Hagar: No conflict of interest\|\|Snir, Yifat: No conflict of interest\|\|Yanai, Henit: No conflict of interest\|\|Yackobovich Gavan, Michal: No conflict of interest\|\|Shimon, Ilan: No conflict of interest\|\|Tsvetov, Gloria: No conflict of interest\|\|Barkan, Revital: No conflict of interest\|\|Dotan, Iris: No conflict of interest |
| P459 | Zacharias, Patricia: No conflict of interest\|\|Perussolo, Milena: No conflict of interest\|\|Magro, Daniela Oliveira: No conflict of interest\|\|Barauna, Fernanda da Silva Barbosa: No conflict of interest\|\|Prof. Kotze, Paulo Gustavo: No conflict of interest |
| P460 | Ms. Inniss, Saskia: No conflict of interest\|\|Simpson, Kate: No conflict of interest\|\|Fragkos, Konstantinos: No conflict of interest\|\|Wood, Christopher: No conflict of interest\|\|Smith, Andrew: No conflict of interest\|\|Rahman, Farooq: No conflict of interest |
| P461 | Mr. Adamou, Adamos: No conflict of interest\|\|Bercher, Magdalena: No conflict of interest\|\|Iesalnieks, Igors: No conflict of interest\|\|Streetz, Konrad: No conflict of interest |

| | |
|---|---|
| P462 | Wong, Emily: No conflict of interest\|\|Dulai, Parambir:\|:\|Parambir S. Dulai has received consulting and/or research support from Takeda, Pfizer, Janssen, BMS, Gilead, Novartis, Lily; Stock options DigbiHealth; Royalties: PreciDiag.\|\|Marshall, John:\|:\|John K. Marshall has received honoraria from Janssen, AbbVie, Allergan, Bristol-Meyer-Squibb, Ferring, Janssen, Lilly, Lupin, Merck, Pfizer, Pharmascience, Roche, Shire, Takeda and Teva.\|\|Jairath, Vipul:\|:\|VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx, Vividion; speaker's fees from, Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi\|\|Reinisch, Walter:\|:\|Walter Reinisch has received support for the following:\|Speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, \|Consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, \|Advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC\|\|Dr. Narula, Neeraj:\|:\|Neeraj Narula has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Merck, Sandoz, Novartis, and Ferring. |
| | |

| | |
|---|---|
| P463 | Dr. Ogino, Takayuki: No conflict of interest\|\|Mizushima, Tsunekazu: No conflict of interest\|\|Sekido, Yuki: No conflict of interest\|\|Fujii, Makoto: No conflict of interest\|\|Eguchi, Hidetoshi: No conflict of interest\|\|Nezu, Riichiro: No conflict of interest\|\|Ikeuchi, Hiroki: No conflict of interest\|\|Uchino, Motoi: No conflict of interest\|\|Futami, Kitaro: No conflict of interest\|\|Okamoto, Kinya: No conflict of interest\|\|Ajioka, Yoichi: No conflict of interest\|\|Sugihara, Kenichi: No conflict of interest\|\|Ishihara, Soichiro: No conflict of interest |
| P464 | Panaccione, Remo:\|:\|Received consulting fees from Abbott, AbbVie, Alimentiv, Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Therapeutics, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; received speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; received research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Takeda, and Theravance.\|\|Danese, Silvio:\|:\|Received honoraria as a speaker, consultant, and/or advisory board member from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, and Vifor.\|\|Wolf, Douglas C.:\|:\|Received research funding from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Elan, Given Imaging, Genentech, Janssen, Millennium, Pfizer, Prometheus, and UCB; lectured for AbbVie, Bristol Myers Squibb, Janssen, Prometheus, Santarus, Salix, Takeda, and UCB; consulted for AbbVie, Bristol Myers Squibb, Genentech, Given Imaging, Janssen, Prometheus Biosciences, Salix, Takeda, and UCB.\|\|Canavan, James B.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Jain, Anjali:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Petersen, AnnKatrin:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Afzali, Anita:\|:\|Served as a consultant for AbbVie, Bristol Myers Squibb, DiaSorin, Eli Lilly, Gilead, Janssen, Pfizer, Takeda, and TLL Pharmaceuticals; received speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda.\|\|Abreu, Maria T.:\|:\|Served as a consultant or advisory board member for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen Ortho, Janssen Global Services, Janssen Biotech NART, Janssen Biotech (nonbranded), Janssen Biotech (Women in GI Advisory Board), Microba, Prometheus Biosciences, UCB Biopharma, and WebMD Global; served as a speaker for Alimentiv, Intellisphere (HCP Live Institutional Perspectives in GI), Janssen, Prime CME, and Takeda; received research support from Pfizer, Prometheus, and Takeda. |

| | |
|---|---|
| | |
| P465 | Armuzzi, Alessandro:\|:\|Served on consultant/advisory boards for AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Galapagos, Gilead, Janssen, Lilly, Merck, Mylan, Pfizer, Protagonist-Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; received speaker fees from AbbVie, Amgen, Arena, AstraZeneca, Biogen, Bristol-Myers Squibb, Ferring, Galapagos, Gilead, Janssen, Merck, Mitsubishi Tanabe Pharma, Nikkiso, Novartis, Pfizer, Roche, Samsung Bioepis, and Takeda; and received research funding from Merck, Pfizer, Takeda, and Biogen.\|\|Rubin, David T.:\|:\|Received research funding from Takeda, and has served as a consultant to AbbVie, Abgenomics, Allergan, Inc., Arena Pharmaceuticals, Biomica, Bristol Myers Squibb, Dizal Pharmaceuticals, Ferring Pharmaceuticals, Inc., Genentech/Roche, Janssen Pharmaceuticals, Lilly, Mahana Therapeutics, Medtronic, Merck & Co., Inc, Napo Pharmaceuticals, Pfizer, Prometheus Laboratories, Shire, Takeda, and Target PharmaSolutions, Inc and is a co-founder of Cornerstones Health, Inc.\|\|Schreiber, Stefan:\|:\|Consultant for AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb; Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresenius, Galapagos, Genentech, GSK, Gilead, I-MAB Biopharma, Janssen, Lilly, Merck, Novartis/Sandoz, Pfizer, Protagonist, Takeda, and Theravance.\|\|Panés, Julian:\|:\|Received consulting fees from AbbVie, Arena Pharmaceuticals, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GSK, Janssen, Mirum, Morphic, Nestle, Origo, Pandion, Progenity, Pfizer, Revolo, Robarts, Roche, Takeda, Theravance, and Wassermann; speaker fees from AbbVie, Biogen, Ferring, Janssen, Pfizer, and Takeda; and research funding from AbbVie and Pfizer.\|\|Fellmann, Marc:\|:\|Employee of Pfizer, Inc. \|\|Bartolome, Lauren:\|:\|Employee of Pfizer Inc. \|\|Goetsch, Martina:\|:\|Employee of Pfizer, Inc. \|\|Bhattacharjee, Abhishek:\|:\|Employee of Pfizer, Inc. \|\|Wu, Joseph:\|:\|Employee and shareholder of Pfizer Inc. \|\|Chaparro, Maria:\|:\|Served as a speaker, or has received research or education funding from MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma.\|\|Dubinsky, Marla C.:\|:\|Consulting fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; and is founder and a shareholder of Trellus Health. |

| | |
|---|---|
| P466 | Mukherjee, Richa:\|:\|Richa Mukherjee: employee of Takeda Pharmaceuticals U.S.A., Inc and holds stock or stock options.\|\|Khan, Rana M Qasim:\|:\|Rana M. Qasim Khan: employees of Takeda Pharmaceuticals U.S.A., Inc and holds stock or stock options.\|\|Liu, Julia J:\|:\|Julia J Liu: received research support from Freenome Holdings and served on the advisory board of Janssen, Eli Lilly, and Bristol Myers Squibb.\|\|Ananthakrishnan, Ashwin N:\|:\|Ashwin N Anathakrishnan: received research support from National Institutes of Health, Crohn's and Colitis Foundation, and Pfizer, and served on the advisory board of Takeda and Gilead.\|\|Lichtenstein, Gary R:\|:\|Gary R. Lichtenstein: served as a consultant and/or research support from AbbVie, Allergan, American Regen, Bristol Myers Squibb, Celgene, Chemed, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, IMEDEX, Ironwood, Janssen Orthobiotech, Kabi, MedEd Consultants, Merck, Morphic Therapeutics, Pfizer, Prometheus Laboratories, Romark, Sandoz, Salix Pharmaceuticals, Shire Pharmaceuticals, Takeda, and UCB.\|\|Uddin, Sharif:\|:\|Sharif Uddin: employee of Takeda Pharmaceuticals U.S.A., Inc and holds stock or stock options.\|\|Young, Lisa:\|:\|Lisa Young: employee of Takeda Pharmaceuticals U.S.A., Inc and holds stock or stock options.\|\|Boules, Mena:\|:\|Mena Boules: employee of Takeda Pharmaceuticals U.S.A., Inc and holds stock or stock options.\|\|Adamson, Paula: No conflict of interest\|\|Reeves, Vonda: No conflict of interest |
| P467 | Atia, Ohad: No conflict of interest\|\|Dr. Goren, Idan: No conflict of interest\|\|Sharar Fischler, Tali: No conflict of interest\|\|Loewenberg Weisband, Yiska: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Ledderman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Magen Rimon, Ramit: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Yanai, Henit: No conflict of interest |
| P468 | Igho-Osagie, Ebuwa:\|:\|Employee of Merck & Co., Inc., North Wales, PA, USA\|\|Knight, Hannah:\|:\|Employee of Adelphi Real World\|\|Barlow, Sophie:\|:\|Employee of Adelphi Real World\|\|Ms. Harvey, Niamh:\|:\|Employee of Adelphi Real World\|\|Khandker, Rezaul:\|:\|Employee of Merck & Co., Inc., North Wales, PA, USA |

| | |
|---|---|
| P469 | Navabi, Seyedehsan:\|:\|Received consulting fees from Eli Lilly and Company advisory board.\|\|D'Haens, Geert:\|:\|G. D'Haens has received consulting and/or lecture fees from AbbVie, Alimentiv, Boehringer Ingelheim, BMS, Celltrion, Cytoki, Eli Lilly, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Immunic, Index Pharmaceuticals, Janssen Biologics, Nextbiotics, Pfizer, Polpharma, Prometheus Biosciences, Prometheus Diagnostics, Tillotts Pharma, Versant\|\|Samaan, Karen Hamrick:\|:\|Employee of Eli Lilly and Company\|\|Li, Xingyuan:\|:\|Employee of Eli Lilly and Company\|\|Arora, Vipin:\|:\|Employee of Eli Lilly and Company\|\|Redondo, Isabel:\|:\|Employee of Eli Lilly and Company\|\|Danese, Silvio:\|:\|Consultant of: AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Enthera, Ferring Pharmaceuticals, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Mundipharma, Mylan, Pfizer, Roche, Sandoz Sublimity, Takeda, TiGenix, UCB Pharma, and Vifor Pharma,\|Speakers bureau of: AbbVie, Amgen, Ferring Pharmaceuticals, Gilead Sciences, Janssen, Mylan, Pfizer, and Takeda |
| P470 | Dr. Abdalla, Solafah: No conflict of interest\|\|Lelievre, Océane: No conflict of interest\|\|Carbonnel, Franck: No conflict of interest\|\|Penna, Christophe: No conflict of interest\|\|Benoist, Stephane: No conflict of interest\|\|Brouquet, Antoine: No conflict of interest |

| | |
|---|---|
| P471 | Johnson, Travis:\|:\|None declared\|\|Reinisch, Walter:\|:\|WR has served as a speaker for Abbott, AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma, Ferring, Immundiagnostik, Medice, Mitsubishi Tanabe, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; served as a consultant for Abbott, AbbVie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, AstraZeneca, Avaxia, Roland Berger, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma, Ferring, Galapagos, Gatehouse Bio, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Landos Biopharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Alimentiv, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; served as an advisory board member for Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC; and has received research funding from Abbott, AbbVie, Aesca, Centocor, Falk Pharma, Immundiagnostik, Janssen, MSD, Sandoz, and Takeda.\|\|Steere, Boyd:\|:\|Employee and minor shareholder of Eli Lilly and Company\|\|Milch, Catherine:\|:\|former employee of Eli Lilly and Company (affiliation at time of study) \|\|Harris, Cynthia:\|:\|employee and minor shareholder of Eli Lilly and Company\|\|Morris, Nathan:\|:\|employee and minor shareholder of Eli Lilly and Company\|\|D'Haens, Geert:\|:\|G. D'Haens has received consulting and/or lecture fees from AbbVie, Alimentiv, Boehringer Ingelheim, BMS, Celltrion, Cytoki, Eli Lilly, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Immunic, Index Pharmaceuticals, Janssen Biologics, Nextbiotics, Pfizer, Polpharma, Prometheus Biosciences, Prometheus Diagnostics, Tillotts Pharma, Versant\|\|Huang, Kun:\|:\|None declared\|\|Krishnan, Venkatesh:\|:\|employee and minor shareholder of Eli Lilly and Company |
| | |

| | |
|---|---|
| P472 | Ms. Karpavičiūtė, Vita: No conflict of interest\|\|Kiudelis, Gediminas: No conflict of interest\|\|Kupčinskas, Juozas: No conflict of interest\|\|Kupčinskas, Limas: No conflict of interest |
| P473 | D'Haens, Geert:\|:\|GDH reports consultancy activities for AbbVie, Agomab, Alimentiv, AstraZeneca, AMT, Bristol Meyers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Galapagos, Index Pharmaceuticals, Kaleido, GlaxoSmithKline, Gossamerbio, Pfizer, Immunic, Johnson & Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist; speaker's bureau for AbbVie, Galapagos, Pfizer, BMS, and Takeda; and data monitoring board activities for Galapagos, AbbVie, Astrazeneca, and Seres Health.\|\|Afzali, Anita:\|:\|AA reports consulting fees from AbbVie, Bristol Myers Squibb/Celgene, DiaSorin, Eli Lilly, Gilead, Janssen, Pfizer, Takeda, and TLL Pharmaceuticals; speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; served on advisory boards for AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Pfizer, and Takeda; has received research/education support from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and co-founded IBD Horizons. \|\|Filip, Rafal:\|:\|RF reports lecture fees from Janssen, Takeda, and Zentiva; research/education support from Egis, Janssen, and Takeda; and consulting fees from Boxer.\|\|Rolim, Alexander:\|:\|AR has served on an advisory board for Janssen and reports lecture fees from AbbVie, Janssen, and Takeda.\|\|Terry, Natalie A.:\|:\|NT is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stock/stock options in Johnson & Johnson. \|\|Salese, Leonardo:\|:\|LS is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stock/stock options in Johnson & Johnson. \|\|Sahoo, Aparna:\|:\|AS is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stock/stock options in Johnson & Johnson. \|\|Frustaci, Mary Ellen:\|:\|MEF is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stock/stock options in Johnson & Johnson. \|\|Yang, Zijiang:\|:\|ZY is an employee of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and owns stock/stock options in Johnson & Johnson. \|\|Andrews, Jane M.:\|:\|JMA reports research support, speaker's fees, and/or honoraria to her institution or the Crohn's Colitis Cure for advisory board participation and coordination of educational events from AbbVie, Allergan, Anatara, Atmo Capsule, Bayer, Bristol Myers Squibb (2020), Celgene, Celltrion, Falk, Ferring Fresenius Kabi, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Organon, Pfizer, RAH research Fund, Sandoz, Shire, Takeda, Vifor, The Hospital Research Fund (2020-2022), and The Helmsley Trust (2020-2023).\|\|Danese, Silvio:\|:\|SD reports consulting fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion Healthcare, Eli Lilly, Enthera, Ferring Pharmaceuticals, Gilead Sciences, Hospira, Inc., Janssen, Johnson & Johnson Health Care Systems, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, |

| | |
|---|---|
| | TiGenix, UCB, and Vifor International; and lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals, Gilead Sciences, Janssen, Mylan, Pfizer, and Takeda. \|\|Hisamatsu, Tadakazu:\|:\|TH reports grant support from AbbVie, Daiichi-Sankyo, EA Pharma Co, Ltd., JIMRO, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer, Inc., Takeda Pharmaceutical Co., Ltd.; consulting fees from EA Pharma Co, Ltd. and Janssen Research & Development, LLC; and lecture fees from AbbVie, EA Pharma Co, Ltd., Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Co., Ltd. |
| P474 | Ms. Reijntjes, Maud: No conflict of interest\|\|Heuthorst, Lianne: No conflict of interest\|\|Stellingwerf, Merle: No conflict of interest\|\|d'Haens, Geert R:\|:\|GD has served as advisor for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Meiers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, DrFALK Pharma, enGene, Galapagos, Gilead, Glaxo Smith Kline, Hospira, Immunic, Johnson and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novo Nordisk, Pfizer, Prometheus laboratories/Nestle, Protagonist, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor and received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts and Vifor. \|\|Bemelman, Willem A:\|:\|WB Speaker fees: Takeda, Johnson & Johnson, Medtronic, Braun Grant: VIFOR, Braun. \|\|Buskens, Christianne J:\|:\|CB received an unrestricted grant from Boehringer Ingelheim and Roche, and honoraria or speaker fees from Abbvie, Tillotts, Takeda and Janssen. |
| P475 | Dr. Majumder, Snehali: No conflict of interest\|\|Melanie , Love: No conflict of interest\|\|Joanne , Davis: No conflict of interest\|\|Naveen, Sharma: No conflict of interest\|\|Quraishi, Mohammed Nabil: No conflict of interest\|\|Cooney, Rachel: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Iacucci, Marietta: No conflict of interest\|\|N Shivaji, Uday: No conflict of interest |

| | |
|---|---|
| P476 | Vermeire, Séverine:\|:\|Received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma.\|\|Yarur, Andres:\|:\|Received consulting fees from Takeda, Prometheus Labs, Arena Pharmaceuticals, and Bristol Myers Squibb; and speakers bureau fees from Bristol Myers Squibb.\|\|Rubin, David T.:\|:\|Received grant support from Takeda; has served as a consultant for AbbVie, Abgenomics, Allergan Inc., Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc.\|\|Dubinsky, Marla C.:\|:\|Received consulting fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; and is founder and a shareholder of Trellus Health.\|\|Regueiro, Miguel:\|:\|Received research support from AbbVie, Janssen, and Takeda; has received unrestricted educational grants from AbbVie, Janssen, Pfizer Inc, Salix, Shire, Takeda, and UCB; and has participated in advisory boards for and been a consultant for AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Miraca Labs, Pfizer Inc, Salix, Takeda, and UCB.\|\|Irving, Peter:\|:\|Rreports grants and personal fees from Takeda, MSD, Pfizer, Galapagos, Gilead, AbbVie, Janssen, Boehringer Ingelheim, Topivert, VH2, Celgene, Arena, Samsung Bioepis, Sandoz, Procise, and Prometheus.\|\|Peyrin-Biroulet, Laurent:\|:\|Received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillotts, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, and ONO Pharma; and is a stockholder of CTMA.\|\|Goetsch, Martina:\|:\|Is an employee of Pfizer Inc. \|\|Gu, Guibao:\|:\|Is an employee of Pfizer Inc. \|\|Wu, Joseph:\|:\|Is an employee and shareholder of Pfizer Inc.\|\|Modesto, Irene:\|:\|Is an employee of Pfizer Inc.\|\|McDonnell, Aoibhinn:\|:\|Is an employee of Pfizer, Inc. \|\|Dr. Rabbat, Christopher J.:\|:\|Is an employee of Pfizer Inc. \|\|Green, Jesse:\|:\|Is an employee of Pfizer Inc.\|\|Anthopoulos, Prodromos:\|:\|Was an employee of Arena Pharmaceuticals at the time of this analysis, which was acquired by Pfizer in March 2022, and is a shareholder of Pfizer Inc. |
| | |
| P477 | Dr. Bossa, Fabrizio: No conflict of interest\|\|Carparelli, Sonia: No conflict of interest\|\|Guerra, Maria: No conflict of interest\|\|Cocomazzi, Francesco: No conflict of interest\|\|Martino, Giuseppina: No conflict of interest\|\|Annese, Monica: No conflict of interest\|\|Nardella, Marianna: No conflict of interest\|\|Bellucci, Nicola: No conflict of interest\|\|Gagliardi, Roberta: No conflict of interest\|\|Terracciano, Fulvia: No conflict of interest\|\|Pacilli, Luigi: No conflict of interest\|\|Perri, Francesco: No conflict of interest |

| | |
|---|---|
| P478 | Ms. Jiao, Jiao: No conflict of interest\|\|Liu, Wentian: No conflict of interest\|\|Wang, Bangmao: No conflict of interest\|\|Cao, Hailong: No conflict of interest |
| P479 | Dr. Solitano, Virginia: No conflict of interest\|\|Schaeffer, David F.:\|:\|DFS has received consulting and speaker fees from Alimentiv Inc, Satisfai health Inc, Amgen, Astellas, Diaceutics, Pfizer, Merck and NEED Inc.\|\|Hogan, Malcolm:\|:\|MH is an employee of Alimentiv Inc.\|\|Pai, Rish K.:\|:\|RiKP has received consulting fees from Alimentiv Inc, Allergan, Eli Lillu, and AbbVie.\|\|Zou, Guangyong:\|:\|GZ has received consulting fees from Alimentiv Inc.\|\|Pai, Reet K.: No conflict of interest\|\|Vande Casteele, Niels:\|:\|NVC received research grant from R-Biopharm; and personal fees from AcelaBio, Alimentiv, Pfizer, ProciseDX, and Ventyx.\|\|Parker, Claire E.:\|:\| CEP is an employee of Alimentiv Inc.\|\|Remillard, Julie:\|:\|JR is an employee of Alimentiv Inc.\|\|Christensen, Britt:\|:\|BC has served as a consultant or received speaker's fees from AbbVie, Bristol Myers Squibb, Celltrion Healthcare, Ferring, Fresenius Kabi, Gilead, Janssen, Pfizer, Sandozz and Takeda.\|\|Panaccione, Remo:\|:\|RP has received consulting and speaker fees from Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, and UCB.\|\|Sands, Bruce E.:\|:\|BES has served as a consultant or received speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio, and stock options from Ventyx Biosciences.\|\|D'Haens, Geert:\|:\|GDH has served as a consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, |

| | |
|---|---|
| | Ventyx Biosciences.\|\|Feagan, Brian G.:\|:\|BGF has received grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., Elan/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix, and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor Inc., Elan/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novonordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma Inc., and Sigmoid Pharma; and speaker's fees from UCB, AbbVie, and J&J/Janssen.\|\|Ma, Christopher:\|:\|CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Takeda, Pendopharm, and Pfizer; royalties from Springer Publishing; research support from Ferring, Pfizer.\|\|Jairath, Vipul:\|:\|VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc., Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker's fees from, Abbvie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi. |
| P480 | Dr. Lim, Chong Teik: No conflict of interest\|\|Tay, Shu Wen: No conflict of interest\|\|Lim, Gek Hsiang: No conflict of interest\|\|Salazar, Ennaliza: No conflict of interest\|\|Ong, Wan Chee: No conflict of interest\|\|Chan, Webber Pak Wo: No conflict of interest\|\|Tan, Malcolm Teck Kiang: No conflict of interest |
| P481 | Dr. Tan, Zhi: No conflict of interest\|\|Chin, Andrew: No conflict of interest\|\|Welman, Christopher J.: No conflict of interest\|\|Thin, Lena W.Y.: No conflict of interest |

| | |
|---|---|
| P482 | Ms. Harston, Elenya: No conflict of interest |
| P483 | Dr. Kumar, Lakshman: No conflict of interest\|\|O'Morain, Neil: No conflict of interest\|\|Sheridan, Juliette: No conflict of interest\|\|Coe, Carolann: No conflict of interest\|\|Egan, Ciara: No conflict of interest\|\|Jones, Fiona: No conflict of interest\|\|Cullen, Garret: No conflict of interest\|\|Doran, Peter: No conflict of interest\|\|Leyden, Jan: No conflict of interest\|\|Galligan, Marie: No conflict of interest\|\|McCarthy, Jane: No conflict of interest\|\|O'Toole, Aoibhlinn: No conflict of interest\|\|Kevans, David: No conflict of interest\|\|Egan, Laurence: No conflict of interest\|\|Doherty, Glen:\|:\|GD has served on advisory boards and as a speaker for AbbVie, MSD, Pfizer, Janssen, Takeda, Shire, Tillotts, Falk, Amgen, Mylan, Celltrion, Gilead/Galapagos and received educational grants from AbbVie, MSD, Pfizer, Janssen, Takeda, Tillotts, Dr. Falk, Amgen, Genuity (Genomics Medicine Ireland), Gilead. |
| P484 | Ms. Yap, Jia: No conflict of interest\|\|Wall, Catherine: No conflict of interest\|\|Meredith-Jones, Kim: No conflict of interest\|\|Iosua, Ella: No conflict of interest\|\|Osborne, Hamish: No conflict of interest\|\|Schultz, Michael: No conflict of interest |
| P485 | Dr. Saunders, Jayne: No conflict of interest\|\|Maroo, Siddharth: No conflict of interest\|\|Brownson, Emily: No conflict of interest\|\|Boulton Jones, Robert: No conflict of interest |

| | |
|---|---|
| P486 | Mr. Van Der Storm, Sebastiaan: No conflict of interest\|\|Jansen, Marilou: No conflict of interest\|\|Marsman, Hendrik A.: No conflict of interest\|\|Molly, Glaresa P.: No conflict of interest\|\|Consten, Esther CJ: No conflict of interest\|\|Groot, Linda M.: No conflict of interest\|\|Boer, Frank C.: No conflict of interest\|\|Corver, Maaike: No conflict of interest\|\|Oosterling, Steven J.: No conflict of interest\|\|Tuynman, Juriaan B.: No conflict of interest\|\|Bemelman, Willem A.: No conflict of interest\|\|Buskens, Christianne J.: No conflict of interest\|\|Schijven, Marlies P.: No conflict of interest |
| P487 | Nu, Khin Phwe: No conflict of interest\|\|Stamp, Katie: No conflict of interest\|\|Shaji, Sebastian: No conflict of interest |
| P488 | Dr. Caballol Oliva, Berta: No conflict of interest\|\|Fernàndez-Clotet, Agnès:\|:\|Has served as a speaker, or has received education funding from Dr.Falk, Janssen, Takeda, Chiesi and Pfizer. \|\|Panés, Julià:\|:\|Has received research grants from AbbVie and Pfizer; speaker's fees from AbbVie, Ferring, Janssen, Merck, Pfizer, Shire, Takeda, and Theravance; and has been a consultant for AbbVie, Arena, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GlaxoSmithKline, GoodGut, Janssen, Merck, Nestlé, Origo, Pandion, Pfizer, Progenity, Robarts Clinical Trials, Roche, Takeda, Theravance, and Wassermann\|\|Masamunt, Maria Carme: No conflict of interest\|\|Gallego, Marta: No conflict of interest\|\|Barastegui, Rebeca: No conflict of interest\|\|Vara, Alejandro: No conflict of interest\|\|Giner, Àngel: No conflict of interest\|\|Ricart, Elena:\|:\|Has received financial support for travelling and educational activities from or has served as an advisory board member or speaker for Pfizer, MSD, Takeda, Abbvie, Kern, Janssen, Fresenius Kabi, Ferring, Chiesi, Galapagos and Adacyte\|\|Ordás, Ingrid:\|:\|Has served as speaker and/or consultant for MSD, Abbvie, Pfizer, Takeda, Janssen, Faes Farma and Chiesi, and has received research funding from Abbvie and Faes Farma |
| P489 | Prof. Iesalnieks, Igors: No conflict of interest\|\|Adamou, Adamos: No conflict of interest\|\|Magdalena, Bercher: No conflict of interest |

| | |
|---|---|
| P490 | Vermeire, Séverine:\|:\|Received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma.\|\|Peyrin-Biroulet, Laurent:\|:\|Received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillotts, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, and ONO Pharma; and is a stockholder of CTMA.\|\|Panés, Julian:\|:\|Received consulting fees from AbbVie, Arena Pharmaceuticals, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GSK, Janssen, Mirum, Morphic, Nestle, Origo, Pandion, Progenity, Pfizer, Revolo, Robarts, Roche, Takeda, Theravance, and Wassermann; speaker fees from AbbVie, Biogen, Ferring, Janssen, Pfizer, and Takeda; and research funding from AbbVie and Pfizer.\|\|Regueiro, Miguel:\|:\|Receives research support from AbbVie, Janssen, Takeda, and Pfizer; unrestricted educational grants from AbbVie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, and Gilead; acted as a consultant for AbbVie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., CME Companies: CME Outfitters, Imedex, GI Health Foundation [GiHF], Cornerstones, Remedy, MJH life sciences; and royalties from Wolters.\|\|Kotze, Paulo G.:\|:\|Reports personal fees from AbbVie, Janssen, Pfizer, and Takeda, and research grants from Pfizer and Takeda.\|\|Charabaty, Aline: No conflict of interest\|\|Goetsch, Martina:\|:\|Employee of Pfizer, Inc.\|\|Shan, Kevin:\|:\|Employee of Pfizer, Inc. \|\|Wu, Joseph:\|:\|Employee and shareholder of Pfizer, Inc.\|\|McDonnell, Aoibhinn:\|:\|Employee of Pfizer, Inc.\|\|Mr. Woolcott, John:\|:\|Employee of Pfizer, Inc.\|\|Danese, Silvio:\|:\|Received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor; and reports payment for expert testimony from AbbVie, Amgen, Ferring Pharmaceuticals Inc, Gilead, Janssen, Mylan, Pfizer, and Takeda. |
| | |

| | |
|---|---|
| P491 | Colombel, Jean-Frédéric:\|:\|JFC has received research grants from AbbVie, Janssen, and Takeda; payment for lectures from AbbVie, Amgen, Ferring, Shire, and Takeda; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enterome, Ferring, Genentech, Janssen, Medimmune, Merck, Novartis, Pfizer, Protagonist Therapeutics, Sandoz, Second Genome, Seres Therapeutics, Shire, Takeda, Theradiag, and Theravance; and holds stock options in Genfit and Intestinal Biotech Development.\|\|Irving, Peter:\|:\|PI has received lecture fees from AbbVie, Bristol Myers Squibb, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, Merck, Janssen, Pfizer, Takeda, Tillotts, Sandoz, Shire, Sapphire Medical, and Warner Chilcott; financial support for research from Celltrion, Merck, Pfizer, and Takeda; advisory fees from AbbVie, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Genentech, Gilead, Hospira, Janssen, Merck, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, and Warner Chilcott.\|\|Rieder, Florian:\|:\|FR has received consultancy honoraria from AbbVie, Agomab, Allergan, Boehringer Ingelheim, Celgene, Cowen, Falk Pharma, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Janssen, Koutif, Mestag, Metacrine, Morphic, Origo, Pfizer, Pliant, Prometheus, Receptos, RedX, Roche, Samsung, Takeda, Techlab, Theravance, Thetis, UCB, and 89Bio; and received research funding from Boehringer Ingelheim, Bristol Myers Squibb, the Crohn's and Colitis Foundation, Helmsley Charitable Trust, Morphic, National Institute of Health, Pliant, Rainin Foundation, and UCB.\|\|Panaccione, Remo:\|:\|RP has received consultancy and/or speaking honoraria from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, GlaxoSmithKline, JAMP Pharma, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Takeda, Theravance, Trellus, UCB, and Viatris.\|\|Schwartz, David:\|:\|DS has served as a consultant for AbbVie, Gilead, Janssen, Pfizer, Takeda, and UCB; is a member of the Data Safety Monitoring Board for Tract; and has received grant support from UCB.\|\|Hayashi, Ryohei:\|:\|RH has received lecture fees from AbbVie, Bristol Myers Squibb, EA Pharma, Eiken Chemical, Janssen, JIMRO, Kyorin, Mitsubishi Tanabe Pharma Corporation, Ono, Sandoz, and Takeda.\|\|Zhu, Xuan: No conflict of interest\|\|Lacerda, Ana P:\|:\|APL is a full-time employee of AbbVie, and may hold AbbVie stock or stock options.\|\|Dubcenco, Elena:\|:\|ED is a full-time employee of AbbVie, and may hold AbbVie stock or stock options.\|\|Marced, Elena:\|:\|EM is a full-time employee of AbbVie, and may hold AbbVie stock or stock options.\|\|Hecht, Patrick:\|:\|PH is a full-time employee of AbbVie, and may hold AbbVie stock or stock options.\|\|Feng, Tian:\|:\|TF is a full-time employee of |

| | |
|---|---|
| | AbbVie, and may hold AbbVie stock or stock options.\|\|Berg, Sofie:\|:\|SB is a full-time employee of AbbVie, and may hold AbbVie stock or stock options.\|\|Reinisch, Walter:\|:\|WR has served as a speaker for AbbVie, Aptalis, Astellas, Celltrion, Danone, Elan, Falk Pharma, Ferring, Immundiagnostik, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; as a consultant for AbbVie, Agomab, Algernon, AltruBio, AM Pharma, Amgen, AMT, AOP Orphan, Arena, Astellas, AstraZeneca, Avaxia, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma, Ferring, Fresenius Kabi, Galapagos, Gatehouse Bio Inc., Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Landos Biopharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestlé, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pfizer, Pharmacosmos, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Roland Berger GmBH, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; as an advisory board member for AbbVie, Aesca, AM Pharma, Amgen, Astellas, AstraZeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Celltrion, Danone, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestlé, Novartis, Ocera, Otsuka, PDL, Pfizer, Pharmacosmos, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC; and has received research funding from AbbVie, Janssen, MSD, Sandoz, and Takeda. |

| | |
|---|---|
| P492 | Sands, Bruce E:\|:\|Consultant/ Speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio\|Stock options from Ventyx Biosciences\|\|Hanauer, Stephen B.:\|:\|Consultancy for AbbVie, Allergan, Amgen, Arena, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos, Catalys Pacific, Covance, Genentech, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, Takeda, TLL, UCB, VHsquared\|Clinical Research for AbbVie, Allergan, Amgen, Celgene, Genentech, GSK, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB, VHsquared\|Speaker for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, Takeda\|Independent Data Monitoring Conference for Arena, Boehringer Ingelheim, Bristol Myers Squibb, Gossamer, Prometheus, Protagonist\|\|Colombel, Jean-Frederic:\|:\|Receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda\|Receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda\|Receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor\|Hold stock options in Intestinal Biotech Development\|\|Sandborn, William:\|:\|Consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv, Beigene, Biora (Progenity), Celltrion, Forbion, Genentech, Gossamer Biosciences, Index Pharmaceuticals, Prometheus Biosciences, Protagonist Therapeutics, Shoreline Biosciences, Vedanta Biosciences, Ventyx Biosciences, Zealand Pharma\|Stock or stock options from BeiGene, Gossamer Bio, Biora (Progenity), Prometheus Biosciences, Prometheus Laboratories, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences\|Employee at Shoreline Biosciences and Ventyx Biosciences.\|\|Schreiber, Stefan:\|:\|Consultancy and personal fees from AbbVie, Arena, BMS, |

| | |
|---|---|
| | Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, and Theravance\|\|Danese, Silvio:\|:\|Consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor\|Lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda\|\|Klopocka, Maria: No conflict of interest\|\|Kulynych, Roman: No conflict of interest\|\|Kierkus, Jaroslaw: No conflict of interest\|\|Soltysiak, Artur: No conflict of interest\|\|Smolinski, Patryk: No conflict of interest\|\|Gonciarz, Maciej: No conflict of interest\|\|Sreckovic, Slobodan: No conflict of interest\|\|Valuyskikh, Ekaterina: No conflict of interest\|\|Horynski, Marek: No conflict of interest\|\|Gasbarrini, Antonio:\|:\|Consulting: Abbvie, Alfasigma, Gilead, Lion Health, Malesci, MSD, Pileje, Roche, Sanofi, Sinovac, Takeda\|\|Kim, Sunghyun:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Bae, Yunju:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Lee, Sunhee:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Mr. Lee, Joon Ho:\|:\|Employee of Celltrion\|Celltrion share holder\|\|Lee, Jimin:\|:\|Employee of Celltrion\|\|Lee, Sang Joon:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Lee, Seul Gi:\|:\|Employee of Celltrion,\|Celltrion share holder\|\|Kim, Jong Min:\|:\|Employee of Celltrion,\|Celltrion share holder |

| | |
|---|---|
| P493 | Peyrin-Biroulet, Laurent:\|:\|Personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, Lilly, MSD, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Tillots and Vifor; grants from AbbVie, MSD and Takeda; stock options from CTMA.\|\|Rubin, David:\|:\|Research funding from Takeda, and has served as a consultant to AbbVie, Altrubio, Allergan, Inc., Arena Pharmaceuticals, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, GalenPharma/Atlantica, Genentech/Roche, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Eli Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, Techlab, Inc and is a co-founder of Cornerstones Health, Inc.\|\|Lichtenstein, Gary:\|:\|Relationships with Abbvie (Consultant), Allergan (Consultant), American College of Gastroenterology (Honorarium for Associate Editor of American Journal of Gastroenterology), American Gastroenterological Association (CME), American Regent (Consultant, Honorarium [CME Program]), Celgene (Research, Consultant), Chemed (CME), Eli Lilly (Consultant, Data Safety Monitoring Board), Endo Pharmaceuticals (Consultant), Ferring (Consultant), Gastroenterology and Hepatology (Gastro-Hep Communication, Editor-Honorarium), Gilead (Consultant), IMEDEX (CME), Ironwood (CME), Janssen/ Janssen Orthobiotech (Consultant, Research, Funding to University of PA [IBD Fellow Education]), MedEd Consultants (Consultant), Merck (Consulting, Honorarium [CME Program]), Morphic Therapeutics (Consultant), Pfizer Pharmaceuticals (Consultant, Funding to University of PA [IBD Fellow Education]), Professional Communications, Inc. (Royalty for writing Textbook), Prometheus Laboratories, Inc (Consultant), Romark (Consultant, Honorarium for CME), Sandoz (Consultant), Salix Pharmaceuticals/Valeant (Consultant), Shire Pharmaceuticals (Consultant), SLACK, Inc (Book Royalty), Springer Science and Business Media (Editor [Honorarium]), Takeda (Consultant, Funding to University of PA [IBD Fellow Education], Research), University of Kentucky (CME), UCB (Consultant, Research), Up-To-Date (Author [Honorarium]), Vindico (CME), and Virgo (Consultant [Stock options]).\|\|Shipitofsky, Nicole:\|:\|Employee of Johnson & Johnson and owns company stock/stock options.\|\|Huang, Kuan-Hsiang:\|:\|Employee of Johnson & Johnson and owns company stock/stock options.\|\|Germinaro, Matthew:\|:\|Employee of Johnson & Johnson and owns company stock/stock options.\|\|Wilson, Rebbecca:\|:\|Employee of Johnson & Johnson and owns company stock/stock options.\|\|Zhang, Hongyan:\|:\|Employee of Johnson & Johnson and owns company stock/stock options.\|\|DuVall, G. Aaron:\|:\|Clinical investigator and consultant for Janssen |

| | |
|---|---|
| | Research & Development, LLC.\|\|Cao, Qian:\|:\|Clinical investigator and consultant for Janssen Research & Development, LLC.\|\|Allegretti, Jessica:\|:\|Consultant for Finch Therapeutics, Artugen, Pfizer, Takeda, Janssen, and Iterative Scopes and receives research support from Merck. Consultant and speaker for BMS.\|\|Feagan, Brian:\|:\|Grant/research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc. / Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, UCB; a consultant for Abbott/AbbVie, AdMIRx Inc., Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Asta Pharma, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, Galen/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc., Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Rebiotix, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Zyngenia; a member of the speakers bureau for Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, UCB Pharma; a member of the scientific advisory board for Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, UCB Pharma; and Senior Scientific Officer – Robarts Clinical Trials Inc.\|\|Hisamatsu, Tadakazu:\|:\|Grant support from AbbVie, Daiichi-Sankyo, EA Pharma Co, Ltd. JIMRO, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmacuetical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Co., Ltd., consulting fees from EA Pharma Co, Ltd., Janssen Research & Development, LLC., and lecture fees from AbbVie, EA Pharma Co, Ltd, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd.\|\|Panés, Julián:\|:\|Grants from Abbvie and Pfizer; consulting fees/honorarium from Abbvie, Arena, Athos, Boehringer Ingelheim, Celgene, Celltrion, Genentech - Roche, GSK, Janssen, Mirum, Morphic, Origo, Pandion, Pfizer, Progenity, Revolo, Takeda, Theravance and Wassermann, TiGenix, Arena, Neste, Pfizer and Progenity; support for travel to meetings from Abbvie and Takeda. |

| | |
|---|---|
| | Redhill, Arena, Reata, Pfizer and Progenity; support for travel to meetings from Abbvie and Takeda, during the conduct of the study; payment for lectures including service on speakers bureaus from Abbott, Takeda, Janssen and Pfizer; payment for development of educational presentations from Abbott, Roche, Pfizer and Janssen.\|\|Dignass, Axel:\|:\|Research support and investigator for AbbVie, Dr. Falk Pharma, Celgene/ BMS, Gilead, Janssen, Biogen and Takeda; consultant for AbbVie, Amgen, Celgene/ BMS, Boehringer Ingelheim, Biogen, Dr Falk Pharma, Ferring, Fresenius Kabi, Celltrion, Sandoz/ Hexal, Lilly, Janssen, MSD, Pfizer, Roche, Takeda, Tillotts, and Vifor; and speaker bureaus for AbbVie, Falk Foundation, Ferring, Janssen, Med Update, Streamed-Up, MSD, Pfizer, Galapagos, Roche, Takeda, Tillotts, and Vifor.\|\|Bressler, Brian:\|:\|Advisor/speaker for Abbvie, BMS, Ferring, Janssen, Merck, Novartis, Organon, Pfizer, Sandoz, Takeda; advisor for Alimentiv, Allergan, AMT, Bausch Health, BMS, Celgene, Celltrion Healthcare, Eupraxia, Fresenius Kabi, Genentech, Gilead, Iterative Scopes, Jamp Pharma, Merck Amgen, Microbiome Insights, Mylan, Pendopharm, Protagonist, Viatris; received research support from Abbvie, Amgen, BI, BMS, Genentech, GSK, Janssen, Merck, Qu Biologic; and reports stock options for Qu Biologic.\|\|Sands, Bruce:\|:\|Research grants from Takeda, Pfizer, Theravance Biopharma R&D, Janssen; consulting fees from 4D Pharma, Abivax, Abbvie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella Bioscience, Celgene, Celltrion Healthcare, ClostraBio, Enthera, F.Hoffmann-La Roche, Ferring, Galapagos, Gilead, Glaxo SmithKline, GossamerBio, Immunic, Index Pharmaceuticals, Innovation Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Shire, Sienna Biopharmaceuticals, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio, Vivante Health, Vivelix Pharmaceuticals; and stock for Vivante Health and Ventyx Biosciences. |
| P494 | Abdelmoula, Alia: No conflict of interest\|\|Chateau, Thomas:\|:\|Personal Fees: Abbvie, MSD, Takeda.\|\|Hupe, Marianne:\|:\|Personal Fees: Abbvie, Janssen\|\|Boschetti, Gilles:\|:\|Personal Fees\| Consulting: Abbvie, MSD, Galapagos, Pfizer, Takeda, Sanofi, Celltrion, Janssen\|\|Roblin, Xavier:\|:\|Personal Fees: Janssen\|\| \|\|Nancey, Stephane:\|:\|Personal Fees: Janssen\|\|Mathieu, Nicolas:\|:\|Personal fees: Abbvie, Amgen, Biogen, Celltrion, Ferring, Galapagos, Janssen, MSD Pfizer, Sandoz, Takeda, Viatris, , |

| | |
|---|---|
| P495 | Mr. Hanzel, Jurij:\|:\|speaker's fees from Abbvie, Janssen, and Takeda; consulting fees from Alimentiv Inc\|\|Baert, Filip:\|:\|grants/research supports from AbbVie, Amgen, Takeda, Janssen, honoraria or consultation fees from AbbVie, Amgen, Arena, MSD, Celgene, Kabi-Fresenius, Takeda, Ferring, Pfizer, Norgine, Janssen and participation in a company sponsored speaker's bureau for AbbVie, MSD, Takeda, Ferring, Pfizer, Janssen.\|\|Löwenberg, Mark:\|:\|served as speaker and/or principal investigator for Abbvie, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico and has received research grants from AbbVie, Merck Sharp & Dohme, Achmea healthcare and ZonMW\|\|Ferrante, Marc:\|:\| research support from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; speaker's fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda and Truvion Healthcare consultancy fees from AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and Thermo Fisher\|\|Bossuyt, Peter:\|:\|research grants from Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda; Lecture fees from AbbVie, Celltrion, Janssen, Lilly and Takeda; Lecture fee; and consulting fees Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros\|\|Hoentjen, Frank:\|:\|served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Pfizer, Celltrion, Teva, Sandoz and Dr Falk, and has received funding (Grants/Honoraria) from Janssen-Cilag, Abbvie and Takeda.\|\|Franchimont, Denis:\|:\|received educational grants from AbbVie, Takeda, MSD, and Janssen; and has received honoraria fees for lectures or consultancy from Ferring, Falk, Chiesi, AbbVie, MSD, Centocor, Pfizer, Amgen, Janssen, Mundipharma, Takeda, and Hospira\|\|Palatka, Károly: No conflict of interest\|\|Peeters, Harald:\|:\|scientific grants, advisory board, lecture or travel fees from Abbvie, Janssen, Takeda, Pfizer, Ferring, MSD, Fresenius Kabi, Johnson & Johnson, Sandoz\|\|Mookhoek, Aart: No conflict of interest\|\|de Hertogh, Gert: No conflict of interest\|\|Clasquin, Esmé: No conflict of interest\|\|Vermeire, Séverine:\|:\|received grant support from Merck Sharp & Dohme, AbbVie, Pfizer, Johnson and Johnson and Takeda, speaker fees from AbbVie, Merck Sharp & Dohme, Ferring Pharmaceuticals, Takeda, Hospira and consultancy fees from AbbVie, Takeda, Pfizer, Ferring Pharmaceuticals, Shire, Merck Sharp & Dohme, Hospira, Mundipharma, Celgene, Galapagos, Genentech/Roche\|\|D'Haens, Geert:\|:\|received consultancy fees from AbbVie, Ablynx, Allergan, AlphaBiomics, Amakem, Amgen, AM-Pharma, Arena Pharmaceuticals, Biogen, Bristol Meiers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Echo Pharmaceuticals, Eli Lilly, EnGene, Ferring, Dr. FALK Pharma, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamer Bio, Pfizer, Immunic, Johnson and Johnson, Kintai Therapeutics, Millennium /Takeda, Medtronic, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Nextbiotics, Novo Nordisk, Otsuka, Pfizer/Hospira, Photopill, ProDigest, Prometheus Laboratories/Nestle, Progenity, Protagonist, RedHill, Robarts Clinical Trials, Samsungbioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Takeda, Teva, TiGenix, Tillotts, TopiVert, Versant, and Vifor |

| | |
|---|---|
| P496 | Dr. Rosiou, Konstantina: No conflict of interest\|\|Broglio, Giacomo: No conflict of interest\|\|Lever, Gillian: No conflict of interest\|\|Chiu, Chun Ming: No conflict of interest\|\|Stocker, Linden J: No conflict of interest\|\|Chipeta, Hlupekile: No conflict of interest\|\|Glanville, Tracey: No conflict of interest\|\|Selinger, Christian P:\|:\|CPS has received unrestricted research grants from Warner Chilcott, Janssen and AbbVie, has provided consultancy to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Galapagos, Ferring, Arena and Janssen, and had speaker arrangements with Warner Chilcott, Dr Falk, AbbVie, MSD, Pfizer, Celltrion and Takeda. |
| P497 | Ms. Husnoo, Nilofer: No conflict of interest\|\|Gana, Tabitha: No conflict of interest\|\|Hague, Adam G: No conflict of interest\|\|Khan, Zarnigar: No conflict of interest\|\|Morgan, Jenna L: No conflict of interest\|\|Wyld, Lynda: No conflict of interest\|\|Brown, Steven Ross: No conflict of interest |
| P498 | Mr. Young, David: No conflict of interest\|\|Booker, Cheryl: No conflict of interest\|\|Samaan, Mark:\|:\|Advisory fees: Janssen, Takeda, Sandoz, Samsung Bioepis, Galapagos, AbbVie, Bristol-Myers Squibb, Pfizer\|Lecture fees: Bristol-Myers Squibb, Janssen, Takeda, MSD, Falk, AbbVie, Galapagos\|\|Limdi, Jimmy:\|:\|Speaker and consultancy fees from : Abbvie, Arena, Bristol-Myers Squibb, Celltrion, Ferring, Galapagos, Janssen, MSD, Pfizer and Takeda. \|Research grants from Galapagos, Takeda\|\|Kok, Klaartje: No conflict of interest\|\|Donovan, Fiona:\|:\|I have been a speaker in the past for Dr Falk, Janssen, AbbVie, Takeda, and have written articles for an App Takeda were funding during Covid-19. I have been on Advisory Boards for Dr Falk and Galapagos.\|\|Hart, Ailsa:\|:\|Professor Hart has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Galapogos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech.\|\|Smith, Melissa: No conflict of interest\|\|Bodger, Keith: No conflict of interest\|\|Batchelor, James: No conflict of interest\|\|Cummings, Fraser:\|:\|FC has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Celltrion, Falk, Ferring, Gilead, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Sandoz, Biogen, Samsung, Tillotts; and Takeda; he has received research funding from Biogen, Amgen, Hospira/Pfizer, Celltrion, Takeda, Janssen, GSK, and AstraZeneca. |

| | |
|---|---|
| P499 | Dr. Chu, Matthew: No conflict of interest\|\|Day, Alice: No conflict of interest\|\|Mathias, Ryan: No conflict of interest\|\|Direen, Tennealle: No conflict of interest\|\|Broad, Lani: No conflict of interest\|\|Lynch, Kate: No conflict of interest\|\|Bryant, Robert: No conflict of interest |
| P500 | Dr. Iborra Colomino, Marisa Isabel: No conflict of interest\|\|Ferreiro-Iglesias, Rocío: No conflict of interest\|\|Martín-Arranz, María Dolores: No conflict of interest\|\|Mesonero-Gismero, Francisco: No conflict of interest\|\|Mínguez, Alejandro: No conflict of interest\|\|Porto Silva, Sol: No conflict of interest\|\|García-Ramírez, Laura: No conflict of interest\|\|García de la Filia, Irene: No conflict of interest\|\|Bastida, Guillermo: No conflict of interest\|\|Nieto García, Laura: No conflict of interest\|\|Suárez Ferrer, Cristina: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Barreiro de Acosta, Manuel: No conflict of interest\|\|Nos, Pilar: No conflict of interest |
| P501 | Prof. Dr. Ochsenkuehn, Thomas: No conflict of interest\|\|Tillack-Schreiber, Cornelia: No conflict of interest\|\|Bader, Franz: No conflict of interest\|\|Maximilian, Sohn: No conflict of interest\|\|Szokodi, Daniel: No conflict of interest\|\|Tomelden, June: No conflict of interest\|\|Waggershauser, Constanze: No conflict of interest\|\|Braun, Isabel: No conflict of interest\|\|Schnitzler, Fabian: No conflict of interest |
| P502 | Dr. Nguyen, Anke: No conflict of interest\|\|Gibson, Peter: No conflict of interest\|\|Upton , Richard: No conflict of interest\|\|Mould, Diane: No conflict of interest\|\|Sparrow, Miles P.: No conflict of interest |

| | |
|---|---|
| P503 | Mr. Rezazadeh Ardabili, Ashkan: No conflict of interest\|\|van Esser, Dirk: No conflict of interest\|\|Wintjens, Dion: No conflict of interest\|\|Cilissen, Mia: No conflict of interest\|\|Deben, Debbie: No conflict of interest\|\|Mujagic, Zlatan:\|:\|ZM reports grants form MLDS, Niels Stensen Fellowship and Galapagos, and has served as speaker for Galapagos, and advisor for Johnson and Johnson, all outside the submitted work.\|\|Russ, Fritzi: No conflict of interest\|\|Stassen, Laurents:\|:\|LS reports participation in another research project partly funded by an investigator- initiated grant from Takeda and has served as speaker for Takeda, both outside the submitted work.\|\|van Bodegraven, Ad:\|:\|AvB has served as speaker, adviser and/or principal investigator for AbbVie, Arandal, Arena, Celgene, Ferring, Galapagos, Janssen, MSD, Pfizer, Roche, Takeda, TEVA, and received research grants from Pfizer, TEVA, Eurostars funding, ZonMW, all outside the submitted work\|\|Wong, Dennis: No conflict of interest\|\|Winkens, Bjorn: No conflict of interest\|\|Jonkers, Daisy:\|:\|DJ reports grants from Top Knowledge Institute (Well on Wheat), grants from Horizon 2020 DISCOvERIE, grants from NWO-CCC Partnership program (Carbokinetics), all outside the submitted work\|\|Romberg-Camps, Mariëlle: No conflict of interest\|\|Pierik, Marieke:\|:\|MP reports grants and non-financial support from Falk Pharma, grants from European commission, grants from ZONMW (Dutch national research fund), grants and non-financial support from Takeda, grants and non-financial support from Johnson and Johnson, grants and non-financial support from Abbvie, non-financial support from Ferring, non-financial support from Immunodiagnostics, non-financial support from MSD, all outside the submitted work |

| | |
|---|---|
| P504 | Atreya, Raja:\|:\|RA served as a paid or unpaid consultant for or received honoraria from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr. Falk Pharma, Ferring, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Janssen, Kliniksa Pharmaceuticals, Merk Sharp & Dohme, Novartis, Pfizer, Roche, Samsung Bioepsis, Stelic, Sterna Biologicals, Takeda, and Tillotts.\|\|Abreu, Maria T.:\|:\|M. Abreu has received grant support and/or consulting fees from Prometheus Bioscience, Takeda, Pfizer, Janssen, Focus Medical Communications, Boehringer Ingelheim, Gilead, Imedex, Cornerstone Health, Landos Biophama, UCB, Eli Lilly, Bristol Myers Squibb, Arena Pharmaceuticals, and Cosmo Pharmaceuticals.\|\|Krueger, James G.:\|:\|JGK served as a consultant for, received honoraria from, and/or received institutional grant support from AbbVie, Allergan, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Eli Lilly, Nimbus Lackshmi, Novartis, Pfizer, and UCB; served as a consultant for and/or received honoraria from Aclaris, Almirall, Arena, Aristea, Asana, Aurigene, Escalier, Galapagos, MoonLake Immunotherapeutics, Sanofi, Sienna Biopharmaceuticals, Sun Pharma, Target-Derm, Valeant, and Ventyx; and received institutional grant support from Akros, Avillion, Exicure, Incyte, Innovaderm, Kyowa Kirin, Novan, Parexel, Regeneron, and Vitae Pharmaceuticals.\|\|Eyerich, Kilian:\|:\|KE received speaker fees from and/or served on an advisory board for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Hexal, LEO Pharma, Eli Lilly, Janssen, Pfizer, Novartis, Sanofi, and UCB.\|\|Sachen, Kacey:\|:\|KS is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Greving, Carrie:\|:\|CG is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Hammaker, Deepa:\|:\|DH is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Bao, Phuc:\|:\|PB is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Lacy, Eilyn:\|:\|EL is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Sarabia, Indra:\|:\|IS is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Deming, Janise:\|:\|JD is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Elloso, M. Merle:\|:\|ME is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Ritchlin, Christopher:\|:\|CR received grant/research support and/or consulting fees from UCB, AbbVie, Amgen, Lilly, Pfizer, Novartis, Gilead, and Janssen.\|\|McInnes, Iain B.:\|:\|IBM received consultant fees from and/or grant research support from Compugen, AstraZeneca, Bristol Myers Squibb, Amgen, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Roche, UCB, AbbVie, Cabaletta, Gilead, Pfizer, and Sanofi; is a shareholder and/or sits on a board of directors for Compugen, Evelo, and Causeway Therapeutics; serves as a board member for National Health Service Greater Glasgow and Clyde; and is a trustee for Versus Arthritis.\|\|Allez, Matthieu:\|:\|M. Allez has received consulting and/or lecture fees and grant support from Janssen, Takeda, and Genentech/Roche; consulting and/or lecture fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, IQVIA, Novartis, Pfizer, and Tillotts.\|\|Fourie, Anne:\|:\|AF is an employee of Janssen and may hold stock in Johnson & Johnson. |

| | |
|---|---|
| P505 | Dr. Mocci, Giammarco: No conflict of interest\|\|Maconi , Giovanni: No conflict of interest\|\|Onidi, Francesca Maria: No conflict of interest\|\|Cataletti, Giovanni: No conflict of interest\|\|Elisei , Walter: No conflict of interest\|\|Scaldaferri, Franco: No conflict of interest\|\|Lorenzetti , Roberto: No conflict of interest\|\|Pagnini, Cristiano: No conflict of interest\|\|Scarcelli, Antonella: No conflict of interest\|\|Graziani , Maria Giovanna: No conflict of interest\|\|Di Paolo , Maria Carla: No conflict of interest\|\|Pranzo, Giuseppe: No conflict of interest\|\|Luppino, Ileana: No conflict of interest\|\|Monterubbianesi, Rita: No conflict of interest\|\|Faggiani, Roberto: No conflict of interest\|\|Ferronato, Antonio: No conflict of interest\|\|Savarino, Edoardo: No conflict of interest\|\|Pica, Roberta: No conflict of interest\|\|Cocco, Andrea: No conflict of interest\|\|Rodino, Stefano: No conflict of interest\|\|Sebkova, Ladislava: No conflict of interest\|\|Zampaletta, Costantino: No conflict of interest\|\|Gaiani, Federica: No conflict of interest\|\|Fanigliulo, Libera: No conflict of interest\|\|Allegretta , Leonardo: No conflict of interest\|\|Cuomo, Antonio: No conflict of interest\|\|Donnarumma, Laura: No conflict of interest\|\|Della Valle , Nicola: No conflict of interest\|\|Forti, Giacomo: No conflict of interest\|\|Antonelli, Elisabetta: No conflict of interest\|\|Bassotti , Gabrio: No conflict of interest\|\|Iannelli, Chiara: No conflict of interest\|\|Aragona, Giovanni: No conflict of interest\|\|Lauria, Angelo: No conflict of interest\|\|Piergallini, Simona: No conflict of interest\|\|Colucci, Raffaele: No conflict of interest\|\|Binaghi, Laura: No conflict of interest\|\|Meucci, Costantino: No conflict of interest\|\|Papa, Alfredo: No conflict of interest\|\|Tursi, Antonio: No conflict of interest |

| | |
|---|---|
| P506 | Siegmund, Britta:\|:\|BS has served as a consultant for AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Falk, Galapagos, Janssen, Lilly, Pfizer, PredictImmune, and Takeda; and served as a speaker for AbbVie, Bristol-Myers Squibb, Celgene, Falk, Ferring, Janssen, Pfizer, and Takeda.\|\|Patel, Kamal:\|:\|KP has received personal fees and non-financial support from AbbVie, Janssen, and Takeda, personal fees from Falk, and non-financial support from Ferring.\|\|Torres, Esther A:\|:\|EAT has received institutional research grants from AbbVie, Bristol-Myers Squibb, and Tigenix, as well as an educational grant from Takeda.\|\|Lakatos, Péter L:\|:\|PLL has received consulting fees or lecture support from AbbVie, Celgene, Celltrion, Ferring, MSD, Pfizer, Roche, and Takeda, and unrestricted research support from AbbVie, Gilead, Pfizer, and Takeda.\|\|Seidelin, Jakob:\|:\|JS has received research grants from the Capital Region Denmark and Takeda, and is the national coordinator of studies from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, and Lilly.\|\|Fleisher, Mark: No conflict of interest\|\|Ford, Sharanya:\|:\|SF is an employee or contractor of AbbVie and may own AbbVie stock or options.\|\|Remple, Valencia:\|:\|VR is an employee or contractor of AbbVie and may own AbbVie stock or options.\|\|Lacerda, Ana P:\|:\|APL is an employee or contractor of AbbVie and may own AbbVie stock or options.\|\|Anyanwu, Samuel:\|:\|SA is an employee or contractor of AbbVie and may own AbbVie stock or options.\|\|Garrison, Andrew:\|:\|AG is an employee or contractor of AbbVie and may own AbbVie stock or options.\|\|Panés, Julian:\|:\|JP has received financial support for research from AbbVie and Pfizer; consultancy fees/honoraria from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance, and Wasserman; payment for lectures including service on speaker bureau from Abbott, Ferring, Janssen, Pfizer, and Takeda; and payment for development of educational presentations from Abbott, Janssen, Pfizer, Roche, and Takeda. |

| | |
|---|---|
| P507 | Travis, Simon:\|:\|Grants: Ferring, Abbvie, Schering-Plough, MSD, Procter & Gamble, Warner Chilcott, International Organisation of IBD, ECCO, UCB, Vifor, Normal Collison Foundation, Buhlmann, Takeda, Janssen, Pfizer, and Lilly.\|\|\|Bleakman, Alison:\|:\|Employee and stockholder of Eli Lilly and Company. \|\|Dubinsky, Marla:\|:\|Consulting: Eli Lilly and Company; Advisory board: Eli Lilly and Company\|\|Rubin, David:\|:\|Consulting: Abbvie, Alimentiv Inc., Altrubio, Arena Pharmaceuticals, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, ClostraBio, Connect BioPharma, EcoR1, Genentech/Roche, Gilead Sciences, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Seres Therapeutics, Takeda, Target RWE, Techlab Inc., and Trellus Health; Leadership role: Crohn's & Colitis Foundation Board of Trustees, Cornerstones Health Board of Trustees; Stockholder: Altrubio, Alike, Iterative Scopes; Patent: GoDuRn\|\|\|Panaccione, Remo:\|:\|Consultant: Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda Pharmaceuticals, Theravance Biopharma, Trellus, Viatris, UCB\|Speaker's Fees: AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Merck, Organon, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals\|Advisory Boards: AbbVie, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, SandozShire, Sublimity Therapeutics, Takeda Pharmaceuticals\|\|\|Hibi, Toshifumi:\|:\|Grants: AbbVie GK, JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical, Zeria Pharmaceutical, kyorin, Otuska Holdings, MIYARISAN Pharmaceutical, Alfresa Pharma Corporation. Advisory/Consultancy fees: Apo Puls Station, Abbvie GK, Bristol-Myaers Squibb, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi-Tanabe Pharma, Nichi-Iko Pharmaceutical, Pfizer, Takeda Pharmaceutical, Zeria Pharmaceutical; Lecture fees: Sondoz K.K., Abbvie GK, GileadSciences, Janssen, Mitsubishi-TanabePharma, Mochida Pharmaceutical, Pfizer, Takeda Pharmaceutical, Zeria Pharmaceutical, EA Pharma, kyorin, JIMRO\|\|\|\|\|Kayhan, Cem:\|:\|Employees and stockholder of Eli Lilly and Company. \|\|Gibble, Theresa Hunter:\|:\|Employee and stockholder of Eli Lilly |

| | |
|---|---|
| | and Company. \|\|Sapin, Christophe:\|:\|Employees and stockholder of Eli Lilly and Company. \|\|Flynn, Eoin:\|:\|Employee and stockholder of Eli Lilly and Company. \|\|Atkinson, Christian: No conflict of interest\|\|Schreiber, Stefan:\|:\|Consulting fees: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, Theravance; Payment/honoraria for lecture/presentation/writing assistance: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, Theravance; Travel support: AbbVie, Lilly, Janssen |
| P508 | Dr. Simpson, Kate: No conflict of interest\|\|Inniss, Saskia: No conflict of interest\|\|Fragkos, Konstantinos C: No conflict of interest\|\|Wood, Christopher P J: No conflict of interest\|\|Smith, Andrew: No conflict of interest\|\|Rahman, Farooq Z: No conflict of interest |
| P509 | Mr. Jenkinson, Philip: No conflict of interest\|\|Plevris, Nik: No conflict of interest\|\|Lyons, Mathew: No conflict of interest\|\|Gros Alcalde, Beatriz: No conflict of interest\|\|Derikx, Lauranne: No conflict of interest\|\|Constantine-Cooke, Nathan: No conflict of interest\|\|Arnott, Ian: No conflict of interest\|\|Jones, Gareth: No conflict of interest\|\|Lees, Charlie: No conflict of interest |

| | |
|---|---|
| P510 | Dr. Matos Coelho Bernardo, Sónia: No conflict of interest\|\|Fernandes, Samuel: No conflict of interest\|\|Serrazina, Juliana: No conflict of interest\|\|Rodrigues, Inês: No conflict of interest\|\|Botto, Inês: No conflict of interest\|\|Bronze, Sérgio: No conflict of interest\|\|Gonçalves, Ana Rita: No conflict of interest\|\|Valente, Ana: No conflict of interest\|\|Santos, Paula Moura dos: No conflict of interest\|\|Tato Marinho, Rui: No conflict of interest\|\|Correia, Luis: No conflict of interest |
| P511 | Ms. Allen, Kezia: No conflict of interest\|\|Munuswamy, Pushpakaran: No conflict of interest |
| P512 | Dr. Kiyohara, Hiroki:\|:\|Hiroki Kiyohara received reseach grant from Mitsubishi Tanabe Pharma.\|\|Yamazaki, Hajime: No conflict of interest\|\|Moriya, Kei: No conflict of interest\|\|Akimoto, Naohiko: No conflict of interest\|\|Kawai, Shoichiro: No conflict of interest\|\|Kobayashi, Taku:\|:\|Taku Kobayashi served as a speaker, a consultant or an advisory role for AbbVie, Janssen Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, and received research grants from AbbVie GK, Activaid, Alfresa Pharma, JMDC, Gilead Sciences, Nippon Kayaku, Eli Lilly Japan, Mochida Pharmaceutical, Janssen Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical, Bristol-Myers Squibb, Google Asia Pacific Pte. Ltd, Mitsubishi Tanabe Pharma, Zeria, and received endowed chairs from Otsuka Holdings, EA Pharma, JIMRO, AbbVie, Zeria, Kyorin, and Mochida Pharmaceutical. |

| | |
|---|---|
| P513 | Dr. Navarro Llavat, Mercedes: No conflict of interest\|\|García-Bosch, Orlando: No conflict of interest\|\|Castro-Poceiro, Jesús: No conflict of interest\|\|Bargalló García, Ana: No conflict of interest\|\|Ruiz Arroyo , Dolores: No conflict of interest\|\|Navas Bravo , Yolanda: No conflict of interest\|\|Erice Muñoz, Eva: No conflict of interest\|\|Barquero Declara, David: No conflict of interest\|\|Mata Bilbao, Alfredo: No conflict of interest\|\|Martín Llahí , Marta: No conflict of interest\|\|Ariza Solé, Xavier: No conflict of interest\|\|Hernández Ballesteros, Carlos: No conflict of interest\|\|Juan Juan , Alba: No conflict of interest\|\|Bustamante Robles, Katherine: No conflict of interest\|\|Berbel Comas, Claudia: No conflict of interest\|\|Blasco Pelicano, Alex: No conflict of interest\|\|Albareda Riera, Mercè: No conflict of interest\|\|Domènech Morral , Eugeni: No conflict of interest |
| P514 | Dr. Hernandez-Camba, Alejandro: No conflict of interest\|\|Rodriguez-Jimenez, Javier: No conflict of interest\|\|Carrillo Palau, Marta: No conflict of interest\|\|Ramos Lopez, Laura: No conflict of interest\|\|Perez-Mendez , Lina: No conflict of interest\|\|Martin-Nuñez , Ernesto: No conflict of interest\|\|Alonso, Inmaculada: No conflict of interest\|\|Vela, Milagros: No conflict of interest\|\|Hernandez Alverez Builla, Noemi: No conflict of interest\|\|Arranz, Laura: No conflict of interest\|\|Hernandez, Anjara: No conflict of interest\|\|Ferraz Amaro, Ivan: No conflict of interest\|\|Navarro-Gonzalez, Juan F.: No conflict of interest |
| P515 | Dr. Hammoudi, Nassim:\|:\|NH received honorarium for consultancy from Janssen and Takeda\|\|Hassid, Deborah: No conflict of interest\|\|Bonnet, Joelle: No conflict of interest\|\|Tran Minh, My-Linh:\|:\|MLTM received honoraria from Abbvie and Janssen. \|\|Baudry, Clotilde: No conflict of interest\|\|Chedouba, Leila: No conflict of interest\|\|Vauthier, Anne: No conflict of interest\|\|Gornet, Jean-Marc:\|:\|JMG has been a speaker and/advisory board member for Abbvie, Amgen, Celltrion, Takeda, Janssen and Sanofi Genzyme. \|\|Allez, Matthieu:\|:\|MA received grant supports from Innate Pharma, Janssen, Takeda, Genentech/Roche, and honoraria for teaching activities or consultancy from Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Genentech, Gilead, IQVIA, Janssen, Novartis, Pfizer, Roche, Takeda, Tillots. |

| | |
|---|---|
| P516 | Caldera, Freddy:\|:\|received research support from Takeda; consulted for Arena Pharmaceuticals, Celgene, GlaxoSmithKline, and Takeda.\|\|Maddux, Rachel:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Ungaro, Ryan:\|:\|advisory board member or consultant for Eli Lilly, Janssen, Pfizer, and Takeda; received research support from AbbVie, Boehringer Ingelheim, and Pfizer.\|\|Kaur, Amandeep:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Brown, Elizabeth:\|:\|employees and/or shareholders of Bristol Myers Squibb\|\|Hu, Sarah:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Sheffield, James K.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Silva, Diego:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Harris, Sarah:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Cree, Bruce A. C.:\|:\|received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics, and Therini Bio; received research support from Genentech. |
| P517 | Ms. Ramos Lopez, Laura: No conflict of interest\|\|Ramos-Díaz, Ruth: No conflict of interest\|\|Alonso-Abreu, Inmaculada: No conflict of interest\|\|Mourani-Padron, Ivette: No conflict of interest\|\|Carrillo-Palau, Marta: No conflict of interest\|\|Reygosa, María Cristina: No conflict of interest\|\|Medina-Chico, Sergio: No conflict of interest\|\|Gutierrez-Nicolas, Fernando: No conflict of interest\|\|Nazco-Casariego, Gloria Julia: No conflict of interest\|\|Hernandez-Guerra, Manuel: No conflict of interest |

| | |
|---|---|
| P518 | Panaccione, Remo:\|:\|Remo Panaccione has received consulting fees, speaker fees and research support from Abbott, AbbVie, Alimentiv (formerly Robarts Clinical Trials), Amgen, Arena Pharmaceuticals, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Élan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Takeda, Theravance and UCB.\|\|Lichtenstein, Gary:\|:\|Gary Lichtenstein has received research support and/or funding from Celgene, Janssen Orthobiotech, Pfizer Inc, Takeda and UCB; consulting fees from AbbVie, American Regent, Cellceutix, Celgene, Eli Lilly, Endo Pharmaceuticals, Ferring Pharmaceuticals, Gilead Sciences, Janssen Orthobiotech, Merck, Morphic Therapeutics, Pfizer Inc., Prometheus Laboratories, Romark, Salix/Valeant, Shire, Takeda and UCB; honoraria from the American College of Gastroenterology, American Regent, Gastroenterology and Hepatology, Merck, Romark, Springer Science and Business Media, and Up-To-Date; and royalties from Professional Communications Inc. and SLACK Inc.\|\|Nakase, Hiroshi:\|:\|Hiroshi Nakase has received support from AbbVie GK, Celgene Corporation, Daiichi Sankyo, EA Pharma, Janssen Pharmaceutical KK, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda and Zeria Pharmaceutical; as well as grants for commissioned/joint research from Boehringer Ingelheim, Bristol Myers Squibb and Hoya Group Pentax Medical.\|\|Armuzzi, Alessandro:\|:\|Alessandro Armuzzi has received consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz and Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda and Tigenix; and research grants from Biogen, MSD, Pfizer and Takeda.\|\|Kucharzik, Torsten:\|:\|Torsten Kucharzik has received consultant fees and speaker honoraria from Abbott, Amgen, Biogen, Celltrion, Falk Pharma, Janssen, MSD, Takeda and UCB.\|\|Levy, Gweneth:\|:\|Gweneth Levy is an employee of AbbVie and may own stock and/or options.\|\|Palac, Hannah:\|:\|Hannah Palac is an employee of AbbVie and may own stock and/or options.\|\|Kujawski, Michelle:\|:\|Michelle Kujawski is an employee of AbbVie and may own stock and/or options.\|\|Klaff, Justin:\|:\|Justin Klaff is an employee of AbbVie and may own stock and/or options.\|\|Cheon, Jae Hee: No conflict of interest |
| P519 | Friedrich, Stuart:\|:\|Employee at time of study\|\|Chua, Laiyi:\|:\|Employee and shareholder\|\|Zhang , Xin Cindy:\|:\|Employee and shareholder |

| | |
|---|---|
| P520 | Prof. Dr. van der Woude, Janneke:\|:\|CJvdW reports research grants from Benelux, Falk, Ferring Pharmaceuticals, Janssen Pharmaceuticals and Pfizer; consultancy fees from Celltrion and Galapagos; and speaker fees from AbbVie and UCB.\|\|Schreiber , Stefan:\|:\|SS reports personal fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos/Gilead, I-Mab, Janssen Pharmaceuticals, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz/Hexal, Takeda, Theravance Biopharma and UCB.\|\|Peyrin-Biroulet , Laurent:\|:\|LP-B reports personal fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, InDex Pharmaceuticals, Inotrem, Janssen Pharmaceuticals, MSD, Mylan, Norgine, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance Biopharma, Thermo Fisher Scientific, Tillotts, Viatris and Vifor; grants from AbbVie, Fresenius Kabi, MSD and Takeda; and stock options from CTMA.\|\|Szekanecz, Zoltan:\|:\|ZS reports speakers fees and consultancy fees from AbbVie, Pfizer, Roche, MSD, Novartis, Lilly and Gedeon Richter.\|\|Choy, Ernest HS:\|:\|EHSC reports research grants from Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi and UCB; consultancy fees from AbbVie, Amgen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Fresenius Kabi, Gilead, Janssen Pharmaceuticals, Merck Serono, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, R-Pharm and Sanofi; and speaker fees from AbbVie, Amgen, Bristol Myer Squibbs, Chugai Pharma, Eli Lilly, Fresenius Kabi, Galapagos, Gilead, Janssen Pharmaceuticals, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, R-Pharm, Sanofi and UCB.\|\|Stiers, Pieter-Jan:\|:\|PJS, TH, KvB, AdH and CR are employees and shareholders of Galapagos NV.\|\|Van Hoek, Paul:\|:\|PVH is a consultant at Galapagos NV.\|\|Van Beneden, Katrien:\|:\|KvB is an employee and shareholder of Galapagos NV.\|\|de Haas, Angela:\|:\|AdH is an employee and shareholder of Galapagos NV.\|\|Rudolph , Christine:\|:\|CR is an employee and shareholder of Galapagos NV.\|\|ten Cate, Hugo:\|:\|HtC reports former research support by Bayer; consultancy fees from Alveron Pharma, AstraZeneca, Galapagos and Viatris; and is a shareholder of Coagulation Profile. All revenues were deposited at the Cardiovascular Research Institute Maastricht (CARIM) School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands. |

| | |
|---|---|
| P521 | Dr. Outtier, An: No conflict of interest\|\|Louis, Edouard:\|:\|Research grant: Janssen, Pfizer, and Takeda; educational grant: AbbVie, Janssen, MSD, and Takeda; speaker fees: AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda; advisory board: AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda, Galapagos, Gilead, Arena, Elli Lilly; consultant: AbbVie\|\|Dewit, Olivier:\|:\|consulting, lectures fees or travel accommodations: Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Galapagos, Janssen, MSD, Mylan, Pfizer and Sandoz.\|\|Schops, Ganel: No conflict of interest\|\|Verstockt, Bram:\|:\|Research support: Pfizer; Speaker's fees: Abbvie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MondayNightIBD, MSD, Pfizer, R-Biopharm, Takeda and Truvion;\|Consultancy fees: Alimentiv, Applied Strategic, Atheneum, Bristol Myers Squibb, Guidepont, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares and Takeda.\|\|Sabino, Joao:\|:\|Research support: Galapagos; Speaker's fees: Abbvie, Falk, Takeda, Janssen, and Fresenius; Consultancy fees: Janssen, Ferring\|\|Vermeire, Séverine:\|:\|Research Support: AbbVie, J&J, Pfizer, Galapagos and Takeda; Consulting and/or speaking fees: AbbVie, Abivax, Agomab, Arena Pharmaceuticals, Avaxia, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, and Tillots Pharma AG.\|\|Ferrante, Marc:\|:\|Research support: AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris;\|Speaker's fees: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda and Truvion Healthcare; Consultancy fees: AbbVie, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Sandoz, Takeda and Thermo Fisher |
| P522 | Prof. Dr. Luglio, Gaetano: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|Tropeano, Francesca Paola: No conflict of interest\|\|Giglio, Mariano Cesare: No conflict of interest\|\|Cricrì, Michele: No conflict of interest\|\|Imperatore, Nicola: No conflict of interest\|\|De Sire, Roberto: No conflict of interest\|\|Guarino, Alessia Dalila: No conflict of interest\|\|Bucci, Luigi: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest\|\|De Palma, Giovanni Domenico: No conflict of interest |

| | |
|---|---|
| P523 | Dr. Cheema, Madiha: No conflict of interest\|\|Narouz, Isaac: No conflict of interest\|\|Pipicella, Joseph: No conflict of interest\|\|Garden , Frances: No conflict of interest\|\|Lynch, Kate: No conflict of interest\|\|Andrews, Jane: No conflict of interest\|\|Ghaly, Simon: No conflict of interest\|\|Connor, Susan: No conflict of interest |
| P524 | Schreiber, Stefan:\|:\|Stefan Schreiber has served as a consultant or advisory board member for AbbVie, Amgen, Arena, Bristol Myers Squibb, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos, Gilead, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz/Hexal, Takeda, Theravance, and UCB; and received lecture fees from HIKMA.\|\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Ben-Horin, Shomron:\|:\|Shomron Ben-Horin has served as a consultant or advisory board member for AbbVie, Celltrion, Falk, Ferring, Galmed, GSK, Janssen, Novartis, Pfizer, and Takeda; and received research support from AbbVie, Celltrion, Galmed, Janssen, Pfizer, and Takeda. \|\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Ye, Byong Duk:\|:\|Byong Duk Ye has received consulting fees from AbbVie Korea, BMS Pharmaceutical Korea Ltd., Celltrion, Chong Kun Dang Pharm, CJ Red BIO, Daewoong Pharma., Ferring Korea, IQVIA, Janssen Korea, Kangstem Biotech, Korea Otsuka Pharm., Korea United Pharm. Inc., Medtronic Korea, NanoEntek, ORGANOIDSCIENCES LTD., Pfizer Korea, Takeda, Takeda Korea; speaker fees from AbbVie Korea, Celltrion, Cornerstones Health, Curacle, Ferring Korea, Janssen Korea, Pfizer Korea, Takeda Korea, and IQVIA; and research support from Celltrion and Pfizer Korea.\|\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Kim, Dong-Hyeon:\|:\|Dong-Hyeon Kim, DVM, PhD, is an employee of Celltrion Healthcare Co., Ltd.\|\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).\|\|Prof. Dr. Reinisch, Walter:\|:\|Walter Reinisch has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Celltrion, Falk Pharma, Ferring, Janssen, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Pfizer, Pharmacosmos, PLS Education, Roche, Shire, Takeda, Therakos, and Vifor; served as a consultant for AbbVie, Algernon, Amgen, Arena Pharmaceuticals, Astellas, AstraZeneca, Bioclinica, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Celgene, Celltrion, Eli Lilly, Ernst & Young, Falk Pharma, Ferring, Fresenius, Galapagos, Gatehouse Bio, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Landos Biopharma, LivaNova, Mallinckrodt, Medahead, MedImmune, Mitsubishi Tanabe |

| | |
|---|---|
| | Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Novartis, OMass, Otsuka, Parexel, Periconsulting, Pfizer, Pharmacosmos, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Roche, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Vifor, and Zealand; received support for attending meetings and/or travel from AbbVie, Janssen, and Takeda; and served on a Data Safety Monitoring Board or advisory board for OSE Pharma.\|\|Funding: This study was supported by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Medical writing support was provided by Julianna Solomons, PhD (Aspire Scientific, Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). |
| P525 | Dr. Taxonera, Carlos:\|:\|CT has served as a speaker, consultant, and advisory board member for MSD, AbbVie, Pfizer, Takeda, Janssen, Galapagos, Fresenius Kabi, Ferring, Faes Farma, Shire Phar-maceuticals, Dr. Falk Pharma, and Tillots. \|\|Olivares, David: No conflict of interest\|\|Olga N, López-García: No conflict of interest\|\|Alba, Cristina:\|:\|CA has served as a speaker for Janssen and has prepared promotional material for Dr. Falk Pharma. |

| | |
|---|---|
| P526 | Mr. Van Linschoten, Reinier: No conflict of interest\|\|Jansen, Fenna: No conflict of interest\|\|Pauwels, Renske: No conflict of interest\|\|Smits, Lisa: No conflict of interest\|\|Atsma, Femke: No conflict of interest\|\|Kievit, Wietske: No conflict of interest\|\|de Jong, Dirk: No conflict of interest\|\|de Vries, Annemarie:\|:\|A. de Vries has participated in advisory boards and/or received financial compensation from Janssen, Takeda, AbbVie, and Tramedico.\|\|Boekema, Paul: No conflict of interest\|\|West, Rachel:\|:\|R. West has participated in advisory board or as speaker for Jansen, Abbvie and Pfizer and research grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, Galapagos and Takeda.\|\|Bodelier, Alexander:\|:\|A. Bodelier has served on advisory boards for Abbvie, Takeda, Janssen, Ferring.\|\|Gisbertz, Ingrid: No conflict of interest\|\|Wolfhagen, Frank: No conflict of interest\|\|Romkens, Tessa:\|:\|T. Römkens has participated in the advisory board for Bristol Meyer Squibb and as speaker for Janssen and Takeda. \|\|Lutgens, Maurice: No conflict of interest\|\|van Bodegraven, Ad:\|:\|A. van Bodegraven has served as speaker, adviser and/or principal investigator for AbbVie, Arandal, ARENA, Celgene, Ferring, Galapagos, Janssen, MSD, Pfizer, Roche, Takeda, TEVA, BMS, and received research grants from TEVA, Eurostars funding, ZonMW, and Pfizer.\|\|Oldenburg, Bas:\|:\|B. Oldenburg has received unrestricted research grants from Galapagos, Pfizer, Celltrion, Ferring and Takeda. He has served on advisory boards from Abbvie, Takeda, Pfizer, BMS, Celltrion, Galapagos, MSD and Ferring.\|\|Pierik, Marieke:\|:\|M. Pierik reports grants and non-financial support from Falk Pharma, grants from European commission, grants from ZonMw (Dutch national research fund), grants and non-financial support from Takeda, grants and non-financial support from Johnson and Johnson, grants and non-financial support from Abbvie, non-financial support from Ferring, non-financial support from Immunodiagnostics, non-financial support from MSD.\|\|Russel, Maurice: No conflict of interest\|\|de Boer, Nanne:\|:\|N. de Boer has served as a speaker for AbbVie and MSD and has served as consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma BV, MLDS and Takeda. \|\|Mallant-Hent, Rosalie: No conflict of interest\|\|ter Borg, Pieter: No conflict of interest\|\|van der Meulen-de Jong, Andrea: No conflict of interest\|\|Jansen, Jeroen: No conflict of interest\|\|Jansen, Sita: No conflict of interest\|\|Tan, Adriaan: No conflict of interest\|\|van der Woude, Christien Janneke:\|:\|C. van der Woude has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. \|\|Hoentjen, Frank:\|:\|F. Hoentjen has served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk. Funding (Grants/Honoraria): Dr Falk, Janssen-Cilag, Abbvie, Takeda. |
| | |

| | |
|---|---|
| P527 | Dr. Tanaka, Akihito: No conflict of interest\|\|Kanmura, Shuji: No conflict of interest\|\|Maeda, Nobuhisa: No conflict of interest\|\|Kuwazuru, Kosuke: No conflict of interest\|\|Komaki, Fukiko: No conflict of interest\|\|Komaki, Yuga: No conflict of interest\|\|Ido, Akio: No conflict of interest |
| P528 | Mrs. Zelinkova, Zuzana:\|:\|- lecture fees from Abbvie, Pfizer, Janssen, Takeda\|\|Podmanicky, Dusan:\|:\|- lecture fees from Takeda\|\|Kadleckova, Barbora:\|:\|- lecture fees from Takeda |
| P529 | Laharie, David:\|:\|Counseling, boards, transports or fees from Abbvie, Biogaran, Biogen, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillotts.\|\|Mrs. Pierron, Gaelle:\|:\|Pfizer employee\|\|Brault, Yves:\|:\|Pfizer employee\|\|Bouhnik, Yoram:\|:\|Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Ferring, Fresenius Kabi, Galapagos, Gilead, Hospira, Iterative Scopes, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Roche, Sandoz, Sanofi, Takeda, Tillotts\|\|Nancey, Stephane:\|:\|Pfizer, Biogen, Abbvie, Janssen, Novartis, Takeda, Amgen |
| P530 | Dr. López-Vico, Manuel: No conflict of interest\|\|Sánchez-Capilla, Antonio Damián: No conflict of interest\|\|Martín-Rodríguez, María del Mar: No conflict of interest\|\|Cabello-Tapia, María José: No conflict of interest\|\|Redondo-Cerezo, Eduardo: No conflict of interest |

| | |
|---|---|
| P531 | Ms. Kantasiripitak, Wannee: No conflict of interest\|\|WIcha, Sebastian G.:\|:\|Sebastian G. Wicha is the developer of the model-informed precision dosing software TDMx. \|\|Thomas, Debby: No conflict of interest\|\|Hoffman , Ilse:\|:\|Ilse Hoffman received financial support for research from Mundipharma Comm. VA, AbbVie, Pfizer, and Takeda. \|\|Ferrante , Marc:\|:\|Marc Ferrante received financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda, and Viatris, speaker fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda, and Truvion Healthcare, and consultancy fees from AbbVie, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Sandoz, Takeda, and Thermo Fisher. \|\|Vermeire , Séverine:\|:\|Séverine Vermeire received financial support for research from AbbVie, Johnson and Johnson, Pfizer, Galapagos, and Takeda, and consultancy and/or speaker fees from AbbVie, Abivax, Agomab, Arena Pharmaceuticals, Avaxia, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, and Tillots Pharma AG. \|\|van Hoeve , Karen:\|:\|Karen van Hoeve received financial support for research from Mundipharma Comm. VA, Celltrion Healthcare Co. \|\|Dreesen, Erwin:\|:\|Erwin Dreesen served as a speaker for Janssen Pharmaceutica and has served as an advisor for Argenx and Alimentiv (all honoraria/fees paid to the University). |
| P532 | Song, Joo Hye: No conflict of interest\|\|Prof. Hong, Sung Noh:\|:\|Speaker and advisory board for Celltrion, Janssen Korea, Takeda Pharmaceutical Korea, and Abbvie Korea\|\|Kim, Eun Ran: No conflict of interest\|\|Kim, Jie En: No conflict of interest\|\|Chang, Dong Kyung: No conflict of interest\|\|Kim, Young-Ho:\|:\|Speaker and advisory board for Celltrion, Janssen Korea, Takeda Pharmaceutical Korea, and Abbvie Korea |
| P533 | Dr. Shimodaira, Yosuke: No conflict of interest\|\|Yoshida, Tatsuki: No conflict of interest\|\|Watanabe, Kenta: No conflict of interest\|\|Takahashi, So: No conflict of interest\|\|Fukuda, Sho: No conflict of interest\|\|Koizumi, Shigeto: No conflict of interest\|\|Matsuhashi, Tamotsu: No conflict of interest\|\|Iijima, Katsunori: No conflict of interest |

| | |
|---|---|
| P534 | Cohen, Shlomi: No conflict of interest\|\|Olbjorn, Christine: No conflict of interest\|\|Kolho, Kaija-Leena: No conflict of interest\|\|Aloi, Marina: No conflict of interest\|\|Musto, Francesca: No conflict of interest\|\|de-Carpi, Javier Martin: No conflict of interest\|\|Lozano-Ruf, Ana: No conflict of interest\|\|Yogev, Dotan: No conflict of interest\|\|Matar, Manar: No conflict of interest\|\|Scarallo, Luca: No conflict of interest\|\|Bramuzzo, Matteo: No conflict of interest\|\|de Ridder, Lissy: No conflict of interest\|\|Kang, Ben: No conflict of interest\|\|Norden, Christoph: No conflict of interest\|\|Wilson, David C.: No conflict of interest\|\|Tzivinikos, Christos: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Dr. Yerushalmy-Feler, Anat: No conflict of interest |
| P535 | Liu, Zhigang: No conflict of interest\|\|Dr. Alexander, James: No conflict of interest\|\|Le, Kaixing: No conflict of interest\|\|Zhou, Xin: No conflict of interest\|\|Ibraheim, Hajir: No conflict of interest\|\|Anandabaskaran, Sulak: No conflict of interest\|\|Saifuddin, Aamir: No conflict of interest\|\|Lin, Kathy: No conflict of interest\|\|Mcfarlane, Leon: No conflict of interest\|\|Anand, Nikhil: No conflict of interest\|\|Constable, Laura: No conflict of interest\|\|Castro-Seoane, Rocio: No conflict of interest\|\|Nice, Rachel: No conflict of interest\|\|Bewshea, Claire: No conflict of interest\|\|D'Mello, Andrea: No conflict of interest\|\|Jones, Gareth R: No conflict of interest\|\|Balarajah, Sharmili: No conflict of interest\|\|Fiorentino, Francesca: No conflict of interest\|\|Sebastian, Shaji: No conflict of interest\|\|Irving, Peter: No conflict of interest\|\|Hicks, Lucy: No conflict of interest\|\|Williams, Horace: No conflict of interest\|\|Kent, Alexandra: No conflict of interest\|\|Linger, Rachel: No conflict of interest\|\|Parkes, Miles: No conflict of interest\|\|Kok, Klaartje: No conflict of interest\|\|Patel, Kamal V: No conflict of interest\|\|Teare, Julian: No conflict of interest\|\|Altmann, Daniel: No conflict of interest\|\|Hart, Ailsa: No conflict of interest\|\|Lees, Charlie: No conflict of interest\|\|Boyton, Rosemary: No conflict of interest\|\|Goodhand, James: No conflict of interest\|\|Kennedy, Nick: No conflict of interest\|\|Pollock, Katrina: No conflict of interest\|\|Ahmad, Tariq: No conflict of interest\|\|Powell, Nick: No conflict of interest |
| P536 | Ms. Ratajczak, Alicja Ewa: No conflict of interest\|\|Michalak, Michał: No conflict of interest\|\|Szymczak-Tomczak, Aleksandra: No conflict of interest\|\|Rychter, Anna Maria: No conflict of interest\|\|Zawada, Agnieszka: No conflict of interest\|\|Skoracka, Kinga: No conflict of interest\|\|Dobrowolska, Agnieszka: No conflict of interest\|\|Krela-Kaźmierczak, Iwona: No conflict of interest |
| P537 | Prof. Dr. Roblin, Xavier: No conflict of interest\|\|Williet, nicolas: No conflict of interest\|\|Faure, Jade: No conflict of interest\|\|Bastide, Laetitia: No conflict of interest\|\|Barrau, Mathilde: No conflict of interest\|\|Paul, Stephane: No conflict of interest |

| | |
|---|---|
| P538 | Dr. De Gregorio, Michael: No conflict of interest\|\|D'Souza, Basil: No conflict of interest\|\|Connell, William: No conflict of interest\|\|Kamm, Michael A: No conflict of interest\|\|Woods, Rodney: No conflict of interest\|\|Connor, Susan J: No conflict of interest\|\|Thompson, Alexander J: No conflict of interest\|\|Ding, Nik S: No conflict of interest |
| P539 | Ms. Schoefs, Elise: No conflict of interest\|\|Vermeire, Séverine: No conflict of interest\|\|Ferrante, Marc: No conflict of interest\|\|Sabino, João: No conflict of interest\|\|Verstockt, Bram: No conflict of interest\|\|Avedano, Luisa: No conflict of interest\|\|De Rocchis, Maria Stella: No conflict of interest\|\|Sajak-Szczerba, Magdalena: No conflict of interest\|\|Saldaña, Roberto: No conflict of interest\|\|Straetemans, Noortje: No conflict of interest\|\|Vandebroek, Martina: No conflict of interest\|\|Huys, Isabelle: No conflict of interest\|\|Janssens, Rosanne: No conflict of interest |
| P540 | Ms. Radford, Shellie: No conflict of interest\|\|Kyriacou, Maro: No conflict of interest\|\|Moran, Gordon: No conflict of interest |

| | |
|---|---|
| P541 | Dr. Guerra Marina, Ivan: No conflict of interest\|\|Barros, Francisco: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|de Francisco, Ruth: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Benítez, José M.: No conflict of interest\|\|Sicilia, Beatriz: No conflict of interest\|\|Martín Arranz, María Dolores: No conflict of interest\|\|de Castro, Luisa: No conflict of interest\|\|Carbajo, Ana Y.: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Calvo, Marta: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|González-Muñoza, Carlos: No conflict of interest\|\|Miguel, Mínguez: No conflict of interest\|\|Alfambra, Erika: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Lucendo, Alfredo J.: No conflict of interest\|\|Tardillo, Carlos A.: No conflict of interest\|\|Almela, Pedro: No conflict of interest\|\|Bujanda, Luis: No conflict of interest\|\|Van Domselaar, Manuel: No conflict of interest\|\|Ramos, Laura: No conflict of interest\|\|Fernández Sánchez, María: No conflict of interest\|\|Hinojosa, Esther: No conflict of interest\|\|Verdejo, Cristina: No conflict of interest\|\|Gimenez, Anna: No conflict of interest\|\|Piqueras, Marta: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Manceñido, Noemí: No conflict of interest\|\|Pérez Calle, José L.: No conflict of interest\|\|Moreno, Mónica del Pilar: No conflict of interest\|\|Delgado, Pedro G.: No conflict of interest\|\|Antolín, Beatriz: No conflict of interest\|\|Ramírez de la Piscina, Patricia: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Carracedo, Ángel: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest |
| P542 | Dr. Cingolani, Linda: No conflict of interest\|\|Barberio, Brigida: No conflict of interest\|\|Zelante, Angelo: No conflict of interest\|\|Ribaldone, Davide: No conflict of interest\|\|Testa, Giulia: No conflict of interest\|\|Bertani, Lorenzo: No conflict of interest\|\|Buda, Andrea: No conflict of interest\|\|Zingone, Fabiana: No conflict of interest\|\|Savarino, Edoardo Vincenzo: No conflict of interest |

| | |
|---|---|
| P543 | Prof. Dr. Baumgart, Daniel C.:\|:\|Within the past five years, Daniel C. Baumgart has served as an expert consultant on external scientific advisory boards, speaker on CME activities and his institutions have received research support from AbbVie, Amgen, Boehringer Ingelheim, Bühlmann AG, CSL Behring, Canon, Ferring, Fresenius, Genentech, Immundiagnostik, Intercept, Merck Serono, Merz, Nestlé, Janssen, Pfizer, Recordati, Roche, Shire, Takeda, All funds were paid to the University of Alberta, Edmonton, Canada or Charité - Universitätsmedizin Berlin. This study was sponsored by Charité - Universitätsmedizin Berlin and supported with an unrestricted research grant from Janssen Cilag GmbH, manufacturer of ustekinumab, to Daniel C. Baumgart. Janssen Cilag GmbH had no role in the design or conduction or interpretation of the results of the study.\|\|Stallmach, Andreas: No conflict of interest\|\|Schubert, Andreas: No conflict of interest\|\|Howaldt, Stefanie: No conflict of interest\|\|von Arnim, Ulrike: No conflict of interest\|\|Ochsenkühn, Thomas: No conflict of interest\|\|Stein, Jürgen: No conflict of interest\|\|Lügering, Andreas: No conflict of interest\|\|Schmidt, Daniel: No conflict of interest\|\|Schulz, Marten: No conflict of interest\|\|Fischer, Andreas: No conflict of interest |
| P544 | Mr. Jessen, Bosse: No conflict of interest\|\|Tóth, Marcell: No conflict of interest\|\|Freise, Inka: No conflict of interest\|\|Staudacher, Jonas: No conflict of interest\|\|Haag, Lea-Maxie: No conflict of interest\|\|Kredel, Lea: No conflict of interest\|\|Schumann, Michael: No conflict of interest\|\|Weidinger, Carl: No conflict of interest\|\|Sonnenberg, Elena: No conflict of interest\|\|Siegmund, Britta: No conflict of interest |
| P545 | Pueschel, Lea: No conflict of interest\|\|Kockelmann, Fabian: No conflict of interest\|\|Kueck, Momme: No conflict of interest\|\|Tegtbur, Uwe: No conflict of interest\|\|Seidler, Ursula: No conflict of interest\|\|Lenzen, Henrike: No conflict of interest\|\|Attaran-Bandarabadi, Masoumeh: No conflict of interest\|\|Bachmann, Oliver: No conflict of interest\|\|Wedemeyer, Heiner: No conflict of interest\|\|Dr. Wiestler, Miriam: No conflict of interest |

| | |
|---|---|
| P546 | Reinisch, Walter:\|:\|Reinisch W: has received support for the following: speaker for Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; consultant for Abbott Laboratories, AbbVie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, AstraZeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trials, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; and advisory board member for Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC.\|\|Panaccione, Remo:\|:\|Panaccione R: has received consulting fees from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, Takeda Pharmaceuticals; speaker fees from AbbVie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals; advisory board member for AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma, Takeda Pharmaceuticals; |

| | |
|---|---|
| | and research/educational support from AbbVie, Ferring, Janssen, Pfizer and Takeda.\|\|Duijvestein, Marjolijn:\|:\|Duijvestein M: Advisory fees from Bristol Myers Squibb, AbbVie, Janssen, Echo Pharma and Robarts Clinical Trials, Inc., speaker fees from BMS, Galapagos, Janssen, Merck & Co., Inc., Pfizer, Takeda and Tillotts Pharma, and nonfinancial support from Dr. Falk Pharm. Chair of the Dutch collaborative research group Initative on Crohn's and Colitis (ICC).\|\|Ceballos Santos, Daniel: No conflict of interest\|\|Melmed, Gil Y.:\|:\|Melmed GY: Consultant for AbbVie, Arena, Boehringer-Ingelheim, Bristol-Myers Squibb, Ferring, Fresenius Kalbi, Genentech, Gilead, Lilly, Janssen, Pfizer, Prometheus Labs, Samsung Bioepis, Takeda, and Techlab.\|\|Xuan, Si:\|:\|Xuan S is an employee of AbbVie and may own stock or options. \|\|Wegrzyn, Lani:\|:\|Wegrzyn L is an employee of AbbVie and may own stock or options. \|\|Levy, Gwen:\|:\|Levy G is an employee of AbbVie and may own stock or options. \|\|Ilo, Dapo:\|:\|Ilo D is an employee of AbbVie and may own stock or options. \|\|Sanchez Gonzalez, Yuri:\|:\|Sanchez Gonzalez Y is an employee of AbbVie and may own stock or options. |
| P547 | Dr. Barnes, Edward: No conflict of interest\|\|Zhang, Xian: No conflict of interest\|\|Long, Millie:\|:\|Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, Target Pharmasolutions and has received research support from Pfizer and Takeda.\|\|Herfarth, Hans:\|:\|Hans H. Herfarth has served as a consultant for Alivio, AMAG, Boehringer, BMS, ExeGi Pharma, Finch, Fresenius Kabi, Gilead, Janssen, Lycera, Merck, Otsuka, Pfizer, PureTech, Seres and research support from Allakos, Artizan Biosciences, Novo Nordisk and Pfizer. \|\|Kappelman, Michael:\|:\|Michael D. Kappelman has served as a consultant for Abbvie, Takeda, Janssen, Pfizer, and Eli Lilly and has received research support from Abbvie and Janssen. |

| | |
|---|---|
| P548 | Atreya, Raja:\|:\|Speaker, or consultant, or received research grants from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellgene, Celltrion Healthcare, DrFalk Pharma, Galapagos, Gilead, InDex Pharmaceuticals, Janssen-Cilag, Lilly, MSD Sharp & Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepis, Takeda Pharma, Viatris\|\|Irving, Peter:\|:\|Grants and personal fees from Janssen, MSD and Takeda, and personal fees from AbbVie, Arena Pharmaceuticals, Dr. Falk Pharma GmbH, Eli Lilly, Ferring Pharmaceuticals, Genentech, Hospira, Pfizer Inc, Pharmacosmos, Samsung Bioepis, Sandoz, Shire, Tillotts Pharma, TopiVert, VHsquared, Vifor Pharma and Warner Chilcott.\|\|Fujiya, Mikihiro:\|:\|Lecture fees from Nippon Kayaku Co, Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., AbbVie GK., JIMRO Co. Ltd., AYUMI Pharmaceutical Corporation, Pfizer Inc., EA Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., ZERIA Pharmaceutical Co. Ltd., and Aspen Japan K.K.; Research grants from MOCHIDA Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Kamui Pharma Inc.; Holds stocks from Kamui Pharma Inc.\|\|Colombel, Jean-Frederic:\|:\|Research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development\|\|Danese, Silvio:\|:\|Speaker, consultant and advisory board member for Schering-Plough, AbbVie, MSD, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson & Johnson, Nikkiso Europe GMBH, and Theravance.\|\|Peyrin-Biroulet, Laurent:\|:\|Personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher. Grants from Abbvie, MSD, Takeda, Fresenius Kabi; has stock options with CTMA.\|\|Bessissow, Talat:\|:\|Speaker or advisory board member for Abbvie, Alimentiv (formerly Robarts), Amgen, Bristol-Myers Squibb, Ferring, Fresenius Kabi, Janssen, Merck,Takeda, Janssen, Abbvie Pendopharm, Merck, Pfizer, Roche Pendopharm, Ferring, Shire, Sandoz, BMS, TakedaRoche, Fresenius Kabi, and Viatris.\|\|Panaccione, Remo:\|:\|Research Grants: |

| | |
|---|---|
| | AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals. Consulting Fees: AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals; Speaker Fees: AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals\|\|D'Haens, Geert:\|:\|Consultant and/or received speaker's fees from AbbVie, Alimentiv, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, Glaxo SmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, Ventyx Biosciences.\|\|van Haaren, Stijn:\|:\|AbbVie employee, holds AbbVie stock\|\|Neimark, Ezequiel:\|:\|AbbVie employee, holds AbbVie stock\|\|Zambrano, Javier:\|:\|AbbVie employee, owns AbbVie stock\|\|Zhang, Yafei:\|:\|AbbVie employee, owns AbbVie stock\|\|Kligys, Kristina:\|:\|AbbVie employee, owns AbbVie stock\|\|Ferrante, Marc:\|:\|Research grants from: AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; Consultancy fees from: AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher; Speakers' fees from: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris |
| P549 | Dr. Dalal, Rahul:\|:\|Grant funding from Pfizer and Janssen, consulting for Centaur Labs.\|\|Sharma, Puza:\|:\|Employed by Pfizer\|\|Bains, Kanwal: No conflict of interest\|\|Pruce, Jordan: No conflict of interest\|\|Allegretti, Jessica:\|:\|Consultant for Abbvie, Janssen, Pfizer, Pandion, Servatus, Finch Therapeutics, Iterative Scopes, BMS, Merck, Summit, Artizan, and Artugen and has grant support from Merck, Pfizer and Janssen |

| | |
|---|---|
| P550 | Taxonera, Carlos:\|:\|Personal fees (honoraria for advisory board participation, speaker fees, and/or research support): AbbVie, Dr Falk Pharma, Faes Farma, Ferring, Fresenius Kabi, Galapagos, Janssen, MSD, Pfizer Inc, Shire Pharmaceuticals, Takeda, Tillots \|\|Ha, Christina:\|:\|Grants: Pfizer Inc; Personal fees (advisory board): AbbVie, BMS, Genentech, InDex Pharmaceuticals, Pfizer, Takeda.\|\|del Pilar Fortes, Maria:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Gardiner, Sean:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Mundayat, Rajiv:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Ghosh, Subrata:\|:\|Personal fees (steering committee): AbbVie, BMS, Janssen; Personal fees (drug monitoring committee): Janssen; Personal fees (advisory board): AbbVie, BMS, Ferring, Galapagos, Gilead, Janssen, Pfizer Inc, Takeda Personal fees (speaker): AbbVie, Eli Lilly, Janssen, Pfizer Inc, Takeda \|\|Connor, Susan J:\|:\|Personal fees (honoraria for advisory board participation, speaker fees, educational support and/or research support): AbbVie, Agency for Clinical Innovation, BMS, Celltrion, Chiesi, Dr Falk Pharma, Eli Lilly, Ferring, Fresenius Kabi, Gastroenterological Society of Australia, Gilead, GlaxoSmithKline, Immunic, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer Inc, Progenity, Revolo, Takeda, Janssen, Medical Research Future Fund, MSD, Novartis, Organon, Pfizer Inc, Sandoz, Takeda, The Leona M and Harry B Helmsley Charitable Trust |
| P551 | Dr. Macedo Silva, Vítor: No conflict of interest\|\|Ferreira, Ana Isabel: No conflict of interest\|\|Lima Capela, Tiago: No conflict of interest\|\|Arieira, Cátia: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Boal Carvalho, Pedro: No conflict of interest\|\|Dias de Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest |
| P552 | Cohen, Yaron: No conflict of interest\|\|Fischman, Maya: No conflict of interest\|\|Waterman, Matti: No conflict of interest\|\|Dolnikov, Katya: No conflict of interest\|\|Azzam, Zaher S.: No conflict of interest\|\|Dr. Ghersin, Itai: No conflict of interest |

| | |
|---|---|
| P553 | Ghosh, Subrata:\|:\|Served as a member of the steering committees of Janssen, AbbVie, Boehringer Ingelheim, Gilead, Celgene, BMS; has received speaker honorarium from AbbVie, Takeda, Janssen, Ferring, Pfizer, and Celltrion; and served on advisory committees of Janssen, Takeda, AbbVie, Eli Lilly, Roche, Pfizer, and Gilead.\|\|Long, Millie:\|:\|Served as a consultant for Pfizer, AbbVie, Janssen, Takeda, UCB, BMS, Gilead, Genentech, Roche, Theravance, Prometheus, Salix, Valeant, Target Pharmasolutions, Calibr, Bristol-Myers Squibb, and Eli Lilly; and received grant support from Pfizer and Takeda.\|\|Ott, Elyssa:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Gasink, Christopher:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Baker, Thomas:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Godwin, Bridget:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Miao, Ye:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Loftus, Edward:\|:\|Reports consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Calibr, Celgene, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Sun Pharma, Surrozen, Takeda, and UCB; and research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. |

| | |
|---|---|
| P554 | D'Haens, Geert:\|:\|Geert D'Haens reports being an advisor for AbbVie, Alimentiv , AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly and Company, Ferring, Galapagos, GlaxoSmithKline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Takeda, Nextbiotics, Pfizer, Progenity, Prometheus Laboratories/Prometheus Biosciences, Protagonist, Tillotts\|\|Higgins, Peter D.R.:\|:\|PDRH has received grants from AbbVie, Connectome Coordination Facility, National Institute of Health, and Takeda; and has served as a consultant for Eli Lilly, Takeda, Pfizer, Vindico Medical Education, Imedex, and GI Health Foundation\|\|Peyrin-Biroulet, Laurent:\|:\|Laurent Peyrin-Biroulet reports grants/contracts from Abbvie, MSD, Takeda, Fresenius Kabi and consulting fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung, Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, Alimentiv, ONO Pharma\|\|Sands, Bruce E.:\|:\|Bruce E. Sands discloses fees from: Abivax: consulting, speaking; Amgen: consulting; Arena Pharmaceuticals: consulting; Artugen Therapeutics: consulting; AstraZeneca: consulting; Bacainn Therapeutics: consulting; Boehringer-Ingelheim: consulting; Boston Pharmaceuticals: consulting; Bristol Myers Squibb: consulting, speaking; Calibr: consulting; Celltrion Healthcare: consulting; ClostraBio: consulting; Entera: consulting; Evommune: consulting; Galapagos: consulting; Genentech: consulting; Gilead Sciences: consulting; GlaxoSmithKline: consulting; Gossamer Bio: consulting; Index Pharmaceuticals: consulting; Inotrem: consulting; Innovation Therapeutics: consulting; Ironwood Pharmaceuticals: consulting; Janssen: consulting, speaking, grant/research support; Kaleido: consulting; Kallyope: consulting; Lilly: consulting; Miro Bio: consulting; Morphic Therapeutics: consulting; MRM Health: consulting; Pfizer: consulting, speaking; Progenity: consulting; Prometheus Biosciences: consulting; Protagonist Therapeutics: consulting; Q32 Bio: consulting; Surrozen: consulting; Takeda: consulting, speaking; Teva: consulting; TLL Pharmaceutical: consulting; USWM Enterprises: consulting; VielaBio: consulting\|\|Lee, Scott:\|:\|Scott Lee reports grants or contracts and consulting fees from: Janssen, Eli Lilly, BMS, Abbvie, BI, AMT, Protagonist\|\|Moses, Richard E.:\|:\|Richard E Moses is a Lilly employee and stockholder\|\|Redondo, Isabel:\|:\|Isabel Redondo is an Ei Lilly employee and stockholder.\|\|Escobar, Rodrigo:\|:\|Rodrigo Escobar is an Eli Lilly employee and stockholder.\|\|Morris, Nathan:\|:\|Nathan Morris is an Eli Lilly employee and stockholder.\|\|Kobayashi, Taku:\|:\|Taku Kobayashi reports grants or contracts, payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events, payment for expert testimony and participation on a Data Safety Monitoring Board or Advisory Board for: Abbie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc, Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., \|Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Holdings, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Google Asia Pacific Pte.Ltd. Thermo Fisher Diagnostics K.K, Galapagos, Bristol Myers Squibb and Eli Lilly. |

| | |
|---|---|
| P555 | Grimsdottir, Sigrun: No conflict of interest\|\|Dr. Attauabi, Mohamed: No conflict of interest\|\|Dahl, Emilie Kristine:\|:\|Research grants from Takeda, paid speaker by MSD, Tillotts. \|\|Burisch, Johan:\|:\|Personal fees from AbbVie, Janssen-Cilag, Celgene, Samsung Bioepis, and Pfizer; grants and personal fees from Takeda, MSD, and Tillots Pharma; grants from Novo Nordisk Foundation and Bristol Meyers Squibb. None of these pertain to the research submitted here. \|\|Seidelin, Jakob Benedict:\|:\|Research grants from Takeda and the Capital Region Denmark, national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here. |
| P556 | Dr. Musto, Francesca: No conflict of interest\|\|Distante, Manuela: No conflict of interest\|\|Dei Rossi, Eleonora: No conflict of interest\|\|Calicchia, Annalisa: No conflict of interest\|\|Veraldi, Silvio: No conflict of interest\|\|Mondi', Filippo: No conflict of interest\|\|Tarani, Francesca: No conflict of interest\|\|D'Arcangelo, Giulia: No conflict of interest\|\|Aloi, Marina: No conflict of interest |
| P557 | Mr. Jenkinson, Philip: No conflict of interest\|\|Plevris, Nik: No conflict of interest\|\|Gros Alcalde, Beatriz: No conflict of interest\|\|Lyons, Mathew: No conflict of interest\|\|Derikx, Lauranne: No conflict of interest\|\|Constantine-Cooke, Nathan: No conflict of interest\|\|Arnott, Ian: No conflict of interest\|\|Jones, Gareth: No conflict of interest\|\|Lees, Charlie: No conflict of interest |

| | |
|---|---|
| P558 | Regueiro, Miguel:\|:\|M. Regueiro receives research support from AbbVie, Janssen, Takeda, and Pfizer; unrestricted educational grants from AbbVie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, and Gilead; acted as a consultant for AbbVie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., CME Companies: CME Outfitters, Imedex, GI Health Foundation [GiHF], Cornerstones, Remedy, MJH life sciences; and royalties from Wolters.\|\|Siegmund, Britta:\|:\|B. Sigmund served as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Falk, Janssen, Lilly, Pfizer, Prometheus and Takeda; and received speaker's fees from AbbVie, CED Service GmbH, Falk, Ferring, Janssen, Novartis and Takeda (served as representative of the Charité).\|\|Yarur, Andres:\|:\|A. Yarur received consulting fees from Takeda, Prometheus Labs, Arena Pharmaceuticals, and Bristol Myers Squibb; and speakers bureau fees from Bristol Myers Squibb.\|\|Steinwurz, Flavio:\|:\|F. Steinwurz has served as an advisory board member for Pfizer and has received consulting and speaker fees from AbbVie, Eurofarma, Ferring Pharmaceuticals, Janssen, Sandoz, Takeda, and UCB.\|\|Gecse, Krisztina B.:\|:\|K.B. Gecse has received grants from Pfizer Inc, Celltrion, and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda; and speaker's honoraria from AbbVie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts.\|\|Goetsch, Martina:\|:\|M. Goetsch is an employee of Pfizer.\|\|Bhattacharjee, Abhishek:\|:\|A. Bhattacharjee is an employee of Pfizer.\|\|Wu, Joseph:\|:\|J. Wu is an employee and shareholder of Pfizer Inc.\|\|Green, Jesse:\|:\|J. Green is an employee and shareholder of Pfizer Inc.\|\|McDonnell, Aoibhinn:\|:\|A. McDonnell is an employee of Pfizer.\|\|Crosby, Catherine:\|:\|C. Crosby is an employee of Pfizer Inc.\|\|Lazin, Krisztina:\|:\|K. Lazin is an employee of Pfizer.\|\|Dr. Ferreira Branquinho, Diogo: No conflict of interest\|\|Modesto, Irene:\|:\|I. Modesto is an employee of Pfizer Inc.\|\|Abreu, Maria T.:\|:\|M.T. Abreu has served as a scientific advisory board member for Boehringer Ingelheim Pharmaceuticals, Gilead, AbbVie, Seres Therapeutics, Shire, and Landos Biopharma; served as a trainer or lecturer for Imedex, Focus Medical Communications, and Cornerstones Health, Inc.; has served as a consultant for Ferring Pharmaceuticals, Allergan, Amgen, Celltrion Healthcare CO, Millennium Pharmaceuticals, Theravance Biopharma Inc., and UCB Biopharma SRL; and has funded projects by Prometheus Laboratories and Pfizer. |
| P559 | Rossier, Laura: No conflict of interest\|\|Seibold, Frank: No conflict of interest |

| | |
|---|---|
| P560 | Prof. Ben-Horin, Shomron:\|:\|Advisory board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, and Eli Lilly, and research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, & Galmed. The Sheba Medical Center has filed intellectual property on the combination of curcumin and QD. EviNature is a spin-off company of Sheba center, Shomron Ben-Horin receives consulting fees and hold equity in EviNature\|\|Salomon, Nir:\|:\|Speaking fees from Janssen. The Sheba Medical Center has filed intellectual property on the combination of curcumin and QD. EviNature is a spin-off company of Sheba center, Nir Salomon is a consultant of and holds equity in EviNature\|\|Karampekos, Georgios: No conflict of interest\|\|Viazis, Nikos:\|:\|Advisory boards fees and/or have received grants from Abbvie, MSD, Janssen, TAKEDA, Pfizer, AMGEN, VIANEX, Galenica and Ferring\|\|Lahat, Adi:\|:\|Advisory boards and/or consulting fees from Abbvie, BMS, Janssen, Takeda, Pfizer, Celltrion, BMS\|\|Ungar, Bella:\|:\|Consultation fees from Neopharm, Takeda, Janssen and Abbvie\|\|Eliakim, Rami:\|:\|consultant and speaker fees from Janssen, Abbvie, Takeda and Medtronic\|\|Kriger-Sharabi, Ofra: No conflict of interest\|\|Reiss-Mintz, Hilla: No conflict of interest\|\|Yanai, Henit:\|:\|research grants from Pfizer; consulting fees from Abbvie, Janssen, Pfizer, and Takeda; Speaker fees from Abbvie, Janssen, Pfizer, and Takeda; Data Safety Monitoring Board or Advisory Board fees from Abbvie, Pfizer and, Takeda\|\|Dotan, Iris:\|:\|grants from Abbott, Abbvie, Athos, Arena, Altman Research, Cambridge Healthcare, Celltrion, Celgene/BMS, Ferring, Falk Pharma, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Integra Holdings, Janssen, Neopharm, Nestle, Pfizer, Rafa laboratories, Roche/Genentech, Sangamo, Sublimity, Sandoz, Takeda, Wildbio. Adi Lahat has received advisory boards and/or consulting fees from Abbvie, BMS, Janssen, Takeda, Pfizer, Celltrion, BMS\|\|Zittan, Eran:\|:\|research support and consulting fees from Janssen, Abbvie, Takeda, Neopharm, Celgene and Pfizer\|\|Maharshak, Nitsan:\|:\|advisory board and/ or speaking and/ or consulting fees from Pfizer, Takeda, Janssen, Ferring, BiomX, BMS, Nestle and grant support from Takeda, Janssen, Abbott, Abbvie, Pfizer, Corundum Innovation Ltd, Nestle, Trobix\|\|Hirsch, Ayal:\|:\|consultation fees from Neopharm, Takeda, Janssen and Abbvie\|\|Weitman, Michal: No conflict of interest\|\|Mantzaris, Gerassimos J:\|:\|consultant and/or speaker fees from AbbVie, Angelini, Genesis, MSD, Celgene, Celtrion, Ferring, Aenorasis, Hospira, Janssen, Pfizer, Takeda, Angelini, Falk Pharma, Mylan, Vianex and research support from AbbVie, Ferring, Genesis, MSD, Galenica, Mylan, and Vianex.\|\|Kopylov, Uri:\|:\|speaker fees from Abbvie, Janssen, BMS, Rafa, Novartis, Pfizer, Takeda, research support from Takeda and Janssen and consulting fees from Takeda and CTS |
| | |

| | |
|---|---|
| P561 | Dr. Bislenghi, Gabriele: No conflict of interest\|\|Baldi, Caterina: No conflict of interest\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|\|Marc Ferrante is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|•Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.\|•Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.\|\|\|Sabino, Joao:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring.\|\|João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|•Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.\|•Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.\|\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|•Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.\|•Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.\|\|\|Wolthuis, Albert: No conflict of interest\|\|Vermeire, Severine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|•Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.\|•Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.\|\|D'Hoore, André: No conflict of interest |
| | |

| | |
|---|---|
| P562 | Dr. Cohen, Nathaniel Aviv: No conflict of interest\|\|Choi, David: No conflict of interest\|\|Garcia, Nicole: No conflict of interest\|\|Choi, Natalie: No conflict of interest\|\|Picker, Emma: No conflict of interest\|\|Krugliak-Cleveland, Noa: No conflict of interest\|\|Cohen, Russell: No conflict of interest\|\|Dalal, Sushila: No conflict of interest\|\|Sakuraba, Atsushi: No conflict of interest\|\|Pekow, Joel: No conflict of interest\|\|Rubin, David:\|:\|David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Laboratories, Reistone, Takeda, and Techlab Inc. |
| P563 | Dr. Logan, Hayley: No conflict of interest\|\|Rimmer, Katherine: No conflict of interest\|\|Doecke, James: No conflict of interest\|\|Patrick, Desmond: No conflict of interest |
| P564 | Dr. Yiu, Tsz Hong: No conflict of interest\|\|Leong, Rupert: No conflict of interest\|\|Ko, Yanna: No conflict of interest\|\|Pudipeddi, Aviv: No conflict of interest |
| P565 | Biscanin, Alen: No conflict of interest\|\|Tomašić, Vedran: No conflict of interest\|\|Mr. Babic, Filip: No conflict of interest\|\|Ćaćić, Petra: No conflict of interest\|\|Ogresta Kordej, Doris: No conflict of interest\|\|Hrabar, Davor: No conflict of interest\|\|Kralj, Dominik: No conflict of interest\|\|Dorosulić, Zdravko: No conflict of interest |

| | |
|---|---|
| P566 | Dr. De Ruvo, Marianna: No conflict of interest\|\|Barberio, Brigida: No conflict of interest\|\|Zingone, Fabiana: No conflict of interest\|\|Bonanno, Laura: No conflict of interest\|\|Dal Maso, Alessandro: No conflict of interest\|\|Stefano, Frega: No conflict of interest\|\|Chiarion Sileni, Vanna: No conflict of interest\|\|Savarino, Edoardo Vincenzo: No conflict of interest |
| P567 | Dr. Ferreira, Ana Isabel: No conflict of interest\|\|Lima Capela, Tiago: No conflict of interest\|\|Macedo Silva, Vítor: No conflict of interest\|\|Xavier, Sofia: No conflict of interest\|\|Arieira, Cátia: No conflict of interest\|\|Cúrdia Gonçalves, Tiago: No conflict of interest\|\|Dias de Castro, Francisca: No conflict of interest\|\|Moreira, Maria João: No conflict of interest\|\|Cotter, José: No conflict of interest |
| P568 | Mrs. Pfeffer-Gik, Tamar: No conflict of interest\|\|Godny , Lihi: No conflict of interest\|\|Ollech, Jacob: No conflict of interest\|\|Wasserberg, Nir: No conflict of interest\|\|White , Ian: No conflict of interest\|\|Barkan , Revital: No conflict of interest\|\|Cohen , Shaken: No conflict of interest\|\|Avni-Biron, Irit: No conflict of interest\|\|Banai, Hagar: No conflict of interest\|\|Snir, Yifat: No conflict of interest\|\|Yanai, Henit: No conflict of interest\|\|Yackobovich Gavan, Michal: No conflict of interest\|\|Shimon , Ilan: No conflict of interest\|\|Tsvetov, Gloria: No conflict of interest\|\|Broitman, Yelena: No conflict of interest\|\|Dotan, Iris: No conflict of interest |
| P569 | Ms. Chehaider, Amira: No conflict of interest\|\|Serghini, Meriem: No conflict of interest\|\|Labidy, Asma: No conflict of interest\|\|Ben Mustapha, Nadia: No conflict of interest\|\|Fekih, Monia: No conflict of interest\|\|Boubaker, Jalel: No conflict of interest |

| | |
|---|---|
| P570 | Dr. Macaluso, Fabio Salvatore:\|:\|Fabio Salvatore Macaluso served as an advisory board member and/or received lecture grants from Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals. \|\|D'Antonio, Elvira: No conflict of interest\|\|Fries, Walter:\|:\|Walter Fries served as an advisory board member and/or received lecture grants from AbbVie, Biogen, MSD, Pfizer, Mundipharma, Zambon, Janssen, Sandoz, and Takeda Pharmaceuticals \|\|Viola, Anna: No conflict of interest\|\|Ksissa, Omar: No conflict of interest\|\|Cappello, Maria:\|:\|Maria Cappello served as an advisory board member for AbbVie, MSD, Pfizer, Takeda Pharmaceuticals, and received lecture grants from AbbVie, MSD, Chiesi, Pfizer, and Takeda Pharmaceuticals\|\|Muscarella, Stefano: No conflict of interest\|\|Belluardo, Nunzio: No conflict of interest\|\|Giangreco, Emiliano: No conflict of interest\|\|Mocciaro, Filippo: No conflict of interest\|\|Di Mitri, Roberto: No conflict of interest\|\|Ferracane, Concetta: No conflict of interest\|\|Vitello, Alessandro: No conflict of interest\|\|Grova, Mauro: No conflict of interest\|\|Renna, Sara: No conflict of interest\|\|Casà, Angelo: No conflict of interest\|\|Ventimiglia, Marco: No conflict of interest\|\|Orlando, Ambrogio:\|:\|Ambrogio Orlando served as an advisory board member for AbbVie, Galapagos, MSD, Janssen, Pfizer, Samsung Bioepis, and Takeda Pharmaceuticals, and received lecture grants from AbbVie, Galapagos, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. |
| P571 | Dr. Park, Yong Eun: No conflict of interest\|\|Kim, Dong Hyun: No conflict of interest\|\|Park, Soo-Kyung: No conflict of interest\|\|Lee, Yoo Jin: No conflict of interest\|\|Lee, Chang Kyun: No conflict of interest\|\|Kim, Eun Soo: No conflict of interest\|\|Kim, Kyeong Ok: No conflict of interest |
| P572 | Dr. Savin, Einat: No conflict of interest\|\|Levartovsky, Asaf: No conflict of interest\|\|Gendelman, Omer: No conflict of interest\|\|Lidar, Merav: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Kopylov, Uri: No conflict of interest |

| | |
|---|---|
| P573 | Louis, Edouard:\|:\|Research grants/support, educational grants, consultancy fees and/or honoraria (Takeda). This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Bossuyt, Peter:\|:\|Research grant: Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda. Lecture fees: AbbVie, Celltrion, Janssen, Lilly and Takeda. Consulting: Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Colard, Arnaud:\|:\|This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Caenepeel, Philip:\|:\|This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Baert, Filip:\|:\|Research grants/support, educational grants, consultancy fees and/or honoraria (Takeda); Grant/Research Support (AbbVie Inc.; Amgen Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited).\|Speakers Bureau participant (AbbVie Inc.; Ferring Holding SA; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; and Takeda).\|Honoraria (AbbVie Inc.; Amgen Inc.; Arena Pharmaceuticals, Inc.; Celgene Corporation; Ferring Holding SA; Fresenius Kabi AG; Galapagos Inc Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; and Takeda). This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Hantson, Anke:\|:\|An employee of Takeda. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Van Gassen, Geert:\|:\|An employee of Takeda. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Zhou, Jie:\|:\|An employee of Takeda and holds Takeda stock or stock options. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda.\|\|Vermeire, Severine:\|:\|Research grants/support, educational grants, consultancy fees and/or honoraria (Takeda);\|Received grants from AbbVie, J&J, Pfizer, Takeda and Galapagos; \|Received consulting and/or speaking fees from: AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. This study was sponsored by Takeda. Medical writing support was provided by Jon Waldron, PhD, of Excel Medical Affairs, and funded by Takeda. |
| | |

| | |
|---|---|
| P574 | Siegmund, Britta:\|:\|Served as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Falk, Janssen, Lilly, Pfizer, Prometheus and Takeda; and received speaker's fees from AbbVie, CED Service GmbH, Falk, Ferring, Janssen, Novartis and Takeda (served as representative of the Charité)\|\|Ryan, Rathi:\|:\|Is an employee of Pfizer Inc.\|\|Abreu, Maria T.:\|:\|Served as a scientific advisory board member for Boehringer Ingelheim Pharmaceuticals, Gilead, AbbVie, Seres Therapeutics, Shire, and Landos Biopharma; served as a trainer or lecturer for Imedex, Focus Medical Communications, and Cornerstones Health, Inc.; served as a consultant for Ferring Pharmaceuticals, Allergan, Amgen, Celltrion Healthcare CO, Millennium Pharmaceuticals, Theravance Biopharma Inc., and UCB Biopharma SRL; and has funded projects by Prometheus Laboratories and Pfizer.\|\|Vermeire, Séverine:\|:\|Received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma.\|\|Dotan, Iris:\|:\|Served as a speaker, consultant, and advisory board member for AbbVie, Abbott, Altmann, Arena, Athos, BMS, Cambridge Healthcare, Celgene, Celltrion, Genentech/Roche, Gilead, Galapagos, Eli-Lilly, Ferring, Falk Pharma, Food industries organization, Integra Holdings, Iterative Scopes, Janssen, Neopharm, Nestle, Wild bio, Pfizer, Rafa Laboratories, Sangamo, Sublimity, and Takeda; and received grant support from Pfizer, BMS, and Altman Research.\|\|Goetsch, Martina:\|:\|Is an employee of Pfizer Inc.\|\|Crosby, Catherine:\|:\|Is an employee of Pfizer Inc.\|\|Mr. Woolcott, John:\|:\|Is an employee of Pfizer Inc.\|\|Komori, H. Kiyomi:\|:\|Formally an employee of Arena Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc at the time of this analysis and is now an employee of Kinevant Sciences.\|\|Danese, Silvio:\|:\|Received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor; and reports payment for expert testimony from AbbVie, Amgen, Ferring Pharmaceuticals Inc, Gilead, Janssen, Mylan, Pfizer, and Takeda. |

| | |
|---|---|
| P575 | Siegmund, Britta:\|:\|B. Sigmund served as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Falk, Janssen, Lilly, Pfizer, Prometheus and Takeda; and received speaker's fees from AbbVie, CED Service GmbH, Falk, Ferring, Janssen, Novartis and Takeda (served as representative of the Charité).\|\|Komori, H. Kiyomi:\|:\|H. K. Komori was formally an employee of Arena Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc at the time of this analysis and is now an employee of Kinevant Sciences.\|\|Abreu, Maria T.:\|:\|M.T. Abreu has served as a scientific advisory board member for Boehringer Ingelheim Pharmaceuticals, Gilead, AbbVie, Seres Therapeutics, Shire, and Landos Biopharma; served as a trainer or lecturer for Imedex, Focus Medical Communications, and Cornerstones Health, Inc.; has served as a consultant for Ferring Pharmaceuticals, Allergan, Amgen, Celltrion Healthcare CO, Millennium Pharmaceuticals, Theravance Biopharma Inc., and UCB Biopharma SRL; and has funded projects by Prometheus Laboratories and Pfizer.\|\|Vermeire, Séverine:\|:\|S. Vermeire received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma.\|\|Dotan, Iris:\|:\|I. Dotan has served as a speaker, consultant, and advisory board member for AbbVie, Abbott, Altmann, Arena, Athos, BMS, Cambridge Healthcare, Celgene, Celltrion, Genentech/Roche, Gilead, Galapagos, Eli-Lilly, Ferring, Falk Pharma, Food industries organization, Integra Holdings, Iterative Scopes, Janssen, Neopharm, Nestle, Wild bio, Pfizer, Rafa Laboratories, Sangamo, Sublimity, and Takeda; and received grant support from Pfizer, BMS, and Altman Research.\|\|Goetsch, Martina:\|:\|M. Goetsch is an employee of Pfizer.\|\|Crosby, Catherine:\|:\|C. Crosby is an employee of Pfizer Inc.\|\|Ryan, Rathi:\|:\|R. Ryan is an employee of Pfizer Inc.\|\|Mr. Woolcott, John:\|:\|J. Woolcott is an employee of Pfizer Inc.\|\|Danese, Silvio:\|:\|S. Danese received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor; and reports payment for expert testimony from AbbVie, Amgen, Ferring Pharmaceuticals Inc, Gilead, Janssen, Mylan, Pfizer, and Takeda. |

| | |
|---|---|
| P576 | D'Haens, Geert:\|:\|GD received research support from Abbvie, Alimentiv, BMS, J&J, Pfizer, Takeda ; has been consultant for Abbvie, Agomab,\|AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist.\|Speaker's bureau for: Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda; Data montoring board: Galapagos, Astrazeneca, Seres Health.\|\|Bossuyt, Peter:\|:\|PB has received financial support for research from Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda; lecture fees from AbbVie, Celltrion, Janssen, Lilly and Takeda; advisory board fees from Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros.\|\|Baert, Filip:\|:\|FB report research support: AbbVie, Amgen, Janssen and Takeda; honoraria from AbbVie, Amgen, Arena, Celgene, Celltrion, Ferring, Fresenius Kabi, Janssen, Merck Sharp & Dohme, Pfizer, Sandoz, and Takeda; and was on speaker bureaus for AbbVie, Arena, Ferring,Galapagos, Janssen, Menarini, Merck Sharp & Dohme, Pfizer and Takeda.\|\|Molnár, Tamas:\|:\|TM research support: AbbVie, Janssen, Pfizer, Vifor Pharma and Takeda; honoraria from AbbVie, Arena, Celltrion, Ferring, Fresenius Kabi, Janssen,, Pfizer, Sandoz, and Takeda.\|\|Clasquin, Esmé: No conflict of interest\|\|Lowenberg, Mark:\|:\|ML has served as speaker and/or principal investigator for: Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, Jansen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts,Tramedico; received research grants from AbbVie, Merck Sharp & Dohme, Dr Falk, Achmea healthcare, Galapagos and ZonMW.\|\|Montazeri, Nahid: No conflict of interest\|\|Peeters, Harald:\|:\|HP reports research support from Takeda, Abbvie, Mylan, Amgen, Sandoz; speaker fess from Speaker fees: Janssen, Takeda, Abbvie and consultancy fees from Janssen, Fresenius-Kabi.\|\|Lambrecht, Guy: No conflict of interest\|\|Vermeire, Séverine:\|:\|SV received research support from AbbVie, J&J, Pfizer, Galapagos, Takeda;Has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals,AstraZeneca, Avaxia, BMS,Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. |

| | |
|---|---|
| P577 | Peyrin-Biroulet, Laurent:\|:\|Personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Biogen, Inotrem, MSD, Amgen, BMS, Vifor, Lilly, Gilead, Protagonist, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Pandion Therapeutics, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied Molecular Transport, GSK, Abivax.\|\|Danese, Silvio:\|:\|Dr. Silvio Danese reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor\|Dr. Silvio Danese reports lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda\|\|Colombel, Jean-Frederic:\|:\|Dr. Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development\|\|Rieder, Florian:\|:\|Adnovate, Agomab, Allergan, AbbVie, Arena, Boehringer-Ingelheim, Celgene/BMS, CDISC, Celsius, Cowen, Ferring, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, Guidepoint, Helmsley, Horizon Therapeutics, Image Analysis Limited, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Mopac, Morphic, Organovo, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Sanofi, Surmodics, Surrozen, Takeda, Techlab, Teva, Theravance, Thetis, UCB, Ysios, 89Bio\|\|Yarur, Andres:\|:\|Consultant Pfizer, Takeda, Boehringer Ingelheim, Procise Inc, Bristol Myers Squibb. Speaker fees Bristol Myers Squibb.\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Lichtiger, Simon:\|:\|Employee and owns stock in Landos Biopharma, Inc\|\|Dr. Mosig, Rebecca:\|:\|Employee of Landos Biopharma, Inc\|\|Cataldi, Fabio:\|:\|Employee of Landos Biopharma, Inc.\|\|Feagan, Brian:\|:\|Consultant: AbbVie, AbolerIS, AgomAB |

| | |
|---|---|
| | Therapeutics, Allianthera, Amgen, AnaptysBio, Applied Molecular Transport Inc, Arena Pharma, Avoro Capital Advisors, Atomwise,, BioJamp, Biora Therapeutics, Boehringer-Ingelheim, Boxer, Celsius Therapeutics,Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Duality, EcoR1, Eli Lilly, Equillium, Ermium,, First Wave, First Word Group, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, Hinge Bio, Hot Spot Therapeutics, Index Pharma, Imhotex, Immunic Therapeutics, JAKAcademy, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Landos Biopharma, Leadiant, L.E.K. Consulting, Lenczner Slaght, LifeSci Capital, Lument AB, Millennium, MiroBio, Morgan Lewis, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Orphagen, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Therapeutics and Diagnostics, Play to Know AG, Progenity, Protagonist, PTM Therapeutics, Q32 Bio, Rebiotix, REDX, Roche, Sandoz, Sanofi, Seres Therapeutics, Silverback Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Tigenix, Tillotts, Ventyx Biosciences, VHSquared Ltd., Viatris, Ysios, Ysopia, Zealand Pharma; Speakers Bureau: AbbVie, Janssen, Takeda\|Member, Scientific Advisory Board, DSMB: AbbVie, Amgen, AMT, AnaptysBio, Boehringer-Ingelheim, Celgene/BMS Eli Lilly, Genentech/Roche, Janssen, MiroBio, Origo BioPharma, Pfizer, Prometheus, REDX Pharma, Sanofi, Takeda,Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, GSK, Axio Research; Stock Shareholder: Gossamer Pharma |

| | |
|---|---|
| P578 | Panés, Julián:\|:\|Received research grants from AbbVie and Pfizer; speaker's fees from AbbVie, Janssen, Pfizer, , Takeda, and Theravance; and has been a consultant for AbbVie, Arena, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts Clinical Trials, Roche, Takeda, Theravance, and Wassermann.\|\|Panaccione, Remo:\|:\|Received consulting fees from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and has served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance, and Takeda.\|\|Sands, Bruce:\|:\|Received research grants from Takeda, Pfizer, Theravance Biopharma R&D, Janssen; consulting fees from 4D Pharma, Abivax, Abbvie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella Bioscience, Celgene, Celltrion Healthcare, ClostraBio, Enthera, F.Hoffmann-La Roche, Ferring, Galapagos, Gilead, Glaxo SmithKline, GossamerBio, Immunic, Index Pharmaceuticals, Innovation Pharmaceuticals, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Shire, Sienna Biopharmaceuticals, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio, Vivante Health, Vivelix Pharmaceuticals; and stock for Vivante Health and Ventyx Biosciences.\|\|Gasink, Christopher:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Marano, Colleen:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Ma, Tony:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Hoops, Tim:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options. |
| | |

| | |
|---|---|
| P579 | Prof. Dr. Buisson, Anthony:\|:\|Consulting fees for Abbvie, Amgen, Arena, Biogen, Celtrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts. Lecture fees for Abbvie, Amgen, Biogen, Fresenius-Kabi Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts and Vifor Pharma. Research grants from Abbvie, Celltrion, Janssen, Pfizer, Takeda.\|\|Serrero, Mélanie:\|:\|declared fees from Pfizer, Abbvie, Takeda, Janssen, MSD, Amgen, Ferring, Tillotts, Celltrion\|\|Altwegg, Romain:\|:\|received lecture and consulting fees from Abbvie, Janssen, MSD, Pfizer, Takeda. \|\|Guilmoteau, Thomas: No conflict of interest\|\|Bouguen, Guillaume:\|:\|received lecture fees from Abbvie, Ferring, MSD, Takeda and Pfizer and consultant fees from Takeda, Janssen.\|\|Nachury, Maria:\|:\|received board membership, consultancy, or lecture fees from Abbvie, Adacyte, Amgen, Arena, Biogen, CTMA, Celltrion, Ferring, Fresenius-Kabi, Janssen, Mayoli-Spindler, MSD, Pfizer, Takeda\|\|Amiot, Aurélien:\|:\|has served as a consultant, served on the advisory board, received lecture fees, and received travel fees from AbbVie, Hospira, Takeda, Gilead, Biocodex, Janssen, Ferring, and MSD. \|\|Vuitton, Lucine: No conflict of interest\|\|Treton, Xavier:\|:\|received honoraria from Abbvie, MSD, Takeda, Ferring, Norgine and Janssen.\|\|Caillo, Ludovic:\|:\|declared fees from Janssen, abbvie, Takeda, amgen, Pfizer, norgine\|\|Pereira, Bruno: No conflict of interest\|\|Fumery, Mathurin:\|:\|Consulting/lecture fees for Abbvie, Amgen, Arena, Biogen, Celtrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts. MSD, Gilead, Celgene, Sandoz and Ferring. |

| | |
|---|---|
| P580 | Dr. Friedberg, Scott: No conflict of interest\|\|Choi, David: No conflict of interest\|\|Hunold, Thomas: No conflict of interest\|\|Choi, Natalie K.: No conflict of interest\|\|Garcia, Nicole M.: No conflict of interest\|\|Picker, Emma A.: No conflict of interest\|\|Cohen, Nathaniel A.: No conflict of interest\|\|Cohen, Russell D.:\|:\|RDC is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/Celgene, Eli Lilly, Genentech, Gilead Sciences, Hoffmann La-Roche, Janssen, Pfizer, Takeda, UCB Pharma. He has received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therpeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. His wife is on the board of directors of Aerpio Theraoeutics, ImmunityBio, and MEI Pharmaceuticals. \|\|Dalal, Sushila R.:\|:\|SRD has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. SD is on the Speaker's Bureau and has served as a consultant for Abbvie and Pfizer.\|\|Pekow, Joel:\|:\|JP has served as a consultant for CVS Caremark\|\|Sakuraba, Atsushi: No conflict of interest\|\|Krugliak Cleveland, Noa:\|:\|N Krugliak Cleveland has served as a consultant for Arena Pharmaceuticals, Neurologica, and Takeda Pharmaceuticals U.S.A., Inc, and received a speaker's fee from Bristol Myers Squibb\|\|Rubin, David T.:\|:\|DTR has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Laboratories, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc |
| P581 | Dr. Revés, Joana: No conflict of interest\|\|Fernandez-Clotet, Agnès: No conflict of interest\|\|Ordás, Ingrid: No conflict of interest\|\|Buisson, Anthony: No conflict of interest\|\|Ellul, Pierre: No conflict of interest\|\|Elorza, Ainara: No conflict of interest\|\|Aduna, Marta: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Freire, Gonçalo: No conflict of interest\|\|Sousa, Pedro: No conflict of interest\|\|Primitivo, Ana: No conflict of interest\|\|Delgado, Ivo: No conflict of interest\|\|Sousa Lajas, Inês: No conflict of interest\|\|Raimundo, Ana: No conflict of interest\|\|Bettencourt, Paulo: No conflict of interest\|\|Rimola, Jordi: No conflict of interest\|\|Torres, Joana: No conflict of interest |

| | |
|---|---|
| P582 | Vermeire, Séverine:\|:\|S. Vermeire received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma.\|\|Sands, Bruce E.:\|:\|; B.E. Sands reports consulting fees from Abivax, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Entera, Evommune, Galapagos, Genentech, Gilead Sciences, GSK, Gossamer Bio, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, Miro Bio, Morphic Therapeutics, MRM Health, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Surrozen, Takeda, Teva, TLL Pharmaceutical, USWM Enterprises, and Viela Bio; speaking fees from Abivax, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and grant/research support from Janssen.\|\|Dubinsky, Marla C.:\|:\|M.C. Dubinsky received consulting fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; and is founder and a shareholder of Trellus Health.\|\|Feagan, Brian G.:\|:\|B.G. Feagan has been a consultant for AbbVie, Admirx, AgomAb Therapeutics, Applied Molecular Transport Inc, Arena Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, F. Hoffmann-La Roche, Janssen, Morphic Therapeutics, OM Pharma, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Theravance, TiGenix, Tillotts, and Zealand Pharma; has received speakers bureau fees from AbbVie, Janssen, and Takeda; served on the Scientific Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, and GSK; is a stockholder of Gossamer Pharma; and is an employee of Western University and Alimentiv Inc.\|\|Panaccione, Remo:\|:\|R. Panaccione reports consulting fees from AbbVie, Abbott, Alimentiv, Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; speaker fees from AbbVie, Arena, Celgene, Ferring, Gilead Sciences, Janssen, Lilly, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; |

| | |
|---|---|
| | research or educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and has served on advisory boards for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance, and Takeda.\|\|Jairath, Vipul:\|:\|V. Jairath has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GSK, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker's fees from AbbVie, Ferring, Bristol Myers Squibb, Galapagos, Janssen, Pfizer, Shire, Takeda, and Fresenius KabI.\|\|Yarur, Andres:\|:\|A. Yarur received consulting fees from Takeda, Prometheus Labs, Arena Pharmaceuticals, and Bristol Myers Squibb; and speakers bureau fees from Bristol Myers Squibb.\|\|Chiorean, Michael:\|:\|M. Chiorean has been a speaker for AbbVie, Janssen, Medtronic, Pfizer Inc, Bristol Myers Squibb, and Takeda; and has served as a consultant for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Medtronic, Pfizer Inc, Lilly, Prometheus, and Takeda.\|\|Panés, Julian:\|:\|J. Panés received consulting fees from AbbVie, Arena Pharmaceuticals, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, GSK, Janssen, Mirum, Morphic, Nestle, Origo, Pandion, Progenity, Pfizer, Revolo, Robarts, Roche, Takeda, Theravance, and Wassermann; speaker fees from AbbVie, Biogen, Ferring, Janssen, Pfizer, and Takeda; and research funding from AbbVie and Pfizer.\|\|Goetsch, Martina:\|:\|M. Goetsch is an employee and shareholder of Pfizer.\|\|Dr. Rabbat, Christopher J.:\|:\|C.J. Rabbat is an employee of Pfizer Inc.\|\|Shah, Pooja:\|:\|P. Shah is an employee of Pfizer Inc.\|\|Wu, Joseph:\|:\|J. Wu is an employee and shareholder of Pfizer Inc.\|\|Ghosh, Subrata:\|:\|S. Ghosh was a member of a steering committee for Janssen, AbbVie, BMS, and Pfizer; was a member of a drug monitoring committee for Janssen; received speakers' fees from Janssen, Pfizer, Takeda, Celltrion; and was a member of an advisory committee for AbbVie, BMS, Takeda, Janssen, Pfizer, Gilead, and Galapagos. |
| P583 | Ms. Ovesen, Pernille Dige: No conflict of interest\|\|Brynskov, Jørn:\|:\|Has been a consultant and/or advisory board member and received fees and/or research grants from Abbvie, Pfizer, MSD, Takeda, Janssen, Bristol Myers Squibb and Gilead.\|\|Seidelin, Jakob Benedict:\|:\|Has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim.\|\|Steenholt, Casper:\|:\|Speaker and advisory board for MSD and Janssen-Cilag. |

| | |
|---|---|
| P584 | Jairath, Vipul:\|:\|VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx, Vividion; speaker's fees from, Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi\|\|Bressler , Brian:\|:\|Dr Brian Bressler: Advisor/Speaker: Ferring, Janssen, Abbvie, Takeda, Pfizer, Novartis, BMS, Merck, Sandoz, Organon. Advisor: Alimentiv, Gilead, Iterative Scopes, AMT, Celgene, Microbiome Insights, Merck, Amgen, Pendopharm, Genentech, BMS, Allergan, Protagonist, Fresenius Kabi, Mylan, Viatris, Bausch Health, Celltrion Healthcare, Jamp Pharma, Eupraxia. Research support: Janssen, Abbvie, GSK, BMS, Amgen, Genentech, Merck, BI, Qu Biologic. Stock Options: Qu Biologic\|\|Silverberg , Mark S.:\|:\|Speaker, Advisory Board and Consulting Fees received from: Abbvie, Janssen, Takeda, Pfizer.\|\|Lee, Li-Yin:\|:\|LL is an employee of Applied Molecular Transport and owns stock in the company \|\|Lugo, Kyler A.:\|:\|KL is an employee of Applied Molecular Transport and owns stock in the company \|\|Mayoral Monibas, Rafael:\|:\|RM is an employee of Applied Molecular Transport and owns stock in the company \|\|Annamalai, Thamil:\|:\|TA is a consultant for Applied Molecular Transport and owns stock in the company \|\|Whitney, J. Andrew:\|:\|JAW is an employee of Applied Molecular Transport and owns stock in the company \|\|Weng, Emily Y.:\|:\|EW is an employee of Applied Molecular Transport and owns stock in the company \|\|Dr. Kanwar, Bittoo:\|:\|BK is an employee of Applied Molecular Transport and owns stock in the company \|\|Danese , Silvio:\|:\|SD received speaker fees from Ferring, Merck Sharp & Dohme, and UCB Pharma; received consulting fees from Abbott Laboratories, AbbVie, AstraZeneca, Schering Plough, Takeda, and Millennium; and served as board member of Merck Sharp & Dohme.\|\|Feagan, Brian:\|:\|Brian Feagan: AbbVie Inc – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. AdMIRx Inc – Consultant. Akebia Therapeutics – Consultant. Allergan – Advisory Committee/Board Member, Consultant. Amgen Inc – Advisory Committee/Board Member, Consultant, Grant/Research Support. Applied Molecular Transport Inc – Consultant. Aptevo Therapeutics – Consultant. Asta Pharma – Consultant. AstraZeneca/MedImmune Ltd. – Advisory Committee/Board Member, Consultant, Grant/Research Support. Atlantic Pharmaceuticals Ltd – Advisory Committee/Board Member, Grant/Research Support. Avaxia Biologics Inc. – Advisory Committee/Board Member. Avir Pharma – Consultant. Biogen Idec – Consultant. BioMx Israel – Consultant. Boehringer Ingelheim – Advisory Committee/Board Member, Consultant, Grant/Research Support. Boston Pharmaceuticals – Consultant. |

| | |
|---|---|
| | Bristol-Myers Squibb – Advisory Committee/Board Member, Consultant. Calypso Biotech – Consultant. Celgene Corporation – Advisory Committee/Board Member, Consultant, Grant/Research Support. Celltech – Grant/Research Support. Centocor Inc – Advisory Committee/Board Member. Elan/Biogen – Advisory Committee/Board Member, Consultant. Eli Lilly – Consultant, Speaker's Bureau. EnGene – Consultant. Ferring Pharma – Consultant. Galapagos – Advisory Committee/Board Member, Consultant. Galen/Atlantica – Consultant. Genentech Inc/Hoffmann-La Roche Ltd – Advisory Committee/Board Member, Consultant, Grant/Research Support. GiCare Pharma – Consultant. Gilead Sciences Inc – Consultant, Grant/Research Support. GlaxoSmithKline (GSK) – Consultant, Grant/Research Support. Gossamer Pharma – Consultant. Inception IBD Inc – Consultant. Intact Therapeutics – Consultant. Janssen Research & Development LLC – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Kyowa Kakko Kirin Co Ltd – Consultant. Lexicon – Consultant. Lycera BioTech – Consultant. Merck – Advisory Committee/Board Member, Consultant. Mesoblast Pharma – Consultant. Millennium – Consultant. Nestles – Advisory Committee/Board Member, Consultant. Nextbiotix – Consultant. Novartis – Advisory Committee/Board Member. Novonordisk – Advisory Committee/Board Member, Consultant. ParImmune – Consultant. Parvus Therapeutics Inc – Consultant. Pfizer Inc – Advisory Committee/Board Member, Consultant, Grant/Research Support. Progenity – Consultant. Prometheus Therapeutics and Diagnostics – Advisory Committee/Board Member, Consultant. Protagonist – Advisory Committee/Board Member, Consultant. Qu Biologics – Consultant. Rebiotix – Consultant. Receptos Inc / Celgene International – Consultant, Grant/Research Support. Robarts Clinical Trials Inc – Other Financial or Material Support, Senior Scientific Officer. Salix Pharma – Advisory Committee/Board Member, Consultant. Sanofi – Grant/Research Support. Santarus Inc – Grant/Research Support. Shire – Consultant. Sienna Biologics – Consultant. Sigmoid Pharma – Consultant. Sterna Biologicals – Advisory Committee/Board Member, Consultant. Synergy Pharma Inc – Consultant. Takeda Development Center Americas Inc – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Teva Pharma – Advisory Committee/Board Member, Consultant. TiGenix – Advisory Committee/Board Member, Consultant. Tillotts – Advisory Committee/Board Member, Consultant, Speaker's Bureau. Tillotts Pharma AG – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. UCB – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speaker's Bureau. Vertex Pharma – Consultant. VHsquared Ltd – Consultant. Vivelix Pharma – Consultant. Zyngenia – Consultant. |

| | |
|---|---|
| P585 | Vermeire, Séverine:\|:\|received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand\|\|Abraham, Bincy:\|:\|received research funding from Takeda; consulted for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Medtronic, Pfizer, Samsung Bioepis, Prometheus, and Takeda; lectured for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda.\|\|Bressler, Brian:\|:\|advisor/speaker for AbbVie, Ferring, Janssen, Merck, Novartis, Pfizer, and Takeda; advisor for Allergan, Amgen, Bristol Myers Squibb, Celgene, Genentech, Merck, Microbiome Insights, Pendopharm, Protagonist, and Robarts Clinical Trials; received research support from AbbVie, Alvine, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, GSK, Janssen, Merck, and Qu Biologics; holds stock options in Qu Biologics.\|\|Reinisch, Walter:\|:\|speaker for 4SC, Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; consulted for Abbott Laboratories, AbbVie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, AstraZeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, ChemoCentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Gatehouse Bio, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Landos Biopharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Peri Consulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, TiGenix, UCB, Vifor, Zealand, and Zyngenia; served as an advisory board member for 4SC, Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, ChemoCentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & |

| | |
|---|---|
| | Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpoint Medical, Takeda, Therakos, TiGenix, UCB, Zealand, and Zyngenia; received research funding from Abbott Laboratories, AbbVie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnostik, Janssen, MSD, Sandoz, and Takeda.\|\|Jain, Anjali:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Memaj, Arteid:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Akukwe, Lucy:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Liu, W. Jerry:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Osterman, Mark:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|employees and/or shareholders of Bristol Myers Squibb.\|\|Sands, Bruce E.:\|:\|received fees for consulting and speaking from Abivax, Bristol Myers Squibb, Janssen, Eli Lilly, Pfizer, and Takeda; received fees for consulting from AbbVie, Adiso Therapeutics, Alimentiv, Amgen, Arena, Artizan Biosciences, Artugen, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Calibr, Celltrion, ClostraBio, Cytoki Pharma, Connect Biopharma, Entera, Evommune, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunic, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Kaleido Biosciences, Kallyope, MiroBio, Morphic Therapeutics, MRM Health, OSE Immunotherapeutics, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Sun Pharma, Surrozen, Synlogic, Target RWE, Teva, Theravance Biopharma, TLL Pharmaceutical, USWM Enterprises, Viela Bio, and VTA Labs; received personal fees and stock options for consulting from Ventyx Biosciences and Thelium Therapeutics. |
| P586 | Dotti, Adriana Zanoni: No conflict of interest\|\|Vilela, Eduardo Garcia: No conflict of interest\|\|Chebli, Julio Maria Fonseca: No conflict of interest\|\|Chebli, Liliana Andrade: No conflict of interest\|\|Magro, Daniela Oliveira: No conflict of interest\|\|Steinwurz, Flavio: No conflict of interest\|\|Argollo, Marjorie: No conflict of interest\|\|Carvalho, Nayara Salgado: No conflict of interest\|\|Parente, Jose Miguel Luz: No conflict of interest\|\|Parra, Rogerio Serafim: No conflict of interest\|\|Perin, Ramir Luan: No conflict of interest\|\|Flores, Cristina: No conflict of interest\|\|Morsoletto, Eloa Marussi: No conflict of interest\|\|Ferreira, Sandro da Costa: No conflict of interest\|\|Ludvig, Juliano Coelho: No conflict of interest\|\|Kaiser Jr, Roberto Luiz: No conflict of interest\|\|Queiroz, Natalia Souza Freitas: No conflict of interest\|\|Faria, MIkaell Alexandre Gouvea: No conflict of interest\|\|Nicollelli, Guilherme Mattioli: No conflict of interest\|\|Andrade, Adriana Ribas: No conflict of interest\|\|Prof. Kotze, Paulo Gustavo: No conflict of interest |

| | |
|---|---|
| P587 | Dr. Lovett, Grace: No conflict of interest\|\|Schulberg, Julien D.: No conflict of interest\|\|Hamilton, Amy L.: No conflict of interest\|\|Wilding, Helen E.: No conflict of interest\|\|Kamm, Michael A.: No conflict of interest\|\|Wright, Emily K.: No conflict of interest |
| P588 | Jairath, Vipul:\|:\|VJ has received consulting/advisory board fees from AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda, and Topivert; and speaker's fees from Abbvie, Ferring, Janssen, Pfizer, Shire, and Takeda.\|\|Zou, Guangyong:\|:\|GZ has received consulting fees from Alimentiv Inc.\|\|Wang, Zhongya:\|:\|ZW is an employee of Alimentiv Inc.\|\|Adsul, Shashi:\|:\|SA is an employee of Takeda Pharmaceuticals.\|\|Colombel, Jean-Frederic:\|:\|JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development.\|\|D'Haens, Geert R.:\|:\|GRD has served as a consultant and/or received speaker fees from AbbVie, Alimentiv, AstraZeneca, Biora (Progenity), Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, and Ventyx Biosciences.\|\|Freire, Marcelo:\|:\|MF is an employee of Takeda Pharmaceuticals. \|\|Moran, Gordon W.:\|:\|GWM is a consultant for Alimentiv and in receipt of research funding from AstraZeneca and Johnson and Johnson.\|\|Peyrin-Biroulet, Laurent:\|:\|LPB has received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Biogen, Inotrem, MSD, Amgen, BMS, Vifor, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Pandion Therapeutics, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied Molecular Transport, GSK, and Abivax.\|\|Sandborn, William J.:\|:\|WJS reports receiving consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv, Beigene, Biora (Progenity), Celltrion, Forbion, Genentech, Gossamer Biosciences, Index Pharmaceuticals, Prometheus Biosciences, Protagonist Therapeutics, Shoreline Biosciences, Vedanta Biosciences, Ventyx Biosciences, and Zealand Pharma; and stock or stock options from BeiGene, Gossamer Bio, Biora (Progenity), Prometheus Biosciences, Prometheus Laboratories, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; he is an employee at Shoreline Biosciences and Ventyx Biosciences. Spouse: Iveric Bio - consultant, stock options; Biora (Progenity) - stock; Prometheus Biosciences - employee, stock, and |

| | |
|---|---|
| | stock options; Prometheus Laboratories – stock and stock options; Ventyx Biosciences – stock and stock options; Vimalan Biosciences – stock and stock options.\|\|Sebastian, Shahji:\|:\|SS reports research grants from Takeda, Pfizer, Tillotts Pharma, Abbvie, and Biogen; and personal fees for speaker role and advisory board meetings from Janssen, Amgen, Tillotts Pharma, Abbvie, Takeda, Celgene, Roche, Phramacosmos, and Falk pharma outside the submitted work.\|\|Travis, Simon:\|:\|ST has received grants/research support from AbbVie, Buhlmann, Celgene, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor, and Norman Collisson Foundation; consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Apexian, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Barco, Biocare, Biogen, BLPharma, Boehringer Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, Chiesi, CisBio, ComCast, Coronado, Cosmo, Ducentis, Dynavax, Elan, Enterome, EQrX, Equillium, Falk, Ferring, FPRT Bio, Galapagos, Genentech/Roche, Genzyme, Gilead, Glenmark, Grunenthal, GSK, GW Pharmaceuticals, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Medarex, Medtrix, Merck, Merrimack, Mestag, Millenium, Neovacs, Novartis, Novo Nordisk, NPS-Nycomed, Ocera, Optima, Origin, Otsuka, Palau, Pentax, Pfizer, Pharmaventure, Phesi, Phillips, P&G, Pronota, Protagonist, Proximagen, Resolute, Robarts, Sandoz, Sanofi, Santarus, Satisfai, Sensyne Health, Shire, SigmoidPharma, Sorriso, Souffinez, Syndermix, Synthon, Takeda, Theravance, Tigenix, Tillotts, Topivert, Trino Therapeutics with Wellcome Trust, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria; speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda, and UCB. He has no stocks or share options.\|\|Vermeire , Séverine:\|:\|SV has received grants from AbbVie, J&J, Pfizer, Takeda, and Galapagos; consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, and Zealand Pharma.\|\|Radulescu, Gabriela:\|:\|GR is an employee of Alimentiv Inc.\|\|Sigler, Julie:\|:\|JuS is an employee of Alimentiv Inc.\|\|Mrs. Mcfarlane, Stefanie: No conflict of interest\|\|Arya, Naveen:\|:\|NA reports no conflicts of interest.\|\|Beaton, Melanie:\|:\|MB has received honoraria from Shire, Allergan, Pfizer, and Takeda; advisory board fees from AbbVie, Takeda, Janssen, Lupin, Gilead, Pfizer, and Novo Nordisk; clinical trials: AbbVie, Novo Nordisk, Gilead, Takeda, Boehringer Ingelheim, Janssen, Pfizer, AstraZeneca, and Intercept; research publications: AbbVie (2021 – letter signed).\|\|Bossuyt, Peter:\|:\|PB reports receiving research grants from Abbvie, Amgen, Celltrion, Mylan, |

| | |
|---|---|
| | signed).\|\|Bessissow, Peter:\|:\|PB reports receiving research grants from AbbVie, Amgen, Celltrion, Mylan, Pfizer, and Takeda; lecture fees from AbbVie, Celltrion, Janssen, Lilly, and Takeda; and consulting fees Abbvie, Arena Pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda, and Tetrameros.\|\|Green, Daniel:\|:\|DG has received advisory board fees from Takeda, Abbvie, Jannsen, Pfizer, Merk, and Freseni Kabi.\|\|Harlan III, William:\|:\|WH reports no conflicts of interest.\|\|Horynski, Marek:\|:\|MH reports no conflicts of interest.\|\|Klopocka, Maria:\|:\|MK has received personal fees from Shire, a Takeda company, during the conduct of the study; personal fees and non-financial support from Takeda; personal fees and non-financial support from Janssen; personal fees and non-financial support from Ferring, outside the submitted work.\|\|Petroniene, Rima:\|:\|RP has received consulting/advisory board fees from AbbVie, Janssen, Pfizer, and Allergan.\|\|Silverberg, Mark S.:\|:\|MSS has received consulting, speaker, and advisory board fees from Abbvie, Janssen, Pfizer, and Takeda.\|\|Wolanski, Lukasz:\|:\|LW reports no conflicts of interest.\|\|Feagan , Brian G.:\|:\|BGF is a scientific advisory board member for AbbVie, Allergan, Amgen, AstraZeneca, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Elan, Biogen, Ferring, Genentech–Roche, Janssen–Johnson & Johnson, Merck, Millennium, Nestlé, Novo Nordisk, Novartis, Pfizer, Prometheus, Protagonist, Receptos, Salix, Sigmoid Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, and UCB Pharma; consulting fees from AbbVie, Actogenix, Akros, Albireo Pharma, Allergan, Amgen, AstraZeneca, Avaxia Biologics, Avir Pharma, Axcan, Baxter Healthcare, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan–Biogen, EnGene, Ferring, Genentech–Roche, GiCare Pharma, Gilead Sciences, Given Imaging, GlaxoSmithKline, Ironwood, Janssen Biotech–Centocor, Janssen–Johnson & Johnson, Kyowa Hakko Kirin, Eli Lilly, Merck, Mesoblast Pharma, Millennium, Nestlé, Novo Nordisk, Novartis, Pfizer, Prometheus, Protagonist, Receptos Salix, Sanofi, Shire, Sigmoid Pharma, Synergy Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, UCB Pharma, Vertex, VHsquared, Wyeth, Zealand, and Zygenia; lecture fees from AbbVie, Janssen–Johnson & Johnson, Takeda, and UCB Pharma, and grant support from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech–Centocor, Janssen–Johnson & Johnson, Pfizer, Receptos, Sanofi, and Takeda, and is the Senior Scientific Officer of Alimentiv Inc.\|Alimentiv, Inc. (formerly Robarts Clinical Trials, Inc.) is an academic gastrointestinal contract research organization (CRO), operating under the Alimentiv Health Trust. Alimentiv, Inc. provides centralized imaging management solutions in clinical trials, including endoscopy, histopathology, and magnetic resonance imaging. Alimentiv, Inc. provides full service CRO capabilities as well as precision medicine services. |
| P589 | Dr. Nardone, Olga Maria: No conflict of interest\|\|Calabrese, Giulio: No conflict of interest\|\|Alfonsi, Lucia: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|La Mantia , Alessia: No conflict of interest\|\|Fierro, Giuseppe: No conflict of interest\|\|Ferrante, Mario: No conflict of interest\|\|Testa, Anna: No conflict of interest\|\|Guarino, Alessia Dalila: No conflict of interest\|\|D'Alessandro, Ermelinda: No conflict of interest\|\|Pasanisi, Fabrizio: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest |

| | |
|---|---|
| P590 | Prof. Dr. Luglio, Gaetano: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|Tropeano, Francesca Paola: No conflict of interest\|\|Cricrì, Michele: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest\|\|De Palma, Giovanni Domenico: No conflict of interest |
| P591 | Dr. Hamoir, Florine: No conflict of interest\|\|De Leuze, Florence: No conflict of interest\|\|Denis, Marie: No conflict of interest\|\|De Vroey, Bénédicte: No conflict of interest\|\|De Suray, Nicolas: No conflict of interest\|\|Burnet, Guillaume: No conflict of interest\|\|Piessevaux, Hubert: No conflict of interest\|\|Dewit, Olivier: No conflict of interest |
| P592 | Dr. Ferronato, Antonio: No conflict of interest\|\|Rigno, Manuela: No conflict of interest\|\|Rodriguez-Castro, Kryssia Isabel: No conflict of interest\|\|Brozzi, Lorenzo: No conflict of interest\|\|Errigo, Gabriella: No conflict of interest\|\|Castelli, Monica: No conflict of interest\|\|Baldassarre, Gianluca: No conflict of interest |

| | |
|---|---|
| P593 | Dr. Geldof, Jeroen:\|:\|has served as advisory board member or speaker for Arena, Janssen and Galapagos\|\|Truyens, Marie: No conflict of interest\|\|Sabino, Joao:\|:\|received speaker's fees from Pfizer, Abbvie, Ferring, Falk, Takeda, Janssen, and Fresenius. JS received consultancy fees from Janssen, Ferring, Fresenius, Abbvie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia. Research support: Galapagos and Viatris. JS is supported by a Senior Clinical researcher grant from the Research foundation – Flanders.\|\|Ferrante, Marc:\|:\|reports being a consultant or speaker for AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk, Ferring, Janssen-Cilag, Lamepro, Eli Lilly, Medtronic, Merck Sharp & Dohme (MSD), Mylan, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda, Thermo Fisher Scientific, and Truvion Healthcare; and received research grants from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda, and Viatris.\|\|Lambert, Jo:\|:\|has received recent grants/speaker fees of and did consulting for AbbVie, Almirall, Bristol Myers Squibb, Celtrion, Janssen, Eli Lilly, Novartis, UCB Pharma – not personal but paid to an institutional university account\|\|Lapeere, Hilde:\|:\|Reports receiving consultancy or speaker fees from AbbVie, Almirall, Amgen, Leo Pharma, Pfizer, – not personal but paid to an institutional university hospital account\|\|Hillary, Tom:\|:\|Has received grants and consulting and/or speaking fees from: AbbVie, Almirall, Amgen, Biogen, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer Inc, Sandoz, Sanofi, UCB Pharma\|\|Van Laethem, An:\|:\|Reports being a consultant or speaker for: AbbVie, Bayer, Falk Pharma, Janssen, Eli Lilly, Novartis, Pfizer Inc, Sanofi, UCB Pharma\|\|de Vlam, Kurt:\|:\|reports being a consultant or speaker for Abbvie, Eli Lilly, Novartis,Pfizer, MSD, Acelyrin, UCB Pharma, Leo Pharma, Amgen and has received financial research support from UCB Pharma and Celgene\|\|Verschueren, Patrick:\|:\|reports being a consultant or speaker for Abbvie, Eli Lilly, Galapagos, Gilead, MSD, Nordic Pharma, Roularta, Sidekick Health and has received financial research support from Pfizer. \|\|Padalko, Elizaveta:\|:\|has received a consultant of speaker's fees/travel grants on institutional account from Hologic, bioMerieux, DiaSorin, Novosanis\|\|Lobaton, Triana:\|:\|has received financial support for research from Abbvie, Mylan, MSD, Mundipharma, Biogen, Janssen, Pfizer and Takeda, Speaker fees fromFerring, MSD, Abbvie, Janssen, Amgen, Fresenius Kabi, Galapagos and Takeda\|and Consultancy fee from Janssen, Galapagos, Amgen, Bristol Myers Squibb, Fresenius Kabi and Takeda \|\|\|Vermeire, Séverine:\|:\|has received grants from AbbVie, J&J, Pfizer, Takeda and Galapagos; and consulting and/or speaking fees from: AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma |
| | |

| | |
|---|---|
| P594 | Ms. Maeda, Masa: No conflict of interest\|\|Sagami, Shintaro:\|:\|AbbVie, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Zeria Pharmaceutical\|\|Tashima, Moyu: No conflict of interest\|\|Yamana, Yoko:\|:\|AbbVie, Activated, Alfresa Pharma, JMDC, Gilead Sciences, Nippon Kayaku, Eli Lilly, Mochida Pharmaceutical, Janssen Pharmaceutical, Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Google, Ferring Pharmaceuticals, Mitsubishi Tanabe Pharma, Zeria Pharmaceutical\|\|Karashima, Ryo: No conflict of interest\|\|Miyatani, Yusuke:\|:\|AbbVie, Japan Foundation for Applied Enzymology, AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, EA Pharma. \|\|Hojo, Aya: No conflict of interest\|\|Nakano, Masaru: No conflict of interest\|\|Hibi, Toshifumi:\|:\|AbbVie, Activated, Alfresa Pharma, Aspen Japan, Bristol-Myers Squibb, EA Pharma, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JIMRO, JMDC, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, MIYARISAN Pharmaceutical Co, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Takeda Pharmaceutical, Zeria Pharmaceutical\|\|Kobayashi, Taku:\|:\|AbbVie, Activated, Alfresa Pharma, Bristol-Myers Squibb, EA Pharma, Eli Lilly, Gilead Sciences, Google, Janssen Pharmaceutical, JIMRO, JMDC, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Pfizer, Takeda Pharmaceutical, Zeria Pharmaceutical |
| P595 | Muñoz-Villafranca, Carmen: No conflict of interest\|\|Arreba , Paz: No conflict of interest\|\|Gomez, Miriam: No conflict of interest\|\|Ms. Ispizua Madariaga, Nahia: No conflict of interest\|\|Buendia, Laura: No conflict of interest\|\|Lopez, Maria Luisa: No conflict of interest\|\|Ugarte, Ane: No conflict of interest\|\|de la Fuente, Iciar: No conflict of interest\|\|Prado, Nicolas: No conflict of interest\|\|Irusta, Leire: No conflict of interest\|\|Jimenez, Miguel Alejandro: No conflict of interest\|\|Santa Cruz, Marta: No conflict of interest\|\|Gonzalez, Maite: No conflict of interest\|\|Bilbao, Amaia: No conflict of interest\|\|Ortiz de Zárate, Jone: No conflict of interest |

| | |
|---|---|
| P596 | Dr. Gebeyehu, Gerum Gashaw: No conflict of interest\|\|Broglio, Giacomo: No conflict of interest\|\|Liu, Eleanor:\|:\|EL has received speaker fees from Janssen and a research grant from Galapagos.\|\|Limdi, Jimmy K:\|:\|JKL has received speaker fees from Dr Falk pharmaceuticals.\|\|Selinger, Christian:\|:\|CS has received unrestricted research grants from Abbvie and Janssen, has provided consultancy to Arena, Galapagos, Dr Falk, Fresenius Kabi, Abbvie, Janssen and Takeda, and had speaker arrangements with Janssen, Dr Falk, Abbvie, Pfizer and Takeda.\|\|Fiske, Joseph: No conflict of interest\|\|Razsanskaite, Violeta: No conflict of interest\|\|Smith, Philip J:\|:\|PJS has received speaker fees from Takeda, Janssen, Celltrion, Abbvie, Amgen, Dr Falk pharmaceuticals, Tillotts Pharma and has been an advisory board member for Abbvie, Celltrion and Janssen.\|\|Flanagan, Paul K:\|:\|PKF received a Shire Innovation Fund award and has received funded conference travel from Shire and Tillotts.\|\|Subramanian, Sreedhar:\|:\|SS has received speaker fees from Abbvie, Dr Falk pharmaceuticals, Takeda, Janssen, Celltrion, Bristol-Myers Squibb and received educational grants from Abbvie, Takeda and Janssen and is an advisory board member for Abbvie, Dr Falk pharmaceuticals, Vifor pharmaceuticals, Janssen, Takeda and Celltrion. SS is an associate editor for AP&T. |
| P597 | Dr. Yamana, Yoko:\|:\|Grant/Research funding from: AbbVie, Alfresa Pharma, JMDC, Gilead Sciences, Nippon Kayaku, Eli Lilly, Mochida Pharmaceutical, Janssen Pharmaceutical, Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Google LLC\|Endowed chair of: Mitsubishi Tanabe Pharma, Zeria Pharmaceutical, Nippon Kayaku\|\|\|Sagami, Shintaro:\|:\|Grants/research funding from: Japan Foundation for Applied Enzymology\|endowed chair of AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. \|\|AbbVie, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical and Zeria Pharmaceutical.\|\|\|Maeda, Masa: No conflict of interest\|\|Karashima, Ryo: No conflict of interest\|\|Miyatani, Yusuke:\|:\|Grants/research funding from: Japan Foundation for Applied Enzymology.\|Endowed chair of: AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, and EA Pharma. \|\|\|Hojo, Aya: No conflict of interest\|\|Nakano, Masaru: No conflict of interest\|\|Maeda, Ichiro: No conflict of interest\|\|Hibi, Toshifumi:\|:\|Grant/Research funding from: AbbVie, Alfresa Pharma, JMDC, Gilead Sciences, Nippon Kayaku, Eli Lilly, Mochida Pharmaceutical, Janssen Pharmaceutical, Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Google LLC\|Endowed chair of: Mitsubishi Tanabe Pharma, Zeria Pharmaceutical, Nippon Kayaku, Otsuka Holdings, AbbVie, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical\|\|\|Kobayashi, Taku:\|:\|Grant/Research funding from: AbbVie, Alfresa Pharma, JMDC, Gilead Sciences, Nippon Kayaku, Eli Lilly, Mochida Pharmaceutical, Janssen Pharmaceutical, Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Google LLC.\|Endowed chair of: Mitsubishi Tanabe Pharma, Zeria Pharmaceutical, Nippon Kayaku, Otsuka Holdings, AbbVie, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mochida Pharmaceutical. |

| | |
|---|---|
| P598 | Dr. Perotti, Serena: No conflict of interest\|\|Mineccia, Michela: No conflict of interest\|\|Daperno, Marco: No conflict of interest\|\|Massucco, Paolo: No conflict of interest\|\|Gonella, Federica: No conflict of interest\|\|Ferrero , Alessandro: No conflict of interest |
| P599 | Dr. Safroneeva, Ekaterina:\|:\|Employee of Tillotts Pharma AG\|\|Gerstner, Ortrud:\|:\|Employee of Tillotts Pharma AG\|\|Laoun, Raphael:\|:\|Employee of Tillotts Pharma AG |
| P600 | Ryan, Kerry: No conflict of interest\|\|Hou, Jason K.: No conflict of interest\|\|Baker, Jessica: No conflict of interest\|\|Krenz, Christopher: No conflict of interest\|\|De Vries, Raymond: No conflict of interest\|\|Dr. Waljee, Akbar K.:\|:\|Dr. Waljee has intellectual property to disclose. His Algorithm to Predict Clinical Response, Adherence, Shunting with Thiopurines has Patent #8, 126,690,B2;1. This patent currently receives no royalties and is a part of his research and protected intellectual property. This patent is not involved in any way in his current research duties. |
| P601 | Martins, Antonio: No conflict of interest\|\|Silva, Fernando: No conflict of interest\|\|Canelas, Gabriela: No conflict of interest\|\|Ribeiro, Lucia: No conflict of interest\|\|Pinto, Stefano: No conflict of interest\|\|Sarmento, Antonio: No conflict of interest\|\|Magro, Fernando:\|:\|FM served as a speaker and received honoraria from Merck Sharp & Dohme, Abbvie, Vifor, Falk, Laboratórios Vitória, Ferring, Hospira, and Biogen. \|\|Prof. Dr. Ferreira de Abreu, Cândida Manuela:\|:\|Grant: the study received funding from Pfizer Independent Grants for Learning & Change (“IGLC”) ID 42420671.\|CA served as a speaker and received honoraria from Janssen Cilag, Merck Sharp & Dohme and Takeda. |

| | |
|---|---|
| P602 | Magro, Fernando:\|:\|F. Magro received lecture fees from Galapagos, AbbVie, Janssen, Ferring, Tillotts, Celltrion, Takeda, Pfizer, Sandoz, Celgene, Biogen, Samsung Bioepis, MSD, Roche, Arena, Amgen, Vifor, Lilly, Fresenius, and Thermo Fisher.\|\|Peyrin-Biroulet, Laurent:\|:\|L. Peyrin-Biroulet received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillotts, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, and ONO Pharma; and is a stockholder of CTMA.\|\|Sands, Bruce E.:\|:\|B. E. Sands reports consulting fees from Abivax, Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Entera, Evommune, Galapagos, Genentech, Gilead Sciences, GSK, Gossamer Bio, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Janssen, Kaleido, Kallyope, Lilly, Miro Bio, Morphic Therapeutics, MRM Health, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Surrozen, Takeda, Teva, TLL Pharmaceutical, USWM Enterprises, and Viela Bio; speaking fees from Abivax, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; and grant/research support from Janssen.\|\|Danese, Silvio:\|:\|S. Danese received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor; and reports payment for expert testimony from AbbVie, Amgen, Ferring Pharmaceuticals Inc, Gilead, Janssen, Mylan, Pfizer, and Takeda.\|\|Jairath, Vipul:\|:\|V. Jairath has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GSK, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso Pharmaceuticals, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker's fees from AbbVie, Ferring, Bristol Myers Squibb, Galapagos, Janssen, Pfizer, Shire, Takeda, and Fresenius Kabi.\|\|Goetsch, Martina:\|:\|M. Goetsch is an employee of Pfizer Inc.\|\|Bhattacharjee, Abhishek:\|:\|A. Bhattacharjee is an employee of Pfizer.\|\|Wu, Joseph:\|:\|J. Wu is an employee of Pfizer Inc.\|\|Dr. Ferreira Branquinho, Diogo:\|:\|D. Branquinho is an employee of Pfizer Inc.\|\|Modesto, Irene:\|:\|I. Modesto is an employee of Pfizer Inc.\|\|Feagan, Brian G.:\|:\|B. G. Feagan has been a consultant for AbbVie, Admirx, AgomAb Therapeutics, Applied Molecular Transport Inc, Arena Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, F. Hoffmann-La Roche, Janssen, Morphic Therapeutics, OM Pharma, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Theravance, TiGenix, Tillotts, and Zealand Pharma; has received speakers bureau fees from AbbVie, Janssen, and Takeda; served on the Scientific Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, and GSK; is a stockholder of Gossamer Pharma; and is an employee of Western University and Alimentiv Inc. |

| | |
|---|---|
| P603 | Dr. Wands, David: No conflict of interest\|\|Scott, Gregor: No conflict of interest\|\|Wilson, David C: No conflict of interest\|\|Hansen, Richard: No conflict of interest\|\|Chalmer, Iain: No conflict of interest |
| P605 | Dr. Resál, Tamás: No conflict of interest\|\|Bacsur, Péter: No conflict of interest\|\|Bor, Renáta: No conflict of interest\|\|Bálint, Anita: No conflict of interest\|\|Katsanos, Konstantinos: No conflict of interest\|\|Michalopoylos, George: No conflict of interest\|\|Ribaldone, Davide Giuseppe: No conflict of interest\|\|Attauabi, Mohamed: No conflict of interest\|\|Mirabella , Zhao: No conflict of interest\|\|Yanai, Henit: No conflict of interest\|\|Bezzio, Cristina: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest\|\|Bar-Gil Shitrit, Ariella: No conflict of interest\|\|Pugliese, Daniela: No conflict of interest\|\|Lakatos, Peter L: No conflict of interest\|\|Savarino, Edoardo: No conflict of interest\|\|Lukáš, Milan: No conflict of interest\|\|Franko, Matej: No conflict of interest\|\|Chashkova, Elena: No conflict of interest\|\|Molander, Pauliina: No conflict of interest\|\|Nancey, Stéphane: No conflict of interest\|\|Bannon, Lian: No conflict of interest\|\|Krznaric, Zeljko: No conflict of interest\|\|Filip, Rafal: No conflict of interest\|\|Szamosi, Tamás: No conflict of interest\|\|Kaštylová, Kristýna: No conflict of interest\|\|Sarlós, Patrícia: No conflict of interest\|\|Ami-Barak, Hadar: No conflict of interest\|\|Rispo, Antonio: No conflict of interest\|\|Limdi, Jimmy: No conflict of interest\|\|Kagramanova, Anna: No conflict of interest\|\|Szepes, Zoltán: No conflict of interest\|\|Farkas, Klaudia: No conflict of interest\|\|Molnár, Tamás: No conflict of interest |
| P606 | Prof. Iesalnieks, Igors: No conflict of interest\|\|Adamou, Adamos: No conflict of interest\|\|Magdalena, Bercher: No conflict of interest\|\|Streetz, Konrad: No conflict of interest |
| P607 | Dr. Doherty, Jayne: No conflict of interest\|\|Ryan, Anthony: No conflict of interest\|\|Quinn, Emma: No conflict of interest\|\|Dolan, Jackie: No conflict of interest\|\|Corcoran, Roisin: No conflict of interest\|\|O' Hara, Fintan: No conflict of interest\|\|Bailey, Yvonne: No conflict of interest\|\|McNamara, Deirdre: No conflict of interest\|\|Doherty, Glen: No conflict of interest\|\|Kevans, David: No conflict of interest |

| | |
|---|---|
| P608 | Dr. Attauabi, Mohamed: No conflict of interest\|\|Dahl, Emilie Kristine:\|:\|Research grants from Takeda, paid speaker by MSD, Tillotts. \|\|Burisch, Johan:\|:\|Personal fees from AbbVie, Janssen-Cilag, Celgene, Samsung Bioepis, and Pfizer; grants and personal fees from Takeda, MSD, and Tillots Pharma; grants from Novo Nordisk Foundation and Bristol Meyers Squibb. None of these pertain to the research submitted here. \|\|Gubatan, John: No conflict of interest\|\|Nielsen, Ole Haagen: No conflict of interest\|\|Seidelin, Jakob Benedict:\|:\|has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark, and is national coordinator of studies from AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. None of these pertain to the research submitted here. |
| P609 | Colombel, Jean-Frédéric:\|:\|Received research grants from AbbVie, Janssen, and Takeda; received payment for lectures from AbbVie, Allergan, Amgen, Bristol Myers Squibb, Ferring Pharmaceuticals, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Immunic, lmtbio, Inotrem, Ipsen, Iterative Scopes, Janssen, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, TiGenix, and Viela Bio; holds stock options in Intestinal Biotech Development.\|\|Rubin, David T.:\|:\|Served as a consultant for AbbVie, Celgene, Janssen, Pfizer, and Takeda; received grant support from Takeda.\|\|Vermeire, Severine:\|:\|Received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Meyers Squibb.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Meyers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Meyers Squibb.\|\|Lawlor, Garrett:\|:\|Employee and/or shareholder of Bristol Meyers Squibb.\|\|Osterman, Mark T.:\|:\|Employee and/or shareholder of Bristol Meyers Squibb.\|\|Dignass, Axel:\|:\|Received fees for participation in clinical trials and review activities (ie, data monitoring boards, statistical analysis, and endpoint committees) from AbbVie, Abivax, Celgene/Bristol Myers Squibb, Falk Foundation, Gilead, Janssen, and Pfizer; received consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Eli Lilly, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor; received payment for lectures, including service on speaker bureaus, from AbbVie, Eli Lilly, Falk Foundation, Ferring, Gilead/Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, and Vifor; received payment for development of educational presentations from Ferring and Tillotts. \|\|Regueiro, Regueiro:\|:\|Served on advisory boards or as a consultant for AbbVie, Alfasigma, Allergan, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target RWE, and UCB. |

| | |
|---|---|
| P610 | Irving, Peter Miles:\|:\|Peter Irving has received Lecture fees: \|AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, Warner Chilcott \|\|Financial support for research:\|Celltrion, MSD, Pfizer, Takeda, Galapagos\|\|Advisory fees: \|AbbVie, Arena, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, Warner Chilcott\|\|Hur, Peter:\|:\|Peter Hur is an employee of Pfizer Inc. and may may hold shares in Pfizer Inc.\|\|Gautam, Raju: No conflict of interest\|\|Guo, Xiang:\|:\|Xiang Guo is an employee of Pfizer Inc. and may hold shares in Pfizer Inc.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire has received grants from AbbVie, J&J, Pfizer, Takeda and Galapagos; \|Séverine Vermeire has received consulting and/or speaking fees from: AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma |
| P611 | Muñoz Nuñez, J Fernando:\|:\|Speaker, scientific advice, consultant and advisory member and research funding: Takeda, Janssen, Abbvie, MSD, Falk, Tillots, Ferring, Amgen, Mylan and Pfizer.\|\|Rodríguez, Cristina:\|:\|No conflicts of interest to declare. \|\|Gisbert, Javier P.:\|:\|Speaker, scientific advice, consultant and advisory member and research funding: MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. \|\|Bernardo, Sonia:\|:\|Speaker: Janssen\|\|Mr. Aparicio, Jesús:\|:\|Full-time employee in Takeda Farmacéutica España\|\|Tagarro, Ignacio:\|:\|Full-time employee in Takeda Farmacéutica España\|\|Casellas, Francesc:\|:\|Speaker and research funding: AbbVie, Ferring, MSD, Shire, Chiesi, Gebro, Takeda, and Zambon. |

| | |
|---|---|
| P612 | Dr. Macaluso, Fabio Salvatore: No conflict of interest\|\|Principi, Mariabeatrice: No conflict of interest\|\|Facciotti, Federica: No conflict of interest\|\|Contaldo, Antonella: No conflict of interest\|\|Todeschini, Alessia: No conflict of interest\|\|Bezzio, Cristina: No conflict of interest\|\|Saibeni, Simone: No conflict of interest\|\|Castiglione, Fabiana: No conflict of interest\|\|Nardone, Olga Maria: No conflict of interest\|\|Spagnuolo, Rocco: No conflict of interest\|\|Fantini, Massimo Claudio: No conflict of interest\|\|Riguccio, Gaia: No conflict of interest\|\|Conforti, Francesco Simone: No conflict of interest\|\|Caprioli, Flavio Andrea: No conflict of interest\|\|Viganò, Chiara: No conflict of interest\|\|Felice, Carla: No conflict of interest\|\|Fiorino, Gionata: No conflict of interest\|\|Correale, Carmen: No conflict of interest\|\|Bodini, Giorgia: No conflict of interest\|\|Milla, Monica: No conflict of interest\|\|Scardino, Giulia: No conflict of interest\|\|Vernero, Marta: No conflict of interest\|\|Desideri, Federico: No conflict of interest\|\|Bossa, Fabrizio: No conflict of interest\|\|Guerra, Maria: No conflict of interest\|\|Ventimiglia, Marco: No conflict of interest\|\|Mannino, Mariella: No conflict of interest\|\|Rizzo, Giuseppe: No conflict of interest\|\|Orlando, Ambrogio: No conflict of interest |
| P613 | Dr. Mcgrory, Lisa: No conflict of interest\|\|Goess, Charlotte: No conflict of interest\|\|Lynch, Kate:\|:\|Kate Lynch has received: \|•Speaker honoraria from Bristol Myers Squibb, Dr Falk, Takeda, Abbvie, Chiesi, Gilead, and Pfizer.\|•Travel expenses for conference attendance from Dr Falk, Intercept Pharmaceuticals, Norgine, Takeda, MSD\|•Consulting fees from Abbvie, Intercept Pharmaceuticals, Janssen-Cilag, Emerge Health and Guidepoint, Bristol Myers Squibb.\|•Conference registration costs from Ferring\|•Previous salary support from MSD |
| P614 | Dr. An, Yoon-Kyo: No conflict of interest\|\|Fernandes, Richard: No conflict of interest\|\|Lindsay, Niamh: No conflict of interest\|\|Khoo, Emi: No conflict of interest\|\|Pham, Hai: No conflict of interest\|\|Wong, Kam-Fai: No conflict of interest\|\|Thin, Lena: No conflict of interest\|\|Goodsall, Tom: No conflict of interest\|\|Bryant, Rob V: No conflict of interest\|\|Wright, Emily: No conflict of interest\|\|Smith, Rebecca: No conflict of interest\|\|Friedman, Antony: No conflict of interest\|\|Begun, Jakob: No conflict of interest |

| | |
|---|---|
| P615 | Mr. Li, Youran: No conflict of interest\|\|Gu, Yunfei: No conflict of interest |
| P616 | Ms. Focht, Gili:\|:\|Last 3 years received consultation fee from Abbvie and Lilly\|\|\|Turner, Shira: No conflict of interest\|\|Carmon, Natalie: No conflict of interest\|\|Lev-Tzion, Raffi: No conflict of interest\|\|Orlanski-Meyer, Esther: No conflict of interest\|\|Ledder, Oren: No conflict of interest\|\|Yogev, Dotan: No conflict of interest\|\|Assa, Amit: No conflict of interest\|\|Turner, Dan:\|:\| Last 3 years received consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS |
| P617 | Dr. Abbas, Rasha: No conflict of interest\|\|Ibrahim, Nazira: No conflict of interest\|\|Elawad, Mamoun: No conflict of interest\|\|Al-Mudahka, Fatma: No conflict of interest\|\|Abdelrhman, Hatim: No conflict of interest\|\|K.Akobeng, Anthony: No conflict of interest |
| P618 | Mr. Sabhan, Haider: No conflict of interest |

| | |
|---|---|
| P619 | Dr. Vieujean, Sophie:\|:\|Speaker fees from Abbvie, Takeda, Janssen\|\|De Vos, Michel:\|:\|M De Vos has receiver speaker fees from Ferring, Merck, Gedeon Richter, Organon and Cooper Surgical.\|\|D'Amico, Ferdinando:\|:\|F D'Amico has served as a speaker for Janssen, Galapagos, Sandoz, and Omega Pharma.\|\|Paridaens, Kristine: No conflict of interest\|\|Daftary, Gaurang: No conflict of interest\|\|Peyrin-Biroulet, Laurent:\|:\|L Peyrin-Biroulet : personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals , Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine ; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance ; Pandion Therapeutics, grants from Abbvie, MSD, Takeda, Fresenius Kabi, stock options : CTMA.\|\|Danese, Silvio:\|:\|S Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. |
| P620 | Mccrossan, Mark: No conflict of interest\|\|O'Moráin, Neil: No conflict of interest\|\|Kumar, Lakshman: No conflict of interest\|\|Rowan, Catherine: No conflict of interest\|\|Sheridan, Juliette: No conflict of interest\|\|Cullen, Garret: No conflict of interest\|\|Doherty, Glen: No conflict of interest\|\|Mulcahy, Hugh: No conflict of interest |
| P621 | Dr. Kim, Seong Jung: No conflict of interest\|\|Lee, Jun: No conflict of interest\|\|Kim, Dong Hyun: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Kim, Eun Soo: No conflict of interest\|\|Kim, Kyeong Ok: No conflict of interest\|\|Lee, Yoo Jin: No conflict of interest\|\|Song, Eun Mi: No conflict of interest\|\|Kim, Dae Sung: No conflict of interest |
| P622 | Mrs. Barth, Iris: No conflict of interest\|\|Stevens, Corien L.: No conflict of interest\|\|Campmans-Kuijpers, Marjo J.E.:\|:\|Marjo Campmans received a research grant from Baxter and Bbraun, and received speaker fees from Takeda and Baxter. \|\|Dijkstra, Gerard:\|:\|Gerard Dijkstra received a research grant from Royal DSM and received speaker fees from Pfizer, Abbvie and Janssen Pharmaceuticals. |

| | |
|---|---|
| P623 | Dr. Musto, Francesca: No conflict of interest\|\|Ranalli, Marco: No conflict of interest\|\|Giordano, Carla: No conflict of interest\|\|Bianchi, Eleonora: No conflict of interest\|\|Veraldi, Silvio: No conflict of interest\|\|Oliva, Salvatore: No conflict of interest\|\|D'Arcangelo, Giulia: No conflict of interest\|\|Aloi, Marina: No conflict of interest |
| P624 | Dr. Burisch, Johan:\|:\|JB reports personal fees from AbbVie, Celgene, Ferring Pharmaceuticals, Galapagos, Janssen-Cilag, Pfizer, Pharmacosmos and Samsung Bioepis; grants and personal fees from MSD, Takeda and Tillotts Pharma; and grants from Bristol Myers Squibb and Novo Nordisk, outside the submitted work.\|\|Hart, Ailsa:\|:\|AH has served as a consultant, advisory board member or speaker for AbbVie, Arena Pharmaceuticals, Atlantic, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Ferring Pharmaceuticals, Janssen Pharmaceuticals, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda; and serves on the Global Steering Committee for Genentech.\|\|Sturm, Andreas:\|:\|AS has received grant support from AbbVie; and consulting or speaker fees from AbbVie, Dr. Falk Pharma, Galapagos, Janssen Pharmaceuticals, MSD, Pfizer, Takeda and Tillotts.\|\|Knight, Hannah:\|:\|HK is an employee of Adelphi Real World. \|\|Rudolph, Christine:\|:\|CR is an employee and shareholder of Galapagos NV.\|\|Meadows, Rachael:\|:\|RM is an employee of Adelphi Real World. \|\|Oortwijn, Alessandra:\|:\|AO is an employee and shareholder of Galapagos NV. \|\|Weatherby, Sarah:\|:\|SW is an employee of Adelphi Real World. \|\|Rolph, Roger:\|:\|RR is an employee and shareholder of Galapagos NV.\|\|Dawod, Fatima:\|:\|FD is an employee of Adelphi Real World. \|\|Armuzzi, Alessandro:\|:\|AA reports consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos NV, Gilead, Janssen Pharmaceuticals, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz and Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Gilead, Janssen Pharmaceuticals, Mitsubishi Tanabe, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda and TiGenix; and research grants from MSD, Pfizer and Takeda. |
| P625 | Llaó, Jordina: No conflict of interest\|\|Martín-Arranz, Eduardo: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|Navarro-Llavat, Mercè: No conflict of interest\|\|Garcia-Planella, Esther: No conflict of interest\|\|Busquets, David: No conflict of interest\|\|Monfort, David: No conflict of interest\|\|Pineda, Juan Ramon: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Villoria, Albert: No conflict of interest\|\|Menchén, Luis: No conflict of interest\|\|Bastida, Guillermo: No conflict of interest\|\|García-Alonso, Fracisco Javier: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Chaparro, María: No conflict of interest\|\|Riestra, Sabino: No conflict of interest\|\|Merino, Olga: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Barreiro-de-Acosta, Manuel: No conflict of interest\|\|Dr. Domènech Moral, Eugeni: No conflict of interest |

| | |
|---|---|
| P626 | Dr. Todeschini, Alessia: No conflict of interest\|\|Geccherle, Andrea: No conflict of interest\|\|Signoretto, Paola: No conflict of interest\|\|Variola, Angela: No conflict of interest |
| P627 | Mrs. Pascual Oliver, Andrea:\|:\|A. Pascual Oliver has received research funding from Janssen and Takeda. \|\|Cuarán, Camila:\|:\|C. Cuarán has received research funding from Janssen and Takeda. \|\|Casas-Deza, Diego:\|:\|Dr. Casas-Deza has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring and Faes Farma. D.C-D. is partially supported by a Rio-Hortega fellowship from Health Institute Carlos III. \|\|García-López, Santiago:\|:\|Santiago García-López has served as a speaker, advisory member for or has received research funding from AbbVie, MSD, Takeda, Janssen and Pfizer. \|\|Corsino-Roche, Pilar:\|:\|P. Corsino-Roche has served as a speaker, for or has received research funding from AbbVie, Janssen and Pfizer\|\|Sierra Moros, Eva: No conflict of interest\|\|Julián-Gomara, Ana Belén:\|:\|A.B Julián-Gomara has received research funding from Casen Recordati, Tillots Pharma, Janssen and Takeda. \|\|Vicente-Lidón, Raquel:\|:\|Dra. Vicente has served as speaker, consultant, and/or advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Ferring, Chiesi and Faes Farma. |
| P628 | Dr. Ledder, Oren: No conflict of interest\|\|Dubinsky, Marla: No conflict of interest\|\|Dolinger, Michael: No conflict of interest\|\|Fatima, Ayesha: No conflict of interest\|\|Suskind, David: No conflict of interest\|\|Scarlett, Jarrad: No conflict of interest\|\|Röeser, Dennis: No conflict of interest\|\|Shouval, Dror: No conflict of interest\|\|Meyer, Gabriele: No conflict of interest\|\|Molle Rios, Zarela: No conflict of interest\|\|Pujol, Gemma: No conflict of interest\|\|Lozano, Anna: No conflict of interest\|\|Kolho, Kaija-Leena: No conflict of interest\|\|Rohani, Pejman: No conflict of interest\|\|Hussey, Seamus: No conflict of interest\|\|de Mejj, Tim: No conflict of interest\|\|Ayers, Travis: No conflict of interest\|\|Navas López, Victor Manuel: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Tzivinikos, Christos: No conflict of interest |

| | |
|---|---|
| P629 | Ylisaukko-oja, Tero:\|:\|Tero Ylisaukko-oja is owner of MedEngine Oy. MedEngine Oy has been paid by Takeda Oy to perform this study.\|\|Af Björkesten, Clas-Göran:\|:\|Clas-Göran af Björkesten has received speaker and consultant honoraria from Abbvie, Janssen, MSD, Pfizer, and Takeda, and consultant honoraria from BMS, Mylan, Ferring, and Vifor Pharma.\|\|Erbel, Anja:\|:\|Anja Erbel has received speaker fees from Janssen-Cilag. \|\|Nuutinen, Heikki:\|:\|Heikki Nuutinen has received a speaking fee from Takeda.\|\|Jussila, Airi: No conflict of interest\|\|Molander, Pauliina:\|:\|Pauliina Molander reports personal fees from Abbvie, BMS, Celltrion, Gilead, Janssen-Cilag, Orion, Pfizer, Roche, Sandoz, Takeda, Tillotts Pharma and Viatris.\|\|Koskela, Ritva:\|:\|Ritva Koskela reports personal fees from ViforPharma, Janssen-Cilag, Takeda and Ferring. \|\|Blomster, Timo: No conflict of interest\|\|Pajala, Markku: No conflict of interest\|\|Ilus, Tuire: No conflict of interest\|\|Haiko, Paula:\|:\|Paula Haiko is employed by Takeda Oy.\|\|Kovac, Bianca:\|:\|Bianca Kovac is employed by Takeda Oy. \|\|Silvola, Saija:\|:\|Saija Silvola is employed by Takeda Oy.\|\|Smith, Sarah:\|:\|Sarah Smith is employed by MedEngine Oy.\|\|Jokelainen, Jari:\|:\|Jari Jokelainen is employed by MedEngine Oy.\|\|Sipponen, Taina:\|:\|Taina Sipponen has received consultant honoraria from Abbvie, BMS, Janssen-Cilag, Pfizer, Takeda and speaking fee from Celltrion and Janssen-Cilag. |
| P630 | Schreiber, Stefan Wolfgang:\|:\|Stefan Schreiber has received consulting fees from AbbVie, Amgen, Arena, BMS, Boehringer Ingelheim, Celltrion, Falk Pharma, Ferring, Galapagos/Gilead, Genentech/Roche, GlaxoSmithKline, IMAB Biopharma, Lilly, MSD, Pfizer, Shire, and Takeda.\|\|Lim, Allen:\|:\|Allen Lim has received research funding from AbbVie, Janssen, Lilly, and Takeda and has served on advisory boards for AbbVie, Ferring, Janssen, and Takeda. He has been a speaker for AbbVie, Janssen, and Takeda and has been a principal investigator for and owns stock in AbbVie.\|\|Lacerda, Ana Paula:\|:\|Ana Paula Lacerda is an employee of AbbVie and may own stock options.\|\|Allegretti, Jessica R.:\|:\|Jessica Allegretti has received consulting from Janssen, Pfizer, AbbVie, Iterative Scopes, Finch Therapeutics, Seres Therapeutics, Ferring, Merck, Bristol Myer Squibb; has received research funding from Pfizer, Janssen and Merck; has served on a speaker's bureau for AbbVie, BMS and Janssen. \|\|Watanabe, Kenji:\|:\|Kenji Watanabe has received consulting fees from AbbVie, EA Pharma, Takeda, Janssen, Pfizer, GlaxoSmithKline, Mitsubishi Tanabe, Kyorin, Kissei, Mochida, Zeria, Nippon Kayaku, Sandoz, Olympus, and JIMRO. He has also received research grants from AbbVie, Helmsley Charitable Trust, EA Pharma, Takeda, Mitsubishi Tanabe, Mochida, Nippon Kayaku, EP CRSU, and JIMRO.\|\|Lukin, Dana:\|:\|Dana Lukin has received consulting from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Palatin Technologies, Prometheus Laboratories, and Pfizer; has received research funding from AbbVie, Janssen, and Takeda; has served on a speaker's bureau for AbbVie and Janssen.\|\|Dubenco, Elena:\|:\|Ana Paula Lacerda is an employee of AbbVie and may own stock options.\|\|Ford, Sharanya:\|:\|Sharanya Ford is an employee of AbbVie and may own stock options.\|\|Oomen, Jessica:\|:\|Jessica Oomen is an employee of AbbVie and may own stock options.\|\|Zhou, Qian:\|:\|Qian Zhou is an employee of AbbVie and may own stock options.\|\|Liu, Jianzhong:\|:\|Jianzhong Liu is an employee of AbbVie and may own stock options.\|\|Louis, Edouard:\|:\|Edouard Louis has received research grants from Janssen, Pfizer, and Takeda; received educational grants from AbbVie, Janssen, MSD, and Takeda; received speaker fees from AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda; served on advisory boards for AbbVie, Arena, Celgene, Ferring, Galapagos, Gilead, Hospira, Janssen, MSD, Pfizer, and Takeda; and served as a consultant for AbbVie. |

| | |
|---|---|
| P631 | Louis, Edouard:\|:\|Educational and research grant: Janssen, Pfizer, Abbvie and Takeda, Fresenius-Kabi; speaker fees: Abbvie, Falk, Ferring, Janssen, Pfizer, Celgene, BMS, Galapagos and Takeda; advisory board: Abbvie, Celgene, Ferring, Janssen, BMS, Pfizer,Takeda, Gilead-Galapagos, Arena, Eli Lilly; consultant: Abbvie\|\|Sebastien, Shaji:\|:\|Research grants from Takeda, Pfizer, Tillotts Pharma, Abbvie, Biogen, personal fees for Speaker role and advisory board meetings from Janssen, Amgen, Tillotts Pharma, Abbvie, Takeda, Celgene, Roche, Phramacosmos, Falk pharma outside the submitted work\|\|Siegmund, Britta:\|:\|Consulting fees from: Abbvie, BMS, Boehringer, Falk, Galapagos, Jassen, Lilly, Pfizer, PredictImmeune, Landos, Takeda; Speaker Fees: Abbvie, Falk, Ferring, Janssen, Pfizer, BMS, Takeda, CED Service GmbH, Lilly; Grant: Pfizer.\|\|Bossuyt, Peter:\|:\|Research grant: Abbvie, Amgen, Celltrion, Mylan, Pfizer and Takeda. Lecture fees: AbbVie, Celltrion, Janssen, Lilly and Takeda. Consulting: Abbvie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros\|\|Danese, Silvio:\|:\|Lecture fees: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim; Consultancy: AbbVie, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim.\|\|de Boer, Nanne:\|:\|Served as a speaker for AbbVie and MSD and has served as consultant and/or principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma BV, MLDS and Takeda.\|\|Loftus, Edward:\|:\|Financial support for research: AbbVie, Takeda, Janssen, UCB, Amgen, Pfizer, Genentech, Celgene, Receptos, Gilead, Bristol-Myers Squibb, Robarts Clinical Trials, Theravance; Consultancy: AbbVie, Takeda, Janssen, UCB, Amgen, Pfizer, Eli Lilly, Celltrion Healthcare, Allergan, Bristol-Myers Squibb, Celgene, Gilead, Genentech, Boehringer Ingelheim, Calibr, Iterative Scopes, Ono Pharma, Sun Pharma, Arena.\|\|Moum, Bjørn:\|:\|Received honoraria for advisory board and speaking fees from Janssen AB, Takeda AS, Ferring Pharma, Tillotts Pharma AB, Bristol Meyer Squibb, Gilead Sci, Galapagos, Norgine. Received research grants from Tillotts Pharma AB and Ferring Pharma.\|\|Peyrin-Biroulet, Laurent:\|:\|Personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enterome, Enthera, Ferring, Fresenius Kabi, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, MSD, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Therevance, Tillotts and Vifor; grants from AbbVie, MSD and Takeda; and stock options from CTMA.\|\|Schreiber, Stefan:\|:\|Consultancy and personal fees from AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Gilead, HIKMA, IMAB, Janssen, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz, Takeda, and Theravance.\|\|Zhou, Jie:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Wernicke, Joe:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Angellotti, Edith:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Siegel, Corey:\|:\|Advisory board for Abbvie, BMS, Fresnius, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, ProciseDx, Prometheus, Takeda, Trellus Health; Speaker for CME activities for Abbvie, Janssen, Pfizer and Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda. |

| | |
|---|---|
| P632 | D'Haens, Geert:\|:\|G. D'Haens receiving consulting fees from AbbVie, AgomAb, AstraZeneca, AMT, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GSK, Gossamer Bio, Pfizer, Immunic, J&J, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist; and speaker fees from AbbVie, Galapagos, Gilead, J&J, Pfizer, BMS, and Takeda.\|\|Dubinsky, Marla C.:\|:\|M. C. Dubinsky received consulting fees from AbbVie, Arena, BMS, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; and is founder and a shareholder of Trellus Health.\|\|Peyrin-Biroulet, Laurent:\|:\|L. Peyrin-Biroulet received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillotts, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, and ONO Pharma; and is a stockholder of CTMA.\|\|Danese, Silvio:\|:\|S. Danese received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc, Gilead, Hospira, Inotrem, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor; and reports payment for expert testimony from AbbVie, Amgen, Ferring Pharmaceuticals Inc, Gilead, Janssen, Mylan, Pfizer, and Takeda.\|\|Sands, Bruce E.:\|:\|B. E. Sands reports consulting and speaking fees from Abivax, Bristol Myers Squibb, Janssen, Lilly, Pfizer, and Takeda; consulting fees from AbbVie, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Calibr, Celltrion Healthcare, ClostraBio, Cytoki Pharma, Connect Biopharma, Entera, Evommune, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunic, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Kaleido, Kallyope, MiroBio, Morphic Therapeutics, MRM Health, OSE Immunotherapeutics, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Sun Pharma, Surrozen, Synlogic, Target RWE, Teva, Theravance Biopharma, TLL Pharmaceutical, USWM Enterprises, VielaBio, and VTA Labs; and personal fees and stock options for consulting from Ventyx Biosciences.\|\|Wolf, Douglas C.:\|:\|D. C. Wolf received consulting and/or speaker honoraria from AbbVie, Arena, BMS, Janssen, Lilly, Pfizer, and Takeda.\|\|Yarur, Andres:\|:\|A. Yarur received consulting fees from Takeda, Prometheus Labs, Arena Pharmaceuticals, and Bristol Myers Squibb; and speakers bureau fees from Bristol Myers Squibb.\|\|Chiorean, Michael:\|:\|M. Chiorean has been a speaker for AbbVie, Janssen, Medtronic, Pfizer |

| | |
|---|---|
| | Inc, Bristol Myers Squibb, and Takeda; and has served as a consultant for AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Medtronic, Pfizer Inc, Lilly, Prometheus, Fresenius-Kabi, and Takeda.\|\|Dr. Dray, Danielle:\|:\|D. Dray is an employee of Pfizer Inc.\|\|Modesto, Irene:\|:\|I. Modesto is an employee of Pfizer Inc.\|\|Tan, Huaming:\|:\|H. Tan is an employee of Pfizer Inc.\|\|Gu, Guibao:\|:\|G. Gu is an employee of Pfizer Inc.\|\|Lopez, Claudia:\|:\|C. Lopez was an employee of Arena Pharmaceuticals at the time of this analysis.\|\|Su, Chinyu:\|:\|C. Su is an employee of Pfizer Inc.\|\|Zhang, Jinkun:\|:\|J. Zhang is an employee of Pfizer Inc.\|\|McDonnell, Aoibhinn:\|:\|A. McDonnell is an employee of Pfizer Inc.\|\|Schreiber, Stefan:\|:\|S. Schreiber has been a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb; Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresenius, Galapagos, Genentech, GSK, Gilead, I-MAB Biopharma, Janssen, Lilly, Merck, Novartis/Sandoz, Pfizer, Protagonist, Takeda, and Theravance.\|\|Feagan, Brian G.:\|:\|B. G. Feagan has been a consultant for AbbVie, Admirx, AgomAb Therapeutics, Applied Molecular Transport Inc, Arena Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, F. Hoffmann-La Roche, Janssen, Morphic Therapeutics, OM Pharma, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Theravance, TiGenix, Tillotts, and Zealand Pharma; has received speakers bureau fees from AbbVie, Janssen, and Takeda; served on the Scientific Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, and GSK; is a stockholder of Gossamer Pharma; and is an employee of Western University and Alimentiv Inc.\|\|Vermeire, Séverine:\|:\|S. Vermeire received grants from AbbVie, J&J, Pfizer, Galapagos, and Takeda; and has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, IMIDomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MRM Health, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand Pharma. |
| P633 | Dhar, Anjan:\|:\|Consultancy fees, honorarium, advisory fees from Takeda, Tillotts, Dr Falk, Janssen, Galapagos, Abbvie, Guidepoint Consulting, GLG Consulting\|\|Wilson, Alan:\|:\|Honorarium/advisory fees from Takeda, Pharmacosmos and Abbvie.\|\|Reid, Vanessa:\|:\|Honorarium/advisory fees from Takeda\|\|Clark, Tanya:\|:\|Honorarium/advisory fees from Takeda and Celltrion\|\|Tibbatts, Clare:\|:\|Honorarium/advisory fees/conferences/charitable grants from Takeda, Abbvie, Tillotts. \|\|Dallongeville, Agathe:\|:\|Employee of Takeda Pharmaceuticals International AG\|\|Robertson, James:\|:\|Employee of Takeda UK Ltd\|\|Mr. Eaton, Jack: No conflict of interest\|\|Cranmer, Holly: No conflict of interest\|\|Owen, Glynn:\|:\|Employee of Takeda UK Ltd |

| | |
|---|---|
| P634 | Dr. Calafat Sard, Margalida: No conflict of interest\|\|Pascual, Isabel: No conflict of interest\|\|Nos, Pilar: No conflict of interest\|\|Barrio, Jesús: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Martín-Arranz, M Dolores: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Gomollón, Fernando: No conflict of interest\|\|Sierra Ausín, Mónica: No conflict of interest\|\|Huguet, José M: No conflict of interest\|\|Guardiola, Jordi: No conflict of interest\|\|Vera, Isabel: No conflict of interest\|\|Varela, Pilar: No conflict of interest\|\|Iglesias, Eva: No conflict of interest\|\|Garcia-Planella, Esther: No conflict of interest\|\|de Castro , Luisa: No conflict of interest\|\|García Sepulcre , Mariana Fe: No conflict of interest\|\|Sicilia, Beatriz: No conflict of interest\|\|Fernández-Salazar, Luis: No conflict of interest\|\|Calvet, Xavier: No conflict of interest\|\|Muñoz, Fernando: No conflict of interest\|\|García-López, Santiago: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Ramos, Laura: No conflict of interest\|\|Martínez Montiel, Pilar: No conflict of interest\|\|Lorente, Rufo: No conflict of interest\|\|Cabriada, José Luis: No conflict of interest\|\|Piqueras, Marta: No conflict of interest\|\|Marín-Jiménez, Ignacio: No conflict of interest\|\|Esteve, Maria: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Sesé, Eva: No conflict of interest\|\|P. Gisbert, Javier: No conflict of interest\|\|Márquez, Lucía: No conflict of interest\|\|Busquets, David: No conflict of interest\|\|Pajares, Ramón: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Mañosa, Míriam: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest |
| P635 | Prof. Bar-Gil Shitrit, Ariella:\|:\|A. Bar Gil Shitrit reports consulting/advisory fees from Takeda, Janssen, Neopharm, Pfizer and Abbvie; Speaking and teaching fees from Takeda, Janssen, Abbvie, Neopharm, Rafa, BMS and Pfizer; and research support from Takeda and Janssen.\|\|Gil, Yoel: No conflict of interest\|\|Israeli, Eran: No conflict of interest\|\|Koslowsky, Benjamin: No conflict of interest\|\|Mazuz, Betty: No conflict of interest\|\|Israel, Ilana: No conflict of interest\|\|Goldenberg, Rosalind: No conflict of interest\|\|Ben-Bassat, Ofer: No conflict of interest\|\|Weisbrud, Amir: No conflict of interest\|\|Ledder, Oren: No conflict of interest\|\|Zinger, Adar: No conflict of interest\|\|Ben Horin, Shomron: No conflict of interest\|\|Goldin, Eran: No conflict of interest\|\|Lahat, Adi: No conflict of interest |

| | |
|---|---|
| P636 | Ferrante, Marc:\|:\|Research grants from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris. Consultancy fees from AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lily, Janssen-Cilag, Medtronic, MSD, Pfizer, Sandoz, Samsung Bioepis, Regeneron, Takeda and Thermo Fisher. Speaker fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda and Truvion Healthcare.\|\|Christensen, Britt:\|:\|Research grants from AbbVie, Janssen, Pfizer and Takeda. Advisor/Speaker fees from: AbbVie, BMS, Celltrion, Falk, Ferring, Fresenius Kabi, Gilead, Janssen-Cilag, MSD, Pfizer, Sandoz and Takeda.\|\|Bressler, Brian:\|:\|Advisor/Speaker: AbbVie, Bristol Myers Squibb, Ferring, Janssen, Merck, Novartis, Pfizer, Takeda. Advisor: Alimentiv, Allergan, Amgen, AMT, Bausch Health, Bristol Myers Squibb, Celgene, Fresenius Kabi, Genentech, Gilead, Iterative Scopes, Merck, Microbiome Insights, Mylan, Pendopharm, Protagonist. Research support: AbbVie, Alvine, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Merck, Qu Biologic. Stock options: Qu Biologic\|\|Brett, Neil:\|:\|Employee of Thermo Fisher Scientific.\|\|Bassel, Marielle:\|:\|Employee of Thermo Fisher Scientific.\|\|Kamble, Pravin:\|:\|Employee of the study sponsor, Takeda, and holds Takeda stock or stock options.\|\|Adsul, Shashi:\|:\|Employee of the study sponsor, Takeda, and holds Takeda stock or stock options.\|\|Gianchetti, Lauren:\|:\|Employee of Thermo Fisher Scientific.\|\|Scharl, Michael:\|:\|Consultancy fees: AbbVie, Celltrion, Fresenius, Gilead, Takeda, Topadur, Roche. Speaker fees: Falk Pharma, Phytolis, Vifor Pharma, Zambon. Research grants: AbbVie, Axalbion, Basilea Pharmaceuticals, Calypso Biotech, Gilead, Gnubiotiocs, Herbodee, LimmatTech, NodThera, PharmaBiome, Roche, Takeda, Topadur, Vifor, Zealand Pharma. Stock options: PharmaBiome, Recolony. |
| P637 | Ms. Dal Buono, Arianna: No conflict of interest\|\|Gabbiadini, Roberto: No conflict of interest\|\|Migliorisi, Giulia: No conflict of interest\|\|Solitano, Virginia: No conflict of interest\|\|Canziani, Lorenzo: No conflict of interest\|\|Repici, Alessandro: No conflict of interest\|\|Armuzzi, Alessandro: No conflict of interest |

| | |
|---|---|
| P638 | Prof. Fumery, Mathurin: No conflict of interest\|\|Defrance, Antoine: No conflict of interest\|\|Roblin, Xavier: No conflict of interest\|\|Altwegg, Romain: No conflict of interest\|\|Caron, Benedicte: No conflict of interest\|\|Hebuterne, Xavier: No conflict of interest\|\|Carmen, Stefanescu: No conflict of interest\|\|Meyer, Antoine: No conflict of interest\|\|Nachury, Maria: No conflict of interest\|\|Laharie, David: No conflict of interest\|\|Nancey, Stephane: No conflict of interest\|\|Le Berre, Catherine: No conflict of interest\|\|Serrero, Melanie: No conflict of interest\|\|Geyl, Sophie: No conflict of interest\|\|Gilletta, Cyrielle: No conflict of interest\|\|Ah Soune, Philippe: No conflict of interest\|\|Duveau, Nicolas: No conflict of interest\|\|Uzza, Mathieu: No conflict of interest\|\|Abitbol, Vered: No conflict of interest\|\|Biron, Amelie: No conflict of interest\|\|Tran Minh, My Linh: No conflict of interest\|\|Paupard, Thierry: No conflict of interest\|\|Vuitton, Lucine: No conflict of interest\|\|Elgharabawy, Yasmine: No conflict of interest\|\|Peyrin-biroulet, Laurent: No conflict of interest |
| P639 | Belvedere, Angela: No conflict of interest\|\|Dajti, Gerti: No conflict of interest\|\|Larotonda, Cristina: No conflict of interest\|\|Angelicchio, Laura: No conflict of interest\|\|Rizzello, Fernando: No conflict of interest\|\|Gionchetti, Paolo: No conflict of interest\|\|Poggioli, Gilberto: No conflict of interest\|\|Prof. Rottoli, Matteo: No conflict of interest |
| P640 | Dr. Edelman-Klapper, Hadar: No conflict of interest\|\|Rabinowitz, Keren Masha: No conflict of interest\|\|Zittan, Eran:\|:\| has received research support and consulting fees from Janssen, Abbvie, Takeda, Neopharm, Celgene and Pfizer.\|\|Bar-Gil Shitrit, Ariella:\|:\|Grant support from Takeda and Janssen, consultancy and lectures fees from Takeda, Janssen, Abbvie, Pfizer, Neopharm and BMS\|\|Goren, Idan: No conflict of interest\|\|Avni-Biron, Irit: No conflict of interest\|\|Ollech, Jacob E.: No conflict of interest\|\|Lichtenstein, Lev: No conflict of interest\|\|Banai-Eran, Hagar: No conflict of interest\|\|Yanai, Henit: No conflict of interest\|\|Snir, Yifat: No conflict of interest\|\|Pauker, Maor H.: No conflict of interest\|\|Friedenberg, Adi: No conflict of interest\|\|Levy-Barda, Adva: No conflict of interest\|\|Segal, Arie: No conflict of interest\|\|Broitman, Yelena: No conflict of interest\|\|Maoz, Eran: No conflict of interest\|\|Ovadia, Baruch: No conflict of interest\|\|Aharoni Golan, Maya: No conflict of interest\|\|Shachar, Eyal: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Mor, Michal: No conflict of interest\|\|Ben Zvi, Haim: No conflict of interest\|\|Perets, Tsachi-Tsadok: No conflict of interest\|\|Eliakim, Rami: No conflict of interest\|\|Barkan, Revital: No conflict of interest\|\|Navon, Michal: No conflict of interest\|\|Gal-Tanamy, Meital: No conflict of interest\|\|Freund, Natalia T.: No conflict of interest\|\|Goren, Sophy: No conflict of interest\|\|Cohen, Dani: No conflict of interest\|\|Dotan, Iris: No conflict of interest |

| | |
|---|---|
| P641 | Dr. Les, Anda: No conflict of interest\|\|Cotruta, Bogdan: No conflict of interest\|\|Iacob , Razvan: No conflict of interest\|\|Saizu, Roxana: No conflict of interest\|\|Gheorghe, Liana: No conflict of interest\|\|Gheorghe, Cristian: No conflict of interest |
| P642 | Chahal, Jacinder: No conflict of interest\|\|Sriranganathan, Danujan: No conflict of interest\|\|Poo, Stephanie: No conflict of interest\|\|Dr. Lo, Sheng Wei: No conflict of interest\|\|Kashkooli, Soleiman: No conflict of interest\|\|Garg, Mayur: No conflict of interest\|\|Segal, Jonathan P: No conflict of interest |
| P643 | Ms. Sanz Segura, Patricia: No conflict of interest\|\|Gomollón, Fernando: No conflict of interest\|\|García García, Sonia: No conflict of interest\|\|Vela, Milagros: No conflict of interest\|\|Fernández-Clotet, Agnès: No conflict of interest\|\|Muñoz, Roser: No conflict of interest\|\|García de la Filia, Irene: No conflict of interest\|\|García Prada, María: No conflict of interest\|\|Ferrer Rosique, Juan Angel: No conflict of interest\|\|García, María José:\|:\|M.J.G. has received financial support for travelling and educational activities from Janssen, Pfizer, AbbVie, Takeda, Kern Pharma, Faes Farma and Ferring.\|\|de Francisco, Ruth: No conflict of interest\|\|Arias, Lara: No conflict of interest\|\|Barrio, Jesús: No conflict of interest\|\|Guerra, Iván: No conflict of interest\|\|Ponferrada Diaz, Angel: No conflict of interest\|\|P. Gisbert, Javier: No conflict of interest\|\|Carrillo-Palau, Marta: No conflict of interest\|\|Calvet, Xavier: No conflict of interest\|\|Márquez-Mosquera, Lucía: No conflict of interest\|\|Gros, Beatriz: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Monfort, David: No conflict of interest\|\|Madrigal, Rosa Eva: No conflict of interest\|\|Roncero, Oscar: No conflict of interest\|\|Laredo, Viviana: No conflict of interest\|\|Montoro, Miguel: No conflict of interest\|\|Muñoz, Carmen: No conflict of interest\|\|López-Cauce, Beatriz: No conflict of interest\|\|Lorente, Rufo: No conflict of interest\|\|Fuentes, Ana: No conflict of interest\|\|Vega, Pablo: No conflict of interest\|\|Martín, Dolores: No conflict of interest\|\|Nerín de la Puerta, Juan: No conflict of interest\|\|Varela, Pilar: No conflict of interest\|\|Casas-Deza, Diego: No conflict of interest\|\|Martínez, Pilar: No conflict of interest\|\|Pajares, Ramón: No conflict of interest\|\|J. Lucendo, Alfredo: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|García-López, Santiago:\|:\|S.G.L. has served as a speaker, advisory member for or has received research funding from AbbVie, MSD, Takeda, Janssen and Pfizer |
| P644 | Dr. Tanaka, Akihito: No conflict of interest\|\|Kanmura, Shuji: No conflict of interest\|\|Maeda, Nobuhisa: No conflict of interest\|\|Kuwazuru, Kosuke: No conflict of interest\|\|Komaki, Fukiko: No conflict of interest\|\|Komaki, Yuga: No conflict of interest\|\|Ido, Akio: No conflict of interest |

| | |
|---|---|
| P645 | Mr. Martinez Navarro, Gorka: No conflict of interest\|\|Palomino Pérez, Laura María: No conflict of interest\|\|Velasco Rodríguez-Belvís, Marta: No conflict of interest\|\|Cañedo Villarroya, Elvira: No conflict of interest\|\|De la Mano Hernández, Agustin: No conflict of interest\|\|Dominguez Ortega, Gloria: No conflict of interest\|\|Martínez Pérez, Jorge: No conflict of interest\|\|Martín Fernández, Carmen: No conflict of interest\|\|Di Campli Zaghlul, Marianna: No conflict of interest\|\|García Hernández, Paloma: No conflict of interest\|\|Sánchez Llorente, Paula: No conflict of interest\|\|Muñoz Codoceo, Rosa Ana: No conflict of interest |
| P646 | Sands, Bruce E:\|:\|Consulting: Amgen, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Calibr, Celltrion Healthcare, ClostraBio, Entera, Evommune, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Kaleido, Kallyope, Lilly, Miro Bio, Morphic Therapeutics, MRM Health, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Surrozen, Teva, TLL Pharmaceutical, USWM Enterprises, VielaBio. \|Consulting, speaking, research funding: Bristol Myers Squibb.\|Consulting, speaking, grant/research support: Janssen; consulting, speaking: Abivax, Pfizer, Takeda.\|\|Feagan, Brian G:\|:\|Brian Feagan: Consulting: AbbVie, AbolerIS, AgomAB Therapeutics, Allianthera, Amgen, AnaptysBio, Applied Molecular Transport Inc., Arena Pharma, Avir, Azora Therapeutics, BioJamp, Biora Therapeutics, Boehringer-Ingelheim, Boston Pharma, Boxer, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Duality, EcoR1, Everest Clinical Research Corp., Lilly, Equillium, Ermium, Ferring, First Wave, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Glenmark, Gossamer Pharma, GSK, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, Imhotex, ImmunExt, Immunic Therapeutics, Intact Therapeutics, JAKAcademy, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Landos Biopharma, Leadiant, L.E.K. Consulting, LifeSci Capital, Lument AB, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Orphagen, Otsuka, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Play to Know AG, Progenity, Protagonist, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, REDX, Roche, Sandoz, Sanofi, Seres Therapeutics, Silverback Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB Pharma, VHSquared Ltd., Viatris, Ysios, Ysopia, Zealand Pharma; speakers bureau: AbbVie, Janssen, Takeda.\|Scientific advisory board member: AbbVie, Amgen, Boehringer-Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda,Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, GSK; stock shareholder: Gossamer Pharma.\|Employment: Western University, Alimentiv Inc.\|\|Gibble, Theresa Hunter:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Keohane, Anthony:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Eastman, William J:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Traxler, Kristina A:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Schreiber, Stefan:\|:\|Consulting and personal fees: AbbVie, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos/Gilead, HIKMA, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Takeda, and Theravance.\|\|Jairath, Vipul:\|:\|Consulting/advisory board fees: AbbVie, Alimentiv Inc., Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, BMS, Celltrion, Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, |

| | |
|---|---|
| | Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx, Vividion. Speaker's fees: Abbvie, Ferring, BMS, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi.\|\|Armuzzi, Alessandro:\|:\|Consulting/advisory board fees: AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda. \|Speaker's fees: AbbVie, Amgen, Arena, Biogen, BMS, Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Tigenix. \|Research grants: MSD, Takeda, Pfizer, Biogen. |
| P647 | Almas, Saima: No conflict of interest\|\|Al-Talib, Ismaeel: No conflict of interest\|\|Rahman, Chadek: No conflict of interest\|\|Ansari, Marriam: No conflict of interest\|\|Jones, Judith: No conflict of interest\|\|Slater, Jayne: No conflict of interest\|\|King, Dominic: No conflict of interest\|\|De Silva, Shanika: No conflict of interest |
| P648 | Dr. Shehab, Mohammad: No conflict of interest\|\|Abdullah, Israa: No conflict of interest\|\|Alostad, Wrood: No conflict of interest\|\|Marei, Alaa: No conflict of interest\|\|Alfadhli, Ahmad: No conflict of interest |

| | |
|---|---|
| P649 | Dr. Carbery, Isabel:\|:\|Dr Carbery has speaker arrangements with Celtrion.\|\|Lin, Simeng:\|:\|Dr. Lin reports non-financial support from Pfizer, non-financial support from Ferring, outside the submitted work.\|\|Chanchlani, Neil: No conflict of interest\|\|Janjua, Malik: No conflict of interest\|\|Nice, Rachel: No conflict of interest\|\|McDonald, Timothy J: No conflict of interest\|\|Bewshea, Claire: No conflict of interest\|\|Kennedy, Nicholas A:\|:\|Dr. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, personal fees and non-financial support from Dr Falk, outside the submitted work. \|\|Ahmad, Tariq:\|:\|Prof. Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, non-financial support from Tillotts, outside the submitted work.\|\|Goodhand, James R:\|:\|Dr. Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, outside the submitted work.\|\|Selinger, Christian P:\|:\|Dr Selinger has received unrestricted research grants from Warner Chilcott, Janssen and AbbVie, has provided consultancy to Warner Chilcott, Dr Falk, AbbVie, Takeda, Fresenius Kabi, Arena, Galapagos, Celltrion, Norgine and Janssen, and had speaker arrangements with Warner Chilcott, Norgine, Galapagos, Fresenius Kabi, Celtrion, Dr Falk, AbbVie, MSD, Pfizer and Takeda. |
| P650 | Dr. Kokkotis, Georgios: No conflict of interest\|\|Chalakatevaki, Konstantina: No conflict of interest\|\|Papathanasiou, Evgenia: No conflict of interest\|\|Tzanoudaki, Marianna: No conflict of interest\|\|Kane, Rediona: No conflict of interest\|\|Liatsis, Manolis: No conflict of interest\|\|Zampeli, Evanthia: No conflict of interest\|\|Michopoulos, Spiridon: No conflict of interest\|\|Bamias, Giorgos:\|:\|GB declares that he has acted as advisor/lecturer and/or received research funding\|and/or participates in clinical trials from Abbvie, Adacyte Therapeutics, Aenorasis,\|Amgen, Cooper, Ferring, Genesis Pharma, Janssen, MSD, Mylan, Pfizer, Takeda. |

| | |
|---|---|
| P651 | Dr. Kim, Jeongseok: No conflict of interest\|\|Sagong, Min: No conflict of interest\|\|Lee, Yoo Jin: No conflict of interest\|\|Kim, Kyeong Ok: No conflict of interest\|\|Kim, Eun Soo: No conflict of interest\|\|Kim, Eun Young: No conflict of interest\|\|Jang, Byung Ik: No conflict of interest |
| P652 | Dr. Mínguez, Alejandro: No conflict of interest\|\|Bastida, Guillermo: No conflict of interest\|\|Terol, Isabel: No conflict of interest\|\|Argumánez, Víctor: No conflict of interest\|\|Iborra, Marisa: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Moret, Inés: No conflict of interest\|\|Cerrillo, Elena: No conflict of interest\|\|Garrido, Alejandro: No conflict of interest\|\|Tortosa, Lluis: No conflict of interest\|\|Nos, Pilar: No conflict of interest |
| P653 | Dr. Fernandes, Samuel Raimundo: No conflict of interest\|\|Bernardo, Sónia: No conflict of interest\|\|Rita Gonçalves, Ana: No conflict of interest\|\|Moura dos Santos, Paula: No conflict of interest\|\|Valente, Ana: No conflict of interest\|\|Tato Marinho, Rui: No conflict of interest\|\|Correia, Luís: No conflict of interest |
| P654 | Gonzalez Lama, Yago: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Carpio, Daniel: No conflict of interest\|\|Bastida, Guillermo: No conflict of interest\|\|Ceballos, Daniel: No conflict of interest\|\|Ginard, Daniel: No conflict of interest\|\|Marín-Jimenéz, Ignacio: No conflict of interest\|\|Menchén, Luis: No conflict of interest\|\|Muñoz, Fernando: No conflict of interest |
| P655 | Mrs. Zelinkova, Zuzana:\|:\|- lecture fees from Abbvie, Takeda, Pfizer\|\|Podmanicky, Dusan:\|:\|- lecture fees from Takeda\|\|Berakova, Katarina:\|:\|- lecture fees from Takeda\|\|Kadleckova, Barbora:\|:\|- lecture fees from Takeda |
| P656 | Dr. Chetwood, John: No conflict of interest\|\|Ko, Yanna: No conflict of interest\|\|Pudipeddi, Aviv: No conflict of interest\|\|Kariyawasam, Viraj: No conflict of interest\|\|Paramsothy, Sudarshan: No conflict of interest\|\|Leong, Rupert: No conflict of interest |

| | |
|---|---|
| P657 | Dr. Dolin, Paul:\|:\|Contracting consultancy services for Astrazeneca\|\|Evans, Kathryn: No conflict of interest\|\|Castañeda, Johann: No conflict of interest\|\|Udayachalerm, Sariya: No conflict of interest\|\|Cabrera, Claudia:\|:\|Employee of Astrazeneca |
| P658 | Reinisch, Walter:\|:\|Walter Reinisch has received support for the following: speaker for Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; consultant for Abbott Laboratories, AbbVie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, AstraZeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trials, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC; and advisory board member for Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC. \|\|Tran, Jacinda:\|:\|Jacinda Tran is currently a contractor at AbbVie and a funded PhD student at the University of Washington. \|\|Patel, Kamal: No conflict of interest\|\|Borruel, Natalia:\|:\|Natalia Borruel has received grants from AbbVie and Takeda; and has received consulting and/or speaking fees from AbbVie, Ferring, Janssen, MSD, Pfizer, Shire, Takeda, Tillots Pharma.\|\|Melmed, Gil Y.:\|:\|Gil Melmed has served as a consultant for Abbvie, Arena, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Ferring, Fresenius Kabi, Gilead, Janssen, Lilly, Pfizer, Prometheus Labs, Samsung Bioepis, Takeda, and Techlab and has received grant funding from Pfizer. \|\|Wegrzyn, Lani:\|:\|Lani Wegrzyn is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Levy, Gwen:\|:\|Gwen Levy is a full-time employees of AbbVie and may hold AbbVie stock and/or stock options.\|\|Ilo, Dapo:\|:\|Dapo Ilo is a full-time employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Sanchez Gonzalez, Yuri:\|:\|Yuri Sanchez Gonzalez is a full-time |

| | |
|---|---|
| | employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Panaccione, Remo:\|:\|Remo Panaccione has received consulting fees from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan, Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals; speaker fees from AbbVie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda Pharmaceuticals; has served on the advisory boards for AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma, and Takeda Pharmaceuticals; and has received research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda. |
| P659 | Dr. Seo, Jeongkuk: No conflict of interest\|\|Kim, Seonok: No conflict of interest\|\|Song, Subin: No conflict of interest\|\|Shin, Seung Hwan: No conflict of interest\|\|Park, Suhyun: No conflict of interest\|\|Hong, Seung Wook: No conflict of interest\|\|Hwang, Sung Wook: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Yang, Dong-Hoon: No conflict of interest\|\|Byeon, Jeong-Sik: No conflict of interest\|\|Myung, Seung-Jae: No conflict of interest\|\|Yang, Suk-Kyun: No conflict of interest\|\|Kim, Ye-Jee: No conflict of interest\|\|Ye, Byong Duk: No conflict of interest |

| | |
|---|---|
| P660 | Dr. McDonnell, Martin:\|:\|Dr McDonnell has eceived a grant to fund PhD and research studies as part of a collaborative investigator led research program from Nestle Health Sciences. Has received educational support from nutriticia. \|\|Sartain , Stephanie:\|:\|Dr Sartain has received educational support from nutriticia.\|\|Westoby , Catherine:\|:\|Mrs Westocy has received speaker fees for talks at educational meetings organised and funded by Nestle Health Sciences and received payment and study support as part of an investigator led collaborative research agreement between Nestle Helath Sciences and University Hospital Southampton. \|\|Katarachia, Vasiliki: No conflict of interest\|\|Davis, Cai: No conflict of interest\|\|Cummings, Fraser:\|:\|Dr. Cummings has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Sandoz, Biogen, Samsung and Takeda. He has received research funding from Biogen, Amgen, Celltrion, Hospira/Pfizer, Janssen, Takeda, GSK and AZ\|\|Wootton, Stephen: No conflict of interest |
| P661 | Panaccione, Remo:\|:\|RP has received consulting fees from AbbVie, Abbott, Alimentiv (formerly Robarts Clinical Trials), Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Lilly, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, Takeda, and UCB. He has received speaker fees from AbbVie, Arena, Celgene, Ferring, Gilead Sciences, Janssen, Lilly, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and has served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmith Kline, Janssen, Lilly, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Takeda, and Theravance.\|\|Dotan, Iris:\|:\|ID has served as a speaker, consultant, and/or advisory board member for AbbVie, Abbott, Arena, Cambridge Healthcare, Celgene/Bristol Myers Squibb, Celltrion, Falk Pharma, Ferring, Food Industries Organization, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Integra Holdings, Iterative Scopes, Janssen, MSD, Neopharm, Nestle, Pfizer, Rafa Laboratories, Sangamo, Sublimity, Takeda, and Wild Biotech.\|\|Ferrante, Marc:\|:\|MF reports being a consultant or speaker for AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Dr Falk, Eli Lilly, Ferring, Janssen-Cilag, Lamepro, Medtronic, MSD, Mylan, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda, Thermo Fisher Scientific, and Truvion Healthcare; and research grants from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda, and Viatris.\|\|Danese, Silvio:\|:\|SD has received lecture fees from AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, CSL Vifor, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Mundipharma, Pfizer, Sandoz, Takeda, Tigenix, and UCB. He has served as a consultant for AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, CSL Vifor, Ferring, Hospira, Johnson & Johnson, Merck, MSD, Mundipharma, Pfizer, Sandoz, Takeda, Tigenix, and UCB.\|\|Bossuyt, Peter:\|:\|PB has received financial support for research from AbbVie, Amgen, Janssen, Mundipharma, Mylan, and Pfizer. He has received lecture fees from AbbVie, Janssen, Pfizer, and Takeda, and advisory board fees from AbbVie, Arena, BMS, Celltrion, Hospira, Janssen, Mundipharma, MSD, Pentax, Pfizer, Roche, Sandoz, and Takeda.\|\|Kligys, Kristina:\|:\|KK is an employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Neimark, Ezequiel:\|:\|EN is an employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Zambrano, Javier:\|:\|JZ is an employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|Liao, Xiaomei:\|:\|XL is an employee of AbbVie and may hold AbbVie stock and/or stock options.\|\|D'Haens, Geert:\|:\|GD'H reports being a consultant or speaker for AbbVie, Alimentiv, |

| | |
|---|---|
| | Boehringer Ingelheim, Celltrion, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Janssen, Lilly, MSD, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Takeda, and Tillotts. |
| P662 | Dr. Lin, Simeng:\|:\|Meeting support fees from Pfizer and Ferring, outside of the submitted work.\|\|Chanchlani, Neil: No conflict of interest\|\|Smith, Rebecca: No conflict of interest\|\|Roberts, Christopher: No conflict of interest\|\|Nice, Rachel: No conflict of interest\|\|McDonald, Timothy J: No conflict of interest\|\|Hamilton, Benjamin: No conflict of interest\|\|Bewshea, Claire: No conflict of interest\|\|Kennedy, Nicholas A:\|:\|Nicholas Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, personal fees and non-financial support from Dr Falk, outside the submitted work. \|\|Goodhand, James R:\|:\|James R Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik outside the submitted work.\|\|Ahmad, Tariq:\|:\|Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik, personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, non-financial support from Tillotts, outside the submitted work. |

| | |
|---|---|
| P663 | Dr. An, Yoon-Kyo:\|:\|Clinical Investigator-Initiated Study Research Funding by Janssen-Cilag Pty Ltd\|\|\|Lindsay, Niamh: No conflict of interest\|\|Allan, Natalie: No conflict of interest\|\|Khoo, Emi: No conflict of interest\|\|Fernandes, Richard: No conflict of interest\|\|Amiss, Anna: No conflict of interest\|\|Pham, Hai: No conflict of interest\|\|Wong, Kam-Fai: No conflict of interest\|\|Ooi, Soong-Yuan: No conflict of interest\|\|Thin, Lena: No conflict of interest\|\|Lightowler, Daniel: No conflict of interest\|\|Connor, Susan J: No conflict of interest\|\|Williams, Astrid Jane: No conflict of interest\|\|De Cruz, Peter: No conflict of interest\|\|Li Wai Suen, Christopher: No conflict of interest\|\|Kariyawasam, Viraj: No conflict of interest\|\|Mitrev, Nikola: No conflict of interest\|\|Ghaly, Simon: No conflict of interest\|\|Andrews, Jane M: No conflict of interest\|\|Christensen, Britt: No conflict of interest\|\|Sparrow, Miles P: No conflict of interest\|\|White, Lauren Sue: No conflict of interest\|\|Bryant, Robert V: No conflict of interest\|\|Ding, Nik: No conflict of interest\|\|Leong, Rupert: No conflict of interest\|\|Van Langenberg, Daniel: No conflict of interest\|\|Seltenreich, Hans: No conflict of interest\|\|Subramaniam, Kavitha: No conflict of interest\|\|Radford-Smith, Graham:\|:\|Clinical Investigator-Initiated Study Research Funding by Janssen-Cilag Pty Ltd\|\|Begun, Jakoib:\|:\|Clinical Investigator-Initiated Study Research Funding by Janssen-Cilag Pty Ltd |

| | |
|---|---|
| P664 | Dr. Vieujean, Sophie: No conflict of interest\|\|Lindsay, James O:\|:\|James O. Lindsay has received consulting fees from AbbVie, Celgene, Ferring, Janssen, Merck, Pfizer Inc, Robarts Clinical Trials, Shire, and Takeda; research grants from Pfizer Inc/Hospira, MSD, Shire, and Takeda; lecture and/or speaker bureau fees from AbbVie, Allergan, Ferring, Janssen, MSD, Shire, and Takeda; and advisory board fees from AbbVie, Atlantic Healthcare, Ferring, Hospira, Janssen, MSD, NAP, Pfizer Inc, Shire, Takeda, and Vifor.\|\|Rubin, David:\|:\|David T Rubin had grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. \|\|D'Amico, Ferdinando:\|:\|F D'Amico has served as a speaker for Janssen, Galapagos, Sandoz, and Omega Pharma.\|\|Ahuja, Vineet: No conflict of interest\|\|Silverberg, Mark S:\|:\|Speaker, advisory board, consulting and clinical trial fees from: Abbvie, Janssen, Pfizer, Takeda, Prometheus, Gilead, Alimentiv.\|\|Sood, Ajit:\|:\|Ajit Sood has received speaker honorarium from Pfizer India.\|\|Yamamoto-Furusho, Jesus K:\|:\|J. K. Yamamoto-Furusho is a speaker bureau member for Abbvie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein, Takeda; is a clinical research investigator Bristol Myers Squibb, Takeda has been member of advisory boards for Abbvie, Celltrion, Ferring, Janssen, Takeda; has received research grants from Takeda; payments for lectures from Abbvie, Alfasigma, Asofarma, Bristol Myers Squibb, Carnot, Celltrion, Chinoin, Farmasa, Ferring, Janssen, Siegfried Rhein, Takeda; and is an advisory board member of the Abbvie, Celltrion, Ferring, Janssen, Takeda.\|\|Nagahori, Masakazu:\|:\|Nagahori M has received consultancy fees from Takeda Pharmaceutical; and payment for lectures including service on speakers bureaus from Kissei Pharmaceutical, and Takeda Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, AbbVie, Mitsubishi Tanabe Pharma, Nippon Kayaku, Asahi Kasei Medical, Zeria Pharmaceutical, Astellas, Nichi-Iko, and Janssen. \|\|Watanabe, Mamoru:\|:\|Mamoru Watanabe has received grants from AbbVie, Alfresa Pharma, EA Pharma, Kissei, Kyorin, Mitsubishi Tanabe Pharma, Mochida, Nippon Kayaku, Takeda and Zeria; consulting and/or speaker fees from AbbVie, EA Pharma, Eli Lilly Japan, Gilead Sciences, Janssen, JIMRO, Kissei, Mitsubishi Tanabe Pharma, Mochida, Nippon Boehringer Ingelheim, Pfizer Japan, Takeda and Zeria.\|\|Koutroubakis, Ioannis E:\|:\|Ioannis Koutroubakis has received support by Abbvie, Genesis, Ferring, Janssen, MSD, Pfizer, Shire, Vianex and Takeda. \|\|Foteinogiannopoulou, Kalliopi: No conflict of interest\|\|Walsh, Alissa:\|:\|Alissa Walsh has received research/consulting/advisory board fees from AbbVie, BMS, Buhlmann, Falk, Ferring, Galapagos, Helmsley Trust, Janssen, Lilly, Norman Collisson Foundation, Pfizer, Takeda, Tillots, UCB Pharma, Vifor; |

| | |
|---|---|
| | No stocks or share options\|\|Outtier, An: No conflict of interest\|\|Abreu, Maria T:\|:\|Consultant/Advisory Board for AbbVie Inc, Arena, Bristol Myers Squibb, Celsius, Eli Lilly, Gilead, Helmsley Charitable Trust, Janssen, Microba, Pfizer, Prometheus Bioscience, UCB Biopharma SRL, WebMD Global LLC\|Teaching, lecturing for Alimentiv, Janssen, Prime CME, Takeda\|\|Dubinsky, Marla:\|:\|Marla Dubinsky is consultant for Abbvie, Arena, BMS, Eli Lilly, Janssen, Pfizer, Prometheus Biosciences, Takeda.\|\|Siegel, Corey: No conflict of interest\|\|Louis, Edouard:\|:\|Research grant: Janssen, Pfizer, Ferring, Falk, Abbvie and Takeda; educational grant: AbbVie, Janssen, Fresenius-Kabi and Takeda; speaker fees: Abbvie, Falk, Ferring, Janssen, Pfizer, Galapagos and Takeda; advisory board: Abbvie, Celgene, Ferring, Janssen, BMS, Pfizer, and Takeda, Galapagos, Gilead, Arena, Elli Lilly; consultant: Abbvie\|\|Dotan, Iris:\|:\|Iris Dotan: research grants from Altman Research Pfizer; Advisory board/consulting fees: Pfizer, Janssen, Abbvie, Takeda, Genentech/Roche, Arena, Neopharm, Gilead, Galapagos, Celltrion, Rafa Laboratories, Ferring, DSM, Cambridge Healthcare, Sublimity, Sangamo, Wild Biotech, Food industries organization, Integra Holdings, Celgene/BMS, Abbott, 89 Bio, Alimentiv; Speakers Bureau: Roche/Genentech, Falk Pharma, Abbvie, Janssen, Pfizer, Takeda Neopharm, Celltrion, Ferring, Nestle, Celgene/BMS.\|\|Reinisch, Walter:\|:\|Walter Reinisch has served \|•as a speaker for Abbvie, Aptalis, Astellas, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, \|•as a consultant for Abbvie, Agomab, Algernon, AltruBio, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Calyx, Cellerix, Chemocentryx, Celgene, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Fresenius, Galapagos, Gatehouse Bio Inc., Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Landos Biopharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, \|•as an advisory board member for Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, |

| | |
|---|---|
| | Galapagos, Genentech, Grunenthal, Merck, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC, and \|•has received research funding from Abbvie, Janssen, MSD, Sandoz, Takeda\|\|Danese, Silvio:\|:\|S Danese has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor.\|\|Peyrin-Biroulet, Laurent:\|:\|L Peyrin-Biroulet : personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals , Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine ; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance ; Pandion Therapeutics, grants from Abbvie, MSD, Takeda, Fresenius Kabi, stock options : CTMA. |
| P665 | Auriat, Oscar:\|:\|Sanofi employee\|\|Mrs. Lucats, Laurence:\|:\|Sanofi Employee\|\|Badalamenti, Salvatore:\|:\|Sanofi Employee\|\|Kruger, Annie:\|:\|Sanofi Employee\|\|Wiekowski, Maria:\|:\|Sanofi Employee\|\|Glotfelty, Lila:\|:\|Sanofi Employee\|\|Van Hoogstraten, Hubert:\|:\|Sanofi Employee\|\|Coulouvrat, Catherine:\|:\|Sanofi Employee |
| P666 | Bislenghi, Gabriele: No conflict of interest\|\|Dr. Vancoillie, Peter-Jan: No conflict of interest\|\|Fieuws, Steffen: No conflict of interest\|\|Verstockt, Bram: No conflict of interest\|\|Sabino, Joao: No conflict of interest\|\|Wolthuis, Albert: No conflict of interest\|\|D'Hoore, André: No conflict of interest |
| P667 | Dr. Chin, Andrew: No conflict of interest\|\|Jeffrey, Angus: No conflict of interest\|\|Teh, Wei Ling: No conflict of interest\|\|Menon, Shankar: No conflict of interest\|\|So, Kenji: No conflict of interest\|\|Venugopal, Kannan: No conflict of interest\|\|Picardo, Sherman:\|:\|Consultant/Speaker - AbbVie, Falk, Janssen, Pfizer, Takeda\|Research support - Janssen |

| | |
|---|---|
| P668 | Dr. Kapizioni, Christina: No conflict of interest\|\|Desoki, Rofaida: No conflict of interest\|\|Balendran, Karthiha: No conflict of interest\|\|Lam, Danielle: No conflict of interest\|\|Shawky, Rasha: No conflict of interest\|\|Pele, Laetitia: No conflict of interest\|\|Parkes, Miles: No conflict of interest\|\|Raine, Tim: No conflict of interest |
| P669 | Dr. Schulberg, Julien:\|:\|Falk\|\|Hamilton, Amy: No conflict of interest\|\|Wright, Emily: No conflict of interest\|\|Holt, Bronte: No conflict of interest\|\|Sutherland, Tom: No conflict of interest\|\|Ross, Alyson: No conflict of interest\|\|Vogrin, Sara: No conflict of interest\|\|Kamm, Michael: No conflict of interest |
| P670 | Ms. Sheldon, Elena: No conflict of interest\|\|Roman, Stefan: No conflict of interest\|\|Randall, Kevin: No conflict of interest\|\|Rachel, Hawkins: No conflict of interest\|\|Winsor, Gemma: No conflict of interest\|\|Wakeman, Ruth: No conflict of interest\|\|Lobo, Alan: No conflict of interest |
| P671 | Turner, Dan:\|:\|DT received consultation fees, research grants, royalties, or honoraria from Janssen, Pfizer, Hospital for Sick Children, Ferring, AbbVie, Takeda, Biogen, Neopharm Group, Uniliver, Atlantic Health, Shire, Celgene, Eli Lilly, and Roche.\|\|Rosh, Joel R.:\|:\|JRR received grant/research support from, served as a consultant for and/or on an advisory board for AbbVie, Janssen, Bristol Myers Squib, Celgene, Eli Lilly, and Pfizer.\|\|Cohen, Stanley A.:\|:\|SAC received grants from and/or served as a consultant for Janssen, Kate Farms, Medtronic, AbbVie, Takeda, Arena, AstraZeneca, and Eli Lilly; and is the chair of a medical advisory committee for Nutrition4IBD as well as an executive of its parent company, Nutrition4Kids.\|\|Griffiths, Anne:\|:\|AG served as a consultant for, served on an advisory board for, received speaker fees from, and/or received research support from AbbVie, Janssen, Bristol Myers Squib, Celgene, Eli Lilly, Pfizer, Roche, and Nestle.\|\|Hyams, Jeffrey S.:\|:\|JSH served on an advisory board for Janssen and AbbVie; and served as a consultant for Pfizer, Eli Lilly, Boehringer Ingelheim, Roche, Allergan, Bristol Myers Squib, and Thetis.\|\|Kierkuś, Jarosław:\|:\|JK received grants from Hoffman-La Roche. \|\|Adedokun, Omoniyi J.:\|:\|OJA is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Strauss, Richard:\|:\| RS is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Kim, Lilianne:\|:\|LK is an employee of Janssen and may hold stock in Johnson & Johnson.\|\|Volger, Sheri:\|:\|SV is an employee of Janssen and may hold stock in Johnson & Johnson. |

| | |
|---|---|
| P672 | Ms. Anjie, Suzanne: No conflict of interest\|\|Hanžel, Jurij:\|:\|JH has received speaker's fees from Abbvie, Janssen, and Takeda; consulting fees from Alimentiv Inc. \|\|Gecse, Krisztina B:\|:\|KG has received grants from Pfizer Inc, Galapagos and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, ImmunicTherapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts.\|\|D'Haens, Geert R:\|:\|GD has received consultancy fees for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity and Protagonist. Speakers bureau for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda. Data montoring board for Galapagos, Astrazeneca and Seres Health.\|\|Brandse, Johannan F:\|:\|JB has received speaker's fees from Janssen Pharmaceuticals. |
| P673 | Ms. Jagt, Jasmijn: No conflict of interest\|\|Galestin, Suzanne: No conflict of interest\|\|Benninga, Marc: No conflict of interest\|\|de Boer, Nanne: No conflict of interest\|\|de Meij, Tim: No conflict of interest |
| P674 | Prof. Dr. Verstockt, Bram:\|:\|B Verstockt reports \|-Research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda.\|-Speaker's fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris.\|-Consultancy fees from Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|\|Vieujean, Sophie:\|:\|Sophie Vieujean reports\|-speaker's fees: Takeda, AbbVie, Janssen\|\|\|Truyens, Marie: No conflict of interest\|\|Julsgaard, Mette: No conflict of interest\|\|Pugliese, Daniela: No conflict of interest\|\|Aslan, Devrim: No conflict of interest\|\|Prokopic, Michal:\|:\|Michal Prokopic reports\|-speaker's fees: Takeda\|\|\|Lim, Samuel: No conflict of interest\|\|Viganò, Chiara: No conflict of interest\|\|Festa, Stefano:\|:\|Stefano Festa reports\|-consultancy fees: Janssen, Pfizer, Takeda\|\|\|Ramos, Laura: No conflict of interest\|\|Garciá, Maria José: No conflict of interest\|\|Plaza, Rocio:\|:\|\|Rocio Plaza reports\|-speaker's fees: Takeda, Abbvie, Janssen.\|-Educational funding: Takeda, Abbvie, Janssen, Ferring, Pfizer.\|\|\|Noviello, Daniele: No conflict of interest\|\|Savarino, Edoardo: No conflict of interest\|\|Drobne, David: No conflict of interest\|\|Imperatore, Nicola: No conflict of interest\|\|Ribaldone, Davide G.:\|:\|Davide G Ribaldone reports\|-speaker's fees: AbbVie, Galapagos, Janssen, Takeda\|\|\|Van Dongen, Jurgen: No conflict of interest\|\|Teich, Niels: No conflict of interest\|\|Wahed, Mahmood: No conflict of interest\|\|Barberio, Brigida: No conflict of interest\|\|Goren, Idan: No conflict of interest |

| | |
|---|---|
| P675 | Dr. Chaparro Sanchez, Maria: No conflict of interest\|\|Acosta, Diana: No conflict of interest\|\|Rodríguez, Cristina: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Vicuña, Miren: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|Fernández-Clotet, Agnès: No conflict of interest\|\|Hernández Martínez, Álvaro: No conflict of interest\|\|Arroyo, Maite: No conflict of interest\|\|Vera, Isabel: No conflict of interest\|\|Ruiz-Cerulla, Alexandra: No conflict of interest\|\|Sicilia, Beatriz: No conflict of interest\|\|Cabello Tapia, María José: No conflict of interest\|\|Muñoz Villafranca, Carmen: No conflict of interest\|\|Castro-Poceiro, Jesús: No conflict of interest\|\|Martínez Cadilla, Jesús: No conflict of interest\|\|Sierra-Ausín, Mónica: No conflict of interest\|\|Vázquez Morón, Juan María: No conflict of interest\|\|Montil Miguel, Enrique: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Royo, Vanesa: No conflict of interest\|\|Calafat, Margalida: No conflict of interest\|\|González-Muñoza, Carlos: No conflict of interest\|\|Leo Carnerero, Eduardo: No conflict of interest\|\|Manceñido Marcos, Noemi: No conflict of interest\|\|Torrealba, Leyanira: No conflict of interest\|\|Alonso-Galán, Horacio: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Ber Nieto, Yolanda: No conflict of interest\|\|Diz-Lois Palomares, M. Teresa: No conflict of interest\|\|García, María José: No conflict of interest\|\|Muñoz, José Fernando: No conflict of interest\|\|Armesto González, Edisa María: No conflict of interest\|\|Calvet, Xavier: No conflict of interest\|\|Hernández-Camba, Alejandro: No conflict of interest\|\|Madrigal Domínguez, Rosa Eva: No conflict of interest\|\|Menchén, Luis: No conflict of interest\|\|Pérez Calle, José Lázaro: No conflict of interest\|\|Piqueras, Marta: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest |
| P676 | Dr. Albshesh, Ahmad: No conflict of interest\|\|Abend, Alon: No conflict of interest\|\|Margalit Yehuda, Reuma: No conflict of interest\|\|Mahajna, Hussein: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Kopylov, Uri: No conflict of interest\|\|Carter, Dan: No conflict of interest |
| P677 | Kang, Jian: No conflict of interest\|\|Wang, Jing: No conflict of interest\|\|Lu, Yueyue: No conflict of interest\|\|Li, Jiao: No conflict of interest\|\|Su, Juan: No conflict of interest\|\|Ying, Anning: No conflict of interest\|\|Ren, Haixia: No conflict of interest\|\|Zhou, Qian: No conflict of interest\|\|Wang, Yang: No conflict of interest\|\|Ding, Yijuan: No conflict of interest\|\|Prof. An, Ping: No conflict of interest |
| P678 | Dr. Bertani, Lorenzo: No conflict of interest\|\|D'Alessandro, Claudia: No conflict of interest\|\|Fornili, Marco: No conflict of interest\|\|Coppini, Francesca: No conflict of interest\|\|Zanzi, Francesco: No conflict of interest\|\|Carmisciano, Luca: No conflict of interest\|\|Geri, Francesca: No conflict of interest\|\|Baiano Svizzero, Giovanni: No conflict of interest\|\|Ceccarelli, Linda: No conflict of interest\|\|Mumolo, Maria Gloria: No conflict of interest\|\|Baglietto, Laura: No conflict of interest\|\|Bellini, Massimo: No conflict of interest\|\|Costa, Francesco: No conflict of interest\|\|De Bortoli, Nicola: No conflict of interest |

| | |
|---|---|
| P679 | Dr. Madigan, Shauna: No conflict of interest\|\|Mountifield, Reme: No conflict of interest\|\|Barnes, Alex: No conflict of interest |
| P680 | Dr. Scarallo, Luca: No conflict of interest\|\|Fioretti, Lorenzo: No conflict of interest\|\|Pochesci, Saverio: No conflict of interest\|\|Pierattini, Valentina: No conflict of interest\|\|Banci, Elena: No conflict of interest\|\|De Blasi, Alessia: No conflict of interest\|\|Di Paola, Monica: No conflict of interest\|\|Lionetti, Paolo:\|:\|P.L has received fees for lectures at symposia for Nestle Health Science, Abbvie, Pfizer, Sandoz and Jannsen |
| P681 | Dr. Tamir-Degabli, Natalie: No conflict of interest\|\|Cohen, Nathaniel A.: No conflict of interest\|\|Hirsch, Ayal: No conflict of interest\|\|Fishman, Sigal: No conflict of interest\|\|Ron, Yulia: No conflict of interest\|\|Thrum, Tamar: No conflict of interest\|\|Maharshak, Nitsan: No conflict of interest |
| P682 | Prof. Dr. Roblin, Xavier: No conflict of interest\|\|Nancey, stephane: No conflict of interest\|\|Bastide, laetitia: No conflict of interest\|\|Veyrard, Pauline: No conflict of interest\|\|Bischetti, Gilles: No conflict of interest\|\|Berger, anne emmanuelle: No conflict of interest\|\|Barrau, mathilde: No conflict of interest\|\|Paul, Stephane: No conflict of interest |
| P683 | Sina, Marsela: No conflict of interest\|\|Djegsi, Aferdita: No conflict of interest\|\|Pemaj, Xhensila: No conflict of interest\|\|Telaku, Skender: No conflict of interest\|\|Babameto, Adriana: No conflict of interest\|\|Prifti, Skerdi: No conflict of interest |
| P684 | Prof. Yao, Jiayin: No conflict of interest\|\|Liu, Tao: No conflict of interest\|\|Min, Zhi: No conflict of interest |

| | |
|---|---|
| P685 | Dr. Lim, Ki-Yun: No conflict of interest\|\|Hwang, Do-Yeon: No conflict of interest\|\|Lee, Jong Kyun: No conflict of interest |
| P687 | Dignass, Axel:\|:\|received fees for participation in clinical trials and review activities (ie, data monitoring boards, statistical analysis, and endpoint committees) from AbbVie, Abivax, Celgene/Bristol Myers Squibb, Falk Foundation, Gilead, Janssen, and Pfizer; received consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Eli Lilly, Falk, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Gilead, Janssen, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor; received payment for lectures, including service on speaker bureaus, from AbbVie, Eli Lilly, Falk Foundation, Ferring Pharmaceuticals, Gilead/Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, and Vifor; received payment for development of educational presentations from Ferring Pharmaceuticals and Tillotts. \|\|Regueiro, Miguel:\|:\|Served on advisory boards or as a consultant for AbbVie, Alfasigma, Allergan, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, TARGET PharmaSolutions, and UCB. \|\|Colombel, Jean-Frederic:\|:\|Received research grants from AbbVie, Janssen, and Takeda; received payment for lectures from AbbVie, Amgen, Allergan, Bristol Myers Squibb, Ferring Pharmaceuticals, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Janssen, Landos, LimmaTech Biologics AG, MedImmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, TiGenix, and Viela Bio; holds stock options in Intestinal Biotech Development.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Lawlor, Garrett:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Osterman, Mark T.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Vermeire, Severine:\|:\|Received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand.\|\|Rubin, David T.:\|:\|Served as a consultant for AbbVie, Celgene, Janssen, Pfizer, and Takeda; received grant support from Takeda. |
| | |

| | |
|---|---|
| P688 | Ms. Straatmijer, Tessa: No conflict of interest\|\|van den Akker-van Marle, Elske: No conflict of interest\|\|van der Horst, Danielle: No conflict of interest\|\|Scherpenzeel, Menne: No conflict of interest\|\|Duijvestein, Marjolijn: No conflict of interest\|\|van der Meulen, Andrea: No conflict of interest |
| P689 | Camba Gómez, Miguel: No conflict of interest\|\|Arosa , Laura: No conflict of interest\|\|Calviño-Suárez, Cristina: No conflict of interest\|\|Bastón-Rey, Iría: No conflict of interest\|\|Ferreiro-Iglesias, Rocío: No conflict of interest\|\|Porto, Marisol: No conflict of interest\|\|Nieto, Laura: No conflict of interest\|\|Domínguez-Muñoz, Juan Enrique: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|Conde-Aranda, Javier: No conflict of interest |

| | |
|---|---|
| P690 | Prof. Dr. Laharie, David:\|:\|DL has received consulting, advisory board and transport fees from AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Janssen Pharmaceuticals, MSD, Novartis, Pfizer, Prometheus, Roche and Takeda. \|\|Sturm, Andreas:\|:\|AS has received grant support from AbbVie; and consulting or speaker fees from AbbVie, Dr. Falk Pharma, Galapagos, Janssen Pharmaceuticals, MSD, Pfizer, Takeda and Tillotts.\|\|Kobayashi, Taku:\|:\|TK has served as a speaker, a consultant or an advisory board member for AbbVie, Activaid, Ajinomoto Bio-Pharma, Alfresa Pharma, Asahi Kasei Medical, Astellas Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, JIMRO, JMDC, Kissei, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, Thermo Fisher Scientific and Zeria Pharmaceutical; and has received research funding from AbbVie, Alfresa Pharma, Asahi Kasei Medical, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Thermo Fisher Scientific and Zeria Pharmaceutical. \|\|Matsumoto, Takayuki:\|:\|TM reports personal fees from AbbVie, EA Pharma, Mitsubishi Tanabe Pharma and Takeda; and grant support from Mitsubishi Tanabe Pharma and Nippon Kayaku Co. \|\|Oortwijn, Alessandra:\|:\|AO is an employee and shareholder of Galapagos NV.\|\|Jamoul , Corinne:\|:\|CJ is a contractor at Galapagos NV. \|\|Faes, Margaux:\|:\|MF is an employee and shareholder of Galapagos NV.\|\|de Haas, Angela:\|:\|AdH is an employee and shareholder of Galapagos NV.\|\|Vermeire , Séverine:\|:\|SV has received grant support from AbbVie, Galapagos, Johnson & Johnson, Pfizer and Takeda; and consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CVasThera, Cytoki Pharma, Dr. Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos, Genentech-Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen Pharmaceuticals, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MrM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance Biopharma, Tillots and Zealand Pharma. |
| P691 | Dr. Haydek, John: No conflict of interest\|\|Oonk, Alexis: No conflict of interest\|\|Cheng, Debbie: No conflict of interest\|\|Ahmed, Waseem: No conflict of interest\|\|Click, Benjamin:\|:\|Consultant or advisory board for Janssen, Takeda, AbbVie, Bristol Myers Squibb, Prometheus Biosciences, TARGET-RWE\|\|Fennimore, Blair: No conflict of interest\|\|Gerich, Mark: No conflict of interest\|\|Hou, Jason: No conflict of interest\|\|Scott, Frank:\|:\|Frank I. Scott reports has served as a consultant to Janssen and Takeda Pharmaceuticals. He has received research funding from Takeda, Janssen, and the Crohn's & Colitis Foundation. He has served as a speaker for PRIME Incorporated, IBD REMEDY, and IBD 101. |

| | |
|---|---|
| P693 | Pugliese, Daniela:\|:\|speaker fees from MSD, Takeda, Galapagos and Janssen, Pfizer; advisory board fees from Pfizer\|\|Dr. Privitera, Giuseppe:\|:\|consultancy fees from Alphasigma and Janssen\|\|Armuzzi, Alessandro:\|:\|consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Arena, Biogen, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi-Tanabe, Nikkiso, Novartis, Pfizer, Sandoz, Samsung Bioepis, Takeda; and re-search grants from MSD, Pfizer, Takeda and Biogen |
| P694 | Dr. Mañosa Ciria, Miriam: No conflict of interest\|\|Oller, Blanca: No conflict of interest\|\|Garcia-Planella, Esther: No conflict of interest\|\|Guardiola, Jordi: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|Gonzalez Muñoza, Carlos: No conflict of interest\|\|Camps, Blau: No conflict of interest\|\|Calafat, Margalida: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest |
| P695 | Dr. McShane, Cathy: No conflict of interest\|\|Varley, Rachel: No conflict of interest\|\|Fennessy, Anne: No conflict of interest\|\|Campion, John: No conflict of interest\|\|Ring, Eabha: No conflict of interest\|\|Kelly, Orlaith: No conflict of interest\|\|Slattery, Eoin: No conflict of interest\|\|Doherty, Glen: No conflict of interest\|\|McCarthy, Jane: No conflict of interest\|\|Kevans, David: No conflict of interest |

| | |
|---|---|
| P696 | Jairath, Vipul:\|:\|VJ has received consulting/advisory board fees from AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Asieris, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda, and Topivert; and speaker's fees from Abbvie, Ferring, Janssen, Pfizer, Shire, and Takeda.\|\|Zou, Guangyong:\|:\|GZ has received consulting fees from Alimentiv Inc.\|\|Radulescu, Gabriela:\|:\|GR is an employee of Alimentiv Inc.\|\|Sigler, Julie:\|:\|JS is an employee of Alimentiv Inc.\|\|Mrs. Mcfarlane, Stefanie C.:\|:\|SCM is an employee of Alimentiv Inc.\|\|Adsul, Shashi:\|:\|SA is an employee of Takeda Pharmaceuticals.\|\|Freire, Marcelo:\|:\|MF is an employee of Takeda Pharmaceuticals.\|\|Peyrin-Biroulet, Laurent:\|:\|LPB has received personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Biogen, Inotrem, MSD, Amgen, BMS, Vifor, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Pandion Therapeutics, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied Molecular Transport, GSK, and Abivax.\|\|Colombel, Jean-Frederic:\|:\|JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor; and holds stock options in Intestinal Biotech Development.\|\|Moran, Gordon W.:\|:\|GWM is a consultant for Alimentiv and in receipt of research funding from AstraZeneca and Johnson and Johnson.\|\|Sebastian, Shaji:\|:\|SS reports research grants from Takeda, Pfizer, Tillotts Pharma, Abbvie, and Biogen; and personal fees for speaker role and advisory board meetings from Janssen, Amgen, Tillotts Pharma, Abbvie, Takeda, Celgene, Roche, Phramacosmos, and Falk pharma outside the submitted work.\|\|Travis, Simon:\|:\|ST has received grants/research support from AbbVie, Buhlmann, Celgene, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor, and Norman Collisson Foundation; consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Apexian, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Barco, Biocare, Biogen, BLPharma, Boehringer Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, Chiesi, CisBio, ComCast, Coronado, Cosmo, Ducentis, Dynavax, Elan, Enterome, EQrX, Equillium, Falk, Ferring, FPRT Bio, Galapagos, Genentech/Roche, Genzyme, Gilead, Glenmark, Grunenthal, GSK, GW Pharmaceuticals, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Medarex, Medtrix, Merck, Merrimack, Mestag, Millenium, Neovacs, |

| | |
|---|---|
| | Novartis, Novo Nordisk, NPS-Nycomed, Ocera, Optima, Origin, Otsuka, Palau, Pentax, Pfizer, Pharmaventure, Phesi, Phillips, P&G, Pronota, Protagonist, Proximagen, Resolute, Robarts, Sandoz, Sanofi, Santarus, Satisfai, Sensyne Health, Shire, SigmoidPharma, Sorriso, Souffinez, Syndermix, Synthon, Takeda, Theravance, Tigenix, Tillotts, Topivert, Trino Therapeutics with Wellcome Trust, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria; speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda, and UCB. He has no stocks or share options.\|\|Vermeire, Séverine:\|:\|SV has received grants from AbbVie, J&J, Pfizer, Takeda, and Galapagos; consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, and Zealand Pharma.\|\|Sandborn, William J.:\|:\|WJS reports receiving consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv, Beigene, Biora (Progenity), Celltrion, Forbion, Genentech, Gossamer Biosciences, Index Pharmaceuticals, Prometheus Biosciences, Protagonist Therapeutics, Shoreline Biosciences, Vedanta Biosciences, Ventyx Biosciences, Zealand Pharma; and stock or stock options from BeiGene, Gossamer Bio, Biora (Progenity), Prometheus Biosciences, Prometheus Laboratories, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; he is an employee at Shoreline Biosciences and Ventyx Biosciences. Spouse: Iveric Bio - consultant, stock options; Biora (Progenity) – stock; Prometheus Biosciences – employee, stock, stock options; Prometheus Laboratories – stock, stock options; Ventyx Biosciences – stock, stock options; Vimalan Biosciences – stock, stock options.\|\|D'Haens, Geert R.:\|:\|GRD has served as a consultant and/or received speaker fees from Abbvie, Alimentiv, AstraZeneca, Biora (Progenity), Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Cytoki Pharma, Eli Lilly, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Immunic, InDex Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Takeda, Tillotts, and Ventyx Biosciences. \|\|Feagan, Brian G.:\|:\|BGF is a scientific advisory board member for AbbVie, Allergan, Amgen, AstraZeneca, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Elan, Biogen, Ferring, Genentech–Roche, Janssen–Johnson & Johnson, Merck, Millennium, Nestlé, Novo Nordisk, Novartis, Pfizer, Prometheus, Protagonist, Receptos, Salix, Sigmoid Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, and UCB Pharma; consulting fees from AbbVie, Actogenix, Akros, Albireo Pharma, Allergan, Amgen, AstraZeneca, Avaxia Biologics, Avir Pharma, Axcan, Baxter |

| | |
|---|---|
| | Healthcare, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan–Biogen, EnGene, Ferring, Genentech–Roche, GiCare Pharma, Gilead Sciences, Given Imaging, GlaxoSmithKline, Ironwood, Janssen Biotech–Centocor, Janssen–Johnson & Johnson, Kyowa Hakko Kirin, Eli Lilly, Merck, Mesoblast Pharma, Millennium, Nestlé, Novo Nordisk, Novartis, Pfizer, Prometheus, Protagonist, Receptos Salix, Sanofi, Shire, Sigmoid Pharma, Synergy Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, UCB Pharma, Vertex, VHsquared, Wyeth, Zealand, and Zygenia; lecture fees from AbbVie, Janssen–Johnson & Johnson, Takeda, and UCB Pharma, and grant support from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Janssen Biotech–Centocor, Janssen–Johnson & Johnson, Pfizer, Receptos, Sanofi, and Takeda, and is the Senior Scientific Officer of Alimentiv Inc.\|Alimentiv, Inc. (formerly Robarts Clinical Trials, Inc.) is an academic gastrointestinal contract research organization (CRO), operating under the Alimentiv Health Trust. Alimentiv, Inc. provides centralized imaging management solutions in clinical trials, including endoscopy, histopathology, and magnetic resonance imaging. Alimentiv, Inc. provides full service CRO capabilities as well as precision medicine services. |
| P697 | Mr. Arenas, Alex: No conflict of interest\|\|Moreta, María José: No conflict of interest\|\|Ordás, Ingrid: No conflict of interest\|\|Fernández-Clotet, Agnès: No conflict of interest\|\|Caballol, Berta: No conflict of interest\|\|Gallego, Marta: No conflict of interest\|\|Vara, Alejandro: No conflict of interest\|\|Barastegui, Rebeca: No conflict of interest\|\|Giner, Angel: No conflict of interest\|\|Prieto, Cristina: No conflict of interest\|\|Masamunt, Maria Carme: No conflict of interest\|\|Ricart, Elena: No conflict of interest |
| P698 | Dr. Preda, Carmen Monica: No conflict of interest\|\|Istratescu, Doina: No conflict of interest\|\|Manuc, Teodora: No conflict of interest\|\|Nitescu, Maria: No conflict of interest\|\|Louis, Edouard: No conflict of interest\|\|Manuc, Mircea: No conflict of interest\|\|Stroie, Tudor: No conflict of interest\|\|Diculescu, Mircea: No conflict of interest |

| | |
|---|---|
| P699 | Dr. Majumder, Snehali: No conflict of interest\|\|Bazarova, Alina: No conflict of interest\|\|Lorenzo Parigi, Tommaso: No conflict of interest\|\|Love , Melanie: No conflict of interest\|\|Davis , Joanne: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Iacucci , Marietta: No conflict of interest\|\|N. Shivaji, Uday: No conflict of interest |
| P700 | Ms. Jatkowska, Aleksandra: No conflict of interest\|\|White, Bernadette:\|:\|The studentships of BW is funded by Nestle Health Science and the University of Glasgow\|\|Jaskolski, Paige: No conflict of interest\|\|Brownson, Emily: No conflict of interest\|\|Clowe, Jennifer: No conflict of interest\|\|Seenan, John Paul: No conflict of interest\|\|Gerasimidis, Konstantinos:\|:\|Konstantinos Gerasimidis received research funding, speakers fee and travel expenses covered by Nestle Health Science.\|\|MacDonald, Jonathan: No conflict of interest |
| P701 | Ms. Kantasiripitak, Wannee: No conflict of interest\|\|Outtier, An: No conflict of interest\|\|Thomas, Debby: No conflict of interest\|\|Sabino, João:\|:\|João Sabino received financial support for research from Galapagos, speaker fees from Abbvie, Falk, Takeda, Janssen, and Fresenius, and consultancy fees from Janssen and Ferring.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire received financial support for research from AbbVie, Johnson and Johnson, Pfizer, Galapagos, and Takeda, and consultancy and/or speaker fees from AbbVie, Abivax, Agomab, Arena Pharmaceuticals, Avaxia, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, and Tillots Pharma AG. \|\|Ferrante, Marc:\|:\|Marc Ferrante received financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda, and Viatris, speaker fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda, and Truvion Healthcare, and consultancy fees from AbbVie, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Sandoz, Takeda, and Thermo Fisher. \|\|Dreesen, Erwin:\|:\|Erwin Dreesen served as a speaker for Janssen Pharmaceutica and has served as an advisor for Argenx and Alimentiv (all honoraria/fees paid to the University). |

| | |
|---|---|
| P702 | Mrs. Spela, Pintar: No conflict of interest\|\|Hanžel, Jurij:\|:\|JH has served as a speaker for Abbvie, Janssen and Takeda; received consulting fees from Alimentiv Inc, all outside the submitted work.\|\|Smrekar, Nataša:\|:\|NS has served as a speaker, a consultant and/or an advisory board member for Abbvie, Takeda, Pfizer, Janssen, Biogen and Amgen outside the submitted work.\|\|Koželj, Matic:\|:\|MK reports lecture fees from Takeda and Abbvie outside the submitted work.\|\|Drobne, David:\|:\|DD has served as a speaker, a consultant and/or an advisory board member for MSD, Abbvie, Takeda, Pfizer and Janssen outside of the submitted work.\|\|Kurent, Tina:\|:\|TK reports lecture fees from Takeda, Abbvie and Biogen outside the submitted work.\|\|Štabuc, Borut:\|:\|BŠ has served as a speaker, a consultant and/or an advisory board member for MSD, Abbvie, Takeda, Pfizer, Amgen, Biogen and Janssen outside of the submitted work.\|\|Novak, Gregor:\|:\|GN has served as a speaker, a consultant and/or an advisory board member for Abbvie, Takeda, Pfizer, Janssen, Sandoz, Biogen and Amgen outside of the submitted work. |
| P703 | Agboton, Christian:\|:\|Employee of the study sponsor, Takeda and holds Takeda stock or stock options.\|\|Kamble, Pravin:\|:\|Employee of the study sponsor, Takeda and holds Takeda stock or stock options. |
| P704 | Dr. Mitrovic, Milos: No conflict of interest\|\|Marković, Srđan: No conflict of interest\|\|Kalaba, Ana: No conflict of interest\|\|Zarić, Dušan: No conflict of interest\|\|Kralj, Đorđe: No conflict of interest\|\|Milić, Aleksandar: No conflict of interest\|\|Svorcan, Petar: No conflict of interest |
| P705 | Nowell, Emma: No conflict of interest\|\|Laird, Susan: No conflict of interest\|\|Bailey, Erin: No conflict of interest\|\|Dr. Brownson, Emily: No conflict of interest\|\|Saunders, Jayne: No conflict of interest\|\|Seenan, John Paul: No conflict of interest\|\|Smith, Graham: No conflict of interest\|\|Macdonald, Jonathan: No conflict of interest |
| P706 | Dr. Dussias, Nikolas: No conflict of interest\|\|Melotti, Laura: No conflict of interest\|\|Mazzotta, Elena: No conflict of interest\|\|Decorato, Anastasio: No conflict of interest\|\|Vanigli, Nicholas: No conflict of interest\|\|Rizzello, Fernando: No conflict of interest\|\|Gionchetti, Paolo: No conflict of interest |

| | |
|---|---|
| P707 | Lehmann, Anouk: No conflict of interest\|\|Nandra, Gurinder: No conflict of interest\|\|Power, Niall: No conflict of interest\|\|Lindsay, James Oliver: No conflict of interest |
| P708 | Dr. Schlosser, Tobias: No conflict of interest\|\|Krasselt , Marco: No conflict of interest\|\|Elsing, Louis: No conflict of interest\|\|Hecker, Martin: No conflict of interest\|\|Holler, Babett: No conflict of interest\|\|Hoffmeister, Albrecht: No conflict of interest |
| P709 | Dr. Viazis, Nikolaos: No conflict of interest\|\|Koustenis, Kanellos: No conflict of interest\|\|Veretanos, Christos: No conflict of interest\|\|Mountaki, Aikaterini: No conflict of interest\|\|Almpani, Foteini: No conflict of interest\|\|Tsatsa, Anastasia: No conflict of interest\|\|Trikola, Artemis: No conflict of interest\|\|Beka, Helen: No conflict of interest\|\|Arvanitis, Konstantinos: No conflict of interest\|\|Georgiadi, Tereza: No conflict of interest\|\|Nousias, George: No conflict of interest\|\|Mylonas, Iordanis: No conflict of interest\|\|Kozompoli, Dimitra: No conflict of interest\|\|Paparizou, Nancy: No conflict of interest\|\|Karaouzas, Lazaros: No conflict of interest\|\|Papastergiou, Vasilis: No conflict of interest\|\|Archavlis, Emmanouel: No conflict of interest\|\|Mela , Maria: No conflict of interest\|\|Christidou, Angeliki: No conflict of interest\|\|Varytimiadis , Kostas: No conflict of interest\|\|Hatzievangelinou, Christina: No conflict of interest\|\|Katopodi, Konstantina: No conflict of interest\|\|Vienna, Eleni: No conflict of interest\|\|Mantzaris, Gerasimos: No conflict of interest |
| P710 | Dr. Shin, Seungyong: No conflict of interest\|\|Oh, Han Na: No conflict of interest\|\|Moon, Jung Min: No conflict of interest\|\|Joo, Hyun Jin: No conflict of interest\|\|Sul, Woo Jun: No conflict of interest\|\|Choi, Chang Hwan: No conflict of interest |

| | |
|---|---|
| P711 | Dr. Yeo, Guo Dong Dillon: No conflict of interest\|\|Qui, Martin: No conflict of interest\|\|Pak, Wo Chan Webber: No conflict of interest\|\|Tan, Chin Kimg: No conflict of interest\|\|Tay, Shu Wen: No conflict of interest\|\|Lim, Chong Teik Thomson: No conflict of interest\|\|Tan, Teck Kiang Malcolm: No conflict of interest\|\|Ong, Wan Chee: No conflict of interest\|\|Lim, Teong Guan: No conflict of interest\|\|Ng, Yun Ting Valerie: No conflict of interest\|\|Wong, Shi Yi Amanda: No conflict of interest\|\|Salazar, Ennaliza: No conflict of interest |
| P712 | Shin, Yeji: No conflict of interest\|\|Prof. Hong, Sung Noh: No conflict of interest\|\|Kim, Eun Ran: No conflict of interest\|\|Chang, Dong Kyung: No conflict of interest\|\|Kim, Young-Ho: No conflict of interest |
| P713 | Ms. Gonzalez Vivo, Maria: No conflict of interest\|\|Carballo Martinez, Nuria: No conflict of interest\|\|Padulles Zamora, Nuria: No conflict of interest\|\|Colominas Gonzalez, Elena: No conflict of interest\|\|Murciano Gonzalo, Francisca: No conflict of interest\|\|Abril Rodriguez, Lourdes: No conflict of interest\|\|Marquez-Mosquera, Lucia: No conflict of interest |
| P714 | Siegel, Corey:\|:\|Advisory board for Abbvie, BMS, Fresnius, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, ProciseDx, Prometheus, Takeda, Trellus Health; Speaker for CME activities for Abbvie, Janssen, Pfizer and Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.\|\|Sebastian, Shaji:\|:\|Research grants from Takeda, Pfizer, Tillotts Pharma, Abbvie, Biogen, personal fees for Speaker role and advisory board meetings from Janssen, Amgen, Tillotts Pharma, Abbvie, Takeda, Celgene, Roche, Phramacosmos, Falk pharma outside the submitted work\|\|Siegmund, Britta:\|:\|Consulting fees from: Abbvie, BMS, Boehringer, Falk, Galapagos, Jassen, Lilly, Pfizer, PredictImmeune, Landos, Takeda; Speaker Fees: Abbvie, Falk, Ferring, Janssen, Pfizer, BMS, Takeda, CED Service GmbH, Lilly; Grant: Pfizer.\|\|Zhou, Jie:\|:\|An employee of Takeda and holds Takeda stock or stock options. \|\|Jones, Stephen:\|:\|Consultant to Takeda.\|\|Adsul, Shashi:\|:\|An employee of Takeda and holds Takeda stock or stock options. \|\|Louis, Edouard:\|:\|Educational and research grant: Janssen, Pfizer, Abbvie and Takeda, Fresenius-Kabi; speaker fees: Abbvie, Falk, Ferring, Janssen, Pfizer, Celgene, BMS, Galapagos and Takeda; advisory board: Abbvie, Celgene, Ferring, Janssen, BMS, Pfizer,Takeda, Gilead-Galapagos, Arena, Eli Lilly; consultant: Abbvie |

| | |
|---|---|
| P715 | Vermeire, Séverine:\|:\|Received grants from AbbVie, J&J, Pfizer, Takeda and Galapagos; received consulting and/or speaking fees from: AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Colombel, Jean-Frederic:\|:\|Received research grants from AbbVie, Janssen, and Takeda; received payment for lectures from AbbVie, Allergan, Amgen, Bristol Myers Squibb, Ferring, Shire, and Takeda; received consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enterome, Ferring, Genentech, Gilead, Immunic, Imtbio, Inotrem, Ipsen, Iterative Scopes, Janssen, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, TiGenix, and Viela Bio; and holds stock options in Intestinal Biotech Development.\|\|Rubin, David T.:\|:\|Received grant support from Takeda; consulted for AbbVie, AltruBio, Arena, Bristol Myers Squibb, Eli Lilly, Genentech/Roche, Gilead, Iterative Scopes, Janssen, Pfizer, Prometheus Biosciences, Takeda, and Techlab.\|\|Ghosh, Subrata:\|:\|Received research funding from AbbVie and GlaxoSmithKline; served as lecturer for AbbVie, Celgene, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Pfizer, and Takeda; and served as consultant for AbbVie, Bristol Myers Squibb, Janssen, Novo Nordisk, Pfizer, Roche, and Takeda.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Lawlor, Garrett:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Osterman, Mark T.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Chiorean, Michael V.:\|:\|Reported advisory/consulting roles with AbbVie, Arena, Bristol Myers Squibb, Eli Lilly, Janssen, Medtronic, and Pfizer; reported speaker role with AbbVie, Bristol Myers Squibb, Janssen, Medtronic, and Pfizer; received research funding from Fuji, Gilead, Janssen, Novartis, Pfizer, and Takeda. |

| | |
|---|---|
| P716 | Mrs. Sigall-Boneh, Rotem:\|:\|Speaker fees, Consulting and Advisory board - Nestlé Health Science \|\|Manuel Navas-López, Víctor:\|:\|Consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, AbbVie, Takeda, and Nestlé Health Science\|\|Hussey, Seamus:\|:\|Research grant from Takeda and Janssen in the past 3 years. No conflict for this study\|\|Pujol Muncunill, Gemma:\|:\|AbbVie, Janssen, Nestle Health Sciences, Nutricia and Adacyte for speaker fee and travel support and Lilly for consulting\|\|Lawrence, Sally:\|:\|Advisory board and speakers bureau for Janssen and AbbVie.\|\|Jonsson Rolandsdotter, Helena:\|:\|Nutricia, Semper and Adacyte for research support and speaker fee. None of those have any relation to the present study.\|\|Otley, Anthony:\|:\|Research support and advisory board for AbbVie, research site for AbbVie, Janssen, Pfizer, Eli Lilly.\|\|Martín-de-Carpi5, Javier:\|:\|honoraria for talks and advisory from Abbvie, Nestle, MSD, Adacyte, Janssen\|\|Abramas, Lee: No conflict of interest\|\|Herrador López , Marta:\|:\|consultation fee, research grant, royalties, or honorarium from Nestlé Health Science \|\|Egea Castillo, Natalia: No conflict of interest\|\|Chen, Min: No conflict of interest\|\|Hurley, Michelle: No conflict of interest\|\|Wingate, Kirsten: No conflict of interest\|\|Olen, Ola:\|:\|Dr. Olén has been PI on projects at Karolinska Institutet financed by grants from Janssen, Takeda, AbbVie, Pfizer, and Ferring, and also report grants from Pfizer and Janssen in the context of national safety monitoring programs. None of those studies have any relation to the present study\|\|yaakov, Michal: No conflict of interest\|\|Levine, Arie:\|:\|Reports grants from Nestle Health Science, Janssen, and Abbvie; advisory boards, travel, speaker fees from Takeda, Nestle Health, and Megapharm, and a licensing and consulting agreement with IP with Nestle Health to develop new products\|\|Van Limbergen, Johan:\|:\|Nestle Health Sciences consulting/research support/speaker fee and Janssen (Research Support/Travel).\|\|Wine, Eytan:\|:\|Advisory board: AbbVie, Nestle Health Sciences, Pfizer, BioJamp; Speaker: AbbVie, Nestle Health Sciences, Janssen, Mead Johnson Nutrition |
| P717 | Dr. Dalal, Rahul: No conflict of interest\|\|Lund, Ken: No conflict of interest\|\|Zegers, Floor: No conflict of interest\|\|Friedman, Sonia: No conflict of interest\|\|Allegretti, Jessica: No conflict of interest\|\|Norgard, Bente: No conflict of interest |
| P718 | Dr. Otero Piñeiro, Ana: No conflict of interest\|\|Lightner , Amy L.:\|:\|Consultant for Takeda Pharmaceuticals, Mesoblast Inc, Ossium Health, Boomerang Health, Direct Biologics\|\|Reese , Jane: No conflict of interest\|\|Ream , Justin: No conflict of interest\|\|Nachand , Douglas: No conflict of interest\|\|Adams , Ashley: No conflict of interest\|\|VanDenBossche, Alex: No conflict of interest\|\|Kurowski, Jacob: No conflict of interest |

| | |
|---|---|
| P719 | Danese, Silvio:\|:\|Received honoraria as a speaker, consultant, and/or advisory board member from AbbVie, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, and Vifor Pharma.\|\|Abreu, Maria T.:\|:\|Consulted and/or served on an advisory board for AbbVie, Arena, Bristol Myers Squibb, Celsius Therapeutics, Eli Lilly, Gilead, Janssen, Microba, Pfizer, Prometheus Biosciences, UCB, and WebMD Global; served as a teacher, lecturer, or speaker for Alimentiv, Intellisphere (HCP Live Institutional Perspectives in GI), Janssen, Prime CME, and Takeda; received grants/research support from Alimentiv, Bristol Myers Squibb, and Takeda\|\|Afzali, Anita:\|:\|Served as consultant for AbbVie, Bristol Myers Squibb, DiaSorin, Eli Lilly, Gilead, Janssen, Pfizer, Takeda, and TLL Pharmaceuticals; received speaker fees from AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Petersen, AnnKatrin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Panaccione, Remo:\|:\|Received consulting fees from AbbVie, Abbott, Alimentiv, Amgen, Arena, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Eli Lilly, Merck, Mylan, Oppilan Pharma, Pandion Therapeutics, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; received speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; received research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; served on an advisory board for AbbVie, Amgen, Arena, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Takeda, and Theravance.\|\|Wolf, Douglas C.:\|:\|Received research funding from AbbVie, Bristol Myers Squibb, Genentech, Janssen, Pfizer (Arena), and Takeda; consulted for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda; received speaker fees from AbbVie, Bristol Myers Squibb, Janssen, and Takeda. |
| P720 | Mr. Hanzel, Jurij:\|:\|speaker's fees from Abbvie, Janssen, Takeda; consulting fees from Alimentiv Inc\|\|Supovec, Eva: No conflict of interest\|\|Smrekar, Nataša:\|:\|consultant, advisory board member and speaker for AbbVie, Amgen, Biogen, Janssen, MSD, Lek, Oktal Pharma and Pfizer\|\|Koželj, Matic:\|:\|speaker's fees from Janssen, Takeda\|\|Kurent, TIna: No conflict of interest\|\|Štabuc, Borut:\|:\|speaker's fees from Abbvie, Janssen, Krka, Lek, Pfizer, SOBI, Takeda\|\|Novak, Gregor:\|:\|speaker’s and consulting fees from Abbvie, Amgen, Janssen, MSD, and Takeda\|\|Drobne, David:\|:\|speaker, a consultant and an advisory board member for MSD, Abbvie, Takeda, Pfizer, Janssen, Amgen, Biogen and Krka |

| | |
|---|---|
| P721 | Dr. Corallo, Frédérique: No conflict of interest |
| P722 | Dr. Tran, Florian:\|:\|Personal fees from AbbVie, Janssen and Falk. \|\|Brard, Raphael:\|:\|Employee of Sanofi\|\|Flechsenhar, Klaus:\|:\|Employee of Sanofi\|\|Aden, Konrad: No conflict of interest\|\|Rosenstiel, Philip: No conflict of interest\|\|Agueusop, Inoncent:\|:\|Employee of Sanofi\|\|Schreiber, Stefan:\|:\|Personal fees from AbbVie, Ferring, Janssen, Merck Sharp Dohme, Novartis, Takeda, and UCB; consultant for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Ferring, Genentech/Roche, Janssen, Lilly, Medimmune/AstraZeneca, Novartis, Merck Sharp Dohme, Pfizer, Protagonist, Sanofi, Takeda, Theravance, and UCB. |
| P723 | Dr. Nishida, Daisuke: No conflict of interest\|\|Ishige, Takashi: No conflict of interest\|\|Arai, Katsuhiro:\|:\|Abbie GK, EA Pharma Co.,Ltd., NobelPharma Co.,Ltd. TakedaPharmaceutical Co.,Ltd. Janssen Pharmaceutical K.K, Mitsubisi Tanabe Pharma.Co.,Ltd, AstraZeneka\|\|Shimizu, Hirotaka: No conflict of interest\|\|Iwama, Itaru: No conflict of interest\|\|Nambu, Ryusuke: No conflict of interest\|\|Kunisaki, Reiko:\|:\|Mitsubishi Tanabe Pharma Corporation, AbbVie GK.,Janssen Pharmaceutical K.K. \|\|Yaguchi, Katsuki: No conflict of interest\|\|Mizuochi, Tatsuki:\|:\|AbbVie GK, EA Pharma Co,.Ltd.\|\|Murakoshi, Takatsugu: No conflict of interest\|\|Saito, Takeshi: No conflict of interest\|\|Kato, Sawako: No conflict of interest\|\|Kudo, Takahiro: No conflict of interest\|\|Iwata, Naomi: No conflict of interest\|\|Inoue, Mikihiro: No conflict of interest\|\|Yodoshi, Toshifumi: No conflict of interest\|\|Hagiwara, Shin-ichiro: No conflict of interest\|\|Toita, Nariaki: No conflict of interest\|\|Tajiri, Hitoshi: No conflict of interest\|\|Mochizuki, Takahiro: No conflict of interest\|\|Kakuta, Fumihiko: No conflict of interest\|\|Kumagai, Hideki: No conflict of interest\|\|Noguchi, Atsuko: No conflict of interest\|\|Sasaki, Mika: No conflict of interest\|\|Nishimata, Shigeo: No conflict of interest\|\|Aomatsu, Tomoki: No conflict of interest\|\|Hirano, Yuri: No conflict of interest\|\|Shimizu, Toshiaki: No conflict of interest |

| | |
|---|---|
| P724 | Dr. Krugliak Cleveland, Noa:\|:\|N Krugliak Cleveland has served as a consultant for Arena Pharmaceuticals, Neurologica, and Takeda Pharmaceuticals U.S.A., Inc, and received a speaker's fee from Bristol Myers Squibb.\|\|Friedberg, Scott: No conflict of interest\|\|Choi, David: No conflict of interest\|\|Hunold, Thomas: No conflict of interest\|\|Choi, Natalie K: No conflict of interest\|\|Garcia, Nicole M: No conflict of interest\|\|Picker, Emma A: No conflict of interest\|\|Cohen, Nathaniel A: No conflict of interest\|\|Cohen, Russell D:\|:\|RDC is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/Celgene, Eli Lilly, Genentech, Gilead Sciences, Hoffmann La-Roche, Janssen, Pfizer, Takeda, UCB Pharma. He has received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therpeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. His wife is on the board of directors of Aerpio Theraoeutics, ImmunityBio, and MEI Pharmaceuticals. \|\|Dalal, Sushila R:\|:\|SRD has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. SD is on the Speaker's Bureau and has served as a consultant for Abbvie and Pfizer. \|\|Pekow, Joel:\|:\|JP has served as a consultant for CVS Caremark. \|\|Sakuraba, Atsushi: No conflict of interest\|\|Rubin, David T:\|:\|DTR has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Laboratories, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. |
| P725 | Ms. Van De Pol, Natasja: No conflict of interest\|\|van der Woude, C. Janneke:\|:\|MSD, FALK Benelux, Abbott laboratories, Mundipharma Pharmaceuticals, Janssen, Takeda, and Ferring\|\|Vis, Marijn:\|:\|Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer\|\|van Doorn, Martijn B.A.:\|:\|Novartis, LEO Pharma, AbbVie, BMS, Celgene, Lilly, MSD, Pfizer, Sanofi Genzyme, Janssen Cilag\|\|Derikx, Lauranne A.A.P.: No conflict of interest\|\|Molendijk, Ilse: No conflict of interest\|\|de Vries, Annemarie C.:\|:\|Pfizer, Galapagos, Jansen, Abbvie, and Takeda |
| P726 | Dr. Ollech, Jacob: No conflict of interest\|\|Yanai, Henit: No conflict of interest\|\|Avni Biron, Irit: No conflict of interest\|\|Dotan, Iris: No conflict of interest |

| | |
|---|---|
| P727 | Dr. Macaluso, Fabio Salvatore:\|:\|Fabio Salvatore Macaluso served as advisory board member and/or received lecture grants from AbbVie, Biogen, Galapagos, Janssen, MSD, Pfizer, Samsung Bioepis, Takeda Pharmaceuticals. \|\|Ventimiglia, Marco: No conflict of interest\|\|Orlando, Ambrogio:\|:\|Ambrogio Orlando served as advisory board member for AbbVie, MSD, Takeda Pharmaceuticals, and received lecture grants from AbbVie, Galapagos, Janssen, MSD, Pfizer, Sofar, Chiesi, and Takeda Pharmaceuticals. |
| P728 | Dr. Cheung, Sun: No conflict of interest\|\|Truong, Don: No conflict of interest |
| P729 | Dr. Ağargün, Besim Fazıl: No conflict of interest\|\|Şenkal, İbrahim Volkan: No conflict of interest\|\|Rustamzade, Aynura: No conflict of interest\|\|Nuriyev, Kanan: No conflict of interest\|\|İstemihan, Zülal: No conflict of interest\|\|İmanov, Ziya: No conflict of interest\|\|Genç, Sezen: No conflict of interest\|\|Çelik, Bilal: No conflict of interest\|\|Şahutoğulları, Dilan: No conflict of interest\|\|Çavuş, Bilger: No conflict of interest\|\|Çifcibaşı Örmeci, Aslı: No conflict of interest\|\|Demir, Kadir: No conflict of interest\|\|Beşışık, Selman Fatih: No conflict of interest\|\|Kaymakoğlu, Sabahattin: No conflict of interest\|\|Akyüz, Filiz: No conflict of interest |
| P730 | Mr. Lundekvam, Jonas Andre: No conflict of interest\|\|Lie Høivik, Marte:\|:\|Dr. Høivik has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma\|\|Anisdahl, Karoline:\|:\|Karoline Anisdahl reports consultant fees from Takeda\|\|Cvancarova Småstuen, Milada: No conflict of interest\|\|Medhus, Asle Wilhelm: No conflict of interest |

| | |
|---|---|
| P731 | Dr. Carbery, Isabel:\|:\|IC has received a research grant from Celltrion, a travel grant from Galapagos and has received speaker honoraria from Celltrion.\|\|Broglio, Giacomo: No conflict of interest\|\|Clark, Tanya: No conflict of interest\|\|Greer, Dan: No conflict of interest\|\|Alakkari, Alaa: No conflict of interest\|\|Selinger, Christian P:\|:\|C.P.S. has received unrestricted research grants from Warner Chilcott, Janssen, Celltrion and AbbVie, has provided consultancy to Warner Chilcott, Falk, AbbVie, Takeda, Fresenius Kabi, Galapagos, Ferring, Arena and Janssen, and had speaker arrangements with Warner Chilcott, Falk, AbbVie, Pfizer, Celltrion and Takeda. |
| P732 | Ms. Gofflot, Amandine: No conflict of interest\|\|Monin, Lucie: No conflict of interest\|\|Seidel, Laurence: No conflict of interest\|\|Reenaers, Catherine: No conflict of interest\|\|Kropp, Sophie: No conflict of interest\|\|Van Kemseke, Catherine: No conflict of interest\|\|Latour, Pascale: No conflict of interest\|\|Forthomme, Bénédicte: No conflict of interest\|\|Croisier, Jean-Louis: No conflict of interest\|\|Louis, Edouard: No conflict of interest\|\|Vieujean, Sophie: No conflict of interest |
| P733 | Resál, Tamás: No conflict of interest\|\|Horváth, Miklós: No conflict of interest\|\|Dr. Bacsur, Péter: No conflict of interest\|\|Szántó, Kata: No conflict of interest\|\|Rutka, Mariann: No conflict of interest\|\|Bálint, Anita: No conflict of interest\|\|Fábián, Anna: No conflict of interest\|\|Bor, Renáta: No conflict of interest\|\|Szepes, Zoltán: No conflict of interest\|\|Fekete, János: No conflict of interest\|\|Miheller, Pál: No conflict of interest\|\|Molnár, Tamás: No conflict of interest |
| P734 | Magro, Fernando:\|:\|FM served as speaker and received honoraria from: Abbvie, Biogen, Falk, Ferring, Hospira, Janssen, Laboratórios Vitoria, Lilly, Pfizer, Merck Sharp & Dohme, Sandoz, Takeda, UCB and Vifor. HTS received fees for serving as speaker for Takeda, AbbVie, Janssen, Pfizer, Ferring and Biogen.\|\|Dr. Estevinho, Maria Manuela: No conflict of interest\|\|Catalano, Gaia: No conflict of interest\|\|Patita, Marta: No conflict of interest\|\|Arroja, Bruno: No conflict of interest\|\|Lago, Paula: No conflict of interest\|\|Rosa, Isadora: No conflict of interest\|\|Tavares-de-Sousa, Helena: No conflict of interest\|\|Ministro, Paula: No conflict of interest\|\|Roseira, Joana: No conflict of interest\|\|Cancela, Eugénia: No conflict of interest\|\|Sousa, Paula: No conflict of interest\|\|Portela, Francisco: No conflict of interest\|\|Correia, Luís: No conflict of interest\|\|Moreira, Paula: No conflict of interest\|\|Santiago, Mafalda: No conflict of interest\|\|Dias, Sandra: No conflict of interest\|\|Afonso, Joana: No conflict of interest\|\|Danese, Silvio: No conflict of interest\|\|Peyrin-Biroulet, Laurent: No conflict of interest\|\|Dias, Cláudia Camila: No conflict of interest |

| | |
|---|---|
| P735 | Parra Izquierdo, Leidy Viviana: No conflict of interest\|\|Dr. Frías-Ordoñez, Juan: No conflict of interest\|\|Márquez, Juan Ricardo: No conflict of interest\|\|Juliao-Baños , Fabián: No conflict of interest\|\|Galindo, Pablo: No conflict of interest\|\|Cuadros, Carlos: No conflict of interest\|\|Rojas, Carlos: No conflict of interest\|\|Rojas, Nelson: No conflict of interest\|\|Ardila, Oscar: No conflict of interest\|\|Tovar-Fierro , German: No conflict of interest\|\|García-Duperly, Rafael: No conflict of interest\|\|Gil Parada, Fabio Leonel: No conflict of interest\|\|Imbeth Acosta, Pedro Luis: No conflict of interest\|\|Puentes, Fabian E: No conflict of interest\|\|Galiano de Sánchez, María Teresa: No conflict of interest\|\|Hani de Ardila, Albis: No conflict of interest\|\|Flórez-Sarmiento, Cristian: No conflict of interest |
| P736 | Prof. Dr. Peyrin-Biroulet, Laurent:\|:\|LP-B reports personal fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, InDex Pharmaceuticals, Inotrem, Janssen Pharmaceuticals, MSD, Mylan, Norgine, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance Biopharma, Thermo Fisher Scientific, Tillotts, Viatris and Vifor; grants from AbbVie, Fresenius Kabi, MSD and Takeda; and stock options from CTMA.\|\|Louis , Edouard:\|:\|EL reports educational and research grants from AbbVie, Fresenius Kabi, Janssen Pharmaceuticals, Pfizer and Takeda; speaker fees from AbbVie, Celgene, Dr. Falk Pharma, Ferring Pharmaceuticals, Galapagos, Janssen Pharmaceuticals, Pfizer and Takeda; advisory board fees from AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Celgene, Eli Lilly, Ferring Pharmaceuticals, Gilead/Galapagos, Janssen Pharmaceuticals, MSD, Pfizer and Takeda; and consulting fees from AbbVie. \|\|Hisamatsu, Tadakazu:\|:\|TH reports a joint research agreement with Alfresa Pharma and EA Pharma; grants from AbbVie, Daiichi Sankyo, EA Pharma, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda and Zeria Pharmaceutical; and consulting and lecture fees from AbbVie, Celgene, EA Pharma, Janssen Pharmaceuticals, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, Pfizer and Takeda. \|\|Jamoul, Corinne:\|:\|CJ is a contractor at Galapagos NV.\|\|Santermans, Eva:\|:\|ES is an employee and shareholder of Galapagos NV.\|\|Harris , Kristina:\|:\|KH is an employee and shareholder of Galapagos NV.\|\|de Haas, Angela:\|:\|AdH is an employee and shareholder of Galapagos NV.\|\|Oortwijn , Alessandra:\|:\|AO is an employee and shareholder of Galapagos NV.\|\|Feagan , Brian:\|:\|BF reports grants and personal fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen Biotech/Centocor, Johnson & Johnson/Janssen, Pfizer, Receptos and Takeda; and personal fees from Ablynx, ActoGeniX, AdMIRx Inc., Akebia Therapeutics Inc., Allergan, Atlantic Pharma, Avaxia Biologics Inc., Avir Pharma, Baxter Healthcare Corporation, Biogen Idec, BiomX Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Calypso Biotech, Celgene, Elan/Biogen, Eli Lilly, enGene, Ferring Pharmaceuticals, Galapagos, Genentech/Roche, gIcare Pharma, Gilead, Given Imaging, Gossamer Bio, GlaxoSmithKline, Inception IBD Inc., Ironwood Pharmaceuticals, Japan Tobacco Company, Kyowa Hakko Kirin Co. Ltd, Lexicon Pharmaceuticals, Lycera, Mesoblast, Millennium Pharmaceuticals, MSD, Nestlé, Nextbiotix, Novartis, Novo Nordisk, Par'Immune, Progenity, Prometheus Therapeutics and Diagnostics, Protagonist, Qu Biologics, Salix Pharmaceuticals, Shire, Sienna Biopharmaceuticals, Sigmoid Pharma, Synergy Pharma, Teva Pharmaceuticals, TiGenix, Tillotts, UCB, Vertex, VHsquared, Vivelix Pharmaceuticals, Wyeth, Zealand Pharma and Zyngenia. |

| | |
|---|---|
| | |
| P737 | Mr. Arroyo Argüelles, José María: No conflict of interest\|\|Suárez Ferrer, Cristina: No conflict of interest\|\|Rueda García, Jose Luis: No conflict of interest\|\|Martín-Arranz, Eduardo: No conflict of interest\|\|Poza Cordón, Joaquín: No conflict of interest\|\|Sánchez-Azofra, María: No conflict of interest\|\|García-Ramírez, Laura: No conflict of interest\|\|Martin-Arranz, María Dolores: No conflict of interest |
| P738 | Dr. Elosua Gonzalez, Alfonso: No conflict of interest\|\|Rubio, Saioa: No conflict of interest\|\|Irisarri, Rebeca: No conflict of interest\|\|Campillo, Ana: No conflict of interest\|\|Nantes, Óscar: No conflict of interest\|\|Vicuña, Miren: No conflict of interest\|\|Angós, Ramón: No conflict of interest\|\|Zozaya, José Manuel: No conflict of interest\|\|Rodríguez, Cristina: No conflict of interest |
| P739 | Dr. Farkas, Bernadett: No conflict of interest\|\|Borsos, Mariann: No conflict of interest\|\|Resál, Tamás: No conflict of interest\|\|Bacsur, Péter: No conflict of interest\|\|Bor, Renáta: No conflict of interest\|\|Bálint, Anita: No conflict of interest\|\|Fábián, Anna: No conflict of interest\|\|Szepes, Zoltán: No conflict of interest\|\|Molnár, Tamás: No conflict of interest\|\|Farkas, Klaudia: No conflict of interest |
| P740 | Dr. Diz Lois Palomares, Maria Teresa: No conflict of interest\|\|Porta Sánchez, Ángeles: No conflict of interest\|\|González Conde, Benito: No conflict of interest\|\|Estévez Prieto, Emilio: No conflict of interest\|\|Vázquez Rey, Mª Teresa: No conflict of interest\|\|Elberdin Pazos, Laida: No conflict of interest\|\|Alonso Aguirre, Pedro: No conflict of interest\|\|Martin Herranz, Isabel: No conflict of interest |

| | |
|---|---|
| P741 | Dr. Tolan, Marie: No conflict of interest\|\|Nartey, Joel: No conflict of interest\|\|Dattoo, Maryam: No conflict of interest\|\|King, Dominic: No conflict of interest\|\|de Silva, Shanika: No conflict of interest |
| P742 | Prof. Dr. Bokemeyer, Bernd: No conflict of interest\|\|Plachta-Danielzek, Sandra: No conflict of interest\|\|Howaldt, Stefanie:\|:\|Personal fees from: MSD, AbbVie, Biogen, Celltrion, Hospira, Takeda, Pfizer, Pharmacosmos, Janssen, R-Biopharm, Norgine, Sandoz, and Shield Therapeutics\|\|Mohl, Wolfgang:\|:\|Consulting fees from: Abbvie, Amgen, Hexal, Janssen, Pfizer, Synformulas, Takeda, outside the submitted work. Fees for lectures and further education from: Abbvie, Alanta health service GmbH, Almirall, Aptalis, Biogen, Falk, Gilead, Janssen, Pfizer, Medtronic, MSD, Shire, Takeda, Vifor, outside the submitted work. Fees for studies from: Abbvie, Janssen, MSD, Pfizer, Takeda, outside the submitted work. Fees for activities in public law bodies as member of the Advisory Commission of the Examination Office for the Saarland, the State Committee of Physicians and Health Insurance Companies and the Extended State Committee, outside the submitted work. Dependent employment in the group of Alanta health group GmbH, Hamburg, outside the submitted work. Shares, other fees from: Abbvie, Gilead, outside the submitted work\|\|Efken, Philipp:\|:\|Personal fees from: Abbvie, BMS, Galapagos, Janssen, Amgen outside the submitted work\|\|Ehehalt, Robert:\|:\|Personal fees from: Takeda, Abbvie, MSD, Biogen, Hexal, Amgen, Celltrion, Viatris\|outside the submitted work\|\|Kahl, Matthias:\|:\|Persdonal fees for lectures and consulting from Abbvie, Ferring, and Galapagos\|\|Krause, Thomas:\|:\|Personal fees from: AbbVie, Janssen, Takeda outside the submitted work\|\|Trentmann, Leo: No conflict of interest\|\|Lügering, Andreas: No conflict of interest\|\|Schnoy, Elisabeth:\|:\|Personal fees from: Janssen-Cilag GmbH, Janssen Steering, Pharmacosmos GmbH, Takeda Pharma GmbH, AbbVie Deutschland, Pfizer GmbH, Tillotts Pharma GmbH, AstraZeneca, Galapagos Biopharma, Lilly GmbH, Celltrion, Dr. Falk Pharma GmbH, BMS outside the submitted work\|\|Jochum, Christoph:\|:\|Personal fees from: Janssen, Abbvie, Takeda, Advanz, Behring\|\|Fajardo Salmon, Samantha: No conflict of interest\|\|Hartmann, Petra:\|:\|Personal fees from: Abbvie, MSD, Shire, Ferring, UCB, Hospira, Takeda, Movetis, Biogen, Mylan, Janssen, BMS, Amgen, Hexal, Stada, Merckle, Mundipharma, Falk, HLR; outside the submitted work\|\|Gilman, Elena: No conflict of interest\|\|Schreiber, Stefan:\|:\|Personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, and Falk, outside the submitted work |

| | |
|---|---|
| P743 | Travis, Simon:\|:\|Grant: Ferring, Abbvie, Schering-Plough, MSD, Procter & Gamble, Warner Chilcott, International Organisation of IBD, ECCO, UCB, Vifor, Normal Collison Foundation, Buhlmann, Takeda, Janssen, Pfizer, Lilly; Other: Abacus; AbbVie; Actial; ai4gi; Alcimed; Allergan; Amgen; Aptel; Arena; Asahi; Aspen; Astellas; Atlantic; AstraZeneca; Barco; Biocare; Biogen; BLPharma; Boehringer Ingelheim; BMS; Buhlmann; Calcico; Celgene; Cellerix; Cerimon; ChemoCentryx; Chiesi; CisBio; ComCast; Coronado; Cosmo; Ducentis; Dynavax; Elan; Enterome; Equillium; Falk; Ferring; FPRT Bio; Galapagos; Genentech/Roche; Genzyme; Gilead; Glenmark; Grunenthal; GSK; GW Pharmaceuticals; Immunocore; Immunometabolism; Indigo; Janssen; Lexicon; Lilly; Medarex; Medtrix; Merck; Merrimack; Mestag; Millenium; Neovacs; Novartis; Novo Nordisk; NPS-Nycomed; Ocera; Optima; Origin; Otsuka; Palau; Pentax; Pfizer; Pharmaventure; Phesi; Phillips; P&G; Pronota; Proximagen; Resolute; Robarts; Sandoz; Santarus; Satisfai; Sensyne Health; Shire; SigmoidPharma; Sorriso; Souffinez; Syndermix; Synthon; Takeda; Theravance; Tigenix; Tillotts; Topivert; Trino Therapeutics with Wellcome Trust; TxCell; UCB Pharma; Vertex; VHsquared; Vifor; Warner Chilcott and Zeria\|\|Wu, Jianmin:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Keohane, Anthony:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Gibble, Theresa Hunter:\|:\|Employment and stockholder: Eli Lilly and Company\|\|Hibi, Toshifumi:\|:\|Lecture fees from Aspen Japan K.K, Abbvie GK, Ferring,GileadSciences, Janssen, JIMRO, Mitsubishi-TanabePharma, Mochida Pharmaceutical, Pfizer, Takeda Pharmaceutical, Advisory/consultancy fees from Apo Puls Station, Abbvie GK, Bristol-Myers Squibb, Celltrion, EA Pharma, Eli Lilly, Gilead Sciences, Janssen,Kyorin,Mitsubishi-TanabePharma.,Nichi-IkoPharmaceutical, Pfizer,Takeda Pharmaceutical, Zeria Pharmaceutical and research grants from Abbvie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc., Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Ferring Pharmaceuticals and Bristol-Myers Squibb; received scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd.; belonged to study group sponsorship by Otsuka Holdings, Abbvie GK, EA Pharma Co., Ltd., Zeria Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. |

| | |
|---|---|
| P744 | Dr. Chaparro, Maria: No conflict of interest\|\|García Donday, María: No conflict of interest\|\|Rubio, Saioa: No conflict of interest\|\|Calviño Suarez, Cristina: No conflict of interest\|\|Nuñez Ortiz, Andrea: No conflict of interest\|\|Figueira, Montserrat: No conflict of interest\|\|Marín Pedrosa, Sandra: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Fernández-Clotet, Agnes: No conflict of interest\|\|Madero, Lucía: No conflict of interest\|\|Diz-Lois Palomares, María Teresa: No conflict of interest\|\|Pérez-Martínez, Isabel: No conflict of interest\|\|Ruiz-Cerulla, Alexandra: No conflict of interest\|\|Arroyo, Maite: No conflict of interest\|\|Piqueras, Marta: No conflict of interest\|\|Suarez Ferrer, Cristina: No conflict of interest\|\|Aguas, Mariam: No conflict of interest\|\|Calvo Moya, Marta: No conflict of interest\|\|Guerra, Iván: No conflict of interest\|\|López Serrano, Pilar: No conflict of interest\|\|Vázquez Morón, Juan María: No conflict of interest\|\|Arias García, Lara: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|Huguet, José María: No conflict of interest\|\|Valldosera Gomis, Gemma: No conflict of interest\|\|Zúñiga de Mora-Figueroa, Beatriz: No conflict of interest\|\|Armesto, Rubén: No conflict of interest\|\|Martínez Montiel, Pilar: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Sendra Rumbeu, Pau: No conflict of interest\|\|Camargo Camero, Raquel: No conflict of interest\|\|Hervías Cruz, Daniel: No conflict of interest\|\|Molina Arriero, Gema: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|Acosta, Diana: No conflict of interest\|\|Brenes, Yanire: No conflict of interest\|\|Hermida, Sandra: No conflict of interest\|\|Parra, Pablo: No conflict of interest\|\|Garre, Ana: No conflict of interest\|\|Gisbert, Javier P: No conflict of interest |
| P745 | Mrs. Gros, Beatriz:\|:\|I have served as a speaker for Abbvie, Jansen, You&us and Galapagos. \|\|Plevris, Nikolas:\|:\|NP has served as a speaker for Janssen, Takeda and Pfizer. \|\|Constantine-Cooke, Nathan:\|:\|. NC-C is supported by the Medical Research Council and The University of Edinburgh via a Precision Medicine PhD studentship (MR/N013166/1)\|\|Lyons, Mathew: No conflict of interest\|\|O'Hare, Claire: No conflict of interest\|\|Noble, Colin:\|:\|CN has acted as a consultant to Galapagos. \|\|Arnott, Ian D: No conflict of interest\|\|Jones, Gareth-Rhys: No conflict of interest\|\|Lees, Charlie W:\|:\|CWL has acted as a consultant to Abbvie, Janssen, Takeda, Pfizer, Galapagos, Bristol Myers Squibb, B.I., Sandoz, Novartis, GSK, Gilead, Vifor Pharma, Dr Falk, Trellus Health and Iterative Scopes; he has received speaking fees and travel support from Pfizer, Janssen, Abbvie, Galapagos, MSD, Takeda, Shire, Ferring, Hospira, and Dr Falk.\|\|Derikx, Lauranne A.A.P:\|:\|LD has served on advisory board for Sandoz and as a speaker for Janssen. |

| | |
|---|---|
| P746 | Morsy, Yasser: No conflict of interest\|\|Pivorunas, Valerie:\|:\|Employees of AbbVie and may own stock/options \|\|Leitner, Claudia:\|:\|Employees of AbbVie and may own stock/options \|\|Birchler, Thomas:\|:\|Employees of AbbVie and may own stock/options \|\|Guay, Heath:\|:\|Employee of AbbVie and may own stock/options \|\|Scharl, Michael:\|:\|M.S. has shares and is co-founder of Recolony AG, Zurich, CH and has shares in PharmaBiome AG, Zurich, CH. M.S. served as Advisor for Abbvie, Gilead, Fresenius, Topadur, Takeda, Roche and Celltrion. He received speaker's honoraria from Falk Pharma, Vifor Pharma, Pileje and Bromatech. He received research grants from Abbvie, Takeda, Gilead, Gnubiotics, Roche, Axalbion, Pharmabiome, Topadur, Basilea, MBiomics, Storm Therapeutics, LimmatTech, Zealand Pharma, NodThera, Calypso Biotech, Pileje, Herbodee, Vifor |
| P747 | Mr. Moralejo Lozano, Óscar: No conflict of interest\|\|Beneyto Martín, Pedro: No conflict of interest\|\|Abanades Tercero, María: No conflict of interest\|\|Muñoz Rosas, Concepción: No conflict of interest\|\|Ruano Díaz, Lucía: No conflict of interest\|\|Salmoral Luque, Rosario: No conflict of interest\|\|Gómez Rodríguez, Rafael: No conflict of interest |
| P748 | Gregg, Richard:\|:\|Employee: Ventyx Biosciences\|\|Dr. Yun, Chohee:\|:\|Employee: Ventyx Biosciences\|\|Naik, Snehal:\|:\|Employee: Ventyx Biosciences\|\|Huyghe, MiRa:\|:\|Former employee: Oppilan Pharma\|\|Harris, Jason:\|:\|Former employee: Oppilan Pharma\|\|Mohan, Raju:\|:\|Employee: Ventyx Biosciences\|\|Nuss, John:\|:\|Employee: Ventyx Biosciences\|\|Sandborn, William J.:\|:\|Employee: Ventyx Biosciences |
| P749 | Dr. Lovett, Grace: No conflict of interest\|\|Schulberg, Julien D.: No conflict of interest\|\|Hamilton, Amy L.: No conflict of interest\|\|Wright, Emily K.: No conflict of interest\|\|Sutherland, Tom R.: No conflict of interest\|\|Kamm, Michael A.: No conflict of interest |
| P750 | Dr. Hou, Jason K.: No conflict of interest\|\|Pham, Codey: No conflict of interest\|\|Sansgiry, Shubhada: No conflict of interest\|\|Modi, Varsha: No conflict of interest\|\|Waljee, Akbar K.: No conflict of interest |

| | |
|---|---|
| P751 | Dr. Lababidi, Nabil El: No conflict of interest\|\|Pavel, Frühauf: No conflict of interest |
| P752 | Vermeire, Séverine:\|:\|Received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand.\|\|Abraham, Bincy:\|:\|Received research funding from Takeda; consulted for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Medtronic, Pfizer, Samsung Bioepis, and Takeda; lectured for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, and Takeda.\|\|Bressler, Brian:\|:\|Served as an advisor/speaker for AbbVie, Ferring, Janssen, Merck, Novartis, Pfizer, and Takeda; served as an advisor for Allergan, Amgen, Bristol Myers Squibb, Celgene, Genentech, Merck, Microbiome Insights, Pendopharm, Protagonist, and Robarts Clinical Trials; received research support from AbbVie, Alvine, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Merck, and Qu Biologics; holds stock options in Qu Biologics.\|\|Reinisch, Walter:\|:\|Speaker for 4SC, Abbott Laboratories, AbbVie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Medice, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; consulted for Abbott Laboratories, AbbVie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, AstraZeneca, Avaxia, Roland Berger GmbH, Bioclinica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Calyx, Cellerix, ChemoCentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Gatehouse Bio, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Intrinsic Imaging, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Landos Biopharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, OMass, Otsuka, Parexel, PDL, Peri Consulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Quell Therapeutics, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpoint Medical, Sigmoid, Sublimity, Takeda, Teva Pharma, Therakos, Theravance, TiGenix, UCB, Vifor, Zealand, and Zyngenia; served as an advisory board member for 4SC, Abbott Laboratories, AbbVie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Cellerix, ChemoCentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, |

| | |
|---|---|
| | Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millennium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpoint Medical, Takeda, Therakos, TiGenix, UCB, Zealand, and Zyngenia; received research funding from Abbott Laboratories, AbbVie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnostik, Janssen, MSD, Sandoz, and Takeda.\|\|Axelrad, Jordan E.:\|:\|Received consulting fees from AbbVie, BioFire Diagnostics, Janssen, and Pfizer; received research grants from BioFire Diagnostics.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Memaj, Arteid:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Akukwe, Lucy:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Liu, W. Jerry:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Osterman, Mark T.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Sands, Bruce E.:\|:\|Received fees for consulting and speaking from Abivax, Bristol Myers Squibb, Janssen, Eli Lilly, Pfizer, and Takeda; received fees for consulting from AbbVie, Adiso Therapeutics, Alimentiv, Amgen, Arena, Artizan Biosciences, Artugen, AstraZeneca, Bacainn Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Calibr, Celltrion, ClostraBio, Cytoki Pharma, Connect Biopharma, Entera, Evommune, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunic, Index Pharmaceuticals, Inotrem, Innovation Therapeutics, Ironwood Pharmaceuticals, Kaleido Biosciences, Kallyope, MiroBio, Morphic Therapeutics, MRM Health, OSE Immunotherapeutics, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Redhill Biopharma, Sun Pharma, Surrozen, Synlogic, Target RWE, Teva, Theravance Biopharma, TLL Pharmaceutical, USWM Enterprises, Viela Bio, and VTA Labs; received personal fees and stock options for consulting from Thelium Therapeutics and Ventyx Biosciences. |
| P753 | Dr. Suo, Paulina: No conflict of interest\|\|Thin, Lena: No conflict of interest\|\|Srinivasan, Ashish: No conflict of interest\|\|Winston, James: No conflict of interest\|\|Jeffrey, Angus: No conflict of interest\|\|Menon, Shankar: No conflict of interest\|\|Ghaly, Simon:\|:\|Speaker fees, educational support, advisory boards and research grants from St Vincent's Clinic foundation, GESA, Gilead, Dr. Falk, Janssen, Pfizer, Takeda, Ferring, Sandoz, Celltrion and Abbvie.\|\|Haifer, Craig:\|:\|Speaker fees, educational support, advisory boards and research grants from St Vincent's Clinic foundation, GESA, Ferring, Royal Australasian College of Physicians, Pfizer, Takeda, Abbvie, Sandoz and Janssen. |

| | |
|---|---|
| P754 | Koehne de Gonzalez, Anne: No conflict of interest\|\|Dr. del Portillo, Armando: No conflict of interest |
| P755 | Ms. Julián, Ana Belén:\|:\|Dr Julián-Gomara has received research funding from Abbvie, Takeda, Janssen and Faes Farma.\|\|Casas-Deza, Diego:\|:\|Dr Casas-Deza has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring and Faes Farma. D.C.-D. is partially supported by a Rio-Hortega fellowship from Instituto de Salud Carlos III.\|\|Vicente-Lidón, Raquel:\|:\|Dra. Vicente has served as speaker, consultant, and/or advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Ferring and Faes Farma.\|\|Beltrán, Belén: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|Gutiérrez-Casbas, Ana: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|Caudevilla-Biota, Eva: No conflict of interest\|\|Corsino-Roche, Pilar: No conflict of interest\|\|Sierra-Moros, Eva: No conflict of interest\|\|Franco-Fobe, Laura Eva: No conflict of interest\|\|Pina-Echevarría, Silvia: No conflict of interest\|\|García-González, Elena: No conflict of interest\|\|Alfambra, Erika: No conflict of interest\|\|Gargallo-Pueyo, Carla:\|:\|Has received research funding from Abbvie, Janssen and Pfizer.\|\|Sicilia, Beatriz:\|:\|Dr Sicilia has received research funding from Abbvie, FAES, Chiesi, Dr. Falk, MSD, Tillots Pharma, Khern Pharma, Janssen, Pfizer y Takeda\|\|Arias, Lara:\|:\|L. Arias has served as a speaker for or has received research funding from Abbvie, FAES, Dr. Falk, MSD, Ferring, Khern Pharma, Janssen, Pfizer y Takeda\|\|Alcala-Escriche, Mª José: No conflict of interest\|\|Madero-Velázquez, Lucía: No conflict of interest\|\|Ferreiro-Iglesias, Rocío:\|:\|Rocío Ferreiro-Iglesias has served as a speaker for or has received research funding from Takeda, MSD, Abbvie, Janssen, Pfizer, Palex, Shire Pharmaceuticals, TillottsPharma, Kern and Casenrecordati.\|\|Palmero-Pérez, Antonia: No conflict of interest\|\|Calafat, Margalida:\|:\|MC has served as a speaker, or has received research or education funding or advisory fees for Takeda, Janssen, Faes Farma, Gilead, Pfizer and MSD.\|\|Rubio-Iturria, Saioa:\|:\|Has served as a speaker for or has received research funding from Janssen, Takeda, FAES FARMA, Ferring, TILLOTTS, AbbVie\|\|Moraleja-Yudego, Irene: No conflict of interest\|\|Ber-Nieto, Yolanda:\|:\|Has received research funding from Abbvie, TAKEDA, Ferring y Pfizer.\|\|García-Mateo, Sandra: No conflict of interest\|\|P. Gisbert, Javier:\|:\|Dr. Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma.\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|García-López, Santiago:\|:\|Santiago García-López has served as a speaker, advisory member for or has received research funding from AbbVie, MSD, Takeda, Janssen and Pfizer. |
| | |

| | |
|---|---|
| P756 | Dr. Majumder, Snehali: No conflict of interest\|\|Love, Melanie: No conflict of interest\|\|Davis, Joanne: No conflict of interest\|\|Sharma, Naveen: No conflict of interest\|\|Nabil Quraishi, Mohammed: No conflict of interest\|\|Cooney, Rachel: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Iacucci, Marietta: No conflict of interest\|\|N Shivaji, Uday: No conflict of interest |
| P757 | Tan, Joel: No conflict of interest\|\|Shadbolt, Bruce: No conflict of interest\|\|Jain, Tarun: No conflict of interest\|\|Subramaniam, Kavitha: No conflict of interest |
| P758 | Dr. Safroneeva, Ekaterina:\|:\|Employee of Tillotts Pharma AG\|\|Laoun, Raphael:\|:\|Employee of Tillotts Pharma AG. |
| P759 | Mr. Conceição, Daniel: No conflict of interest\|\|Rajão Saraiva, Margarida: No conflict of interest\|\|Lemos Garcia, Joana: No conflict of interest\|\|Rosa, Isadora: No conflict of interest\|\|Moleiro, Joana: No conflict of interest\|\|Simões, Carolina: No conflict of interest\|\|Claro, Isabel: No conflict of interest |
| P760 | Dr. Saladino, Marica: No conflict of interest\|\|Celsa, Ciro: No conflict of interest\|\|Amato, Livia Maria: No conflict of interest\|\|Di Giorgio, Francesca Maria: No conflict of interest\|\|Muscarella, Stefano: No conflict of interest\|\|Melatti, Piera: No conflict of interest\|\|Brinch, Daniele: No conflict of interest\|\|Cappello, Maria: No conflict of interest |
| P761 | Dr. Madigan, Shauna: No conflict of interest\|\|Prichard, Ivanka: No conflict of interest\|\|Smart, Claire: No conflict of interest\|\|Prosser, Ruth: No conflict of interest\|\|Mountifield, Reme: No conflict of interest |

| | |
|---|---|
| P762 | Dr. Seo, Jeongkuk: No conflict of interest\|\|Lee, Moon Hee: No conflict of interest\|\|Hong, Heejoo: No conflict of interest\|\|Oh, Eun Hye: No conflict of interest\|\|Hwang, Sung Wook: No conflict of interest\|\|Park, Sang Hyoung: No conflict of interest\|\|Yang, Dong-Hoon: No conflict of interest\|\|Byeon, Jeong-Sik: No conflict of interest\|\|Myung, Seung-Jae: No conflict of interest\|\|Yang, Suk-Kyun: No conflict of interest\|\|Bae, Kyun-Seop: No conflict of interest\|\|Ye, Byong Duk: No conflict of interest |
| P763 | Kaltenbach, Tanja: No conflict of interest\|\|Schulte, Lucas-Alexander: No conflict of interest\|\|Kranzeder, Alexandra: No conflict of interest\|\|Klaus, Jochen: No conflict of interest\|\|Ms. Sularz, Melanie: No conflict of interest |
| P764 | Wu, Yi-Hua: No conflict of interest\|\|Dr. Chou, Jen-Wei: No conflict of interest\|\|Huang, Po Ju: No conflict of interest\|\|Wang, Chu Ping: No conflict of interest\|\|Cheng, Ken Sheng: No conflict of interest |
| P765 | Dr. Carlson, Sean: No conflict of interest\|\|Evgeniou, Varvara: No conflict of interest\|\|Kok, Klaartje: No conflict of interest |
| P766 | Russell, Erin: No conflict of interest\|\|Dr. Trakman, Gina: No conflict of interest\|\|Hamilton, Amy L: No conflict of interest\|\|Wilson-O'Brien, Amy: No conflict of interest\|\|Hendricks, Nadia: No conflict of interest\|\|Simmance, Natalie: No conflict of interest\|\|Thompson, Emily: No conflict of interest\|\|Niewiadomski, Ola: No conflict of interest\|\|Kamm, Michael: No conflict of interest |
| P767 | Zorzi, Francesca: No conflict of interest\|\|De Cristofaro, Elena: No conflict of interest\|\|Abreu, Maria Teresa: No conflict of interest\|\|Montesano, Laura: No conflict of interest\|\|Cuccagna, Elisa: No conflict of interest\|\|Essofi, Sara: No conflict of interest\|\|Biancone, Livia: No conflict of interest\|\|Monteleone , Giovanni: No conflict of interest\|\|Calabrese, Emma: No conflict of interest |

| | |
|---|---|
| P768 | Dr. Foteinogiannopoulou, Kalliopi: No conflict of interest\|\|Nicolaou, Pinelopi: No conflict of interest\|\|Mala, Anastasia: No conflict of interest\|\|Theodoraki, Eirini: No conflict of interest\|\|Orfanoudaki, Eleni: No conflict of interest\|\|Theodoropoulou, Angeliki: No conflict of interest\|\|Karmiris, Konstantinos: No conflict of interest\|\|Koutroubakis, Ioannis: No conflict of interest |
| P769 | Dr. Wall, Catherine: No conflict of interest\|\|Glyn, Tamara: No conflict of interest\|\|Rowbotham, David: No conflict of interest\|\|Haines, Melissa: No conflict of interest\|\|Bissett, Ian: No conflict of interest\|\|Eglinton, Tim: No conflict of interest\|\|Gearry, Richard: No conflict of interest |
| P770 | Voskens, Caroline: No conflict of interest\|\|Stoica, Diane: No conflict of interest\|\|Rosenberg, Marita: No conflict of interest\|\|Weidinger, Carl: No conflict of interest\|\|Vitali, Francesco: No conflict of interest\|\|Zundler, Sebastian: No conflict of interest\|\|Ganslmayer, Marion: No conflict of interest\|\|Wiesinger, Manuel: No conflict of interest\|\|Wunder, Jutta: No conflict of interest\|\|Kummer, Mirko: No conflict of interest\|\|Siegmund, Britta: No conflict of interest\|\|Schnoy, Elisabeth: No conflict of interest\|\|Rath, Timo: No conflict of interest\|\|Hartmann, Arndt: No conflict of interest\|\|Hackstein, Holger: No conflict of interest\|\|Schuler-Thurner, Beatrice: No conflict of interest\|\|Berking, Carola: No conflict of interest\|\|Schuler, Gerold: No conflict of interest\|\|Atreya, Raja: No conflict of interest\|\|Neurath, Markus Friedrich: No conflict of interest |
| P771 | Dr. Cassinotti, Andrea: No conflict of interest\|\|Saibeni, Simone: No conflict of interest\|\|De Silvestri, Annalisa: No conflict of interest\|\|Mezzina, Nicolo: No conflict of interest\|\|Di Paolo, Dhanai: No conflict of interest\|\|Alimenti, Eleonora: No conflict of interest\|\|Annunziata, Maria Laura: No conflict of interest\|\|Albertini Petroni, Guglielmo: No conflict of interest\|\|Segato, Simone: No conflict of interest\|\|Canova, Lorenzo: No conflict of interest\|\|Italia, Angelo: No conflict of interest\|\|Zammarchi, Irene: No conflict of interest\|\|Casini, Valentina: No conflict of interest\|\|Ricci, Chiara: No conflict of interest\|\|Di Sabatino, Antonio: No conflict of interest\|\|Invernizzi, Pietro: No conflict of interest\|\|Maconi, Giovanni: No conflict of interest\|\|Pace, Fabio: No conflict of interest\|\|Pagano, Nico: No conflict of interest\|\|Segato, Sergio: No conflict of interest\|\|Bezzio, Cristina: No conflict of interest\|\|Pastorelli, Luca: No conflict of interest\|\|Vecchi, Maurizio: No conflict of interest\|\|Ardizzone, Sandro: No conflict of interest |

| | |
|---|---|
| P772 | Jairath, Vipul:\|:\|VJ has received has received consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Prometheus, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso pharmaceuticals, Takeda, Teva, Topivert, Ventyx, Vividion; speaker's fees from, Abbvie, Ferring, Bristol Myers Squibb, Galapagos, Janssen Pfizer Shire, Takeda, Fresenius Kabi\|\|Armuzzi, Alessandro:\|:\|AA has received consulting/advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; speaker's fees from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; and research grants from Biogen, MSD, Pfizer, and Takeda.\|\|Pai, Rish K.:\|:\|RKP has received consulting fees from Alimentiv Inc, Allergan, Eli Lilly, and AbbVie.\|\|Sun, Diana:\|:\|DS is an employee of Genentech\|\|Li, Yue:\|:\|YL is an employee of Roche.\|\|Bassel, Marielle:\|:\|MB is an employee of PPD.\|\|Dr. Brett, Neil R.:\|:\|NB is an employees of PPD.\|\|Bojic, Daniela:\|:\|DB is an employee of Roche |

| | |
|---|---|
| P773 | Vermeire, Séverine:\|:\|Received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; received consultancy and/or speaker fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts, and Zealand.\|\|Colombel, Jean-Frederic:\|:\|Has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol Myers Squibb, Ferring, Shire, and Takeda; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, Imtbio, Inotrem, Janssen, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, and Viela Bio; and holds stock options in Intestinal Biotech Development.\|\|Chiorean, Michael V.:\|:\|MVC: reported advisory/consulting roles with AbbVie, Arena, Bristol Myers Squibb, Eli Lilly, Janssen, Medtronic, and Pfizer; reported speaker role with AbbVie, Bristol Myers Squibb, Janssen, Medtronic, and Pfizer; received research funding from Fuji, Gilead, Janssen, Novartis, Pfizer, and Takeda.\|\|Ghosh, Subrata:\|:\|Received research funding from AbbVie and GlaxoSmithKline; served as lecturer for AbbVie, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Ferring, MSD, Pfizer, and Takeda; and served as consultant for AbbVie, Bristol Myers Squibb, Janssen, Novo Nordisk, Pfizer, Roche, and Takeda.\|\|Jain, Anjali:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Lawlor, Garrett:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Osterman, Mark T.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Wu, Hsiuanlin:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Canavan, James B.:\|:\|Employee and/or shareholder of Bristol Myers Squibb.\|\|Rubin, David T.:\|:\|Received grant support from Takeda; consulted for AbbVie, AltruBio, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Genentech/Roche, Gilead, Iterative Scopes, Janssen, Pfizer, Prometheus Biosciences, Takeda, and Techlab. |

| | |
|---|---|
| P774 | Dr. Atia, Ohad: No conflict of interest\|\|Shavit-Brunschwig, Zivia: No conflict of interest\|\|Quteineh, Ahmad: No conflict of interest\|\|Lev-Tzion, Raffi: No conflict of interest\|\|Stein, Ronen: No conflict of interest\|\|Broide, Efrat: No conflict of interest\|\|Urlep, Darja: No conflict of interest\|\|Hyams, Jeffrey: No conflict of interest\|\|Aloi, Marina: No conflict of interest\|\|Shouval, Dror S.: No conflict of interest\|\|Assa, Amit: No conflict of interest\|\|Hussey, Seamus: No conflict of interest\|\|Markowitz, James: No conflict of interest\|\|Yerushalmy, Anat: No conflict of interest\|\|Miele, Erasmo: No conflict of interest\|\|Russell, Richard K: No conflict of interest\|\|Turner, Dan:\|:\|Funding: The European Crohn's and Colitis Organization (ECCO), the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), and Takeda. The sponsors were not involved in any part of the study, including protocol writing, data collection, analyses, and writing. |

| | |
|---|---|
| P775 | Shinzaki, Shinichiro:\|:\|Grants: Sekisui Medical\|Consulting Fees: Abbvie Inc., Janssen Pharmaceutical K.K., Takeda Pharmaceutical\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Alfresa Pharma Corporation, Astra Zeneka K.K., EA Pharma, Eisai, Gilead Sciences, Kissei Pharmaceutical, Kyorin Pharmaceutical, Janssen Pharmaceutical K.K., JIMRO, Mitsubishi-Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Pharmaceuticals, Sekisui Medical, Takeda Pharmaceutical, Zeria Pharmaceutical\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Member of International Exchange Committee of JSIBD, Clinical Epidemiology Committee of JSIBD, and Board of education of The Japanese Society for Mucosal Immunology, Council member of The Japanese Society of Gastroenterological Immunology,\|\|\|Matsuoka, Katsuyoshi:\|:\|Grants: AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Mochida, Kyorin, Kissei, JIMRO, Nippon Kayaku\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, EA Pharma, Mochida, Kyorin, Kissei, Janssen, JIMRO, Gilead Sciences, Pfizer, Takeda, Zeria, Miyarisan, Nippon Kayaku, Celltrion Healthcare, Eli Lilly, Mitsubishi Tanabe Pharma\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Chairman of Clinical Epidemiology Committee of JSIBD, Council member of The Japanese Society for Mucosal Immunology, member of International Exchange Committee of The Japanese Society for Mucosal Immunology, and AOCC Governing Board, Director of Japan Small Intestine Society, SI of MHLW, Grant-in-Aid for Scientific Research on Intractable Diseases, “Research on Intractable Inflammatory Bowel Disorders”\|\|Fujii, Toshimitsu:\|:\|Grants: Janssen Pharmaceutical K.K, AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, EA, Kissei, Takeda, Alfresa Corporation, Celgene, Eli Lilly, Gilead Sciences, Sekisui Medical\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K, AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, EA, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nichiiko, Nippon Kayaku, Takeda, Zeria\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: member of Clinical Epidemiology Committee of JSIBD, and Specialist system Committee of JSIBD\|\|Okamoto, Ryuichi:\|:\|Grants: Mitsubishi Tanabe, Zeria, Mochida, Takeda\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Chairman of Research Grant Committee of JSIBD, member of International Exchange Commitee of JSIBD\|\|Yamada, Akihiro:\|:\|Grants: Abbie GK, Mitsubishi Tanabe, EA, Mochida\|\|Kunisaki, Reiko:\|:\|Grants: Janssen Pharmaceutical K.K, AbbVie GK, EA, Viatris, Takeda, Eli Lilly\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K, AbbVie GK, EA, Kissei, Kyorin, Nippon Kayaku, Mitsubishi Tanabe, Takeda, |

| | |
|---|---|
| | Zeria, Pfizer Inc., Viatris\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: member of Committee on Public Information of JSIBD\|\|Matsuura, Minoru:\|:\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K, Mitsubishi Tanabe Pharma Co., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Viatris Inc., Sandoz AG., Nippon Kayaku Co., Ltd., JIMRO Co., Ltd., EA pharma Co., Ltd., ZERIA Pharmaceutical Co.,Ltd.\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Council of The Japanese Society of Gastroenterology, Japan Gastroenterological Endoscopy Society, The Japanese Society for Mucosal Immunology, and The Japanese Society of Small Intestine Disease, Member of Clinical epidemiology committee of Japanese Society of Inflammatory Bowel Disease (JSIBD), and Committee on Public Information of the Japanese Society for Mucosal Immunology\|\|\|Watanabe, Kenji:\|:\|Grants: EA Pharma, Takeda, EP CRSU\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: JIMRO, EA Pharma, Takeda, AbbVie Japan\|other board, society, committee or advocacy group, paid or unpaid: Chairman of Finance committee of JSIBD. Council member of Japan Small Intestine Society, and The Japanese Society for Mucosal Immunology, Member of Public Relations Committee of The Japanese Society for Mucosal Immunology\|\|Shiga, Hisashi:\|:\|Grants: Janssen Pharmaceutical K.K\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Mitsubishi Tanabe Pharma Corp., EA Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., AbbVie Inc., Janssen Pharmaceutical K.K., Pfizer Inc.\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Member of Education Committee of JSIBD, and Specialist System Committee of JSIBD\|\|Takatsu, Noritaka: No conflict of interest\|\|Bamba, Shigeki:\|:\|Grants: AbbVie GK\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie GK, Mitsubishi Tanabe, Kyorin, Janssen, Mochida, EA\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Council member of Japan Small Intestine Committee, and The Japanese Society for Mucosal Immunology, Member of the Conflict of Interest and Ethics Committee of The Japanese Society for Mucosal Immunology\|\|Mikami, Yohei:\|:\|Grants: Janssen Pharmaceutical KK\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Member of Clinical Epidemiology Committee of JSIBD, and Research Grant Committee of JSIBD, Council member of The Japanese Society for Mucosal Immunology\|\|Yamamoto, Takayuki:\|:\|Grants: Janssen Pharmaceutical KK\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Member of Internatinal |

| | |
|---|---|
| | in other board, society, committee or advocacy group, paid or unpaid: Member of International exchange committee of JSIBD, and Clinical Epidemiology Committee of JSIBD\|\|Shimoyama, Takahiro: No conflict of interest\|\|Motoya, Satoshi:\|:\|Grants: AbbVie GK, Takeda, Janssen, Pfizer Japan Inc., EA\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Mitsubishi Tanabe, AbbVie GK, Mochida, Takeda, Janssen\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Member of Public Relations Committee of JSIBD, and Clinical Epidemiology Committee of JSIBD. Council member of Japan Small Intestine Society\|\|Torisu, Takehiro: No conflict of interest\|\|Kobayashi, Taku:\|:\|Grants: Abbie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc, Gilead Sciences, Inc., Nippon Kayaku Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Holdings, EA Pharma Co., Ltd., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd. Google Asia Pacific Pte.Ltd\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Takeda Pharmaceutical Co., Ltd., Activaid, Alfresa Pharma, orporation, Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Abbie GK, Pfizer Japan Inc., Janssen Pharmaceutical K.K., Thermo Fisher Diagnostics K.K., JIMRO Co., Ltd., Galapagos\|Payment for expert testimony: Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., KISSEI Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., Activaid, Pfizer Japan Inc., Nippon Kayaku Co., Ltd., Alfresa Pharma Corporation, Kyorin Pharmaceutical Co., Ltd., Abbie GK, Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma corporation\|Participation on a Data Safety Monitoring Board or Advisory Board: Janssen, Bristol Myers Squibb, Eli Lilly, EA Pharma\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SI of MHLW, Grant-in-Aid for Scientific Research on Intractable Diseases, “Research on Intractable Inflammatory Bowel Disorders”, Chairman of International Exchange Committee of JSIBD, Council member of The Japanese Society for Mucosal Immunology. member of International Exchange Committee of the Japanese Society for Mucosal Immunology.\|\|Ohmiya, Naoki:\|:\|Grants: Abbvie GK, Daiichi Sankyo, Bristol-Myers Squibb, Takeda, Eli Lilly, Mitsubishi Tanabe, Nippon Kayaku\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: EA, Janssen\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Director of Japan Small Intestine Society\|\|Saruta, Masayuki:\|:\|Grants: Mochida Pharmaceutical Co.,Ltd, Zeria Pharma Co.,Ltd, EA Pharma Co.,Ltd, Kissei Pharmaceutical Co., Ltd, EPS Corporation\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Abbvie GK, Janssen |

| | |
|---|---|
| | presentations, speakers bureaus, manuscript writing or educational events: Abbvie GK, Janssen Pharmaceutical K.K, Mitsubishi Tanabe, Pharma Co.,Ltd., Takeda Pharmaceutical Co.,Ltd., EA Pharma Co.,Ltd., Gilead Sciences K.K.\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SI of MHLW, Grant-in-Aid for Scientific Research on Intractable Diseases, “Research on Intractable Inflammatory Bowel Disorders”. Councilor of The Japanese Society of Internal Medicine, and The Japan Gastroenterological Endoscopy Society. Foundation Councilor of The Japanese Society of Gastroenterology, Council member of The Japanese Society for Mucosal Immunology. Chairman of General Affairs Committee of Japanese Society of Inflammatory Bowel Disease. Governing Board of Asian Organization for Crohn's & Colitis. Director of Japan Small Intestine Society\|\|Matsuda, Koichiro:\|:\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Jansen Pharmaceutical K.K, Mitsubisi Tanabe Pharma Corporation, Takeda Pharmaceutical Co.,Ltd., AbbVie Inc., Eli Lilly Japan K.K.\|Participation on a Stock or Data Safety Monitoring Board or Advisory Board: Jansen Pharmaceutical K.K.\|Stock or stock options: Gilead Sciences, Inc.\|\|\|Matsumoto, Takayuki:\|:\|Grants: Janssen Pharmaceutical K.K, Mitsubishi Tanabe\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K, Tanabe Mitsubishi Pharmaceutical, EA Pharma, Abbvie, Takeda Pharmaceutical\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SI of MHLW, Grant-in-Aid for Scientific Research on Intractable Diseases, “Research on Intractable Inflammatory Bowel Disorders”. Auditor of JSIBD. Officer in charge of General Affairs Committee of JSIBD. President of Japan Small Intestine Society. Director of The Japanese Gastroenterological association, and Japanese Gastroenterological Endoscopy Society\|\|\|Nakase, Hiroshi:\|:\|Grants: Hoya Group Pentax Medical, Boehringer Ingelheim GmbH, Bristol-Myers Squibb\|Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: SI of MHLW, Grant-in-Aid for Scientific Research on Intractable Diseases, “Research on Intractable Inflammatory Bowel Disorders”. Vice president of JSIBD, Officer in charge of JSIBD, International Exchange Committee, Director in charge of Bulletin editorial committee of JSIBD, Director of Japan Small Intestine Society, The Japanese Society for Mucosal Immunology, and The Japanese Society of Gastroenterology, Chairman of Finance committee of the Japanese Society for Mucosal Immunology, and Society Steering Committee of the Japanese Society for Mucosal Immunology, \|\|\|Maemoto, Atsuo: No conflict of interest\|\|Murata, Yoko:\|:\|All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing |

| | |
|---|---|
| | charges, etc.) : Employee of Janssen Pharmaceutical K.K.\|Stock or stock options: Stock Ownership of Johnson & Johnson\|\|Yoshigoe, Shinichi:\|:\|All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) : Employee of Janssen Pharmaceutical K.K.\|Stock or stock options: Stock Ownership of Johnson & Johnson\|\|Tsuchiya, Hiroaki:\|:\|All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) : Employee of Janssen Pharmaceutical K.K.\|Stock or stock options: Stock Ownership of Johnson & Johnson\|\|Hisamatsu, Tadakazu:\|:\|Research Grants from Janssen Pharmaceutical K.K, Alfresa, EA, Mitsubishi Tanabe, AbbVie GK, JIMRO, Zeria, Daiichi-Sankyo, Kyorin, Nippon Kayaku, Takeda, Pfizer Inc., Mochida\|Advisory fees from Janssen Pharmaceutical K.K, AbbVie GK, Takeda, Pfizer Inc., Gilead\|Honoraria for presentations from Janssen Pharmaceutical K.K, EA, Mitsubishi Tanabe, AbbVie GK, JIMRO, Kyorin, Takeda, Pfizer Inc., Mochida, Gilead\|Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: PI of MHLW, Grant-in-Aid for Scientific Research on Intractable Diseases, “Research on Intractable Inflammatory Bowel Disorders”, Director of JSIBD, Japan Small Intestine Society, The Japanese Society for Mucosal Immunology, and The Japanese Society of Clinical Immunology |
| P776 | Kuo, Hellen: No conflict of interest\|\|Tognolini, Katrina: No conflict of interest\|\|Willmann, Laura: No conflict of interest\|\|Haig, Adam: No conflict of interest\|\|Subhaharan, Deloshaan: No conflict of interest\|\|Mutsekwa, Rumbidzai: No conflict of interest\|\|Shukla, Dheeraj: No conflict of interest\|\|Moattar, Hadi: No conflict of interest\|\|Dorrington, Alex: No conflict of interest\|\|Ishaq, Naveed: No conflict of interest\|\|Bhullar, Maneesha: No conflict of interest\|\|Edwards, John: No conflict of interest\|\|Mohsen, Waled: No conflict of interest\|\|Kakkadasam Ramaswamy, Pradeep: No conflict of interest |

| | |
|---|---|
| P777 | Peyrin-Biroulet, Laurent:\|:\|Personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enterome, Enthera, Ferring, Fresenius Kabi, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, MSD, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Therevance, Tillotts and Vifor; grants from AbbVie, MSD and Takeda; and stock options from CTMA.\|\|Rubin, David:\|:\|Grant support from AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, and Takeda. Consultant for AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GlaxoSmithKline Services, Ichnos Sciences, InDex Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab\|\|Weber, Christopher:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Adsul, Shashi:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Freire, Marcelo:\|:\|An employee of Takeda and holds Takeda stock or stock options.\|\|Biedermann, Luc:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Koelzer, Viktor:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Bressler, Brian:\|:\|Advisor/Speaker: Ferring, Janssen, Abbvie, Takeda, Pfizer, Novartis, BMS, Merck. Advisor: Alimentiv, Gilead, Iterative Scopes, AMT, Celgene, Microbiome Insights, Merck, Amgen, Pendopharm, Genentech, BMS, Allergan, Protagonist, Fresenius Kabi, Mylan. Research support: Janssen, Abbvie, GSK, BMS, Amgen, Genentech, Merck, BI, Qu Biologic, Celgene, Alvine. Stock Options: Qu Biologic\|\|Xiong, Wei:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Niess, Jan:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Matthias Matter, Matthias Matter:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Kopylov, Uri:\|:\|research support – Medtronic, Jannsen, Takeda. Speaker/advisory fees – Abbvie, BMS, Jannsen, Pfizer, Takeda, MSD, Rafa. \|\|Barshack, Iris:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Mayer, Chen:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Magro, Fernando:\|:\|Fees for presenting from AbbVie, Ferring, Falk, Hospira, PharmaKern, MSD, Schering, Laboratórios Vitoria, Vifor Pharma, and OM Pharma\|\|Carneiro, Fatima:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Maharshak, Nitsan:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Greenberg, Ariel:\|:\|Investigator in this study which was sponsored by Takeda.\|\|Hart, Simon:\|:\|An employee of IAG and holds IAG stock or stock options. \|\|Dehmeshki, Jamshid:\|:\|An employee of IAG and holds IAG stock or stock options. \|\|Kubassova, Olga:\|:\|An employee of IAG and holds IAG stock or stock options. |
| | |

| | |
|---|---|
| P778 | Dr. García, María José:\|:\|María José García has received financial support for travelling and educational activities from Janssen, Pfizer, AbbVie, Takeda, Kern Pharma, Faes Farma and Ferring. \|\|Riestra, Sabino:\|:\|Sabino Riestra has served as speaker, consultant, and advisory member for or has received research funding from MSD, AbbVie, Takeda, Janssen, Pfizer, Mylan, Biogen, Kern Pharma, Ferring and Faes Farma.\|\|Amiot, Aurelien:\|:\|Aurelien Amiot has received consulting fees from Abbvie, Tillotts pharma, Janssen, Hospira, Takeda, Fresenius Kabi, Pfizer and Gilead as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Biogen, Tillotts pharma, Fresenius Kabi, Takeda and MSD. \|\|Julsgaard, Mette:\|:\|M. Julsgaard has received research grants for other investigator-driven studies from Takeda, has received consultation fee from Ferring and Takeda, and has received speaker's fees from MSD, Ferring, and Takeda\|\|García de la Filia, Irene: No conflict of interest\|\|Calafat, Margalida:\|:\|Margalida Calafat has served as a speaker or has received educational or advisory fees from Takeda, Janssen, Faes Farma, Ferring, Galapagos, Gilead and MSD;\|\|Aguas, Mariam: No conflict of interest\|\|de la Peña, Luisa: No conflict of interest\|\|Roig-Ramos, Cristina: No conflict of interest\|\|Caballol, Berta: No conflict of interest\|\|Casanova, María José:\|:\|María José Casanova, has received education funding from Pfizer, Takeda, Janssen, MSD, Ferring and Abbvie.\|\|Farkas, Klaudia: No conflict of interest\|\|Boysen, Trine: No conflict of interest\|\|Bujanda, Luis: No conflict of interest\|\|Cuarán, Camila: No conflict of interest\|\|Dobru, Daniela: No conflict of interest\|\|Fousekis, Fotios: No conflict of interest\|\|Gargallo-Puyuelo, Carla Jerusalén: No conflict of interest\|\|Savarino, Edoardo:\|:\|E.S. has served as speaker for AbbVie, AGPharma, Alfasigma, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Medtronic, Novartis, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda and Unifarco; has served as consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Falk, Fresenius Kabi, Janssen, Merck & Co., Reckitt Benckiser, Regeneron, Sanofi, Shire, SILA, Sofar, Synformulas GmbH, Takeda and Unifarco; and has received research support from Reckitt Benckiser, SILA, Sofar and Unifarco\|\|Calvet, Xavier:\|:\|"Grants or contracts from any entity AbbVie, Janssen, Kern, Takeda, Galapagos, Pfizer Consulting fees: Janssen. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, AbbVie, Janssen, Takeda, Pfizzer.\|Support for attending meetings and/or travelFerring, Janssen."\|\|Huguet, José María:\|:\|Educational activities research projects scientific meetings or advisory boards sponsored by MSD, Ferring, Abbvie\|\|Kupcinskas, Limas: No conflict of interest\|\|López-Cardona, Julia: No conflict of interest\|\|Raine, Tim:\|:\|TR has received research/educational grants and/or speaker/consultation fees from Abbvie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda and UCB\|\|van Oostrom, Joep:\|:\|Received speaker's fees from Tillots\|\|P. Gisbert*, Javier:\|:\|Javier P. Gisbert has served as a speaker, a consultant and advisory member for or has received research funding from MSD, AbbVie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma.\|\|Chaparro*, María:\|:\|María Chaparro has served as a speaker, as consultant or has received research or education funding from MSD, AbbVie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Biogen, Gilead and Lilly. |

| | |
|---|---|
| P779 | Casellas Jorda, Francisco:\|:\|Speaker and research funding: AbbVie, Ferring, MSD, Shire, Chiesi, Gebro, Takeda, and Zambon. \|\|Rodríguez, Cristina:\|:\|No conflicts of interest to declare\|\|Gisbert, Javier P.:\|:\|Speaker, scientific advice, consultant and advisory member and research funding: MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene, Gilead, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. \|\|Bernardo, Sonia:\|:\|Speaker: Janssen\|\|Mr. Aparicio, Jesús:\|:\|Full-time employee in Takeda Farmacéutica España.\|\|Tagarro, Ignacio:\|:\|Full-time employee in Takeda Farmacéutica España.\|\|Muñoz, Fernando:\|:\|Speaker, scientific advice, consultant and advisory member and research funding: Takeda, Janssen, Abbvie, MSD, Falk, Tillots, Ferring, Amgen, Mylan and Pfizer. |
| P780 | Mr. Yaguchi, Katsuki: No conflict of interest\|\|Kinoshita, Hiroto: No conflict of interest\|\|Kunisaki, Reiko: No conflict of interest\|\|Madarame, Akira: No conflict of interest\|\|Tatsuno, Mizuki: No conflict of interest\|\|Nishikawa, Yurika: No conflict of interest\|\|Hama, Takanori: No conflict of interest\|\|Onishi, Misa: No conflict of interest\|\|Kobayashi, Kei: No conflict of interest\|\|Shibui, Shunsuke: No conflict of interest\|\|Toritani, Kenichiro: No conflict of interest\|\|Nishida, Daisuke: No conflict of interest\|\|Matsubayashi, Mao: No conflict of interest\|\|Nakamori, Yoshinori: No conflict of interest\|\|Nishio, Masafumi: No conflict of interest\|\|Umezawa, Shotaro: No conflict of interest\|\|Ogashiwa, Tsuyoshi: No conflict of interest\|\|Sasaki, Tomohiko: No conflict of interest\|\|Fujii, Ayako: No conflict of interest\|\|Kimura, Hideaki: No conflict of interest\|\|Kato, Jun: No conflict of interest\|\|Maeda, Shin: No conflict of interest |

| | |
|---|---|
| P781 | Rubin, David T:\|:\|Grant: Takeda; Personal fees (consulting): AbbVie, Altrubio, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, Eli Lilly, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Pfizer Inc, Prometheus Biosciences, Reistone Biopharma, Takeda, Techlab Inc\|\|Panés, Julian:\|:\|Grants: AbbVie, Pfizer Inc; Personal fees: AbbVie, Arena, Athos, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Immunic, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer Inc, Progenity, Revolo, Takeda, Theravance Biopharma, Wassermann\|\|Torres, Joana: No conflict of interest\|\|Kobayashi, Taku:\|:\|Grants: AbbVie, Alfresa Pharma, EA Pharma Co Ltd, GK Pharma, Kyorin Pharmaceutical Co Ltd, Mitsubishi Tanabe Parma, Mochida Pharmaceutical, Nippon Kyaku, Otsuka Holdings Co Ltd, Sekisui Medical, Thermo Fisher Scientific, ZERIA; Personal fees: AbbVie GK, Ajinomoto Pharma, Alfresa Pharma, Asahi Kase Medical, Astellas Covidien, Celltrion, EA Pharma Co Ltd, Eisai Co Ltd, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Google, Janssen, JIMRO Co Ltd, Kyorin Pharmaceutical Co Ltd, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kyaku, Pfizer Inc, Takeda Pharmaceutical, Thermo Scientific, ZERIA; Personal fees (funding to attend study-related meetings): Pfizer Inc\|\|Su, Chinyu:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Lawendy, Nervin:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Modesto, Irene:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Segovia, Michelle:\|:\|Other (post-Doctoral Fellow with Fellowship funding): Pfizer Inc; Other (employee): Rutgers University, Ernest Mario School of Pharmacy\|\|Gardiner, Sean:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc \|\|Wang, Wenjin:\|:\|Personal fees (shareholder): Pfizer Inc; Other (employee): Pfizer Inc\|\|Vermeire, Séverine:\|:\|Grant: AbbVie, Galapagos, MSD, Pfizer Inc, Takeda; Personal fees (speaker fees): AbbVie, Dr Falk Pharma, Ferring, Hospira, MSD, Takeda, Tillotts; Personal fees (consulting): AbbVie, AbolerIS Pharma, Alimentiv, Arena, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, Hospira, Imidomics, Janssen, Johnson and Johnson, Materia Prima, MiroBio, Morphic, MrMHealth, MSD, Mundipharma, Pfizer Inc, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance Biopharma, Tillots Pharma AG, Zealand Pharma |
| P782 | Dr. Holvoet, Tom: No conflict of interest\|\|Truyens, Marie: No conflict of interest\|\|Reenaers, Catherine: No conflict of interest\|\|Baert, Filip: No conflict of interest\|\|Vandenbranden, Stijn: No conflict of interest\|\|Cremer, Anneline: No conflict of interest\|\|Pouillon, Lieven: No conflict of interest\|\|Dewint, Pieter: No conflict of interest\|\|Van Moerkercke, Wouter: No conflict of interest\|\|Rahier, Jean-Francois: No conflict of interest\|\|Vandermeulen, Liv: No conflict of interest\|\|Van Dongen, Jurgen: No conflict of interest\|\|Peeters, Harald: No conflict of interest\|\|Lambrecht, Guy: No conflict of interest\|\|Vijverman, Anne: No conflict of interest\|\|Lobaton, Triana: No conflict of interest |

| | |
|---|---|
| P783 | Matsuoka, Katsuyoshi:\|:\|Grants; AbbVie, EA Pharma, Mitsubishi Tanabe Pharma, Mochida, Kyorin, Kissei,JIMRO, Nippon Kayaku,AbbVie\|Personal Fees; EA Pharma, Mochida, Kyorin, Kissei, Janssen, JIMRO, Gilead Sciences, Pfizer, Takeda, Zeria, Miyarisan, Nippon Kayaku, Celltrion Healthcare, Eli Lilly, Mitsubishi Tanabe Pharma\|Other; Clinical Epidemiology Committee of JSIBD (Chairman), The Japanese Society for Mucosal Immunology (Council member), International Exchange Committee of The Japanese Society for Mucosal Immunology (member), AOCC Governing Board (member), Japan Small Intestine Society (Director), MHLW / Grant-in-Aid for Scientific Research on Intractable Diseases, "Research on Intractable Inflammatory Bowel Disorders" (SI)\|\|\|\|Dr. Katsumasa, Nagano:\|:\|Personal Fees; Janssen Pharmaceutical K.K. (Employee)\|Other; Johnson & Johnson (Stock Ownership)\|\|Murata, Yoko:\|:\|Personal Fees; Janssen Pharmaceutical K.K. (Employee)\|Other; Johnson & Johnson (Stock Ownership)\|\|Hisamatsu, Tadakazu:\|:\|Grants; Janssen Pharmaceutical K.K, Alfresa, EA, Mitsubishi Tanabe, AbbVie GK, JIMRO, Zeria, Daiichi-Sankyo, Kyorin, Nippon Kayaku, Takeda, Pfizer Inc., Mochida\|Personal Fees; Janssen Pharmaceutical K.K, AbbVie GK, Takeda, Pfizer Inc., Gilead, EA, Mitsubishi Tanabe, JIMRO, Kyorin, Mochida\|Other; MHLW / Grant-in-Aid for Scientific Research on Intractable Diseases, "Research on Intractable Inflammatory Bowel Disorders" (PI), JSIBD (Director), Japan Small Intestine Society (Director), The Japanese Society for Mucosal Immunology (Director), The Japanese Society of Clinical Immunology (Director) |

| | |
|---|---|
| P784 | Dr. Plachta-Danielzik, Sandra: No conflict of interest\|\|Bokemeyer, Bernd:\|:\|consulting fees from: AbbVie, MSD, Shire, Ferring, Hospira, Takeda, Galapagos, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, and Celgene, outside the submitted work. Financial support for lectures and teaching from: AbbVie, Ferring, MSD, Merckle, Falk, Galapagos, Shield Therapeutics, Pfizer, Celltrion, Takeda, Janssen, and Galapagos, outside the submitted work. Grant and financial support for research from AbbVie; Takeda, Jansen, Pfizer, Galapagos and Ferring, outside the submitted work\|\|Efken, Philipp:\|:\|Fees for consulting, travel and lectures from: Abbvie, BMS, Galapagos, Janssen, Amgen outside the submitted work\|\|Mohl, Wolfgang:\|:\|consulting fees from: Abbvie, Amgen, Hexal, Janssen, Pfizer, Synformulas, Takeda, outside the submitted work. Fees for lectures and further education from: Abbvie, Alanta health service GmbH, Almirall, Aptalis, Biogen, Falk, Gilead, Janssen, Pfizer, Medtronic, MSD, Shire, Takeda, Vifor, outside the submitted work. Fees for studies from: Abbvie, Janssen, MSD, Pfizer, Takeda, outside the submitted work. Fees for activities in public law bodies as member of the Advisory Commission of the Examination Office for the Saarland, the State Committee of Physicians and Health Insurance Companies and the Extended State Committee, outside the submitted work. Dependent employment in the group of Alanta health group GmbH, Hamburg, outside the submitted work. Shares, other fees from: Abbvie, Gilead, outside the submitted work\|\|Hoffstadt, Martin: No conflict of interest\|\|Krause, Thomas:\|:\|consulting fees from: AbbVie, Janssen, Takeda outside the submitted work\|\|Schweitzer, Axel:\|:\|Personal fees from: AbbVie Deutschland GmbH & Co. KG, Janssen-Cilag GmbH, Tillotts Pharma GmbH , Pfizer Pharma GmbH, Unternehmensgruppe Dr. Willmar Schwabe outside the submitted work\|\|Schnoy, Elisabeth:\|:\|Personal fees from: Janssen-Cilag GmbH, Pharmacosmos GmbH, Takeda Pharma GmbH, AbbVie Deutschland, Pfizer GmbH, Tillotts Pharma GmbH, AstraZeneca, Galapagos Biopharma, Lilly GmbH, Celltrion, Dr. Falk Pharma GmbH, BMS outside the submitted work\|\|Ehehalt, Robert:\|:\|Personal fees from: Takeda, Abbvie, MSD, Biogen, Hexal, Amgen, Celltrion, Viatris outside the submitted work\|\|\|Trentmann, Leo: No conflict of interest\|\|Teich, Niels:\|:\|personal fees from: Abbvie, Falk Foundation, Janssen and Takeda outside the submitted work\|\|Atreya, Raja:\|:\|Personal fees from: AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr. Falk Pharma, Ferring, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, MSD Sharp & Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepsis, Stelic Institute, Sterna Biologicals, Takeda Pharma, Tillotts Pharma AG, Viatris outside the submitted work\|\|Franzenburg, Sina: No conflict of interest\|\|Hartmann, Petra:\|:\|Personal fees from: Abbvie, MSD, Shire, Ferring, UCB, Hospira, Takeda, Movetis, Biogen, Mylan, Janssen, BMS, Amgen, Hexal, Stada, Merckle, Mundipharma, Falk, HLR outside the submitted work\|\|Wenske, Thomas: No conflict of interest\|\|Schreiber, Stefan:\|:\|personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, and Falk, outside the submitted work |

| | |
|---|---|
| P785 | Ms. Pokryszka, Jagoda: No conflict of interest\|\|Stadlmann, Michael: No conflict of interest\|\|Primas, Christian: No conflict of interest\|\|Gerold, Nathalie: No conflict of interest\|\|Reinisch, Sieglinde: No conflict of interest |
| P786 | Panés, Julián:\|:\|Julian Panes: received financial support for research from AbbVie and Pfizer; consultancy fees/honorarium from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance and Wasserman; reports payment for lectures including service on speaker bureau from Abbott, Ferring, Janssen, Pfizer and Takeda; and reports payment for development of educational presentations from Abbott, Janssen, Pfizer Roche and Takeda.\|\|Louis, Edouard:\|:\|Edouard Louis: received research grants from Janssen, Pfizer, and Takeda; educational grant from AbbVie, Janssen, MSD, and Takeda; speaker fees for AbbVie, Falk, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda; served on an advisory board for AbbVie, Celgene, Ferring, Hospira, Janssen, MSD, Pfizer, and Takeda, Galapagos, Gilead, Arena; served as a consultant for AbbVie.\|\|Bossuyt, Peter:\|:\|Peter Bossuyt: received research grants from AbbVie, Amgen, Celltrion, Mylan, Pfizer and Takeda; received lectura fees from AbbVie, Celltrion, Janssen, Lilly and Takeda; served as a consultant for AbbVie, Arena pharmaceuticals, BMS, Celltrion, Dr Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda and Tetrameros.\|\|Joshi, Namita:\|:\|Namita Joshi is an AbbVie employee and may own AbbVie stock and/or options.\|\|Lee, Wan-Ju:\|:\|Wan-Ju Lee is an AbbVie employee and may own AbbVie stock and/or options.\|\|Lacerda, Ana:\|:\|Ana Lacerda is an AbbVie employee and may own AbbVie stock and/or options.\|\|Remple, Valencia:\|:\|Valencia Remple is an AbbVie employee and may own AbbVie stock and/or options.\|\|Xuan, Si:\|:\|Si Xuan is an AbbVie employee and may own AbbVie stock and/or options.\|\|Loftus Jr. , Edward V.:\|:\|Edward V. Loftus: served as a consultant for AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Calibr, Celgene, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Morphic Therapeutics, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Surrozen, Sun Pharma, Takeda, and UCB; and received research grants from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. |

| | |
|---|---|
| P787 | Dr. Husman, Julia:\|:\|Support for travel: Abbvie\|\|Matthes, Katja: No conflict of interest\|\|Gilger, Maximilian: No conflict of interest\|\|Arsova, Maia: No conflict of interest\|\|Schmidt, Alexandra: No conflict of interest\|\|Hampe, Jochen: No conflict of interest\|\|Zeißig, Sebastian:\|:\|Consultant: AbbVie Deutschland GmbH & Co KG, Amgen GmbH, Biogen GmbH, Bristol Myers Squibb GmbH & Co KG, Celgene GmbH, Celltrion Healthcare, Ferring Arzneimittel GmbH, Galápagos Biopharma Germany GmbH, Hogg Robinson GmbH, Janssen Pharmaceutica NV, Janssen Cilag GmbH, MICE Service GmbH, Mylan, Pfizer Pharma GmbH, Takeda Pharma GmbH\|\|Speaker Bureau: AbbVie Deutschland GmbH & Co KG, Amgen GmbH, Biogen GmbH, Bristol Myers Squibb GmbH & Co KG, CED Service GmbH, Falk Foundation e.V., Ferring Arzneimittel GmbH, FORGA Solutions GmbH, GWT-TUD GmbH, Janssen Cilag GmbH, Janssen Pharmaceutica NV, MSD Sharp & Dome, Roche, Pfizer Pharma GmbH, Pharma Zentrale GmbH, Takeda Pharma GmbH, WebMD Global\|\|\|Schmelz, Renate:\|:\|Consultant: Abbvie, Janssen, Takeda\|Speaker Bureau: Abbvie, BMS, Falk Foundation, Janssen, MSD, Pharmacosmos, Takeda |
| P788 | Mr. Bak, Michiel: No conflict of interest\|\|Albéniz, Eduardo: No conflict of interest\|\|East, James:\|:\|JE has served on clinical advisory boards for Paion; has served on the clinical advisory board and has share options in Satisfai Health; and reports speaker fees from Falk and Janssen outside the submitted work. In addition, he is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. \|\|Coelho-Prabhu, Nayantara:\|:\|NCP is a consultant for Boston Scientific Corporation and Alexion Pharma; and has received research funding from Cook Endoscopy outside the submitted work. \|\|Suzuki, Noriko: No conflict of interest\|\|Saito, Yutaka: No conflict of interest\|\|Matsumoto, Takayuki: No conflict of interest\|\|Banerjee, Rupa: No conflict of interest\|\|Kaminski, Michal:\|:\|MK has equipment on loan from Fujifilm; he has received speaker's fees from Boston Scientific, Ipsen, and Recordati, and a research grant from Olympus; he has provided consultancy for Olympus and ERBE outside the submitted work.\|\|Kiesslich, Ralf: No conflict of interest\|\|Coron, Emmanuel: No conflict of interest\|\|de Vries, Annemarie:\|:\|AV has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer outside the submitted work. \|\|van der Woude, C.Janneke:\|:\|CW received research grants and/or fee for advisory boards and presentations from Pfizer, Abbvie, Celltrion, Falk Benelux, Takeda, Janssen, and Ferring outside the submitted work. \|\|Bisschops, Raf:\|:\|RB has received research grants Fujifilm, Pentax, Medtronic, Norgine; he has received speaker's fee or provided consultancy for Ferring, Pentax, Fujifilm, Medtronic, Boston Scientific, Ipsen outside the submitted work; in addition, he is supported by a research grant from Research Foundation Flanders (FWO).\|\|Hart, Ailsa:\|:\|AH has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Galapogos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda outside the submitted work. She also serves on the Global Steering Committee for Genentech.SI has received consulting fees from Exact Sciences Corporation and Geneoscopy; and received unrestricted research grants from Exact Sciences Corporation and Freenome outside the submitted work\|\|Itzkowitz, Steven:\|:\|SI has received consulting fees from Exact Sciences Corporation and Geneoscopy; and received unrestricted research grants from Exact Sciences Corporation and Freenome outside the submitted work. \|\|Pioche, Mathieu:\|:\|MP serves as a consultant for Boston Scientific Corporation and Norgine outside the submitted work. \|\|Moons, Leon:\|:\|LM serves as a consultant for Boston Scientific Corporation outside the submitted work. \|\|Oldenburg, Bas: No conflict of interest |

| | |
|---|---|
| | |
| P789 | Mr. Constantine-Cooke, Nathan: No conflict of interest\|\|Monterrubio-Gómez, Karla: No conflict of interest\|\|Plevris, Nikolas:\|:\|Consultancy fees from Takeda, speaker fees and/or travel support from Abbvie, Takeda, Norgine.\|\|Derikx, Lauranne A.A.P:\|:\|Consultancy fees from Sandoz, speaking fees from Janssen\|\|Lyons, Matthew: No conflict of interest\|\|Jenkinson, Phillip W.: No conflict of interest\|\|Gros, Beatriz:\|:\|Consultancy fees from Abbvie\|\|Jones, Gareth-Rhys:\|:\|Speaker fees from Abbvie, Takeda, Pfizer, Ferring and Janssen\|\|Vallejos, Catalina A.: No conflict of interest\|\|Lees, Charlie W.:\|:\|Research support from Abbvie and Gilead, consultancy fees from Abbvie, Pfizer, Janssen, Gilead, Celltrion, Pharmacosmos, Takeda, Vifor, Iterative Scopes, Trellus Health, Galapagos, Vifor Pharma, Bristol Meyers Squibb, Boehringer Ingelheim, Sandoz, Novartis, Fresnius, and Kabi Tillotts; speaker fees and/or travel support from Janssen, Abbvie, Pfizer, Dr Falk, Ferring, Hospira, GSK, and Takeda |
| P790 | Thoo, MamTing: No conflict of interest\|\|Baynton, Elizabeth: No conflict of interest |
| P791 | Dr. Lababidi, Nabil El: No conflict of interest\|\|Pavel, Frühauf: No conflict of interest |
| P792 | Mr. Markovic, Srdjan: No conflict of interest\|\|Kralj, Djordje: No conflict of interest\|\|Odanovic, Olga: No conflict of interest\|\|Homšek, Ana: No conflict of interest\|\|Kalaba, Ana: No conflict of interest\|\|Svorcan, Petar: No conflict of interest\|\|Vučićević, Katarina: No conflict of interest |

| | |
|---|---|
| P793 | Dr. Wang, Zhigang: No conflict of interest\|\|Afif , Waqqas:\|:\|Waqqas Afif is a speaker, advisory board member, and or clinical investigator for Abbvie, Amgen, Arena Pharmaceuticals, Dynacare, Eli-Lilly, Janssen, Merck, Novartis, Pfizer, Prometheus, Sandoz, Takeda and Theradiag.\|\|Hanžel, Jurij:\|:\|- speaker's fees from Abbvie, Janssen, and Takeda\|- consulting fees from Alimentiv Inc\|\|Kobayashi , Taku:\|:\|Taku Kobayashi has served as a speaker, a consultant or an advisory board member for AbbVie, Activaid, Ajinomoto Pharma, Asahi Kasei Medical, Astellas, Alfresa Pharma, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO, JMDC, Kissei, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Thermo Scientific and Zeria Pharmaceutical, and has received research funding from AbbVie, Alfresa Pharma, Asahi Kasei Medical, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Thermo Fisher Scientific and Zeria Pharmaceutical.\|\|Papamichail , Konstantinos:\|:\|Konstantinos Papamichael has received fees as a speaker, a consultant and as advisory board member for Mistubishi Tanabe Pharma, Physicians Education Resource LLC, Grifols, Prometheus Laboratories Inc and has received and scientific support from ProciseDx and Scipher Medicine Corporation.\|\|Roblin , Xavier:\|:\|MSD, Celltrion, Pfizer, Takeda, Abbvie, Amgen, Biogen, Janssen, Theradiag, Galapagos\|\|Peyrin-Biroulet , Laurent:\|:\|Personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Biogen, Inotrem, MSD, Amgen, BMS, Vifor, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Pandion Therapeutics, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied Molecular Transport, GSK, Abivax.\|\|Vermeire , Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Dreesen, Erwin:\|:\|Erwin Dreesen received consultancy fees from argenx (all fees paid to University) |
| P794 | Sakurai, Kensuke: No conflict of interest\|\|Katsurada, Takehiko: No conflict of interest\|\|Aoyama, Keiya: No conflict of interest\|\|Fukushima, Shinya: No conflict of interest\|\|Onishi, Reizo: No conflict of interest\|\|Yagisawa, keiji: No conflict of interest\|\|Nishimura, Haruto: No conflict of interest\|\|Ito, Takahiro: No conflict of interest\|\|Furukawa, Shigeru: No conflict of interest\|\|Maemoto, Atsuo: No conflict of interest\|\|Sakamoto, Naoya: No conflict of interest |
| P795 | Dr. Sina, Marsela: No conflict of interest\|\|Pemaj, Xhensila: No conflict of interest\|\|Djegsi, Aferdita: No conflict of interest\|\|Telaku, Skender: No conflict of interest\|\|Osmanaj, Dorina: No conflict of interest\|\|Babameto, Adriana: No conflict of interest\|\|Prifti, Skerdi: No conflict of interest |

| | |
|---|---|
| P796 | Dr. Kimura, Michiaki: No conflict of interest\|\|Shimizu, Momoko: No conflict of interest\|\|Shirai, Moeko: No conflict of interest\|\|Sakaguchi, Yoshiro: No conflict of interest\|\|Kobayashi, Kaede: No conflict of interest\|\|Iruya, Rei: No conflict of interest\|\|Seki, Shunsuke: No conflict of interest\|\|Naitou, Daisuke: No conflict of interest\|\|Nishimiya, Tetsuo: No conflict of interest\|\|Oouchi, Yuka: No conflict of interest\|\|Shibamoto, Mai: No conflict of interest\|\|Iwashita, Hiroaki: No conflict of interest\|\|Miyamura, Miyuki: No conflict of interest\|\|Kikuchi, Hidemasa: No conflict of interest\|\|Yamada, Akihiro:\|:\|Speaker fees: EA pharma, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Abbvie \|\|Nakamura, Kentaro: No conflict of interest\|\|Matsuoka, Katsuyoshi:\|:\|Speaker fees: Tanabe Mitsubishi, Janssen, Abbvie, Pfizer, Takeda Pharmaceutical, EA Pharma, Mochida Pharmaceutical, Kyorin Pharmaceutical, Zeria Pharmaceutical, Gilead, Eli Lilly, Celltrion, Nihon Kayaku Pharmaceutical, Kissei Pharmaceutical, JIMRO\|Research Grant: Tanabe Mitsubishi, EA Pharma, Mochida Pharmaceutical, Kyorin Pharmaceutical, Zeria Pharmaceutical, Nihon Kayaku Pharmaceutical, Kissei Pharmaceutical, JIMRO |
| P797 | Bikar, Alexander: No conflict of interest\|\|Farkas, Nelli: No conflict of interest\|\|Resál, Tamás: No conflict of interest\|\|Szepes, Zoltán: No conflict of interest\|\|Klaudia, Farkas: No conflict of interest\|\|Vincze, Áron: No conflict of interest\|\|Miheller, Pál: No conflict of interest\|\|Molnár , Tamás: No conflict of interest\|\|Dr. Sarlós, Patrícia: No conflict of interest |

| | |
|---|---|
| P798 | Dr. Chanchlani, Neil: No conflict of interest\|\|Lin, Simeng:\|:\|Non-financial support from Pfizer, non-financial support from Ferring, outside the submitted work.\|\|Hamilton, Benjamin: No conflict of interest\|\|Bewshea, Claire: No conflict of interest\|\|Thomas, Amanda: No conflict of interest\|\|Smith, Rebecca: No conflict of interest\|\|Roberts, Chris: No conflict of interest\|\|Nice, Rachel: No conflict of interest\|\|McDonald, Timothy J: No conflict of interest\|\|Goodhand, James R:\|:\|Grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during the conduct of the study.\|\|Ahmad, Tariq:\|:\|Grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during the conduct of the study; personal fees from Biogen Inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, non-financial support from Tillotts, outside the submitted work.\|\|Kennedy, Nicholas A:\|:\|Grants from AbbVie, Biogen, Celgene, Celtrion, Galapagos, MSD, Napp, Pfizer, Pharmacosmos, Roche, and Takeda; consulting fees from Amgen, Bristol Myers Squibb, Falk, Janssen, Mylan, Pharmacosmos, Galapagos, Takeda, and Tillotts; personal fees from Allergan, Celltrion, Falk, Ferring, Janssen, Pharmacosmos, Takeda, Tilllotts, and Galapagos; and support for attending meetings from AbbVie, Falk, and Janssen, outside the submitted work. AS has received travel expense support from Janssen. |
| P799 | Carlson, Sean: No conflict of interest\|\|Evgeniou, Varvara: No conflict of interest\|\|Kok, Klaartje: No conflict of interest |

| | |
|---|---|
| P800 | Dr. Friedberg, Scott: No conflict of interest\|\|Choi, David: No conflict of interest\|\|Hunold, Thomas: No conflict of interest\|\|Choi, Natalie K.: No conflict of interest\|\|Garcia, Nicole M.: No conflict of interest\|\|Picker, Emma A.: No conflict of interest\|\|Cohen, Nathaniel A.: No conflict of interest\|\|Cohen, Russell D.:\|:\|RDC is on the speaker's bureau from AbbVie and Takeda. He is a consultant/advisor for AbbVie Laboratories, BM/Celgene, Eli Lilly, Genentech, Gilead Sciences, Hoffmann La-Roche, Janssen, Pfizer, Takeda, UCB Pharma. He has received clinical trial support/grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn's and Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd., Osiris Therpeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. His wife is on the board of directors of Aerpio Theraoeutics, ImmunityBio, and MEI Pharmaceuticals.\|\|Dalal, Sushila R.:\|:\|SRD has served as a consultant for Pfizer and is on the speaker's bureau for AbbVie. SD is on the Speaker's Bureau and has served as a consultant for Abbvie and Pfizer.\|\|Pekow, Joel:\|:\|JP has served as a consultant for CVS Caremark\|\|Sakuraba, Atsushi: No conflict of interest\|\|Cleveland, Noa Krugliak:\|:\|N Krugliak Cleveland has served as a consultant for Arena Pharmaceuticals, Neurologica, and Takeda Pharmaceuticals U.S.A., Inc, and received a speaker's fee from Bristol Myers Squibb\|\|Rubin, David T.:\|:\|DTR has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Laboratories, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. |

| | |
|---|---|
| P801 | Dr. Plachta-Danielzik, Sandra: No conflict of interest\|\|Bokemeyer, Bernd:\|:\|consulting fees from: AbbVie, MSD, Shire, Ferring, Hospira, Takeda, Galapagos, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, and Celgene, outside the submitted work. Financial support for lectures and teaching from: AbbVie, Ferring, MSD, Merckle, Falk, Galapagos, Shield Therapeutics, Pfizer, Celltrion, Takeda, Janssen, and Galapagos, outside the submitted work. Grant and financial support for research from AbbVie; Takeda, Jansen, Pfizer, Galapagos and Ferring, outside the submitted work\|\|Efken, Philipp:\|:\|Personal fees from: Abbvie, BMS, Galapagos, Janssen, Amgen outside the submitted work\|\|Mohl, Wolfgang:\|:\|consulting fees from: Abbvie, Amgen, Hexal, Janssen, Pfizer, Synformulas, Takeda, outside the submitted work. Fees for lectures and further education from: Abbvie, Alanta health service GmbH, Almirall, Aptalis, Biogen, Falk, Gilead, Janssen, Pfizer, Medtronic, MSD, Shire, Takeda, Vifor, outside the submitted work. Fees for studies from: Abbvie, Janssen, MSD, Pfizer, Takeda, outside the submitted work. Fees for activities in public law bodies as member of the Advisory Commission of the Examination Office for the Saarland, the State Committee of Physicians and Health Insurance Companies and the Extended State Committee, outside the submitted work. Dependent employment in the group of Alanta health group GmbH, Hamburg, outside the submitted work. Shares, other fees from: Abbvie, Gilead, outside the submitted work\|\|Krause, Thomas:\|:\|personal fees from: AbbVie, Janssen, Takeda outside the submitted work\|\|Hoffstadt, Martin: No conflict of interest\|\|Ehehalt, Robert:\|:\|Personal fees from: Takeda, Abbvie, MSD, Biogen, Hexal, Amgen, Celltrion, Viatris outside the submitted work\|\|Trentmann, Leo: No conflict of interest\|\|Schweitzer, Axel:\|:\|Personal fees from: AbbVie Deutschland GmbH & Co. KG, Janssen-Cilag GmbH, Tillotts Pharma outside the submitted work\|\|Jessen, Petra:\|:\|Personal fees from: Abbvie, BMS, Janssen, Falk, Medtronic, Pfizer, Ferring\|\|Franzenburg, Sina: No conflict of interest\|\|Hartmann, Petra:\|:\|Personal fees from: Abbvie, MSD, Shire, Ferring, UCB, Hospira, Takeda, Movetis, Biogen, Mylan, Janssen, BMS, Amgen, Hexal, Stada, Merckle, Mundipharma, Falk, HLR; outside the submitted work\|\|di Giuseppe, Romina: No conflict of interest\|\|Schreiber, Stefan:\|:\|personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, and Falk, outside the submitted work |

| | |
|---|---|
| P802 | Walsh, Alissa:\|:\|AW has received research/consulting/advisory board fees from AbbVie, BMS, Buhlmann, Falk, Ferring, Galapagos, Helmsley Trust, Janssen, Lilly, Norman Collisson Foundation, Pfizer, Takeda, Tillots, UCB Pharma, Vifor; No stocks or share options.\|\|Kormilitzin, Andrey:\|:\|AK has received grants from GSK, Alzheimer's Research UK and the UK National Institute for Health and Care Research.\|\|Friedrich, Matthias:\|:\|MF has received grant and research support from Lee Placito Medical Fund, Crohn's and Colitis UK, Eli Lilly.\|\|Pakpoor, Julia: No conflict of interest\|\|Dr. Hosack, Tom: No conflict of interest\|\|Matini, Lawrence: No conflict of interest\|\|Kantschuster, Ramona: No conflict of interest\|\|Sharda, Anita: No conflict of interest\|\|Dunbar, Grace: No conflict of interest\|\|Cheung, Vincent Ting Fung:\|:\|VC has received grants from Norman Collisson Foundation and Oxfordshire Health Services Research Committee (OHSRC), part of Oxford Hospitals Charity. He has received consulting fees/ speaker fees from Janssen, BMS and Galapagos.\|\|Ambrose, Timothy: No conflict of interest\|\|Brain, Andrew Oliver:\|:\|AB has received speaker fees from Abbvie, Janssen-Cilag, Galapagos NV, Bristol Myers Squid and Takeda UK Ltd. He has received advisory board fees from Galapagos NV and AbbVie.\|\|Palmer, Rebecca: No conflict of interest\|\|Satsangi, Jack:\|:\|JS has received lecture fees from Roche. He has received research funding from the Helmsley Trust, European Commission, ECCO, Action Medical Research, and Crohn's Colitis UK. He is also the director of UK IBD Registry.\|\|Travis, Simon Piers Leigh:\|:\|ST has received grants and research support from AbbVie, Buhlmann, Celgene, ECCO, Helmsley Trust, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, UKIERI, Vifor, and Norman Collisson Foundation. He has received consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Apexian, Aptel, Arena, Asahi, Aspen, Astellas, Atlantic, AstraZeneca, Barco, Biocare, Biogen, BLPharma, Boehringer Ingelheim, BMS, Buhlmann, Calcico, Celgene, Cellerix, Cerimon, ChemoCentryx, Chiesi, CisBio, ComCast, Coronado, Cosmo, Ducentis, Dynavax, Elan, Enterome, EQrX, Equillium, Falk, Ferring, FPRT Bio, Galapagos, Genentech/Roche, Genzyme, Gilead, Glenmark, Grunenthal, GSK, GW Pharmaceuticals, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Medarex, Medtrix, Merck, Merrimack, Mestag, Millenium, Neovacs, Novartis, Novo Nordisk, NPS-Nycomed, Ocera, Optima, Origin, Otsuka, Palau, Pentax, Pfizer, Pharmaventure, Phesi, Phillips, P&G, Pronota, Protagonist, Proximagen, Resolute, Robarts, Sandoz, Sanofi, Santarus, Satisfai, Sensyne Health, Shire, SigmoidPharma, Sorriso, Souffinez, Syndermix, Synthon, Takeda, Theravance, Tigenix, Tillotts, Topivert, Trino Therapeutics with Wellcome Trust, TxCell, UCB Pharma, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria. He has received speaker fees from AbbVie, Amgen, Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer, Shire, Takeda, and UCB. No stocks or share options. |
| | |

| | |
|---|---|
| P803 | Ms. Elgood Hunt, Georgia: No conflict of interest\|\|Adams, Alex: No conflict of interest\|\|Senard, Thomas: No conflict of interest\|\|Gardner, Richard: No conflict of interest\|\|Jonge, Wouter: No conflict of interest\|\|Li Yim, Andrew: No conflict of interest\|\|Noble, Alex: No conflict of interest\|\|Satsangi, Jack: No conflict of interest\|\|Joustra, Vincent: No conflict of interest\|\|D'Haens, Geert: No conflict of interest\|\|Spencer, Daniel: No conflict of interest |
| P804 | Ms. Jatkowska, Aleksandra: No conflict of interest\|\|White, Bernadette:\|:\|The studentships of Bernadette White is funded by Nestle Health Science and the University of Glasgow. \|\|Nichols, Ben: No conflict of interest\|\|Svolos, Vaios: No conflict of interest\|\|Gkikas, Konstantinos:\|:\|The studentship of Konstantinos Gkikas is funded by Nestle Health Science and the University of Glasgow.\|\|Hansen, Richard: No conflict of interest\|\|Russell, Richard K: No conflict of interest\|\|Gaya, Daniel: No conflict of interest\|\|Brownson, Emily: No conflict of interest\|\|Seenan, John Paul: No conflict of interest\|\|Milling, Simon: No conflict of interest\|\|MacDonald, Jonathan: No conflict of interest\|\|Gerasimidis, Konstantinos:\|:\|Konstantinos Gerasimidis received research funding, speakers fee and travel expenses covered by Nestle Health Science. |
| P805 | Dr. Klughammer, Barbara: No conflict of interest\|\|Piali, Luca:\|:\|Employee\|\|Nica, Alexandra-Cristina:\|:\|Employee\|\|Nagel, Sandra:\|:\|Employee\|\|Bailey, Lorna:\|:\|Employee\|\|Jochum, Christoph: No conflict of interest\|\|Ignatenko, Stanislav: No conflict of interest\|\|Bläuer, Angela:\|:\|Employee\|\|Danilin, Sabrina:\|:\|Employee\|\|Gulati, Pratiksha:\|:\|Employee\|\|Hayward, Joanne:\|:\|Consultant\|\|Scepanovic, Petar:\|:\|Employee\|\|Retout, Sylvie:\|:\|Employee\|\|Zhang, Jitao David:\|:\|Employee\|\|Bhosale, Satish:\|:\|Business partner\|\|Sue-Ling, Kim:\|:\|Employee\|\|Chong, Chui Fung:\|:\|Employee\|\|Christ, Andreas:\|:\|Employee |
| P806 | Dr. Shani, Uria: No conflict of interest\|\|Ben Shabat, Niv: No conflict of interest\|\|Klang, Eyal: No conflict of interest\|\|Ungar, Bella: No conflict of interest\|\|Ben-Horin, Shomron: No conflict of interest\|\|Kopylov, Uri:\|:\|Speaker and avisory fees: Abbvie BMS Celltrion Jannsen Pfizer Medtronic Taked\|Research support- Jannsen Taked Medtronic |

| | |
|---|---|
| P807 | Dr. Avni Biron, Irit: No conflict of interest\|\|Hayat, Lior: No conflict of interest\|\|Ollech, Jacob E.: No conflict of interest\|\|Banai-Eran, Hagar: No conflict of interest\|\|Narkis, Bar: No conflict of interest\|\|Houri, Ohad: No conflict of interest\|\|Pauker, Maor H.: No conflict of interest\|\|Shay, Vardit: No conflict of interest\|\|Dotan, Iris: No conflict of interest\|\|Hadar, Eran: No conflict of interest\|\|Yanai, Henit: No conflict of interest |
| P808 | Dr. Blad, William: No conflict of interest\|\|Whitley, Lisa: No conflict of interest\|\|Harrow, Paul: No conflict of interest |
| P809 | Dr. Revés, Joana: No conflict of interest\|\|Morão, Bárbara: No conflict of interest\|\|Montanaro, Gabriella: No conflict of interest\|\|Sciberras, Nicole: No conflict of interest\|\|Bravo, Ana Catarina: No conflict of interest\|\|Glória, Luísa: No conflict of interest\|\|Ellul, Pierre: No conflict of interest\|\|Torres, Joana: No conflict of interest |
| P810 | Dr. Bertin, Luisa: No conflict of interest\|\|Gubbiotti, Alessandro: No conflict of interest\|\|Buda, Andrea: No conflict of interest\|\|Zingone, Fabiana:\|:\|Sofar, Borgone, Janssen, Takeda, Ehi\|\|Savarino, Edoardo Vincenzo:\|:\|Edoardo Savarino has served as speaker for Abbvie AGPharma, Alfasigma, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Pfizer. Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Unifarco; has served as consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Falk, Fresenius Kabi, Janssen, Merck & Co. Reckitt Benckiser. Regeneron, Sanofi, Shire, SILA. Sofar, Synformulas GmbH, Takeda, Unifarco; he received research support from Reckitt Benckiser, SILA, Sofar, Unifarco\|\|Barberio, Brigida:\|:\|Janssen, MSD, Takeda, Sofar, Alfasigma, Doxapharma |

| | |
|---|---|
| P811 | Feitosa, Flavio:\|:\|Feitosa F received lecture fee[s] from Takeda, and Pfizer; is advisory committee member for Takeda\|\|Parra, Rogerio: No conflict of interest\|\|Queiroz, Natália:\|:\|Queiroz NSF received lecture fee[s] from Janssen and Takeda; is advisory committee member for Janssen and Takeda.\|\|Flores, Cristina:\|:\|Flores C received lecture fee[s] from Janssen and Takeda; is advisory committee member for Janssen and Takeda\|\|Schiavetti, Bianca:\|:\|Schiavetti B received lecture fee[s] / Advisory boards from AbbVie, Fresenius, Janssen, Takeda, Amgen, Celltrion, Ferring and Pfizer.\|\|Azevedo, Matheus:\|:\|Azevedo MFC reports receiving consulting fees from Janssen and Takeda, lecture fees from Janssen, Takeda, Pfizer and Abbvie, and travel grant support from Takeda, Janssen, and Abbvie\|\|Porto Alegre Rosa, Carlos: No conflict of interest\|\|Chebli, Liliana:\|:\|Chebli LA reports receiving consulting fees from Abbvie, Janssen, and Takeda.\|\|Chebli, Julio:\|:\|Chebli JMF reports receiving consulting fees / lectures from Abbvie, Janssen, and Takeda. |
| P812 | Mrs. Van Der Waaij, Anne: No conflict of interest\|\|Gabriëls, Ruben: No conflict of interest\|\|Linssen, Matthijs: No conflict of interest\|\|Volkmer, Pia: No conflict of interest\|\|Robinson, Dominic: No conflict of interest\|\|Hermoso, Marcela: No conflict of interest\|\|Karrenbeld, Arend: No conflict of interest\|\|Festen, Eleonora: No conflict of interest\|\|Dijkstra, Gerard: No conflict of interest\|\|Kats-Urgulu, Gursah: No conflict of interest\|\|Nagengast, Wouter: No conflict of interest |
| P813 | Ms. Demers, Karlijn: No conflict of interest\|\|Bak, Michiel T.J.: No conflict of interest\|\|Bongers, Bart C.: No conflict of interest\|\|de Vries, Annemarie C:\|:\|Annemarie C. de Vries has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer outside the submitted work. \|\|Jonkers , Daisy M.A.E.:\|:\|Daisy M.A.E. Jonkers reports grants from Top Knowledge Institute (Well on Wheat), grants from Horizon 2020 DISCOvERIE, grants from NWO-CCC Partnership program (Carbokinetics), all outside the submitted work. \|\|Pierik , Marieke J.:\|:\|Marieke J. Pierik reports grants and non-financial support from Falk Pharma, grants from European commission, grants from ZONMW (Dutch national research fund), grants and non-financial support from Takeda, grants and non-financial support from Johnson and Johnson, grants and non-financial support from Abbvie, non-financial support from Ferring, non-financial support from Immunodiagnostics, non-financial support from MSD, all outside the submitted work.\|\|\|Stassen, Laurents P.S.:\|:\|Laurents P.S. Stassen has served as a speaker and received research support from Takeda, outside the submitted work. |

| | |
|---|---|
| P814 | Khan, Rana M Qasim:\|:\|Rana M. Qasim Khan is an employees of Takeda Pharmaceuticals U.S.A., Inc., and hold stock or stock options. \|\|Schwartz, David A:\|:\|David A. Schwartz served as a consultant for AbbiVie, Gilead, Janssen, Takeda and was a member of a Data Safety and Monitoring board for Tract. \|\|Sands, Bruce E:\|:\|Bruce E. Sands served as a consultant or received speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, GlaxoSmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TTL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio and has stock options in Ventyx Biosciences.\|\|Hanauer, Stephen:\|:\|Stephen Hanauer sevred as a consultant for AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cosmos, Catalys Pacific, Covance, Eli Lilly, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Sorriso, Takeda, TLL Pharma, UCB Pharma, VH squared and was a member of a Data Safety and Monitoring board for Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Gossamer, Prometheus, and Protagonist. \|\|Uddin, Sharif:\|:\|Sharif Uddin is an employee of Takeda Pharmaceuticals U.S.A., Inc., and hold stock or stock options. \|\|Mukherjee, Richa:\|:\|Richa Sagar Mukherjee is an employee of Takeda Pharmaceuticals U.S.A., Inc., and hold stock or stock options. \|\|Lichtenstein, Gary:\|:\|Gary R. Lichtenstein served as a consultant or received speaker's fees from AbbVie, Allergan, American Regen, Bristol Myers Squibb, Celgene, Chemed, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, IMEDEX, Ironwood, Janssen Orthobiotech, Kabi, MedEd Consultants, Merck, Morphic Therapeutics, Pfizer, Prometheus Laboratories, Romark, Sandoz, Salix Pharmaceuticals, Shire Pharmaceuticals, Takeda, UCB. |
| P815 | Ms. Playford, Charlotte: No conflict of interest\|\|Asghar, Zahid: No conflict of interest\|\|Armstrong, Stephanie: No conflict of interest\|\|Ngomba, Richard: No conflict of interest\|\|Rochford, Andrew: No conflict of interest |
| P816 | Mr. Laheij, Robin: No conflict of interest\|\|van Knippenberg, Yara: No conflict of interest\|\|Heil, Annelijn: No conflict of interest\|\|Mannaerts, Britt: No conflict of interest\|\|Bruin, Karlien: No conflict of interest\|\|Lutgens, Maurice: No conflict of interest\|\|Sikkema, Marjolein: No conflict of interest\|\|de Wit, Ulrike: No conflict of interest\|\|Laheij, Robert: No conflict of interest |

| | |
|---|---|
| P817 | Dr. Schlosser, Tobias: No conflict of interest\|\|Krasselt, Marco: No conflict of interest\|\|Elsing, Louis: No conflict of interest\|\|Hecker, Martin: No conflict of interest\|\|Holler, Babett: No conflict of interest\|\|Hoffmeister, Albrecht: No conflict of interest |
| P818 | Mrs. García Ramírez, Laura: No conflict of interest\|\|Suárez Ferrer, Cristina: No conflict of interest\|\|Rueda Garcia, Jose Luis: No conflict of interest\|\|Martín-Arranz, Eduardo: No conflict of interest\|\|Poza Cordón, Joaquín: No conflict of interest\|\|Sánchez-Azofra, María: No conflict of interest\|\|Martin-Arranz, María Dolores: No conflict of interest |
| P819 | Dr. Liang, Raymond: No conflict of interest\|\|Lin, Huiyu: No conflict of interest\|\|Lim, Wee Chian: No conflict of interest |
| P820 | Ms. Zhao, Zehua: No conflict of interest\|\|Chen, Chulin: No conflict of interest\|\|Li, Yi: No conflict of interest\|\|Ye, Xianghong: No conflict of interest\|\|Zhu, Weiming: No conflict of interest |
| P821 | Mrs. Juvik, Anne Fogh: No conflict of interest\|\|Poulsen, Jacob Kvist: No conflict of interest\|\|Roikjaer, Ole: No conflict of interest\|\|Fransgaard, Tina: No conflict of interest |
| P822 | Cooney , Rachel:\|:\|Consultancy: Takeda, Celltrion\|Educational presentations: Galapagos, Jannsen, Falk\|\|\|Barrett, Kevin: No conflict of interest\|\|Prof. Russell, Richard K.: No conflict of interest |

| | |
|---|---|
| P823 | Silva, Ana Carolina Veronese: No conflict of interest\|\|Tumelero, Taina Julia: No conflict of interest\|\|Magro, Daniela Oliveira: No conflict of interest\|\|Yamamoto, Danielle Reis: No conflict of interest\|\|Ribeiro, Luciana Bandeira Mendez: No conflict of interest\|\|da Silva, Giovana Stival: No conflict of interest\|\|Truppel, Sabine Kruger: No conflict of interest\|\|Vieira, Mario C: No conflict of interest\|\|Prof. Kotze, Paulo Gustavo: No conflict of interest |
| P824 | Dr. Gutiérrez Casbas, Ana: No conflict of interest\|\|Madero Velázquez, Lucía: No conflict of interest\|\|Herreros, Belen: No conflict of interest\|\|Zapater, Pedro: No conflict of interest\|\|Rodríguez, Andrés: No conflict of interest\|\|Muñoz, Roser: No conflict of interest\|\|Bernal, Lorena: No conflict of interest\|\|Orts, Beatriz: No conflict of interest\|\|Belen, Olivia: No conflict of interest\|\|Sempere, Laura: No conflict of interest\|\|Moreno-Pérez, Oscar: No conflict of interest\|\|Francés, Rubén: No conflict of interest |
| P825 | Dr. Filipec Kanizaj, Tajana: No conflict of interest |
| P826 | Dr. Brunet, Eduard: No conflict of interest\|\|Melcarne, Luigi: No conflict of interest\|\|Llovet, Laura Patricia: No conflict of interest\|\|Garcia-Sague, Belen: No conflict of interest\|\|Vela, Emili: No conflict of interest\|\|Cleries, Montserrat: No conflict of interest\|\|Pontes, Caridad: No conflict of interest\|\|García-Iglesias, Pilar: No conflict of interest\|\|Puy, Anna: No conflict of interest\|\|Villoria, Albert: No conflict of interest\|\|Calvet, Xavier: No conflict of interest |
| P827 | Ms. Van De Pol, Natasja: No conflict of interest\|\|Pan, Qiuwei: No conflict of interest\|\|Derikx, Lauranne A.A.P.: No conflict of interest\|\|Bakker, Linda: No conflict of interest\|\|van der Woude, C Janneke:\|:\|MSD, FALK Benelux, Abbott laboratories, Mundipharma Pharmaceuticals, Janssen, Takeda, and Ferring\|\|de Vries, Annemarie C:\|:\|Pfizer, Galapagos, Jansen, Abbvie, and Takeda |

| | |
|---|---|
| P828 | Dr. Papa, Alfredo: No conflict of interest\|\|Lopetuso, Loris Riccardo: No conflict of interest\|\|Mignini, Irene: No conflict of interest\|\|Settanni, Carlo Romano: No conflict of interest\|\|Scaldaferri, Franco: No conflict of interest\|\|Pugliese, Daniela: No conflict of interest\|\|Laterza, Lucrezia: No conflict of interest\|\|Covino, Marcello: No conflict of interest\|\|Franceschi, Francesco: No conflict of interest\|\|Gasbarrini, Antonio: No conflict of interest |
| P829 | Wetwittayakhlang, Panu: No conflict of interest\|\|Golovics , Petra: No conflict of interest\|\|Gonczi , Lorant: No conflict of interest\|\|Khoury , Alex: No conflict of interest\|\|Kurti , Zsuzsanna: No conflict of interest\|\|Pandur , Tunde: No conflict of interest\|\|David , Gyula: No conflict of interest\|\|Erdelyi , Zsuzsanna: No conflict of interest\|\|Szita , Istvan: No conflict of interest\|\|Lakatos, Laszlo: No conflict of interest\|\|Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest |
| P830 | Dr. Chhibba, Tarun: No conflict of interest\|\|Tandon, Parul: No conflict of interest\|\|Natt, Navneet: No conflict of interest\|\|Brar, Gurmun: No conflict of interest\|\|Gurpreet, Malhi: No conflict of interest\|\|Geoffrey, Nguyen: No conflict of interest |
| P831 | Dr. Froes, Renata:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda, Ferring and Pfizer; is advisory committee member for Janssen and Takeda\|\|Andrade , Adriana Ribas:\|:\|received lecture fee[s] from AbbVie, Janssen\|\|Faria, Mikaell Alexandre Guovea:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda, Nestlé,advisory committee member for Janssen \|\|\|Parra, Rogerio Serafim:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda, and Pfizer; is advisory committee member for Janssen and AbbVie\|\|Zaltman, Cyrla:\|:\|received lecture fee[s] from Janssen, Takeda, Celltrion Pfizer\|\|Souza, Heitor Siffert Pereira: No conflict of interest\|\|Santos, Carlos Henrique Marques dos Santos:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda\|\|Bafutto, Mauro:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda\|\|Quaresma , Abel Botelho:\|:\| received lecture fee[s] from AbbVie, Janssen\|\|Santana , Genoile Oliveira:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda, Ferring and Pfizer; is advisory committee member for Janssen \|\|\|Rafael Luís Luporini, Rafael Luís:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda\|\|Lima Junior , Sérgio Figueiredo de: No conflict of interest\|\|Miszputen, Sender Jankiel: No conflict of interest\|\|Souza , Mardem Machado de:\|:\|received lecture fee[s] from AbbVie, Janssen, Takeda\|\|Herrerias , Giedre Soares Prates: No conflict of interest\|\|Kaiser Junior, Roberto Luiz: No conflict of interest\|\|Nascimento , Catiane Rios do: No conflict of interest\|\|Féres , Omar: No conflict of interest\|\|Barros , Jaqueline Ribeiro de: No conflict of interest\|\|Guimarães , Camila da Silveira: No conflict of interest\|\|Sassaki , Ligia Yukie:\|:\|received lecture fee[s] from Janssen\|\|Saad-Hossne, Rogerio:\|:\|received lecture fee[s] and advisory committee member for AbbVie, Takeda, Janssen, Pfizer, Fresenius and Amgen |

| | |
|---|---|
| P832 | Dr. Dasu, Neethi: No conflict of interest\|\|John, Jason: No conflict of interest\|\|Blair, Brian: No conflict of interest\|\|Khalid, Yaser: No conflict of interest\|\|Walters, Richard: No conflict of interest\|\|Chhoun, Christopher: No conflict of interest\|\|Suga, Herman: No conflict of interest |
| P833 | Prof. Dr. Kim, Hyun-Soo: No conflict of interest\|\|Kim, Hosook: No conflict of interest\|\|Kim, Kaeun: No conflict of interest |
| P834 | Dr. Villumsen, Marie: No conflict of interest\|\|Poulsen, Anja: No conflict of interest\|\|Thomsen, Tanja: No conflict of interest\|\|Jess, Tine: No conflict of interest\|\|Aadahl, Mette: No conflict of interest\|\|Allin, Kristine: No conflict of interest |
| P835 | Dr. Sehgal, Priya: No conflict of interest\|\|Su, Steven: No conflict of interest\|\|Zech, John: No conflict of interest\|\|Nobel, Yael: No conflict of interest\|\|Luk, Lyndon: No conflict of interest\|\|Economou, Ioannis: No conflict of interest\|\|Shen, Bo: No conflict of interest\|\|Kiran, Pokala: No conflict of interest\|\|Freedberg, Daniel: No conflict of interest |
| P836 | Ms. Karpavičiūtė, Vita: No conflict of interest\|\|Kiudelis, Gediminas: No conflict of interest\|\|Kupčinskas, Juozas: No conflict of interest\|\|Kupčinskas, Limas: No conflict of interest |
| P837 | Gonczi, Lorant: No conflict of interest\|\|Lakatos, Laszlo: No conflict of interest\|\|Golovics, Petra A.: No conflict of interest\|\|Pandur, Tunde: No conflict of interest\|\|David, Gyula: No conflict of interest\|\|Erdelyi, Zsuzsanna: No conflict of interest\|\|Szita, Istvan: No conflict of interest\|\|Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest |

| | |
|---|---|
| P838 | Dr. Moon, Jung Min:\|:\|National Research Foundation of Korea (NRF) grant funded by Ministry of Education (NRF-2021R1I1A1A01056204)\|\|Kwon, Kyoung-Eun: No conflict of interest\|\|Jung, Sun-Young: No conflict of interest\|\|Choi, Chang Hwan: No conflict of interest\|\|Lee, Ju Won: No conflict of interest\|\|Shin, Seung Yong: No conflict of interest\|\|Joo, Hyun Jin: No conflict of interest |
| P839 | Mrs. Sarbagili Shabat, Chen: No conflict of interest\|\|Zelber-Sagi, Shira: No conflict of interest\|\|Fliss Isakov, Naomi: No conflict of interest\|\|Hirsch, Ayal: No conflict of interest\|\|Ron, Yulia: No conflict of interest\|\|Thurm, Tamar: No conflict of interest\|\|Maharshak, Nitsan: No conflict of interest |
| P840 | Ms. Dehbidi Assadzadeh, Layla: No conflict of interest\|\|Youn, Elizabeth You Jin: No conflict of interest\|\|Huang, Felix: No conflict of interest\|\|Djani, Lotfi: No conflict of interest\|\|Belmesk, Lina: No conflict of interest\|\|Madagh, Sabrina: No conflict of interest\|\|Kanters, Caitlyn: No conflict of interest\|\|Yang, Xindy: No conflict of interest\|\|Chennou, Fella: No conflict of interest\|\|Geng, Si Yuan: No conflict of interest\|\|Bouthot , Jacob: No conflict of interest\|\|Colette , Deslandres: No conflict of interest\|\|Jantchou, Prevost: No conflict of interest |
| P841 | Palomino Pérez, Laura María: No conflict of interest\|\|Delgado Fernández-Valdés, María: No conflict of interest\|\|Velasco Rodríguez-Belvís, Marta: No conflict of interest\|\|Cañedo Villarroya, Elvira: No conflict of interest\|\|De la Mano Hernández, Agustín: No conflict of interest\|\|Dominguez Ortega, Gloria: No conflict of interest\|\|Martínez Pérez, Jorge: No conflict of interest\|\|Martinez Navarro, Gorka: No conflict of interest\|\|Martín Fernández, Carmen: No conflict of interest\|\|Di Campli Zaghlul, Marianna: No conflict of interest\|\|García Hernández, Paloma: No conflict of interest\|\|Sánchez Llorente, Paula: No conflict of interest\|\|Muñoz Codoceo, Rosa Ana: No conflict of interest |
| P842 | Dr. Delaleeuwe, Isha: No conflict of interest\|\|Aoun, Jennifer: No conflict of interest\|\|Hoyois, Alice: No conflict of interest\|\|Brasseur, Celine: No conflict of interest\|\|Di Romana, Silvana: No conflict of interest\|\|Vinciane, Muls: No conflict of interest |

| | |
|---|---|
| P843 | Dr. Neri, Benedetto: No conflict of interest\|\|Pizzi, Francesca: No conflict of interest\|\|Savino, Luca: No conflict of interest\|\|Salvatori, Silvia: No conflict of interest\|\|Mossa, Michelangela: No conflict of interest\|\|Lolli, Elisabetta: No conflict of interest\|\|Calabrese, Emma: No conflict of interest\|\|Sica, Giuseppe: No conflict of interest\|\|Petruzziello, Carmelina: No conflict of interest\|\|Monteleone, Giovanni: No conflict of interest\|\|Biancone, Livia: No conflict of interest |
| P844 | Liava, Christina: No conflict of interest\|\|Sinakos, Emmanouil: No conflict of interest\|\|Dimitroulas, Theodoros: No conflict of interest\|\|Navrozidou, Christina: No conflict of interest\|\|Akriviadis, Evangelos: No conflict of interest |
| P845 | Mr. Marijam, Alen:\|:\|AM is an employee of/holds shares in the GSK group of companies. AM declares no financial and non-financial relationships and activities and no conflicts of interest.\|\|Vroom, Nikki:\|:\|NV is an employee of P95/Pallas. P95/Pallas received funding from the GSK group of companies for the submitted work, and holds/held contracts with AstraZeneca, the GSK group of companies, Pfizer, Sanofi and Seqirus outside of the submitted work. Pallas, a P95 company holds/has held contracts with Orchard, Biomarin, Daiichi, Bavarian Nordic, Bayer and Sanofi outside of the submitted work. NV declares no financial and non-financial relationships and activities and no conflicts of interest.\|\|Bhavsar, Amit:\|:\|AB is an employee of/holds shares in the GSK group of companies. AB declares no financial and non-financial relationships and activities and no conflicts of interest.\|\|Posiuniene, Inga:\|:\|IP is an employee of/holds shares in the GSK group of companies. IP declares no financial and non-financial relationships and activities and no conflicts of interest.\|\|Lecrenier, Nicolas:\|:\|NL is an employee of/holds shares in the GSK group of companies. NL declared patents from the GSK group of companies. NL declares no financial and non-financial relationships and activities and no conflicts of interest.\|\|Vroling, Hilde:\|:\|HV is an employee of P95/Pallas. P95/Pallas received funding from the GSK group of companies for the submitted work, and holds/held contracts with AstraZeneca, the GSK group of companies, Pfizer, Sanofi and Seqirus outside of the submitted work. Pallas, a P95 company holds/has held contracts with Orchard, Biomarin, Daiichi, Bavarian Nordic, Bayer and Sanofi outside of the submitted work. HV declares no financial and non-financial relationships and activities and no conflicts of interest. |
| P846 | Liava, Christina: No conflict of interest\|\|Sinakos, Emmanouil: No conflict of interest\|\|Dimitroulas, Theodoros: No conflict of interest\|\|Navrozidou, Christina: No conflict of interest\|\|Akriviadis, Evangelos: No conflict of interest |

| | |
|---|---|
| P847 | Dr. Barnes, Alex: No conflict of interest\|\|Andrews, Jane: No conflict of interest\|\|Bryant, Robert V: No conflict of interest\|\|Mountifield, Reme: No conflict of interest |
| P848 | Dr. Di Giorgio, Francesca Maria: No conflict of interest\|\|Modica, Stefania Pia: No conflict of interest\|\|Ciminnisi, Stefania: No conflict of interest\|\|Saladino, Marica: No conflict of interest\|\|Muscarella, Stefano: No conflict of interest\|\|Melatti, Piera: No conflict of interest\|\|Brinch, Daniele: No conflict of interest\|\|Petta, Salvatore: No conflict of interest\|\|Cappello, Maria: No conflict of interest |
| P849 | Dr. Rodríguez-Lago, Iago: No conflict of interest\|\|Rodríguez, Ainhoa: No conflict of interest\|\|Elorza, Ainara: No conflict of interest\|\|Sampedro, Blanca: No conflict of interest\|\|Jiménez, Itxaso: No conflict of interest\|\|Erdozáin, Inés: No conflict of interest\|\|Rodríguez, Pelayo: No conflict of interest\|\|Fraga, Amaia: No conflict of interest\|\|De Castro, Leticia: No conflict of interest\|\|Oyón, Daniel: No conflict of interest\|\|Huerta, Alain: No conflict of interest\|\|Carmona, Mar: No conflict of interest\|\|Esáin, Andrea: No conflict of interest\|\|Cabriada, José Luis: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest |
| P850 | Mr. Lund, Ken: No conflict of interest\|\|Zegers, Floor Dijkstra: No conflict of interest\|\|Nielsen, Jan: No conflict of interest\|\|Brodersen, Jacob Broder: No conflict of interest\|\|Knudsen, Torben: No conflict of interest\|\|Kjeldsen, Jens: No conflict of interest\|\|Larsen, Michael Due: No conflict of interest\|\|Nørgård, Bente Mertz: No conflict of interest |
| P851 | Dr. Maldonado, Fernando: No conflict of interest\|\|Penz, Erika: No conflict of interest\|\|Jones, Jennifer: No conflict of interest\|\|Pena-Sanchez, Juan-Nicolas: No conflict of interest |

| | |
|---|---|
| P852 | Mrs. Lujan, Rona: No conflict of interest\|\|Atia, Ohad: No conflict of interest\|\|Focht, Gili: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Loewenberg Weisband, Yiska: No conflict of interest\|\|Lederman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris:\|:\|ID - received in the last 3 years consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Genentech/Roche, Neopharm, Ferring, Rafa Laboratories, Falk Pharma, Nestle, Given Imaging/Medtronic, Gilead, Galapagos, Celgene/BMS, Arena, Sublimity, Sangamo, Celltrion, Wilbio, Cambridge Healthcare, Abbott, Food Industries Organization, Altman, Athos \|\|Turner, Dan:\|:\|Last 3 years received consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS |
| P853 | Dr. Nielsen, Kari Rubek: No conflict of interest\|\|Midjord, Jóngerð: No conflict of interest\|\|Hammer, Turid: No conflict of interest\|\|Vang, Amanda: No conflict of interest\|\|Berbisá, Marjun á Fríðriksmørk: No conflict of interest\|\|Johannesen, Herborg: No conflict of interest\|\|Burisch, Johan: No conflict of interest |
| P854 | Khan, Rana M Qasim:\|:\|Rana M Qasim Khan: employee of Takeda Pharmaceuticals U.S.A., Inc and hold stock or stock options\|\|Ananthakrishnan, Ashwin N:\|:\|Ashwin N Ananthakrishnan: received research support from National Institutes of Health, Crohn's and Colitis Foundation, and Pfizer, and served on the advisory board of Takeda and Gilead. \|\|Loftus Jr, Edward V:\|:\|Edward V Loftus Jr: served as a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Calibr, Celgene, Celltrion Healthcare, Eli Lilly, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Surrozen, Sun Pharma, Takeda, and UCB, and received research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. \|\|Iroku, Ugonna:\|:\|Ugonna Iroku: served on the advisory board of AbbVie and Janssen\|\|Mukherjee, Richa:\|:\|Richa Mukherjee: employee of Takeda Pharmaceuticals U.S.A., Inc and hold stock or stock options\|\|Uddin, Sharif:\|:\|Sharif Uddin: employee of Takeda Pharmaceuticals U.S.A., Inc and hold stock or stock options\|\|Odufalu, Florence-Damilola:\|:\|Florence-Damilola Odufalu: served on the advisory board of Pfizer and Janssen\|\|Prof. Liu, Julia:\|:\|Julia J Liu: received research support from Freenome Holdings and served on the advisory board of Janssen, Eli Lilly, and Bristol Myers Squibb |

| | |
|---|---|
| P855 | Mr. Sharara, Ala: No conflict of interest\|\|Ibrahim, Mohamad Ali: No conflict of interest\|\|Allam, Jad: No conflict of interest\|\|Haidar-Ahmad, Dima: No conflict of interest\|\|Chalhoub, Caroline: No conflict of interest\|\|Francis, Rita: No conflict of interest |
| P856 | Narula, Neeraj:\|:\|Neeraj Narula holds a McMaster University Department of Medicine Internal Career Award. Neeraj Narula has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Merck, and Ferring\|\|Wong, Emily C.L.: No conflict of interest\|\|Dr. Pray, Cara: No conflict of interest\|\|Marshall, John K.:\|:\|John K. Marshall has received honoraria from Janssen, AbbVie, Allergan, Bristol-Meyer-Squibb, Ferring, Janssen, Lilly, Lupin, Merck, Pfizer, Pharmascience, Roche, Shire, Takeda and Teva.\|\|Rangarajan, Sumathy: No conflict of interest\|\|Islam, Shofiqul: No conflict of interest\|\|Bahonar, Ahmad: No conflict of interest\|\|Alhabib, Khalid F: No conflict of interest\|\|Kontsevaya, Anna: No conflict of interest\|\|Ariffin, Farnaza: No conflict of interest\|\|Co, Homer U.: No conflict of interest\|\|Al Sharief, Wadeia: No conflict of interest\|\|Szuba, Andrzej: No conflict of interest\|\|Wielgosz, Andreas: No conflict of interest\|\|Diaz, Maria Luz: No conflict of interest\|\|Yusuf, Rita: No conflict of interest\|\|Kruger, Lanthé: No conflict of interest\|\|Soman, Biju: No conflict of interest\|\|Li, Yang: No conflict of interest\|\|Wang, Chuangshi: No conflict of interest\|\|Yin, Lu: No conflict of interest\|\|Erkin, Mirrakhimov: No conflict of interest\|\|Lanas, Fernando: No conflict of interest\|\|Davletov, Kairat: No conflict of interest\|\|Rosengren, Annika: No conflict of interest\|\|Lopez-Jaramillo, Patricio: No conflict of interest\|\|Khatib, Rasha: No conflict of interest\|\|Oguz, Aytekin: No conflict of interest\|\|Iqbal, Romaina: No conflict of interest\|\|Yeates, Karen: No conflict of interest\|\|Avezum, Álvaro: No conflict of interest\|\|Reinisch, Walter:\|:\|Walter Reinisch has received support for the following:\|Speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, \|Consultant for Abbott Laboratories, Abbvie, Aesca, Algernon, Amgen, AM Pharma, AMT, AOP Orphan, Arena Pharmaceuticals, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, DSM, Elan, Eli Lilly, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, LivaNova, Mallinckrodt, Medahead, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nash Pharmaceuticals, Nestle, Nippon Kayaku, Novartis, Ocera, Omass, Otsuka, Parexel, PDL, Periconsulting, Pharmacosmos, Philip Morris Institute, Pfizer, Procter & Gamble, Prometheus, Protagonist, Provention, Robarts Clinical Trial, Sandoz, Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, Sigmoid, Sublimity, Takeda, Therakos, Theravance, Tigenix, UCB, Vifor, Zealand, Zyngenia, and 4SC, \|Advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, |

| | |
|---|---|
| | Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, DSM, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Sandoz, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zealand, Zyngenia, and 4SC\|\|Moayyedi, Paul: No conflict of interest\|\|Yusuf, Salim: No conflict of interest |
| P858 | Dr. Dharap, Vikram: No conflict of interest\|\|Abraham, Philip: No conflict of interest\|\|Desai, Devendra: No conflict of interest\|\|Gupta, Tarun: No conflict of interest\|\|Dhoble, Pavan: No conflict of interest\|\|Mehta, Nirad: No conflict of interest\|\|Modhe, Jagdish: No conflict of interest |
| P859 | De Francisco Garcia, Ruth Maria: No conflict of interest\|\|Pérez-Martínez, Isabel: No conflict of interest\|\|Castaño-García, Andrés: No conflict of interest\|\|Celada-Sendino, Miriam: No conflict of interest\|\|Fernández-González, Emilia: No conflict of interest\|\|García-Pérez, Cristina: No conflict of interest\|\|Martínez-Gozález, Susana: No conflict of interest\|\|Rolle, Valeria: No conflict of interest\|\|Queiro, Ruben: No conflict of interest\|\|Alonso-Castro, Sara: No conflict of interest\|\|Santos-Juanes, Jorge: No conflict of interest\|\|Gueimonde, Miguel: No conflict of interest\|\|Dr. Riestra, Sabino: No conflict of interest |

| | |
|---|---|
| P860 | Dr. Burisch, Johan: No conflict of interest\|\|Zhao, Mirabella:\|:\|M Zhao has received support for attending a meeting from Takeda.\|\|Odes, Shmuel: No conflict of interest\|\|De Cruz, Peter:\|:\|P De Cruz has received grants or contracts from Janssen, Takeda, Ferring, Shire, AbbVie, Celltrion and Baxter; been a speaker, consultant and advisory board member for: AbbVie, Janssen, Takeda, Celltrion, Ferring, Shire and Baxter; received support for attending meetings and/or travel from Ferring, Shire, Janssen, AbbVie, Takeda, Celltrion and Baxter; and has been a member of the Australia and New Zealand IBD Research Consortium\|\|Vermeire , Severine:\|:\|S Vermeire has received research grants from Pfizer, Galapagos, Abbvie, J&J and Takeda; consulting fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma; speaker fees from Alimentiv, BMS, Boehringer Ingelheim, Celgene, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Janssen, J&J, Lilly, Materia Prima, Pfizer, Takeda, Tillots Pharma AG.\|\|Bernstein, Charles N.: No conflict of interest\|\|Kaplan, Gilaad G.:\|:\|G Kaplan has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer, Amgen, Sandoz, Pendopharm and Takeda. He has received research support from Ferring. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018.\|\|\|Duricova, Dana:\|:\|D Duricova has received lecture/consultancy fees from Takeda, Janssen, Pfizer as well as support for attending meetings and/or travel from Janssen, Takeda.\|\|Greenberg, Dan: No conflict of interest\|\|Melberg, Hans Olav:\|:\|HO Melberg has received research grants from Takeda and Biogen, consulting fees from Takeda, and speaking fees from Pfizer and Biogen.\|\|Watanabe, Mamoru:\|:\|M Watanabe has received grants or contracts from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd, Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., AbbVie GK., EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., Alfresa Pharma Corporation; consulting fees from AbbVie GK., EA Pharma Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co., Ltd.; and honoraria from EA Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Pfizer Japan Inc.\|Kissei Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Gilead Sciences, Inc., Janssen Pharmaceutical K.K., Celltrion Healthcare Co., Ltd., JIMRO, Eli Lilly Japan K.K., Mochida Pharmaceutical |

| | |
|---|---|
| | Co., Ltd.\|\|\|Ahn, Hyeong Sik: No conflict of interest\|\|Targownik, Laura:\|:\|L Targownik gas received grants or contracts from Janssen, Abbvie, Pfizer, Takeda, Roche, Gilead, Sandoz and Amgen; consulting fees from Janssen, Abbvie, Pfizer, Takeda, Roche, Gilead, Sandoz, Amgen, Fresnius Kabi and Viatris; honoraria for lectures from Janssen, Abbvie, Pfizer, Takeda, Roche, Gilead, Sandoz, Amgen and Organon; and was EDI Lead for Canadian Associaion of Gastroenterology.\|\|Pittet, Valérie E. H.: No conflict of interest\|\|Annese, Vito: No conflict of interest\|\|Park, Kt:\|:\|KT Park is an employee of Genentech Roche and a shareholder of the Roche Group.\|\|Konstantinos H. , Konstantinos H.:\|:\|K Katsanos has served as speaker, consultant, and advisory member for or has received research funding from AbbVie, Amgen, Enorasis, Epsilon Health, Falk, Faran Ferring, Genesis, Grifols S.A., Janssen, Koper, MSD, Mylan, Shire,Takeda, and Vianex.\|\|Høivik, Marte L.:\|:\|ML Høivik has received investigator-initiated research grants from Tillotts, Ferring, Takeda and Pfizer; Advisory board honoraria from Takeda and AbbVie, and speaking fees from Takeda, Abbvie, Tillotts, Ferring, Galapagos, Janssen and MSD.\|\|Krznaric, Zeljko:\|:\|Z Krznaric has served as speaker for Abbvie, Takeda, Janssen, Freseinus, and Oktal Pharma/Celltrion.\|\|Chaparro, María:\|:\|M Chaparro has served as a speaker, as consultant or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Biogen, Gilead and Lilly.\|\|Loftus, Edward V.:\|:\|EV Loftus, Jr. has received grants or contracts from AbbVie, Bristol-Myers Squibb, Celgene/Receptos, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Takeda, Theravance, and UCB; consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, CALIBR, Celgene, Fresenius Kabi, Genentech, Gilead, Gossamer Bio, Janssen, Iterative Scopes, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Surrozen, Takeda, and UCB; reports the following patents: USA 11,249,084, USA 10,041,948 (issued); USA 17/668,915 (pending); has participated on a Data Safety Monitoring Board or Advisory Board: Eli Lilly, Morphic; owns stock in Exact Sciences and is a board member of Crohn's & Colitis Foundation, Minnesota-Dakotas Chapter.\|\|Lakatos, Peter L:\|:\|PL Lakatos has been a speaker and/or advisory board member: AbbVie, Amgen, BioJamp, Bristol Myers Squibb, Fresenius Kabi, Genetech, Gilead, Janssen, Merck, Mylan, Organon, Pendopharm, Pfizer, Roche, Takeda ,Tillots and Viatris and has received unrestricted research grant: AbbVie, Gilead, Takeda and Pfizer.\|\|Gisbert, Javier P.:\|:\|JP Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma.\|\|Bemelman, Willem:\|:\|W Bemelman has received research |

| | |
|---|---|
| | Pharmaceutical, Norgine and Vifor Pharma.\|\|Bemelman, Willem:\|:\|W Bemelman has received research grants from VIFOR and Braun; consulting fees from Takeda and Braun; speaker fees from Medtronic, Takeda, Braun and Johnson & Johnson; is a stock owner of Semiflex Company and holds leadership positions in UEG and IOIBD. \|\|Moum, Bjørn: No conflict of interest\|\|Gearry, Richard B.:\|:\|RB Gearry has received grants or contracts from AbbVie and Janssen; consulting fees from AbbVie, and honoraria for lectures from AbbVie and Cornerstone Health. \|\|Kappelman, Michael D.:\|:\|MD Kappelman has received grants or contracts from Pfizer, Takeda, Janssen, AbbVie, Lilly, Genentech, Boehringer Ingelheim, Bristol Meyers Squibb, Celltrion and Arenapharm; consulting fees from Takeda and Pfizer; speaker fees from AbbVie; has participated on data safety monitoring board or advisory board for Eli Lull; and owns stock in Johnson & Johnson\|\|Hart, Ailsa: No conflict of interest\|\|Pierik, Marieke:\|:\|MJ Pierik has received grants or contracts from Takeda, Janssen, Galapagos, Tramedico, MSD, Takeda, Janssen-Cilag, and Bristol-Myers-Squibb; honoraria for lectures from BMS, Janssen-Cilag, Abbvie, Galapagos; consulting fees from Janssen-Cilag and Gilead; and leadership or fiduciary role in myCoach foundation, IBD committee NVMDL and Dutch Initiative on Crohn and colitis.\|\|Andrews, Jane:\|:\|J Andrews has served as speaker, consultant, and advisory member for AbbVie, Allergan, Anatara, Atmo Capsule, Bayer, BMS, Celgene, Celltrion, Falk, Ferring Fresenius Kabi, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Pfizer, Sandoz, Shire, Takeda, and Vifor; has participated on a data Safety Monitoring Board or Advisory Board for Janssen; has received research grants from RAH research Fund, The Hospital Research Fund 2020-2022, and The Helmsley Trust 2020-2023; is a board member of Gastroenterological Society of Australia, and board chair of Crohn's Colitis Cure and member of scientific and medical advisory group of Crohn's & Colitis Australia\|\|Ng, Siew:\|:\|\|SC Ng has received grants or contracts from AbbVie, Ferring, and Olympus and Janssen; consulting fees from Abbvie, Pfizer, Ferring and Janssen; honoraria for lectures from AbbVie, Ferring, Janssen, Menarini, Takeda, Tillotts and Pfizer; Participation on a Data Safety Monitoring Board or Advisory Board for Abbvie, Pfizer, Ferring and Janssen; is a shareholder of GeniBiome Limited and is a director of the Microbiota I Center, Hong Kong.\|\|\|D'Inca, Renata: No conflict of interest\|\|Munkholm, Pia: No conflict of interest |
| P861 | Liava, Christina: No conflict of interest\|\|Sinakos, Emmanouil: No conflict of interest\|\|Dimitroulas, Theodoros: No conflict of interest\|\|Navrozidou, Christina: No conflict of interest\|\|Akriviadis, Evangelos: No conflict of interest |
| P862 | Mr. Mallon, Kristian: No conflict of interest\|\|McBride , Ciara: No conflict of interest\|\|Doherty , Professor Glen: No conflict of interest\|\|Burns, Dr Richéal: No conflict of interest |

| | |
|---|---|
| P863 | Dr. Chatten, Kelly: No conflict of interest\|\|Kalra, Philip: No conflict of interest\|\|Bower, Peter: No conflict of interest\|\|Mclaughlin, John: No conflict of interest\|\|Ghosh, Subrata: No conflict of interest\|\|Limdi, Jimmy: No conflict of interest |
| P864 | Ms. Fons, Anne: No conflict of interest\|\|Asscher, Vera: No conflict of interest\|\|van der Meulen-de Jong, Andrea: No conflict of interest\|\|Stuyt, Rogier: No conflict of interest\|\|Baven-Pronk, Martine: No conflict of interest\|\|van der Marel, Sander: No conflict of interest\|\|Jacobs, Rutger: No conflict of interest\|\|Mooijaart, Simon: No conflict of interest\|\|Kalisvaart, Kees: No conflict of interest\|\|Maljaars, Jeroen: No conflict of interest |
| P865 | Dr. Connaughton, Roisin: No conflict of interest\|\|Kafienah, y: No conflict of interest\|\|Ramkalawan, km: No conflict of interest\|\|Stacey, w: No conflict of interest\|\|Walker, c: No conflict of interest\|\|O'Donnell, s: No conflict of interest\|\|Ryan, b: No conflict of interest\|\|O'Connor, a: No conflict of interest |
| P866 | Jonaityte, Ieva Renata: No conflict of interest\|\|Kiudelis, Gediminas: No conflict of interest\|\|Valiukeviciene, Skaidra: No conflict of interest\|\|Kupcinskas, Juozas: No conflict of interest\|\|Prof. Dr. Jonaitis, Laimas: No conflict of interest |
| P867 | Dr. Leeds, Ira: No conflict of interest\|\|Prien, Chris: No conflict of interest\|\|Dill-Macky, Arabella: No conflict of interest\|\|Li, Hengjian: No conflict of interest\|\|Lincango, Eddy: No conflict of interest\|\|Holubar, Stefan: No conflict of interest |

| | |
|---|---|
| P868 | Dr. Umeno, Junji: No conflict of interest\|\|Fuyuno, Yuta: No conflict of interest\|\|Torisu, Takehiro: No conflict of interest\|\|Matsuno, Yuichi: No conflict of interest\|\|Esaki, Motohiro: No conflict of interest\|\|Yanai, Shunichi: No conflict of interest\|\|Ohmiya, Naoki: No conflict of interest\|\|Hisamatsu, Tadakazu: No conflict of interest\|\|Watanabe, Kenji: No conflict of interest\|\|Hosoe, Naoki: No conflict of interest\|\|Ogata, Haruhiko: No conflict of interest\|\|Hirai, Fumihito: No conflict of interest\|\|Hisabe, Takashi: No conflict of interest\|\|Matsui, Toshiyuki: No conflict of interest\|\|Kitazono, Takanari: No conflict of interest\|\|Matsumoto, Takayuki: No conflict of interest |
| P869 | Mr. Rivera, Jesus: No conflict of interest\|\|López-Marte, Paola: No conflict of interest\|\|Vallejo-Tagle, Génesis: No conflict of interest\|\|Hernández-Torres, Julián: No conflict of interest\|\|Torres, Esther A.: No conflict of interest\|\|Viñas-Joy, Grace: No conflict of interest |
| P870 | Smolovic, Brigita: No conflict of interest\|\|Lukic, Milos: No conflict of interest\|\|Djurovic, Marija: No conflict of interest\|\|Muhovic, Damir: No conflict of interest\|\|Bojovic, Stefan: No conflict of interest |
| P871 | Mr. Bakkaloglu, Oguz Kagan: No conflict of interest\|\|Eskazan, Tugce: No conflict of interest\|\|Onal, Ugur: No conflict of interest\|\|Candan, Selcuk: No conflict of interest\|\|Balamir, Melek: No conflict of interest\|\|Kurt, Enes ali: No conflict of interest\|\|Hatemi, Ibrahim: No conflict of interest\|\|Erzin, Yusuf: No conflict of interest\|\|Celik, Aykut Ferhat: No conflict of interest |
| P872 | Hassan, Mosbah: No conflict of interest\|\|Dr. Ghersin, Itai: No conflict of interest |

| | |
|---|---|
| P874 | Dr. Indellicati, Giuseppe: No conflict of interest\|\|Rendina, Maria: No conflict of interest\|\|Todeschini, Alessia: No conflict of interest\|\|Lillo, Chiara: No conflict of interest\|\|Castellaneta, Antonino: No conflict of interest\|\|D'Uggento, Angela Maria: No conflict of interest\|\|Di Leo, Alfredo: No conflict of interest\|\|Principi, Mariabeatrice: No conflict of interest |
| P875 | Mr. Wewer, Mads Damsgaard:\|:\|\|This study was funded by an unrestricted grant by Bristol Meyers Squibb\|\|Salupere, Riina: No conflict of interest\|\|Kievit, Hendrika Adriana Linda: No conflict of interest\|\|Nielsen, Kári Rubek: No conflict of interest\|\|Midjord, Jóngerð: No conflict of interest\|\|Domislovic, Viktor: No conflict of interest\|\|Krznarić, Željko: No conflict of interest\|\|Pedersen, Natalia: No conflict of interest\|\|Jens, Kjeldsen: No conflict of interest\|\|Eriksson, Carl: No conflict of interest\|\|Halfvarson, Jonas: No conflict of interest\|\|Talbot, Alison: No conflict of interest\|\|Sebastian, Shaji: No conflict of interest\|\|Goldis, Adrian: No conflict of interest\|\|Misra, Ravi: No conflict of interest\|\|Arebi, Naila: No conflict of interest\|\|Ilus, Tuire: No conflict of interest\|\|Oksanen, Pia: No conflict of interest\|\|Neuman, Anders: No conflict of interest\|\|Andersen, Vibeke: No conflict of interest\|\|Skamnelos, Alexandros: No conflict of interest\|\|Katsanos, Konstantinos H.: No conflict of interest\|\|Negru, Iulian: No conflict of interest\|\|Turcan, Svetlana: No conflict of interest\|\|Borg, Bernard: No conflict of interest\|\|Ellul, Pierre: No conflict of interest\|\|Kupcinskas, Juozas: No conflict of interest\|\|Kiudelis, Gediminas: No conflict of interest\|\|Yzet, Clara: No conflict of interest\|\|Fumery, Mathurin: No conflict of interest\|\|Kaimakliotis, Ioannis P.: No conflict of interest\|\|Lorenzon, Greta: No conflict of interest\|\|D'Inca, Renata: No conflict of interest\|\|Hernandez, Vicent: No conflict of interest\|\|Fernandez, Alberto: No conflict of interest\|\|Langholz, Ebbe: No conflict of interest\|\|Munkholm, Pia: No conflict of interest\|\|Burisch, Johan: No conflict of interest |
| P876 | Dr. Jougon, Julia: No conflict of interest\|\|Leroyer, Ariane: No conflict of interest\|\|Wils, Pauline: No conflict of interest\|\|Guillon, Natalie: No conflict of interest\|\|Sarter, Helene: No conflict of interest\|\|Gower-Rousseau, Corinne: No conflict of interest\|\|Savoye, Guillaume: No conflict of interest\|\|Turck, Dominique: No conflict of interest\|\|Fumery, Mathurin: No conflict of interest\|\|Ley, Delphine: No conflict of interest |
| P877 | Prof. Dr. Kim, Hyun-Soo: No conflict of interest\|\|Kim, Hosook: No conflict of interest\|\|Kim, Kaeun: No conflict of interest |

| | |
|---|---|
| P878 | Dr. Selin, Katja Anneli: No conflict of interest\|\|Andersson, Sara:\|:\|S.A has received speaker fees from Ferring, Mylan, Tillots and consultancy fees from Ferring. None of these activities have any relation to the present study.\|\|Bilén, Katarina: No conflict of interest\|\|Strid, Hans: No conflict of interest\|\|Björk, Jan: No conflict of interest\|\|Bresso, Francesca:\|:\|F Bresso has acted as local principal investigator for clinical trials for Janssen, Ferring and Abbvie. None of these activities have any relation to the present study.\|\|Hedin, Charlotte:\|:\|C. R. H. Hedin has received speaker fees from Takeda, Ferring, AbbVie, and Janssen, and consultancy fees from Pfizer. She has acted as local principal investigator for clinical trials for Janssen and GlaxoSmithKline. She is PI on projects at the Karolinska Institutet partly funded by investigator-initiated grants from Takeda and Tillotts. None of these activities have any relation to the present study. |
| P879 | Dr. Cabrera-Moksnes, Claudia:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Fernandez-Llaneza, Daniel:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Neisen, Jessica:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Angermann, Bastian R.:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Gehrmann, Ulf:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Olsson, Marita:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Cairns, Junmei:\|:\|Employee of AstraZeneca and holds AZ stock.\|\|Powell, Nick:\|:\|Speaker, advisory consultant and/or research grants from: Abbvie, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Dr Falk Pharma UK Ltd, Ferring, Galapagos, Janssen, Roche, Pfizer, Sobi, Takeda, Tillotts and Vifor |
| P880 | Flanagan, Amanda: No conflict of interest\|\|Dr. O'Connor, Sam: No conflict of interest\|\|Allsop, Susan: No conflict of interest\|\|Tobin, Jacinta: No conflict of interest\|\|Pretorius, Casper: No conflict of interest\|\|Brown, Ian: No conflict of interest\|\|Bell, Sally: No conflict of interest\|\|Daveson, Alfred James: No conflict of interest |
| P881 | Mauriz Barreiro, Maria Violeta: No conflict of interest\|\|Ruano-Ravina, Alberto: No conflict of interest\|\|Ferreiro-Iglesias, Rocio: No conflict of interest\|\|Baston-Rey, Iria: No conflict of interest\|\|Porto-Silva, Sol: No conflict of interest\|\|Nieto-Garcia, Laura: No conflict of interest\|\|Martinez-Seara, Xurxo: No conflict of interest\|\|Martin-Gisbert, Lucia: No conflict of interest\|\|Dominguez-Munoz, J.Enrique: No conflict of interest\|\|Dr. Barreiro-de Acosta, Manuel: No conflict of interest |

| | |
|---|---|
| P882 | Dr. Anisdahl, Karoline:\|:\|The project has received funding from Takeda. KA reports personal fees from Takeda outside the submitted work.\|\|Lirhus, Sandre S.:\|:\|SSL reports grants and consultant fees from Takeda. \|\|Medhus, Asle W.: No conflict of interest\|\|Moum, Bjørn:\|:\|BM reports consultant fees from Takeda, Janssen, AbbVie, Pfizer; advisory board Takeda, Janssen, AbbVie, Pfizer, Sandoz, Pharma Cosmos; speaker fees from Takeda, Janssen, AbbVie, Sandoz, Orion Pharma.\|\|Melberg, Hans Olav:\|:\|HOM reports grants and consultant fees from Takeda.\|\|Høivik, Marte L.:\|:\|MLH has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma |
| P883 | Mallon, Kristian: No conflict of interest\|\|Ms. Mcbride, Ciara: No conflict of interest\|\|Doherty, Glen: No conflict of interest\|\|Burns, Richéal: No conflict of interest |
| P884 | Mrs. Esmingeaud, Léa: No conflict of interest\|\|Jantchou, Prévost: No conflict of interest\|\|Nicolau, Belinda: No conflict of interest\|\|Madathil, Sreenath: No conflict of interest\|\|Rousseau, Marie-Claude: No conflict of interest |
| P885 | Ms. Kim, Bohyoung: No conflict of interest\|\|Sung Hoon, Jung: No conflict of interest\|\|Jiyoung, Lim: No conflict of interest |
| P886 | Dr. De Castro Parga, Maria Luisa: No conflict of interest\|\|Dagraza, María: No conflict of interest\|\|Hernández, Vicent: No conflict of interest\|\|García-Morales, Natalia: No conflict of interest\|\|Pineda, Juan R: No conflict of interest\|\|Rodriguez-Prada, Ignacio: No conflict of interest |

| | |
|---|---|
| P887 | McKay, Caroline:\|:\|CM is currently an employee and shareholder in Takeda and a shareholder in Merck and Johnson & Johnson\|\|Pacis, Scarlette:\|:\|SB is an employee of Cytel. Cytel's work was financially supported by Takeda Pharmaceuticals USA\|\|Bolzani, Anna:\|:\|AB is an employee of Cytel. Cytel's work was financially supported by Takeda Pharmaceuticals USA\|\|Geransar, Parnia:\|:\|PG is an employee and shareholder of Takeda Pharmaceuticals\|\|Panés, Julian:\|:\|JP received financial support for research from AbbVie and Pfizer consultancy fees/honorarium from AbbVie, Arena, Athos, Atomwise, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GlaxoSmithKline, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Takeda, Theravance and Wasserman reports payment for lectures including service on speaker bureau from Abbott, Ferring, Janssen, Pfizer and Takeda and reports payment for development of educational presentations from Abbott, Janssen, Pfizer Roche and Takeda. |
| P888 | Ms. Jang, Minyoung: No conflict of interest\|\|Yoo, HyunKyeong: No conflict of interest\|\|Kwon, Taeksang: No conflict of interest |
| P889 | Dr. Rodríguez-Lago, Iago: No conflict of interest\|\|Cabriada, José Luis: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest |
| P890 | Dr. Marino, Marco:\|:\|Takeda, Janseen, Sofar, Galapagos\|\|Sigura, Elena: No conflict of interest\|\|Castagnaviz, Eleonora: No conflict of interest\|\|Dottor, Francesca: No conflict of interest\|\|Colombo, Anna: No conflict of interest\|\|Solito, Sonia: No conflict of interest\|\|Terrosu, Giovanni:\|:\|Sofar\|\|Buda, Andrea:\|:\|Takeda, Galapagos\|\|Berretti, Debora: No conflict of interest |
| P891 | Ms. Karachaliou, Alexandra: No conflict of interest\|\|Yannakoulia, Mary: No conflict of interest\|\|Bletsa, Maria: No conflict of interest\|\|Mantzaris, Gerassimos J.: No conflict of interest\|\|Tzouvala, Maria: No conflict of interest\|\|Bamias, Giorgos: No conflict of interest\|\|Kontogianni, Meropi D.: No conflict of interest |

| | |
|---|---|
| P892 | Prof. Na, Soo-Young: No conflict of interest\|\|Choi, Hwang: No conflict of interest\|\|Ji, Jeong-Seon: No conflict of interest\|\|Kim, Sang-Yong: No conflict of interest |
| P893 | Ms. Yoo, Hyun Kyeong: No conflict of interest\|\|Jang, Min Young: No conflict of interest\|\|Kwon, Taek Sang: No conflict of interest |
| P894 | Huang, Vivian: No conflict of interest\|\|Albadrani, Ahmed: No conflict of interest\|\|Dr. Alshowair, Mishal: No conflict of interest |
| P895 | Dr. Straume, Zane: No conflict of interest\|\|Krūmiņa, Nikola: No conflict of interest\|\|Ozoliņa, Juliana: No conflict of interest\|\|Krūmiņa, Angelika: No conflict of interest\|\|Skuja, Vita: No conflict of interest |
| P896 | Dr. Elwood, Shane: No conflict of interest\|\|Clarke, Maeve: No conflict of interest\|\|Lukose, Tincy: No conflict of interest\|\|Lardner, Caroline: No conflict of interest\|\|Mc Gettigan, Neasa: No conflict of interest\|\|Boland, Karen: No conflict of interest\|\|Patchett, Stephen: No conflict of interest |
| P897 | Mr. Cervera Seco, Luis Manuel: No conflict of interest\|\|Sánchez Mayor, Milagros: No conflict of interest\|\|Corraliza, Ana Maria: No conflict of interest\|\|Salas, Azucena: No conflict of interest\|\|Panés, Julian: No conflict of interest\|\|M. Marigorta, Urko: No conflict of interest |

| | |
|---|---|
| P898 | Mr. Gaite, Adrian: No conflict of interest\|\|Sánchez-Mayor, Milagros: No conflict of interest\|\|Bujanda, Luis: No conflict of interest\|\|M. Marigorta, Urko: No conflict of interest |
| P899 | Dr. Leibovitzh, Haim: No conflict of interest\|\|Neustaeter, Anna: No conflict of interest\|\|Lee, Sun-Ho: No conflict of interest\|\|Xue, Mingyue: No conflict of interest\|\|Espin-Garcia, Osvaldo: No conflict of interest\|\|Olivera, Pablo A.: No conflict of interest\|\|Mbareche, Hamza: No conflict of interest\|\|Huynh, Hien Q.: No conflict of interest\|\|Griffiths, Anne M.: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|Madsen, Karen L.: No conflict of interest\|\|Silverberg, Mark S.: No conflict of interest\|\|Steinhart, A. Hillary: No conflict of interest\|\|Mack, David R.: No conflict of interest\|\|Jacobson, Kevan: No conflict of interest\|\|Moayyedi, Paul: No conflict of interest\|\|Aumais, Guy: No conflict of interest\|\|Bernstein, Charles N.: No conflict of interest\|\|Marshall, John K.: No conflict of interest\|\|Panaccione, Remo: No conflict of interest\|\|Xu, Wei: No conflict of interest\|\|Turpin, Williams: No conflict of interest\|\|Croitoru, Kenneth: No conflict of interest |
| P900 | Mr. Miguel González, Juan Antonio: No conflict of interest\|\|Sánchez Mayor, Milagros: No conflict of interest\|\|Cervera Seco, Luis Manuel: No conflict of interest\|\|Gaite Reguero, Adrián: No conflict of interest\|\|Pavlidis, Polychronis: No conflict of interest\|\|Martínez Marigorta, Urko: No conflict of interest |

| | |
|---|---|
| P901 | Ms. Jans, Deborah: No conflict of interest\|\|Lee, Ho-Su: No conflict of interest\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|Marc Ferrante is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Cleynen, Isabelle: No conflict of interest |
| P902 | Dr. Pérez, Tamara: No conflict of interest\|\|Bustamante, Maria Leonor: No conflict of interest\|\|Magne, Fabien: No conflict of interest\|\|Travisany, Dante: No conflict of interest\|\|Alvarez-Lobos, Manuel: No conflict of interest\|\|Hernandez-Rocha, Cristian: No conflict of interest\|\|Azocar, Lorena: No conflict of interest\|\|Aguilar, Nataly: No conflict of interest\|\|Espino, Alberto: No conflict of interest\|\|Estela, Ricardo: No conflict of interest\|\|Escobar, Sergio: No conflict of interest\|\|Zazueta, Alejandra: No conflict of interest\|\|Baez, Pablo: No conflict of interest\|\|Silva, Veronica: No conflict of interest\|\|Arriagada, Elizabeth: No conflict of interest\|\|Barahona, Carol: No conflict of interest\|\|Zollner, Linda: No conflict of interest\|\|Miquel , Juan Francisco: No conflict of interest\|\|Lorenzo-Bermejo, Justo: No conflict of interest |
| P903 | Dr. Garcia-Etxebarria, Koldo: No conflict of interest\|\|Merino, Olga: No conflict of interest\|\|Ezcurra, Ander: No conflict of interest\|\|Segues, Nerea: No conflict of interest\|\|Arzallus, Teresa: No conflict of interest\|\|Marigorta, Urko M.: No conflict of interest\|\|Vignau, Raquel: No conflict of interest\|\|Bujanda, Luis: No conflict of interest |

| | |
|---|---|
| P904 | Dr. Pérez, Tamara: No conflict of interest\|\|Bustamante, Maria Leonor: No conflict of interest\|\|Travisany, Dante: No conflict of interest\|\|Magne, Fabien: No conflict of interest\|\|Hernandez-Rocha, Cristian: No conflict of interest\|\|Alvarez-Lobos, Manuel: No conflict of interest\|\|Orellana, Matias: No conflict of interest\|\|Ascui, Gabriel: No conflict of interest\|\|Azocar, Lorena: No conflict of interest\|\|Espino, Alberto: No conflict of interest\|\|Aguilar, Nataly: No conflict of interest\|\|Baez, Pablo: No conflict of interest\|\|Zazueta, Alejandra: No conflict of interest\|\|Estela, Ricardo: No conflict of interest\|\|Silva, Veronica: No conflict of interest\|\|Escobar, Sergio: No conflict of interest\|\|De la Vega, Andres: No conflict of interest\|\|Arriagada, Elizabeth: No conflict of interest\|\|Miquel, Juan Francisco: No conflict of interest\|\|Alvares, Danilo: No conflict of interest |
| P905 | Dr. Guerra Marina, Ivan: No conflict of interest\|\|Barros, Francisco: No conflict of interest\|\|Chaparro, María: No conflict of interest\|\|Benítez, José M.: No conflict of interest\|\|Martín Arranz, María Dolores: No conflict of interest\|\|de Francisco, Ruth: No conflict of interest\|\|Piqueras, Marta: No conflict of interest\|\|de Castro, Luisa: No conflict of interest\|\|Carbajo, Ana Y.: No conflict of interest\|\|Bermejo, Fernando: No conflict of interest\|\|Mínguez, Miguel: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Cañete, Fiorella: No conflict of interest\|\|González-Muñoza, Carlos: No conflict of interest\|\|Calvo, Marta: No conflict of interest\|\|Sicilia, Beatriz: No conflict of interest\|\|Alfambra, Erika: No conflict of interest\|\|Tardillo, Carlos A.: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Lucendo, Alfredo J.: No conflict of interest\|\|Bujanda, Luis: No conflict of interest\|\|Van Domselaar, Manuel: No conflict of interest\|\|Almela, Pedro: No conflict of interest\|\|Ramos, Laura: No conflict of interest\|\|Fernández Sánchez, María: No conflict of interest\|\|Hinojosa, Esther: No conflict of interest\|\|Verdejo, Cristina: No conflict of interest\|\|Gimenez, Anna: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Manceñido, Noemí: No conflict of interest\|\|Pérez Calle, José L.: No conflict of interest\|\|Moreno, Mónica del Pilar: No conflict of interest\|\|Delgado-Guillena, Pedro Genaro: No conflict of interest\|\|Antolín, Beatriz: No conflict of interest\|\|Ramírez de la Piscina, Patricia: No conflict of interest\|\|Casanova, María José: No conflict of interest\|\|Carracedo, Ángel: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|Gisbert, Javier P.: No conflict of interest |

| | |
|---|---|
| P906 | Dr. Pérez, Tamara: No conflict of interest\|\|Bustamante, Maria Leonor: No conflict of interest\|\|Magne, Fabien: No conflict of interest\|\|Alvares, Danilo: No conflict of interest\|\|Álvarez-Lobos, Manuel: No conflict of interest\|\|Hernandez-Rocha, Cristian: No conflict of interest\|\|Aguliar, Nataly: No conflict of interest\|\|Azocar, Lorena: No conflict of interest\|\|Baez, Pablo: No conflict of interest\|\|Zazueta, Alejandra: No conflict of interest\|\|Estela, Ricardo: No conflict of interest\|\|Escobar, Sergio: No conflict of interest\|\|Silva, Verónica: No conflict of interest\|\|De la Vega, Andres: No conflict of interest\|\|Arriagada, Elizabeth: No conflict of interest\|\|Espino, Alberto: No conflict of interest\|\|Miquel, Juan Francisco: No conflict of interest\|\|Travisany, Dante: No conflict of interest |
| P907 | Behnisch, Susanne: No conflict of interest\|\|Reiner, Johannes: No conflict of interest\|\|Witte, Maria: No conflict of interest\|\|Holle, Albrecht: No conflict of interest\|\|Schäffler, Holger: No conflict of interest\|\|Huth, Astrid: No conflict of interest\|\|Jaster, Robert: No conflict of interest\|\|Lamprecht, Georg: No conflict of interest |
| P908 | Ms. Markandey, Manasvini: No conflict of interest\|\|Bajaj, Aditya: No conflict of interest\|\|Verma, Mahak: No conflict of interest\|\|Virmani, Shubi: No conflict of interest\|\|Singh, Mukesh: No conflict of interest\|\|Gaur, Preksha: No conflict of interest\|\|Das, Prasenjit: No conflict of interest\|\|Srikanth, Chittur: No conflict of interest\|\|Makharia, Govind: No conflict of interest\|\|Kedia, Saurabh: No conflict of interest\|\|Ahuja, Vineet: No conflict of interest |
| P909 | Binyamin, Dana: No conflict of interest\|\|Turjeman, Sondra: No conflict of interest\|\|Koren, Omry: No conflict of interest\|\|Ben Ya'acov, Ami: No conflict of interest\|\|Gold, Gila: No conflict of interest\|\|Goldenberg, Rosalind: No conflict of interest\|\|Bar-Gil Shitrit, Ariella: No conflict of interest |
| P910 | Prof. Dr. Lopetuso, Loris Riccardo: No conflict of interest\|\|Vetrone, Lorenzo: No conflict of interest\|\|Petito, Valentina: No conflict of interest\|\|Pugliese, Daniela: No conflict of interest\|\|Parisio, Laura: No conflict of interest\|\|Laterza, Lucrezia: No conflict of interest\|\|Gasbarrini, Antonio: No conflict of interest\|\|Scaldaferri, Franco: No conflict of interest\|\|Papa, Alfredo: No conflict of interest |

| | |
|---|---|
| P911 | Mr. Hurych, Jakub: No conflict of interest\|\|Mascellani Bergo, Anna: No conflict of interest\|\|Lerchová, Tereza: No conflict of interest\|\|Hlináková, Lucie: No conflict of interest\|\|Kubát , Michal: No conflict of interest\|\|Malcová, Hana: No conflict of interest\|\|Cebecauerová, Dita: No conflict of interest\|\|Schwarz, Jan: No conflict of interest\|\|Karásková, Eva: No conflict of interest\|\|Hecht, Tomáš: No conflict of interest\|\|Vyhnánek, Radim: No conflict of interest\|\|Ťoukálková, Lenka: No conflict of interest\|\|Dotlačil, Vojtěch: No conflict of interest\|\|Kobrová, Kateřina: No conflict of interest\|\|Čížková, Anabela: No conflict of interest\|\|Horváth, Rudolf: No conflict of interest\|\|Bronsky, Jiří: No conflict of interest\|\|Havlík, Jaroslav: No conflict of interest\|\|Hradský, Ondřej:\|:\|O. Hradsky received payment for for lectures from MSD, Abbvie, Nestlé, Nutricia, Sandoz; neither of the lectures was related to the subject of the study\|\|Cinek, Ondřej: No conflict of interest |
| P912 | Dr. Battat, Robert:\|:\|Research Support: Weill Cornell Medicine Fund for the Future. Consulting: Prometheus Laboratories, Bristol Myers Squibb \|\|Scherl, Ellen:\|:\|Grant/Research Support: Abbott (AbbVie), AstraZeneca, CCFA, Janssen Research & Development, Johns Hopkins University, , National Institute of Diabetes and Digestive and Kidney (NIDDK), National Institute of Health (NIH), New York Crohn's Foundation, Pfizer, UCB, UCSF–CCFA Clinical Research Alliance, Genentech. Seres Therapeutics, Celgene Corporation Consultant/Advisory Board: AbbVie, Crohn's and Colitis Foundation of America (CCFA), Entera Health, Evidera, GI Health Foundation, Janssen, Protagonist Therapeutics, Seres Health, Takeda Pharmaceuticals, Bristol Myers Squibb\|Stock Shareholder: Gilead Honoraria: GIHealth Foundation for non-branded speaker's bureau, Janssen for nonbranded speaker's bureau \|\|Lukin, Dana:\|:\|Consulting: Abbvie, BI, BMS, Eli Lilly, Janssen, Palatin Technologies, Pfizer Speaking: Abbvie Grants: Abbvie, Janssen, Takeda, Kenneth Rainin Foundation\|\|Charilaou, Paris: No conflict of interest\|\|Mahtani, Prerna: No conflict of interest\|\|Gerber, Juliette: No conflict of interest\|\|Gandara, Jorge: No conflict of interest\|\|Dündar, Friederike: No conflict of interest\|\|Zumbo , Paul: No conflict of interest\|\|Betel , Doron: No conflict of interest\|\|Guo , Chun-Jun: No conflict of interest\|\|Longman, Randy:\|:\|Consultant, Pfizer, ancilia SAB. research support: National Institute of Diabetes and Digestive and Kidney (NIDDK), National Institute of Health (NIH) |
| P913 | Prof. Dr. Eun, Chang Soo: No conflict of interest\|\|Oh, Eun Hye: No conflict of interest\|\|Lee, A-Reum: No conflict of interest\|\|Park, Chan Hyuk: No conflict of interest\|\|Han , Dong Soo: No conflict of interest |
| P914 | Dr. Nag, Dhrubajyoti: No conflict of interest\|\|Raychaudhuri, Saumya: No conflict of interest\|\|Withey, Jeffrey: No conflict of interest |

| | |
|---|---|
| P915 | Singh, Parul: No conflict of interest\|\|Murugesan, Selvasankar: No conflict of interest\|\|Kumar, Manoj: No conflict of interest\|\|Saadaoui, Marwa: No conflict of interest\|\|Elhag, Duaa Ahmed: No conflict of interest\|\|Hendaus, Mohamed A: No conflict of interest\|\|Ibrahim, Nazira: No conflict of interest\|\|Al-Mudhaka, Fatma: No conflict of interest\|\|AbuHazima, Khaled: No conflict of interest\|\|Akobeng, Anthony: No conflict of interest\|\|Elawad , Mamoun: No conflict of interest\|\|Dr. Al Khodor, Souhaila: No conflict of interest |
| P916 | Ms. Verburgt, Charlotte: No conflict of interest\|\|Dunn, Katherine: No conflict of interest\|\|Sigall Boneh, Rotem: No conflict of interest\|\|Wine, Eytan: No conflict of interest\|\|Benninga, Marc: No conflict of interest\|\|de Jonge, Wouter: No conflict of interest\|\|Van Limbergen, Johan: No conflict of interest |
| P917 | Dr. Reider, Simon: No conflict of interest\|\|Posch, Wilfried: No conflict of interest\|\|Koch, Robert: No conflict of interest\|\|Orth-Höller, Dorothee: No conflict of interest\|\|Würzner, Reinhard: No conflict of interest\|\|Wilflingseder, Doris: No conflict of interest\|\|Tilg, Herbert: No conflict of interest\|\|Moschen, Alexander: No conflict of interest |
| P918 | Dr. Zhang, Kexin: No conflict of interest\|\|Dong, Yue: No conflict of interest\|\|Li, Mengfan: No conflict of interest\|\|Zhang, Wanru: No conflict of interest\|\|Ding, Yiyun: No conflict of interest\|\|Wang, Xin: No conflict of interest\|\|Chen, Danfneg: No conflict of interest\|\|Liu, Tianyu: No conflict of interest\|\|Wang, Bangmao: No conflict of interest\|\|Zhong, Weilong: No conflict of interest\|\|Cao, Hailong: No conflict of interest |
| P919 | Dr. Lee, Chang Kyun: No conflict of interest\|\|Oh, Shin Ju: No conflict of interest\|\|Kim, Hyo Jong: No conflict of interest\|\|Kim, Bo-Hyung: No conflict of interest\|\|Kim, Byung Kwon: No conflict of interest\|\|Park, Young-Kyu: No conflict of interest\|\|Yang, Bo-Gie: No conflict of interest |

| | |
|---|---|
| P920 | Mr. Hyll Hansen, Simen: No conflict of interest\|\|Gjerstad Maseng, Maria: No conflict of interest\|\|Björkqvist, Olle: No conflict of interest\|\|Halfvarsson, Jonas:\|:\|Has received personal fees as speaker and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB and received grant support from Janssen, MSD and Takeda.\|\|\|Bang, Corinna: No conflict of interest\|\|Detlie, Trond Espen:\|:\|Personal fees from Ferring, personal fees from Tillotts, personal fees from Pharmacosmos, personal fees from Vifor Pharma.\|\|\|Huppertz-Hauss, Gert: No conflict of interest\|\|Kristensen, Vendel:\|:\|Has served as speaker, consultant, and advisory member for or has received investigator inititated research funding from Takeda, Janssen, Ferring and Tillotts Pharma\|\|\|Opheim, Randi: No conflict of interest\|\|Perminow, Gøri: No conflict of interest\|\|Asak, Øivind: No conflict of interest\|\|Bengtson, May-Bente: No conflict of interest\|\|Boyar Cetinkaya, Raziye: No conflict of interest\|\|Henriksen, Magne: No conflict of interest\|\|Hovde, Øistein: No conflict of interest\|\|Medhus, Asle Wilhelm:\|:\|Unrestricted research grant from Takeda.\|\|\|Pallenschat, Jens: No conflict of interest\|\|Strande, Vibeke: No conflict of interest\|\|Valeur, Jørgen: No conflict of interest\|\|Svendsen Vatn, Simen: No conflict of interest\|\|Bergene Aabrekk, Tone: No conflict of interest\|\|Høivik, Marte Lie:\|:\|Dr. Høivik has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Gilead/Galapagos, Ferring and Tillotts Pharma.\|\|Hov, Johannes Roksund: No conflict of interest |

| | |
|---|---|
| P921 | Ms. Deleu, Sara: No conflict of interest\|\|Caenepeel , Clara: No conflict of interest\|\|Verstockt, Sare: No conflict of interest\|\|Vazquez Castellanos, Jorge Francisco: No conflict of interest\|\|Arnauts , Kaline: No conflict of interest\|\|Braekeleire, Sara: No conflict of interest\|\|Machiels, Kathleen:\|:\|Postdoctoral fellow of the Fund for Scientific Research-Flanders, Belgium (FWO-Vlaanderen) until 5/01/2021. Pfizer Medical advisor employee in inflammation and immunology since 5/01/2021.\|\|Baert, Filip:\|:\|Filip Baert Has a financial interest/relationship or affiliation in the form of: Grant/Research Support from AbbVie Inc.; Amgen Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited. Speakers Bureau participant with AbbVie Inc.; Ferring Holding SA; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; and Takeda Pharmaceutical Company Limited. Honoraria from AbbVie Inc.; Amgen Inc.; Arena Pharmaceuticals, Inc.; Celgene Corporation; Ferring Holding SA; Fresenius Kabi AG; Galapagos Inc Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Pfizer Inc.; and Takeda Pharmaceutical Company Limited.\|\|Mana, Fazia: No conflict of interest\|\|Pouillon, Lieven:\|:\|Lieven Pouillon received advisory board fees from Celltrion, Galápagos, Janssen-Cilag, Sandoz and Takeda; consultancy fees from Ismar Healthcare funded by Viatris; presentation fees from AbbVie, Celltrion, Ferring and Galápagos; and personal fees (congress support) from AbbVie, Galápagos, Ferring, Norgine and Takeda.\|\|Hindryckx, Pieter: No conflict of interest\|\|Lobaton Ortega, Triana: No conflict of interest\|\|Louis, Edouard:\|:\|Research grant: Janssen, Pfizer, Ferring, Falk, Abbvie and Takeda; educational grant: AbbVie, Janssen, Fresenius-Kabi and Takeda; speaker fees: Abbvie, Falk, Ferring, Janssen, Pfizer, Galapagos and Takeda; advisory board: Abbvie, Celgene, Ferring, Janssen, BMS, Pfizer, and Takeda, Galapagos, Gilead, Arena, Elli Lilly; consultant: Abbvie\|\|Franchimont, Denis:\|:\|Denis Franchimont receives financial support for research from AbbVie, J&J, Takeda, Celltrion, and Amgen; receives speaker or consultancy fee from AbbVie, AstraZeneca, Dr Falk Pharma, Ferring, J&J, Mundipharma, MSD, Pfizer, Takeda, and Amgen.\|\|Verstockt , Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris.\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer |

| | |
|---|---|
| | Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|Marc Ferrante is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|\|Sabino, João:\|:\|João Sabino receives financial support for research from Galapagos and Viatris; receives speakers' fees from Pfizer, Abbvie, Ferring, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Ferring, Fresenius, Abbvie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia.\|João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|\|Vieira-Silva, Sara: No conflict of interest\|\|Falony, Gwen: No conflict of interest\|\|Raes, Jeroen:\|:\|Consulting and/or speaking fees: Yakult, Tsumura, Dr Falk Pharma, GSK, MRM health, Biofortis, Ferring, Merck, Nutricia, Takeda, Janssen Pharmaceuticals.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. |
| P922 | Ms. Yu, Si: No conflict of interest\|\|Ge, Xaomeng: No conflict of interest\|\|Tan, Bei: No conflict of interest\|\|Tian, Bowen: No conflict of interest\|\|Shi, Yujie: No conflict of interest\|\|Dai, Yimin: No conflict of interest\|\|Hu, Songnian: No conflict of interest\|\|Li, Yue: No conflict of interest\|\|Qian, Jiaming: No conflict of interest |
| P923 | Dr. Rimmer, Peter: No conflict of interest\|\|Cheesbrough, Jonathan: No conflict of interest\|\|Iqbal, Asif: No conflict of interest\|\|Sharma, Naveen: No conflict of interest\|\|Iqbal, Tariq: No conflict of interest\|\|Quraishi, Nabil: No conflict of interest |
| P924 | Raghunathan, Nalini: No conflict of interest\|\|Joshi, Varun: No conflict of interest\|\|Patel, Rajendra: No conflict of interest\|\|Mekala, Dhanush: No conflict of interest\|\|Pal, Partha: No conflict of interest\|\|Dr. Banerjee, Rupa: No conflict of interest |

| | |
|---|---|
| P925 | Teh, Jing Jie: No conflict of interest\|\|Kang, Seungha: No conflict of interest\|\|Zhang, Jingwan: No conflict of interest\|\|Hu, Jielun: No conflict of interest\|\|Hamilton, Amy L.: No conflict of interest\|\|Wilson-O'Brien, Amy: No conflict of interest\|\|Trakman, Gina L.: No conflict of interest\|\|Lin, Winnie: No conflict of interest\|\|Ching, Jessica: No conflict of interest\|\|Sung, Joseph J.Y.: No conflict of interest\|\|Yu, Jun: No conflict of interest\|\|Ng, Siew C.: No conflict of interest\|\|Kamm, Michael Albert: No conflict of interest\|\|Prof. Morrison, Mark: No conflict of interest |
| P926 | Dr. Lee, Chanhyung: No conflict of interest\|\|Koh, Seong-Joon: No conflict of interest\|\|Hong, Hyun Taek: No conflict of interest\|\|Park, Hyunsun: No conflict of interest\|\|Im, Jong Pil: No conflict of interest\|\|Kim, Joo Sung: No conflict of interest |
| P927 | Singh , Parul: No conflict of interest\|\|Sundararajan, Saraswathi: No conflict of interest\|\|Terranegra, Annalisa: No conflict of interest\|\|Elawad, Mamoun: No conflict of interest\|\|Akobeng, Anthony: No conflict of interest\|\|Dr. Al Khodor, Souhaila: No conflict of interest |
| P928 | Namjoo, Kim: No conflict of interest\|\|Prof. Beom Jae , Lee: No conflict of interest\|\|Jeong-An , Gim: No conflict of interest\|\|Seung Han, Kim: No conflict of interest\|\|Moon Kyung , Joo: No conflict of interest\|\|Jong-Jae , Park: No conflict of interest |
| P929 | Mrs. Ventin-Holmberg, Rebecka: No conflict of interest\|\|Lindholm, Julia: No conflict of interest\|\|Eberl, Anja: No conflict of interest\|\|Taina, Sipponen: No conflict of interest\|\|Saavalainen, Päivi: No conflict of interest |

| | |
|---|---|
| OP01 | Ms. Verstockt, Sare:\|:\|Sare Verstockt is postdoctoral fellow of the Research foundation – Flanders (FWO), Belgium.\|\|Machiels, Kathleen:\|:\|Kathleen Machiels: postdoctoral fellow of the Fund for Scientific Research-Flanders, Belgium (FWO-Vlaanderen) until 5/01/2021. Pfizer Medical advisor employee in inflammation and immunology since 5/01/2021.\|\|Dehairs, Jonas: No conflict of interest\|\|Rems, Kirsten: No conflict of interest\|\|De Greef, Ine: No conflict of interest\|\|Jans, Deborah: No conflict of interest\|\|Sabino, João:\|:\|João Sabino receives financial support for research from Galapagos; receives speakers' fees from Abbvie, Falk, Takeda, Janssen, and Fresenius; and does consultancy for Janssen, Ferring.\|\|João Sabino is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|\|Ferrante, Marc:\|:\|Marc Ferrante receives financial support for research from AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris; receive speakers' fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare and Viatris; and does consultancy for AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda and ThermoFisher.\|Marc Ferrante is a senior clinical investigator of the Research foundation – Flanders (FWO), Belgium.\|\|Vermeire, Séverine:\|:\|Séverine Vermeire receives financial support for research from AbbVie, J&J, Pfizer, Takeda and Galapagos; receives speakers' and consultancy fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma.\|\|Séverine Vermeire holds a BOF-FKO from the KU Leuven.\|\|\|Verstockt, Bram:\|:\|Bram Verstockt receives financial support for research from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; receives speakers' fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; and does consultancy for Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. |
| OP02 | Mr. Pierre, Nicolas: No conflict of interest\|\|Huynh-Thu, Vân Anh: No conflict of interest\|\|Baiwir, Dominique: No conflict of interest\|\|Mazzucchelli, Gabriel: No conflict of interest\|\|Fléron, Maximilien: No conflict of interest\|\|Trzpiot, Lisette: No conflict of interest\|\|Eppe, Gauthier: No conflict of interest\|\|Laharie, David: No conflict of interest\|\|Satsangi, Jack: No conflict of interest\|\|Colombel, Jean-Frédéric: No conflict of interest\|\|Hertervig, Erik: No conflict of interest\|\|Meuwis, Marie-Alice: No conflict of interest\|\|Louis, Edouard: No conflict of interest |

| | |
|---|---|
| OP03 | Mr. Joustra, Vincent:\|:\|Received speaker fees from Janssen Pharmaceutical N.V and Ltd. China\|\|Li Yim, Andrew: No conflict of interest\|\|Hageman, Ishtu: No conflict of interest\|\|Levin, Evgeni: No conflict of interest\|\|Noble, Alexandra: No conflict of interest\|\|Chapman, Thomas: No conflict of interest\|\|McGregor, Colleen: No conflict of interest\|\|Adams, Alex: No conflict of interest\|\|Satsangi, Jack:\|:\|Lecture fees from Roche. Research funding from the Helmsley Trust, European Commission, ECCO, Action Medical Research, Crohn's Colitis UK. Director UK IBD Registry.\|\|de Jonge, Wouter: No conflict of interest\|\|Henneman, Peter: No conflict of interest\|\|D'Haens, Geert:\|:\|reports being a consultant or speaker for AbbVie, Alimentiv, Boehringer Ingelheim, Celltrion, , Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Janssen, Lilly, MSD, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Progenity, Takeda, Tillotts, |
| OP04 | Vermeire, Séverine:\|:\|S. Vermeire has received grants from AbbVie, Galapagos, Johnson & Johnson, Pfizer and Takeda; and consulting and/or speaking fees from AbbVie, Abivax, Alimentiv (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Avaxia, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, Hospira, Janssen, MSD, Mundipharma, Pfizer, Prodigest, Progenity, Prometheus, Second Genome, Shire, Takeda, Theravance and Tillotts Pharma AG.\|\|Danese, Silvio:\|:\|S. Danese served as speaker, consultant and/or advisory board member for AbbVie, Allergan, Alfa Wassermann, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Johnson and Johnson, Merck, MSD, Mundipharma, Pfizer, Sandoz, Takeda, Tigenix, UCB Pharma and Vifor.\|\|Hébuterne, Xavier:\|:\|X. Hébuterne reports clinical research funding from AbbVie, Abivax, Alphasigma, Arena, Eli Lilly, Enterome, Fresenius-Kabi, Gilead, Janssen, InDex Pharmaceuticals, Pfizer, Prometheus Biosciences, Sangamo, Takeda and Theravance; serving on advisory boards for AbbVie, Abivax, Boehringer Ingelheim, Celltrion, Fresenius-Kabi, Galapagos, Janssen, Nestlé Health Sciences, Nordic Pharma and Viatris; and participating in lectures and educational activities for AbbVie, Amgen, Celltrion, Fresenius-Kabi, Janssen, MSD, Nordic Pharma, Nestlé Health Sciences, Nutricia, Pfizer, Takeda, Tillots and Viatris.\|\|D'Haens, Geert:\|:\|G. D'Haens has received consulting and/or lecture fees from AbbVie, ActoGeniX, AIM, Boehringer Ingelheim, Centocor, ChemoCentryx, Cosmo Technologies, Dr Falk Pharma, Elan Pharmaceuticals, enGene, Ferring, Galapagos, Giuliani SpA, Given Imaging, GlaxoSmithKline, Janssen, MSD, Neovacs, Novo Nordisk, Otsuka, PDL BioPharma, Pfizer, Receptos, Salix, SetPoint, Shire, Schering-Plough, Takeda, Tillotts, UCB Pharma, Versant and Vifor Pharma; research grants from AbbVie, Dr Falk Pharma, Given Imaging, Janssen, MSD and PhotoPill; and speaking honoraria from AbbVie, Ferring, MSD, Norgine, Shire, Tillotts, Tramedico and UCB Pharma.\|\|Takeuchi, Ken:\|:\|K. Takeuchi has received consulting fees from Thermo Fisher Diagnostics K.K.; has received research grants from AbbVie and Takeda; and served as a speaker for AbbVie, Celltrion, EA pharma, Janssen, Kyorin, Mochida, Takeda, Tanabe Mitsubishi and Zeria.\|\|Finney-Hayward, Tricia:\|:\|T. Finney-Hayward is an employee of AbbVie and may own stock and/or options. \|\|Klaff, Justin:\|:\|J. Klaff is an employee of AbbVie and may own stock and/or options. \|\|Holweg, Cecile T.J.:\|:\|C.T.J. Holweg is an employee of AbbVie and may own stock and/or options. \|\|Rubin, David T.:\|:\|D. Rubin has received research funding from Takeda, and has served as a consultant to AbbVie, Abgenomics, Allergan, Inc., Arena Pharmaceuticals, Biomica, Bristol Myers Squibb, Dizal Pharmaceuticals, Eli Lilly, Ferring, Genentech/Roche, Janssen, Mahana Therapeutics, Medtronic, Merck & Co., Inc, Napo Pharmaceuticals, Pfizer, Prometheus Laboratories, Shire, Takeda and Target PharmaSolutions, Inc and is a co-founder of Cornerstones Health, Inc. |

| | |
|---|---|
| | |
| OP05 | Ms. Pibiri, Paola:\|:\|study funded by Takeda\|\|Sun, Shiqiang:\|:\|study funded by Takeda\|\|Karmi, Naomi:\|:\|study funded by Takeda\|\|Oelen, Roy:\|:\|study funded by Takeda\|\|de Jong, Sofie:\|:\|study funded by Takeda\|\|Bangma, Amber:\|:\|study funded by Takeda\|\|Hermoso, Marcela:\|:\|study funded by Takeda\|\|Paraskevopoulou, Maria:\|:\|Employee of Takeda\|\|Farahmand, Saman:\|:\|Employee of Takeda\|\|Weersma, Rinse:\|:\|study funded by Takeda\|\|Bigaeva, Emilia:\|:\|study funded by Takeda\|\|Festen, Eleonora:\|:\|study funded by Takeda\|\|Xia, Guliang:\|:\|Employee of Takeda\|\|Teunis, Johan:\|:\|study funded by Takeda\|\|Bleck, Bertram:\|:\|Employee of Takeda |
| OP06 | Dr. Jha, Divya: No conflict of interest\|\|Al-Taie, Zainab: No conflict of interest\|\|Krek, Azra: No conflict of interest\|\|Eshghi, Shadi: No conflict of interest\|\|Tankelevich, Michael: No conflict of interest\|\|Meringer, Hadar: No conflict of interest\|\|Cossarini, Francesca: No conflict of interest\|\|Canales-Herrerias, Pablo: No conflict of interest\|\|Livanos, Alexandra E: No conflict of interest\|\|Polydorides, Alexandros D: No conflict of interest\|\|Martin, Jerome: No conflict of interest\|\|Ko, Huaibin M.: No conflict of interest\|\|McBride, Jacqueline: No conflict of interest\|\|Hackney, Jason: No conflict of interest\|\|Colombel, Jean Frederic:\|:\|JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, BMS, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Genentech, Glaxo Smith Kline, Janssen Pharmaceuticals, Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Merck, Microbia, Novartis, PBM Capital, Pfizer, Protagonist Therapeutics, Sanofi,Takeda, TiGenix, Vifor and holds stock options in Intestinal Biotech Development.\|\|Argmann, Carmen: No conflict of interest\|\|Suarez-Farinas, Mayte: No conflict of interest\|\|Petralia, Francesca: No conflict of interest\|\|Mehandru, Saurabh:\|:\|SM reports receiving research grants from Genentech and Takeda receiving payment for lectures from Takeda, Genentech, Morphic and receiving consulting fees from Takeda, Morphic, Ferring and Arena Pharmaceuticals. |
| OP07 | Mr. Yang, Yuanhang: No conflict of interest\|\|Ludviggson, Jonas F.: No conflict of interest\|\|Olén, Ola: No conflict of interest\|\|Sjölander, Arvid: No conflict of interest\|\|Carrero, Juan Jesus: No conflict of interest |

| | |
|---|---|
| OP08 | Jairath, Vipul:\|:\|Consulting/advisory board fees from AbbVie, Alimentiv Inc, Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, Vividion; speaker's fees from, AbbVie, Ferring, Fresenius Kabi, Galapagos, Janssen, Pfizer, Shire, and Takeda.\|\|Feagan, Brian G.:\|:\|Consultant: AbbVie; AdMIRx; AgomAB Therapeutics; Akebia; Alivio Therapeutics; Allakos; Amgen; Applied Molecular Transport Inc; Arena Pharma; Avir; Azora Therapeutics; Boehringer Ingelheim; Boston Pharma; Celgene/BMS; Connect BioPharma; Cytoki; Disc Medicine; Everest Clinical Research Corp.; Eli Lilly; Equillium; Ferring; Galapagos; Galen Atlantica; Genentech/Roche; Gilead; Glenmark; Gossamer Pharma; GlaxoSmithKline; Hoffmann-LaRoche; Hot Spot Therapeutics; Index Pharma; ImmunExt; Intact Therapeutics; Janssen; Japan Tobacco Inc.; Kaleido Biosciences; Leadiant; Millennium; MiroBio; Morphic Therapeutics; Mylan; OM Pharma; Origo BioPharma; Otsuka; Pandion Therapeutics; Pfizer; Prometheus Therapeutics and Diagnostics; Progenity; PTM Therapeutics; Q32 Bio; Rebiotix; RedHill; Biopharma; REDX; Sandoz; Sanofi; Seres Therapeutics; Surrozen Inc.; Takeda; Teva; Thelium; Theravance; Tigenix; Tillotts; UCB Pharma; VHsquared Ltd.; Viatris; Ysios; Zealand Pharma. Speaker's bureau: AbbVie; Janssen, Takeda. Member, Scientific Advisory Board: AbbVie; Amgen; Boehringer Ingelheim; Celgene/BMS; Genentech/Roche; Janssen; Novartis; Origo BioPharma; Pfizer; Prometheus; Takeda; Tillotts Pharma; Teva; Progenity; Index; Ecor1Capital; Morphic; GlaxoSmithKline. Member, Board of Directors: Alimentiv Inc., London (Senior Scientific Director). Stock/shareholder: and Gossamer Pharma.\|\|Silverberg, Mark S.:\|:\|Has received research support from: AbbVie, Gilead, Janssen, Takeda, Prometheus, and Pfizer. Has received speaker fees, consulting fees or advisory board fees from: AbbVie, Janssen, Takeda, Pfizer, and Gilead.\|\|Danese, Silvio:\|:\|Has received lecture/consulting fees from AbbVie, Allergan, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring,\|Hospira, Johnson & Johnson, Merck, Merck Sharp & Dohme, Mundipharma, Pfizer, Sandoz, Takeda, TiGenix, UCB, and Vifor.\|\|Gionchetti, Paolo:\|:\|Has received honoraria or consultation fees from Janssen, AbbVie, Pfizer, Celgene, Takeda, Ferring, MSD, Alfa-Sigma, Amgen, Gilead, Arena. Has participated in a company sponsored speaker's bureau for AbbVie, Janssen, Takeda, Ferring, MSD, Sofar, and Chiesi.\|\|Löwenberg, Mark:\|:\|Has served as speaker and/or principal investigator for: AbbVie, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Robarts Clinical Trials, Takeda, Tillotts, and Tramedico.\|He has received research grants from AbbVie, Achmea healthcare, Merck Sharp & Dohme, Dr Falk, and ZonMW.\|\|Bressler, Brian:\|:\|Advisor/Speaker: |

| | |
|---|---|
| | Ferring, Janssen, AbbVie, Takeda, Pfizer, Novartis, BMS, Merck. Advisor: Alimentiv, Gilead, Iterative Scopes, AMT, Celgene, Microbiome Insights, Merck, Amgen, Pendopharm, Genentech, BMS, Allergan, Protagonist, Fresenius Kabi, Mylan, Bausch Health. Research support: Janssen, AbbVie, GlaxoSmithKline, BMS, Amgen, Genentech, Merck, BI, Qu Biologic, Celgene, Alvine. Stock Options: Qu Biologic.\|\|Ferrante, Marc:\|:\|Research grants from: AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris. Consultancy fees from: AbbVie, Boehringer Ingelheim, Celgene, Celltrion, Janssen-Cilag, Eli Lilly, Medtronic, MSD, Pfizer, Samsung Bioepis, Regeneron, Sandoz, Takeda, and Thermo Fisher. Speakers' fees from: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda, and Truvion Healthcare.\|\|Hart, Ailsa:\|:\|Served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol Myers Squibb, Celgene, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda. She also serves on the Global Steering Committee for Genentech.\|\|Lindner, Dirk:\|:\|Employee of Takeda and holds Takeda stock or stock options\|\|Escher, Armella:\|:\|Employee of Takeda and holds Takeda stock or stock options\|\|Jones, Stephen:\|:\|External consultant to Takeda\|\|Shen, Bo:\|:\|Consulting for Janssen, AbbVie, Takeda, BMS; Speakers for AbbVie, and Takeda.\|\|Travis, Simon:\|:\|Has received research support, been advisor to or lectured for Abacus; AbbVie; Actial; ai4gi; Alcimed; Allergan; Amgen; Aptel; Arena; Asahi; Aspen; Astellas; Atlantic; AstraZeneca; Barco; Biocare; Biogen; BLPharma; Boehringer Ingelheim; BMS; Buhlmann; Calcico; Celgene; Cellerix; Cerimon; ChemoCentryx; Chiesi; CisBio; ComCast; Coronado; Cosmo; Ducentis; Dynavax; Elan; ECCO; Enterome; Falk; Ferring; FPRT Bio; Galapagos; Genentech/Roche; Genzyme; Gilead; Glenmark; Grunenthal; GlaxoSmithKline; GW Pharmaceuticals; Helmsley Trust; Immunocore; Immunometabolism; Indigo; IOIBD; Janssen; Lexicon; Lilly; Medarex; MediAdd; Medtrix; Merck; Merrimack; Millennium; Neovacs; Norman Collisson Foundation Novartis; Novo Nordisk; NPS-Nycomed; Ocera; Optima; Origin; Otsuka; Palau; Pentax; Pfizer; Pharmaventure; Phesi; Phillips; P&G; Pronota; Protagonist; Proximagen; Resolute; Robarts; Sandoz; Santarus; Satisfai; Sensyne; Shire; Sigmoid Pharma; Souffinez; Syndermix; Synthon; Takeda; Theravance; Tigenix; Tillotts; Topivert; Trino Therapeutics with Wellcome Trust; TxCell; UCB Pharma; and Vifor. |
| OP09 | Prof. Dr. Lakatos, Péter Laszlo: No conflict of interest\|\|Gonczi, Lorant: No conflict of interest\|\|Lakatos, Laszlo: No conflict of interest\|\|Golovics, Petra A.: No conflict of interest\|\|Pandur, Tunde: No conflict of interest\|\|David, Gyula: No conflict of interest\|\|Erdelyi, Zsuzsanna: No conflict of interest\|\|Szita , Istvan: No conflict of interest |

| | |
|---|---|
| OP10 | Mrs. Mol, Bregje: No conflict of interest\|\|van Nieuwamerongen, Moyrha: No conflict of interest\|\|van Munster, Kim: No conflict of interest\|\|van Munster, Sanne: No conflict of interest\|\|de Vries, Annemarie: No conflict of interest\|\|van der Meer, Adriaan: No conflict of interest\|\|Goet, Jorn: No conflict of interest\|\|Weersma, Rinse: No conflict of interest\|\|Inderson, Akin: No conflict of interest\|\|Boonstra, Kirsten: No conflict of interest\|\|van Meer, Suzanne: No conflict of interest\|\|de Boer, Ynte: No conflict of interest\|\|Spanier, Marcel: No conflict of interest\|\|Drenth, Joost: No conflict of interest\|\|de Vries, Elsemieke: No conflict of interest\|\|Beuers, Ulrich: No conflict of interest\|\|Bogaards, Johannes: No conflict of interest\|\|Ponsioen, Cyriel: No conflict of interest |
| OP11 | Dr. Agrawal, Manasi: No conflict of interest\|\|Ebert, Anthony: No conflict of interest\|\|Poulsen, Gry: No conflict of interest\|\|Ungaro, Ryan: No conflict of interest\|\|Faye, Adam: No conflict of interest\|\|Jess, Tine: No conflict of interest\|\|Colombel, Jean-Frederic:\|:\|JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, TiGenix,; and hold stock options in Intestinal Biotech Development.\|\|Allin, Kristine: No conflict of interest |

| | |
|---|---|
| OP12 | Focht, Gili: No conflict of interest\|\|Mrs. Lujan, Rona: No conflict of interest\|\|Atia, Ohad: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Kariv, Revital: No conflict of interest\|\|Loewenberg Weisband, Yiska: No conflict of interest\|\|Lederman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris:\|:\|received in the last 3 years consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Genentech/Roche, Neopharm, Ferring, Rafa Laboratories, Falk Pharma, Nestle, Given Imaging/Medtronic, Gilead, Galapagos, Celgene/BMS, Arena, Sublimity, Sangamo, Celltrion, Wilbio, Cambridge Healthcare, Abbott, Food Industries Organization, Altman, Athos \|\|Turner, Dan:\|:\|Last 3 years received consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS |
| OP13 | Ms. Riviere, Pauline: No conflict of interest\|\|Dragoni, Gabriele: No conflict of interest\|\|Allez, Matthieu: No conflict of interest\|\|Allocca, Mariangela: No conflict of interest\|\|Arebi, Naila: No conflict of interest\|\|Bemelman, Willem: No conflict of interest\|\|Bislenghi, Gabriele: No conflict of interest\|\|Brown, Steven: No conflict of interest\|\|Carvello, Michele: No conflict of interest\|\|De Vries, Annemarie: No conflict of interest\|\|Domenech, Eugeni: No conflict of interest\|\|Hammoudi, Nassim: No conflict of interest\|\|Kapizioni, Christina: No conflict of interest\|\|Kotze, Paulo Gustavo: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Myrelid, Pär: No conflict of interest\|\|Oliveira-Cunha, Melissa: No conflict of interest\|\|Noor, Nurulamin N: No conflict of interest\|\|Pellino, Gianluca: No conflict of interest\|\|Pouillon, Lieven: No conflict of interest\|\|Savarino, Edoardo: No conflict of interest\|\|Verstockt, Bram: No conflict of interest\|\|Panis, Yves: No conflict of interest\|\|Ferrante, Marc: No conflict of interest |

| | |
|---|---|
| OP14 | D'Haens, Geert:\|:\|GD'H reports being a consultant or speaker for AbbVie, Alimentiv Boehringer Ingelheim, Celltrion, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Janssen, Lilly, MSD, Pfizer, Prometheus Biosciences, Prometheus Laboratories, Progenity, Takeda, Tillotts.\|\|Taxonera, Carlos:\|:\|CT has served as a speaker, consultant, and advisory board member for MSD, AbbVie, Pfizer, Takeda, Janssen, Galapagos, Fresenius Kabi, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, and Tillots.\|\|Lopez-Sanroman, Antoni: No conflict of interest\|\|Nos Mateu, Pilar:\|:\|Educational activities, research projects and scientific meetings sponsored by Abbvie, MSD, Janssen, Ferring, Faes, Vifor, Galapagos, Kern, Sandoz, Otsuka, Takeda and Tillots\|\|Danese, Silvio: No conflict of interest\|\|Armuzzi, Alessandro:\|:\|AA has received consulting/advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; speaker's fees from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; and research grants from Biogen, MSD, Pfizer, and Takeda.\|\|Roblin, Xavier:\|:\|MSD, Pfizer, Abbvie, Celltrion, Amgen, Biogen, Sandoz, janssen, Takeda, Galapagos, Theradiag\|\|Peyrin-Biroulet, Laurent:\|:\|Personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Biogen, Inotrem, MSD, Amgen, BMS, Vifor, Lilly, Gilead, Protagonist, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Pandion Therapeutics, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied Molecular Transport, GSK, Abivax.\|\|West, Rachel:\|:\|Advisory fees: Pfizer, Galapagos, Janssen, Ferring\|\|Witteman, Ben: No conflict of interest\|\|Duijvestein, Marjolijn:\|:\|I report advisory fees from Bristol Meiers Squibb, Abbvie, Janssen, Echo Pharma and Robarts Clinical Trials, Inc., speaker fees from BMS, Galapagos, Janssen, Merck & Co., Inc., Pfizer, Takeda and Tillotts Pharma, and nonfinancial support from Dr. Falk Pharm. I am the chair of the Dutch collaborative research group Initative on Crohn's and Colitis (ICC).\|\|Gecse, Krisztina:\|:\|KG has received grants from Pfizer Inc, Celltrion and Galapagos; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Tekeda and speaker's honoraria from Abbvie, Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepsis, Takeda and Tillotts.\|\|Hulshoff, Melanie: No conflict of interest\|\|Mostafavi, Nahid: No conflict of interest\|\|Clasquin, Esmé: No conflict of interest\|\|Bouhnik, Yoram: No conflict of interest\|\|Laharie, David:\|:\|DL declares counseling, boards, transports or fees from Abbvie, Biogaran, Biogen, Celltrion, Ferring, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Prometheus, Roche, Takeda, Theradiag, Tillotts. |
| | |

| | |
|---|---|
| OP15 | Danese, Silvio:\|:\|Reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc. and Vifor; and reports lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer and Takeda\|\|Afif, Waqqas:\|:\|Reports having received grant support from Janssen Research & Development, LLC.\|\|Abreu, Maria:\|:\|Reports having received grant support from Prometheus Bioscience, Takeda, and Pfizer; consulting fees from Janssen Research & Development, LLC., Prometheus Bioscience, Takeda, Focus Medical Communications, Pfizer, Boehringer Ingelheim Pharmaceuticals, Gilead, Imedex, Cornerstone Health, Inc, Landos Biophama, UCB Biopharma SRL, Eli Lilly, Bristol Myers Squibb, Arena Pharmaceuticals, and Cosmo Biopharma\|\|Sandborn, William:\|:\|Reports research grants from Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Meyers Squibb, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Laboratories, Seres Therapeutics, Shire Pharmaceuticals, Takeda, Theravance Biopharma; consulting fees from Abbvie, Abivax, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Allakos, Amgen, Arena Pharmaceuticals, AstraZeneca, Atlantic Pharmaceuticals, Beigene, Boehringer Ingelheim, Bristol Meyers Squibb, Celltrion, Clostrabio, Forbion, Galapagos, Genentech (Roche), GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Iota Biosciences, Janssen, Lilly, Morphic Therapeutics, Novartis, Oppilan Pharma (now Ventyx Biosciences), Pfizer, Pharm Olam, Polpharm, Progenity, Prometheus Biosciences, Protagonist Therapeutics, PTM Therapeutics, Seres Therapeutics, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Vedanta Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences, Xencor, Zealand Pharmaceuticals; stock or stock options from Allakos, BeiGene, Gossamer Bio, Oppilan Pharma (now Ventyx Biosciences), Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; and employee at Shoreline Biosciences and Ventyx Biosciences. Spouse: Iveric Bio - consultant, stock options; Progenity - stock; Oppilan Pharma (now Ventyx Biosciences) – stock; Prometheus Biosciences - employee, stock, stock options; Prometheus Laboratories – stock, stock options, consultant; Ventyx Biosciences – stock, stock options; Vimalan Biosciences – stock, stock options.\|\|Miao, Ye:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Zhang, Hongyan:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary.\|\|Panaccione, Remo:\|:\|Received consulting fees from AbbVie, Abbott, Alimentiv (formerly |

| | |
|---|---|
| | Robarts), Amgen, Arena, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Therapeutics, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance, UCB, and Takeda; speaker fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, and Takeda; research/educational support from AbbVie, Ferring, Janssen, Pfizer, and Takeda; and has served on an advisory board for AbbVie, Amgen, Arena,, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance, and Takeda.\|\|Hisamatsu, Tadakazu:\|:\|Received grant support from AbbVie, Daiichi-Sankyo, EA Pharma Co, Ltd. JIMRO, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmacuetical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Co., Ltd., consulting fees from EA Pharma Co, Ltd., Janssen Research & Development, LLC.,, and lecture fees from AbbVie, EA Pharma Co, Ltd, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd.\|\|Scherl, Ellen:\|:\|Reports having received grant support from AbbVie, AstraZeneca, Crohn's and Colitis Foundation, Janssen Research & Development, LLC., New York Crohn's Foundation, Pfizer, UCB, Genentech, Seres Therapeutics, and Celgene; consulting fees: AbbVie, Abgenomics, Crohn's and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takeda Stock: Gilead; speaker fees from GI Health Foundation, Prime Therapeutics. \|\|Leong, Rupert:\|:\|Grant support from NHMRC, GESA, Janssen, Shire, Endochoice, Ferring; and consulting fees from Janssen Research & Development, LLC. Aspen, AbbVie, Celgene, Ferring, Pfizer, Hospira, Novartis, Dr Falk Pharma, MSD, Takeda.\|\|Rowbotham, David:\|:\|Reports research funding and/or has served as a speaker, consultant, and/or advisory board member for Abbott Laboratories, Janssen Research & Development, LLC, Merck Research Laboratories, Merck Serono, UCB Pharma, Millenium/Takeda, Genentech/Hoffman LaRoche, Neovacs, Bristol Myers Squibb, Robarts, Tillotts, Pfizer, and Falk Pharma.\|\|Arasaradnam, Ramesh:\|:\|Reports having received grant support and consulting fees from Janssen Research & Development, LLC, AbbVie and Dr Falk Pharma\|\|Peyrin-Biroulet, Laurent:\|:\|Reports receiving personal fees from Galapagos, AbbVie, Janssen, Genentech, Alimentiv, Ferring, Tillots, Celltrion, Takeda, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Inotrem, Allergan, MSD, Roche, Arena, Gilead, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, OSE Immunotherapeutics, Enthera, Theravance, Pandion Therapeutics, Gossamer Bio, Viatris, Thermo Fisher, ONO Pharma, Mopac, Cytoki Pharma, Morphic, Prometheus, Applied |

| | |
|---|---|
| | Bio, Vidra, Thermo Fisher, GNE Pharma, Mopac, Cytek Pharma, Morphic, Prometheus, Applied Molecular Transport; grants from Abbvie, MSD, Takeda, Fresenius Kabi, Celltrion; and stock options from CTMA.\|\|Sands, Bruce:\|:\|Reports grants, personal fees and other from Abivax, during the conduct of the study; personal fees from Abbvie, personal fees from Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), personal fees from Amgen, personal fees and other from Arena Pharmaceuticals, personal fees from Astra Zeneca, personal fees from Bausch Health (Salix Pharmaceuticals), personal fees from Boehringer Ingelheim, personal fees from Boston Pharmaceuticals, personal fees and other from Bristol Meyer Squibb, personal fees and other from Celgene, personal fees from Celltrion, personal fees from Clostrabio, personal fees from Equillium, personal fees from Galapagos, personal fees from Genentech (Roche), personal fees from Gilead Sciences, personal fees from GlaxoSmithKline, personal fees from Gossamer Bio, personal fees from Immunic, personal fees from Index Pharmaceuticals, personal fees from Inotrem, grants, personal fees and other from Janssen, grants, personal fees and other from Lilly, personal fees from Morphic Therapeutics, personal fees from Novartis, personal fees from Oppilan Pharma (acquired by Ventyx Biosciences, personal fees from Otuska, grants, personal fees and other from Pfizer, personal fees from Progenity, personal fees from Prometheus Biosciences, personal fees from Prometheus Laboratories, personal fees from Protagonists Therapeutics, personal fees from Seres Therapeutics, personal fees from Shire Pharmaceuticals, personal fees from Surrozen, grants, personal fees and other from Takeda, grants and personal fees from Theravance Biopharma, personal fees from Teva, personal fees from UCB, personal fees from Vedanta Biosciences, personal fees and other from Ventyx Biosciences, personal fees from Vivelix Pharmaceuticals, personal fees from Ironwood Pharmaceuticals, personal fees from OSE Immunotherapeutics, personal fees from Redhill Biopharma, personal fees from Target RWE, personal fees from Bacainn Therapeutics, personal fees from Capella Bioscience, personal fees from Palatin Technologies, personal fees from Rheos Medicines, personal fees from USWM Enterprises, personal fees from Viela Bio, personal fees from Artugen Therapeutics, personal fees from Calibr, personal fees from Entera, personal fees from Evommune, personal fees from Innovation Pharmaceuticals, personal fees from Kaleido, personal fees from Merck, personal fees from MRM Health, personal fees from Q32 Bio, personal fees from Sun Pharma, personal fees from TLL Pharmaceutical, other from Vivante Health, outside the submitted work.\|\|Marano, Colleen:\|:\|Employee of Janssen and owns stock in Johnson & Johnson, of which Janssen is a subsidiary. |

| | |
|---|---|
| OP16 | Peyrin-Biroulet, Laurent:\|:\|LP-B has received personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Hikma, InDex Pharmaceuticals, Inotrem, Janssen, Lilly, MSD, Mylan, Nestle, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Theravance, Tillots, and Vifor; and research grants from AbbVie, Fresenius Kabi, MSD, and Takeda; and stock options from CTMA.\|\|Parkes, Gareth:\|:\|GP has received personal fees and/or speaking honoraria fees from AbbVie, Allergan, Bristol Myers Squibb, Celltrion, Ferring, Galapagos, Janssen, Napp Pharmaceuticals, Takeda, and Tilotts; travel grants or fellowships from AbbVie, Celltrion, Ferring, Janssen, Takeda, and Tillotts; and is a director and shareholder for Ampersand Health.\|\|Rodríguez, Cristina:\|:\|CR has received consultancy and/or speaking honoraria fees from AbbVie, Ferring, Galapagos, Janssen, Pfizer, and Takeda.\|\|Siffledeen, Jesse:\|:\|JS has received consultancy and/or speaking honoraria fees from AbbVie, Allergan, BIOJAMP, Ferring, Fresenius Kabi, Janssen, Pfizer, Shire, and Takeda, and educational grants from AbbVie and BIOJAMP.\|\|Wright, John: No conflict of interest\|\|Broide, Efrat:\|:\|EB has received speaking honoraria fees from AbbVie, Ferring, Jensen, and Takeda.\|\|Ford, Sharanya:\|:\|SF is an employee or contractor of AbbVie, and may own AbbVie stock or options.\|\|Lacerda, Ana P:\|:\|APL is an employee or contractor of AbbVie, and may own AbbVie stock or options.\|\|Oomen, Jess:\|:\|JO is an employee or contractor of AbbVie, and may own AbbVie stock or options.\|\|Garrison, Andrew:\|:\|AG is an employee or contractor of AbbVie, and may own AbbVie stock or options.\|\|Berg, Sofie:\|:\|SB is an employee or contractor of AbbVie, and may own AbbVie stock or options.\|\|Rubin, David T.:\|:\|DTR has received grant support from Takeda and has served as a consultant for AbbVie, Abgenomics, Allergan, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences, InDex Pharmaceuticals, Iterative Scopes, Janssen, Lilly, Materia Prima, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Takeda, and Techlab. |

| | |
|---|---|
| OP17 | Feagan, Brian Gordon:\|:\|Brian G. Feagan has served as a consultant for AbbVie, AdMIRx, AgomAB Therapeutics, Akebia, Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc, Arena Pharmaceuticals, Avir, Azora Therapeutics, Biopharma, Boehringer Ingelheim, Boston Pharma, Bristol Myers Squibb, Connect BioPharma, Cytoki, Disc Medicine, Everest Clinical Research Corp., Equillium, Ferring, Galapagos, Galen Atlantica, Gilead, Glenmark, Gossamer Pharma, GlaxoSmithKline, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, ImmunExt, Intact Therapeutics, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Leadiant, Lilly, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Therapeutics and Diagnostics, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, REDX, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB, VHsquared Ltd., Viatris, Ysios, and Zealand Pharma; speaker for AbbVie, Janssen, and Takeda; advisory board member for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, EcoR1 Capital, GlaxoSmithKline, Hoffman-LaRoche, Index, Janssen, Morphic, Novartis, Origo BioPharma, Pfizer, Progenity, Prometheus, Takeda, Teva, and Tillotts Pharma; Board of Directors member for Alimentiv Inc. He is a stock shareholder of Goassmer Pharma.\|\|Horst, Sara:\|:\|Sara Horst is a consultant for AbbVie, Takeda, BMS, and Janssen. \|\|Dryden, Gerald:\|:\|Gerald Dryden has received consulting fees from AbbVie, Allergan, Gilead, Janssen, and Takeda; and has received research funding from AbbVie, Gilead, Janssen, Lilly, MedImmune, Takeda, and TiGenix.\|\|Lindsay, James O.:\|:\|James O. Lindsay has received consulting and/or speaker fees from AbbVie, Allergan (Warner Chilcott), Atlantic Healthcare, Bristol Myers Squibb, Celgene, Celltrion, Ferring Pharmaceuticals, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Napp, Pfizer, Shire, Takeda, and Vifor Pharma; and investigator-led research grants from AbbVie, Gilead, Pfizer, Shire, and Takeda.\|\|Ferrante, Marc:\|:\|Marc Ferrante has received speaker and/or consultant fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Dr Falk, Eli Lilly, Ferring, Janssen-Cilag, Lamepro, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda, Thermo Fisher, Truvion Healthcare and Viatris; Research Grants: AbbVie, Amgen, Biogen, Janssen, Pfizer, Takeda and Viatris.\|\|Dubenco, Elena:\|:\|Elena Dubcenco is an AbbVie employee and may own stock.\|\|Lacerda, Ana Paula:\|:\|Ana Paula Lacerda is an AbbVie employee and may own stock.\|\|Ford, Sharanya:\|:\|Sharanya Ford is an AbbVie employee and may own stock.\|\|Anyanwu, Samuel I:\|:\|Samuel I. Anyanwu is an AbbVie employee and may own stock.\|\|Zhou, Qian:\|:\|Qian Zhou is an AbbVie employee and may own stock.\|\|Liu, Jianzhong:\|:\|Jianzhong Liu is an AbbVie employee and may own stock.\|\|Chen, Minhu:\|:\|Minhu Chen has received support for clinical research from Janssen and Takeda; and served as an advisory board member for Boehringer Ingelheim GmbH and Janssen; and provided educational activities for AbbVie, China Medical System, IPSEN, Janssen, and Takeda.\|\|Schreiber, Stefan:\|:\|Stefan Schreiber has received consulting fees from AbbVie, Amgen, Arena, BMS, Boehringer Ingelheim, Celltrion, Falk Pharma, Ferring, Galapagos/Gilead, Genentech/Roche, GlaxoSmithKline, IMAB Biopharma, Lilly, MSD, Pfizer, Shire, and Takeda. |

| | |
|---|---|
| OP18 | Mr. Wewer, Mads Damsgaard:\|:\|This study was funded by an unrestricted grant by Bristol Meyers Squibb\|\|Salupere, Riina: No conflict of interest\|\|Kievit, Hendrika Adriana Linda: No conflict of interest\|\|Nielsen, Kári Rubek: No conflict of interest\|\|Midjord, Jóngerð: No conflict of interest\|\|Domislovic, Viktor: No conflict of interest\|\|Krznarić, Željko: No conflict of interest\|\|Pedersen, Natalia: No conflict of interest\|\|Kjeldsen, Jens: No conflict of interest\|\|Eriksson, Carl: No conflict of interest\|\|Halfvarson, Jonas: No conflict of interest\|\|Talbot, Alison: No conflict of interest\|\|Sebastian, Shaji: No conflict of interest\|\|Goldis, Adrian: No conflict of interest\|\|Misra, Ravi: No conflict of interest\|\|Arebi, Naila: No conflict of interest\|\|Ilus, Tuire: No conflict of interest\|\|Oksanen, Pia: No conflict of interest\|\|Neuman, Anders: No conflict of interest\|\|Andersen, Vibeke: No conflict of interest\|\|Skamnelos, Alexandros: No conflict of interest\|\|Katsanos, Konstantinos H.: No conflict of interest\|\|Platon, Valentina: No conflict of interest\|\|Turcan, Svetlana: No conflict of interest\|\|Borg, Bernard: No conflict of interest\|\|Ellul, Pierre: No conflict of interest\|\|Kupcinskas, Juozas: No conflict of interest\|\|Kiudelis, Gediminas: No conflict of interest\|\|Yzet, Clara: No conflict of interest\|\|Fumery, Mathurin: No conflict of interest\|\|Kaimakliotis, Ioannis P.: No conflict of interest\|\|Lorenzon, Greta: No conflict of interest\|\|D'Inca, Renata: No conflict of interest\|\|Hernandez, Vicent: No conflict of interest\|\|Fernandez, Alberto: No conflict of interest\|\|Langholz, Ebbe: No conflict of interest\|\|Munkholm, Pia: No conflict of interest\|\|Burisch, Johan: No conflict of interest |
| OP19 | Dr. Fiorino, Gionata: No conflict of interest |

| | |
|---|---|
| OP20 | Prof. Dr. D'Haens, Geert:\|:\|has served as an adviser for AbbVie, Ablynx, Allergan, Alphabiomics, Amakem, Amgen, AM Pharma, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Meyers Squibb, Boehringer Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Echo Pharmaceuticals, Eli Lilly, Engene, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Hospira/Pfizer, Immunic, Johnson and Johnson, Kintai Therapeutics, Lycera, Medimetrics, Millenium/Takeda, Medtronics, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Pfizer/Hospira, Photopill, Prodigest, Prometheus laboratories/Nestle, Progenity, Protagonist, RedHill, Robarts Clinical Trials, Salix, Samsung Bioepis, Sandoz, Seres/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor, and has received speaker fees from AbbVie, Biogen, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts and Vifor\|\|Tran, Jacinda:\|:\|currently a contractor at AbbVie and PhD student at the University of Washington\|\|Danese, Silvio:\|:\|has received consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, Pfizer, Roche, Sandoz, Takeda, TiGenix, UCB, and Vifor Pharma\|\|Rubin, David T.:\|:\|has received grant support from Takeda; and has served as a consultant for AbbVie, Altrubio, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc.\|\|Aoyama, Nobuo: No conflict of interest\|\|Lügering, Andreas:\|:\|received lecture fee(s) from AbbVie, Ferring, Janssen, MSD, Pfizer, Takeda, Tillots; and received consultancy fees from AbbVie, Celltrion, Glaxo Smith Kline, Janssen, Pfizer, Takeda\|\|Klaff, Justin:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Xuan, Si:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Ilo, Dapo:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Sanchez Gonzalez, Yuri:\|:\|full-time employee of AbbVie and may hold AbbVie stock and/or stock options\|\|Panes, Julian:\|:\|received financial support for research from AbbVie and Pfizer; received lecture fee(s) from AbbVie, Ferring, Janssen, Pfizer, Takeda; and received consultancy fees from AbbVie, Arena, Athos, Boehringer Ingelheim, Celltrion, Ferring, Galapagos, Genentech, GSK, Janssen, Mirum, Morphic, Nestlé, Origo, Pandion, Pfizer, Progenity, Protagonist, Revolo, Robarts, Roche, Takeda, Theravance, and Wassermann |
| | |

| | |
|---|---|
| OP21 | Mr. Kucha, Piotr:\|:\|Support for attending meetings or travel from Janssen.\|\|Walkiewicz, Dorota: No conflict of interest\|\|Wieszczy, Paulina: No conflict of interest\|\|Reguła, Jarowsław:\|:\|Support for attending meetings or travel from Servier and Alfasigma and individual honoraria for consultancy or lectures from Alfasigma, Servier, Janssen, Takeda, Amgen and Ipsen.\|\|Zagórowicz, Edyta:\|:\|Support for attending meetings or travel from Takeda and Ferring and individual honoraria for consultancy or lectures from BMS, Takeda, Janssen, Ferring and Fresenius Kabi. |
| OP22 | Ehrström, Andrea: No conflict of interest\|\|Jansson, Sabine: No conflict of interest\|\|Malham, Mikkel: No conflict of interest\|\|Wewer, Vibeke: No conflict of interest |
| OP23 | Dr. Brunet, Eduard: No conflict of interest\|\|Selva, Anna: No conflict of interest\|\|Bas-Cutrina, Francesc: No conflict of interest\|\|Brujats, Anna: No conflict of interest\|\|Caballol, Berta: No conflict of interest\|\|Gomez, Bàrbara: No conflict of interest\|\|Gonzalez, Carlos: No conflict of interest\|\|Busquets, David: No conflict of interest\|\|Monfort, David: No conflict of interest\|\|Vera, Diana Patrícia: No conflict of interest\|\|Maristany, Elisabet: No conflict of interest\|\|Cirera, Gemma: No conflict of interest\|\|Torres, Gisela: No conflict of interest\|\|Castro-Poceiro, Jesús: No conflict of interest\|\|Lopez, Joel: No conflict of interest\|\|Gonzalez-Gonzalez, Laura: No conflict of interest\|\|Marquez-Mosquera, Lucia: No conflict of interest\|\|Gallach, Marta: No conflict of interest\|\|Esteve, Maria: No conflict of interest\|\|Tremosa, Gemma: No conflict of interest\|\|Torra, Sandra: No conflict of interest\|\|Robles, Virgina: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Calvet, Xavier: No conflict of interest |

| | |
|---|---|
| OP24 | Dr. Liu, Zhigang: No conflict of interest\|\|Le, Kaixing: No conflict of interest\|\|Zhou, Xin: No conflict of interest\|\|Alexander, James: No conflict of interest\|\|Lin, Simeng:\|:\|SL reports non-financial support from Pfizer and Ferring outside the submitted work. \|\|Bewshea, Claire: No conflict of interest\|\|Chanchlani, Neil: No conflict of interest\|\|Nice, Rachel: No conflict of interest\|\|McDonald, Timothy: No conflict of interest\|\|Lamb, Christopher:\|:\|CAL declares research support and/or fees for development and delivery of non-promotional education from Janssen, Takeda, Abbvie, AstraZeneca, Eli Lilly, Orion, Pfizer, Roche, Sanofi Aventis, Ferring, Dr Falk, UCB, Biogen and Genentech Inc.\|\|Sebastian, Shaji:\|:\|SS reports grants from Takeda, Tillots Pharma, Janssen and Amgen; speak honoraria from Janssen, Tillotts Pharma, Amgen, Abbvie and Ferring; personal fees from Takeda, Janssen and Tillots Pharma; and serves as advisory board for Takeda, outside the submitted work. \|\|Kok, Klaartje:\|:\|KK reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen and Ferring; support for attending meetings or travel from Janssen and Takeda; and participation on a data safety monitoring board or advisory board for Janssen and PredictImmune. \|\|Lees, Charlie:\|:\|CWL reports personal consulting fees from Galapagos, AbbVie, Takeda, Pfizer, Janssen, and Iterative Scopes; institutional consulting fees from Trellus Health; personal fees and support for attending meetings from Galapagos, AbbVie, Takeda, Pfizer, Janssen, GSK, Gilead, Fresenius Kabi, Ferring, and Dr Falk. \|\|Hart, Ailsa:\|:\|ALH has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Galapogos, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda; she also serves on the Global Steering Committee for Genentech. \|\|Pollok, Richard: No conflict of interest\|\|Boyton, Rosemary: No conflict of interest\|\|Altmann, Danniel: No conflict of interest\|\|Pollock, Katrina:\|:\|KMP is chief, principal or co-investigator for vaccine clinical trials and experimental medicine studies (NCT05007275, NCT04753892, EudraCT 2020-001646-20, NCT04400838, NCT04324606, EudraCT 2017-004610-26, NCT03970993, NCT03816137), is a member of the data safety monitoring board for NCT05249829 and NCT05575492, has received a fee for speaking from Seqirus and Sanofi Pasteur, and has research funding from the Chan Zuckerberg Initiative, the MRC/UKRI, the Vaccine Task Force, and NIHR Imperial BRC outside the submitted work. \|\|Goodhand, James:\|:\|JRG reports grants from F. Hoffmann-La Roche AG, Biogen Inc, Celltrion Healthcare, Takeda and Galapagos during the study. \|\|Kennedy, Nicholas:\|:\|NAK reports grants from F. Hoffmann-La Roche AG, Biogen Inc, Celltrion Healthcare, Takeda and Galapagos during the conduct of the study; grants and non-financial support from AbbVie, MSD, Napp, Pfizer, Celgene and Pharmacosmos; grants and personal fees from Celltrion; personal fees and non-financial support from Janssen, Tillots Pharma |

| | |
|---|---|
| | and Dr Falk; personal fees from Allergan, Ferring, Pharmacosmos, Takeda, Amgen, Bristol-Myers Squibb and Mylan, outside the submitted work. \|\|Ahmad, Tariq:\|:\|TA reports grants from F. Hoffmann-La Roche AG, Biogen Inc, Celltrion Healthcare, Takeda, Galapagos and Crohn's and colitis UK during the conduct of the study; payment for educational event for Takeda; and serves as medical advisor to Crohn's and colitis UK, outside the submitted work. \|\|Powell, Nick:\|:\|NP reports grants from F. Hoffmann-La Roche AG, Biogen Inc, Celltrion Healthcare, Takeda, Galapagos and Crohn's and colitis UK during the conduct of the study; has received research grants from Bristol Myers Squibb and Pfizer, reports personal fees from Takeda, Janssen, Pfizer, Galapagos, Bristol Myers Squibb, AbbVie, Roche, Lilly, Allergan, Celgene and Astra Zeneca outside the submitted work; and has served as a speaker or advisory board member for AbbVie, Allergan, Bristol Myers Squibb, Celgene, Dr Falk, Galapagos, AstraZeneca and Vifor Pharma. |
| OP25 | Mr. Van Linschoten, Reinier: No conflict of interest\|\|van Leeuwen, Nikki: No conflict of interest\|\|Hazelzet, Jan Antonius: No conflict of interest\|\|van der Woude, C. Janneke:\|:\|C. van der Woude has served on advisory boards for Abbvie, Takeda, Pfizer and Celltrion. She is supported by research funding from ZonMW, Tramedico, and Pfizer. \|\|van Noord, Desirée:\|:\|Dr. Leemreis reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, Galapagos and Takeda and personal fees from Takeda and Janssen outside the submitted work.\|\|West, Rache Louise:\|:\|Dr. West reports grants from AbbVie, Falk, Ferring, Janssen, MSD, Pfizer, Galapagos and Takeda and personal fees from AbbVie, Janssen and Pfizer outside the submitted work. |

| | |
|---|---|
| OP26 | Dr. Aguas Peris, Maríam: No conflict of interest\|\|Del Hoyo, Javier: No conflict of interest\|\|Vicente, Raquel: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|Melcarne, Luigi: No conflict of interest\|\|Hernández-Camba, Alejandro: No conflict of interest\|\|Alfambra, Erika: No conflict of interest\|\|Madero, Lucía: No conflict of interest\|\|Sicilia, Beatriz: No conflict of interest\|\|Chaparro, María: No conflict of interest\|\|Martín-Arranz, María Dolores: No conflict of interest\|\|Pajares, Ramón: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Martínez, Pilar: No conflict of interest\|\|Chacón , Silvia: No conflict of interest\|\|Tosca, Joan: No conflict of interest\|\|Marín, Sandra: No conflict of interest\|\|Sanromán, Luciano: No conflict of interest\|\|Calvo, Marta: No conflict of interest\|\|Monfort, David: No conflict of interest\|\|Saiz, Empar: No conflict of interest\|\|Zabana, Yamile: No conflict of interest\|\|Guerra, Iván: No conflict of interest\|\|Varela, Pilar: No conflict of interest\|\|Faubel, Raquel: No conflict of interest\|\|Corsino, Pilar: No conflict of interest\|\|Porto-Silva, Sol: No conflict of interest\|\|Brunet, Eduard: No conflict of interest\|\|Gutiérrez, Ana: No conflict of interest\|\|Nos, Pilar: No conflict of interest |

| | |
|---|---|
| OP27 | Dr. Rubín De Célix, Cristina:\|:\|Cristina Rubín de Célix has received education funding from Ferring, Abbvie, Norgine, MSD, Pfizer, Takeda and Janssen and is supported by a grant from the Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, Rio Hortega CM21/00025) and Co-financed by the European Social Fund Plus (ESF+) "Co-financed by the European Union"). \|\|Martín de Carpi, Javier: No conflict of interest\|\|Pujol, Gemma: No conflict of interest\|\|Palomino, Laura: No conflict of interest\|\|Velasco, Marta: No conflict of interest\|\|Martín-Masot, Rafael: No conflict of interest\|\|Navas-López, Víctor Manuel: No conflict of interest\|\|Ricart, Elena: No conflict of interest\|\|Casanova, María José:\|:\|María José Casanova, has received research or education funding from Pfizer, Takeda, Janssen, MSD, Ferring, Abbvie, Biogen, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi and Norgine.\|\|Rodríguez Martínez, Alejandro: No conflict of interest\|\|Leo, Eduardo: No conflict of interest\|\|Alcaraz, Alba: No conflict of interest\|\|Mañosa, Miriam:\|:\|Miriam Mañosa has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Galapagos, Janssen, MSD, Pfizer, Faes, Takeda, Tillots and Falk.\|\|Hernández, Vicent:\|:\|Vicent Hernandez has served as consultant, has served as speaker, has received travel support or research funding from MSD, AbbVie, Ferring, FAES Farma, Dr. Falk Pharma, Tillotts Pharma, Otsuka Pharmaceutical, Pfizer, Takeda, Janssen, KernPharma Biologics, Gebro Pharma, Adacyte, Sandoz, Biogen and Fresenius-Kabi. \|\|Fernández, Romina: No conflict of interest\|\|Sánchez, César: No conflict of interest\|\|Menchén, Luis: No conflict of interest\|\|Mesonero, Francisco: No conflict of interest\|\|Barreiro-De Acosta, Manuel:\|:\|Manuel Barreiro-De Acosta has received financial support for traveling and educational activities from or has served as an advisory board member for Pfizer, MSD, Takeda, Abbvie, Kern, Janssen, Fresenius Kabi, Biogen, Ferring, Faes Farma, Shire Pharmaceuticals, Falk Pharma, Chiesi, Gebro Pharma, Otsuka Pharmaceuticals, and Tillotts Pharma.\|\|Martinon, Nazareth: No conflict of interest\|\|Tejido Sandoval, Coral: No conflict of interest\|\|Rendo Vázquez, Alicia: No conflict of interest\|\|Corsino, Pilar: No conflict of interest\|\|Vicente, Raquel:\|:\|Raquel Vicente has received education funding from Abbvie, Jannsen, MSD, Pfizer, FAES-FARMA, Ferring, Shire y Takeda. \|\|Hernández-Camba, Alejandro: No conflict of interest\|\|Alberto Alonso, José Ramón: No conflict of interest\|\|Alonso-Abreu, Inmaculada: No conflict of interest\|\|Castro Millán, Ana María: No conflict of interest\|\|Peries Reverter, Laia: No conflict of interest\|\|Castro, Beatriz: No conflict of interest\|\|Fernández-Salgado, Estela:\|:\|Estela Fernández-Salgado has served as speaker, consultant from Abbvie, Takeda, Janssen, Ferring and has received education funding from Abbvie, Pfizer, Takeda, Janssen, Tillots Pharma, Falk, MSD, Faes, Ferring.\|\|Busto Cuiñas, M Mercedes: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Madero, Lucía: No conflict of |

| | |
|---|---|
| | interest\|\|Clemente, Fernando: No conflict of interest\|\|Riestra, Sabino:\|:\|Sabino Riestra has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Takeda, Janssen, Pfizer, Mylan, Biogen, Kern Pharma, Ferring, Faes Farma, Tillots Pharma Shire Pharmaceuticals, Dr. Falk Pharma and Adacyte Therapeutics.\|\|Jiménez-Treviño, Santiago: No conflict of interest\|\|Boscá, Maia: No conflict of interest\|\|Chaparro, María:\|:\|María Chaparro has served as a speaker, consultant and advisory member for, or received re-search funding from, AbbVie, Celltrion, Chiesi, Faes Farma, Falk Pharma, Ferring Pharmaceuticals, Gebro Pharma, Janssen, MSD, Otsuka Pharmaceuticals, Pfizer Inc, Roche, Shire Pharmaceuticals, Takeda and Tillotts Pharma.\|\|Gisbert, Javier P:\|:\|Javier P. Gisbert has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. |
| OP28 | Dr. Cooney, Rachel:\|:\|Consulting fees outside the submitted work for: Takeda and Celltrion\|Payment for development of educational presentations outside the submitted work for: Galapagos, Jannsen and Falk\|\|Tang, Daniel:\|:\|Employee of Pfizer Ltd\|\|Barrett, Kevin: No conflict of interest\|\|Russell, Richard K:\|:\|Consultancy fees outside the submitted work for: Nestle Health Sciences, AbbVie, Takeda, Pharmacosmos, Lilly, Celltrion Healthcare, Pfizer\|\|Payment for lectures including service on speakers bureaus outside the submitted work for: Nestle Health Sciences, AbbVie, Takeda, Pharmacosmos, Lilly, Celltrion Healthcare, Pfizer |

| | |
|---|---|
| OP29 | Dr. Lee, Sun-Ho: No conflict of interest\|\|Qiu, Lanhui: No conflict of interest\|\|A. Olivera, Pablo: No conflict of interest\|\|Leibovitzh, Haim: No conflict of interest\|\|Xue, Mingyue: No conflict of interest\|\|Neustaeter, Anna: No conflict of interest\|\|Mbareche, Hamza: No conflict of interest\|\|Xu, Wei: No conflict of interest\|\|Espin-Garcia, Osvaldo: No conflict of interest\|\|L. Aumais, Guy: No conflict of interest\|\|Q. Huynh, Hien: No conflict of interest\|\|Panaccione, Remo: No conflict of interest\|\|Steinhart, A. Hillary: No conflict of interest\|\|Cino, Maria: No conflict of interest\|\|Mack, David: No conflict of interest\|\|K. Marshall, John: No conflict of interest\|\|Ropeleski, Mark: No conflict of interest\|\|Bitton, Alain: No conflict of interest\|\|Jacobson, Kevan: No conflict of interest\|\|McGraft, Jerry: No conflict of interest\|\|Yerushalmi, Baruch: No conflict of interest\|\|Abreu, Maria: No conflict of interest\|\|N. Bernstein, Charles: No conflict of interest\|\|Radford-Smith, Graham: No conflict of interest\|\|Lees, Charlie: No conflict of interest\|\|Turner, Dan: No conflict of interest\|\|L. Madsen, Karen: No conflict of interest\|\|S. Guttman, David: No conflict of interest\|\|S. Silverberg, Mark: No conflict of interest\|\|Turpin, Williams: No conflict of interest\|\|Croitoru, Kenneth: No conflict of interest |
| OP30 | Liu, Limin: No conflict of interest\|\|Zhao, Jingwen: No conflict of interest\|\|Ye, Yulin: No conflict of interest\|\|Ms. Feng, Zelin: No conflict of interest\|\|Wang, Xiaoli: No conflict of interest\|\|Cao, Xiaocang: No conflict of interest |
| OP31 | Mrs. Wang, Chen: No conflict of interest\|\|Gu, Yu: No conflict of interest\|\|Cao, Hailong: No conflict of interest |

| | |
|---|---|
| OP32 | Facoetti, Amanda: No conflict of interest\|\|Massimino, Luca: No conflict of interest\|\|Palmieri, Orazio: No conflict of interest\|\|Fuggetta , Davide: No conflict of interest\|\|Spanò , Salvatore: No conflict of interest\|\|D'Alessio , Silvia: No conflict of interest\|\|Furfaro, Federica: No conflict of interest\|\|D'Amico, Ferdinando: No conflict of interest\|\|ZIlli, Alessandra: No conflict of interest\|\|Fiorino, Gionata: No conflict of interest\|\|Noviello, Daniele: No conflict of interest\|\|Latiano, Anna: No conflict of interest\|\|Bossa, Fabrizio: No conflict of interest\|\|Pirola, Alessandra: No conflict of interest\|\|Mologni, Luca: No conflict of interest\|\|Piazza, Rocco: No conflict of interest\|\|Abbati, Danilo: No conflict of interest\|\|Perri, Francesco: No conflict of interest\|\|Bonini , Chiara: No conflict of interest\|\|Peyrin-Biroulet, Laurent:\|:\|LPB has served as consultant for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, Jndex Pharmaceuticals, Amgen, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestlé, Enterome, Mylan, HAC-Pharma, Tigenix, and has served as speaker for Merck, Abbvie, Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Takeda, Boerhinger-Ingelheim, Pfizer, Amgen, Biogen, Samsung Bioepis. \|\|\|\|\|Malesci, Alberto: No conflict of interest\|\|Danese, Silvio:\|:\|SD has served as a speaker, consultant, and advisory board member for Schering Plough, Abbott (AbbVie) Laboratories, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, AstraZeneca, Novo Nordisk, Vifor, and Johnson and Johnson. \|\|\|Ungaro, Federica: No conflict of interest |
| OP33 | Dr. Raine, Timothy: No conflict of interest\|\|Vaja, Simran: No conflict of interest\|\|Subramanian, Sreedhar: No conflict of interest\|\|Brezina, Biljana: No conflict of interest\|\|Probert, Christopher SJ: No conflict of interest\|\|Steel, Alan: No conflict of interest\|\|Lofthouse, Martina: No conflict of interest\|\|Speight, Richard Alexander: No conflict of interest\|\|Lamb, Christopher: No conflict of interest\|\|Sebastian, Shaji: No conflict of interest\|\|Kane, Jack: No conflict of interest\|\|Thut, Jessica: No conflict of interest\|\|Din, Shahida: No conflict of interest\|\|Arnott, Ian: No conflict of interest\|\|Smith, Linda: No conflict of interest\|\|Galea, James: No conflict of interest\|\|Hendy, Philip: No conflict of interest\|\|Flores, Leah: No conflict of interest\|\|Selinger, Christian: No conflict of interest\|\|Onoviran, Felicia: No conflict of interest\|\|Steed, Helen: No conflict of interest\|\|Green, Marie: No conflict of interest\|\|Williams, John: No conflict of interest\|\|Jairath, Vipul: No conflict of interest\|\|Qian, Wendi: No conflict of interest\|\|Pavey, Holly: No conflict of interest\|\|Champion, Karlena: No conflict of interest\|\|Dowling, Francis: No conflict of interest\|\|Thomas, Martin: No conflict of interest\|\|Wolf, Kerstin: No conflict of interest\|\|Davis-Wilkie, Carol: No conflict of interest\|\|Parkes, Miles: No conflict of interest\|\|Kaser, Arthur: No conflict of interest |

| | |
|---|---|
| OP34 | Mrs. Plotkin, Luba: No conflict of interest\|\|Lujan, Rona: No conflict of interest\|\|Focht, Gili: No conflict of interest\|\|Greenfeld, Shira: No conflict of interest\|\|Loewenberg Weisband, Yisca: No conflict of interest\|\|Lederman, Natan: No conflict of interest\|\|Matz, Eran: No conflict of interest\|\|Dotan, Iris:\|:\| received in the last 3 years consultation fee, research grant, or honorarium from Janssen, Pfizer, Abbvie, Takeda, Genentech/Roche, Neopharm, Ferring, Rafa Laboratories, Falk Pharma, Nestle, Given Imaging/Medtronic, Gilead, Galapagos, Celgene/BMS, Arena, Sublimity, Sangamo, Celltrion, Wilbio, Cambridge Healthcare, Abbott, Food Industries Organization, Altman, Athos\|\|Turner, Dan:\|:\|Last 3 years received consultation fee, research grant, royalties, or honorarium from Janssen, Pfizer, Hospital for Sick Children, Ferring, Abbvie, Takeda, Atlantic Health, Shire, Celgene, Lilly, Roche, ThermoFisher, BMS |
| OP35 | Prof. Dr. Feagan, Brian Gordon:\|:\|BF reports grants and personal fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen Biotech/Centocor, Johnson & Johnson/Janssen, Pfizer, Receptos and Takeda; personal fees from Ablynx, ActoGeniX, Akebia Therapeutics Inc., Allergan, Atlantic Pharma, Avaxia Biologics Inc., Avir Pharma, Baxter Healthcare Corporation, Biogen Idec, BiomX Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Calypso Biotech, Celgene, Elan/Biogen, Eli Lilly, enGene, Exeliom Biosciences, Ferring Pharmaceuticals, Galapagos, Genentech/Roche, Gilead, Given Imaging, gIcare Pharma, GlaxoSmithKline, Gossamer Bio, Inception IBD Inc., Ironwood, Japan Tobacco Company, Kyowa Hakko Kirin Co., Ltd, Lexicon, Lycera Biotech, Merck, Mesoblast Pharma, Millennium, Nestlé, Novartis, Novo Nordisk, Par'Immune, Progenity, Prometheus Therapeutics and Diagnostics, Protagonist, Q32 Bio, Qu Biologics, Salix, Shire, Sienna Biologics, Sigmoid Pharma, Synergy Pharma, Teva Pharmaceuticals, TiGenix, Tillotts, UCB, Vertex, VHsquared, Vivelix Pharmaceuticals, Wyeth, Zealand and Zyngenia; and is the Senior Scientific Director of Alimentiv Inc. and a Professor of Medicine at Western University. \|\|Matsuoka, Katsuyoshi:\|:\|KM reports personal fees from AbbVie, Bristol Myers Squibb, Celltrion, EA pharma, Eli Lilly, Gilead, Janssen Pharmaceuticals, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Takeda and Zeria Pharmaceutical; and research grants from AbbVie, EA Pharma, JIMRO, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku and Takeda.\|\|Rogler, Gerhard:\|:\|GR reports personal fees from AbbVie, AstraZeneca, Augurix, Bristol Myers Squibb, Boehringer Ingelheim, Calypso, Celgene, Dr. Falk Pharma, Ferring Pharmaceuticals, Fisher, Genentech, Gilead, Janssen Pharmaceuticals, MSD, Novartis, Pfizer, Phadia, Pierre Fabre, Roche, Takeda, Tillotts, UCB, Vifor, Vital Solutions and Zeller; and grants from AbbVie, Ardeypharm, Augurix, Calypso, Dr. Falk Pharma, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillotts, UCB and Zeller. \|\|Faes, Margaux:\|:\|MF is an employee and shareholder of Galapagos NV. \|\|Oortwijn, Alessandra:\|:\|AO is an employee and shareholder of Galapagos NV. \|\|de Haas, Angela:\|:\|AdH is an employee and shareholder of Galapagos NV. \|\|Rudolph, Christine:\|:\|CR is an employee and shareholder of Galapagos NV. \|\|Peyrin-Biroulet, Laurent:\|:\|LP-B reports personal fees from AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, InDex Pharmaceuticals, Inotrem, Janssen Pharmaceuticals, MSD, Mylan, Norgine, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Theravance Biopharma, Thermo Fisher Scientific, Tillotts, Viatris and Vifor; grants from AbbVie, Fresenius Kabi, MSD and Takeda; and stock options from CTMA. |

| | |
|---|---|
| | |
| OP36 | Prof. Dr. Bokemeyer, Bernd: No conflict of interest\|\|Plachta-Danielzik, Sandra: No conflict of interest\|\|Deppe, Herbert: No conflict of interest\|\|Mohl, Wolfgang:\|:\|consulting fees from: Abbvie, Amgen, Hexal, Janssen, Pfizer, Synformulas, Takeda, outside the submitted work. Fees for lectures and further education from: Abbvie, Alanta health service GmbH, Almirall, Aptalis, Biogen, Falk, Gilead, Janssen, Pfizer, Medtronic, MSD, Shire, Takeda, Vifor, outside the submitted work. Fees for studies from: Abbvie, Janssen, MSD, Pfizer, Takeda, outside the submitted work. Fees for activities in public law bodies as member of the Advisory Commission of the Examination Office for the Saarland, the State Committee of Physicians and Health Insurance Companies and the Extended State Committee, outside the submitted work. Dependent employment in the group of Alanta health group GmbH, Hamburg, outside the submitted work. Shares, other fees from: Abbvie, Gilead, outside the submitted work.\|\|Teich, Niels:\|:\|Personal fees from: Abbvie, Falk Foundation, Janssen and Takeda outside the submitted work.\|\|Hoffstadt, Martin: No conflict of interest\|\|Schweitzer, Axel:\|:\|Personal fees from: AbbVie Deutschland GmbH & Co. KG, Janssen-Cilag GmbH, Tillotts Pharma outside the submitted work\|\|von der Ohe, Manfred: No conflict of interest\|\|Gauss, Annika:\|:\|Travel fees from Abbvie and Janssen, speaker's fees from Janssen, Abbvie, MSD, Tillotts, Pfizer and Takeda, and consultation fees from Janssen, AMGEN, Hexal, Takeda, Abbvie, Pfizer\|\|Atreya, Raja:\|:\|Personal fees from: AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr. Falk Pharma, Ferring, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, MSD Sharp & Dohme, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepsis, Stelic Institute, Sterna Biologicals, Takeda Pharma, Tillotts Pharma AG, Viatris outside the submitted work\|\|Krause, Thomas:\|:\|Personal fees from: AbbVie, Janssen, Takeda outside the submitted work\|\|Blumenstein, Irina:\|:\|Consulting and lecture fees from Janssen\|\|Fajardo Salmon, Samantha: No conflict of interest\|\|Hartmann, Petra:\|:\|Personal fees from: Abbvie, MSD, Shire, Ferring, UCB, Hospira, Takeda, Movetis, Biogen, Mylan, Janssen, BMS, Amgen, Hexal, Stada, Merckle, Mundipharma, Falk, HLR; outside the submitted work\|\|Gilman, Elena: No conflict of interest\|\|Schreiber, Stefan:\|:\|Personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, and Falk, outside the submitted work |
| | |

| | |
|---|---|
| OP37 | Dr. Chaparro, Maria:\|:\|M Chaparro: has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma.\|\|García Donday, María: No conflict of interest\|\|Riestra, Sabino: No conflict of interest\|\|Lucendo, Alfredo J: No conflict of interest\|\|Benítez, José Manuel: No conflict of interest\|\|Navarro-Llavat, Mercè: No conflict of interest\|\|Barrio, Jesús: No conflict of interest\|\|Morales-Alvarado, Víctor J.: No conflict of interest\|\|Rivero, Montserrat: No conflict of interest\|\|Busquets, David: No conflict of interest\|\|Leo Carnerero, Eduardo: No conflict of interest\|\|Merino Ochoa, Olga: No conflict of interest\|\|Nantes Castillejo, Oscar: No conflict of interest\|\|Navarro, Pablo: No conflict of interest\|\|Van Domselaar, Manuel: No conflict of interest\|\|Gutiérrez Casbas, Ana: No conflict of interest\|\|Alonso-Abreu, Inmaculada: No conflict of interest\|\|Mejuto, Rafael: No conflict of interest\|\|Fernández Salazar, Luis: No conflict of interest\|\|Iborra, Marisa: No conflict of interest\|\|Martín-Arranz, María Dolores: No conflict of interest\|\|Pineda, Juan Ramón: No conflict of interest\|\|Sampedro, Manuela Josefa: No conflict of interest\|\|Serra Nilsson, Katja: No conflict of interest\|\|Bouhmidi Assakali, Abdel: No conflict of interest\|\|Batista, Lissette: No conflict of interest\|\|Muñoz Villafranca, Carmen: No conflict of interest\|\|Rodríguez-Lago, Iago: No conflict of interest\|\|Ceballos Santos, Daniel Sebastián: No conflict of interest\|\|Guerra, Iván: No conflict of interest\|\|Mañosa, Miriam: No conflict of interest\|\|Marín Jimenez, Ignacio: No conflict of interest\|\|Vera Mendoza, Isabel: No conflict of interest\|\|Barreiro-de Acosta, Manuel: No conflict of interest\|\|Domènech, Eugeni: No conflict of interest\|\|Esteve, María: No conflict of interest\|\|García-Sánchez, Valle: No conflict of interest\|\|Nos, Pilar: No conflict of interest\|\|Panés, Julian: No conflict of interest\|\|Gisbert, Javier P.:\|:\|JP Gisbert: has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen,\|Takeda, Janssen, Roche, Sandoz, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka\|Pharmaceutical, Vifor Pharma. |
| OP38 | Naydenov, Nayden: No conflict of interest\|\|Le, Thi Hong Nga: No conflict of interest\|\|Lechuga Villarauz, Susana: No conflict of interest\|\|Elias, Michael: No conflict of interest\|\|West, Gail: No conflict of interest\|\|Czarnecki, Doug: No conflict of interest\|\|Plesec, Thomas: No conflict of interest\|\|Ivanov, Andrei: No conflict of interest\|\|Prof. Rieder, Florian: No conflict of interest |

| | |
|---|---|
| OP39 | Ghosh, Subrata:\|:\|Member of steering committees of Janssen, Abbvie, Boehringer Ingelheim, Gilead, Celgene, BMS; has received speaker honorarium from Abbvie, Takeda, Janssen, Ferring, Pfizer, Celltrion; and served on advisory committees of Janssen, Takeda, Abbvie, Eli Lilly, Roche, Pfizer, Gilead.\|\|Feagan, Brian:\|:\|Received grant/research support from AbbVie Inc., Amgen Inc., AstraZeneca/MedImmune Ltd., Atlantic Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline (GSK), Janssen Research & Development LLC., Pfizer Inc., Receptos Inc. / Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts Pharma AG, UCB; a consultant for Abbott/AbbVie, AdMIRx Inc., Akebia Therapeutics, Allergan, Amgen, Applied Molecular Transport Inc., Aptevo Therapeutics, Asta Pharma, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, Galen/Atlantica, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc, Intact Therapeutics, JnJ/Janssen, Kyowa Kakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestles, Nextbiotix, Novonordisk, ParImmune, Parvus Therapeutics Inc., Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Qu Biologics, Rebiotix, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Zyngenia; a member of the speakers bureau for Abbott/AbbVie, JnJ/Janssen, Lilly, Takeda, Tillotts, UCB Pharma; a member of the scientific advisory board for Abbott/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Galapagos, Genentech/Roche, JnJ/Janssen, Merck, Nestles, Novartis, Novonordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts Pharma AG, UCB Pharma; and Senior Scientific Officer – Robarts Clinical Trials Inc. \|\|Ott, Elyssa:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Gasink, Christopher:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Marano, Colleen:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Miao, Ye:\|:\|Employee of Janssen Research & Development, LLC. at the time of the study and owns stock/stock options.\|\|Sandborn, William:\|:\|Research grants from Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Meyers Squibb, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Laboratories, Seres Therapeutics, Shire Pharmaceuticals, Takeda, Theravance Biopharma; consulting |

| | |
|---|---|
| | fees from Abbvie, Abivax, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Allakos, Amgen, Arena Pharmaceuticals, AstraZeneca, Atlantic Pharmaceuticals, Beigene, Boehringer Ingelheim, Bristol Meyers Squibb, Celltrion, Clostrabio, Forbion, Galapagos, Genentech (Roche), GlaxoSmithKline, Gossamer Bio, Index Pharmaceuticals, Iota Biosciences, Janssen, Lilly, Morphic Therapeutics, Novartis, Oppilan Pharma (now Ventyx Biosciences), Pfizer, Pharm Olam, Polpharm, Progenity, Prometheus Biosciences, Protagonist Therapeutics, PTM Therapeutics, Seres Therapeutics, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Vedanta Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences, Xencor, Zealand Pharmaceuticals; stock or stock options from Allakos, BeiGene, Gossamer Bio, Oppilan Pharma (now Ventyx Biosciences), Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Gastrosciences; and employee at Shoreline Biosciences and Ventyx Biosciences. Spouse: Iveric Bio - consultant, stock options; Progenity - stock; Oppilan Pharma (now Ventyx Biosciences) – stock; Prometheus Biosciences - employee, stock, stock options; Prometheus Laboratories – stock, stock options, consultant; Ventyx Biosciences – stock, stock options; Vimalan Biosciences – stock, stock options. \|\|Danese, Silvio:\|:\|Consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc. and Vifor; and reports lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer and Takeda\|\|Abreu, Maria:\|:\|Reports having received grant support from Prometheus Bioscience, Takeda, and Pfizer; consulting fees from Janssen Research & Development, LLC., Prometheus Bioscience, Takeda, Focus Medical Communications, Pfizer, Boehringer Ingelheim Pharmaceuticals, Gilead, Imedex, Cornerstone Health, Inc, Landos Biophama, UCB Biopharma SRL, Eli Lilly, Bristol Myers Squibb, Arena Pharmaceuticals, and Cosmo Biopharma\|\|Sands, Bruce:\|:\|Reports grants, personal fees and other from Abivax, during the conduct of the study; personal fees from Abbvie, personal fees from Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), personal fees from Amgen, personal fees and other from Arena Pharmaceuticals, personal fees from Astra Zeneca, personal fees from Bausch Health (Salix Pharmaceuticals), personal fees from Boehringer Ingelheim, personal fees from Boston Pharmaceuticals, personal fees and other from Bristol Meyer Squibb, personal fees and other from Celgene, personal fees from Celltrion, personal fees from Clostrabio, personal fees from Equillium, personal fees from Galapagos, personal fees from Genentech (Roche), personal fees from |

| | |
|---|---|
| OP40 | Sands , B.(1):\|:\|as served as a consultant or received speaker's fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio, and stock options from Ventyx Biosciences.\|\|Peyrin-Biroulet, L.:\|:\|Grant:Takeda, Fresenius Kabi, Celltrion\|Personal Fees:AbbVie, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Prometheus, Protagonist, Roche, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax\|Other:Stock options: CTMA.\|\|Danese, S.:\|:\|Received consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor; and lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda\|\|Rubin, D.T.:\|:\|serves as a consultant for Abbvie, Altrubio, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Chronicles, Corp/Syneos, ClostraBio, Connect BioPharma, Eco R1, Genentech/Roche, Gilead Sciences, Iterative Health, Janssen Pharmaceuticals, Kaleido Biosciences, Lilly, Pfizer, Prometheus Biosciences, Reistone, Seres Therapeutics, Takeda, Target RWE, Trellus Health, has received grant support from Takeda, Helmsley Charitable Trust, GastroIntestinal Research Foundation.\|\|Vermeire, S.:\|:\|has received grants from AbbVie, J&J, Pfizer, Takeda and Galapagos; receuved consulting and/or speaking fees from: AbbVie, Abivax, AbolerIS Pharma, AgomAb, Alimentiv, |

| | |
|---|---|
| | Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma\|\|Laurent, O.:\|:\|is an employee of Prometheus Biosciences\|\|Luo, A.:\|:\|is an employee of Prometheus Biosciences\|\|Nguyen, D.:\|:\|is an employee of Prometheus Biosciences\|\|Lu, JD.:\|:\|is an employee of Prometheus Biosciences\|\|Wiechowska-Kozlowska, A.:\|:\|No Disclosures\|\|Leszczyszyn, J.:\|:\|Has received speaker fees from Astra Zeneca, MSD, Janssen, Gilead. Research grant from Johnson&Johnson\|\|Kempinski, R.:\|:\|has received grants from Janssen and Takeda\|\|Kierkus, J.:\|:\|has received consultation fees, research grants, or honoraria from AbbVie, Egis, Janssen, Nestlé, Nutricia, and Takeda\|\|Ma, C.:\|:\|has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Prometheus Biosciences Inc., Roche, Sanofi; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Takeda, Pendopharm, and Pfizer; royalties from Springer Publishing; research support from Ferring, Pfizer.\|\|Ritter, T.:\|:\|Speaker for Takeda Pharmaceuticals, Janssen, Pfizer, Bristol Myers Squibb and Abbvie; serves on advisory boards for Abbvie, Ardelyx, Arena, Boehringer Ingelheim, Bristol Myers Squibb / Celgene, Ferring, Genentech / Roche, Gilead, Intercept<br>Iterative Scopes ( and shareholder), Janssen, Lilly, Pfizer, Prometheus Biosciences, Sanofi, and Takeda\|\|Feagan , B.G.:\|:\|Is a consultant for AbbVie, AbolerIS, AgomAB Therapeutics, Allianthera, Amgen, AnaptysBio, Applied Molecular Transport Inc, Arena Pharma, Avoro Capital Advisors, Atomwise,, BioJamp, Biora Therapeutics, Boehringer-Ingelheim, Boxer, Celsius Therapeutics,Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Duality, EcoR1, Eli Lilly, Equillium, Ermium,, First Wave, First Word Group, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Gossamer Pharma, GSK, Hinge Bio, Hot Spot Therapeutics, Index Pharma, Imhotex, Immunic Therapeutics, JAKAcademy, Janssen, Japan Tobacco Inc., Kaleido Biosciences, Landos Biopharma, Leadiant, L.E.K. Consulting, Lenczner Slaght, LifeSci Capital, Lument AB, Millennium, MiroBio, Morgan Lewis, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Orphagen, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Therapeutics and Diagnostics, Play to Know AG, Progenity, Protagonist, PTM Therapeutics, Q32 Bio, Rebiotix, REDX, Roche, Sandoz, Sanofi, Seres Therapeutics, Silverback Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Tigenix, Tillotts, Ventyx Biosciences, VHSquared Ltd., Viatris, Ysios, Ysopia, Zealand Pharma; on the Speakers' Bureau for AbbVie, Janssen, Takeda; and on advisory boards for AbbVie, Amgen, AMT, AnaptysBio, Boehringer-Ingelheim, Celgene/BMS Eli Lilly, Genentech/Roche, Janssen, MiroBio, Origo BioPharma, Pfizer, Prometheus, REDX Pharma, Sanofi, Takeda,Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, GSK, Axio Research\|\|Targan, S.:\|:\|has received consulting fees from Robarts Clinical Trials and Prometheus Biosciences, and owns stock in Prometheus Biosciences; Subrata Ghosh is a member of steering committees of Janssen, AbbVie, Boehringer Ingelheim, Gilead, Celgene, and Bristol-Meyers Squibb, has received speaker honorarium from AbbVie, Takeda, Janssen, Ferring, Pfizer, and Celltrion, and has served on advisory committees of Janssen, Takeda, AbbVie, Eli Lilly, Pfizer, Gilead, Galapagos, and Roche\|\| |